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Abstract 
 
Polychlorinated dibenzo-p-dioxins, dibenzofurans, and polychlorinated biphenyls are 
persistent environmental pollutants which ubiquitously occur as complex mixtures and 
accumulate in the food and feed chain due to their high lipophilic properties. Of the 419 
possible congeners, only 29 share a common mechanism of action and cause similar effects, 
the so called dioxin-like compounds. Dioxin-like compounds evoke a broad spectrum of 
biochemical and toxic responses, i.e. enzyme induction, dermal toxicity, hepatotoxicity, 
immunotoxicity, carcinogenicity as well as adverse effects on reproduction, development, and 
the endocrine system in laboratory animals and in humans. Most, if not all, of the 
aforementioned responses, are mediated by the aryl hydrocarbon receptor. In the present 
work, the elicited biochemical effects of a selection of dioxin-like compounds and the non 
dioxin-like PCB 153 were examined in mouse (in vivo) and in human liver cell models (in 
vitro). Emphasis was given to the main contributors to the total toxic equivalents in human 
blood and tissues TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126, and PCB 156, which 
likewise contribute about 90 % to the dioxin-like activity in the human food chain.  
Three mouse in vivo studies were carried out aiming to characterize the alterations in hepatic 
gene expression as well as the induction of hepatic xenobiotic metabolizing enzymes after 
single oral dose. Based on the results obtained from mouse 3-day and 14-day studies, the 
seven test compounds can be categorized into three classes; the ones which are 'pure' AhR 
ligands (TCDD, 1-PnCDD, 4-PnCDF, and PCB 126) or solely CAR inducers (PCB 153), and 
the ones which are AhR/CAR mixed-type inducers (PCB 118, PCB 156). Moreover, the 
analysis of hepatic gene expression patterns after a single oral dose of either TCDD or PCB 
153 revealed that the altered genes fundamentally differed. Profiling of significantly altered 
genes led to the conclusion that changes in gene expression were associated with different 
signalling pathways, in fact by AhR and CAR. 
For investigating the role of the AhR in mediating biological responses, several experimental 
approaches were carried out, such as the analysis of blood plasma metabolites in Ahr 
knockout and wild-type mice. Genotype specifics and similarities were determined by HPLC-
MS/MS analysis. Several plasma metabolites could be identified in both genotypes, but also 
differences were detected. Furthermore, an in vivo experiment was performed aiming to 
characterize AhR-dependent and -independent effects in female Ahr knockout and wild-type 
mice. For this purpose, mice received a single oral dose of TCDD and were killed 96 h later. 
Microarray analysis of mouse livers revealed that although the Ahr gene was knocked out in 
Ahr-/- mice, the quantity of affected genes were in the same order of magnitude as for Ahr+/+ 
mice, but the pattern of altered genes distinctly differed. In addition, the relative liver weights 
of TCDD-treated Ahr+/+ mice were significantly increased which led to the conclusion, that 
TCDD induced the development of hepatic steatosis in female Ahr wild-type. 
The performed in vitro experiments aimed to characterize the effects elicited by selected 
DLCs and PCB 153 in human liver cell models by the use of HepG2 cells and primary human 
hepatocytes. In general, primary human hepatocytes were less responsive than HepG2 cells. 
This was not only observed in EC values derived from EROD assay, but also regarding 
microarray analysis in terms of differently regulated genes. In vitro REPs gained from both 
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liver cell models widely confirmed the current TEFs, but some deviations occurred. The 
comparison of the TCDD-altered genes in both human cell types revealed that only a 
considerably small number of genes was in common up regulated by both human liver cell 
models, such as the established AhR-regulated highly inducible cytochrome P450s 1A1, 1A2, 
and 1B1 as well as other AhR target genes. Although the overlap was rather small, the TCDD-
induced genes could be consistently associated with the broad spectrum of established dioxin-
related biological responses. The gene expression pattern in primary human hepatocytes after 
treatment with selected DLCs (TCDD, 1-PnCDD, 4-PnCDF, and PCB 126) and PCB 153 was 
additionally characterized by microarray analysis. The highest response in terms of 
significantly altered genes was determined for TCDD, followed by 4-PnCDF, 1-PnCDD, and 
PCB 126, whereas exposure to PCB 153 did not evoke any significant changes in gene 
expression. The pattern of significantly altered genes was very homogenous among the four 
congeners. Genes associated with well-established DLC-related biological responses as well 
as novel dioxin-inducible target genes were identified, whereby an extensive overlap in terms 
of up regulated genes by all four DLCs occurred. In conclusion, the results from the in vitro 
experiments performed in primary human hepatocytes provided fundamental insight into the 
congeners' potencies and caused alterations in gene expression patterns. The obtained findings 
implicate that although the extent of enzyme inducibilities varied, the gene expression 
patterns are coincidental. Microarray analysis identified species-specific (mouse vs. human) 
as well as model-specific (in vitro vs. in vivo and transformed cells vs. untransformed cells) 
differences. In order to identify novel biomarkers for AhR activation due to treatment with 
dioxin-like compounds, five candidates were selected based on the microarray results i.e. 
ALDH3A1, TIPARP, HSD17B2, CD36, and AhRR. Eventually, ALDH3A1 turned out to be the 
most reliable and suitable marker for exposure to DLCs in both human liver cell models 
eliciting the highest mRNA inducibility among the five chosen candidates. In which way 
these species- and cell type-specific markers are involved in the dioxin-elicited toxic 
responses should be further characterized in vivo and in vitro.  
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Deutsche Zusammenfassung 
 
Polychlorierte Dibenzo-p-Dioxine, Dibenzofurane und polychlorierte Biphenyle sind 
persistente Umweltkontaminaten, welche als komplexe Gemische ubiquitär vorkommen und 
sich aufgrund ihrer lipophilen Eigenschaften in der Nahrungskette anreichern. Von den 419 
möglichen Kongeneren teilt nur eine verhältnismäßig kleine Gruppe von 29 Verbindungen 
den gleichen Wirkmechanismus und das gleiche biologische Wirkspektrum, die sogenannten 
Dioxin-artigen Verbindungen. Dioxin-artige Verbindungen verursachen eine Vielzahl von 
biochemischen und toxischen Effekten, z. B. die Induktion von Enzymen, dermale Toxizität, 
Lebertoxizität, Immuntoxizität, und Kanzerogenität. Aber auch die Beeinträchtigung der 
Fortpflanzung, der normalen Entwicklung und des Hormonhaushalts konnten im Tiermodell 
und am Menschen beobachtet werden. Die meisten, wenn nicht sogar alle Wirkungen werden 
durch die Bindung der Dioxin-artigen Kongenere an den Arylhydrocarbon Rezeptor 
hervorgerufen. In der vorliegenden Arbeit, wurden die biochemischen Effekte durch 
Behandlung mit einer Auswahl Dioxin-artiger Verbindungen sowie von PCB 153, ein nicht 
Dioxin-artiges polychloriertes Biphenyl, im Mausmodell (in vivo) und in humanen 
Leberzellmodellen (in vitro) untersucht. Im Mittelpunkt standen sieben Kongenere, TCDD,  
1-PnCDD, 4-PnCDF, PCB 118, PCB 126, PCB 153 und PCB 156, welche mit ca. 90 % den 
größten Anteil zur gesamten Dioxin-Aktivität in der Nahrungskette beisteuern. Im 
Vordergrund der in vivo Mausstudien stand die Untersuchung der Veränderungen in der 
Expression hepatischer Gene sowie die Überprüfung der möglichen Induktion hepatischer 
fremdstoffmetabolisierender Enzyme nach einmaliger oraler Gabe der Testsubstanzen. Die 
sieben getesteten Kongenere können aufgrund der erhaltenen Resultate aus den 3-Tage und 
14-Tage Mausstudien in drei Klassen eingeteilt werden: „reine“ AhR Liganden (TCDD,       
1-PnCDD, 4-PnCDF, PCB 126), CAR Induktoren (PCB 153) sowie diejenigen, die sowohl 
den AhR als auch CAR aktivieren können (PCB 118, PCB 156). Zusätzlich wurde der 
mögliche Einfluss auf die Expression hepatischer Gene nach einmaliger oraler Gabe von 
TCDD und PCB 153 mit Hilfe der Microarrays untersucht. Es konnte gezeigt werden, dass 
die Art und die Anzahl der beeinflussten Gene sich grundlegend unterscheiden und 
unterschiedlichen Signalwegen (AhR und CAR) zugeordnet werden konnten. Des Weiteren 
wurde die physiologische Rolle des AhR sowie dessen Einfluss auf die TCDD-induzierten 
Veränderungen des Genexpressionsmusters in der Mausleber näher untersucht. Durch die 
HPLC-MS/MS-gestützte Untersuchung des Blutplasmas von Ahr Wild-Typ und Knockout 
Mäusen konnten Genotyp-spezifische Besonderheiten und Gemeinsamkeiten bestimmt 
werden. Mit Hilfe der etablierten Analysemethode war es möglich einige Plasmametabolite in 
beiden Genotypen zu identifizieren, aber auch spezifische Unterschiede konnten 
nachgewiesen werden. Darüber hinaus, wurde eine in vivo Mausstudie durchgeführt, um 
AhR-abhängige und AhR-unabhängige Effekte zu charakterisieren. Ahr Knockout und Wild-
Typ Mäusen wurde TCDD einmalig oral verabreicht und die Tiere nach 96-stündiger 
Exposition getötet. Die anschließende Microarrayanalyse der Mauslebern zeigte, dass obwohl 
das Ahr Gen in den Ahr Knockout Mäusen nicht exprimiert war die Anzahl der durch TCDD- 
Behandlung beeinflussten Gene in derselben Größenordnung lag als bei den Wild-Typ 
Mäusen, jedoch das Genexpressionsmuster in der Leber sich grundlegend unterschied. Die 
TCDD-induzierten Veränderungen auf hepatischer Genexpressionsebene von Ahr Wild-Typ 
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Mäusen sowie das erhöhte relative Lebergewicht der Tiere ließen die Schlussfolgerung zu, 
dass TCDD im vorliegenden Fall zu Entwicklung einer Fettleber in Wild-Typ Mäusen geführt 
hat. In den in vitro Versuchen sollten die Auswirkungen einer Reihe Dioxin-artiger 
Verbindungen und PCB 153 in menschlichen Leberzellmodellen (HepG2 Zellen und primäre 
humane Hepatozyten) untersucht werden. Allgemein konnte gezeigt werden, dass primäre 
humane Hepatozyten weniger sensitiv auf die Behandlung mit den Testsubstanzen reagiert 
haben als die immortalisierte Leberkarzinomzelllinie HepG2. Das wurde nicht nur anhand der 
EC-Werte aus dem EROD Assay beobachtet, sondern auch anhand der Anzahl veränderter 
Gene, welche mittels Microarray analysiert wurden. Die in vitro REPs, abgeleitet aus den 
Versuchen in den Leberzellmodellen, bestätigten überwiegend die aktuellen TEFs, jedoch 
wurde in einigen Fällen Abweichungen beobachtet. Der Vergleich TCDD-induzierter 
Veränderungen auf Genexpressionsebene in beiden Leberzellmodellen zeigte, dass nur eine 
verhältnismäßig kleine Anzahl von Genen übereinstimmend hoch reguliert wurde u. a. die 
etablierten AhR-regulierten, hoch induzierbaren Cytochrom P450 1A1, 1A2, und 1B1 sowie 
weitere etablierte AhR Zielgene. Diese hoch regulierten Gene konnten mit den vielfältigen 
etablierten biologischen Wirkungen von Dioxinen in Verbindung gebracht werden. Weiterhin 
wurde die Veränderungen der Genexpression in primären humanen Hepatozyten nach 
Behandlung mit ausgewählten Kongeneren (TCDD, 1-PnCDD, 4-PnCDF und PCB 126) 
sowie PCB 153 untersucht. TCDD verursachte die größte Anzahl an Veränderungen auf Gen-
expressionsebene, gefolgt von 4-PnCDF, 1-PnCDD und PCB 126, wohingegen die 
Behandlung mit PCB 153 keinen Einfluss auf die Genexpression zeigte. Ein Vergleich der 
durch die vier Kongenere hoch regulierten Gene lieferte ein homogenes Bild mit einer großen 
Anzahl übereinstimmend induzierter Gene, wobei sowohl Gene, welche mit den biologischen 
und toxischen Wirkungen von Dioxinen in Zusammenhang gebracht werden, als auch neue 
Dioxin-induzierbare Gene identifiziert werden konnten. Zusammenfassend konnte gezeigt 
werden, dass obwohl das Ausmaß der CYP1A1 Induzierbarkeit abhängig vom Leberspender 
interindividuell stark variierte, die Veränderungen auf Ebene der Genexpression eine enorme 
Übereinstimmung aufwiesen. Weiterhin konnten mittels Microarrayanalyse Spezies-
Abhängigkeiten (Maus vs. Mensch), als auch Modell-Abhängigkeiten (in vitro vs. in vivo 
sowie transformierte Zellen vs. nicht-transformierte Zellen) nachgewiesen werden. Die Suche 
nach neuen Biomarkern für die Exposition gegenüber Dioxin-artigen Verbindungen bildete 
einen weiteren Schwerpunkt der vorliegenden Arbeit. Der Vergleich der Microarrays führte 
zu fünf Spezies- und Zelltyp-spezifischen potentiellen Biomarker-Kandidaten, ALDH3A1, 
TIPARP, HSD17B2, CD36 und AhRR. Von diesen, stellte sich ALDH3A1 als der am besten 
geeignete Marker gegenüber der Exposition mit Dioxin-artigen Verbindungen in beiden 
humanen Leberzellmodellen heraus, welcher die höchste mRNA Induzierbarkeit unter den 
ausgewählten Kandidaten besaß. Auf welche Weise diese spezifischen Marker 
möglicherweise zu den Dioxin-vermittelten toxischen Wirkungen beitragen, sollte anhand 
weiterer in vivo und in vitro Experimente untersucht werden.  
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I Introduction 
 
Humans are daily exposed to a myriad of chemicals either by inhalation, ingestion, or dermal 
absorption. A class of chemicals, which is in focus of the public attention and research 
objectives due to industrial incidents and various food scandals are polychlorinated aromatic 
hydrocarbons (PCAHs). 
The family of structurally-related compounds consists of three groups, the polychlorinated 
dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), and biphenyls (PCBs). A total of 419 
possible congeners exist, whereas only 7 PCDDs, 10 PCDFs, and 12 non-ortho and mono-
ortho PCBs (dioxin-like PCBs) share a common mechanism of action and cause similar 
biochemical and toxic effects. These 29 dioxins and dioxin-like compounds bind to a 
transcription factor, the aryl hydrocarbon receptor. It has been established that the aryl 
hydrocarbon receptor mediates most, if not all, biological and toxicological effects of dioxins 
and dioxin-like compounds (Holsapple et al., 1991) (Birnbaum, 1994) (IARC, 1997) (Schmidt 
et al., 1996) (Fernandez-Salguero et al., 1996) (Gonzalez et al., 1998) (Nebert et al., 2000) 
(Schrenk et al., 1995). 
Since dioxins and dioxin-like compounds are highly lipophilic and persistent, they 
ubiquitously occur as complex mixtures in the environment and in the human food chain, 
whereby humans are predominantly exposed by food of animal origin such as meat, fish, 
eggs, milk, and other dairy products (EFSA, 2010). The establishment of emission limit 
values for dioxins and furans, binding limits for the 29 congeners in food and feed products as 
well as the monitoring of food and environmental matrices led to the remarkably reduction of 
exposure levels in most European countries (Liem et al., 2000) (Malisch et al., 2003) (EFSA, 
2010) (EFSA, 2012). Nevertheless, various populations such as newborns and infants or 
humans that are exposed to higher amounts of dioxin-like compounds by occupation or 
accidents exhibit higher exposure levels than the established tolerable daily intake of 1-4 pg 
TEQ/kg bw (WHO, 1998) (IARC, 1997) (IARC, 2012). 
For improvement of the human risk assessment the European project SYSTEQ was initiated 
in 2009 which aimed to derive and establish in vitro TEFs (REPs) based on data from human 
and animal in vitro systems after exposure to a selection of PCDD/Fs and dioxin-like PCBs. 
These in vitro REPs/TEFs will be compared to novel systemic REPs/TEFs obtained from in 
vivo mouse and rat experiments to clarify species differences and provide important 
knowledge in extrapolation from the in vitro to the in vivo human situation. The present thesis 
provides essential research data about a myriad of congener's potencies, as the available data 
for most of the 29 dioxin-like compounds is insufficient in human liver cell models. The 
current work predominantly deals with SYSTEQ research objectives, but also aspires to 
elucidate the role of the aryl hydrocarbon receptor in mediating the toxicity of dioxin-like 
compounds in mouse. The presented doctoral thesis has been performed under the supervision 
of Prof. Dr. Dr. D. Schrenk in the Department of Food Chemistry and Toxicology at the 
University Kaiserslautern. 
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II Theoretical Background 
 
II.1 Polychlorinated Dioxins, Furans, and Biphenyls 
 
Polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans and polychlorinated 
biphenyls are widespread persistent environmental pollutants. In total possible 75 PCDDs, 
135 PCDFs, and 209 PCBs exist depending on the number and position of chlorine atoms-
bound to the respective molecule. Amongst the 210 PCDD/F congeners, only 7 PCDDs and 
10 PCDFs, with chlorine atoms in the lateral ring positions 2, 3, 7, and 8 of the molecule, 
cause dioxin-like biological and toxic effects.  
All 209 PCBs have the ability to rotate around the phenyl-phenyl-axis. The 209 PCBs are 
categorized into two groups based on the respective elicited toxicological responses, the small 
group of 12 dioxin-like PCBs and the large group of 198 non dioxin-like PCBs. 8 mono-ortho 
and 4 non-ortho substituted PCBs are categorized as dioxin-like compounds because they 
exhibit a dioxin-like activity and similar toxic responses. 
All 29 structurally-related dioxin-like compounds are persistent and bioaccumulate as well as 
they share a common mechanism of action by binding to the aryl hydrocarbon receptor (AhR) 
and evoke the same spectrum of biological and toxic responses. The most toxic congener and 
reference compound for the class of dioxin-like compounds is 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (TCDD) (IARC, 1997) (Fiedler, 2003) (van den Berg et al., 2006). TCDD represents 
the best studied congener among the group of dioxin-like compounds. 
 
 
 
 
 
 
 
Figure 1. Molecular structures of PCDDs (I), PCDFs (II), and PCBs (III).  
Molecular structure of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is featured in (IV). 
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II.1.1 Toxic Equivalency Factors and Total Toxic Equivalence  
(TEF/TEQ Concept) 
 
Polychlorinated aromatic hydrocarbons (PCDD/Fs and PCBs) usually occur as complex 
mixtures of congeners in environmental and biological matrices. Therefore, the toxic 
equivalency concept was developed during the 1980's (OMEA et al., 1985) (NATO, 1988). 
Each dioxin-like compound is assigned a toxic equivalency factor (TEF) which expresses the 
relative effect potency (REP) derived from in vivo and in vitro studies of individual dioxin-
like compounds to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD). TCDD is the most toxic 
compound of the group of dioxin-like congeners and serves as prototype which was assigned 
a TEF value of 1.0. A compound must fulfil several requirements to be attributed with a TEF 
value; it has to exhibit structural similarities to PCDD/Fs and bind to the aryl hydrocarbon 
receptor. Furthermore it must evoke AhR-mediated biochemical and toxic effects and be 
persistent and accumulate in the food chain (Birnbaum, 1994) (van den Berg et al., 1998) (van 
den Berg et al., 2006) (Haws et al., 2006). The total toxic equivalent (TEQ) concept was 
developed for risk assessment and is based on the assumption that the toxic responses elicited 
by all dioxin-like compounds (DLCs), existing in the examined sample, are additive. The 
formula for TEQ value calculation is featured in the following equation. The concentration of 
each DLC is multiplied by its respective TEF and the products are ultimately summed up to 
obtain the TEQ value of the environmental or biological matrix. The resulting TEQ value 
estimates the TCDD-like activity of the compound mixture in the analyzed sample. 
 
TEQ =  C × TEF


 
  With: TEFi = toxic equivalency factor of the individual congener 
n = total numbers of congeners present in the sample 
   i = individual congener  
Ci = concentration of individual congener  
 
During the last three decades the TEF values were evaluated respectively re-evaluated by 
WHO expert meetings taking into account new published in vivo and in vitro experiments 
(Ahlborg et al., 1994) (van den Berg et al., 1998) (van den Berg et al., 2006). Therefore, it is 
essential for risk assessment that publications state which TEF values were used for 
calculation of the total TEQ concentration in the given samples.  
An overview of the human and mammalian WHO-TEFs of the year 1998 and the current TEF 
values, re-evaluated by the WHO in 2005, for PCDDs, PCDFs, and dioxin-like PCBs are 
summarized in Table 1. Publications on the relative effect potencies of dioxin-like compounds 
often feature significant differences in REP values of the same congener. These differences 
can be due to various reasons, for instance, they can be based on different study designs (e.g. 
acute, subchronic, or chronic), species, and addressed endpoints. In publications methods for 
calculation of relative effect potencies (REPs) differ. Therefore, the WHO expert panel gave 
general guidelines and criterias for in vivo and in vitro studies in which REP values are 
determined (van den Berg et al., 2006).  
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Table 1. TEF values of PCDDs, PCDFs, and dioxin-like PCBs re-evaluated by WHO in 1998 and 2005. 
(van den Berg et al., 1998) (van den Berg et al., 2006) 
 
Compound 
 
TEF (WHO, 1998) TEF (WHO, 2005) 
Chlorinated dibenzo-p-dioxins  
2,3,7,8-TetraCDD TCDD 1.0 1.0 
1,2,3,7,8-PentaCDD 1-PnCDD 1.0 1.0 
1,2,3,4,7,8-HexaCDD 1,4-HxCDD 0.1 0.1 
1,2,3,6,7,8-HexaCDD 1,6-HxCDD 0.1 0.1 
1,2,3,7,8,9-HexaCDD 1,9-HxCDD 0.1 0.1 
1,2,3,4,6,7,8-HeptaCDD 1,6-HpCDD 0.01 0.01 
1,2,3,4,6,7,8,9-OctaCDD OCDD 0.0001 0.0003 
Chlorinated dibenzofurans  
2,3,7,8-TetraCDF TCDF 0.1 0.1 
1,2,3,7,8-PentaCDF 1-PnCDF 0.05 0.03 
2,3,4,7,8-PentaCDF 4-PnCDF 0.5 0.3 
1,2,3,4,7,8-HexaCDF 1,4-HxCDF 0.1 0.1 
1,2,3,6,7,8-HexaCDF 1,6-HxCDF 0.1 0.1 
1,2,3,7,8,9-HexaCDF 1,9-HxCDF 0.1 0.1 
2,3,4,6,7,8-HexaCDF 4,6-HxCDF 0.1 0.1 
1,2,3,4,6,7,8-HeptaCDF 1,4,6-HpCDF 0.01 0.01 
1,2,3,4,7,8,9-HeptaCDF 1,4,9-HpCDF 0.01 0.01 
1,2,3,4,6,7,8,9-OctaCDF OCDF 0.0001 0.0003 
Non-ortho substituted PCBs  
3,3',4,4'-TetraCB PCB 77 0.0001 0.0001 
3,4,4',5-TetraCB PCB 81 0.0001 0.0003 
3,3',4,4',5-PentaCB PCB 126 0.1 0.1 
3,3',4,4',5,5'-HexaCB PCB 169 0.01 0.03 
Mono-ortho substituted PCBs  
2,3,3',4,4'-PentaCB PCB 105 0.0001 0.00003 
2,3,4,4',5-PentaCB PCB 114 0.0005 0.00003 
2,3',4,4',5-PentaCB PCB 118 0.0001 0.00003 
2',3,4,4',5-PentaCB PCB 123 0.0001 0.00003 
2,3,3',4,4',5-HexaCB PCB 156 0.0005 0.00003 
2,3,3',4,4',5'-HexaCB PCB 157 0.0005 0.00003 
2,3',4,4',5,5'-HexaCB PCB 167 0.00001 0.00003 
2,3,3',4,4',5,5'-HeptaCB PCB 189 0.0001 0.00003 
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II.1.2 Physicochemical Properties 
 
The physicochemical properties vary widely among polychlorinated dibenzo-p-dioxins, 
furans, and biphenyls (Mackay et al., 2006). Nevertheless, in general they are poorly water 
soluble, but soluble in organic solvents (for instance dimethyl sulfoxide). Furthermore, they 
exhibit high oil and fat solubility. They are chemically very stable and are low-flammable 
compounds. PCBs exhibit a low electrical and high thermal conductivity. Due to their 
resistance to chemical and biological degradation under normal conditions PCDD/Fs and 
dioxin-like PCBs are highly persistent and accumulate in the feed and food chain (Lohmann 
et al., 1998) (Jones et al., 1999) (Cornell, 2005).  
 
II.1.3 Production, Occurrence, and Exposure 
 
PCDDs and PCDFs were never synthesized for commercial purposes, except in small scale 
for scientific research. Predominantly, they are unintendedly generated in chemical 
combustion processes such as waste and sewage sludge incinerations as well as in other 
chemical processes such as paper pulp bleaching or metal smelting and subsequently are 
released into the environment. PCDD/PCDFs are also unwanted by-products during the 
synthesis of chlorinated phenols. In particular, TCDD is formed during the manufacturing of 
2,4,5-trichlorophenol. 2,3,4-tricholorphenol was utilized to synthesize the herbicide and 
defoliant 2,4,5-trichlorophenoxyacetic acid being a component of Agent Orange which was 
used for weed control and defoliation during the Vietnam War (Poland et al., 1982a) 
(ATSDR, 1998) (Pereira et al., 2004). Additionally, PCDD/Fs are formed as inadvertent by-
products during the synthesis of polychlorinated biphenyls. To a lesser extent, they are formed 
by natural causes such as the partial combustion of organic material, e.g. in forest fires 
(ATSDR, 1998).  
Polychlorinated biphenyls were commercially synthesized due to their physicochemical 
properties and applied in a wide variety of industrial products such as transformators and 
capacitors, hydraulic lubricants, heat transfer fluids, adhesives, plasticisers and sealants. PCBs 
were marketed as mixtures referring to the percentage of the respective chlorine content under 
several trade names such as Aroclor (Monsanto, USA), Clophen (Bayer, Germany), 
Kanechlor (Kanegafuchi, Japan), Santotherm (Mitsubishi, Japan) as well as Phenaclor and 
Pyralene (Prodolec, France). About 55 years after the first manufacturing of PCBs the 
production, distribution well as the usage was banned in Europe and the USA during the mid 
1980's (Alcock et al., 1998) (Fiedler et al., 1995) (Pereira et al., 2004). Due to their 
widespread usage in various technical applications, PCBs are still released into the 
environment by leaks of transformators and capacitors as well as from improper waste 
disposal (Pereira et al., 2004). 
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Humans are predominantly exposed to TCDD and related compounds primarily through diet, 
which contributes more than 90 % to the total human exposure. Since PCDD/Fs and PCB 
accumulate in fat-rich organisms, main sources of PCDD/Fs and DL-PCBs contaminants are 
lipid-rich food of animal origin; the highest levels were determined in fish, meat, eggs, milk, 
and other dairy products (EFSA, 2010). Other routes of exposure are by inhalation of air or 
ingestion of water contaminated with PCDD/Fs and DL-PCBs (Liem et al., 2000). 
An overview of the average estimated dietary intakes of PCDD/Fs and DL-PCBs for adults in 
different countries is presented in Table 2. Estimated dietary intakes presented in Table 2 vary 
about a factor of three. TEQ values for PCDD/Fs range from 0.5 pg TEQ/kg bw/day in the 
Netherlands to 1.67 pg TEQ/kg bw/day in the USA, whereby highest PCB-TEQ values were 
estimated in Japan (1.36 pg TEQ/kg bw/day) and lowest dietary intake levels were assessed 
for the Netherlands (0.5 pg TEQ/kg bw/day). The differences can be attributed to different 
calculation methods, different statistical analysis, and different DL-compounds analyzed. 
Additionally, the dietary habits in food consumption in the countries also contribute to the 
aforementioned variations of the estimated daily human intakes of TCDD and related 
compounds (Fattore et al., 2006). 
 
Table 2. Average estimate daily human intakes of PCDD/Fs and DL-PCBs expressed as pg TEQ/kg bw/day.  
TEQs calculated with WHO1998-TEFs. Thereby, (a) upper bound estimates (b) lower bounds estimates 
(c) medium bound estimates (d) only non-ortho PCBs analyzed 
 
Country PCDD/Fs DL-PCBs Reference  
Italy(a) 0.96 1.30 Fattore et al. 2006 
Germany 0.7 1.3 Mathar et al., 2003 
Belgium(a)(d) 1.00 1.04 Focant et al., 2002 
Finland(b) 0.79 0.74 Kiviranta et al., 2004 
The Netherlands(a) 0.6 0.5 Baars et al., 2004 
France(a) 0.5 1.2 Tard et al., 2007 
Japan(a) 0.89 1.36 Tsutsumi et al., 2001 
USA(c) 1.67 0.65 Schecter et al., 2001 
 
In 1998 the World Health Organization established a tolerable daily intake (TDI) for dioxins 
and dioxin-like compounds of 1-4 pg TEQ/kg bw/day. The TDI was calculated by applying an 
uncertainty factor of 10 to the range of lowest adverse effect levels (LOAELs) 14-37 TCDD 
pg/kg bw/day for the most sensitive adverse effects from different experimental species. In 
addition, the animal body burden was included in the TDI calculation. The upper limit of 4 pg 
TEQ/kg bw/day should be regarded as maximal tolerable intake, whereas the aspired aim is to 
decrease the human intake levels below 1 pg TEQ/kg bw/day (WHO, 1998).  
In all studies presented in Table 2 the estimated TEQs are within the range of established 
WHO-TDI. Though the tolerable daily intake established by the Scientific Committee on 
Food (SCF) of 2 pg TEQ (PCDD/Fs and DL-PCBs)/kg bw/day is slightly exceeded in some 
cases. Recently published results from health monitoring studies revealed that the dioxin 
intake levels further decreased resulting in estimated dietary intake levels for PCDD/Fs and 
Theoretical Background 
 
7 
 
DL-PCBs ranging between 0.57 to 1.64 pg TEQWHO05/kg bw/day for adults in 15 European 
studies (EFSA, 2012). 
The studies summarized in Table 2 only represent the estimated daily intake of an average 
adult human. Other subpopulations such as newborns and children are exposed to higher 
PCDD/F and PCB levels due to the maternal body burden and consumption of fat-rich 
products such as milk and other dairy products. In 2012, the European Food Safety Authority 
published data from the two monitoring surveys in which the dietary exposure of dioxins and 
DL-compounds in infants, toddlers, and other children were analyzed. The estimated infant 
exposure level was 1.17 pg TEQ/kg bw/day in a Bulgarian survey and 1.08 pg TEQ/kg 
bw/day in an Italian study. Levels for toddlers ranged from 1.25 to 2.54 pg TEQ/kg bw/day 
assessed in 9 surveys, whereas the daily exposure of the sum of PCDD/Fs and DL-PCBs in 
older children was in the same order of magnitude (1.08 - 2.49 pg TEQ/kg bw/day) (EFSA, 
2012). In all the aforementioned studies human milk was not taken into account. Several 
studies demonstrated that the TEQ exposure in nursing infants is several orders of magnitude 
higher than in infants feed with formula (Ulaszewska et al., 2011). The estimated average 
intake levels of PCDD/Fs and DL-PCBs by human milk was 77 pg TEQ/kg bw/day for an 
three month-old German infant in the year 2009 (BfR, 2011). This value exceeds the TDI by 
far, but with the increasing age and body weight the infant exposure levels decrease quickly. 
Furthermore, since the 1980's levels of dioxins and dioxin-like compounds are steadily 
declining in human milk in most European countries, whereby a decrease of more than 80 % 
for the average PCDD/Fs contamination in milk fat was examined in Germany up until 2009 
(van Leeuwen et al., 2002) (BfR, 2011) (Focant et al., 2013). This affirmative development 
could be attributed to the decreased PCDD/F emission, the strict food and feed monitoring 
and furthermore to a change in human dietary habits.  
Since July 2002, maximal limits for PCDDs and PCDFs expressed as WHO-PCDD/F-TEQ 
using WHO1998-TEFs in food and feed became effective which were set by the Council of the 
European Commission (IP/02/1669 andIP/02/1670). In addition to the maximum limits for the 
sum of PCDD/Fs in food and feed, maximum levels for the sum of PCDD/Fs and DL-PCBs 
were settled as well as recommended action levels, in 2006. In 2011, established maximum 
levels were adjusted using WHO2005-TEFs and maximum limits for NDL-PCBs expressed as 
the sum of six indicator PCBs (PCB 28, 52, 101, 138, 153, and 180) were set. 
Besides the exposure by food and feed, humans are exposed to dioxins and related compounds 
by occupation or by industrial accidents (IARC, 2012). In 1976, an explosion of a 
trichlorophenol reactor led to the release of a cloud containing up to 30 kg TCDD and other 
toxic components on a chemical plant in Italy. Seveso was the municipal mostly affected by 
the aerosol cloud, whereupon the tragic incident was called 'Seveso disaster'. The Seveso 
disaster resulted in the highest known TCDD exposure levels in humans, whereat a median 
TCDD level of 56 ppt (ranging between 2.5-56000 ppt) was measured in a large female 
cohort in the most contaminated zones A and B (Eskenazi et al., 2004) (Mocarelli et al., 
2008).  
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II.1.4 Toxicokinetics and Metabolism 
 
The toxicokinetics of PCDD/Fs and dioxin-like PCBs is based on the congener's lipophilicity, 
metabolism, and binding to CYP1A2 in the liver. TCDD and related compounds are 
predominantly absorbed through the gastrointestinal tract and to a much lesser extent by 
inhalative and dermal absorption. Distribution in the organism is mediated by binding of 
congeners to serum lipids and lipoproteins (van den Berg et al., 1994). TCDD and related 
compounds are highly lipophilic, whereby lipophilicity increases with chlorination and has 
impact on the compound's absorption as well as tissue partitioning. Metabolism acts as the 
rate-limiting step for elimination of these environmental contaminants. Since they are highly 
persistent, they are slowly metabolized and eliminated. Subsequently they accumulate in liver 
and adipose tissues of humans and animals (WHO, 1998). 
CYP1A2 induction results in the hepatic sequestering of TCDD and related compounds which 
has been demonstrated among others by the use of transgenic mouse model. Cyp1a2 knockout 
mice treated with a single dose of 25 µg [3H] TCDD/kg bw or 300 µg [14C] 4-PnCDF/kg bw 
exhibited high amounts of the radiolabelled compounds in the adipose tissue, but not in liver 
four days after administration. In contrast, C57BL/6N mice, which were exposed to the same 
dosages of the radiolabelled chemicals, featured higher compound concentrations in the liver 
than in the adipose tissue (Diliberto et al., 1999). Metabolism of PCDD/Fs correlates with the 
number and position of chlorination. Higher chlorinated congeners are metabolized to a lesser 
degree than less chlorinated ones (van den Berg., 1994). The toxicity of dioxins and dioxin-
like compounds depends on the parent compound and the slow formation of metabolites 
contributes to the fatal toxic responses as well. Biotransformation of several PCDD/Fs and 
PCBs has been demonstrated in various animal species in which congeners are primarily 
epoxidized and subsequently hydroxylated polar metabolites are formed which can be readily 
glucoronidated and in the following be excreted by bile or kidney (van den Berg et al., 1994) 
(Peirera et al., 2004).  
TCDD is the most toxic congener among the group of dioxins and related compounds, 
whereas little is known about its metabolism in humans. Sorg and co-workers identified two 
TCDD metabolites (2,3,7-trichloro-8-hydroxydibenzo-p-dioxin and 1,3,7,8-tetrachloro-2-
hydroxy-dibenzo-p-dioxin) in feces, urine, and serum of a patient after acute TCDD 
intoxication (Sorg et al., 2009).  
The apparent body half-life depends on several factors such as dose, body composition, age, 
and sex (van Leeuwen et al., 2000). Different PCDDs, PCDFs, and PCBs have different 
persistence in humans and animals which is reflected in their different reported half-lives 
(Milbrath et al., 2009). The elimination half-life of TCDD in rodents is normally 2-4 weeks 
(Rose et al., 1976) (Birnbaum, 1986). In humans, the TCDD elimination half-life has been 
estimated to range between 7-11 years (Pirkle et al., 1989) (Wolfe et al., 1994) (Milbrath et 
al., 2009). 
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II.1.5. Toxicity and Carcinogenicity of TCDD and Related Compounds 
 
TCDD and related compounds evoke a spectrum of biochemical and toxicological responses 
in different species such as enzyme induction, dermal toxicity, immunotoxicity, 
hepatotoxicity and carcinogenicity as well as adverse effects on reproduction, development, 
and the endocrine system has been demonstrated (Holsapple et al., 1991) (Birnbaum, 1994) 
(Schmidt et al., 1996) (Fernandez-Salguero et al., 1996) (Gonzalez et al., 1998) (Nebert et al., 
2000) (Schrenk et al., 1995) (IARC, 1997). Most, if not all, of these biological and toxic 
effects are mediated by the aryl hydrocarbon receptor (AhR). Elicited responses of DL-
compounds range species-, gender-, age-, strain-, organ-, and tissue-dependent. TCDD is the 
most toxic member of the class of DL-compounds and features the most extensive 
toxicological database from all DL-compounds (DLCs). 
Hence, the following chapters primarily deal with the biochemical and toxic effects of TCDD, 
preferentially in liver, but studies of other DLCs as well as NDL-PCB 153 are additionally 
presented. 
 
II.1.5.1. TCDD in Rodents 
 
II.1.5.1.1 Toxicity  
 
One-time administration of TCDD at high doses (lethal or near lethal) causes in rodents a 
severe body weight loss (up to 50 % of the original body weight) which contributes to the 
lethality of animals (Moffat et al., 2010). This effect is called wasting syndrome. Up to the 
present day, the mechanism of the TCDD-induced wasting is still not clarified, but it has been 
demonstrated that the aryl hydrocarbon receptor is involved in the excessive weight loss, 
since TCDD does not evoke 'wasting' in Ahr knockout mice (Seewald et al., 1984) 
(Fernandez-Salguero et al., 1996) (Gonzalez et al., 1998).  
In rodents, the liver is the organ predominantly affected by TCDD and related compounds. 
TCDD induces extremely enlarged liver (hepatomegaly) based on hyperplasia and 
hypertrophy of parenchymal cells in rodents and in various other species (Poland et al., 
1982a). Further hepatotoxic effects include alterations in hepatic genes and enzyme induction 
as well as shift in serum enzyme activities, increased liver weight, hepatic inflammation, 
necrosis, hepatic steatosis, disruption of hepatic energy metabolism, decreased vitamin A 
levels, porphyria as well as the impairment of the membrane function, hyperbilirubinemia and 
hypercholesterolemia in mice and rats (Shen et al., 1991) (Smith et al., 1998) (Niittynen et al., 
2002) (Angrish et al., 2011) (Angrish et al., 2013).  
The TCDD-induced toxic responses have been associated with AhR-mediated alterations in 
hepatic gene expression. These changes occur rather quickly, whereas TCDD-elicited toxic 
effects in rodents such as the wasting syndrome, hepatotoxicity, and lethality usually are 
developed after a delay period. 
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One of the established TCDD-induced biochemical responses in rodent livers is the induction 
of xenobiotic metabolizing enzymes such as CYP1A1, CYP1A2, and CYP1B1 (Nebert et al., 
2000). The induction of CYP1A1 is the most sensitive and earliest indicator for exposure to 
dioxins and DL-congeners (Vanden Heuvel et al., 1993) (Drahushuk et al., 1996). In which 
way the induction of CYP1A isoenzymes contribute to the adverse effects of TCDD is still 
not completely clarified. The induction of CYPs could lead to the generation of reactive 
oxygen species and oxidative stress which has been linked to oxidative DNA damage (Park et 
al., 1996). CYP1A1 is required for the generation of TCDD-induced cardiovascular 
superoxide anions in mice livers resulting in endothelial dysfunction as well as hypertension 
(Kopf et al., 2010).  
In addition, TCDD induces the AhR-mediated transcriptional up regulation of other genes 
linked to phase I and II of the xenobiotic metabolism, summarized as the classical murine 
AhR gene battery including Nqo1, Aldh3a1, Gsta1, and Ugt1a6 in liver (Nebert et al., 2000). 
The respective enzymes are involved in detoxifying processes, i.e. biotransformation of 
exogenous and endogenous compounds. Furthermore, TCDD alters genes associated with cell 
development, growth, and differentiation. It has been proven that these processes are 
regulated by the aryl hydrocarbon receptor (Bock et al., 2006). By the establishment of a new 
toxicogenomic approach during the last decades, the microarray analysis, it has been possible 
to identify a large number of genes altered by TCDD in different cell types and tissues which 
can be linked to TCDD-elicited adverse responses (Boverhof et al., 2006) (Kim et al., 2009) 
(Dere et al., 2011). 
Many recently published toxicogenomic studies aimed to identify the mechanism of the 
TCDD-induced hepatotoxicity in rodents. In a study performed by Forgacs and co-workers, 
female ovariectomiced C57BL/6 mice and immature female Sprague-Dawley rats were 
treated with a single dose of either sesame oil as vehicle or 30 µg/kg bw TCDD for mice and 
10 µg/kg bw for rats by gavage and were sacrificed 24, 72, 120, or 168 h post-treatment. 
Comparative toxicogenomic profiling revealed that the TCDD-caused hepatic steatosis in 
mice is due to down regulation of genes associated with the de novo fatty acid synthesis and 
triglyceride biosynthesis as well as the up regulation of genes linked to the hepatic lipid 
uptake and the metabolism of saturated fatty acids to mono-unsaturated fatty acids and poly-
saturated fatty acids. Histopathological examinations of mouse livers were consistent with the 
toxicogenomic findings. The vacuolization of the hepatic mouse tissue was a result of 
triglyceride and fatty acid accumulation as well as inflammatory cell accumulation and 
apoptosis. TCDD also induced an increase of the relative liver weight in rats, but no hepatic 
steatosis was detected 168 h after single dose treatment. Histopathology of rat livers unveiled 
a moderate lipid accumulation which was on account of the evolved hepatocellular 
hypertrophy. These findings were in accordance with the alterations in gene expression linked 
to cellular growth and lipid metabolism (Boverhof et al., 2006) (Forgacs et al., 2012) (Angrish 
et al., 2012) (Forgacs et al., 2013). 
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II.1.5.1.2 Carcinogenicity and Tumour Promotion 
 
Toxic effects presumably contribute to the TCDD-evoked carcinogenesis and tumour 
promotion in rodents. A multitude of carcinogenicity studies were conducted with TCDD in 
animals. It was demonstrated that TCDD caused tumours in various organs and tissues, e.g. 
liver, lung, skin, thyroid, hard palate, nasal turbinates, and tongue in rodents and hamsters 
(IARC, 2012).  
Toth et al. analyzed the carcinogenic potential of TCDD in male Swiss/H/Riop mice which 
were treated with 0.007, 0.7, 7 µg TCDD /kg bw by gavage once a week over a period of one 
year. Afterwards animals were observed over a life span. The overall incidence of 
hepatocellular adenomas and carcinomas was increased in the selected mouse strain (Toth et 
al., 1979). In a long-term carcinogenicity study performed by the National Toxicology 
Program, male and female B6C3F1 mice were treated by gavage with 0.01, 0.05, or 0.5 µg 
TCDD/kg bw (males) and 0.04, 0.2, or 2 µg TCDD/kg bw (females) twice a week for 104 
weeks (NTP, 1982). The incidences of hepatocellular adenomas and carcinomas were dose-
related increased relative to the respective vehicle controls in both sexes. In female mice, the 
incidences of follicular adenomas of the thyroid gland were also dose-related elevated as well 
as lymphomas in the hematopoietic system and fibrosarcomas in the subcutaneous tissues. 
Furthermore, a dose-related increase in alveolar/bronchial adenomas and carcinomas was 
observed in male mice.  
Della Porta et al. performed two mouse studies in which the carcinogenic potential of TCDD 
has been characterized. In the first study, male and female C57Bl/6J x C3Hf mice were given 
2.5 or 5 µg TCDD/kg bw by gavage once a week for 52 weeks. Animals were observed until 
week 104. A dose-related increase of hepatocellular adenomas and carcinomas was 
determined in both sexes. The incidence of other tumour types was low and not related to 
TCDD treatment (Della Porta et al., 1987). In a second study, 10-days old male and female 
B6C3 and B6C mice were treated intraperitoneally once a week with 1, 3, or 60 µg TCDD/kg 
bw for five weeks. Animals were observed until 78 weeks of age. Hepatocellular carcinomas 
occurred dose-dependently in male B6C3 mice only, whereas hepatocellular adenomas were 
observed in both sexes in a dose-dependent manner. Thymic lymphomas were determined at 
60 µg/kg bw in both hybrids and sexes and at 30 µg/kg bw in all but female B6C3 mice (Della 
Porta et al., 1987). 
In a study performed by Wyde et al. TCDD was topically applied three times a week at doses 
of 5, 17, 36, 76, 121, 166, 355, or 760 ng TCDD/kg bw (equivalent to average daily doses of 
2.1, 7.3, 15, 33, 52, 71, 152, or 326 ng TCDD/kg bw/day) or by gavage five times a week at 
doses of 105, 450, or 1250 ng TCDD/kg body weight (equivalent to average daily doses of or 
0, 75, 321, and 893 ng TCDD/kg/day) for 26 weeks. The incidence of squamous cell 
papillomas and carcinomas has been dose-dependently increased compared to the respective 
vehicle control animals by dermal and oral administration of TCDD, but the response of 
TCDD-induced cutaneous papillomas was greater in mice by dermal route than by oral 
administration (Wyde et al., 2004).  
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TCDD acts as tumour promoter during the process of carcinogenesis, meaning that the 
administration of TCDD after the initial treatment with a known carcinogen (such as 
diethylnitrosamine (DEN), 7,12-dimethylbenz[a]anthracen (DMBA), or N-methyl-N9-nitro-
N-nitrosoguanidine (MNNG)) increases the incidences of multiple tumour types such as lung 
and liver adenomas, hepatoblastomas, or skin papillomas in mice. Furthermore, TCDD is also 
a tumour promoting agent in several rat strains (Knerr et al., 2006). 
In a tumour promotion study, 5 weeks old male C57BL/6, DBA/2, and B6D2F1 mice were 
initially given a single dose of 90 mg DEN/kg bw intraperitoneally. Three weeks later, 
TCDD-treatment started and mice received 0.05 µg TCDD/kg bw per week for 20 weeks. 
Animals did not receive any further chemical treatment and were observed until week 52 of 
age. TCDD increased the liver tumour incidences (all types of tumours) in B6D2F1 mice, 
relative to mice only treated with DEN. In the two other strains, liver tumour incidences were 
not significantly elevated. No significant increase in lung tumours was observed after TCDD 
treatment in all three mice strains. However, mice treated with DEN alone had a high 
incidence of lung tumours which excluded the determination of TCDD-mediated responses in 
the mouse lung (Beebe et al., 1995a). In a second study performed by Beebe et al. the tumour 
promoting potential of TCDD in the lung was investigated. 5 weeks old male Swiss mice 
were given either a single dose i. p. (1.6, 16, or 48 µg/kg bw) or repeated doses (0.05 µg/kg 
bw/week for 20 weeks) of TCDD following tumour initiation with N-nitrosodimethylamine 
(25 mg NDMA/kg bw). Animals were observed until 52 weeks of age. Alveolar-cell 
adenomas and carcinomas were observed in all mice and in all treatment groups. In addition, 
lung tumour multiplicity was significantly enhanced by low dose TCDD treatment (1.6 µg/kg 
bw) and repeated TCDD administration (0.05 µg/kg bw (x 20)) (Beebe et al., 1995b). 
In a study performed by Poland and co-workers, female haired and hairless HRS/J mice were 
initially treated with a single application of DMBA (200 nM) followed by applications of 20 
ng TCDD/mouse twice a week for eight weeks, followed by 50 ng TCDD/mouse for another 
17 weeks. Skin tumours (papillomas) were only determined in hairless HRS/J mice, but not in 
haired mice (Poland et al., 1982b). In a second study, female hairless HRS/J mice were given 
single applications of 5 µmol MNNG (N-methyl-N9-nitro-N-nitrosoguanidine) followed by 
doses of 3.75, 7.5, 15, or 30 ng TCDD/mouse twice a week for another 20 weeks. Skin 
tumour incidences were increased in all TCDD treatment groups compared to mice solely 
exposed to MNNG (Poland et al., 1982b).  
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II.1.5.2. TCDD in Humans 
 
Toxic and carcinogenic effects of TCDD are summarized in the following section. The 
presented toxicological data is mainly based on case reports and epidemiologic studies which 
describe effects linked to the exposure to materials contaminated with TCDD. Humans are 
exposed to high doses of TCDD mainly by occupation or accident. It has to be considered that 
humans are in particular not only exposed to TCDD, but also to other chemicals such as 
organic solvents or herbicides. However, toxic responses are dependent on exposure level and 
period. 
 
II.1.5.2.1 Toxicity 
 
In humans, the most commonly observed effect after acute and chronic exposure to TCDD 
(and other polychlorinated aromatic compounds) is chloracne (Jirasek et al., 1976) (ATSDR, 
1996). Chloracne is an acne-like condition which is distinguished by follicular hyperkeratosis 
(comedones) with or without cystsand papules (Crow, 1978) (Crow, 1981). Chloracne occurs 
on the face and neck, but may extend to other body regions (for example upper arms, back or 
chest). Other acute dermatologic responses associated with TCDD exposure include 
hypertrichosis and hyperpigmentation (Jirasek et al., 1976) (ATSDR, 1998). Acute hepatic 
effects reported in case or cohort studies implied liver cirrhosis, enlargement, or elevated 
hepatic enzyme levels (lactate dehydrogenase (LDH), aspartate transaminase (AST), and 
alanine transaminase (ALT)) (Reggiani et al., 1980) (Caramaschi et al., 1981) (Ideo et al., 
1982) (Ott et al., 1994) (ATSDR, 1998). Other acute responses observed in humans were 
elevated lipid levels (triglycerides and cholesterol), porphyria (porphyria cutea tarda and 
uroporphyria), impairment of the thyroid function, as well as renal, neurologic and pulmonary 
disorders (Suskind et al., 1984) (Zober et al., 1994) (ATSDR, 1998). 
Long-term effects examined in adults were again chloracne as well as increased serum 
gamma-glutamyl transferase concentrations (Calvert et al., 1992). In addition, exposure of 
humans to TCDD has been connected to other adverse effects such as cardiovascular disease, 
diabetes, and perturbation of the glucose metabolism, as well as reproductive and 
developmental disturbances and impairment of the immune system, but further research is 
required to confirm the correlation between these disorders and TCDD exposure (Moses et al., 
1984) (USAF, 1991) (Egeland et al. 1994) (Flesch-Janys et al. 1995) (Huisman et al., 1995) 
(Mocarelli et al. 1996) (Henriksen et al., 1997) (ATSDR, 1998) (U. S. EPA, 2006).  
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II.1.5.2.2 Carcinogenicity 
 
The International Agency for Research on Cancer (IARC) evaluated the evidence for the 
carcinogenic potential of TCDD in humans based on several studies in which humans were 
accidentally or occupationally exposed to high TCDD levels. Cohort studies of herbicide 
producers from the USA, the Netherlands, Germany, a cohort from Seveso (Italy), and a 
multicountry study from the IARC formed the basis for this evaluation. An increased risk for 
incidence of lung cancer, non-Hodgkin lymphomas, and soft-tissue sarcomas was reported, 
though the increase was mostly not significant compared to control groups. Other malignant 
neoplasms were also observed such as breast and rectal cancers as well as myeloid leukaemia 
in the Seveso cohort, bladder cancer and several types of myeloma in the US cohort, bladder 
and genital cancers in the Dutch cohort, several cancer types of the oral cavity and pharynx in 
the German cohort studies as well as kidney cancer in the IARC study (IARC, 1997) (IARC, 
2012). 
Altogether, an elevated risk for all cancers combined has been determined, though the 
increase was rather small with the relative risk being 1.4 in the subcohorts. It has to be taken 
into consideration that the general population is exposed to TCDD levels several magnitudes 
lower than the aforementioned industrial populations (IARC, 1997) (IARC, 2012).  
Based on the evidence from the animal carcinogenicity data as well as the carcinogenicity 
data from humans exposed to TCDD, the IARC classified TCDD as carcinogenic to humans 
(Group 1) in 1997 (IARC, 1997).  
 
II.1.5.3 DLCs and NDL-PCB 153 
 
The TEF concept is based on the fact that dioxin-like compounds share a common mechanism 
of action by binding to the AhR and evoke the same pattern of biological and toxic effects. 
They only differ in their respective potencies (expressed as the congener's TEF value). In the 
following chapter, studies are presented in which rodents were exposed to DLCs or NDL-
PCB 153 with emphasis on tumour promoting and carcinogenic effects.  
The induction of xenobiotic metabolizing enzymes as immediate response to the exposure to 
PCDD/Fs and PCBs in vivo and in vitro is an established biochemical response. The induction 
of CYP1A isoenzymes are the earliest indicators for exposure to DLCs (Vanden Heuvel et al., 
1993) (Nebert et al., 2000). Dioxin-like PCBs are classified into subgroups as a result of their 
respective CYP isoenzyme inducibility. For instance, PCB 77 and 126 are solely CYP1A 
inducers (TCDD-like inducers), whereas PCB 105, 118, and 156 are mixed-type congeners 
(phenobarbital (PB)- and TCDD-like inducers) which induce CYP1A and CYP2B isoenzymes 
levels (McFarland et al., 1989). NDL-PCB 153 has been characterized as a PB-type congener 
which only induces CYP2B enzyme activities (McFarland et al., 1989) (van Birgelen et al., 
1994) (Martin et al., 2010) (Roos, 2011). 
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Several lifetime (2-year) carcinogenicity studies in rats were conducted by the National 
Toxicology Program (NTP) during the last decades to evaluate carcinogenicity of dioxin-like 
compounds (amongst others TCDD, 4-PnCDF, PCB 118, PCB 126) and NDL-PCB 153 
(NTP, 2006a) (NTP, 2006b) (NTP, 2006c) (NTP, 2006d) (NTP, 2010).  
Female Harlan Sprague-Dawley rats were treated with TCDD (3, 10, 22, 46, or 100 ng/kg 
bw), 4-PnCDF (6, 20, 44, 92, or 200 ng/kg bw), PCB 126 (30, 100, 175, 300, 550, or 1000 
ng/kg bw), or PCB 118 (100, 220, 460, 1000, or 4600 µg/kg bw) by gavage 5 days a week for 
a period of 104 weeks. Histopathological findings after 104 weeks included non-neoplastic 
effects in various organs such as liver, lung, pancreas, adrenal cortex, thyroid gland, and 
kidney after treatment with all four compounds. Various types of neoplastic lesions were 
determined in different organs after exposure to the DLCs. Three specific neoplasms were 
reported in all four rat studies: cholangiocarcinomas and hepatocellular adenomas of the liver 
as well as cystic keratinizing epitheliomas (CKE) of the lung. A dose-dependent increase of 
tumour incidences was obtained for all aforementioned tumour types except for CKEs. 
Additionally, squamous cell carcinomas of the oral mucosa were determined in the TCDD,    
4-PnCDF, and PCB 126 carcinogenicity studies (NTP, 2006a) (NTP, 2006b) (NTP, 2006c) 
(NTP, 2010). 
Waern and co-workers conducted a study to evaluate the tumour promoting activity of          
1-PnCDD and 4-PnCDF compared to TCDD in rat. Partially hepatoectomized female 
Sprague-Dawley rats were initially treated with NDEA (30 mg/kg bw). After five weeks, rats 
were administered either vehicle, 1-PnCDD (0.088, 0.35, or 1.4 pg/kg bw), 4-PnCDF (0.16, 
0.64, or 2.6 pg/kg bw) or TCDD (0.044, 0.175, or 0.7 pg/kg bw) each week by subcutaneous 
injections for 20 weeks. Determined effects included the dose-dependent increase of the 
relative liver weight, thymus weight, EROD activity, and plasma protein levels (ALT and 
AST). The dose-dependent decrease of the hepatic vitamin A concentration was additionally 
determined. The dose-dependent increase of altered hepatic γ-glutamyltranspeptidase positive 
(GGT+) foci (per cent foci in liver and number of foci per liver) were examined in the rat 
liver, indicating that all three congeners are potent liver tumour promoters in female SD rats. 
The obtained results suggest that 1-PnCDD is as potent as TCDD, while 4-PnCDF reaches 
about ten per cent of the other two congeners' potencies (Waern et al., 1991).  
In a study performed by Hemming and co-workers, the tumour promoting potential of       
PCB 126 was investigated, while TCDD was used as established tumour promoting agent in 
the performed animal experiment. Partially hepatoectomized female rats were 
intraperitoneally treated with the tumour initiator nitrosoethylamine (30 mg/kg bw). After 5 
weeks, rats were given PCB 126 (0.316, 1, 3.16, or 10 µg PCB 126/kg bw) or TCDD (0.1, 
0.316, or 1 µg TCDD/kg bw) or vehicle by weekly subcutaneous injections for 20 weeks. 
Both substances induced a dose-related thymic atrophy which has been detected in a 
decreased relative thymus weight as well as the dose-dependent increase of the relative liver 
weight. Comparing the liver tumour activity of both chemicals, PCB 126 caused about 10 % 
of the TCDD`s tumour promoting activity in relation to the administered doses which was 
determined as the formation of γ-glutamyl-transpeptidase-positive altered hepatic foci in the 
rat liver (Hemming et al., 1995). 
 
Theoretical Background 
 
16 
 
PCB 153 belongs to the group of non dioxin-like PCBs and is commonly used as 
representative of NDL-PCBs in both in vivo and in vitro studies. Diverse toxic responses were 
determined for NDL-PCBs such as neurological and reproductive toxicity, as well as 
alterations in the endocrine system (Giesy et al., 1998). Additionally, Umannova and co-
workers showed that PCB 153 affects the intercellular communication in rat liver progenitor 
cells. PCB 153 led to the release of arachidonic acid in WB-F344 cells. Earlier studies 
performed by Marks et al. and Telliez et al. demonstrated that the interference in arachidonic 
acid signalling could conduce to toxic responses, including tumour promotion, of NDL-PCBs 
(Marks et al., 2000) (Telliez et al., 2006) (Umannova et al., 2008). 
The National Toxicology Program performed a 2-year study in female Sprague-Dawley rats 
in which PCB 153 was administered by gavage (10, 100, 300, 1000, or 3000 μg/kg bw) 5 days 
a week for 105 weeks. Increased incidences of non-neoplastic lesions of the liver, thyroid 
gland, ovary, oviduct, and uterus were reported. Non-neoplastic liver lesions included 
hepatocyte hypertrophy, diffuse fatty change, and bile duct hyperplasia which increased in a 
dose-dependent manner. Neoplastic lesions were not reported, but two cases of cholangioma 
of the liver were observed in the 1000 µg/kg bw dose group. Based on these findings the NTP 
working group concluded that there is only equivocal evidence of carcinogenic activity of 
PCB 153 in female SD rats (NTP, 2006d).  
The International Agency for Research on Cancer classified the entire group of 
polychlorinated biphenyls as probably carcinogenic to humans (Group 2A) in 1987 based on 
the available data at that time (IARC, 1987).  
In 1997, polychlorinated dibenzo-p-dioxins (other than 2,3,7,8-Tetrachlorodibenzo-p-dioxin) 
and polychlorinated dibenzofurans were categorized as Group 3 carcinogens by the IARC, 
implying that they are not classifiable as to their carcinogenicity in humans due to the 
published data up to this IARC evaluation (IARC, 1997). 
Since then, new data on carcinogenicity of DLCs was published resulting in the re-evaluation 
of two congeners (4-PnCDF and PCB 126) by the IARC in 2012. The International Agency 
for Research on Cancer classified 4-PnCDF and PCB 126 as carcinogenic to humans (Group 
1) based on the carcinogenic effects obtained in laboratory animals and because both 
congeners exhibit activities similar to TCDD for all stages of the mechanism which was 
reported for the TCDD-mediated carcinogenesis in humans (IARC, 2012). 
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II.2 Xenobiotic Metabolism 
 
Organisms are daily exposed to substances which cannot be used as either physiological 
component or as energy supply. These 'unusable' xenobiotics must be rapidly eliminated to 
prevent their accumulation in the organism. Main routes of elimination are the kidney and 
bile, whereas the lung and breast milk represent minor elimination routes. Usually, 
xenobiotics are highly lipophilic substances. Due to the lipophilic properties they can be 
easily resorbed in the gastrointestinal tract and would be only slowly eliminated from the 
organism. The xenobiotic metabolism is a multi-phase mechanism in which lipophilic 
substances are transformed into hydrophilic conjugates which subsequently can be more 
readily excreted. The liver is the major organ for biotransformation of xenobiotics in higher 
organisms, but also other tissues such as the gut, kidney, and lung express xenobiotic 
metabolizing enzymes (Forth et al., 2001) (Marquardt et al., 2004). 
The xenobiotic metabolism is distinguished into three consecutive phases: 
In phase I, functional groups (e.g. OH, SH, or NH2) are introduced into substrates, whereupon 
more hydrophilic metabolites are formed. Several enzymes participate in these 
functionalization reactions such as oxidoreductases of the cytochrome P450-dependent 
monooxygenases (CYPs), aldehyde dehydrogenases (ALDHs) flavin-dependent 
monooxygenases (FMOs), and monoamine oxidases (MAOs) (Forth et al., 2001) (Marquardt 
et al., 2004). 
In phase II, functionalized metabolites are conjugated with highly hydrophilic, negatively 
charged endogenous molecules (e.g. glutathione, glucuronic acid, and sulphate). Conjugation 
reactions are catalyzed by 'transferase' enzymes such as the glutathione S-transferase (GST), 
UDP-glucuronosyl-transferase (UGT) or sulfotransferases (ST) (Forth et al., 2001) 
(Marquardt et al., 2004). 
In phase III, the highly hydrophilic conjugated metabolites are transported out of the cell to 
the excretion organs. Active transport systems are the ABC transporter (ATP-binding 
cassette) as well as solute carrier transport systems such as the organic anion and cation 
transporters (OATs, OCTs) and organic anion transport polypeptides (OATPs) (Forth et al., 
2001) (Marquardt et al., 2004) (Omiecinski et al., 2011). 
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II.2.1 Cytochrome P450 Enzymes 
 
Cytochrome P450 monooxygenases play key roles in the oxidative phase I xenobiotic 
metabolism. CYPs catalyze a wide variety of functionalization reactions, among others the 
aliphatic and aromatic hydroxylation, epoxidation or N-oxidation. The number '450' is derived 
from the wavelength of the absorption maximum of the enzymes when they are in their 
reduced state and complexed with carbon monoxide. Cytochrome P450 enzymes are 
hemeproteins that consist of heme B as prosthetic group which is anchored to cysteine in the 
active centre of the enzyme. CYPs are located in the membrane of the endoplasmatic 
reticulum and are associated with the NADPH cytochromes P450 reductase to a reactive 
complex. The monooxygenase reaction additionally requires molecular oxygen, NADPH, and 
phospholipids, especially phosphatidylcholine. During the monooxygenase reaction one 
oxygen atom is transferred onto the substrate, and the other oxygen atom is reduced to water 
by proton absorption. The equation of the monooxygenase reaction is summarized in the 
following equation: 
 
RH + O2 + NADPH + H
+→ ROH + H2O + NADP
+
 
 
The scheme of the monooxygenase reaction is featured in Figure 2 below. The 
monooxygenase reaction is a multistep mechanism. The substrate (RH) binds to the resting 
enzyme which is in its ferric state. The NADPH-dependent cytochrome P450 reductase 
transfers a single electron to the heme iron (FeIII) of the cytochromes P450. Afterwards, the 
resulting oxidized heme iron (FeII) is able to bind molecular oxygen, whereupon the ferric 
superoxide complex is formed. The transfer of a second electron by the NADPH reductase 
results in the ferric peroxy anion, which is subsequently protonated resulting in the formation 
of the ferric hydroperoxo complex. The obtained ferric hydroperoxo intermediate is unstable 
and after the further protonation a porphyrin radical cation is formed. The ferryl intermediate 
reacts with the substrate, whereupon the hydroxylated metabolite is released. The enzyme 
returns in its resting ferric state after re-equilibration with water (de Montello et al., 2010). 
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Figure 2. Scheme of the monooxygenase reaction (according to de Montello et al., 2010). 
The heme group is featured as two solid blue bars with the iron (Fe) in between. 
The cysteine thiolate provided by the protein is represented as SCys.  
The abbreviation RH represents the substrate hydrocarbon and ROH is the hydroxylated product. 
 
According to the official international guidelines, cytochromes P450 enzymes are designated 
with the abbreviation CYP, followed the Arabic numeral for the family (> 40 % amino 
acididentity), then the Latin numeral for the subfamily (> 55 % amino acid identity), and the 
Arabic numeral for the isoenzyme (Danielson et al., 2002) (Forth et al., 2001).  
In mammals, 18 CYP gene families exist, and about 60 individual CYP genes can be found in 
the different species. CYPs are involved in various metabolic processes of in the metabolism 
of endogenous lipophilic compounds such as steroids, bile acids, eicosanoids, and retinoids 
but also play key roles in the metabolism of exogenous xenobiotics such as environmental 
pollutants, drugs, and carcinogens. The enzymes of the CYP1-4 families predominantly 
catalyze phase I reactions of xenobiotics (Honkakoski et al., 2000) (Forth et al., 2001) (Nebert 
et al., 2002). 
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II.2.1.1 CYP1 Family 
 
II.2.1.1.1 CYP1A1, CYP1A2, and CYP1B1  
 
In humans and rodents the CYP1 subfamily consists of CYP1A1, CYP1A2, and CYP1B1. 
They are able to catalyze the metabolic activation of polycyclic aromatic hydrocarbons, 
heterocyclic and aromatic arylamines, which leads to the formation of ultimate carcinogens 
(Murray et al., 1988) (Honkakoski et al., 2000). CYP1A1/Cyp1a1 and CYP1B1/Cyp1b1 are 
predominantly expressed in extrahepatic tissues such as lung, kidney, and placenta. CYP1A2 
is a liver-specific enzyme. The human CYP1A2 gene is constitutively expressed and 
contributes 13 % to the total CYP content in the human liver (Guengerich, 2010). In humans, 
CYP1A2 is only expressed in the adult liver (Xu et al., 2000). They are inducible by 
polyhalogenated aromatic hydrocarbons such as TCDD and related compounds as well as 
dioxin-like polychlorinated biphenyls. Ligands, such as TCDD, bind to the aryl hydrocarbon 
receptor (AhR) resulting in the activation of the AhR signalling pathway. Several studies 
performed in immortalized cell lines and primary cultured cells demonstrated that the 
inducibility of human hepatic CYP1A enzymes by DLCs was weaker than the inducibility of 
CYP1A enzymes in rat liver. However, distinctive differences in responsiveness based on 
donor health status or genetic background (polymorphism) were determined (Murray et al., 
1988) (Honkakoski et al., 2000) (Shimada et al., 2002a) (Silkworth et al., 2005) (Connor et 
al., 2006) (Budinsky et al., 2010) (Black et al., 2012). A recently published study by Forgacs 
and co-workers demonstrated that mouse primary hepatocytes are as sensitive as rat 
hepatocytes in terms of Cyp1a1 mRNA inducibility (Forgacs et al., 2013).  
 
II.2.1.1.2 CYP1 Induction by AhR Signalling Pathway 
 
The induction of CYP1 enzymes by exposure to dioxins and related compounds is regulated 
by the aryl hydrocarbon receptor (AhR) which belongs to the group of the basic helix-loop-
helix/Per-ARNT-Sim (bHLH/PAS) transcription factors. The mechanism of the AhR signal 
transduction is featured in Figure 3 below.  
In the absence of a ligand, the inactive AhR forms together with two molecules of HSP90 
(heat shock protein with 90 kDa), XAP2 (hepatitis b virus X-associated protein 2, also known 
as AhR-interacting protein), and p23 (23-kDa co-chaperone protein) a cytosolic multiprotein 
complex. Upon ligand binding to the AhR (such as TCDD), the AhR supposedly undergoes a 
conformational change resulting in the exposure of a nuclear localization sequence which 
leads in the following to the translocation of the complex into the nucleus. It is most likely 
that XAP2 dissociates from the AhR/ligand complex prior to the nuclear translocation of the 
activated AhR complex (Fujii-Kuriyama et al., 2010) (Denison et al., 2011). After the release 
of the co-chaperones HSP90 and p23, the AhR dimerizes with ARNT (AhR nuclear 
translocator), another member of the bHLH/PAS family.  
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Subsequently, the ligand/AhR/ARNT complex binds to its specific DNA recognition site, the 
so called xenobiotic responsive element (XRE) also known as dioxin responsive element 
(DRE) and recruits in the following coactivators such as CBP/p300, SCR-1, or 
NCoA2/GRIP1/TIF2 resulting in the transcription of CYP1A/Cyp1a genes and other AhR-
responsive genes (Denison et al., 2002) (Denison et al., 2003) (Mimura et al., 1999) (Fujii-
Kuriyama et al., 2010). Detailed information about the AhR and AhR-regulated target genes 
are featured in II.3 Aryl hydrocarbon receptor (AhR). 
 
 
Figure 3. Molecular mechanism of activation of Cyp1 by AhR (according to Denison et al., 2011). 
 
II.2.1.2 CYP2B Subfamily  
 
II.2.1.2.1 Mouse and Human CYP2B Isoenzymes 
 
In mouse, the CYP2B subfamily consists of the isoenzymes CYP2B9, CYP2B10, CYP2B13, 
CYP2B19, and CYP2B23. Cyp2b9 and Cyp2b10 are the major mouse Cyp2b genes. Cyp2b9 
is only expressed in the female mouse liver. Cyp2b10 is predominantly expressed in both 
mouse genders in extrahepatic tissues such as lung, duodenum, ileum, and colon (Renaud et 
al., 2011). In humans, the CYP2B family consists of the CYP2B6 gene and the CYP2B7P1 
pseudogene (Nelson et al., 2004). CYP2B6 is primarily expressed in liver, but also to a lesser 
degree in extrahepatic tissues such as kidney, brain, intestine, and lung. The relative 
expression levels of CYP2B6 range between 2 to 10 % of the total hepatic CYP content. The 
pseudogene CYP2B7P1 is only expressed in the human lung (Ding et al., 2003) (Wang et al., 
2003). CYP2B enzymes catalyze the hydroxylation of various xenobiotics and steroids. 
CYP2B isoforms are inducible by industrial solvents, barbiturates, antimycotics and NDL-
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PCBs. Phenobarbital (PB) belongs to the group of barbiturate and is the prototype of 
xenobiotics which specifically induce CYP2B isoforms by the constitutive androstane 
receptor signalling pathway (Honkakoski et al., 1996) (Kawamoto et al., 1999) (Honkakoski 
et al., 2000) (Cheng et al., 2005).  
 
II.2.1.2.2 CYP2B Induction by CAR Signalling Pathway 
 
The induction of cytochromes P450 2B isoforms is mediated by the constitutive androstane 
receptor (CAR). CAR belongs to the group of orphan nuclear receptors and is predominantly 
expressed in the liver where it primarily regulates the transcriptional up regulation of 
CYP2B/Cyp2b genes and to a lesser extent the CYP3A/Cyp3a transcription.  
In the absence of an inducer CAR is located in the cytoplasm associated with HSP90 (heat 
shock protein with 90 kDa) and CCRP (cytoplasmic CAR retention protein) forming a 
complex. CAR can be indirectly activated in the presence of an activator such as 
phenobarbital (Figure 4) or directly by ligand binding such as TCPOBOP (1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene) (Figure 5). Upon activation, the protein phosphatase 2A 
(PP2A) is recruited which leads to the dephosphorylation of CAR, resulting in the release of 
HSP90 and CCRP. In the following, CAR translocates into the nucleus where it forms a 
heterodimer with the retinoid X receptor (RXR). The CAR-RXR heterodimer binds with the 
aid of coactivators (such as the steroid receptor coactivator 1 (SRC-1) or glucocorticoid 
receptor-interacting protein 1 (GR-interacting protein 1)) to the PB-responsive enhancer 
module (PBREM) resulting in the transcription of CYP2B/Cyp2b isoforms (Kawamoto et al., 
1999) (Swales et al., 2004) (Hernandez et al., 2009) (Timsit et al., 2006). 
 
 
Figure 4. Molecular mechanism of activation of Cyp2b by CAR activators (according to Timsit et al., 2006). 
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Figure 5. Molecular mechanism of activation of Cyp2b by CAR ligands (according to Timsit et al., 2006). 
 
Furthermore, CAR additionally regulates genes that are involved in metabolic detoxification 
processes such as sulfotransferases, glucoronosyl transferases, glutathione S-transferases, and 
transporters as well as hepatic genes associated with the energy metabolism in presence of an 
CAR activator such as phenobarbital (Ueda et al., 2001) (Assem et al., 2004) (Konno et al., 
2008) (Gao et al., 2010). 
 
II.2.1.3 CYP3A Subfamily  
 
II.2.1.3.1 Mouse and Human CYP3A Isoenzymes 
 
The CYP3A subfamily consists of eight isoenzymes CYP3A11, CYP3A16, CYP3A25, 
CYP3A41, CYP3A44, CYP3A57, and CYP3A59 in the mouse. Mouse Cyp3a isoforms are 
primarily expressed in liver and intestine. Cyp3a41 and Cyp3a44 are predominatly expressed 
in livers of female mice (Sakuma et al., 2002). The human CYP3A subfamily consists of 
CYP3A4, CYP3A5, CYP3A7, and CYP3A43. As in mouse, they are predominantly expressed 
in the adult liver and intestine. In humans, the CYP3A isoenzymes contribute about 30 % to 
the total hepatic CYP content. CYP3As metabolize endogenous substrates such as steroids 
(testosterone and progesterone) and bile acids, but the subfamily plays also an important role 
in metabolization of xenobiotics. More than 50 % of all available prescriptive drugs are 
metabolized by CYP3A4 such as antimycotics, antibiotics, and contraceptive steroids as well 
as antidepressants. CYP3As are inducible by broad range of compounds such as antibiotics, 
polychlorinated biphenyls or organochloride pesticides, though species-dependent differences 
were determined. For instance rifampicin, which is amacrocyclic antibiotic, induces the 
expression of the human CYP3A4 and rabbit CYP3A6 to a high extent, but not the respective 
Cyp3a analogues in rat or mice (Goodwin et al., 2002) (Kliewer et al., 2002a) (Kliewer et al., 
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2002b). Besides the induction of CYP3A4, there is a broad range of CYP3A4 inhibitors such 
as erythromycin (an antibiotic), ketoconazole, and itraconazole (antimycotics) or components 
of the grapefruitjuice (such as bergamottin) (He et al., 1998) (Gibbs et al., 1999). Therefore, 
the transcriptional regulation of CYP3A isoenzymes is the centre of interest especially in 
relation to drug-drug interactions. 
 
II.2.1.3.2 CYP3A Induction by PXR Signalling Pathway 
 
The mechanism of the transcriptional up regulation of Cyp3a (analogous for CYP3A) by the 
pregnane X receptor (PXR) is featured in Figure 6. PXR belongs to the group of orphan 
nuclear receptors and is predominantly expressed in liver and intestine in humans, rats, mice, 
and rabbits (Wang et al., 2003). In the absence of an inducer PXR is located in the cytoplasma 
associated with HSP90 (heat shock protein with 90 kDa) and CCRP (cytoplasmic CAR 
retention protein) forming a complex. Upon ligand binding, such as rifampicin, to the PXR, 
HSP90 and CCRP are released and PXR translocates into the nucleus. In the nucleus, PXR 
forms a heterodimer with the retinoid X receptor (RXR). The PXR-RXR heterodimer binds 
with the aid of cofactors (such as SRC-1 or TIF2/GRIP1) to core promoter elements (DR3 and 
ER6 motifs in the CYP3A gene promoter, species-dependent) within the xenobiotic 
responsive enhancer module (XREM) resulting in the upstream of CYP3A/Cyp3a isoforms 
(Timsit et al., 2006). 
 
 
Figure 6. Molecular mechanism of activation of Cyp3a by PXR (according to Timsit et al., 2006). 
 
The pregnane X receptor furthermore regulates the induction of genes involved in xenobiotic 
metabolism such as members of the cytochrome 2B subfamily and cytochromes 2C subfamily 
as well as sulfotransferases and glucoronosyl transferases. CYP2B and CYP2C isoenzymes 
are induced to a lesser extent than CYP3A isoenzymes by PXR. Hepatic genes associated 
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with the energy metabolism as well as genes involved in the bile acid homeostasis are also 
regulated by PXR (Ueda et al., 2001) (Goodwin et al., 2002) (Assem et al., 2004) (Konno et 
al., 2008) (Gao et al., 2010) (Fahmi et al., 2010). 
 
II.3 Aryl hydrocarbon Receptor (AhR) 
 
In 1976, Poland and Glover identified in the hepatic cytosol of C57BL/6J mice a high affinity 
binding site that reversibly binds radiolabelled TCDD (Poland et al., 1976). This protein was 
characterized and later named aryl hydrocarbon receptor due to its specific binding affinity to 
aryl hydrocarbons (Poland et al., 1982a). 
The AhR is a member of the basic helix-loop-helix/Per-ARNT-Sim (bHLH/PAS) family of 
transcription factors which regulates ligand-dependently the expression of various genes 
(Denison et al., 2003). The AhR is expressed in many tissues. Highest levels were determined 
in lung, liver, thymus, and testes (Hahn et al., 1998). The scheme of the AhR protein, which 
outlines the different domains, is presented in Figure 7. 
The N-terminal functional domains are responsible for DNA binding (DBD), ligand binding 
(LBD), and the dimerization with ARNT. The C-terminal domain of the AhR protein is in 
charge of transactivation. In the bHLH region the AhR maintains a nuclear localization signal 
(NLS) and a nuclear export signal (NES). The AhR forms a cytosolic multiprotein complex 
consisting of two molecules HSP90, p23, and XAP2 in the absence of ligands. It is suggested 
that due to binding of HSP90 the nuclear localization signal (NLS) is disguised and the AhR 
retains in the cytoplasma. The import of the ligand-AhR complex is inhibited by 
phosphorylation of the NLS by protein kinase C. The NR box consists of a LxxLL motif (x 
stands for any amino acid) which is additionally responsible for the cytosolic retention of the 
AhR by protein-protein interactions (Kawajiri et al., 2007) (Fujii-Kuriyama et al., 2010). 
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Figure 7. Scheme of the functional domains (up) and the NH2-terminal functional domains (down)  
of the AhR (Kawajiri et al., 2007) 
Annotations:  A, B: weakly homologous repeated regions. 
                      Q: glutamine-rich transcription activation region 
                      DBD: DNA binding domain; LBD: ligand binding domain 
                      NLS: nuclear localization signal, NES: nuclear export signal,  
                      NR box: nuclear receptor box 
 
II.3.1 AhR Signal Transduction 
 
The AhR-mediated signalling pathway is featured in a previous chapter (II.2.1.1.2 CYP1 
induction by AhR signalling pathway). Ligand binding ultimately leads to the transcriptional 
up or down regulation of AhR-responsive genes. Classic AhR target genes are involved in 
phase I and phase II of biotransformation processes including cytochromes P450 family 1, 
UDP glucuronosyl transferases (UGT1A1, Ugt1a6/UGT1A6), NAD(P)H: quinine oxido-
reductase (Nqo1/NQO1), aldehyde dehydrogenase 3 family 1 (Aldh3a1/ALDH3A1), and 
glutathione S-transferase Ya (Gsta1/GSTA1) (Rowlands et al., 1997) (Nebert et al., 2000) 
(Schrenk et al., 1995). Besides those 'classic' AhR target genes involved in xenobiotic 
metabolism, the AhR regulates genes involved in cell cycle control and differentiation (Bock 
et al., 2006). A gene which negatively regulates the AhR activity is the aryl hydrocarbon 
receptor repressor. The AhRR is constitutively located in the nucleus where it forms a 
heterodimer with ARNT. The binding of the AhRR/ARNT heterodimer inhibits the 
transcriptional upstream of AhR-regulated genes. Furthermore, the AhR regulates the 
induction of the Ahrr/AHRR expression suggesting that the Ahrr/AHRR forms a negative 
feedback loop with the AhR (Evans et al., 2008) (Fujii-Kuriyama et al., 2010). 
However, the transcriptional response due to ligand binding is species-, tissue-, and cell type-
specific (Denison et al., 2003). Sun et al. developed a comparative computational approach in 
which the putative XREs of human, mouse, and rat were compared. Based on the analysis of 
XREs, there is striking evidence that the XREs are not well conserved across species, which 
could be the explanation for the species-dependent differences in gene expression (Sun et al., 
2004). Recent microarray studies confirmed the earlier findings of Sun and co-workers. The 
analysis of the TCDD-altered gene expression in different species led to conclusion that the 
differential gene expression is not conserved between species which most likely contributes to 
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the species-specific responses and compound sensitivity (Dere et al., 2011) (Forgacs et al., 
2013).  
Despite the classical genomic mechanism of AhR signal transduction, the AhR interact in a 
variety of intracellular signalling pathways including several protein kinases (receptor 
tyrosine kinases, mitogen-activated protein kinases, c-Src kinases) and phosphatases 
(phosphodiesterase 2A) as well as the ligand/AhR interplay affects the calcium signalling 
pathways. Furthermore the crosstalk between the AhR and other ligand-activated transcription 
factors (among others estrogen receptor, glucocorticoid receptor, retinoic acid receptor, 
epidermal growth factor receptor) has been shown (Matthews et al., 2006) (Beischlag et al., 
2008) (Haarmann-Stemmann et al., 2009) (Denison et al., 2011).  
 
II.3.2 Physiological Role of the AhR 
 
During the last two decades, the endogenous functions of the AhR in normal physiology and 
development were elucidated by the generation of mice with a mutation in the Ahr gene locus 
(Schmidt et al., 1996). Due to the knockout of the Ahr gene, mice do not express the AhR 
protein and classic AhR target genes (e.g. Cyp1a1 or Cyp1a2) are not inducible by treatment 
with TCDD. Ahr knockout mice are resistent to the TCDD-mediated toxic effects which led to 
the conclusion that the AhR mediates most, if not all, biological and toxic effects of TCDD 
(Schmidt et al., 1996) (Denison et al., 2002) (Denison et al., 2003).  
In the first few weeks after birth, Ahr knockout mice exhibited a slower growth rate and 
decreased body weights compared to Ahr wild-type mice (Schmidt et al., 1996) (Mimura et 
al., 2003). Furthermore, Ahr knockout mice display reduced liver weights compared to their 
wild-type littermates (Schmidt et al., 1996). The decreased liver weight is directly related to 
the reduction of hepatocyte size resulting from a portosystemic shunting in Ahr-/- mice. The 
portosystemic shunting is based on an open ductus venosus (Lahvis et al., 2000). In addition 
to the vascular defects in liver, several other abnormalities in the liver of Ahr knockout mice 
were detected such as fatty metamorphosis, portal fibrosis, and prolonged extramedullary 
hematopoesis (Schmidt et al., 1996) (Fernandez-Salguero et al., 1996). Liver fibrosis in Ahr 
knockout mice is most likely due to hepatic accumulation of retinoic acid as a result of the 
suppressed retinoic acid metabolism (Andreola et al., 2004).  
Furthermore, the AhR seems to play a crucial role in the reproductive system. Female Ahr 
knockout mice exhibit infertility. This effect is most likely based on failures of follicular 
maturation and ovulation, probably due to insufficient synthesis of estradiol in the follicles of 
female knockout mice (Schmidt et al., 1996) (Mimura et al., 1997) (Baba et al., 2005).  
There are indications that the AhR also plays a role in the immune system. Ahr knockout mice 
display reduced amounts of lymphocytes in the spleen compared to Ahr wildtype mice. This 
effect subsequently resulted in the decrease of splenic T and B cells. This disturbance in the 
peripheral immune system is probably the reason for premature deaths of newborns and older 
animals as a consequence of opportunistic bacterial infections.  
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Other clinical findings in aged Ahr knockout mice (eight months and older) included 
hypertrophy and fibrosis in the heart, hyperplasia and fibrosis in the skin, hyperplasia in the 
gastric pylorus, and extreme calcification in the uterus (Fernandez-Salguero et al., 1997) 
(Gonzalez et al., 1998). 
As outlined above, the AhR plays an essential role in organ and cell physiology and 
homeostasis which supports the theory that the AhR is able to translocate into the nucleus due 
to endogenous signalling (Denison et al., 2003). 
 
II.3.3 Types of AhR Ligands 
 
A broad range of structurally diverse chemicals can bind to the AhR which leads in the 
following to its activation. Basically, ligands can be divided into two major categories, those 
that bind with 'high affinity' and those that bind only with 'low affinity' to the AhR. The 
majority of 'high affinity' ligands are aromatic, planar, and hydrophobic compounds such as 
halogenated aromatic hydrocarbons (polychlorinated dibenzo-p-dioxins, dibenzofurans, and 
dioxin-like biphenyls) and polycyclic aromatic hydrocarbons (benzo[a]pyrene, 3-
methylcholanthrene) (Hankinson, 1995). Recently, a new group of AhR ligands and inducers 
was identified which differs in structure and physicochemical properties from the 'classical' 
AhR ligands. Compared to the 'high affinity' AhR ligand TCDD, the non-classical synthetic 
AhR ligands/agonists are rather weak CYP1A1 inducers and 'low affinity' AhR ligands. 
Members of the non-classical synthetic AhR ligands and inducers include thiabendazole 
(fungicide and parasiticide), omeprazole (agastric proton pump inhibitor), as well as the 
hepatoprotective agent YH439 (Upadhyay et al., 1980) (Quattrochi et al., 1993) (Lee et al., 
1996) (Denison et al., 2002) (Denison et al., 2003) (Igaul-Adell et al., 2004) (Hong et al., 
2005). 
Humans and animals are mainly exposed to AhR ligands through their diet. Despite the 
synthetic AhR ligands, a great variety of natural AhR ligands has been identified in 
vegetables, fruits, teas, and herbs. The AhR signalling pathway can be activated and/or 
inhibited by those naturally occurring dietary substances. Natural AhR ligands include diverse 
dietary plant compounds such as indole-3-carbinol (I3C), curcumin, carotinoids, flavonoids, 
and polyphenols. Naturally occurring dietary compounds are weak AhR ligands, but can be 
converted into relatively potent AhR ligands. For example I3C is a natural AhR ligand which 
is found in vegetables of the Brassica genus such as cabbage, cauliflower, and Brussel 
sprouts. I3C itself is a weak AhR ligand compared to its generated acid condensation products 
identified after administration of I3C to male Sprague-Dawley rats by oral gavage in the 
acidic environment of the gastro intestinal tract. ICZ (indolo[3,2-b]carbazole) is the most 
potent AhR agonist of the I3C acid condensation products. Bjeldanes and co-workers 
demonstrated by the use of a competitive binding assay thatICZ binds with a much 
higheraffinity compared to I3C to the AhR. The Kd-value of ICZ is 1.9 x 10
-9 M, I3C has a 
Kd-value of 2.5 x 10
-5 M, and the Kd-value of TCDD is 7.1 x 10
-12 M in Hepa1c1c7 cells 
(Bjeldanes et al., 1991) (Ciolino et al., 1998) (Denison et al., 2003) (Gouédard et al., 2004) 
(Jeuken et al., 2003). 
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As mentioned in the previous chapter, several studies in Ahr knockout mice indicate that the 
AhR is responsible for normal development, physiological function, and homeostasis, 
suggesting the existence of endogenous ligands which bind to the AhR. Furthermore, several 
in vitro and in vivo experiments demonstrated the presence of the activated AhR in the 
nucleus in absence of exogenous ligands which also supports this theory (Abbott et al., 1994) 
(Chang et al., 1998) (Singh et al., 1996) (Fernandez-Salguero et al., 1996) (Tijet et al., 2005) 
(Boutros et al., 2009). 
Divers endogenous compounds which regulate the AhR activity have been identified such as 
indoles, tetrapyroles, or arachidonic acid metabolites. However, a single endogenous ligand 
with high affinity for the AhR that mediates its endogenous functions has not been identified 
up to the present day (Denison et al., 2002) (Denison et al., 2003) (Nguyen et al., 2008) 
(Denison et al., 2011).  
The vast majority of AhR ligands are generated from tryptophan by different biological and 
physicochemical processes. For instance, photooxidation of tryptophan leads to the formation 
of endogenous AhR ligands such as FICZ (6-formylindolo[3,2-b]carbazole). FICZ possesses 
structural similarities to the indole-derived high affinity AhR ligand ICZ. Various other 
examples for the formation of tryptophan metabolites upon light exposure, which can bind to 
the AhR, activate it, and regulate the AhR-dependent gene expression, have been described 
(Rannug et al., 1987) (Rannug et al., 1995) (Denison et al., 2003) (Diani-Moore et al., 2006) 
(Haarmann-Stemmann et al., 2009). The tryptophan catabolites kynurenine and kynurenic 
acidwere also identified as endogenous ligands of the human and murine AhR (Denison et al., 
2003) (DiNatale et al., 2010) (Opitz et al., 2011). 
A large variety of endogenous AhR activators/ligands were identified, though their 
physiological role and contribution to the abnormalities of the Ahr knockout mice is still 
uncertain, which therefore trigger the need for further investigations. 
Research Problem and Objectives 
 
30 
 
III Research Problem and Objectives 
 
Polychlorinated dioxins, furans, and biphenyls are widespread persistent environmental 
pollutants which accumulate in the feed and food chain (Poland et al., 1982a). Exposure to 
dioxin-like compounds results in a myriad of biochemical and toxic responses including 
dermal toxicity, immunotoxicity, hepatotoxicity and carcinogenicity as well as adverse effects 
on reproduction, development, and the endocrine system (Holsapple et al., 1991) (Birnbaum, 
1994) (Schmidt et al., 1996) (Fernandez-Salguero et al., 1996) (Gonzalez et al., 1998) (Nebert 
et al., 2000) (Schrenk et al., 1995) (IARC, 1997) (Kerkvliet et al., 2002). Most, if not all, toxic 
and biological responses elicited by dioxin-like compounds in different species are mediated 
by the aryl hydrocarbon receptor. Since DLCs occur as complex mixtures in the human diet, 
the toxic equivalency (TEQ) concept was developed to assess human exposure and risk 
(NATO, 1988) (Ahlborg et al., 1991) (Denison et al., 2011). Current human TEQs have been 
mainly derived from in vivo animal experiments resulting in so called 'intake' toxic 
equivalency factors (TEFs). These 'intake' TEFs are commonly used to calculate human TEQs 
for blood and tissues, although only insufficient data is currently available to confirm if the 
use of 'intake' TEFs for calculation of the human risk is appropriate or not (van den Berg et 
al., 2006).  
Therefore, the SYSTEQ project was initiated which primarily focused on the development, 
validation, and establishment of human systemic TEFs (relative effect potencies REPs) and 
TEQs as biomarkers for dioxin-like compounds. The potency of a compound relative to 
TCDD gained by a single in vivo or in vitro study is featured as REP value (van den Berg et 
al., 1998). Additionally, in vitro TEFs (REPs) from human and rodent experimental cellular 
models from different endpoints will be derived for a large group of PCDD/Fs and DL-PCBs 
which will be compared to the 'systemic' situation. The European Commission funded the 
project under the 7th framework programme. Further major objectives of the SYSTEQ project 
included the search for novel quantifiable biomarkers for AhR activation as well as the 
identification of differences between human and experimental species. Our research 
objectives within the SYSTEQ project were divided into several subprojects, as presented in 
the following passage. 
In two mouse in vivo studies (mouse 3-day and 14-day study), the influence of selected 
dioxin-like compounds (TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126, and PCB 156) as 
well as non dioxin-like PCB 153 on the hepatic xenobiotic metabolism should be determined 
after a single dose of each test compound. Hence, three cytochrome P450s involved in phase I 
in the xenobiotic metabolism were selected Cyp1a1, Cyp2b10, and Cyp3a44. Their respective 
hepatic mRNA expression was analyzed by quantitative real-time PCR. The induction of 
CYP1A, CYP2B, and CYP3A is associated with the activation of three different receptor-
mediated signalling pathways, i.e. AhR, CAR, and PXR, respectively.  
In order to find, establish, and implement novel biomarkers for AhR activation due to 
exposure to dioxin-like compounds, a microarray study was performed using liver samples 
from mouse 3-day study (TCDD as reference compound for DLCs and as negative control 
NDL-PCB 153). The alterations in hepatic gene expression by TCDD and NDL-PCB 153 
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should provide further information about AhR-dependent and AhR-independent mechanisms 
in mouse. 
Further major objectives included in vitro experiments performed in human hepatocellular 
carcinoma cell line HepG2 and freshly isolated primary human hepatocytes. Primary human 
liver cells represent the closest in vitro model to the human liver (Hewitt et al., 2007). HepG2 
cells were applied in the present work to characterize possible similarities and differences 
between tumour-derived immortalized cells and non-transformed cells because HepG2 cells 
are frequently used to assess biological responses of DL-compounds in in vitro studies (Lipp 
et al., 1992) (Zeiger et al., 2001) (Kim et al., 2009) (Dere et al., 2011). Since pronounced 
differences in TEFs, e.g. relative effect potencies (REPs), were determined in different animal 
species (Haws et al., 2006), the use of human in vitro models, especially primary human 
hepatocytes, should provide essential datasets which function as a basis for novel human in 
vitro TEFs.  
As preliminary test method, a cytotocixity assay, i.e. the Alamar Blue assay, was performed 
with all experimentally applied substances in both human cell models to exclude cytotoxic 
effects of test compounds in the subsequent experimental approaches. 
The induction of CYP1A1 is the most sensitive marker for exposure to dioxins and dioxin-
like compounds (Vanden Heuvel et al., 1993) (Drahushuk et al., 1996) (Behnisch et al., 2002) 
and was used in the present work to assess the relative effect potencies and efficencies of the 
selected compounds. Therefore, the catalytic CYP1A1 activity was measured after exposure 
to TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126, and PCB 156 as well as NDL-PCB 153 
in both human cell models. These five DL-compounds are with about 90 % the major 
contributors to the total dioxin-like activity in the human diet (Liem et al., 2000). Despite the 
concentration-dependent changes in the catalytic CYP1A1 activity of the seven core 
congeners, CYP1A1 and CYP1B1 mRNA levels were additionally determined in HepG2 cells 
by RT-PCR. Concentration-dependent effects on the CYP1A1 catalytic activity were also 
determined for seven further DL-compounds (1,6-HxCDD, 1,4,6-HpCDD, TCDF, 1,4-
HxCDF, 1,4,6-HxCDF, PCB 77, and PCB 105) by EROD assay as well as CYP1A1 protein 
levels were assessed after exposure to further PCDD/Fs congeners in HepG2 cells by Western 
blot analysis. 
Gene expression alterations elicited by DL-compounds in both human liver models ought to 
be characterized in two performed microarray experiments. In the first experimental 
toxicogenomic approach, altered gene expression in primary human hepatocytes of selected 
DL-compounds (TCDD, 1-PnCDD, 4-PnCDF, and PCB 126) and NDL-PCB 153 ought to be 
analyzed, and if possible, affected metabolic processes and pathways ought to be 
characterized. The emphasis of this experiment was to outline commonly regulated genes by 
DLCs to identify novel quantifiable biomarkers for DL-compounds. 
In the second performed microarray experiment, TCDD- and PCB 153-elicited gene 
expression alterations in HepG2 cells were determined and afterwards compared to the 
obtained findings for these two compounds in primary human hepatocytes. Additionally, the 
TCDD-altered gene expression data obtained from the microarray experiments (hHeps, 
HepG2, and mouse 3-day study) was used to select AhR target genes in search for novel 
quantifiable biomarkers for DL-compounds. Subsequently, the mRNA expression levels of 
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chosen AhR target genes were verified by the use of RT-PCR analysis. Based on these 
findings, the role of individual AhR target genes as novel quantifiable biomarkers ought to be 
critically discussed.  
Another major research objective within the present work focused on the physiological role of 
the AhR and the AhR-mediated biological effects elicited by TCDD in the mouse liver. It has 
been postulated that the AhR mediates most, if not all, biological and toxic responses of 
TCDD and related compounds. Furthermore, various studies demonstrated that the AhR is 
responsible for normal development, physiological function, and homeostasis in absence of an 
exogenous ligand (Schmidt et al., 1996) (Mimura et al., 1997) (Fernandez-Salguero et al., 
1996) (Denison et al., 2002) (Mimura et al., 2003). A research project was initiated which 
focused on the investigation of AhR-dependent and AhR-independent responses in the livers 
of Ahr knockout and Ahr wild-type mice.The project was funded by the 'Stiftung Rheinland-
Pfalz für Innovation'. 
In a first experimental approach, blood plasma metabolites of Ahr knockout and wild-type 
mice should be identified and genotype-specific differences in metabolite spectrum ought to 
be characterized. Hence, an extraction method for blood plasma metabolites was established 
and a HPLC-ESI-MS/MS program setup was developed and validated in the present work.  
AhR-dependent and -independent effects of TCDD on livers of Ahr knockout and wild-type 
mice were assessed in vivo after administration of a single dose of TCDD.  
The mouse liver was the target tissue and primary topic of interest in the subsequently 
performed experiments. TCDD and related compounds induce several xenobiotic 
metabolizing enzymes in the liver. Therefore, the hepatic mRNA expression levels of selected 
cytochrome P450s (Cyp1a1, Cyp1a2, Cyp2b10, and Cyp3a44) were determined by RT-PCR. 
Additionally, TCDD-induced changes in hepatic gene expression in Ahr knockout and wild-
type mice were assessed by microarray analysis whereupon metabolic processes and pathways 
ought to be identified. 
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IV Results and Discussion 
 
IV.1 in vivo Experiments Part I 
 
IV.1.1 Mouse Studies I and II 
 
The EU-project SYSTEQ aimed to develop, validate, and establish human systemic TEFs and 
TEQs as indicators of toxicity for dioxin-like compounds (DLCs). The best known AhR-
regulated marker for dioxin exposure is the induction of the cytochrome isoenzymes, i.e. 
CYP1A1, 1A2, and 1B1. The in vivo studies presented within this work focused on the search 
and establishment of a novel quantifiable biomarker for DL-compounds as well as analyzing 
the AhR-dependent and AhR-independent effects due to DLC treatment. 
The 3-day and 14-day mouse studies were performed within the framework of the European 
project SYSTEQ at the Department of Toxicology, Institute for Risk Assessment Sciences 
(IRAS) at Utrecht University, the Netherlands, under supervision of Prof. Dr. Martin van den 
Berg. The dioxin-like compounds analyzed in the mouse 3-day and 14-day study (TCDD,      
1-PnCDD, 4-PnCDF, PCB 118, PCB 126, and PCB 156) contribute about 90 % to the dioxin-
like activity in the human food chain (Liem et al., 2000). The non dioxin-like PCB 153 is used 
as negative control in the animal experiments. In both acute toxicity studies, mice received a 
single dose by gavage, only the post-treatment time varied. Blood and tissues were shipped to 
the different European project partners. In the present work the mouse liver is the centre of 
interest. Detailed information about the preparation of mouse livers is given in chapter six (VI 
Methods). 
 
IV.1.1.1 Study I - Mouse 3-day Study 
 
In the 3-day study, adult female C57BL/6 mice were exposed to seven selected compounds 
(TCDD, 1-PnCDD, 4-PnCDF, PCB 126, PCB 118, PCB 153, and PCB 156). The examined 
dose levels used in mouse study I are featured in the table below. Each dose group consisted 
of six female C57BL/6 mice. Total RNA was isolated using Qiagen RNeasy Mini Kit 
(Qiagen, Hilden) according to the manufacturer’s instruction. The RNA concentration was 
spectrophotometrically determined at an absorption wavelength of 260 and 280 nm via 
NanoDrop (Peqlab, Erlangen). The RNA purity and integrity was verified using 2100 
Bioanalyzer (Agilent Technologies, Waldbronn) and associated RNA 6000 Pico LabChip Kit 
(VI Methods). Subsequently isolated RNA was used for microarray analysis (TCDD or PCB 
153-treated mice) or transcribed into cDNA to perform gene expression analysis by RT-PCR. 
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Table 3. Overview mouse study I - 3-day (dose levels). 
 
Study Treatment Single dose (µg/kg bw) TEF (WHO, 2005) 
3-day 
TCDD 0 0.5 2.5 10  1.0 
1-PnCDD 0 0.5 2.5 10  1.0 
4-PnCDF 0 5 25 100  0.3 
PCB 126 0 5 25 100  0.1 
PCB 118 0    150000 0.00003 
PCB 153 0    150000 - 
PCB 156 0    150000 0.00003 
 
IV.1.1.1.1 Gene Expression Analysis by RT-PCR 
 
The mRNA expression levels of genes, which play key roles in xenobiotic metabolism, were 
measured in the following RT-PCR experiments. Therefore, genes were selected for assessing 
the activation of different receptor-mediated signalling pathways (AhR, CAR, and PXR). The 
induction of Cyp1a1 implicates that the respective test compound presumly has bound to the 
AhR and actives the AhR signalling pathway. Cyp2b10 represents the murine analog to the 
human CYP2B6 which is primarily CAR-regulated, whereas Cyp3a44 was chosen to analyze 
the possible ligand binding to the PXR due to compound exposure. Complementary DNA 
(cDNA) was synthesized using iScript cDNA Synthesis Kit (BioRad). 1 µl of the transcribed 
cDNA was used to perform each RT-PCR. The Cyp1a1, Cyp2b10, and Cyp3a44 mRNA 
expression was normalized using 36b4 as housekeeping gene and calculated relative to the 
expression in the corresponding vehicle control (0 µg/kg bw). 
TCDD-treated animals revealed no change in gene expression of Cyp2b10 and Cyp3a44 as 
expected, whereas a dose-dependent increase of Cyp1a1 expression was determined in the 
present study as shown in Figure 8. A statistically significant induction of Cyp1a1 mRNA 
expression was measured starting from 2.5 µg/kg bw which resulted in a 1382.08 ± 378.28-
fold induction. After the treatment of female C57BL/6 mice with 1-PnCDD in the chosen four 
dose levels, there was no statistically significant increase in gene expression, neither with 
Cyp2b10 nor with Cyp3a44. A dose-dependent induction of Cyp1a1 mRNA expression by    
1-PnCDD was measured in mouse study I. A statistically highly significant induction of 
Cyp1a1 was detected after treatment with 2.5 µg/kg bw (970.24 ± 443.08) and 10 µg/kg bw   
1-PnCDD (1860.10 ± 750.21) as featured in Figure 8 on the right-hand side.  
 
Results and Discussion 
 
35 
 
  
 
Figure 8. Real-time PCR ratios of female mice treated with TCDD (left) or 1-PnCDD (right) - mouse study I. 
36b4 served as housekeeping gene, compound as one-time administered dose. 
Data represent means + SD of six different adult female mice, normalized to corresponding  
vehicle control. One-way analysis of variance (ANOVA) with Dunnett’s post-test ,**= p ≤0.01. 
 
A dose-dependent increase in Cyp1a1 mRNA expression was also determined after treatment 
with 4-PnCDF (Figure 9) as shown before for TCDD and 1-PnCDD, however, accomplished 
with higher dose levels. A statistically highly significant Cyp1a1 induction was achieved with 
a dosage of ≥ 25 µg/kg bw, while no alterations of the Cyp2b10 and Cyp3a44 mRNA gene 
expression were examined. Six female C57BL/6 mice were also exposed to PCB 126 in four 
dose level groups from 0-100 µg/kg bw (Figure 9). A dose-dependent increase in Cyp1a1 
mRNA was obtained for the DL-PCB resulting in a statistically highly significant induction 
after exposure to ≥ 25 PCB 126 µg/kg bw. Gene expression of the CAR-regulated Cyp2b10 
was not statistically significantly changed in the selected doses. A slight but statistically 
significant increase of Cyp3a44 mRNA levels was determined after treatment with 25 µg 
PCB 126/kg bw which led to a fold-change of 3.14 ± 1.49. No dose-dependent increase was 
observed in mouse study I. However, the Cyp3a44 fold induction of one animal was two 
times higher than that of the other five animals. 
Figure 10 displays the results of the RT-PCR analysis of PCB 118, PCB 156, and PCB 153. 
Vehicle control animals were compared to animals which received a single dose of 150000 
µg/kg bw of the respective test compound. Treatment with PCB 118 resulted in a high 
induction of Cyp1a1 mRNA expression (fold-change 1539.50 ± 427.56), which was 
statistically extremely significant (p ≤ 0.001). Cyp2b10 mRNA expression was also induced, 
but about seventy-times lower than the Cyp1a1 mRNA levels (20.95 ± 4.80). The Cyp3a44 
mRNA levels were neither up nor down regulated by the selected dosage. As pictured in 
Figure 10, PCB 153, which belongs to the family of non dioxin-like biphenyls, led to the 
induction of Cyp2b10 mRNA expression (67.06 ± 28.19). Hepatic Cyp1a1 and Cyp3a44 
mRNA levels were not significantly altered after the treatment with 150000 µg/kg bw PCB 
153. Cyp1a1, Cyp2b10, and Cyp3a44 mRNA levels were all significantly induced in mouse 
liver samples after treatment with PCB 156 as shown in Figure 10. The Cyp1a1 mRNA 
expression achieved the highest induction with 2599.23 ± 1065.00-fold over control, followed 
by Cyp2b10 (88.91 ± 26.93-fold), and Cyp3a44 (4.69 ± 4.27-fold). 
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Figure 9. Real-time PCR ratios of female mice treated with 4-PnCDF (left) or PCB 126 (right) - mouse study I. 
36b4 served as housekeeping gene, compound as one-time administered dose. 
Data represent means + SD of six different adult female mice, normalized to corresponding  
vehicle control. One-way analysis of variance (ANOVA) with Dunnett’s post-test ,**= p ≤0.01. 
 
  
 
 
Figure 10. Real-time PCR ratios of female mice treated with PCB 118 (up left), PCB 156 (up right), or  
PCB 153 (down middle) - mouse study I. 
36b4 served as housekeeping gene, compound as one-time administered dose. 
Data represent means + SD of six different adult female mice, normalized to corresponding  
vehicle control. One-way analysis of variance (ANOVA) with Dunnett’s post-test,*= p ≤0.05, 
**= p ≤0.01. 
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In summary, the mouse 3-day acute toxicity study after single dose administration of the 
selected compounds revealed the dose-dependent AhR-mediated increase of Cyp1a1 mRNA 
expression after treatment with TCDD, 1-PnCDD, 4-PnCDF, and PCB 126. Neither CAR, nor 
PXR were activated due to treatment with the four test compounds. In case of the 
polychlorinated biphenyls, the administered high dosages of PCB 118 and PCB156 led to the 
activation of AhR and CAR, though the Cyp1a1 mRNA expression was 73-fold and 23-fold 
higher compared to the Cyp2b10 mRNA expression. Furthermore, the hepatic Cyp3a44 
mRNA expression was also significantly increased in case of PCB 156 although the high 
standard deviation has to be taken into consideration. Treatment of female C57BL/6 mice 
with PCB 153 only resulted in the induction of Cyp2b10 mRNA levels leading to the 
suggestion that only CAR was activated. 
 
IV.1.1.1.2 Microarray Analysis - Mouse Study I 
 
Microarray analysis is a powerful tool to examine a large number of genes simultaneously. 
Application of this new molecular biological technique could reveal further information about 
gene expression after exposure to dioxin-like compounds. In a 3-day study, six female 
C57BL/6 mice received a single dose of either TCDD (25 µg/kg bw) or non dioxin-like PCB 
153 (150000 µg/kg bw) by gavage, whereas vehicle control animals were treated with corn 
oil.  
 
Table 4. Overview dose levels mouse 3-day study for microarray analysis. 
 
Study Treatment Single dose (µg/kg bw) TEF (WHO, 2005) 
3-day 
TCDD 0 25 1.0 
PCB 153 0 150000 - 
 
At day three animals were sacrificed by CO2/O2 asphyxiation, tissues including mouse liver 
was extracted surgically and immediately frozen in liquid nitrogen and stored at -80 °C until 
usage. Total RNA was isolated using Qiagen RNeasy Mini Kit (Qiagen, Hilden). RNA 
concentrations were determined via NanoDrop (Peqlab, Erlangen). RNA purities were 
verified by Agilent 2100 Bioanalyzer and associated RNA 6000 Pico LabChip kit (Agilent 
Technologies, Waldbronn). Afterwards, Agilent's Two-Color Microarray-based Expression 
Analysis according to Agilent's Low Input Quick Amp Labeling Kit was performed using 
cyanine 3- and cyanine 5-labelled targets to measure expression in experimental and control 
samples. Vehicle control samples and compound-treated samples were stained oppositionally. 
100 ng per sample was selected as starting RNA concentration. Whole Mouse Genome Oligo 
Microarray 4x44K (Agilent Technologie, Waldbronn) was used to measure altered genes 
between control groups (treated with corn oil) and compound-treated mice. Further 
information about the experimental procedures and conditions as well as data processing and 
statistical analysis are presented in chapter six (VI Methods). 
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Further studies, not presented in this work, included microarray analysis of mouse liver 
samples after treatment with 1-PnCDD (25 µg/kg bw), 4-PnCDF (250 µg/kg bw), PCB 118 
(150000 µg/kg bw), PCB 126 (250 µg/kg bw), and PCB 156 (150000 µg/kg bw). Microarray 
data derived from all seven core congeners was summarized in one single data file. 
Microarray results were filtered by selected cut-off values for the signal intensity A ≥ 7, the 
log2 fold-change ≥ 1 or ≤ -1, and the p-value ≤ 0.05.  
 
 
 
Figure 11. Microarray results of mouse study I - 3-day study - mouse study I. 
Selected parameters: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05. 
 
                             
 
Figure 12. Microarray results of mouse study I featured as Venn diagram. 
Up and down regulated genes in livers of female C57BL/6 mice after treatment with  
TCDD (25 µg/kg bw) or PCB 153 (150000 µg/kg bw). 
Selected parameters: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05. 
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IV.1.1.1.2.1 Microarray Results - TCDD Treatment 
 
After treatment with TCDD (25 µg/kg bw) 125 unique genes were up and 95 genes down 
regulated in female mouse liver (Figure 11). A complete list of all significantly up and down 
regulated genes is attached to the present work (Tables 81 and 82). 
An overview of the 10 highest up and down regulated genes is given in Table 5 below. The 
highest up regulated gene after TCDD treatment in livers of C57BL/6 mice was Cyp1a1 by 
far. Induction of Cyp1a1 is up to the present day the most sensitive marker for AhR activation 
upon dioxin treatment. Other established dioxin-inducible members of the Cyp1 family, 
Cyp1b1 and Cyp1a2, were additionally strongly induced in livers of female C57BL/6 mice 
(Table 5). The fragile histidine triad (Fhit) was also among the ten highest up regulated genes 
in livers of TCDD-treated female C57BL/6 mice. FHIT is a known tumour suppressor gene in 
humans (Schlott et al., 1999). The up regulation of the human FHIT gene was demonstrated in 
a previous performed microarray study in human liver cell line (HL1-1) after treatment with 
TCDD (10 nM) (Kim et al., 2009). 
Tuba8 (tubulin alpha 8) was also among the ten highest up regulated genes. Alpha-tubulin and 
beta-tubulin form a heterodimer complex that assembles into microtubules which constitute 
one of the major components of the cytoskeleton in eukaryotic cells and are therefore 
involved in various essential processes including cell division, motility, and intracellular 
transport. The potential role of TUBA8 in the regulation of cell growth, proliferation, and 
cellular migration was demonstrated in an in vitro study in which Huh7 and HepG2 cells were 
stable transfected with the murine Tuba8 gene (Kamino et al., 2011). The induction of Tuba8 
was also observed in TCDD-treated male C57BL/6 mice in a microarray study performed by 
Tijet and co-workers (Tijet et al., 2006). Slc46a3 was also up regulated in female C57BL/6 
mice. Slc46a3 encodes a protein which is involved in transmembrane transport.  
Tiparp (TCDD-inducible poly(ADP-ribose) polymerase) was also among the ten highest up 
regulated genes upon TCDD-treatment. Ma and co-workers identified Tiparp as TCDD-
inducible gene in the mouse hepatoma cell line Hepa1c1c7 (Ma et al., 2001). Diani-Moore et 
al. demonstrated in their study for the first time that an AhR target gene (Tiparp) directly 
mediates a TCDD-elicited toxic effect, in particular the suppression of hepatic 
gluconeogenesis (Diani-Moore et al., 2010). Gsta1, the glutathione S-transferase gene was 
also up regulated in mouse study I. Gsta1 encodes an enzyme which belongs to the murine 
aromatic hydrocarbon gene battery (Nebert et al., 2000). Glutathione S-transferases play key 
roles in xenobiotic metabolism, precisely during phase II of drug metabolism, by conjugating 
xenobiotics (Boverhof et al., 2006) (Yeager et al., 2009). Htatip2 was among the ten highest 
up regulated hepatic genes in TCDD-treated female C57BL/6 mice. Htatip2 is a tumour 
suppressor gene which encodes a protein that promotes apoptosis and furthermore inhibits 
angiogenesis (Ito et al., 2003). Induction of Htatip2 after TCDD treatment in an AhR-
dependent manner in liver and kidney was demonstrated by Boutros and co-workers in 
mouse, but not in rat (Boutros et al., 2009). Furthermore, Htatip2 was altered in livers of mice 
with a constitutively active AhR (Moennikes et al., 2004). 
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TCDD treatment led to the down regulation of 95 unique genes based on the chosen criteria 
(A ≥ 7, log2 fc ≤ -1, p-value ≤ 0.05). The highest down regulated gene was the Kruppel-like 
factor 10 (Klf10). Kruppel-like transcription factors are DNA-binding transcriptional 
regulators which play key roles in regulating biological processes such as cell growth, 
differentiation, and embryogenesis. KLF10 is formerly known as TIEG1 (transforming growth 
factor beta-inducible early gene 1) which received its name as a consequence to the primary 
response to TGF-β treatment in human osteoblasts (Subramaniam et al., 2005). The Rgs16 
(regulator of G-protein signalling 16) gene was also down regulated in livers of C57BL/6 
mice. G protein-coupled receptor pathways control the glucose and fatty acid metabolism. 
Pashkov and co-workers demonstrated that RSG16 inhibits hepatic fatty acid oxidation in a 
carbohydrate response element-binding protein (ChREBP)-dependent manner (Pashkov et al., 
2011). The peptidase inhibitor pseudogene (Serpina4-PS1) was also down regulated in the 
present microarray study although Serpina6, Serpinb6a, and Serpinb6c were up regulated in 
livers of TCDD-treated C57BL/6 mice. These findings suggest that the encoded proteins 
maintain different cellular functions.  
The hepatic Egfr (epidermal growth factor receptor) gene expression was down regulated 
after exposure to TCDD compared to the respective vehicle control animals. EGFR protein is 
a transmembrane glycoprotein with a ligand-dependent intrinsic tyrosine kinase activity. The 
receptor and its downstream pathways play key roles in the regulation of normal cellular 
processes such as cell proliferation, differentiation, and migration. The EGFR expression rate 
is abnormally high in the majority of human epithelial cancers in which EGFR activation 
appears to be critical for tumour progession and pathogenesis. The interplay between TCDD 
and the EGFR-triggered signalling pathways has been described in various studies. TCDD 
does neither bind to the EGFR itself, nor changes it the binding affinity of EGF to its receptor. 
It was postulated that the decline in EGF-binding seems to be due to a reduced EGFR content 
on the cell membrane (Clark et al., 1992) (Sewall et al., 1995) (Haarmann-Stemmann et al., 
2009). Socs2 (suppressor of cytokine signalling 2) gene was also down regulated in livers of 
female C57BL/6 mice after treatment with TCDD. Socs2 has been associated with the 
regulation of growth hormone signalling. Socs2-deficient mice feature gigantism which was 
postulated to be the result of the deregulated growth hormone signalling (Alexander et al., 
2003) (Burns-Naas et al., 2006). TCDD-mediated mRNA induction of Socs2 (about 3-fold) 
was also detected in the murine CH12.LX B cells, but not in the other tested AhR-responsive 
cells (Hepa1c1c7 and MCF-7). The slight induction of Socs2 by TCDD seems to be a cell-
type specific effect (Boverhof et al., 2006). Perhaps the suppression of Socs2 in female 
C57BL/6 mice could be the result of the TCDD-mediated interference in growth factor 
signalling. Moreover, the suppression of Socs2 could be the result of a female-mouse specific 
effect. Csad (cysteine sulfinic acid decarboxylase) was also among the ten highest down 
regulated genes. Csad encodes an enzyme which is involved in biosynthesis of taurine. 
Taurine is needed for fundamental biological processes such as the development of the brain 
and eye, reproduction as well as osmoregulation (Park et al., 2002). Csad was also among the 
down regulated genes in livers of TCDD-treated (100 µg/kg bw) male Ahr+/+ mice after 72 h 
in a study performed by Yoon and co-workers (Yoon et al., 2006). Bcl6 (B-cell 
leukemia/lymphoma 6) gene was also among the ten highest down regulated genes. The Bcl6 
gene encodes a protein which acts as transcriptional repressor and plays key roles in germinal 
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centre formation, T helper cell differentiation, and in the development of lymphomas 
(lymphomagenesis) (Pixeley et al., 2005).  
125 were up and 95 down regulated in liver by TCDD treatment in the mouse study I. 
Considering all up and down regulated genes, mainly genes involved in xenobiotic, lipid, and 
glucose metabolism were altered in the performed microarray study. Various genes are linked 
to biotransformation processes (amongst others Cyp1a1, 1a2, 1b1, Ugt1a6a, Ugt1a10, 
Sult5a1, Gsta1, Gsta2, Gstm2, Gstp1, and Gstp2). Nqo1 and Nqo2 were both highly up 
regulated, but due to the cut-off value for the colour intensity of 7, Nqo1 is not listed among 
all significantly up regulated genes (Table 81). In addition, several other genes which were 
linked to the AhR (Tiparp, Cd36, Hsd17b2, and Ahrr) were up regulated by TCDD treatment. 
Aldh3a1 was not significantly up regulated by TCDD in the present study, although it belongs 
to the group of classic murine AhR target genes according to Nebert et al. (2000). Hence, it 
might be reasonably expected that this gene should be up regulated in the mouse liver by 
TCDD, too. Nevertheless, the lack of induction in the present study was also demonstrated in 
other in vivo studies (Vasiliou et al., 1993) (Alnouti et al., 2006). However, Aldh3a1 was 
induced by TCDD in various mouse and other carcinoma cell lines and in rat in vivo. Alnouti 
et al. postulated that Aldh3a1 was categorized to the murine AhR gene battery most likely due 
to the aforementioned findings.  
Tuba8, Fmo3, and Pcp4l1 were highly up regulated by TCDD as it was also demonstrated in a 
microarray study performed by Tijet and co-workers in which AhR-dependent and AhR-
independent effects were outlined in livers of TCDD-treated male Ahr+/+ and Ahr-/- mice. The 
constitutive expression of Tuba8 was much lower in Ahr+/+ mice than in Ahr-/- mice which led 
to the suggestion that the AhR suppresses Tuba8 in absence of a ligand. Treatment of TCDD 
results in the rehabilitation of Tuba8 mRNA levels in Ahr+/+ mice. Fmo3, the flavin 
containing monooxygenase 3, belongs to the group of microsomal enzymes which convert 
highly lipophilic substrates into oxygenated metabolites with higher polarity thereby 
faciliating their excretion (Celius et al., 2008). The AhR dependency of Fmo3 was proven in 
several studies (Tijet et al., 2006) (Celius et al., 2008). 
Genes involved in lipid metabolism were also altered in the present study in a way that 
several were up and others down regulated by TCDD. Amongst the up regulated genes related 
to lipid metabolism were Acot1 (acyl-CoA thioesterase 1), Fabp4 (fatty acid-binding protein 
4), Lpin1 (lipin 1), Mgll (monoglyceride lipase), Pla2g12a (phospholipase A2, group XIIA), 
Cd36 (CD36 antigen), and Vldlr (very low density lipoprotein receptor). The acetyl-
Coenzyme A carboxylase alpha (Acaca), the ATP citrate lyase (Acly), the elongation of very 
long-chain fatty acids 2 (Elovl2) and 6 (Elovl6), fatty acid-binding protein 5 (Fabp5), and the 
fatty acid synthase (Fasn) were on the contrary down regulated in mouse livers. 
Acot1 belongs to the class of Acyl-CoA thioesterases which play key roles in fatty acid 
metabolism. They hydrolyze acyl CoAs to the corresponding free fatty acid and CoASH and 
therefore control the intracellular levels of both (Hunt et al., 2006). Fatty acid-binding 
proteins play key roles in the intracellular fatty acid transport. Fabp4 was up and Fabp5 down 
regulated in the present study which hints at the tight metabolic regulation. FAPBs are 
associated with the metabolic syndrome and obesity (Maeda et al., 2003). Lipin1 
dephosphorylates phosphatic acid in order to generate diacylglycerol which displays the 
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penultimate step in the triglyceride synthesis. Furthermore, Lipin1 also acts as coregulatory 
protein which is able to translocate to the nucleus and regulates the activity of the DNA-
bound transcription factors (for example PPAR) (Mitra et al., 2012). Mgll and Pla2g12a 
belong to the class of lipolytic genes which encode proteins that hydrolyze hepatocellular 
triglyceride levels into free fatty acids and monoglycerides (Giller et al., 1992) (Angrish et al., 
2012). CD36 and VLDLR are cell surface receptors involved in the uptake of lipoproteins. 
CD36 is addionally responsible for the transport of fatty acids and has a high affinity for the 
uptake of long-chain fatty acids (Febbraio et al., 1999) (Bonen et al., 2004) (Boverhof et al., 
2006). However, VLDLR regulates the internalization and degradation of triglyceride-rich 
lipoproteins (Yagyu et al., 2002) (Boverhof et al., 2006).  
The acetyl-Coenzyme A carboxylase alpha (ACACA) and the ATP citrate lyase (ACLY) play 
key roles in the synthesis of fatty acids. ACACA catalyzes the carboxylation of acetyl CoA to 
malonyl-CoA which represents the first and rate-limiting step in the de novo fatty acid 
biosynthesis (Colbert et al., 2010). The gene long-chain fatty acid synthase (Fasn) was also 
down regulated after treatment with TCDD which leads to the suggestion that the total 
increase of the hepatic lipid content is most likely not based on the de novo fatty acid 
synthesis (Mashima et al., 2009) (Forgacs et al., 2012) (Angrish et al., 2012). ELOVL2 has 
been shown to be involved in the elongation of C20 and C22 polyunsaturated fatty acids 
(PUFAs) to produce C24:4n-6 and C24:5n-3 PUFAs (Zadravec et al., 2011). ELOVL6 is 
involved in the elongation of stearate (C18) from palmitate (C16), as well as the elongation of 
vaccinate (C18:1n-7) from palmitoleate (C16:1n-7) (Matsuzaka et al., 2007). 
The glucose-6-phosphatase (G6pc), the phosphoenolpyruvate carboxykinase 1 (Pck1), and the 
pyruvate kinase liver and red blood cells (Pklr) were among the down regulated genes in the 
present study. These genes play key roles in glycolysis (Pklr) and glyconeogenesis (G6pc, 
Pck1) (Berg et al., 2003). The disturbance of the glycolysis and glyconeogenesis by TCDD 
postulates a direct interference with the triglyceride synthesis. 
These findings once more outline the role of TCDD in the dysregulation of the hepatic lipid 
metabolism. TCDD is known to cause extremely enlarged livers (hepatomegaly) as well as 
hepatocellular neoplasms, inflammation, necrosis, and steatosis. Several mouse in vivo studies 
demonstrated that the expression of genes involved in metabolism and transport of lipids is 
fatally altered by TCDD (Poland et al., 1982a) (Huff et al., 1991) (Boverhof et al., 2006) 
(Kopec et al., 2010a) (Kopec et al., 2010b) (Angrish et al., 2012). 
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Table 5. 10 highest up and down regulated genes in livers of TCDD-treated female C57BL/6 mice (Mouse study I - mouse 3-day study). 
TCDD as one time administered dose (25 µg/kg bw). 
Selected parameters for microarray analysis: cut-off values: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
Annotations:  '*'calculated mean log2 fc-value from identical probes 
                                '#'analysis revealed non-identical probes of this gene have different log2 fc values 
 
Gene Gene description Probe name Systematic name Log2 fc 
Up regulation 
Cyp1a1 Cytochromes P450 family 1, subunit a, polypeptide 1 A_51_P279693 NM_009992 9.48 
Cyp1b1 Cytochromes P450 family 1, subunit b, polypeptide 1 A_51_P255456 NM_009994 5.17 
Cyp1a2 Cytochromes P450 family 1, subunit a, polypeptide 2 A_52_P595871 NM_009993 3.99 
Fhit Fragile histidine triad gene  A_55_P2032714 NM_010210 3.58 
Tuba8 Tubulin alpha 8 A_66_P119518 NM_017379 3.38 
Slc46a3 Solute carrier family 46, member 3 A_51_P299805 NM_027872 3.10 
Tiparp TCDD-inducible poly(ADP-ribose) polymerase  A_55_P1985890 NM_178892 2.90 
Gsta1 Glutathione S-transferase alpha 1 (Ya) A_55_P2032946 NM_008181 2.82 
Gm9933 Predicted gene ENSMUSG00000054044  A_55_P2004099 XM_001477458 2.72 
Htatip2 HIV-1 tat interactive protein 2 homolog (human), transcript variant 1 A_52_P515036 NM_016865 2.68 
Down regulation 
Klf10 Kruppel-like factor 10  A_55_P2022074 NM_013692 -2.85 
Rgs16 Regulator of G-protein signalling 16  A_51_P249286 NM_011267 -2.60 
Serpina4-ps1 Serine (or cysteine) peptidase inhibitor clade A, member 4, pseudogene 1 (cDNA clone IMAGE:5123840) A_55_P1997003 BC031891 -2.57 
Serpina4-ps1 Serine (or cysteine) peptidase inhibitor clade A, member 4, pseudogene 1, non coding RNA A_55_P2004606 NR_002861 -2.49 
Egfr# Epidermal growth factor receptor, transcript variant 1 A_52_P106259 NM_207655 -2.18* 
Socs2# Suppressor of cytokine signalling 2, transcript variant 1 A_51_P107362 NM_007706 -2.07* 
Csad Cysteine sulfinic acid decarboxylase  A_51_P268529 NM_144942 -2.03 
LOC100046261 Predicted: similar to myosin XV  A_55_P1954698 XM_001475897 -1.89 
Bcl6 B-cell leukemia/lymphoma 6  A_52_P161495 NM_009744 -1.89 
LOC676974 Predicted: similar to Glucose phosphate isomerase 1, transcript variant 2 A_55_P2073789 XM_001003154 -1.82 
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IV.1.1.1.2.2 Microarray Results - PCB 153 Treatment 
 
In mouse liver samples, a total of 86 genes were identified as expressed above background in 
all six C57BL/6 mice treated with NDL-PCB 153, from which 65 genes were up and 21 genes 
down regulated based on the chosen criteria (A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05). The 
top ten of the highest up und down regulated genes is shown in Table 6. A list with all 
significantly up and down regulated genes is attached to the present work (Tables 83 and 84). 
Gsta1 (glutathione S-transferase, alpha 1) was the highest up regulated gene in livers of 
C57BL/6 mice after treatment with PCB 153 (150000 µg/kg bw). Another member of the 
glutathione S-transferases, by name Gsta2, was also among the ten highest up regulated genes 
due to treatment with PCB 153. Gsta1 belongs to the murine aromatic hydrocarbon gene 
battery (Nebert et al., 2000), but considering the fact that PCB 153 is a non dioxin-like PCB, 
the induction of Gsta1 must be due to activation of a different receptor. NDL-PCB 153 leads 
to the activation of the constitutive androstane receptor (CAR). CAR is able to induce the 
expression of several detoxification genes (enzymes) linked to phase II of xenobiotic 
metabolism such as glutathione S-transferases (e.g. Gsta1, Gsta2) or UDP-glucoronosyl 
transferases (Ugt1a1) (Hernandez et al., 2009). Cyp2b10 was also up regulated due to 
treatment with PCB 153. The up regulation of Cyp2b10 expression is known to be primarily 
mediated by CAR. Earlier presented RT-PCR data confirmed these findings; Cyp2b10 mRNA 
levels were significantly induced in livers of female C57BL/6 mice after treatment with PCB 
153 (150000 µg/kg bw) (IV.1.2.1.1 Gene expression analysis RT-PCR) as well as Cyp2b9 
mRNA levels. The Cyp3a44 gene was not significantly up regulated in livers of female 
C57BL/6 mice after exposure to PCB 153 which was confirmed by earlier presented RT-PCR 
results. The Cyp3a44 gene expression is above all expressed in female mice and was 
demonstrated to be inducible by PXR ligands in a female mice-specific manner (Anakk et al., 
2007). Cyp3a11, the major isoform of the Cyp3a's in mice is slightly, but significantly up 
regulated (log2 fc value of 1.25). Whether this up regulation is based on the PXR activation or 
not has to be analyzed in further experiments (e.g. RT-PCR, Western blot) because CAR 
activators such as phenobarbital are also able to induce the Cyp3a11 mRNA expression via 
cross-talk between CAR and PXR. 
Cyp2c38 and Cyp2c54 were also among the ten highest up regulated genes in the present 
study. Other members of the cytochromes 2c family were also significantly up regulated 
including Cyp2c29, Cyp2c37, and Cyp2c39. The mouse CYP2Cs play important roles in 
arachidonic acid (AA) and linoleic acid (LA) metabolism with different catalytic efficiencies 
and profiles. CYP2C54 primarly metabolizes AA to epoxyeicosatrienoic acids (EETs), and 
linoleic acid to epoxyoctadecenoic acids (EOAs). CYP2C29 mainly produces 14R, 15S-EET, 
and CYP2C37 primarily 8S,9R-EET, whereas CYP2C39 is responsible for the stereoselective 
formation of 8R,9S-EET (Wang et al., 2004). Umannova and co-workers demonstrated in a rat 
liver epithelial cell line (WB-F344) that NDL-PCB 153 extremely induced the release of 
arachidonic acid, but not DL-PCB 126. Arachidonic acid (AA) functions as second messenger 
and is involved in the modulation of cell survival and proliferation. Therefore, it has been 
suggested that the interference in the AA signalling pathways could possibly contribute to the 
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carcinogenic and toxic responses of non dioxin-like PCBs (Marks et al., 2000) (Umannova et 
al., 2008).  
The Orm3 (orosomucoid 3) gene was also up regulated in livers of female C57BL/6 mice by 
PCB 153 in the present study. Orm3 encodes an acute phase protein. Acute phase proteins are 
a special class of proteins whose plasma concentrations increase or respectively decrease in 
response to inflammation, tissue injury, or bacterial infection (Carter et al., 1991) (Miura et 
al., 2009). The Akr1b7 gene encodes the AKR1B7 protein. AKR1B7 belongs to the class of 
aldo-keto reductases which belong to the family of phase I metabolizing enzymes. They 
mediate the detoxification of harmful aldehydes and ketones generated for example from 
xenobiotics. The mouse Akr1b7 is a shared transcriptional target gene of PXR and CAR in 
liver and intestine. The induction of the Akr1b7 gene expression was demonstrated using a 
selective mCAR activator (TCPOBOP) (Liu et al., 2009) (Tolson et al., 2010). The Ces6 gene 
was also among the ten highest up regulated genes in C57BL/6 mice after exposure to PCB 
153. Carboxylesterase (CES) enzymes are predominantly involved in hydrolytic 
biotransformation processes in liver and intestine of mammals (Satoh et al., 1998). CES 
family members participate in biotransformation as well as hydrolysation of endogenous 
compounds such as short- and long-chain acyl-gylcerols and long chain acyl-CoA esters 
(Satoh et al., 1998) (Xu et al., 2009). Xu and co-workers demonstrated that Ces6 is a CAR- 
and PXR-shared target gene in mice (Xu et al., 2009). 
The number of down regulated genes was marginal. A total of 21 unique hepatic genes were 
down regulated in female C57BL/6 mice after treatment with PCB 153 (150000 µg/kg bw). 
Log2 fc values were only slightly, but statistically significantly down regulated (log2 fc 
values ≤ -1). The highest down regulated genes was Tnni2 (troponin I, skeletal fast 2) with a 
log2 fc-value of -2.51. Troponin is a complex of three subunits, troponin I, troponin C, and 
troponin T which plays an important role in excitation-contraction coupling in the striated 
muscle. Troponin I is an actin-binding protein that is primarily responsible for the ability of 
troponin to inhibit the contractile interaction between myosin and actin-tropomyosin (Guenet 
et al., 1996). The tropomyosin 1 (Tpm1) gene itself was also among the ten highest down 
regulated genes in the present study due to treatment with PCB 153. Tropomyosin is an α-
helical coiled-coil fibrous protein which is involved in the striated muscle contraction (Rajan 
et al., 2007). The Neb gene encodes the myofibrillar protein nebulin that is involved in the 
regulation of the actin filament assembly in the skeletal muscle (Schiaffino et al., 1996) 
(Gokhin et al., 2010). The gene Eno3 encodes the protein β-enolase. The enzyme enolase (2-
phospho-D-glycerate hydrolase) plays an important role in glycolysis by catalyzing the 
conversion of 2-phospho-D-glycerate to 2-phosphoenolpyruvate. Interestingly, the protein 
encoded by the Eno3 gene is found in the skeletal muscle where it is appears to be involved in 
the muscle development and regeneration (Comi et al., 2001). The obtained data implicates 
that because of the exposure to the high dosage of PCB 153 (150000 µg/kg bw) possibly the 
muscle contraction in the liver could be an affected metabolic process. 
Various genes which are involved in lipid metabolism were also among the 10 highest down 
regulated ones such as Acot1 and Cyp4a14. Acot1 encodes a cytosolic acyl-coenzyme A 
thioesterase I which hydrolyzes long-chain acyl-CoAs to free fatty acids and CoA and was 
identified as peroxisome proliferator-inducible enzyme in the rodent liver (Dongol et al., 
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2007). The Cyp4a14 gene was not the only gene of the cytochromes P450 family 4a 
subfamily which was down regulated, Cyp4a10 and Cyp4a31 were also significantly down 
regulated after treatment with PCB 153 (Table 84). The members of the CYP4 family 
contribute to the ω-hydroxylation of fatty acids in liver and kidney (Hsu et al., 2007) 
(Hardwick et al., 2009). Cyp4a10 and Cyp4a14 are established PPARα-responsive genes. 
PPARα is a ligand-activated transcription factor that serves as a biological sensor for the 
intracellular fatty acid levels (Fisher et al., 2008) (Bumpus et al., 2011). The Pdk4 (pyruvate 
dehydrogenase kinase, isoenzyme 4) gene encodes a protein which is also involved in energy 
delivering processes such as glucose metabolic processes or regulation of fatty acid 
biosynthetic process (Bowker-Kinley et al., 1999). Cox7a1 was also among the ten highest 
down regulated genes in livers of PCB 153-treated C57BL/6 mice. The cytochrome c oxidase, 
which is located in the inner mitochondrial membrane, is involved in the mitochondrial 
electron transport within the respiratory chain. It has been therefore associated with the 
oxidation-reduction process (Hüttemann et al., 2001). 
 
Summarizing the PCB 153-mediated hepatic effects in female C57BL/6 mice, 65 genes were 
up and 21 genes down regulated in mouse study I. However, the corresponding log2 fold 
change values of the regulated genes were not exceeding 3.6 or deceeding -2.5 implicating 
that the dosage of 150000 µg/kg bw PCB 153 had only a moderate impact on the alteration of 
the hepatic gene expression. 
Genes involved in xenobiotic metabolism (Cyp2b10, Cyp3a11, Aldh1a1, Akr1b7, Gsta1, 
Gsta2, Gstm4, Gstp1, Gstp2) were up regulated due to treatment with the NDL-congener. 
Several cytochromes of the Cyp2c class (Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c38, Cyp2c39, 
and Cyp2c54) which are involved in arachidonic acid metabolism were also up regulated 
suggesting the arachidonic acid signalling pathway was influenced in female mice by 
treatment with PCB 153. Umannova et al. suggested that the deregulation of the arachidonic 
acid signalling pathways could possibly contribute to the NDL-PCB-mediated carcinogenic 
and toxic effects (Umannova et al., 2008). Several genes associated with the lipid metabolism 
(Acot1, Cyp4a10, Cyp4a14, and Pdk4) were also down regulated in livers of female C57BL/6 
mice after treatment with PCB 153. 
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Table 6. 10 highest up and down regulated genes in livers of PCB 153-treated female C57BL/6 mice (Mouse study I - mouse 3-day study). 
PCB 153 as one time administered dose (150000 µg/kg bw). 
Selected parameters for microarray analysis: cutoff values: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
Annotations:  '#'analysis revealed non-identical probes of this gene have different log2 fc-values 
 
Gene name Gene description Probe name Systematic name Log2 fc 
Up regulation 
    
Gsta1 Glutathione S-transferase alpha 1 (Ya) A_55_P2032946 NM_008181 3.56 
Cyp2c38 Cytochromes P450 family 2, subfamily c, member 38 A_55_P2116272 NM_010002 3.34 
Gm10639# Predicted gene 10639  A_55_P2102065 NM_001122660 2.69 
Cyp2b10 Cytochromes P450 family 2, subfamily b, member 10 A_55_P2044653 NM_009999 2.51 
Orm3 Orosomucoid 3 A_51_P311958 NM_013623 2.32 
Akr1b7 Aldo-keto reductase family 1 member b7 A_51_P331288 NM_009731 2.32 
Ces6 Carboxylesterase 6 A_55_P2293013 NM_133960 2.13 
Gsta2 Glutathione S-transferase alpha 2 (Yc2) A_55_P2170454 NM_008182 2.04 
A_55_P2107528 Unknown A_55_P2107528 A_55_P2107528 1.97 
Cyp2c54# Cytochromes P450 family 2, subfamily c, member 54 A_52_P154580 NM_206537 1.94 
Down regulation 
    
Tnni2 Troponin I, skeletal fast 2 A_55_P2040893 NM_009405 -2.51 
Acot1 Acyl-CoA thioesterase 1  A_55_P2038358 NM_012006 -1.95 
Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 A_51_P350453 NM_013743 -1.83 
Cyp4a14 Cytochromes P450 family 4, subfamily a, polyeptide 14 A_51_P238576 NM_007822 -1.67 
Tpm1 Tropomyosin 1 alpha A_55_P2187043 NM_001164248 -1.56 
Gm3734 Predicted: hypothetical protein LOC100046708  A_55_P2162970 XM_001476671 -1.49 
Cox7a1 Cytochromes c oxidase subunit VIIa 1 A_51_P148612 NM_009944 -1.43 
Neb Nebulin  A_55_P2116973 NM_010889 -1.43 
Eno3 Enolase 3 beta muscle, transcript variant 2  A_55_P1977533 NM_001136062 -1.37 
ENSMUST00000113016 Gelsolin Precursor (Actin-depolymerizing factor)(ADF)(Brevin)  A_55_P2055638 ENSMUST00000113016 -1.29 
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IV.1.1.1.2.3 Comparison TCDD and PCB 153 Treatment 
 
One major research topic within the present work was the identification, establishment, and 
implementation of novel biomarkers for the activation of the AhR due to treatment with 
dioxins and dioxin-like compounds. Several research approaches were used as described in 
detail in chapter VI.3.5 which finally led to 5 potential biomarker candidates. Within this 
chapter and the following chapters, the alterations on the mRNA expression of these target 
genes will be critically discussed to analyze if one or more of these target genes are suitable 
biomarkers for the activation of the AhR. 
As expected, only a marginal overlap of in commonly altered gene expression occurred due to 
treatment with TCDD and NDL-PCB 153 (Table 7). Nine genes were in common up and two 
genes in common down regulated. After treatment of the C57BL/6 mice with the AhR ligand 
TCDD and the CAR activator PCB 153 several glutathione S-transferases (Gsta1, Gsta2, 
Gstp1, and Gstp2) were up regulated in liver. Considering the receptor-dependent inducibility, 
the induction of these four genes is in case of TCDD AhR-mediated and in case of PCB 153 
CAR-mediated. Cyp2c54 was also up regulated in liver due to both compound treatments. 
Though after treatment with PCB 153 additional cytochromes of the Cyp2c class were 
likewise up regulated (Cyp2c29, Cyp2c37, Cyp2c38, and Cyp2c39). In case of PCB 153 
various genes of the Cyp2c class were up regulated, thus implicating the role of NDL-PCBs in 
the deregulation of the arachidonic acid signalling pathway (Umannova et al., 2008). Ces2, a 
carboxylesterase was significantly up regulated in livers of female C57BL/6 mice after 
treatment with TCDD and PCB 153. Carboxylesterases are enzymes which catalyze the 
hydrolysis of a diverse range of ester-containing endogenous and xenobiotic compounds. The 
murine Ces2 was up regulated after activation of the AhR (TCDD) and CAR (PCB 153). This 
allows drawing the conclusion that the altered Ces2 expression is not based on a strictly AhR- 
or CAR-mediated mechanism. However, the murine Ces6 gene expression was only induced 
in liver upon treatment with PCB 153, but not after exposure to TCDD. Xu and co-workers 
demonstrated that Ces6 is a CAR- and PXR-shared target gene in mice (Xu et al., 2009). Ces6 
is an obviously CAR-regulated target gene in the present study after treatment with PCB 153, 
but a clear nuclear receptor dependency could not be derived for the murine Ces2. The 
prominin 1 (Prom1) gene was also up regulated in livers of both compound-treated animals. 
The mammalian prominin gene family consists of two members the genes Prom1 and Prom2 
which encode multispan transmembrane glycoproteins that are specifically sorted to 
microvilli and other plasma membrane protrusions. Prom1 (alias CD133) was originally 
identified and cloned by Weigmann and co-workers as a protein selectively concentrated at 
the apical domain of neuroepithal progenitor cells and adult kidney proximal tubules. The 
human PROM1 was first identified as surface antigen in hemotopotetic stem and progenitor 
cells (Zacchigna et al., 2009) (Katoh et al., 2007). The results gained within this study, 
however, indicate that the induction of Prom1 does not depend on AhR or CAR activation. 
Cox7a1 and Cyp26b1 are the two genes which were in common down regulated in the female 
mouse liver after exposure to TCDD and PCB 153 respectively. CYP26 enzymes are likely 
responsible for metabolism of all-trans retinoic acid and furthermore contribute to the 
regulation of all-trans retinoic acid homeostasis and signalling. CYP26B1 is a hydroxylase 
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which forms 4-OH-retinoic acid and 18-OH-retinoic acid from all-trans retinoic acid (Topletz 
et al., 2012). TCDD treatment affects the retinoic homeostasis. Exposure to TCDD leads to 
growth retardation, abnormal immune function, and developmental defects reminiscent of 
vitamin A-deficient states postulate that dioxin-like compounds reduce all-trans retinoic acid 
signalling (Murphy et al., 2007) (Jacobs et al., 2011). However, Cyp26b1 was also down 
regulated after exposure to PCB 153. The activation of the cytosolic CAR upon 
phentobarbital exposure leads after dissociation from different co-chaperone partners to the 
translocation of CAR into the nucleus where it forms a complex with the retinoid X receptor 
(RXR) (Kawamoto et al., 1999). RXR is also able to form a heterodimer with RAR (retinoic 
acid receptor) and can be actively involved in retinoic acid signalling pathways by regulating 
the retinoic acid-mediated gene transcription (Balmer et al., 2002). This poses a reasonable 
explanation why Cyp26b1 levels were altered after exposure to a high dose of PCB 153. 
 
Log2 fc values of selected genes after TCDD or PCB 153 treatment, identified by microarray 
analysis, are summarized in Table 8. Selected genes include the members of the murine 
aromatic hydrocarbongene battery (Cyp1a1, Cyp1a2, Nqo1, Aldh3a1, Ugt1a6, and Gsta1) 
(Nebert et al., 2000) as well as other cytochromes P450 genes (Cyp2b10, Cyp3a11, and 
Cyp3a44) and the additional selected target genes (Aldh3a1, Tiparp, Hsd17b2, Cd36, and 
Ahrr). All genes of the aromatic hydrocarbon gene battery were up regulated in C57BL/6 
mice after treatment with TCDD except Aldh3a1. Several other mouse microarray studies, 
described in literature, failed to demonstrate the up regulation of Aldh3a1 in the murine liver 
by TCDD treatment (Tijet et al., 2005) (Boutros et al., 2009). The induction of Aldh3a1 
mRNA in mouse hepatoma cell lines has been only demonstrated in vitro, but not in vivo after 
treatment of either C57BL/6J or DBA/2J mice with an extremely high dosage of 200 µg/kg 
bw TCDD (Vasiliou et al., 1993). The lack of Aldh3a1 mRNA induction by TCDD (34 µg/kg 
bw administered as single dose) in the murine liver was also shown in the recent work of 
Alnouti and co-workers (Alnouti et al., 2006). This leads to the conclusion that the Aldh3a1 
gene is neither inducible by TCDD nor by PCB 153 in the mouse liver.  
 
Treatment with PCB 153 led only to the induction of Gsta1, but no alteration in gene 
expression was observed for the other genes. As discussed above, the up regulation of Gsta1 
after exposure to PCB 153 is most likely CAR-mediated considering that the regulation of the 
non dioxin-like compound is based on an AhR-independent mechanism (Hernandez et al., 
2009). Cyp1b1 is an associated member of the murine AhR target gene battery. The strong 
induction of CYP1B1 after dioxin exposure in mouse und human liver was demonstrated in 
several studies. CYP2B10 on the other hand belongs to the P450 isoenzymes which featured a 
high induction upon treatment with NDL-congeners (Roos, 2011). In the present study the 
murine hepatic Cyp2b10 expression was significantly up regulated due to treatment with PCB 
153. The Cyp3a44 gene was chosen in the present work to examine if the the nuclear receptor 
PXR has been activated after exposure to the seven core compounds. Cyp3a44 is a female 
mouse-specific PXR-regulated gene (Bhadhprasit et al., 2007). No up regulation was 
determined after single dose exposure to PCB 153 (150000 µg/kg bw) in the present 
microarray study. However, Cyp3a11 was slightly, but statistically signifiantly induced by 
treatment with PCB 153 in the microarray. Also no increase of the hepatic Cyp3a44 mRNA 
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expression levels was measured after one-time exposure to 200000 µg/kg bw PCB 153 24 h 
after treatment in male and female C57BL/6 mice. Likewise, no increase of Cyp3a44 mRNA 
levels was determined in mouse livers of both genders in a five days mouse study (2 doses of 
200000 µg/kg bw PCB 153 on day 0 and 2). Only subchronic exposure to PCB 153 (ten doses 
of 200000 µg/kg bw PCB 153 during 28 days) led to a significant induction of the hepatic 
Cyp3a44 mRNA expression (Roos, 2012).  
The aim of the present microarray study was to determine AhR-dependent and AhR-
independent effects on the hepatic mRNA gene expression in female C57BL/6 mice. 
Furthermore, the selected target genes (Aldh3a1, Tiparp, CD36, Hsd17b2, and Ahrr) in search 
for a novel quantifiable biomarker were all up regulated except Aldh3a1 in livers of female 
mice after treatment with TCDD (25 µg/kg bw), but not after exposure to PCB 153 (150000 
µg/kg bw). Due to different signalling pathways only a small overlap (9 up, 2 down) in altered 
gene expression occurred by single dose administration of TCDD (25 µg/kg bw) and PCB 153 
(150000 µg/kg bw), respectively.  
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Table 7. In common up and down regulated genes after treatement with TCDD (25 µg/kg bw) and PCB 153 (150000 µg/kg bw) - mouse study I. 
Selected parameters for microarray analysis: cutoff values: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
 
Gene name Gene description Probe name Systematic name 
log2 fc 
TCDD 
log2 fc 
PCB 153 
In common up regulated genes 
     
Gsta1 Glutathione S-transferase alpha 1 (Ya) A_55_P2032946 NM_008181 2.82 3.56 
Gsta2 Glutathione S-transferase alpha 2 (Yc) A_55_P2170454 NM_008182 1.30 2.04 
Gstp1 Glutathione S-transferase pi 1 A_55_P2031668 NM_013541 1.86 1.05 
Gstp2 Glutathione S-transferase pi 2 A_55_P2008704 NM_181796 1.56 1.01 
Cyp2c54 Cytochromes P450, family 2, subfamily c, polypeptide 54 A_52_P154580 NM_206537 1.37 1.94 
Ces2 Carboxylesterase 2  A_52_P318361 NM_145603 1.65 1.59 
  
A_55_P2124712 NM_145603 1.70 1.54 
Prom1 Prominin 1, transcript variant 2 A_55_P2059931 NM_001163577 1.76 1.53 
Gm10639 Predicted gene 10639 A_55_P2102065 NM_001122660 1.85 2.69 
  
A_55_P2069969 NM_001122660 1.04 1.76 
BC015286 cDNA sequence BC015286  A_52_P627269 NM_198171 1.63 1.52 
In common down regulated genes 
    
Cox7a1 Cytochromes c oxidase, subunit VIIa 1 A_51_P148612 NM_009944 -1.04 -1.43 
Cyp26b1 Cytochromes P450 family 26, subfamily b, polypeptide 1 A_51_P501844 NM_175475 -1.54 -1.01 
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Table 8. Comparison of selected genes in liver of female C57BL/6 mice treated with TCDD or PCB 153. 
The table features aspects such as gene name, probe name, systematic name, colour intensity value, and 
corresponding log2 fc values.  
Selected parameters: log2 fc ≥ 1, p-value ≤ 0.05. 
Annotations:       '→' gene was not up regulated in microarray experiment. 
 
Gene name Probe name Gene description Colour intensity 
Log2 fc 
TCDD 
Log2 fc 
PCB 153 
Cyp1a1 A_51_P279693 NM_009992 10.23 9.48 → 
Cyp1a2 A_52_P595871 NM_009993 13.33 3.99 → 
Cyp1b1 A_51_P255456 NM_009994 7.16 5.17 → 
Cyp2b10 A_55_P2044653 NM_009999 13.31 → 2.51 
Cyp3a11 A_55_P2121225 NM_007818 14.96 → 1.25 
Cyp3a44 A_52_P366803 NM_177380 10.41 → → 
Nqo1 A_51_P424338 NM_008706 6.97 1.75 → 
Gsta1 (Ya) A_55_P2032946 NM_008181 9.36 2.82 3.56 
Ugt1a6a A_55_P2143765 NM_145079 8.42 1.60 → 
Aldh3a1 A_55_P2065562 NM_007436 8.62 → → 
Tiparp A_55_P1985890 NM_178892 7.10 2.90 → 
Hsd17b2 A_51_P441914 NM_008290 11.34 1.41 → 
Cd36 A_51_P375146 NM_007643 7.22 1.76 → 
Ahrr A_51_P254425 NM_009644 5.65 3.91 → 
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IV.1.1.2 Study II - Mouse 14-day Study 
 
In this short-term 14-day acute toxicity study, groups of six adult female C57BL/6 mice 
received a single dose of each chosen compound or corn oil by gavage. An overview of 
examined dose levels is featured in Table 9. Each compound-treated group will be compared 
to its corresponding vehicle control group (0 µg/kg bw). Immediately after the sacrifice of the 
animals, blood and tissue samples were collected, instantly frozen in liquid nitrogen and 
stored at -80 °C until usage. In the present work the mouse liver represents the target tissue. 
Liver sample preparation and further isolation of RNA are described in chapter six (VI 
Methods) in detail. Concentration and purity of liver samples were spectrophotometrically 
determined by NanoDrop (Peqlab, Erlangen). Influence and effects of the administered 
compounds were measured by quantitative real-time PCR on mRNA level.  
 
Table 9. Overview mouse study II - 14-day study (dose levels). 
 
Study Treatment Single dose (µg/kg bw) TEF (WHO, 2005) 
14-day 
TCDD 0 25   1.0 
1-PnCDD 0 25   1.0 
4-PnCDF 0  250  0.3 
PCB 126 0  250  0.1 
PCB 118 0   150000 0.00003 
PCB 153 0   150000 - 
PCB 156 0   150000 0.00003 
 
IV.1.1.2.1 Gene Expression Analysis by RT-PCR 
 
The mRNA expression levels of three genes which play key roles in xenobiotic metabolism 
were measured in the following RT-PCR experiments. Genes were accordingly selected to 
identify receptor-mediated specific effects after treatment with test compounds. Alterations in 
Cyp1a1 gene expression reveal the affinity of the test compound to the AhR. Cyp2b10 
represents the murine analog to the human CYP2B6 which is primarily CAR-regulated. 
Additionally, Cyp3a44 was chosen to analyze the PXR-mediated effects in the female mouse 
liver due to compound exposure. Complementary DNA (cDNA) was synthesized using 
iScriptc DNA Synthesis Kit (BioRad). 1 µl of the transcribed cDNA was used to perform each 
RT-PCR. The Cyp1a1, Cyp2b10, and Cyp3a44 mRNA expression was normalized using 36b4 
as housekeeping gene and calculated relative to the expression in the corresponding vehicle 
control (0 µg/kg bw). 
 
An extremely high Cyp1a1 mRNA induction (5914.35 ± 1224.90) was measured after 
treatment with 25 µg/kg bw TCDD in the 14-day mouse study, whereas no alterations in the 
hepatic Cyp2b10 mRNA expression were determined by RT-PCR. Cyp3a44 was significantly 
down regulated resulting in a fold-change of 0.60 ± 0.29 compared to the corresponding 
vehicle control (Figure 13). The hepatic Cyp1a1 mRNA expression was induced up to 
Results and Discussion 
 
54 
 
5908.92 ± 1185.28 after treatment with 1-PnCDD. A small but statistically significant 
increase in Cyp2b10 mRNA expression was measured after treatment with 1-PnCDD which 
led to an induction of 2.07 ± 0.94. However, Cyp3a44 mRNA expression levels were not 
altered in livers of female C57BL/6 mice (Figure 13).  
 
  
 
Figure 13. Real-time PCR ratios of female mice treated with TCDD (left) or 1-PnCDD (right) - mouse study II. 
36b4 served as housekeeping gene, compound as one-time administered dose. 
Data represent means + SD of six different adult female mice, normalized to corresponding vehicle 
control. One-tailed unpaired Student’s t-test with Welch correction, *= p ≤ 0.05, ***= p ≤ 0.001. 
 
The results of the real-time PCR analysis after the treatment with 250 µg/kg bw 4-PnCDF 
revealed a high Cyp1a1 mRNA induction resulting in a fold-change of 6063.98 ± 914.96 
(Figure 14). In addition, Cyp2b10 mRNA levels were also significantly increased resulting in 
a fold-change of 4.11 ± 1.10, whereas no alteration of Cyp3a44 expression was measured by 
RT-PCR. A high, statistically significant Cyp1a1 mRNA induction (5150.62 ± 1521.82) was 
furthermore measured after female C57BL/6 mice received a single dose of 250 µg/kg bw 
PCB 126 (Figure 14). In addition, a small but significant increase of the Cyp2b10 mRNA 
expression (3.11 ± 1.35) was determined in mouse study II. Cyp3a44 mRNA levels were not 
affected by treatment with PCB 126. 
Treatment with PCB 118 led to the high Cyp1a1 induction resulting in a fold-change of 
782.48 ± 156.85 (Figure 15). Moreover, Cyp2b10 mRNA levels (33.09 ± 5.39) were 
additionally significantly induced by PCB 118 in mouse study II. However, Cyp3a44 mRNA 
levels were down regulated (0.33 ± 0.12) compared to the corresponding vehicle control. 
After treatment with 15000 µg/kg bw PCB 153 no alterations of Cyp1a1 and Cyp3a44 mRNA 
expression levels were measured by RT-PCR, whereas Cyp2b10 mRNA levels were 
significantly induced (25.09 ± 7.36-fold) (Figure 15).  
Single-dose treatment with PCB 156 resulted in a high induction of the Cyp1a1 (3443.01 ± 
863.65) and Cyp2b10 (90.56 ± 25.01) mRNA levels in the 14-day study, while the Cyp3a44 
mRNA gene expression was down regulated (0.45 ± 0.12). 
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Figure 14. Real-time PCR ratios of female mice treated with 4-PnCDF (left) or PCB 126 (right) - mouse study II. 
36b4 served as housekeeping gene, compound as one-time administered dose. 
Data represent means + SD of six different adult female mice, normalized to corresponding  
vehicle control. One-tailed unpaired Student’s t-test with Welch correction, *= p ≤ 0.05, ***= p ≤ 0.001. 
 
  
 
 
Figure 15. Real-time PCR ratios of female mice treated with PCB 118 (up left), PCB 153 (up right right),  
or PCB 153 (down middle) - mouse study II. 
36b4 served as housekeeping gene, compound as one-time administered dose. 
Data represent means + SD of six different adult female mice, normalized to corresponding  
vehicle control. One-tailed unpaired Student’s t-test with Welch correction, ***= p ≤ 0.001. 
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In summary, the mouse 14-day acute toxicity study confirmed the findings of the mouse 3-day 
studies, though distinct differences were observed. Fourteen days after single dose treatment 
with TCDD (25 µg/kg bw), only Cyp1a1 mRNA levels were highly induced due to activation 
of the AhR. In addition to the detected high Cyp1a1 expression levels, the statistically 
significant increase of the Cyp2b10 mRNA levels after treatment with 1-PnCDD (25 µg/kg 
bw), 4-PnCDF (250 µg/kg bw), and PCB 126 (250 µg/kg bw) imply that exposure to dioxins 
and dioxin-like compounds in the chosen doses primarily led to the activation of the AhR, but 
the nuclear receptor CAR could be also activated fourteen days after single exposure. 
Fourteen days after the single dose administration of the DL-PCBs, PCB 118, and PCB 156 
(150000 µg/kg bw) resulted in the activation of the AhR. The Cyp1a1 mRNA response to 
PCB 156 was 4-times higher compared to PCB 118. Furthermore, the measured Cyp2b10 
mRNA induction draws to the conclusion that CAR was additionally activated by both dioxin-
like PCBs. However, Cyp3a44 mRNA levels were significantly down regulated by PCB 118 
and 156 fourteen days after single dose treatment. 
 
IV.1.1.3 Summary and Discussion in vivo Experiments Part I 
 
In the present work, the influence of polychlorinated dibenzo-p-dioxins (TCDD, 1-PnCDD), 
dibenzofurans (4-PnCDF), polychlorinated dioxin-like biphenyls (PCB 118, 126, and 156) 
and the non dioxin-like biphenyl (PCB 153) on mRNA expression of selected genes 
associated with different xenobiotic signalling pathways (AhR, CAR, and PXR) were 
elucidated in both mouse studies (Table 10). 
 
Table 10. Summary of in vivo experiments part I featuring gene expression changes in female mouse liver. 
'↑' mRNA gene expression increased compared to vehicle control. 
'↓' mRNA gene expression reduced compared to vehicle control. 
'→' mRNA gene expression not significantly altered compared to vehicle control. 
 
Compound TCDD 1-PnCDD 4-PnCDF PCB 118 PCB 126 PCB 153 PCB 156 
Study 3 14 3 14 3 14 3 14 3 14 3 14 3 14 
Cyp1a1 ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ ↑↑ → → ↑↑ ↑↑ 
Cyp2b10 → → → ↑ → ↑ ↑ ↑ → ↑ ↑ ↑ ↑ ↑ 
Cyp3a44 → ↓ → → → → → ↓ → → → → ↑ ↓ 
 
Single dose exposure toTCDD, 1-PnCDD, 4-PnCDF, and PCB 126 in both mouse studies led 
to the activation of the AhR, demonstrated by the examined high hepatic Cyp1a1 mRNA 
expression. A weak activation of CAR could be additionally postulated in case of 1-PnCDD, 
4-PnCDF, and PCB 126 in mouse 14-day study based on the slight increase of hepatic 
Cyp2b10 mRNA expression. Treatment of mice with PCB 118 and PCB 156 led to the 
activation of the AhR and CAR in both studies. The induction of Cyp1a1 mRNA was much 
more pronounced than the increase of the Cyp2b10 mRNA expression. Hepatic Cyp3a44 
levels were slightly increased in the mouse 3-day study, but suppressed in mouse 14-day 
study, therefore no consistnent trend could be derived. PCB 153 belongs to the class of non 
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dioxin-like PCBs. PCB 153 treatment caused the induction of Cyp2b10 mRNA levels in 
mouse liver, whereby no alterations in Cyp1a1 and Cyp3a44 mRNA levels were determined 
by RT-PCR. Based on these findings, single dose exposure of female mice to PCB 153 only 
led to the activation of CAR.  
Furthermore, a microarray study was performed in search for novel quantifiable biomarkers 
for AhR activation by DLCs. The alterations in hepatic gene expression were determined 
three days after treatment with a single dose of either TCDD (25 µg/kg bw) or PCB 153 
(150000 µg/kg bw) by gavage in livers of female C57BL/6 mice by microarray analysis. 
A total of 125 unique genes were up and 95 down regulated by TCDD. Treatment with PCB 
153 resulted in 65 up and 21 down regulated genes in mouse livers (identified by the selected 
cut-off values: A ≥7, log2 fc ≥ 1 or ≤ -1, and p-value ≤ 0.05). As expected, only a vanishingly 
small number of hepatic genes were regulated in common (9 up, 2 down) by both compounds.  
TCDD treatment caused the high up regulation of genes associated with the xenobiotic 
metabolism such as Cyp1a1, 1a2, and 1b1. But also other members of the AhR gene battery 
were highly up regulated (e.g. Ugt1a6a and Gsta1). In addition, various genes involved in 
lipid metabolism were also significantly altered by TCDD treatment in the present study. 
These results outline the role of TCDD in the dysregulation of the hepatic lipid metabolism 
which is primarily based on the AhR-mediated enhanced uptake of fatty acids and 
accumulation of triglycerides in the murine liver (Polandet al., 1982a) (Huff et al., 1991) 
(Boverhof et al., 2006) (Kopec et al., 2010a) (Kopec et al., 2010b) (Angrish et al., 2012). 
PCB 153 had a weaker impact on the murine hepatic gene expression compared to TCDD. 
Single dose administration of 150000 µg/kg bw PCB 153 resulted in the up regulation of 
genes associated with xenobiotic metabolism such as Cyp2b9, Cyp2b10, Cyp3a11, Aldh1a1, 
Akr1b7, Gsta1, and Gstp1. Cyp2b9 and Cyp2b10 are markers for the activation of constitutive 
androstane receptor (CAR). The induction of the Cyp2b10 mRNA expression was confirmed 
by RT-PCR analysis (Table 10) while the mRNA expression of Cyp3a44 was not 
significantly induced. Cyp3a44 is a female mouse-specific gene which is primarily and 
selectively regulated by PXR and not by CAR (Bhadhprasit et al., 2007) (Anakk et al., 2007). 
Cyp3a11 was slightly up regulated in the performed microarray study. CYP3A11 is the main 
representative of the CYP3A isoenzyme class and commonly used as marker for PXR 
activation. Previous studies demonstrated the CAR-dependent regulation of Cyp3a11, e.g. by 
phenobarbital, a CAR inducer (Anakk et al., 2004) (Anakk et al., 2007). These findings 
strongly suggest that the up regulation of Cyp3a11 is most likely mediated by the constitutive 
androstane receptor. The Cyp3a44 mRNA expression was neither up regulated in the 
microarray study nor in RT-PCR analysis, implying that the PXR was not activated by PCB 
153. Several cytochromes of the Cyp2c class (Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c38, 
Cyp2c39, and Cyp2c54), which are involved in arachidonic acid metabolism, were also up 
regulated. The deregulation of the arachidonic acid signalling pathway by NDL-PCBs has 
been demonstrated in previously performed studies (Marks et al., 2000) (Umannova et al., 
2008).  
The implemented microarray study confirmed the role of TCDD as prototype for effects 
mediated by the aryl hydrocarbon receptor (AhR), whereas the effects caused by PCB 153, a 
NDL-PCB, are mainly faciliated by the constitutive androstane receptor (CAR). 
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IV.2 in vivo Experiments Part II 
 
The aryl hydrocarbon receptor mediates most, if not all, biological and toxic effects of DLCs 
(Poland et al., 1982a). TCDD, as the most potent representative, was classified with a Toxic 
Equivalency Factor (TEF) of 1.0 (Ahlborg et al., 1991). The TCDD-mediated toxic 
mechanisms are expected to be clarified in the following animal experiment by elucidation of 
the role of the aryl hydrocarbon receptor. The assessment of the systemic exposure is the 
centre of interest by investigating the blood (metabolomics) as well as the gene expression 
(RT-PCR and microarray analysis) in livers of Ahr knockout and control mice. The research 
project was gratefully supported by the 'Stiftung Innovation Rheinland-Pfalz'. 
Heterozygous C57BL/6 mice (Ahr+/-) were obtained from Jackson Laboratory (Bar Habor, 
ME, USA). Breeding of Ahr knockout mice was started at the National Institute for Health 
and Welfare, Kupio, Finland, under supervision of Dr. Matti Viluksela and continued in our 
laboratory animal unit at the University Kaiserslautern. All animals were genotyped before 
different experimental approaches were carried out. Further information about the genetic 
background, breeding, and genotyping of transgenic mice is given in chapter six (VI 
Methods). 
 
IV.2.1 Metabolomics 
 
The terminus 'metabolomics' means the global analysis of metabolites in a biofluid or tissue. 
This innovative powerful technique aims to capture all small molecules generated in the 
process of metabolism. Metabolomics and the other 'omics approaches, including genomics, 
transcriptomics, and proteomics aspire to understand the biology of an organism and its 
response to exogenous or endogenous stimuli or respectively to genetic perturbance. Two 
different strategies in metabolomic analysis have emerged during the last decade, metabolic 
profiling and metabolic fingerprinting. Metabolic profiling focuses on the quantitative 
analysis of a group of metabolites related to a class of compounds or to a specific metabolic 
pathway. Metabolic fingerprinting, however, constitutes a global screening approach by 
comparing patterns or 'fingerprints'. The emphasis is not to identify each metabolite but to 
detect distinctions between, i.e. different genotypes (Fiehn, 2002) (Dettmer et al., 2007). 
In the present work, possible differences between aryl hydrocarbon receptor-deficient mice 
(Ahr-/-) and wild-type mice (Ahr+/+) were investigated by analyzing mouse plasma of each 
genotype by HPLC-ESI-MS/MS. Both approaches were used in the present work with the 
emphasis being on the identification of differences in patterns of the mouse plasma. 
Additionally, a database consisting of mouse plasma metabolites has been initiated. 
Adult female and male Ahr+/+ and Ahr-/-mice aged 4 - 9 month were narcotized and mouse 
blood was isolated from vena cava caudalis. Mouse plasma was segregated from whole 
blood, proteins were then extracted, and the protein-free mouse plasma extracts were 
evaporated to dryness and immediately measured or stored at -80 °C. Mouse plasma extracts 
were solved in water/methanol (95:5) immediately before HPLC-MS/MS analysis.  
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Detailed information about the isolation of mouse plasma and extraction steps is given in 
chapter six (VI Methods). 
The following tables feature information about HPLC-specific parameters (Table 11) as well 
as mass spectrometer conditions applied to each identified substance (Table 12).  
 
Table 11. Instrument specific parameters of HPLC (Perkin-Elmer). 
 
Column LiChroCart - LiChrosphere, Merck 
Material RP18, 250 mm x 4 mm, 5 µm 
Flow rate 0.75 ml/min 
Solvents A: water (0.1 % HCOOH) B: methanol 
Injection volume 30 µl 
UV detection 260 nm 
Time (min) Solvent A (%) Solvent B (%) 
0.1 100 0 
41 10 90 
44 10 90 
50 100 0 
55 100 0 
 
Table 12. Instrument specific parameters mass spectrometer (API 2000, AB Sciex). 
DP: declustering potential; EP: entrance potential; CE: collision energy; CEP: cell entrance potential;  
CXP: cell exit potential; CUR: curtain gas; CAD: collisionally activated dissociation;  
IS: ionspray voltage; TEM: temperature; GS1: gas 1; GS2: gas 2. 
 
Parameter (Quadrupole) Values 
DP (V) 20 
EP (V) 200 
CE (V) 15-25 
CEP (V) 9.69 
CXP (V) 15 
Source/gas  Values 
CUR (psi) 20 
CAD 5 
IS (V) 4200 
TEM (°C) 400 
GS1 20 
GS2 20 
 
The collision energy varied depending on the analyzed plasma metabolite resulting in the 
following CE values: tryptophan (CE: 25); phenylalanine: (CE: 15); tyrosine (CE: 15); valine 
(CE: 20); leucine (CE:15); methionine (CE:15); betaine (CE:15).  
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IV.2.1.1 Metabolic Profiling 
 
First of all, the established HPLC-MS/MS method described in detail in the prior chapter was 
used to perform preliminary experiments using plasma samples of Ahr wild-type mice. 
The identification of metabolites was not possible only with the aid of the total ion current 
(TIC) chromatogram (Figure 16 at top) due to the low metabolite concentrations in the mouse 
plasma. Nevertheless, the UV chromatogram (Figure 16 at bottom) revealed a number of 
peaks. Obviously, patterns of both Ahr wild-type mice were similar to each other, only the 
peak height varied. These differences in peak height can be explained by interindividual 
differences and variations of isolated blood volumes, but these effects cannot be attributed to 
a specific gender without doubt.  
 
 
 
Figure 16. Measurement of mouse plasma metabolites of two adult Ahr+/+ mice by HPLC-MS/MS. 
At top total ion current (TIC) chromatogram, at bottom UV chromatogram (260 nm). 
Overlay of two different Ahr wild-type mice with different genders: male (blue), female (red). 
 
The analysis of the chromatographic fingerprints of Ahr knockout and wild-type mice was the 
major research objective with emphasis on the identification of differences and similarities 
between both genotypes. Several complications affected the research task. Unfortunately, the 
breeding of Ahr knockout mice was proven very difficult due to the infertility of Ahr 
knockout mice. Homozygous Ahr-/- mice and homozygous Ahr+/+ mice were achieved by 
mating female and male heterozygous Ahr+/-mice. A few hours after birth or within the first 
two to three weeks the majority of Ahr knockout mice died. These findings outline the 
physiological role of the aryl hydrocarbon receptor in normal development. 
The following figure displays the comparison of UV chromatograms of plasma extracts 
obtained from Ahr knockout and wild-type mice. Comparing the four UV chromatograms at 
260 nm by overlaying UV data from Ahr knockout mouse (green) and Ahr wild-type mice 
(red, grey, and blue) resulted in an interestingly large overlap of various peaks (black arrows 
in Figure 17). As indicated in Figure 16 before, the peak heights differ most likely due to the 
♂ Ahr+/+ 
♀ Ahr+/+ 
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maintained blood volume. Most differences in UV peak pattern were observed at an early 
stage (retention times four to ten minutes) where hydrophilic compounds were expected to be 
eluted due to the selected HPLC conditions.  
With retention times between six to seven minutes two peaks were identified as Ahr-/--specific 
(green arrows). Furthermore, two additional peaks with retention times between eight to ten 
minutes were only visible in plasma extracts obtained from Ahr-/- mouse. Nevertheless, it was 
not possible to detect significant differences in peak patterns with increasing retention times 
until the end of the established program. In summary, by analyzing the metabolic profile of 
Ahr knockout and Ahr wild-type mice with the established HPLC-MS/MS set up, it was 
possible to detect differences in the peak pattern of both genotypes, suggesting putative 
hydrophilic metabolites which were rather Ahr-/--specific.  
 
 
 
Figure 17. Metabolic profiling approach - results from HPLC-MS/MS analysis. 
Overlay of UV chromatograms at 260 nm. 
Comparing mouse plasma metabolites of 3 adult Ahr+/+ mice to an adult Ahr-/- mouse. 
Male Ahr-/- mouse (green); male Ahr+/+ mice (red, grey); female Ahr+/+ mouse (blue). 
 
 
 
 
 
 
 
 
 
 
♂ Ahr-/- 
♂ Ahr+/+ 
♂ Ahr+/+ 
♀ Ahr+/+ 
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IV.2.1.2 Metabolic Fingerprinting 
 
The last chapter dealt with the metabolic profiling leading to UV peaks which were Ahr-/--
specific. In the following chapter the centre of interest lays on the identification of these 
peaks, e.g. by HPLC-MS/MS. As shown in Figure 17, the peak pattern of an Ahr knockout 
mouse looks similar to a wild-type mouse, but additional peaks were detected in the UV 
chromatogram of the Ahr knockout mouse. 
Figure 18 displays the results of the metabolic analysis by HPLC-MS/MS of mouse plasma 
obtained from an adult male Ahr knockout mouse featuring the stratetic approach for plasma 
metabolite identification. Because of the low plasma metabolite concentrations, the 
identification of metabolites only with the aid of the total ion current (TIC) chromatogram 
was not possible (Figure 18, at top). Nevertheless, the UV chromatogram (second up) led to a 
number of peaks. Each peak in the UV chromatogram was analyzed by examination of the 
mass to charge ratios (m/z) underneath (third). 
First, a peak of interest was picked. In this case, the selected peak in the UV chromatogram 
with the retention time of 21.33 min (Figure 18, second up). Afterwards, the background 
around the chosen peak (± 1 min) was subtracted (not shown) to eliminate mass to charge 
ratios which were not relevant for the selected peak. All mass to charge ratios with an 
intensity ≥ 1000 cps were selected separately and examined if their intensities significantly 
exceeded the background noise. Of all detected mass to charge ratios (between 50-500 amu) 
in Q1 (Figure 18, third), only an m/z value of 205.2 led to an explicit peak with a correlating 
retention time in the extracted ion chromatogram (XIC). Retention times always differ 
between the UV and MS detector due to the order of instruments. Summarizing all gained 
information, it's highly probable that the m/z value of 205.2 only represents one unique 
plasma metabolite. By comparing data from metabolomic databases (Human Metabolome 
Database (HMDB), METLIN (Metabolite and Tandem MS Database)) and further 
experimental analysis via product ion scan of the selected mass to charge ratio of 205.2 led to 
the conclusion that tryptophan (Trp) is the mouse plasma metabolite with the featured 
characteristics. Finally, tryptophan as pure substance was also measured with the same 
HPLC-MS/MS settings confirming that the mouse plasma metabolite was positively identified 
as tryptophan. 
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Figure 18. Metabolic fingerprinting approach in mouse plasma samples. 
From top to bottom: total ion current (TIC) chromatogram, UV chromatogram (260 nm), 
Q1 mass scan of mass to charge ratios (m/z) of selected peak, extracted ion chromatogram (XIC)  
of selected peak with m/z 205.2. 
 
This strategy was used to identify further metabolites (Table 13). Though not all detected 
mouse metabolites were UV active. All peaks in the UV chromatogram at 260 nm were 
examined one by one with the chosen approach. In addition, tyrosine (Tyr), phenylalanine 
(Phe), valine (Va), leucine (Leu), methionine (Met), and betaine could be identified by this 
experimental approach. Extracted ion (XIC) chromatograms of mouse plasma metabolites are 
shown in Figure 19. 
 
Table 13. Overview identified mouse plasma metabolites. 
 
Metabolite 
Molecular weight 
(g/mol) 
UV absorbance  
at 260 nM 
   [M+H]+ 
Tryptophan (Trp) 204.23 + 205.2 
Phenylalanine (Phe) 165.19 - 166.2 
Tyrosine (Tyr) 181.19 + 182.2 
Valine (Va) 117.15 - 118.2 
Leucine (Leu) 131.18 - 132.2 
Methionine (Met) 149.21 - 150.2 
Betaine 117.15 - 118.2 
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Figure 19.  Extracted ion (XIC) chromatograms of identified plasma metabolites in Ahr+/+ and Ahr-/- mice. 
From top to bottom: tryptophan, phenylalanine, tyrosine, valine, leucine, methionine, and betaine. 
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The identification of mouse plasma metabolites with priority on recognizing Ahr knockout-
specific metabolites were the main objectives of the metabolic fingerprinting approach. Figure 
20 below summarizes the obtained findings. 
 
 
Figure 20. Identification of plasma metabolites of an adult male Ahr-/- mouse. 
At top total ion current (TIC) chromatogram, at bottom UV chromatogram (260 nm). 
Identified metabolites included: betaine, valine (Val), methionine (Met), tyrosine (Tyr),  
leucine (Leu), phenylalanine (Phe), and tryptophan (Trp). 
 
The identification of seven mouse plasma metabolites in mice of both genotypes was achieved 
with the developed, optimized, and established HPLC-ESI-MS/MS program and settings. 
Betaine, Val, Met, Leu, Phe, Tyr, and Trp were successfully identified, thus only the last two 
were UV active at 260 nm. It was unfortunately not possible to detect the UV active Ahr-/--
specific peaks (green marking). This leads to the suggestion that the metabolites disguised 
underneath these peaks likely compromise similar polarities. Another difficulty in the chosen 
approach was the low plasma metabolite concentrations. In the present work, plasma samples 
of each genotype were measured separately to achieve individual information from each 
animal. Another possible research approach would be the pooling of the samples, whereas 
individual information would get lost and a possible abnormality of one sample could lead to 
ambiguous conclusions. 
 
 
 
 
 
 
 
Tyr Trp 
Leu 
betaine 
Met 
Val 
Phe 
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IV.2.2 Mouse Study III - Transgenic Mouse Study 
 
The transgenic mouse five days study was performed at the University Kaiserslautern. Four 
female mice of each genotype (Ahr-/- and Ahr+/+) were either treated with a single dose of 
TCDD (25 µg/kg bw) or corn oil by gavage. The application volume was 2.5 ml/kg bw. Mice 
were anesthetized with an overdose of pentobarbital and liver samples were extracted 
surgically from animals 96 h after single dose treatment, cut into slices, and were snap frozen 
immediately in liquid nitrogen and stored at -80 °C. Further information about the animal 
experiment is given in chapter six (VI Methods).  
 
IV.2.2.1 Relative Liver Weights 
 
The relative liver weight was calculated as the ratio between the absolute liver weight and the 
related body weight of each animal. Figure 21 summarizes the results of the mouse five days 
study. Relative liver weights of Ahr-/- mice were significantly reduced compared to their 
Ahr+/+ littermates. The decrease in liver weight is directly related to a reduction in hepatocyte 
size which is a result of the massive portosystemic shunting in Ahr-/- mice (Lahvis et al., 
2000). A small, but not significant increase of the relative liver weights was determined 
comparing the Ahr-/- vehicle control animals (3.51 % ± 0.27 %) to the TCDD-treated Ahr-/- 
animals (4.27 % ± 1.17 %). The high standard deviations were due to interindividual 
differences between the four animals. A significant increase of the relative liver weight was 
measured between Ahr+/+ vehicle control mice (4.41 % ± 0.24 %) and TCDD-treated Ahr+/+ 
animals (6.52 % ± 0.29 %). In a toxicogenomic study performed by Boverhof et al (2006), the 
relative liver weights of male Ahr+/+ were also significantly increased after treatment with 
TCDD (100 and 300 µg/kg bw), whereas lower TCDD-doses (0.001 - 10 µg/kg bw) had no 
impact on the murine liver weight. 
 
 
Figure 21. Relative liver weights of female Ahr-/- and Ahr+/+ mice in mouse study III. 
Absolute liver weights related to body weights, application volume 2.5 ml/kg bw. 
TCDD as one time administered dose (25 µg/kg bw), vehicle control treated with corn oil 
Data represent means ± SD of four different adult female mice. One-tailed unpaired Student’s t-test, 
###= p ≤ 0.001 (vehicle control Ahr knockout vs. vehicle control Ahr wild-type), ***= p ≤ 0.001 
(comparing vehicle control vs. TCDD-treated animals). 
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IV.2.2.2 Gene Expression Analysis by RT-PCR 
 
The effects of TCDD on mRNA gene expression of Cyp1a1, Cyp1a2, Cyp2b10, and Cyp3a44 
in the mouse study III are presented in Figures 22. Single dose administration of TCDD (25 
µg/kg bw) led to an extensive induction of Cyp1a1 mRNA levels in female Ahr+/+animals, i.e. 
5346.81 ± 1079.35-fold. In female Ahr-/- mice Cyp1a1 mRNA levels were below Cyp1a1 
mRNA expression of related vehicle control animals resulting in a fold-change of 0.55 ± 0.23. 
Cyp1a2 mRNA expression, as additional marker for AhR activation, was additionally 
examined. TCDD significantly induced the hepatic Cyp1a2 expression in Ahr+/+ animals 
(66.67 ± 27.78-fold) compared to control animals and Ahr-/- animals (0.26 ± 0.08-fold). The 
hepatic Cyp2b10 mRNA levels in female Ahr+/+ animals were also significantly enhanced by 
TCDD compared to control animals and resulted in a fold-change of 2.09 ± 0.30. TCDD had 
no influence on Cyp2b10 levels in female Ahr-/- animals in this study compared to 
corresponding vehicle control animals. Cyp3a44 mRNA levels were in TCDD-treated Ahr 
wild-type and in Ahr knockout mice below the Cyp3a44 expression of the respective vehicle 
control group. The genes Cyp2b10 and Cyp3a44 encode proteins which function as hepatic 
xenobiotic metabolising enzymes. Their expression is not regulated through the AhR, but 
through different transcription factors CAR and PXR, respectively. The mRNA levels for 
Cyp3a44 were suppressed about the same order of magnitude in both. Cyp3a44 is a female 
mouse-specific gene which is primarily regulated by PXR (Sakuma et al., 2002). Considering 
the fact that Cyp3a44 mRNA expression was down regulated in Ahr wild-type and knockout 
mice by TCDD, an AhR-independent mechanism could be responsible for this effect.  
 
 
 
Figure 22. Real-time PCR ratios of female Ahr+/+ / Ahr-/- mice treated with TCDD - mouse study III. 
36b4 served as housekeeping gene, TCDD as one-time administered dose (25 µg/kg bw). 
Data represent means + SD of four different adult female mice. Normalized to corresponding vehicle 
control. One-tailed unpaired Student’s t-test with Welch correction, *= p ≤ 0.05, **= p ≤ 0.01 
(comparing vehicle control vs. TCDD-treated animals), #= p ≤ 0.05, ##= p ≤ 0.01 (comparing TCDD-
treated Ahr wild-type vs. TCDD-treated Ahr knockout animals). 
0
2
4
1000
2000
3000
4000
5000
6000
7000
****
mRNA expression of Cyp1a1/Cyp1a2/Cyp2b10/Cyp3a44 
                  in Ahr wild-type and knockout mice
0                                                 25
#
##
**
##
**
##
**
**
x
-f
o
ld
TCDD (µg/kg bw)
 Cyp1a1/36b4    Ahr
+/+
 Cyp1a1/36b4    Ahr
-/-
 Cyp1a2/36b4    Ahr
+/+
 Cyp1a2/36b4    Ahr
-/-
 Cyp2b10/36b4   Ahr
+/+
 Cyp2b10/36b4   Ahr
-/-
 Cyp3a44/36b4   Ahr
+/+
 Cyp3a44/36b4   Ahr
-/-
Results and Discussion 
 
68 
 
IV.2.2.3 Microarray Analysis - Mouse Study III 
 
Results of the real-time PCR analysis revealed distinct differences between TCDD-treated 
Ahr knockout and wild-type mice (IV.2.2.2 Gene expression analysis by RT-PCR). 
Alterations in gene expression of the different genotypes after TCDD treatment were 
examined by applying microarray analysis of the female mouse liver. After sacrificing of the 
animals, tissues including mouse liver and kidney were isolated, cut into smaller pieces       
(30 mg), immediately snap frozen in liquid nitrogen, and stored at -80 °C until further usage. 
In the present work the female mouse liver was the centre of attention. As a result of this, the 
following microarray analysis was performed using samples of female mouse livers.  
Whole Mouse Genome Oligo Microarray 4x44K (Agilent Technologies, Waldbronn) was 
used to measure altered genes between control groups (treated with corn oil) and compound-
treated mice. Further information about the experimental procedures and conditions as well as 
data processing and statistical analysis are given in chapters six and seven (VI Methods and 
VII Materials) of the present work. Microarray data from liver and kidney of each genotype is 
summarized in one data file to extract all information from this microarray experiment. The 
microarray analysis of mouse livers is featured in the present chapter. Microarray results were 
filtered by cut-off values for the signal intensity A ≥ 7, the log2 fold-change ≥ 1 or ≤ -1, and 
the p-value ≤ 0.05. 
The mRNA alteration of a specific oligonucleotide sequence of a gene (probe) displays the 
possible up or down regulation of the respective gene. On the Agilent microarray slide 
sometimes different mRNA sequences (oligonucleotides) of the corresponding gene were 
spotted. In some cases those mRNA sequences differed in their respective up or down 
regulated mRNA expression which led to different log2 fold-changes. This phenomenon can 
be due to various reasons. On one hand, this can be attributed to the manufacturer's chosen 
nucleotide sequence which results in different binding affinities of the sample onto the slide. 
On the other hand, it could also depend on the RNA integrity of the samples. The last 
aformentioned suggestion can be excluded because the purity of the applied RNA was 
verified by Bioanalyzer before starting the experimental procedure as well as during the 
experiment by measuring the cRNA purity by nanodrop before hybridization. It both cases the 
applied samples were proven to be of good quality. Microarray analysis after exposure to an 
exogenous stimulus provides important and useful information about induced and suppressed 
metabolic pathways, but it requires further experimental gene analysis. Subsequent 
verification of gene expression levels, e.g. by RT-PCR, is necessary and fundamental. 
In the present work fold-changes of a gene with identical probes and RefSeq accession 
numbers (NM_) were calculated as average values. No average fold-change values were 
calculated if non-identical probes of one gene were obtained by microarray analysis. Though 
the term gene is used to present the microarray results, it has to be considered that the 
alteration of mRNA expression of an oligonucleotide was measured within this microarray 
experiment. 
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IV.2.2.3.1 Microarray Results - Overview Mouse Study III 
 
The large number of genes affected in livers of female wild-type and Ahr knockout mice by 
single dose treatment with TCDD (25 µg/kg bw) and subsequent sacrificing after 96 h were 
unexpected (Figure 23). 282 unique genes were up and 203 down regulated in TCDD-treated 
Ahr+/+ mice. Treatment with TCDD led to 242 up and 234 down regulated genes in Ahr-/-
mice. Interestingly, the number of altered genes in both mouse genotypes was within the same 
extent although the aryl hydrocarbon receptor was knocked out. The following chapters deal 
with the separate closer examination of genes affected in livers of female Ahr+/+ and Ahr-/-
mice first, before up and down regulated genes of both genotypes are compared to each other. 
First, an overview of the obtained results is featured in the presented heatmap below (Figure 
24). Both heatmaps show how differently genes were altered in both genotypes. An up 
regulation is illustrated as intense, bright red (Cyp1a1) and the down regulation of a gene is 
pictured in the heatmap as a light, vibrant green (Sult3a1). The two featured heatmaps 
visualize the TCDD-mediated alterations in hepatic gene expression in livers of Ahr+/+ and 
Ahr-/- mice which will be analyzed in the following chapters. 
 
 
 
Figure 23. Microarray results of mouse five days study - mouse study III. 
Quantity of affected genes in female mouse livers after treatment with TCDD (25 µg/kg bw)  
in Ahr wild-type (left-hand side) and Ahr knockout (right-hand side). 
Selected cut-off values: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
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                                    TCDD-treated Ahr -/-  TCDD-treated Ahr +/+ 
 
Figure 24. Heatmaps obtained from microarray data - mouse study III. 
Two times Pearson correlation, cutoff-values: A ≥ 7, log2 fc ≥ 2 or ≤ -2, p-value ≤ 0.05. 
 
 
IV.2.2.3.2 TCDD-treated Ahr Wild-type Mice 
 
Due to the large amount of affected genes after treatment with TCDD, only a selection of the 
most relevant genes is described in detail in the following chapter. A list of all significantly up 
and down regulated genes is attached to the present work (Tables 85 and 86). TCDD 
treatment led to 282 unique up and 203 down regulated genes in livers of female Ahr+/+ mice 
by applying selected cut-off values (Figure 23). From the 282 up regulated genes in female 
mice livers after exposure to TCDD (25 µg/kg bw) the majority of genes (about 70 %) were 
only slightly, but statistically significantly up regulated (log2 fc values between 1 - 2). Only 
13 genes had log2 fc-values ≥ 3. The top ten of the highest up and down regulated are listed in 
the Table 14. The highest up regulated genes in female mouse liver were the best known 
markers for AhR activation upon dioxin-exposure namely Cyp1a1, 1b1, and 1a2 with Cyp1a1 
being by far the highest up regulated gene in livers of Ahr wild-type mice treated with TCDD, 
followed by Cyp1b1 and Cyp1a2. 
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Tuba8 (tubulin alpha 8) was also among the ten highest up regulated genes. Alpha-tubulin and     
β-tubulin form a heterodimer complex that assembles into microtubules which constitute one 
of the major components of the cytoskeleton in eukaryotic cells and are therefore involved in 
various essential processes including cell division, motility, and intracellular transport. The 
potential role of TUBA8 in the regulation of cell growth, proliferation, and cellular migration 
was demonstrated in an in vitro study in which Huh7 and HepG2 cells were stable transfected 
with the murine Tuba8 (Kamino et al., 2011). The induction of Tuba8 was also observed in 
TCDD-treated male Ahr wild-type mice in a study performed by Tijet and co-workers (Tijet 
et al., 2006). Gsta1 (glutathione S-transferase alpha 1) belongs to the murine aromatic 
hydrocarbon gene battery (Nebert et al., 2000) and was also induced in livers of female Ahr 
wild-type mice. Other members of the family of glutathione S-transferases were likewise up 
regulated in livers of TCDD-treated wild-type mice including Gsta2, Gstm1, Gstm2, Gstm3, 
Gstm4, Gstp1, Gstp2, and Gstt2. Glutathione S-transferases play key roles within drug 
metabolism, more concretely, during phase II drug metabolism by conjugating xenobiotics 
(Boverhof et al., 2006) (Yeager et al., 2009). Consistently, UDP glucorosyltransferases which 
are also involved in biotransformation of xenobiotics (Ugt1a6a, Ugt1a10, and Ugt2b35) were 
up regulated in TCDD-treated wild-type mice. 
Serpine1 (serine (or cysteine) peptidase inhibitor clade E, member 1) was also among the ten 
highest up regulated genes in livers of Ahr+/+ mice. Three other members of this class of 
peptidase inhibitors were also significantly up regulated including Serpina6, Serpinb6a, and 
Serpinb6c. Likewise, insulin-like 6 (Insl6) was among the 10 highest up regulated genes. 
Insl6 encodes a protein with several physiological functions (Burnicka-Turek et al., 2009) 
(Zeng et al., 2010). Insl6 mRNA levels were strikingly induced upon skeletal muscle injury. 
Zeng et al. demonstrated that insulin-like 6 is a myokine and that its overexpression resulted 
in the stimulated proliferation and reduced apoptosis in cultured myogenic cells. The 
knockdown of Insl6 led to the reduced proliferation and increased apoptosis in mice (Zeng et 
al., 2010). Tiparp (TCDD-inducible poly (ADP-ribose) polymerase) and Hsd17b2 
(hydroxysteroid (17-beta) dehydrogenase) were also significantly up regulated in livers of Ahr 
wild-type mice. Fhit, the flavin histidine triade gene, was also among the top ten of 
significantly up regulated genes in wild-type mice. FHIT is a known tumour suppressor gene 
in humans (Schlott et al., 1999). The up regulation of the human FHIT by TCDD was 
furthermore demonstrated in a microarray study by the use of the human liver cell line HL1-1 
(Kim et al., 2009). 
From the 203 down regulated genes the majority of genes were slightly but statistically 
significantly suppressed (-1 ≤ log2 fc ≥ -1) in livers of TCDD-treated female Ahr wild-type 
mice. The highest down regulated gene in TCDD-treated Ahr wild-type mice was Sult3a1 
(sulfotransferase family 3a, member 1). Sulfotransferases belong to the phase II enzymes 
which are responsible to convert xenobiotics and their metabolites into hydrophilic products 
which afterwards can be excreted by the organism (Alnouti et al., 2006). In a previously 
published study it was demonstrated that Sult3a1 mRNA levels after TCDD treatment were 
down regulated in livers of female Ahr+/+ and Ahr-/- mice compared to the genotype-specific 
vehicle controls. However, hepatic Sult3a1 mRNA levels were not affected in livers of male 
mice of each genotype after TCDD-treatment. The constitutive hepatic levels of female Ahr-/- 
mice were already decreased compared to female Ahr+/+ mice (Aleksunes et al., 2012).  
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In conclusion the down regulation of Sult3a1 in the present mouse study is probably the result 
of a gender-specific effect. 
As displayed in Table 14, in some cases genes, i.e. olionucleotides sequences are spotted on 
the microarray slide, but their biological functions are not fully determined. For instance at 
the time of the microarray design, Gm7231 was annotated by Agilent Technologies as 
predicted gene. Analysis of the probe nucleotide sequence by using nucleotide BLAST 
software (National Center for Biotechnology Information) revealed that the Gm7231-assigned 
probe was specific for Sult2a7 (sulfotransferase family 2a, dehydroepiandrosterone (DEHA)-
preferring, member 7). Hydroxysteroid sulfotransferases such as SULT2A7 catalyze the 
sulfonation of xenobiotics, hydroxysteroids, and toxic hydrophobic bilde acids. Seven hepatic 
Sult2a (Sult2a1-7) genes are expressed in mouse. Their expression is regulated age- and sex-
dependent. Sult2a7 is expressed in the adult male and female liver, but not detected in the pre-
pubertal mouse liver of either sex (Kocarek et al., 2008). 
Serpinb1a (serine (or cysteine) peptidase inhibitor, clade B, member 1a) was also strongly 
suppressed in livers of TCDD-treated female wild-type mice. Other down regulated peptidase 
inhibitors were Serpina3h, Serpina7, and Serpina11. The mRNA down regulation of 
Serpinb1a, Serpina3h, Serpina7, and Serpina11 is in harsh contrast to the strong induction of 
Serpine1, Serpina6, Serpinb6a, and Serpinb6c. This leads to the suggestion that the class of 
Serpin proteins have a broad range of biological functions which are tightly regulated by the 
different family members. The Hao1 (hydroxyacid oxidase 1) gene was also among the group 
of the highest down regulated genes. In addition, the Hao2 mRNA expression of this gene 
was also suppressed in livers of Ahr wild-type mice. Furthermore, the hepatic Cyp3a44 gene 
was additionally down regulated in TCDD-treated female Ahr wild-type mice. CYP3A44, a 
member of the cytochrome P450 isoenzymes, is a female-specific xenobiotic metabolizing 
enzyme in the mouse liver. Regulation of Cyp3a44 expression is mediated through the 
pregnane-X-receptor (PXR) (Anakk et al., 2004) (Bhadhprasit et al., 2007) (Roos, 2011).  
Another gene down regulated in the mouse five days study was Mup3 (major urinary protein 
3). Mup3 was not the only member of Mups which was down regulated in mouse study III. 
The mRNA expression of Mup9 and Mup21 were also significantly down regulated compared 
to the vehicle controls. MUP is the major protein component of the mouse urine. Its 
expression is sex-dependent. Adult male mice secrete 5- to 20-times more MUPs than their 
female counterparts (Flower et al., 1996). Hakk and co-workers identified mouse MUP as 
TCDD carrier protein in which the highly lipophilic TCDD is at least partly eliminated by 
urine (Hakk et al., 2009) in Cyp1a2-deficient mice as well as in wild-type ones. Csad 
(cysteine sulfinic acid decarboxylase) was also among the ten highest down regulated genes. 
Csad encodes an enzyme which is involved in the biosynthesis of taurine. Taurine is needed 
for fundamental biological processes such as the development of brain and eye, reproduction, 
and the anti-inflammatory activity of leukocytes (Park et al., 2002). The suppression of Csad 
by TCDD in male Ahr+/+ mice was demonstrated by Yoon and co-workers in a previous 
performed study (Yoon et al., 2006).  
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Due to the large amount of data the Gene set enrichment analysis with topGo was used to 
search for the key pathways which were affected in female mouse liver of Ahr+/+ mice after 
treatment with TCDD. Different methods can be used to localize dependencies. In the 
following the method 'classic' was used to calculate the enrichment of each GO term 
independently based on a multiple t-test. Further information about data processing is given in 
chapter VI.3.7.2 Microarray data analysis and processing. Table 15 and 16 feature enriched 
GO terms and corresponding genes involved in up (Table 15) and down regulation (Table 16) 
in livers of Ahr wild-type mice after one-time treatment with TCDD (25 µg/kg bw). Affected 
pathways derived from up regulated genes included predominantly the response to a chemical 
stimulus (GO:0071466, GO:0009410, and GO:0042221), in particular xenobiotic metabolism 
(GO:0006805, GO:0071466, and GO:0042178) as well as various processes involved in small 
molecule metabolic processes (GO:0044281, GO:0042180, GO:0019752, GO:0043436, 
GO:0006082, and GO:0032787) and lipid metabolism (GO:0006629). The first position in the 
list of enriched GO terms based on data from up regulated genes was assigned to the 
glutathione metabolic process (GO:0006749) which is a metabolic branch of the sulphur 
compound metabolic process (GO:0006790). Furthermore, cellular metabolic processes 
involved in amino acid metabolisms were affected in TCDD-treated Ahr wild-type mice 
(GO:0006575 and GO:0006520), too. 
 
Enriched GO terms based on data of down regulated genes in the present microarray study 
revealed suppressed metabolic branches. Predominantly processes within lipid metabolism 
(GO:0008610, GO:0044255, and GO:0006638) were down regulated such as triglyceride 
(GO:0019432 and GO:0006641), fatty acid (GO:0006631) and acylglycerol (GO:0006639) 
metabolic processes. Neutral lipid (e.g. triglyerides, fatty acids) metabolic processes include 
the chemical reaction and pathways involving neutral lipids which are only soluble in solvents 
of very low polarity. However, metabolic processes concerning small molecules 
(GO:0044281, GO:0044283, GO:000602, GO:0019752, GO:0043436, GO:0042180, 
GO:0044281, GO:0032787, GO:0016053, and GO:0046394) were also identified as enriched 
GO terms from the data of up regulated genes, whereas the genes associated with the different 
cellular processes differed from one another. 
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Table 14. 10 highest up and down regulated genes in livers of TCDD-treated Ahr wild-type mice (mouse study III - mouse five days study). 
TCDD as one time administered dose (25 µg/kg bw). 
Selected parameters for microarray analysis: cut-off values: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
Annotations:  '*'calculated mean log 2 fc-value from identical probes. 
                                '#'analysis revealed non-identical probes of this gene have different log2 fc values. 
 
Gene name Gene description Probe name Systematic name Log2 fc 
Up regulation (top 10)       
 
Cyp1a1 Cytochrome P450 family 1, subunit a, polypeptide 1 A_51_P279693 NM_009992 9.11 
Cyp1b1 Cytochrome P450 family 1, subunit b, polypeptide 1 A_51_P255456 NM_009994 6.00 
Cyp1a2 Cytochrome P450 family 1, subunit a, polypeptide 2 A_52_P595871 NM_009993 5.38 
Tuba8 Tubulin alpha 8 A_66_P119518 NM_017379 4.39 
Gsta1 Glutathione S-transferase alpha 1 (Ya) A_55_P2032946 NM_008181 3.98 
Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 A_55_P2119257 NM_008871 3.90 
Gm9933 Predicted gene ENSMUSG00000054044 A_55_P2004099 XM_001477458 3.73 
Insl6 Insulin-like 6  A_51_P459108 NM_013754 3.66 
Tiparp# TCDD-inducible poly(ADP-ribose) polymerase  A_55_P1985890 NM_178892 3.39 
Fhit# Fragile histidine triad gene  A_55_P2032714 NM_010210 3.30 
Down regulation (top 10)       
 
Sult3a1 Sulfotransferase family 3A, member 1 A_55_P2129449 NM_020565 -4.36 
Gm7231 (aka Sult2a7) Predicted gene EG638251 A_52_P293682 XM_001477336 -3.44 
Serpinb1a Serine (or cysteine) peptidase inhibitor clade B, member 1a A_55_P2006008 NM_025429 -3.19 
Loc100047222 Similar to anti-glycoprotein-B of human Cytomegalovirus immunoglobulin Vl chain A_52_P614207 XM_001477680 -2.97 
ENSMUST00000103426 Immunoglobulin heavy chain C gene segment A_51_P485421 ENSMUST00000103426 -2.93* 
ENSMUST00000103401 Immunoglobulin Kappa light chain V gene segment  A_52_P502849 ENSMUST00000103401 -2.89 
Hao1 Hydroxyacid oxidase 1 A_66_P105270 NM_010403 -2.86 
Cyp3a44 Cytochrome P450 family 3, subunit a, polypeptide 44 A_52_P366803 NM_177380 -2.82 
Mup3 Major urinary protein 3  A_55_P1971237 NM_001039544 -2.80 
Csad Cysteine sulfinic acid decarboxylase  A_51_P268529 NM_144942 -2.72 
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Table 15. Gene Ontology (GO) analysis using topGO of up regulated genes in Ahr wild-type mice (A-value ≥ 7, log2 fc ≥ 1, p ≤ 0.05). 
Classical enrichment analysis by testing the over-representation of GO terms within the group of differentially expressed genes was performed using Fisher's exact test. 
Annotations:   '°' two unique probes of this gene were up regulated. 
                       '>' three unique probes of this gene were up regulated. 
 
 
GO.ID Term Genes 
1 GO:0006749 Glutathione metabolic process Gpx3, Gss, Gsta1, Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2 
2 GO:0042180 Cellular ketone metabolic process Acot1, Acot2, Acot3°, Acot4, Cbr1, Chdh, Cyb5, Cyp1A1, CYP1A2, CYP4a10>, Elovl5, Gss, Gsta1, 
Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2, Htatip2, Lpl°, Mgll°, Nags, Pdk2, Ppd4, Pkm2, 
Slc22a5, Slc35d1, Ucp3, Ugdh, Wdtc1 
3 GO:0019752 Carboxylic acid metabolic process Acot1, Acot2, Acot3°, Acot4, Cbr1, Chdh, Cyb5, Cyp1A1, CYP1A2, CYP4a10>, Elovl5, Gss, Gsta1, 
Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2, Htatip2, Lpl°, Mgll°, Nags, Pdk2, Ppd4, Pkm2, 
Slc22a5, Slc35d1, Ucp3, Ugdh, Wdtc1 
4 GO:0043436 Oxoacid metabolic process Acot1, Acot2, Acot3°, Acot4, Cbr1, Chdh, Cyb5, Cyp1A1, CYP1A2, CYP4a10>, Elovl5, Gss, Gsta1, 
Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2, Htatip2, Lpl°, Mgll°, Nags, Pdk2, Ppd4, Pkm2, 
Slc22a5, Slc35d1, Ucp3, Ugdh, Wdtc1 
5 GO:0006082 Organic acid metabolic process Acot1, Acot2, Acot3°, Acot4, Cbr1, Chdh, Cyb5, Cyp1A1, CYP1A2, CYP4a10>, Elovl5, Gss, Gsta1, 
Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2, Htatip2, Lpl°, Mgll°, Nags, Pdk2, Ppd4, Pkm2, 
Slc22a5, Slc35d1, Ucp3, Ugdh, Wdtc1 
6 GO:0006805 Xenobiotic metabolic process Cyp1a1, Gsta1, Gsta2, Gstm2>, Gstm4, Gstp1°, Gstp2° 
7 GO:0071466 Cellular response to xenobiotic stimulus Cyp1a1, Gsta1, Gsta2, Gstm2>, Gstm4, Gstp1°, Gstp2° 
8 GO:0006518 Peptide metabolic process Gpx3, Gss, Gsta1, Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2 
9 GO:0009410 Response to xenobiotic stimulus Cyp1a1, Gsta1, Gsta2, Gstm2>, Gstm4, Gstp1°, Gstp2° 
10 GO:0044281 Small molecule metabolic process 6430573F11RIK, Acot1, Acot2, Acot3°, Acot4, Aldh1l1, Car2, Cat, Cbr1, Ccno, Chdh, Cyb5, 
Cyp1a2, Cyp1b1, Cyp4A10>, DCXR, Elovl5, ENSMUST00000106148, Entpd2, Entpd5, Fhit*, 
Gbp2, Gpx3, Gss, Gsta1, Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2, Htatip2, Lpl°, Mgll°, 
Nags, Pdk2, Pdk4, Pkm2, Pld6, Pmm1°, Retsat, Saa1, Slc22a5, Slc35d1, Srd5a3, Tgfb1, Tmem86b, 
Tpm1, Tuba8, Ucp3, Tubb4, Ugdh, Upp1, Vldlr, Wdr92, Wdtc1, Xdh 
11 GO:0042178 Xenobiotic catabolic process Cyp1a1, Gsta1, Gsta2, Gstm2>, Gstm4 
12 GO:0001676 Long-chain fatty acid metabolic process Acot1, Acot2, Acot3°, Acot4, Cyp4a10>, Elovl5, Mgll° 
13 GO:0006575 Cellular modified amino acid metabolic process Chdh, Gpx3, Gss, Gsta1, Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2° 
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14 GO:0006629 Lipid metabolic process Acot1, Acot2, Acot3°, Acot4, Cat, Cyb5, Cyp1a1, Cyp1a2, Cyp1b1, Cyp4a10>, Elovl5, 
ENSMUST00000109462, Hexa, Hsd17b2, Hsd17b6, Lpl°, Mgll°, Naga, Pla2g12a, Pla2g7°, Pld6, 
Retsat, Saa1, Serpina6, Srd5a3, Stard5, Tiparp°, Tmem86b, Ucp3, Vldlr, Wdtc1 
15 GO:0070887 Cellular response to chemical stimulus Cat, Ccl2, Ccl6, Cdh1, Col1a1, Col3a1, Col4a1, Csf2rb2, Cxcl10, Cyp1a1, 
ENSMUST00000105501, ENSMUST00000109462, Fcer1g, Fcgr3, Gbp2, Gpx3, Gsta1, Gsta2, 
Gstm2>, Gstm4, Gstp1°,Gstp2°, Hba-a2, Hmgb2, Il1r1, Jak3, Lcn2, Nfe2l2, Saa1, Serpine1, Vldlr, 
Wdtc1 
16 GO:0032787 Monocarboxylic acid metabolic process Acot1, Acot2, Acot3°, Acot4, Cyb5, Cyp1a1, Cyp1a2, Cyp4a10>, Elovl5, Lpl°, Mgll°, Pdk2, Pdk4, 
Pkm2, Slc35d1, Ucp3, Ugdh, Wdtc1 
17 GO:0006790 Sulfur compound metabolic process Gpx3, Gss, Gsta1, Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Gstt2 
18 GO:0042221 Response to chemical stimulus Acot2, Casp6, Cat, Ccl2, Ccl6, Ccnd3, CD14, Cdh1, Ces2°, Clec7a, Col1a1, Col3a1, Col4a1, 
Csf2rb2, Cxcl10, Cyp1a1, Cyp1a2, Cyp1b1, ENSMUST00000105501, ENSMUST00000109462, 
Ephx1, Fcer1g, Fcgr3, Gbp2, Gpx3, Gss, Gsta1, Gsta2, Gstm2>, Gstm4, Gstp1°, Gstp2°, Hba-a2, 
Hmgb2, Hsd17b2, Il1r1, Jak3, Lcn2, Nfe2l2, Nqo1, Sqq1, Selk, Serpine1, Slc22a5, Tgfb1, Txnip, 
Ucp2, Ucp3, Vldlr, Wdtc1, Xdh 
19 GO:0006520 Cellular amino acid metabolic process Chdh, Gpx3, Gss, Gsta1, Gstm1, Gstm2>, Gstm3°, Gstp1°, Gstp2°, Htatip2, Slc22a5 
20 GO:0071926 Endocannabinoid signalling pathway Abhd6°, Mgll° 
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Table 16. Gene Ontology (GO) analysis using topGO of down regulated genes in Ahr wild-type mice (A-value ≥ 7, log2 fc ≤ -1, p ≤ 0.05). 
Classical enrichment analysis by testing the over-representation of GO terms within the group of differentially expressed genes was performed using Fisher's exact test. 
Annotations:        '°' two unique probes of this gene were down regulated. 
                            'tv' transcript variant. 
 
 GO.ID Term Genes 
1 GO:0006082 Organic acid metabolic process Acly°, Acnat2°, Acot11, Acsl3, Acss2, Afmid, Amdhd1, Avpr1a, Ccbl1, Cmah, Csad, Cyp4f14, Ddo, Dpys, 
Elovl2, Elovl6, Ensmust00000097698, Ensmust00000102901, Fasn, Ghr (tv 1), Ghr (tv 2), Gldc, Glud1, 
Got1, Hao1, Hao2, Me1°, Pah, Pdhb, Pecr, Pklr, Prkag2, Slc17a3, Slc37a4, Srebf1, Tars, Ugp2 
2 GO:0019752 Carboxylic acid metabolic process Acly°, Acnat2°, Acot11, Acsl3, Acss2, Afmid, Amdhd1, Avpr1a, Ccbl1, Cmah, Csad, Cyp4f14, Ddo, Dpys, 
Elovl2, Elovl6, Ensmust00000097698, Ensmust00000102901, Fasn, Ghr (tv 1), Ghr (tv 2), Gldc, Glud1, 
Got1, Hao1, Hao2, Me1°, Pah, Pdhb, Pecr, Pklr, Prkag2, Slc37a4, Srebf1, Tars, Ugp2 
3 GO:0043436 Oxoacid metabolic process Acly°, Acnat2°, Acot11, Acsl3, Acss2, Afmid, Amdhd1, Avpr1a, Ccbl1, Cmah, Csad, Cyp4f14, Ddo, Dpys, 
Elovl2, Elovl6, Ensmust00000097698, Ensmust00000102901, Fasn, Ghr (tv 1), Ghr (tv 2), Gldc, Glud1, 
Got1, Hao1, Hao2, Me1°, Pah, Pdhb, Pecr, Pklr, Prkag2, Slc37a4, Srebf1, Tars, Ugp2 
4 GO:0042180 Cellular ketone metabolic process Acly°, Acnat2°, Acot11, Acsl3, Acss2, Afmid, Amdhd1, Avpr1a, Ccbl1, Cmah, Csad, Cyp4f14, Ddo, Dpys, 
Elovl2, Elovl6, Ensmust00000097698, Ensmust00000102901, Fasn, Ghr (tv 1), Ghr (tv 2), Gldc, Glud1, 
Got1, Hao1, Hao2, Me1°, Pah, Pdhb, Pecr, Pklr, Prkag2, Slc37a4, Srebf1, Tars, Ugp2 
5 GO:0044281 Small molecule metabolic process Aadac, Acly°, Acnat2°, Acot11, Acsl3, Acss2, Afmid, Aldob, Amdhd1, Avpr1a, Car3, Ccbl1, Cmah, Csad, 
Cxcl13, Cyp4f14, Ddo, Dgat2, Dpys, Ebpl, Elovl2, Elovl6, Ensmust00000097698, Ensmust00000102901, 
Ensmust00000106328, Entpd8, Fasn, Fdps, Ghr (tv 1), Ghr (tv 2), Gldc, Glud1, Got1, Gpd2, Hao1, Hao2, 
Hmgcs1, Inmt, Khk, Me1°, Ntrk2, Pah, Pdhb, Pecr, Pklr, Prkag2, Pygl, Sc5d, Setdb2, Sgsm1, Slc17a3, 
Slc37a4, Sqle, Srebf1, Tars, Thrsp, Tk1, Ugp2 
6 GO:0032787 Monocarboxylic acid metabolic process Acly°, Acnat2°, Acot11, Acsl3, Acss2, Avpr1a, Ccbl1, Cyp4f14, Elovl2, Elovl6, ENSMUST00000097698, 
Fasn, Ghr (tv 1), Ghr (tv 2), Hao1, Hao2, Pdhb, Pecr, Pklr, Prkag2, Slc37a4, Srebf1, Ugp2 
f GO:0006629 Lipid metabolic process Aadac, Acly°, Acnat2°,Acot11, Acsl3, Acss2, Avpr1a, Cyp4f14, Dgat2, Ebpl, Elovl2, Elovl6, 
ENSMUST00000080361, ENSMUST00000097698, ENSMUST00000102901, Fasn, Fdps, Ghr (tv 1), Ghr 
(tv 2), Hao1, Hao2, Hmgcs1, Mid1ip1, Pecr, Pla1a, Prkag2, Rdh11, Sc5d, Slc37a4, Sqle, Srd5a1, Srebf1, 
St6galnac6, Thrsp 
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8 GO:0044283 Small molecule biosynthetic process Acly°, Acsl3, Acss2, Avpr1a, Ccbl1, Elovl2, Elovl6, ENSMUST00000097698, ENSMUST00000102901, 
Fasn, Fdps, Glud1, Got1, Gpd2, Pah, Pecr, Pklr, Prfag2, Pygl, Srebf1, Ugp2 
9 GO:0016053 Organic acid biosynthetic process Acly°, Acsl3, Acss2, Avpr1a, Ccbl1, Elovl2, Elovl6, ENSMUST00000097698, ENSMUST00000102901, 
Fasn, Glud1, Got1,Pah, Pecr, Pklr, Prkag2, Srebf1, Ugp2 
10 GO:0046394 Carboxylic acid biosynthetic process Acly°, Acsl3, Acss2, Avpr1a, Ccbl1, Elovl2, Elovl6, ENSMUST00000097698, ENSMUST00000102901, 
Fasn, Glud1, Got1,Pah, Pecr, Pklr, Prkag2, Srebf1, Ugp2 
11 GO:0019432 Triglyceride biosynthetic process Acly°, Acsl3, Dgat2, Elovl2, Elovl6, ENSMUST00000102901, Fasn, Srebf1, Thrsp 
12 GO:0046460 Neutral lipid biosynthetic process Acly°, Acsl3, Dgat2, Elovl2, Elovl6, ENSMUST00000102901, Fasn, Srebf1, Thrsp 
13 GO:0046463 Acylglycerol biosynthetic process Acly°, Acsl3, Dgat2, Elovl2, Elovl6,ENSMUST00000102901, Fasn, Srebf1, Thrsp 
14 GO:0046504 Glycerol ether biosynthetic process Acly°, Acsl3, Dgat2, Elovl2, Elovl6, ENSMUST00000102901, Fasn, Srebf1, Thrsp 
15 GO:0006641 Triglyceride metabolic process Aadac, Acly°, Acsl3, Dgat2, Elovl2, Elovl6, ENSMUST00000102901, Fasn, Slc37a4, Srebf1, Thrsp 
16 GO:0006631 Fatty acid metabolic process Acly°, Acnat2°, Acot11, Acsl3, Avpr1a, Cyp4f14, Elovl2, Elovl6, ENSMUST00000097698, Fasn, Ghr (tv 1), 
Ghr (tv2), Hao1, Hao2, Pecr, Prkag2, Srebf1 
17 GO:0006639 Acylglycerol metabolic process Aadac, Acly°, Acsl3, Dgat2, Elovl2, Elovl6, ENSMUST00000102901, Fasn, Slc37a4, Srebf1, Thrsp 
18 GO:0006638 Neutral lipid metabolic process Aadac, Acly°, Acsl3, Dgat2, Elovl2, Elovl6, ENSMUST00000102901, Fasn, Slc37a4, Srebf1, Thrsp 
19 GO:0008610 Lipid biosynthetic process Acly°, Acsl3, Acss2, Avpr1a, Dgat2, Elovl2, Elovl6, ENSMUST00000080361, ENSMUST00000097698, 
ENSMUST00000102901, Fasn, Fdps, Hmgcs1, Mid1ip1, Pecr, Prkag2, Sc5d, Srd5a1, Srebf1, St6galnac6, 
Thrsp 
20 GO:0044255 Cellular lipid metabolic process Aadac, Acly°, Acnat2°, Acot11, Acsl3, Avpr1a, Cyp4f14, Dgat2, Elovl2, Elovl6, ENSMUST00000097698, 
ENSMUST00000102901, Fasn, Fdps, Ghr (tv 1), Ghr (tv 2), Hao1, Hao2, Hmgcs1, Pecr, Prkag2, Slc37a4, 
Srebf1, St6galnac6, Thrsp 
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IV.2.2.3.3 TCDD-treated Ahr Knockout Mice 
 
Single dose treatment with TCDD (25 µg/kg bw) led to the up regulation of 242 and to down 
regulation of 234 unique genes in female Ahr knockout mice applying selected cut-off values. 
These findings were unexpected because the aryl hydrocarbon receptor was not present in the 
organism. This draws to the conclusion that the exogenous stimulus (TCDD) affected the 
hepatic gene expression in an AhR-independent manner. In the following, the TCDD-altered 
hepatic gene expression in female Ahr knockout mice is characterized and possible 
explanations are given for this phenomenon.  
Because of the large amount of genes being up regulated in female mouse liver only the ten 
highest up and down regulated genes are listed below (Table 17). A list of all up and down 
regulated genes within the range of the selected parameters (A ≥ 7, log2 fc ≥ 2, and p ≤ 0.05) 
is attached to the present work (Tables 87 and 88).  
The highest up regulated gene in female mouse liver of Ahr-/- mice was the endothelial cell-
specific molecule 1 (Esm1). Esm1 encodes a dermatan sulphate proteoglycan which circulates 
in the blood in the healthy organism. Due to its circulating proteoglycan activity it can be 
rather fast present at sites of inflammation or tumour sites. Experimental evidence suggests its 
involvement in the modulation of major biological processes such as cell adhesion, 
inflammatory abnormalities, and tumour progression (Sarrazin et al., 2006). No correlation 
between TCDD treatment and the up regulation of Esm1 gene has been described so far. The 
up regulation of Esm1 in the present study leads to the suggestion that TCDD, as exogenous 
stimulus, evoked an inflammatatory response in Ahr knockout mice which is AhR-
independent. Lysmd2 (LysM putative peptidoglycan-binding, domain containing 2) was also 
among the ten highest up regulated hepatic genes in TCDD-treated Ahr knockout mice. Its 
role and function in metabolism of rodents and humans has not been characterized up to the 
present day. The gene lipoprotein lipase (Lpl) encodes a protein that is a key enzyme in lipid 
metabolism which is responsible for storing fatty acids as triglycerides in the adipose tissue. 
The liver-specific Lpl overexpression has been associated with the development of fatty liver 
(Olson et al., 1998) (Hong et al., 2011).  
Alpha fetoprotein (Afp) was additionally among the highest up regulated genes in livers of 
female Ahr knockout mice after exposure to TCDD. The Afp gene belongs to a multigenic 
family comprised of related genes encoding albumin, α-albumin, and vitamin D binding 
protein. Gabant et al. elucidated Afp's role in female fertility as they demonstrated that female 
Afp-deficient mice to be infertile in their performed study (Gabant et al., 2002). The leptin 
receptor (Lepr) gene encodes a protein which functions as 'adipostat' by passing information 
to the body about its status of energy storage in adipose tissues (Tartaglia et al., 1997). In 
addition, the calcium and integrin binding family member 3 (Cib3) was among the ten highest 
up regulated genes in female Ahr knockout mice. Integrins are heterdimeric adhesion 
receptors on the surface of platelets proteins which therefore play a fundamental role in 
homeostasis (Yamniuk et al., 2006) (DeNofrio et al., 2008). Consistently, another gene 
involved in cell-cell adhesion was also up regulated, namely cadherin 1 (Cdh1). Cdh1 
encodes the epithelial-cadherin protein (E-cadherin). Cadherins are calcium-dependent cell-
cell adhesion molecules. Cadherins of the type E play important roles in salivary gland 
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morphogenesis (Shirayoshi et al., 1986) (Walker et al., 2008). Ras responsive element binding 
protein 1 (Rreb1, transcript variant 1) was furthermore up regulated in TCDD-treated Ahr 
knockout mice. RREB1 was identified as vascular estrogen-regulated transcription factor by 
Schnoes and co-workers (Schnoes et al., 2008). A gene involved in the cellular amino acid 
metabolism (asparagine synthetase, Asns) (Barbosa-Tessmann et al., 2000) was also among 
the highest up regulated genes in female TCDD-treated Ahr-/- mice. 
 
234 unique genes were down regulated in livers of TCDD-treated Ahr-/- mice although only 
14 genes obtained log2 fc values ≤ -3 compared to the corresponding corn-oil treated Ahr-/- 
mice using the selected parameters (A ≥ 7, log 2 fc ≤ -1, and p ≤ 0.05). On closer examination 
of 10 highest down regulated genes (Table 17), various genes were only predicted genes at the 
time of performing the microarray experiment. During analysis of the obtained microarray 
results the oligonucleotide sequences (probes) of those predicted genes (Gm7231, Gm5584, 
and GM6957) were blasted online using NCBI's Basic Local Alignment Search Tool 
(BLAST®, National Center for Biotechnology Information). Nucleotide BLAST software 
compares the inserted nucleotide sequences with species-specific database annotations. In 
case of the highest down regulated gene Gm7231, nucleotide blasting revealed that it is 100 % 
match with Sult2a7 (sulfotransferase family 2a, dehydroepiandrosterone (DEHA)-preferring, 
member 7). Both nucleotide probes corresponding to Gm5584 were down regulated. The 
nucleotide sequence of the probe A_52_P218833 was matching with the Sult2a3 
(sulfotransferase family 2a, dehydroepiandrosterone (DEHA)-preferring, member 3) and 
A_55_P2113587 was a 100 % match with Sult2a4 (sulfotransferase family 2a, dehydro-
epiandrosterone (DEHA)-preferring, member 4). Blasting of the nucleotide sequence of 
Gm6957 (A_55_P2107223) led to 100 % match with Sult2a6 (sulfotransferase family 2a, 
dehydroepiandrosterone (DEHA)-preferring, member 6). However, three other members 
(Sult2a1, Sult2a5, and Sult2a3) of the DEHA-preferring sulfotransferase genes led to a good 
correlation, too. 
All of Agilent’s annotated predicted genes discussed in the in the previous passage probably 
belong to the group of DEHA-preferring sulfotransferases. An additional member of this 
group, Sult2a1, was also among the highest down regulated genes in TCDD-treated Ahr-/- 
mice. Hydroxysteroid sulfotransferases catalyze the sulfonation of xenobiotics, 
hydroxysteriods, and toxic hydrophobic bile acids. Seven hepatic Sult2a (Sult2a1-7) enzymes 
are expressed in mice, but their mRNA expression is regulated age- and sex-dependent 
(Kocarek et al., 2008). The hepatic Sult2a1 gene expression can be stimulated by PXR and 
CAR (Echchgadda et al., 2004). Therefore, it was unexpected that TCDD treatment led to the 
down regulation of those hydroxysteriod sulfotransferases in livers of Ahr knockout mice 
since both nuclear receptors are not involved in the dioxin-mediated biological responses. 
This allows drawing the conculsion that as a result of the Ahr knockdown, the signalling 
pathways of other nuclear receptors could additionally be affected but to verify this 
assumption further intensive research work is nessecary. Sult2a1 is the predominant form of 
the hydroxysteroid sulfotransferases. No cellular effects and possible involvement in 
metabolism are described so far for the other isoforms as only the age- and sex-dependent 
expression in mouse liver has been demonstrated (Kocarek et al., 2008).  
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Among the other top ten of down regulated genes in liver of TCDD-treated Ahr knockout 
mice were the major urinary proteins and their precursor proteins (Mup5, Mup9, 
ENSMUST00000107481, and ENSMUST00000107490). Other MUP genes were also down 
regulated including Mup2, Mup6, and Mup20. MUPs belong to the lipocailin superfamily 
consisting of extracellular proteins such as retinol binding protein, β-lactoglobulin, and fatty 
acid binding protein, which bind small lipophilic molecules. MUP is the main protein 
component of the mouse urine. Its expression is sex-dependent. Adult male mice secrete 5- to 
20-times more MUPs than females (Flower et al., 1996). Hakk and co-workers identified 
mouse MUP as TCDD carrier protein to which the highly lipophilic TCDD is bound and then 
is partly eliminated in the urine (Hakk et al., 2009). 
 
In addition, gene set enrichment analysis with topGo was performed with the microarray data 
obtained from livers of TCDD-treated female Ahr knockout mice. Different methods can be 
used to localize dependencies. The method 'classic' was used to calculate the enrichment of 
each GO term independently, based on a multiple t-test. Additional information about the 
microarray data analysis and processing is given in chapter VI.3.7.2. Table 18 and 19 display 
the enriched GO terms and corresponding genes identified being up (Table 18) or down 
regulated (Table 19) in Ahr knockout mice after single dose treatment with TCDD (25 µg/kg 
bw).  
TCDD treatment of Ahr knockout mice led to the up regulation of various cellular processes 
involved in the regulation of homeopoesis (GO:0002328, GO:0002244, GO:0030195, 
GO:1900047, GO:0032964,GO:0048821, and GO:0050819), cellular transport, and 
movements mechanisms (GO:0031340, GO:2000008, and GO:0006928). Genes involved in 
the regulation of prostaglandin biosynthesis (GO:0031392, GO:0031394) as well as the 
regulation of unsaturated fatty acid biosynthetic processes (GO:2001279, GO:2001280) were 
also enriched compared to the vehicle control animals. Furthermore, genes associated with the 
triglyceride biosynthetic process (GO:0019432) were additionally up regulated. 
Gene ontology pathway profiling of the significantly down regulated genes in livers of 
TCDD-treated Ahr knockout mice resulted in diverse affected metabolic processes. 
Remarkably, TCDD treatment of Ahr knockout mice led to the enrichment of the metabolic 
processes involved in the response to a chemical stimulus (GO:0042221). Though, it must be 
taken into consideration that the respective genes which are responsible for the enrichment of 
those metabolic branches are down regulated in the present microarray study. The small 
molecule metabolic processes (GO:0006082, GO:0042180, GO:0019752, GO:0043436, and 
GO:0032787) were also down regulated in Ahr-/- mice as was the case for Ahr+/+ mice. 
However, the genes which led to the down regulation of the mentioned metabolic processes 
overwhelmingly differed for both genotypes. Other down regulated cellular processes in livers 
of Ahr-/- mice included lipid metabolism (GO:0006629), regulation of hormone levels 
(GO:0010817, GO:0042445), secondary metabolic processes (GO:0019748), and processes 
involved in cellular oxidation-reduction (GO:0055114). Genes (Pax2, Pax8) involved in 
kidney processes (GO:0072017 and GO:0072025) were furthermore down regulated.  
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Upon closer examination of the enriched GO terms, only a small number of the 234 up 
regulated genes were associated with different metabolic processes. Besides the large amount 
of up and down regulated genes in liver of Ahr knockout mice, the overall gene inducibiliy 
resp. suppression was rather weak. Additionally, the majority of the significantly enriched 
pathways are associated with common metabolic processes drawing the conclusion that no 
specific pathway was affected by TCDD treatment in the female mouse liver of Ahr-/- mice, 
but rather the exogenous stimulus evoked a diverse AhR-independent response. 
. 
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Table 17. 10 highest up and down regulated genes in livers of TCDD-treated Ahr knockout mice (mouse study III - mouse five days study). 
TCDD as one time administered dose (25 µg/kg bw). 
Selected parameters for microarray analysis: cutoff values: A ≥ 7, log 2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
Annotations:      '*' calculated mean log 2 fc value from identical probes. 
                            '#' analysis revealed non-identical probes of this gene have different values (colour intensity, p-value or log2 fc value). 
 
Gene name Gene description Probe name Systematic name Log2 fc 
Up regulation (top 10)         
Esm1 Endothelial cell-specific molecule 1  A_52_P257625 NM_023612 3.51 
Lysmd2 LysM putative peptidoglycan-binding domain containing 2 A_51_P233160 NM_027309 3.09* 
Lpl* Lipoprotein lipase  A_51_P259296 NM_008509 2.86# 
Afp Alpha fetoprotein  A_51_P510891 NM_007423 1.07 
Lepr Leptin receptor, transcript variant 3 A_55_P2192662 NM_001122899 2.72 
Cib3 Calcium and integrin binding family member 3  A_55_P2078494 NM_001080812 2.66 
Rreb1 Ras responsive element binding protein 1, transcript variant 1 A_55_P1981714 NR_033218 2.64 
Fabp5l2 Predicted gene EG622384 A_55_P2150976 XM_886827 2.44 
Asns Asparagine synthetase  A_55_P1959748 NM_012055 2.42 
Cdh1 Cadherin 1 A_51_P137336 NM_009864 2.39* 
Down regulation (top 10)         
Gm7231 Predicted gene EG638251 A_52_P293682 XM_001477336 -4.35 
Gm5584 Predicted gene 5584 A_52_P218833 NM_001101586 -3.96 
Gm5584 Predicted gene 5584 A_55_P1952507 NM_001101586 -3.46 
ENSMUST00000107481 Major urinary protein 4 precursor (Mup 4) partial (69%) [TC1781567] A_55_P2113587 ENSMUST00000107481 -3.71 
Mup9 Major urinary protein 9  A_55_P1979904 NM_001126319 -3.56# 
Mup5 Major urinary protein 5  A_52_P412506 NM_008649 -3.48 
ENSMUST00000107490 uo03b07.y1 Sugano mouse liver mlia Mus musculus cDNA cloneIMAGE:2582293 
5' similar to gb:M16358 Mouse major urinary protein IV (MOUSE) 
A_55_P2033321 ENSMUST00000107490 -3.45 
LOC635091 Similar to Predicted gene OTTMUSG00000007485  A_55_P2103703 XM_001475400 -3.39 
Gm6957 Predicted gene 6957 A_55_P2107223 NM_001081325 -3.37 
C730007P19Rik RIKEN cDNA C730007P19 gene A_55_P2172532 NM_009286 -3.23# 
Sult2a1 Sulfotransferase family 2a dehydroepiandrosterone (DHEA)-preferring, member 1 A_55_P1952517 NM_001111296 -3.32 
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Table 18. Gene Ontology (GO) analysis using topGO of up regulated genes in Ahr knockout mice (A-value ≥ 7, log2 fc ≥ 1, p ≤ 0.05). 
Classical enrichment analysis by testing the over-representation of GO terms within the group of differentially expressed genes was performed using Fisher's exact test. 
Annotations:        '°' two unique probes of this gene were up regulated 
 
 GO.ID Term Genes 
1 GO:0060693 Regulation of branching involved in salivary gland morphogenesis Cdh1, Fgfr1, Pdgfa 
2 GO:0031340 Positive regulation of vesicle fusion Anxa1, Pla2g4a 
3 GO:2000008 Regulation of protein localization to cell surface Dch1, Egf 
4 GO:0002328 Pro-B cell differentiation Prkdc, Xrcc4 
5 GO:0010890 Positive regulation of sequestering of triglyceride Lpl° 
6 GO:0002244 Hemopoietic progenitor cell differentiation Fst, Prkdc, Xrcc4 
7 GO:0030195 Negative regulation of blood coagulation F11, Pdgfa, Tspan8 
8 GO:1900047 Negative regulation of hemostasis F11, Pdgfa, Tspan8 
9 GO:0006928 Cellular component movement Abi2, Amot, Angpt2, Bbs4, Cckar,Ccl5, CD34, CD9, Cdhst3, Col1a1, Ctgf, Cyp1b1, 
Erbb4, F3, Fgfr1, Nck2, Pdgfa, Prkdc, Tlr2, Tuba1a1, Tuba8, Tubb6  
10 GO:0031392 Regulation of prostaglandin biosynthetic process Anxa1, Pla2g4a  
11 GO:0031394 Positive regulation of prostaglandin biosynthetic process Anxa1, Pla2g4a 
12 GO:2001279 Regulation of unsaturated fatty acid biosynthetic process Anxa1, Pla2g4a 
13 GO:2001280 Positive regulation of unsaturated fatty acid biosynthetic process Anxa1, Pla2g4a 
14 GO:0032964 Collagen biosynthetic process Col1a1, Col3a1, Ctgf 
15 GO:0019432 Triglyceride biosynthetic process Acsl4, Agpat9, Lpl° 
16 GO:0006303 Double-strand break repair via nonhomologous end joining Prkdc, Xrcc4 
17 GO:0046717 Acid secretion Anxa1, Cckar, Pla2g4a 
18 GO:0010740 Positive regulation of intracellular protein kinase cascade Ark2bp, C3, Ccl5, F3, Lepr, Nenf, Pdgfa, S100a4, Slc20a1, Ubd, Zdhhc13 
19 GO:0048821 Erythrocyte development Hba-a2, Hbb-b1, Hbb-b2 
20 GO:0050819 Negative regulation of coagulation F11, Pdgfa, Tspan8 
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Table 19. Gene Ontology (GO) analysis using topGO of down regulated genes in Ahr knockout mice (A-value ≥ 7, log2 fc ≤ -1, p ≤ 0.05). 
Classical enrichment analysis by testing the over-representation of GO terms within the group of differentially expressed genes was performed using Fisher's exact test. 
Annotations:         '°' two unique probes of this gene were down regulated 
 
 
GO.ID Term Genes 
1 GO:0006082 Organic acid metabolic process Aacs, Acnat2, Acot3°, Acss2, Akr1d1, Aldh1a1, Cyp1a2, Fmo1, Ggt1, Glul, Gstm2, Hpgd, 
Lpin2, Me1°, Med1, Mgll, Pax8, Pdk1, Pklr, Rdh16, Sars2, Ucp3 
2 GO:0042180 Cellular ketone metabolic process Aacs, Acnat2, Acot3°, Acss2, Adra1b, Akr1d1, Aldh1a1, Cyp1a2, Foxo1, Ggt1, Glul, Gstm2, 
Hpgd,Lpin2, Me1°, Med1, Mgll, Pax8, Pdk1, Pklr, Rdh16, Sars2, Ucp3 
3 GO:0019752 Carboxylic acid metabolic process Aacs, Acnat2, Acot3°, Acss2, Adra1b, Akr1d1, Aldh1a1, Asna1, Ggt1, Glul, Gstm2, 
Hpgd,Lpin2, Me1°, Med1, Mgll, Pdk1, Pklr, Rdh16, Sars2, Ucp3 
4 GO:0043436 Oxoacid metabolic process Aacs, Acnat2, Acot3°, Acss2, Adra1b, Akr1d1, Aldh1a1, Asna1, Ggt1, Glul, Gstm2, 
Hpgd,Lpin2, Me1°, Med1, Mgll, Pdk1, Pklr, Rdh16, Sars2, Ucp3 
5 GO:0044281 Small molecule metabolic process Aacs, Acnat2, Acot3°, Acss2, Adra1b, Akr1d1, Aldh1a1, Asna1, Cyp1a2, Cyp2e1, Diras1, 
Fmo1, Foxo1, Ggt1, Glul, Gstm2, Hpgd, Inmt, Jun, Lpin2, Me1°, Med1, Mgll, Mogat1, Ncor1, 
Npr2, P2ry1, Pax8, Pdk1, Pklr, Ppp2r4, Rdh16, Sars2, Setmar, Slc9a3r1, Tbc1d20, Tmem86b, 
Tpm2°, Tubg2, Ucp3 
6 GO:0032787 Monocarboxylic acid metabolic process Aacs, Acnat2, Acot3°, Acss2, Akr1d1, Aldh1a1, Cyp1a2, Hpgd, Lpin2, Mgll, Pdk1, Pklr, 
Rdh16, Ucp3 
7 GO:0017144 Drug metabolic process Cyp1a2, Cyp2e1, Fmo3 
8 GO:0010817 Regulation of hormone levels Aacs, Akr1d1, Aldh1a1, Dio1°, Glul, Med1, P2ry1, Pax8, Rdh16, Slc22a1, Ugt2b1 
9 GO:0019748 Secondary metabolic process Cyp1a2, Dct°, Fmo1 
10 GO:0042445 Hormone metabolic process Akr1d1, Aldh1a1, Dio1°, Med1, Pax8, Rdh16, Ugt2b1 
11 GO:0006629 Lipid metabolic process Aacs, Acnat2, Acot3°, Acss2, Akr1d1, Aldh1a1, Cyp1a2, Cyp2e1, Hpgd, Inpp5e, Lpin2,Med1, 
Mgll, Mogat1, Pnpla1, Ptdss1, Rdh16, Sult2A1, Tmem86b, Ucp3, Ugt2b1 
12 GO:0055114 Oxidation-reduction process Adra1b, Akr1d1, Aldh1a1, Cyp1a2, Cyp2b13, Cyp2c37, Cyp2e1, Cyp3a44, Dhrs1, Dio1°, 
Duox1, Fmo1, Fmo3, Hpgd, Me1°, Prkaca, Rdh16, Sepw1, Vat1 
13 GO:0009719 Response to endogenous stimulus Aacs, Adra1b, Ar, Cfl1, Esrrg, Foxo1, Me1°, Pax8, Prkaca, Rorc°, Slc1a2°, Socs2 
14 GO:0042493 Response to drug Aacs, Aldh1a1, Cyp1a2, Fos, Jun, Slc1a2, Slc22a1 
15 GO:0032788 Saturated monocarboxylic acid metabolic process Acot3° 
16 GO:0032789 Unsaturated monocarboxylic acid metabolic process Acot3° 
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17 GO:0042221 Response to chemical stimulus Aacs, Adra1b, Adh1a1, Ar, Asna1, Cfl1, Chac1,Cryaa, Cyp1a2, Cyp2e1, Duox1, 
ENSMUST00000062980, Esrrg, Fga, Fos, Foxo1, Glul, Gstm2, Jun, Lifr, Me1, Mup20, Pax8, 
Pklr, Prkaca, Prlr, Rorc°, Slc1a2°, Slc22a1, Socs2, Ucp3, Ugt2b1 
18 GO:0006721 Terpenoid metabolic process Aldh1a1, Cyp1a2, Cyp2e1, Rdh16 
19 GO:0072017 Distal tubule development Pax2, Pax8 
20 GO:0072025 Distal convoluted tubule development Pax2, Pax8 
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IV.2.2.3.4 Comparison of Microarray Gene Expression Data 
 
The pattern of regulated gene in the murine liver elicited by TCDD predominantly differed in 
each genotype, resulting only in a small overlap of affected genes with 15 genes in common 
up and 18 genes in common down regulated (Figure 25). The entire list of all in common up 
and down regulated genes is attached to the present work. As expected due to the knockdown 
of the AhR the number of genes being in common up or down regulated in Ahr wild-type and 
knockout mice is remarkably small and will be discussed in the following passage. In 
addition, several genes are selected including established members of the murine aromatic 
hydrocarbon gene battery (Cyp1a1, Cyp1a2, Nqo1, Aldh3a1, Ugt1a6, and Gsta1) for 
discussion in the following paragraph (Nebert et al., 2000). 
 
                      
  
Figure 25. Comparison of in common up and down regulated gene expression in livers of Ahr wild-type and  
knockout mice treated with TCDD.  
TCDD as one time administered dose (25 µg/kg bw). 
Selected cut-off values: A ≥ 7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05. 
 
 
               TCDD-treated                  TCDD-treated 
     Ahr wild-type mice          Ahr knockout mice 
 
                 TCDD-treated                 TCDD-treated 
               Ahr wild-type mice         Ahr knockout mice 
 
Figure 26. Comparison of differently regulated gene expression in livers of wild-type and knockout mice  
after treatment with TCDD. TCDD as one time administered dose (25 µg/kg bw). 
Selected cut-off values: A ≥ 7, log2 fc ≥ 1 ≤ -1, p-value ≤ 0.05. 
 
TCDD-treated    
Ahr wild-type mice
TCDD-treated    
Ahr knockout mice
267              15            227 
185              18            216 
       Up regulation             Down regulation       Down regulation           Up regulation 
268      17      217 191      12      242 
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The induction of CYP1A1, CYP1A2, and CYP1B1 is an established marker for AhR 
activation by dioxin exposure in mouse (Shimada et al., 2002a). A high induction of Cyp1a1 
was obtained from TCDD-treated Ahr wild-type mice, whereas no significant increase or 
decrease was determined in livers of Ahr knockout mice as expected. Furthermore, the 
Cyp1a2 gene was also highly up regulated in wild-type mice, whereas Cyp1a2 was slightly, 
but statistically significantly down regulated in Ahr knockout mice. Cyp1a2 belongs to the 
murine AhR gene battery and is known to be inducible by TCDD (Nebert et al., 2000) (Nebert 
et al., 2004). Tijet and co-workers demonstrated that male Ahr+/+ mice featured a higher a 
Cyp1a2 expression (about 4-fold) compared to Ahr-/- mice (Tijet et al., 2006). The lowered 
constitutive expression of the murine Cyp1a2 gene in livers of Ahr-/- mice was demonstrated 
by Shimada et al., too (Shimada et al., 2002b). A high Cyp1b1 mRNA expression was 
obtained from Ahr wild-type mice, thus the Cyp1b1 gene was also slightly up regulated in Ahr 
knockout mice. It was observed in various studies that the TCDD-induced Cyp1b1 induction 
is based on AhR activation. (Nebert et al., 2004) (Tijet et al., 2006) (Boutros et al., 2009). 
However, Cyp1b1 is only constitutively expressed at very low levels in livers of wild-type and 
Ahr knockout mice (Shimada et al., 2002b). Bui and co-workers demonstrated that the hepatic 
Cyp1b1 mRNA expression levels after treatment with TCDD (50 µg/kg bw) in Ahr knockout 
mice were also slightly higher compared to mRNA levels of Cyp1a1 and Cyp1a2 in livers of 
Ahr-/- mice (Bui et al., 2012). The slight, but significant up regulation of this gene could be 
mediated by a different receptor than the AhR, but this possibility has to be confirmed by 
further analysis. Of the four non Cyp P450 classic AhR-regulated genes Nqo1, Gsta1, and 
Ugt1a6a showed a solid induction in Ahr wild-type mice, but not in knockout mice, whereas 
no change in Aldh3a1 gene expression was determined for both genotypes in the present 
microarray study. The AhR-mediated induction of Aldh3a1 was demonstrated in various 
carcinoma cell lines and in rat, but the high dosage of TCDD (200 µg/kg bw) did not induce 
the hepatic Aldh3a1 expression in mouse in vivo, only in vitro in several murine hepatoma 
cell lines (Vasiliou et al., 1993) (Alnouti et al., 2006) (Tijet et al., 2006). In order to find novel 
quantifiable biomarkers for dioxin exposure five target genes were selected (Aldh3a1, Tiparp, 
Hsd17b2, Cd36, and Ahrr); within those candidates Tiparp, Hsd17b2, and Ahrr were up 
regulated in the present mouse microarray study, but the obtained colour intensity for Ahrr 
were below the selected value of 7. 
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Table 20. Comparison of selected genes in Ahr-/- and Ahr+/+ mice. 
Table features aspects such as gene name, probe name, systematic name, and corresponding  
log2 fold-changes.  
Annotations:     '→' gene was not up regulated in microarray experiment. 
 
Gene name Probe name Systematic name Colour intensity  
Log2 fc 
Ahr+/+ 
Log2 fc 
Ahr-/- 
Cyp1a1 A_51_P279693 NM_009992 8.29 9.11 → 
Cyp1a2 A_52_P595871 NM_009993 9.86 5.38 -2.19 
Cyp1b1 A_51_P255456 NM_009994 9.46 6.00 1.51 
Nqo1 A_51_P424338 NM_008706 10.40 1.79 → 
Gsta1 (Ya) A_55_P2032946 NM_008181 11.78 3.98 → 
Ugt1a6a A_55_P2143765 NM_145079 9.48 1.76 → 
Ugt1a6a A_55_P1962404 NM_145079 16.21 1.44 → 
Aldh3a1 A_55_P2065562 NM_007436 6.47 → → 
Tiparp A_55_P1985890 NM_178892 9.35 3.39 → 
Tiparp A_51_P514961 NM_178892 9.90 3.26 → 
Hsd17b2 A_51_P441914 NM_008290 10.73 1.54 → 
Cd36 A_51_P375146 NM_007643 10.98 → → 
Ahrr A_55_P2128388 NM_009644 5.06 1.07 → 
Ahrr A_51_P254425 NM_009644 6.44 3.98 → 
 
Table 21 features the differently regulated hepatic genes, i.e. which were up regulated in Ahr 
wild-type mice and down regulated in Ahr knockout mice. The most striking contrast in gene 
expression between both genotypes was gained for Cyp1a2 which was already discussed in 
the previous part.  
Fmo3, the flavin containing monooxygenase 3, belongs to the group of microsomal enzymes 
which convert highly lipophilic substrates into oxygenated metabolites with higher polarity to 
facilitate the excretion by the organism. The Fmo3 gene was strongly induced in female Ahr 
wild-type mice and suppressed in female Ahr knockout mice. These findings suggest an AhR-
dependent mechanism which was additionally postulated by Tijet and co-workers (Tijet et al., 
2006). The published microarray study revealed the induction of Fmo2 and Fmo3 mRNA 
expression by TCDD in livers of male C57BL/6J mice (wild-type mice), but not in Ahr 
knockout mice (Tijet et al., 2006). The Fmo2 mRNA expression was not affected by TCDD 
treatment in both genotypes leading to the conculsion that the up regulation of Fmo2 is a 
male-mouse specific effect. It was demonstrated that the TCDD-induced Fmo3 induction was 
a primary AhR-mediated response in 2008 (Celius et al., 2008). Furthermore, no significant 
Fmo induction by TCDD was determined in the rat liver (Moffat et al., 2010).  
Gstm2, the glutathione S-transferase m2, was induced in Ahr wild-type mice and suppressed 
in Ahr knockout mice. Other members of the family of glutathione S-transferases were also up 
regulated in livers of TCDD-treated wild-type mice including Gsta1, Gsta2, Gstm1, Gstm3, 
Gstm4, Gstp1, Gstp2, and Gstt2. No alterations of mRNA levels were measured in Ahr 
knockout mice for these glutathione S-transferase genes. Glutathione S-transferases play key 
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roles within drug metabolism, more precisely during phase II of drug metabolism in which 
xenobiotics are conjugated with highly hydrophilic endogenous molecules (Boverhof et al., 
2006) (Yeager et al., 2009). 
Purkinje cell protein 4-like 1 (Pcp4l1) encodes a neuronal protein. No studies on its 
biochemical properties are performed up to the present day (Morgan et al., 2012). The strong 
induction of Pcp4l1 was also determined in livers of male mice treated with TCDD (1000 
µg/kg) (Tijet et al., 2006). Ucp3 (mitochondrial uncoupling protein 3) gene encodes a protein 
which is involved in the regulation of the energy metabolism in muscle cells by dissipating 
the proton gradient in the inner mitochondrial membrane. It was postulated that a UCP3-
mediated proton leak might help to limit oxidative damage (Krauss et al., 2005). 
The genes Mgll (monoglyceride lipase), Acot3 (acyl-CoA thioesterase 3), and Acot 5 (acyl-
CoA thioesterase 5) were all up regulated in Ahr wild-type mice and at the same time down 
regulated in Ahr knockout mice. Mgll encodes a lipolytic enzyme which is involved in various 
cellular processes within lipid metabolism such as arachidonic acid metabolic process. Acyl-
CoA thioesterases (ACOTs) play key roles in fatty acid metabolism by catalyzing the 
hydrolysis of acyl-CoAs of different chain lengths to free fatty acids and CoASH (Hunt et al., 
2006). Tmem86b encodes the transmembrane protein 86b which has been additionally linked 
to lipid metabolism. Lhpp and Slc26a10 were also among the genotype-specific differently-
expressed genes. Lhpp encodes an enzyme which is involved in phosphate metabolism and 
Slc26a10 encodes a solute carrier which is involved in the transmembrane sulphate transport. 
The expression of the immediate early response 3 gene (Ier3) is induced upon a diverse 
variety of stimuli (cytokines, growth hormones, and other types of stress). The encoded 
protein is involved in the cell cycle control and apoptosis (Arlt et al., 2011). Otherwise, 
ELMO3 protein plays a major role in the engulfment and removal of cells during the 
apoptosis (Gumienny et al., 2001). Sunc1 (aka Sun3) encodes a protein which belongs to a 
protein family that is linked to infertility in mice of both genders. SUN1 is needed for 
telomere attachment to the nuclear envelope during meiosis. Sun1-/- mice of both genders are 
infertile due to massive apoptotic events in the gonads of Sun1-deficient mice (Ding et al., 
2007). The Lmnb2 gene encodes the proteinlamin B2 (Lmb2). B-type of lamins are major 
components of the nuclear lamina which are believed to be essential for cell proliferation and 
survival (Kim et al., 2011). 
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Table 21. Overview hepatic genes up regulated in Ahr+/+ mice and down regulated by Ahr-/- mice. 
Table features aspects such as gene name, probe name, systematic name, and corresponding  
log2 fold-changes. Selected parameters: A ≥ 7, log2 fc ≥ 1 ≤ -1, p-value ≤ 0.05. 
 
Gene name Probe name Systematic name 
Log2 fc 
Ahr+/+ 
Log 2 fc 
Ahr-/- 
Cyp1a2 A_52_P595871 NM_009993 5.38 -2.12 
Fmo3 A_55_P2059586 NM_008030 3.16 -2.80 
Fmo3 A_51_P269404 NM_008030 2.97 -2.38 
Gstm2 A_55_P1966438 NM_008183 1.28 -1.25 
Pcp4l1 A_55_P1983754 NM_025557 2.70 -2.11 
Ucp3 A_66_P108247 NM_009464 2.80 -1.40 
Mgll A_55_P2063312 NM_001166250 1.32 -1.37 
Acot3 A_55_P2069907 NM_134246 2.08 -1.60 
Acot3 A_55_P2038347 NM_134246 1.47 -1.22 
Acot5 A_55_P2038362 NM_145444 1.88 -1.16 
Tmem86b A_52_P183524 NM_023440 2.65 -1.14 
Lhpp A_66_P140507 NM_029609 1.18 -1.23 
Slc26a10 A_52_P140881 NM_177615 1.01 -1.22 
Ier3 A_51_P286488 NM_133662 1.63 -1.39 
Elmo3 A_55_P2295933 NM_172760 1.05 -1.06 
Sunc1 A_55_P2040860 NM_177576 1.66 -1.22 
Lmnb2 A_55_P2219059 NM_010722 1.49 -1.50 
ENSMUST00000063239 A_55_P2065249 ENSMUST00000063239 1.12 -1.33 
Gm7120 A_55_P2183914 NM_001039244 1.32 -1.22 
 
 
IV.2.3 Summary and Discussion in vivo Experiments Part II 
 
The AhR is a ligand-activated transcription factor. The activation of the AhR by xenobiotics 
(e.g. dioxins) results in the transcriptional up regulation of the AhR-responsive genes, i.e. so 
called 'classic' AhR target genes (Cyp1a1, Cyp1a2, Nqo1, Aldh3a1, Ugt1a6, and Gsta1) 
(Nebert et al., 2000). The corresponding enzymes are involved in oxidative detoxification or 
activation of ligands. The activation of the AhR by endogenous ligands was postulated by 
various research groups during the last decades. The AhR possesses various enogenous 
functions, for instance in different systems such as the immune, cardiovascular, neural, and 
reproductive system as well as in different tissues such as in hepatocytes, skin cells, and 
adipocytes (Nebert et al., 2000) (Nebert et al., 2004).  
The aim of the performed metabolomics study was to provide a basis for the establishment of 
an AhR metabolomics platform. Therefore, an HPLC-ESI-MS/MS method was developed and 
established to analyze the spectrum of mouse plasma metabolites in both Ahr genotypes. 
Several substances could be identified in blood plasma of Ahr wild-type and knockout mice, 
namely tryptophan, phenylalanine, leucine, thyrosin, valin, methionine, and betaine.  
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Amino acids play fundamental roles in metabolism, for instance they can be converted into 
metabolic intermediates which subsequently can be used to form glucose via gluconeogenesis 
(Berg et al., 2006). The suppression of gluconeogenesis represents a major characteristic of 
the TCDD-induced AhR-mediated hepatotoxicity in rodents (Viluksela et al., 1999) (Diani-
Moore et al., 2010).  
Furthermore, distinct differences could be detected by the use of the HPLC-UV-Vis-MS/MS 
between Ahr wild-type and knockout mice. The identification of these outstanding peaks was 
not possible, probably due to the low plasma metabolite concentrations and the rather limited 
number of animals. Nevertheless, the performed metabolomics experiments demonstrated that 
the mouse plasma metabolites of Ahr wild-type and knockout mice differ. Further analysis is 
necessary, in particular with regard to AhR-mediated alterations of plasma amino acid 
concentrations, since the impact on the circulating amino acid levels likely contribute to the 
TCDD-elicited hepatotoxic effects in rodents. Moreover, the use of whole blood instead of 
blood plasma could be another research approach which not only increases the analyze 
volume, but also could enhance the number of detectable metabolites.  
The aim of mouse study III was to analyse AhR-dependent and -independent effects in female 
Ahr knockout and wild-type mice 96 h after single dose treatment with 25 µg/kg bw TCDD. 
In the present study the relative liver weights of Ahr-/-control animals were significantly 
reduced compared to their Ahr+/+ littermates. The decrease in the relative liver weight is 
directly related to the reduction in hepatocyte size which is a result of the massive 
portosystemic shunting in Ahr-/- mice (Lahvis et al., 2000). The relative liver weights of 
TCDD-treated Ahr+/+ mice were significantly increased compared to the respective vehicle 
control animals, whereas the relative liver weights of Ahr-/- mice were not significantly 
changed by TCDD. Microarray analysis and the subsequently performed Gene set enrichment 
analysis of the TCDD-treated Ahr+/+ mouse livers revealed that a large number of genes 
associated with the lipid metabolism were altered by TCDD. For example TCDD induced 
several Acyl-CoA thioesterases (Acot 1, 2, 3, and 4) which hydrolyze acyl CoAs to free fatty 
acid and CoASH resulting in the regulation of the intracellular levels of both (Hunt et al., 
2006). Other lipolytic genes up regulated by TCDD were Lpl, Plas2g12, Plas2g7, and Mgll. 
The lipoprotein lipase (LPL), the phospholipases (PLA2G12A and PLA2G7), and 
monoglyceride lipase (MGLL) hydrolyze the hepatocellular triglyceride stores into free fatty 
acids and monoglycerides (Giller et al., 1992) (Angrish et al., 2011). The very low density 
lipoprotein receptor (VLDLR) is a cell surface receptor involved in the uptake of lipoproteins 
by internalization and degradation of triglyceride-rich lipoproteins (Yagyu et al., 2002) 
(Boverhof et al., 2006). The Elovl5 (fatty acid elongase 5) gene encodes a key enzyme which 
is involved in polyunsaturated fatty acid (PUFA) synthesis. ELOVL5 regulates the C20-22 
PUFA content, different signalling pathways (Act and PP2A), and diverse transcriptional 
factors (SREBP-1, PPARα, FoxO1, and PGC1α) which control fatty acid synthesis and 
gluconeogenesis (Jump, 2011). 
On the other hand, several genes involved in lipid metabolism were down regulated, e.g. Acly, 
Fasn, Elovl2, and Elovl6. ACLY (ATP citrate lyase) plays a key role in the synthesis of fatty 
acids. The TCDD-elicited down regulation of Fasn allows drawing the conclusion that the 
increase of the hepatic lipid content is not based on the de novo fatty acid synthesis (Forgacs 
et al., 2012) (Angrish et al., 2012). ELOVL2 has been shown to be involved in the elongation 
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of C20 and C22 polyunsaturated fatty acids (PUFAs) to produce C24:4n-6 and C24:5n-3 
PUFAs (Zadravec et al., 2011). ELOVL6 is responsible for the elongation of stearate (C18) 
from palmitate (C16), as well as the elongation of vaccinate (C18:1n-7) from palmitoleate 
(C16:1n-7) (Matsuzaka et al., 2007). 
The significantly increased liver weights together with the distinct alterations in mRNA 
expression of genes associated with lipid metabolism in female Ahr+/+ mice suggest the 
development of a hepatic steatosis due to single dose treatment with 25 µg/kg bw TCDD. 
TCDD is known to cause extremely enlarged livers as well as other liver pathologies 
including hepatic steatosis. Additionally, recent microarray studies revealed numerous 
alterations in the expression of genes linked to lipid metabolism and transport in mouse livers 
predominantly involved in hepatic steatosis (Poland et al., 1982a) (Huff et al., 1991) 
(Boverhof et al., 2006) (Kopec et al., 2010a) (Kopec et al., 2010b) (Angruish et al., 2012). 
Furthermore, various genes linked to the xenobiotic metabolism (Cyp1a1, Cyp1a2, Nqo1, 
Ugt1a6a, Gsta1, Gsta2, Gstm2, Gstm4, Gstp1, and Gstp2) were up regulated in female Ahr+/+ 
mice, but not in Ahr-/- mice. Cyp1a1 was by far the highest up regulated gene by TCDD in 
Ahr+/+ mice, followed by Cyp1b1 and Cyp1a2. Associated AhR-responsive genes such as 
Tuba8, Fmo3, and Pcp4l1 (Tijet et al., 2006) were recently reported to be inducible by TCDD 
in Ahr+/+ mice. From the group of selected target genes Tiparp, Hsd17b2, and Ahrr were also 
up regulated in Ahr+/+ mice, although Ahrr had a diminished colour intensity value compared 
to the selected value.  
Unexpectedly, one-time administration of TCDD resulted in the up and down regulation of a 
large number of hepatic genes in female Ahr-/- mice. The pattern of significantly up and down 
regulated genes in Ahr-/- mice distinctly differed from Ahr+/+ mice. Gene set enrichment 
analysis was additionally carried out to identify significantly enriched functional categories 
(Gene Ontology terms) based on the significantly up and down regulated genes in Ahr-/- mice. 
Only a vanishingly small number of genes could be associated to diverse cellular processes 
such as homeopoesis, cellular transport and movement, or lipid metabolism implying that 
most, if not all, TCDD-mediated effects are AhR-dependent. Single dose treatment with 
TCDD led to alterations of a large amount of genes in absence of the AhR. These findings 
should be analyzed in further experimental approaches to determine if these altered AhR-
independent genes contribute to the TCDD-mediated toxicity in mice and also in other 
species. 
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IV.3 in vitro Experiments  
 
In the present work human liver cell models (primary human hepatocytes and HepG2 cells) 
were used to assess the effects mediated by dioxins and dioxin-like compounds. The liver 
represents the target tissue in which TCDD has been shown to elicit carcinogenic and tumour 
promoting effects in rodents (Knerr et. al, 2006). Humans are predominantly exposed to 
PnCDD/PnCDFs and PCBs through the food chain, but also as a consequence to their 
occupations or accidents (for example Sevenso, Italy 1976). Performing essential in vitro 
experiments by the use of primary human hepatocytes and the human hepatocellular 
carcinoma cell line (HepG2) provides important information which could lead to a better 
understanding of the risk after exposure to PnCDD/Fs and PCBs in humans. Furthermore, the 
challenging task was to identify, validate, and establish quantifiable novel biomarkers for 
dioxin exposure and AhR-dependent modes of action.  
A set of seven core compounds, i.e. TCDD, 1-PnCDD, 4-PnCDF, PCB 126, PCB 118, PCB 
153, and PCB 156 and additional congeners TCDF, 1,4-HxCDF, 1,4,6-HpCDF, 1,6-HxCDD, 
1,4,6-HpCDD, PCB 77, and PCB 105 were selected for analysis in the present work (Table 
22). All test compounds were dissolved in DMSO. Final DMSO concentrations in culture 
medium did not exceed 1 % for all experiments. Primary human hepatocytes (hHeps) as well 
as the immortalized human hepatocellular carcinoma cell line HepG2 were used in the present 
work to determine concentration-dependent effects on induction of AhR-regulated gene 
expression and enzyme activity. Effects of core congeners were examined in hHeps and 
HepG2, whereas effects of further congeners were only determined in HepG2 cells. Cells 
were treated over an incubation period of 24 h with selected test substances in all 
experiments. Afterwards cells were processed depending on the subsequent experimental 
procedure (VI Methods). 
 
Table 22. Applied test compounds for in vitro experiments in order from high to low TEF values. 
Seven core congeners are indicated in bold. 
 
Test compound TEF (WHO, 2005) 
TCDD 1.0 
1-PnCDD 1.0 
1,6-HxCDD 0.1 
1,4,6-HpCDD 0.01 
TCDF 0.1 
4-PnCDF 0.3 
1,4-HxCDF 0.1 
1,4,6-HpCDF 0.01 
PCB 77 0.001 
PCB 105 0.00003 
PCB 118 0.00003 
PCB 126 0.1 
PCB 153 - 
PCB 156 0.00003 
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IV.3.1 Primary Human Hepatocytes  
 
Primary human liver cells represent the closest in vitro model to the human liver as they 
express the complete spectrum of hepatic drug-metabolizing enzymes (Hewitt et al., 2007). 
The characterization of the responses elicited by dioxins, dioxin-like, and non dioxin-like 
compounds in primary human hepatocytes provide a basis for the establishment of human in 
vitro TEFs/TEQs. Furthermore, the comparison with results obtained from the immortalized 
human hepatocellular carcinoma cell line HepG2 will provide essential insight about 
similarities and differences between untransformed cells and immortalized tumour-derived 
cell lines. (Lipp et al., 1992) (Zeiger et al., 2001) (Kim et al., 2009) (Dere et al., 2011). 
 
IV.3.1.1 Cytotoxicity Testing 
 
The Alamar Blue assay was applied to measure cell viability after incubation with the test 
compounds for 24 h under standard conditions. Assay conditions and further information 
about the experimental procedure are given in chapter six (VI Methods). In order to examine 
if the chosen test compounds cause cytotoxic effects, the viability of primary human 
hepatocytes was determined after incubation with the selected compounds. The Alamar Blue 
assay was primarily performed to identify non-cytotoxic concentration levels that could be 
used for further experimental testing. Each experiment consisted of negative controls (DMSO 
0.1 %, 0.5 %, or 1 % respectively and culture medium) as well as saponine (0.1 % in culture 
medium) as positive control.  
The seven core congeners showed no significant effects on cell viability in primary human 
hepatocytes after incubation for 24 hours. The viability values of the compound-treated 
cellswere at the same levels as the corresponding solvent controls. Therefore, test compound 
concentrations could be applied to subsequent experimental testing. 
 
 
Figure 27. Cytotoxicity testing - Alamar Blue assay in hHeps after exposure to seven core congeners. 
Data represent means ± SD, n ≥ 3, results normalized to solvent control (DMSO 0.1 %, 0.5 % or 1 %). 
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IV.3.1.2 Ethoxyresorufin-O-deethylase (EROD) Activity 
 
The catalytic activity of CYP1A1 in primary human hepatocytes was examined by measuring 
the ethoxyresorufin-O-deethylase (EROD) assay. The following figures display the results of 
the EROD assay after exposure to the seven core congeners. All experiments consisted of 
negative controls (DMSO 0.1, 0.5, or 1 % in cell culture medium) as well as one positive 
control for CYP1A1 induction (TCDD 10 nM). Findings are presented as box plot diagrams. 
Box plots, also known as box-and-whisker plots, are tools of descriptive statistics which 
display differences between populations, in the present work, between different donors.  
Figure 28 features the results of the catalytic activity of CYP1A1 in EROD assay after 
exposure to TCDD (left) and 1-PnCDD (right). A concentration-dependent increase in EROD 
activity was measured as expected for both congeners until a full response was reached. 
Maximal induction in hHeps after treatment with TCDD (1000 nM) and 1-PnCDD (500 nM) 
led to an EROD activity of 7.58 ± 2.21 and 20.04 ± 5.80 pmol/min*mg protein. The 
efficiency varied donor- and compound-dependent as featured in the figures presented below.  
Treatment of primary human hepatocytes with 4-PnCDF and PCB 126 also resulted in a 
concentration-dependent induction of CYP1A1 in EROD assay as presented in Figure 29. 
Maximal CYP1A1 induction was reached after hHeps were exposed to 1000 nM 4-PnCDF 
and 500 nM PCB 126 leading to an EROD activity of 20.35 ± 10.45 and 15.48 ± 5.76 
pmol/min*mg protein, respectively. Large differences in CYP1A1 inducibility were observed 
after exposure of hHeps to high concentrations of 4-PnCDF and PCB 126. On one hand, this 
occurrence could be due to the overall higher response in EROD activity and on the other 
hand, this effect could be based on interindividual variability among donors.  
PCB 118, PCB 156, and NDL-PCB 153 did not evoke any EROD induction in primary 
human hepatocytes as pictured in Figure 30 below. 
 
  
Figure 28. EROD assay results visualized by box plot diagrams (n ≥ 4) - TCDD and 1-PnCDD.  
Left-hand side diagram visualizes results of EROD assay in hHeps after exposure to TCDD,  
right-hand side results of EROD assay after exposure to 1-PnCDD. EROD activity of the respective 
solvent control was considered as background level and subtracted from the data. 
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Figure 29. EROD assay results visualized by box plot diagrams (n ≥ 4) - 4-PnCDF and PCB 126.  
Left-hand side diagram visualizes results of EROD assay in hHeps after exposure to 4-PnCDF,  
right-hand side results of EROD assay after exposure to PCB 126. EROD activity of the respective 
solvent control was considered as background level and subtracted from the data. 
 
 
  
Figure 30. EROD assay results visualized by box plot diagrams (n = 3) - PCB 118, 153, and 156.  
At top box: plot diagram visualizes results of EROD assay in hHeps after exposure to PCB 118.  
At bottom: left-hand side diagram reflect results of EROD assay in hHeps after exposure to PCB 153, 
right-hand side results of EROD assay after exposure to PCB 156. EROD activity of the respective 
solvent control was considered as background level and subtracted from the data. 
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In Figure 31 the used compound concentrations are plotted in a logarithmic scale against 
gained EROD activities. EC50 values were derived by sigmoidal fitting using Origin software 
(Microcal Software, Northhampton, MA, USA). The respective solvent control was regarded 
as background level and subtracted from EROD activity data. The EC50 value represents the 
test compound concentration where 50 % of its maximal effect is obtained. For EC20 values, 
the upper limit of the TCDD-derived EROD activity in hHeps was set 100 % and the 
congener concentration needed to achieve 20 % of the maximal TCDD response was 
calculated as EC20. Relative effect potencies (REPs) were obtained by dividing the EC50/EC20 
of the reference compound TCDD by the EC50/EC20 of the test compound.  
 
 
Figure 31. EROD activity (pmol resorufin/min*mg protein) plotted in a logarithmic scale - hHeps. 
Primary human hepatocytes treated with either TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126,  
PCB 153, or PCB 156 for 24 h. The respective solvent control was regarded as background level and 
subtracted from the corresponding EROD activity. 
 
Figure 31 displays the concentration-response curves for the seven core congeners and Table 
23 the derived parameters from this data. The concentration-response curves of TCDD,         
1-PnCDD, and 4-PnCDF featured similar curve shapes in the range of the respective EC50 
values, whereas in the range of the TCDD-derived EC20 level distinct differences could be 
determined. The EROD activity obtained from 1-PnCDD and 4-PnCDF increased at low 
concentrations (≤ 5 x 10-10 M) but no increase was determined by TCDD in this concentration 
range. Furthermore, the TCDD-elicited EROD activity in hHeps reached its maximum before 
1-PnCDD and 4-PnCDF reached their respective maxima. Moreover, 1-PnCDD and 4-PnCDF 
revealed both higher efficiencies. PCB 126 also reached a high efficiency, but by the use of 
high concentrations of this congener compared to TCDD. 
EC50/EC20 values and respective derived REP values are compiled and compared with WHO-
TEFs (van den Berg et al., 2006) in Table 23. The dose-dependent induction of the EROD 
activity by TCDD resulted in an EC50 value of 1.06 ± 0.57 nM which is less sensitive 
compared to other published data from hHeps (EC50 TCDD 0.15 nM Silkworth et al., 2005; 
EC50 TCDD 0.24 nM Budinski et al., 2010). The human diversity in EROD response has to be 
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considered which is characterized by sensitivity and maximal response (Silkwort et al., 2005). 
Previously performed studies on primary human hepatocytes suggested that humans have 
similar sensitivities towards TCDD, but differ in their maximal response (Schrenk et al., 
1995). Figure 31 displays the difference in EROD inducibility of different donors which 
illustrates the individual variability in maximal EROD response. 
EC50 values of 1-PnCDD and 4-PnCDF were markably below the EC50 value of TCDD, the 
opposite was obtained for the EC20 levels. No EC values could be derived for PCB 118, 153, 
and 156 which was due to their lack of EROD activity in hHeps. The higher EC20 (and 
corresponding REP) values are probably based on the fact that 1-PnCDD and 4-PnCDF 
induced the EROD activity in hHeps at lower concentrations than TCDD and furthermore as a 
result of the higher CYP1A1 inducibilities of both congeners compared to TCDD. The 
developed EC20 calculation concept was used in the present work as an approach to assess the 
potency of weaker substances compared to TCDD since they might not reach the respective 
EC50 levels. This EC20 calculation method was based on a consensus between all SYSTEQ 
project partners to assess the potencies of weaker test compounds compared to TCDD.  
REP values are additionally featured in Table 23. The relative effect potency (REP) describes 
the congener’s potency in relation to the reference compound TCDD. REPs were obtained by 
dividing the EC value (EC50/EC20) of the reference compound TCDD by the EC value 
(EC50/EC20) of the test compound. REPs of TCDD are constantly 1.0, as the TEF concept is 
based on TCDD being the reference compound. It was not possible to derive any REPs for the 
PCBs (118, 153, and 156) because of the lack in EROD induction in hHeps. REPs derived 
from EC50 values of 1-PnCDD and 4-PnCDF were below the current WHO-TEF by 3-fold 
and 5-fold in particular. These results are in harsh contrast to REPs derived from EC20 values 
of 1-PnCDD and 4-PnCDF which were about 3-fold and 6-fold higher than the current WHO-
TEF. REPs derived of PCB 126 in primary human hepatocytes were 63-fold and 53-fold 
below the current WHO-TEF, respectively. As described above, EC50 values are based on the 
obtained data from each compound itself, whereas EC20 values were calculated in relation to 
TCDD. REPs based on EC20 values are higher than the current WHO-TEF and most likely do 
not reflect the true potencies of both congeners. The developed concept for EC20 calculation is 
only applicable if test compounds have a similar or weaker activity than TCDD. It must be 
analyzed if a different calculation concept would be more suitable such as the separate 
calculation of EC20 values, as used for EC50 values, on the basis of the concentration-response 
data from each congener itself not in relation to TCDD. 
 
Table 23. Derived parameters from EROD induction in primary human hepatocytes. 
 
Congener EC50 (nM) REP (EC50) EC20 (nM) REP (EC20) TEF (WHO, 2005) 
TCDD 1.06 ± 0.57 1.0 0.420 1.0 1.0 
1-PnCDD 3.07 ± 2.44 0.35 0.158 2.66 1.0 
4-PnCDF 18.00 ± 8.59 0.059 0.242 1.74 0.3 
PCB 118 - - - - 0.00003 
PCB 126 678.45 ± 90.36 0.0016 216.74 0.0019 0.1 
PCB 153 - - -  - 
PCB 156 - - -  0.00003 
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IV.3.1.3 Microarray Analysis 
 
The induction of cytochrome P450 isoenzymes, i.e. CYP1A1, CYP1A2, and CYP1B1 is the 
best known indicator for AhR activation due to treatment with DLCs (Shimada et al., 2002). 
The development, validation, and establishment of novel quantifiable biomarkers for exposure 
to DLCs were the aspired targets of the following toxicogenomic study in primary human 
hepatocytes. Primary human hepatocytes were treated with TCDD, 1-PnCDD, 4-PnCDF,   
PCB 126, or NDL-PCB 153 for 24 h. 
Donor and treatment information is summarized in Tables 24 and 25. After RNA isolation, 
the sample RNA concentration was determined via NanoDrop (Peqlab, Erlangen). RNA 
purity was additionally verified by Agilent 2100 Bioanalyzer and associated RNA 6000 Pico 
LabChip kit (Agilent Technolgies, Waldbronn).  
In Figure 32 a representative electropherogram is featured. RNA integrity, i.e. the ratio 
between the 18S to 28S ribosomal subunits of all donors, was determined and the so called 
RINs (RNA Integrity Numbers) were obtained. All samples featured high-quality RNA (RIN 
≥ 8.9). Afterwards, Agilent's Two-Color Microarray-based Expression Analysis according to 
Agilent's Low Input Quick Amp Labeling Kit was performed using cyanine 3- and cyanine 5-
labelled targets to measure expression in experimental and control samples. Solvent control 
samples and compound-treated samples were stained oppositionally. 100 ng per sample was 
chosen as starting RNA concentration. Alterations in mRNA expression of the spotted 
oligonucleotides were measured using the Whole Human Genome Oligo Microarray 4x44K 
(Agilent Technologies, Waldbronn). Further information about the experimental procedures 
and conditions as well as data processing and statistical analysis are given in chapter six (VI 
Methods). 
 
 
Figure 32. Representative electropherogram analyzing RNA quality. 
RNA isolated from TCDD-treated (10 nM) primary human hepatocytes (Donor 2). 
Obtained RIN value: 9.7. 
 
 
 
18S 
28S 
Marker 
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Table 24. Background information about human donors - hHeps used for microarray and real-time PCR analysis. 
 
Donor 
Age 
(years) 
Gender Ethnicity 
Viability 
(%) 
HIV1/HBC/HCVa Smoking Alcohol Diabetes Heart Disease Hypertension Liver pathology 
1 63 Female Unknown 91 negative no no no no no Not available 
2 48 Female Caucasian 88 negative yes no no no no Adenocarcinoma from a rectosigmoid cancer 
3 64 Male Unknown 95 negative no no no no yes Left liver tumour 
4 45 Female Caucasian 94 negative no no no no no Hepatocellular carcinoma (HCC) 
5 59 Male Unknown 85 negative no yes no no yes Hepatic metastases 
6 65 Male Unknown 93 negative yes unknown no unknown unknown Hepatic metastases 
7 61 Male Unknown 82 negative no no no no no Liver metastases from carcinoma of the colon 
8 60 Female Unknown 86 negative no unknown no unknown unknown Hepatic metastases 
9 73 Male Caucasian 85 unknown unknown unknown unknown yes yes Not available 
10 50 Male Caucasian 88 negative no no no no no Liver metastases from carcinoma of the colon 
 
aHuman immunodeficiency virus 1/Hepatitis B virus/Hepatitis C virus  
 
Primary human hepatocytes from donors 1-5 were exposed to TCDD as positive control, PCB 153 as negative control, and DMSO as solvent 
control (DMSO 0.1 % in culture medium) for 24 h. After these first experiments were carried out, further studies were realized by treatment of 
hHeps isolated from donors 6-10 with 1-PnCDD, 4-PnCDF, PCB 126, and DMSO (solvent control 0.1 % in culture medium). Based on current 
WHO-TEFs, treatment-concentrations were chosen, whereby for NDL-PCB 153 the highest stock solution was used for treatment. 
 
Table 25. Microarray analysis of hHeps - test compound incubation concentrations. 
 
Congener Concentrations (nM) TEF (WHO, 2005) 
TCDD 10 1.0 
1-PnCDD 10 1.0 
4-PnCDF 30 0.3 
PCB 126 100 0.1 
PCB 153 1000 - 
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Microarray data of all compound treatments (TCDD, 1-PnCDD, 4-PnCDF, PCB 126, and 
PCB 153) is summarized in one data file. Results are filtered by cut-off values for the signal 
intensity A ≥ 7, the log2 fold-change ≥ 1 or ≤ -1, and the p-value ≤ 0.05.  
Figure 33 displays the principle component analysis (PCA) based on the microarray data from 
all human donors and all treatments. The derived microarray data of donors concerning the 
respective treatment was highly homogenous, no outliners could be identified. Considering 
the results of the PCA, all performed microarray experiments were included in data analysis.  
 
 
 
Figure 33. Principle component analysis of hHeps microarray results with emphasis on treatment. 
Blue: TCDD (10 nM), green: 1-PnCDD (10 nM), orange: 4-PnCDF (30 nM),  
brown: PCB 126 (100 nM), yellow: PCB 153 (1000 nM). 
 
The quantity of affected genes in primary human hepatocytes is displayed in Figure 34. 
TCDD treatment resulted in the up regulation of 112 genes, whereas only 17 genes were 
down regulated. Treatment with 1-PnCDD affected a total of 96 genes, whereby 74 were up 
and 12 down regulated in hHeps. Moreover, 4-PnCDF treatment had impact on 95 (up) and 7 
(down). On the other hand, PCB 126 treatment led to smaller numbers resulting in 26 unique 
up regulated genes and no significantly down regulated genes. Treatment with NDL-PCB 153 
did not affect the mRNA gene expression in primary human hepatocytes within the range of 
the selected parameters. 
The most extensive overlap (Figure 35) was detected between TCDD and 4-PnCDF treatment 
by sharing 71 up and 6 down regulated genes. With 62 in common up and 9 down regulated 
genes, TCDD and 1-PnCDD treatment resulted additionally in a large overlap. The very small 
numbers of genes affected by PCB 126 treatment were almost completely overlapping with 
those affected by TCDD leading to 25 in common up regulated genes by both compounds. 
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Figure 34. Microarray results primary human hepatocytes - unique up and down regulated genes. 
Selected parameters: A ≥7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05. 
 
 
  
Figure 35. Up and down regulated genes illustrated as Venn diagrams. 
Comparison between TCDD and 1-PnCDD, 4-PnCDF as well as PCB 126. 
Selected parameters: A ≥7, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05. 
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The obtained microarray data was extremely homogenous among DL-compounds (TCDD,             
1-PnCDD, 4-PnCDF, and DL-PCB 126) as shown in the heatmaps (Figure 36) below. An 
intensive red colour (for example CYP1B1 and CYP1A1) represents the strong up regulation 
of genes, whereas the fading of red towards black indicates that these genes were less 
induced, if at all. 
 
 
 
 
                                                  PCB 153       PCB 126       TCDD         1-PnCDD    4-PnCDF 
 
Figure 36. Heatmaps microarray analysis in hHeps. 
Two times Pearson correlation, cut-off values: log2 fc ≥ 2, p-value ≤ 0.05. 
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Figure 37. In common up and down regulated genes in hHeps. 
Overlap between dioxin-like compounds featured as Venn diagram. 
Selected parameters: A ≥ 7, log2 fc ≥ 1 or ≤ 1, p-value ≤ 0.05. 
 
The aim of the present microarray experiment was to find quantifiable novel biomarkers for 
AhR activation due to dioxin exposure. Therefore, the following data analysis focuses on the 
in common up regulation of genes by dioxins and dioxin-like compounds to investigate the 
mechanisms of action and to assess the potentially dioxin-mediated toxicity in humans.  
25 in common genes were up regulated by TCDD, 1-PnCDD, 4-PnCDF, and PCB 126 (Table 
26). The entire list of the 25 in common up regulated genes is featured in Table 26 below. 
Comparing genes affected by TCDD, 1-PnCDD, and 4-PnCDF led to a large overlap of 50 up 
and 6 down regulated genes among the group of PnCDDs and PnCDFs. This outstanding gene 
overlap between DLCs was already elucidated in the presented heatmaps above.  
The following passage deals with the closer examination of in common up regulated genes 
with emphasis on TCDD, 1-PnCDD, 4-PnCDF, and PCB 126. Among the highest up 
regulated genes are members of the cytochrome P450 superfamily CYP1A1, 1A2, and 1B1 
(featured in an intense red colour in the heatmaps in Figure 36). The induction of those CYP 
isoenzymes by dioxins and dioxin-like compounds is mediated by the AhR signalling 
pathway. Down to the present day, the induction of CYP1A1 is the best and most sensitive 
marker for AhR activation by dioxins. Other enzymes involved in xenobiotic metabolism are 
also highly up regulated such as SLC7A5, TIPARP, and ALDH3A1. 
SLC5A7 is an amino acid transporter which is involved in the sodium-independent amino 
acid exchange of large neutral amino acids (Babuet al., 2003). SLC5A7 was already identified 
as TCDD-responsive gene in HepG2 cells by Sarkar et al. (1999). Viluksela et al. 
demonstrated that circulating concentrations of amino acids were remarkebly increased by 
TCDD in L/E rats (Viluksela et al., 1999). TIPARP was additionally up regulated in hHeps 
after exposure to DLCs. TIPARP was described as novel TCDD-responsive gene by Ma et al. 
TCDD
4-PnCDF
1-PnCDD
PCB 126
25 
 0 
50 
 6  
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in 2001. The AhR-mediated induction of TIPARP results in the suppression of the hepatic 
glucose production (Diani-Moore et al., 2010). Both transcript variants of the ALDH3A1 gene 
were highly up regulated. Class 3 aldehyde dehydrogenases are normally not measurable in 
liver, but are highly inducible by xenobiotics such as TCDD and other members of the group 
of polycyclic aromatic hydrocarbons. Induction of ALDH3A1 by TCDD is based on an AhR-
dependent mechanism which was demonstrated in mouse in vivo (Nebert et al., 1987) (Boesch 
et al., 1996) (Sládek et al., 2002) (Vasiliou et al. 2004) (Bock et al., 2006). 
Moreover, the LRRC25 gene was significantly up regulated in hHeps. Several leucine rich 
repeat proteins with distinct cellular functions have been identified in various organisms 
including humans and rodents (mouse and rat). LRR proteins participate among others in 
signal transduction, cell adhesion, development, DNA repair, recombination, transcription as 
well as RNA processing (Kobe et al., 1995). Although LRRC proteins have various functions 
in different cellular components, they do have specific repetitive sequences in common and 
they all are involved in protein-protein interactions. LRRC25 was identified as a novel AhR-
regulated target gene which takes part in the PAH-induced immunotoxicity (Iwano et al., 
2010).  
Amphiregulin (AREG) plays a role in the epidermal growth factor signalling pathway. The 
epidermal growth factor receptor (EGFR) and its downstream signalling pathways are 
involved in diverse cellular processes such as cell proliferation, differentiation, and migration. 
Furthermore, EGFR activation is likely to be involved in tumour progression and 
pathogenesis. The interplay between TCDD and EGFR has been described intensively as a 
direct cross-talk of the AhR and EGFR signal transduction (Haarmann-Stemmann et al., 
2009). Amphiregulin as endogenous ligand of the EGFR leads to its activation upon binding 
to the EGFR (Shoyab et al., 1989) (Haarmann-Stemmann et al., 2009). TNFaiP2 encodes the 
tumour necrosis factor alpha-induced protein 2 which is regulated by TNFα, e.g. in 
endothelial cells. TNFaiP2 protein is likely to be involved in angiogenesis (Sarma et al., 
1992). In 2010, Rivera and co-workers identified Tnfaip2 as novel dioxin-inducible gene in 
the mouse Hepa-1 hepatoma cell line. High expression of TNFAIP2 in haematopoietic and 
lymphoid tissue indicated that TNFAIP2 is probably involved in haematopoiesis/myelopoiesis 
(Rivera et al., 2007). Interestingly, it was demonstrated in mouse that TCDD also increased 
myelopoiesis (Choi et al., 2003). 
UGCG, the UDP-glucose ceramide glycosyltransferase gene was also slightly up regulated in 
hHeps after exposure to DLCs. The UGCG enzyme is involved in glycosphingolipid 
biosynthesis in which it catalyzes the transfer of glucose from UDP-glucose to ceramide 
(Ichikawa et al., 1996). Glycosphingolipids are integral plasma membrane proteins which 
play substantial roles in various cellular processes such as cell recognition, proliferation, 
differentiation, and signal transduction (Paul et al., 1996) (Yamashita et al., 1999). Interleukin 
17 receptor B (IL17RB) gene is involved in the cytokine-mediated signalling pathway. 
IL17RB specifically binds to IL17B and IL17E. IL17RB is only expressed in selected B cells, 
T cells, and myeloid cell lines whichleads to the suggestion that its dysregulation could lead 
to myeloid leukemia (Tian et al., 2000) (Shi et al., 2000) (Moseley et al., 2003). 
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The NKD2 protein is a negative regulator of the Wnt signalling pathway, in particular by 
binding to so called Dishevelled proteins (Dsh) during the canonical Wnt signalling pathway 
(Creyghton et al., 2005). NDK2 encodes also a protein which is responsible for the transport 
of the transforming growth factor α to the basolateral plasma membrane (Li et al., 2004). The 
Wnt signalling pathway is involved in various cellular processes such as development, 
differentiation, and cellular homeostasis (Behari et al., 2010). Interactions between β-catenin 
(key regulator of the canonical Wnt signalling) and the AhR due to treatment with TCDD 
were shown in liver progenitor cells (Procházková et al., 2011).  
The guanine nucleotide binding protein (G protein) alpha z polypeptidegene, in short GNAZ, 
was additionally up regulated in hHeps by all DLCs. Heterotrimeric G proteins are involved 
in G protein receptor signalling pathways. GNAZ only mediates signal transduction in 
pertussis toxin insensitive systems (Fong et al., 1988) (Matsuoka et al., 1990) (Casey et al., 
1990). Recently the possible involvement of GNAZ in melanoma progression was described 
as a result of the detected high somatic mutation rates in this gene (Cardenas-Navia et al., 
2010). The protein encoded by the exophilin 5 gene (EXPH 5) takes part in regulation of 
exocytosis and may act as rabphillin (Rab) effector protein. Rabphillin proteins function in 
processes involving vesicle trafficking (Kondo et al., 2006). A protein which can also be 
involved in cellular trafficking is Rho GTPase activating protein 44 (ARHGAP44). 
ARHGAP44 belongs to the GTPase superfamily which acts as molecular switches activated 
by extracellular stimuli. Active GTP-bound Rho proteins take part in diverse cellular 
processes which lead to the regulation of gene transcription as well as structural cell aspects 
(actin cytoskeleton re-arrangement) (Moon et al., 2003).  
The CDK5RAP2 gene was also up regulated. The CDK5RAP2 protein directly regulates 
CDK5 and CDK5R1 (isoform of CDK5) activities. Both are involved in the cell cycle process 
(Kraemer et al., 2011). Furthermore, Barrera et al. (2010) demonstrated in mice that 
CDK5RAP2 is required for the maintenance of centriole engagement and cohesion. 
Proprotein convertase subtilisin/kexin type 5 (PCKS5) is a member of the subtilisin/kexin-like 
proprotein convertase enzymes which are responsible for functional maturation of target 
proteins (Turpeinen et al., 2011). The lymphocyte-activation gene 3 (LAG3) is expressed in 
human activated T and NK cells (Triebel et al., 1989) and is involved in the cell surface 
signalling pathway. LAG3 negatively regulates T cell homeostasis (Workman et al., 2005). 
RTP3 alias TMEM7 encodes the transmembrane protein 7 which likely plays a role in 
hepatocarcinogenesis, i.e. human hepatocellular carcinomas (HCC). The induction of 
TMEM7 is linked to tumour suppression and invasion. Zhou and co-workers postulated that 
TMEM7 possess tumour suppressor activity which could be used in therapy of hepatocellular 
carcinoma (Zhou et al., 2007). Another gene involved in human liver pathogenesis, especially 
hepatocellular carcinoma, is HULC (Panzitt et al., 2007). HULC is the short form of 'highly 
up regulated in liver cancer'. The apolipoprotein A5 (APOA5) gene is involved in lipid 
metabolism by regulating triglyceride levels (Pennacchio et al., 2002). APOA5 was identified 
as liver-specific protein which is linked to early stages of liver regeneration in rat (van der 
Vliet et al., 2001) (Ress et al., 2011). 
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Table 26. List of in common up regulated genes by TCDD, 1-PnCDD, 4-PnCDF, and PCB 126 in hHeps. 
Selected parameters: A ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
Gene Name  Gene Description  Systematic name Probe name 
Log2 fc 
TCDD 
Log2 fc  
1-PnCDD 
Log2 fc  
4-PnCDF 
Log2 fc 
PCB 126 
ALDH3A1  Aldehyde dehydrogenase 3 family, member 1A, transcript variant 1 NM_001135168 A_33_P3238433 4.20 3.11 3.41 2.81 
ALDH3A1  Aldehyde dehydrogenase 3 family, member 1A, transcript variant 2 NM_000691 A_23_P207213 4.41 3.54 3.79 3.33 
APOA5 Apolipoprotein A-V, transcript variant 1 NM_052968 A_23_P75630 2.01 2.00 2.08 1.31 
AREG Amphiregulin NM_001657 A_23_P259071 1.65 1.70 1.69 1.77 
NM_001657 A_33_P3419190 1.20 1.58 1.63 1.64 
ARHGAP44 Rho GTPase activating protein 44  NM_014859 A_23_P26854 3.53 3.57 3.93 3.09 
CDK5RAP2  CDK5 regulatory subunit associated protein 2, transcript variant 1  NM_018249 A_23_P83110 1.64 1.66 1.88 1.28 
NM_018249 A_33_P3389060 1.44 1.35 1.68 1.16 
C14orf135 cDNA FLJ38170 fis clone FCBBF1000024. AK095489 A_33_P3397795 3.26 2.07 2.64 1.84 
CYP1A1  Cytochrome P450, family 1, subfamiliy A, polypeptide 1 NM_000499 A_23_P163402 5.37 4.61 4.93 4.71 
CYP1A2  Cytochrome P450, familiy 1, subfamiliy A, polypeptide 2  NM_000761 A_33_P3253747 2.63 2.06 2.23 2.19 
CYP1B1  Cytochrome P450, familiy 1, subfamiliy B, polypeptide 1 NM_000104 A_33_P3290343 4.43 3.89 4.11 4.02 
NM_000104 A_23_P209625 6.59 5.46 5.96 5.45 
EXPH5 Exophilin 5  NM_015065 A_23_P403335 1.57 1.66 1.54 1.13 
GNAZ Guanine nucleotide binding protein (G protein) alpha z polypeptide NM_002073 A_23_P416581 3.11 2.72 2.61 1.91 
HULC Highly up-regulated in liver cancer (non-protein coding) NR_004855 A_33_P3222762 2.71 2.44 2.45 1.50 
IL17RB Interleukin 17 receptor B  NM_018725 A_24_P157370 2.95 2.82 2.71 1.33 
LAG3 Lymphocyte-activation gene 3  NM_002286 A_23_P116942 1.93 1.63 1.94 1.23 
LOC285957 cDNA FLJ40207 fis clone TESTI2020946. AK097526 A_33_P3734384 2.28 1.66 2.02 1.87 
LOC100507055 Hypothetical LOC100507055 NM_001195520 A_32_P49867 3.17 2.73 3.52 2.11 
LRRC25  Leucine rich repeat containing 25  NM_145256 A_23_P165136 4.58 4.03 4.32 3.19 
NKD2  Naked cuticle homolog 2 (Drosophila)  NM_033120 A_23_P41804 2.24 2.02 1.84 1.41 
PCSK5  Proprotein convertase subtilisin/kexin type 5 transcript variant 2 NM_006200 A_23_P257003 2.12 1.85 1.97 1.10 
RTP3 Receptor (chemosensory) transporter protein 3  NM_031440 A_23_P57910 2.29 2.53 2.47 1.90 
SLC7A5  Solute carrier family 7 (amino acid transporter light chain L system) member 5 NM_003486 A_24_P335620 2.14 2.20 2.28 1.65 
TIPARP TCDD-inducible poly(ADP-ribose) polymerase, transcript variant 2 NM_015508 A_23_P143845 2.31 2.61 2.19 1.45 
TNFAIP2 Tumour necrosis factor alpha-induced protein 2 NM_006291 A_23_P421423 1.81 1.34 1.84 1.36 
UGCG UDP-glucose ceramide glucosyltransferase  NM_003358 A_23_P313389 1.26 1.15 1.31 1.07 
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One major research objective of the SYSTEQ project was the identification of novel 
quantifiable biomarkers for AhR activation by dioxins and dioxin-like compounds. Based on 
the experimental data gained from microarray experiments in hHeps, HepG2 cells, mouse 3-
day study as well as a microarray experiment performed by a project partner from the 
Karolinska Institutet in Ahr-/- and Ahr+/+ mice potential candidates were selected.  
Data combination resulted in the selection of five target genes (ALDH3A1, HSD17B2, CD36, 
TIPARP, and AHRR). The following table (Table 27) summarizes the results of the microarray 
data derived from hHeps treated with different DLCs with regard to the chosen target genes. 
Additionally, the obtained log2 fc values of the established markers for AhR activation 
(cytochromes P450 1A1, 1A2, and 1B1) are featured. Cytochromes P450 1A1, 1A2, 1B1, both 
transcript variants of ALDH3A1, and TIPARP were all up regulated by TCDD, 1-PnCDD,      
4-PnCDF, and PCB 126. However, HSD17B2 was only up regulated in the present microarray 
study after exposure to PnCDD/Fs, but not after treatment with DL-PCB 126. Genes CD36 
and AHRR were not up regulated within the range of the selected parameters.  
The mRNA levels of all eight genes were subsequently measured by RT-PCR. Further 
experimental analysis is necessary to verify if one of the genes could be chosen as 
quantifiable novel biomarker for AhR activation. 
 
Table 27. AhR target genes in hHeps microarray experiments. 
Table features aspects such as gene name, systematic name, and corresponding fold-change. 
Selected parameters: A ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
Annotations:         (1) transcript variant 1; (2) transcript variant 2; 
                             '*' log2 fc value calculated as mean from identical probes of the corresponding gene 
                                '→' this gene was not up regulated in  microarray experiments. 
 
Gene name Probe name Systematic name 
Log2 fc 
TCDD 
Log2 fc 
1-PnCDD 
Log2 fc 
4-PnCDF 
Log2 fc 
PCB 126 
CYP1A1 A_23_P163402 NM_000499 5.37 4.61 4.93 4.71 
CYP1A2 A_33_P3253747 NM_000761 2.63 2.06 2.23 2.19 
CYP1B1 A_23_P209625 NM_000104 6.59 5.46 5.96 5.45 
CYP1B1 A_32_P3290343 NM_000104 4.43 3.89 4.11 4.02 
ALDH3A1 (1) A_33_P2328433 NM_001135168 4.12 3.11 3.41 2.81 
ALDH3A1 (2) A_23_P207213 NM_000691 4.41 3.54 3.79 3.33 
HSD17B2 A_23_P118065 NM_002153 1.24* 1.05* 1.19* → 
CD36 A_23_P111583 NM_001001547 → → → → 
TIPARP A_23_P143845 NM_015508 2.31 2.61 2.19 1.45 
AHRR A_23_P358709 NM_020731 → → → → 
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In summary, the highest up regulated genes in primary human hepatocytes after treatment 
with dioxin-like compounds were primarily genes known to be dioxin-inducible, i.e. genes 
which are associated with the xenobiotic metabolism such as CYP1A1, CYP1A2, CYP1B1, 
SLC5A7, ALDH3A1, as well as genes mediating TCDD-induced toxicity (TIPARP). The 
LRRC25 gene was highly induced in the present study. Moreover, an AhR-dependent 
mechanism was postulated by Iwano and co-workers (Iwano et al., 2010). Commonly up 
regulated genes by dioxins and dioxin-like compounds also included genes linked to diverse 
cellular processes such as cell cycle regulation (CDK5RAP2), cellular trafficking 
(ARHGAP44, EXPH5), and cell surface signalling (LAG3) as well as cell angiogenesis 
(TNFAIP2).  
Furthermore, genes associated with lipid metabolism (APOA5, UGCG) were also up regulated 
as well as a gene involved in the cytokine-mediated signalling pathway (IL17RB). Indications 
for a receptor crosstalk could also be determined in the present microarray study (AREG, 
NKD2). For instance, AREG is involved in the epidermal growth factor signalling pathway. 
The up regulation of AREG by dioxins and dioxin-like compounds in hHeps could be due to 
direct interactions between the AhR and EGFR, since the interplay between TCDD and EGFR 
had been demonstrated in several studies (Haarmann-Stemmann et al., 2009).  
 
IV.3.1.4 Gene Expression of Target Genes by RT-PCR 
 
The genes aldehyde dehydrogenase 3A1 (ALDH3A1), hydrosteroid dehydrogenase 17 beta 2 
(HSD17B2), CD36 (thrombospondin receptor), TIPARP (TCDD-inducible poly(ADP-ribose) 
polymerase), and AHRR (aryl hydrocarbon receptor repressor) were selected as potential 
novel target genes for AhR activation based on the experimental data gained from three 
performed microarray experiments in the present work as well as a microarray experiment 
performed by a project partner from the Karolinska Institutet.  
Therefore, RNA of hHeps (the same as applied in the microarray experiment) was transcribed 
into complementary DNA and subsequently mRNA gene expression of the chosen five genes 
were determined by RT-PCR. Additionally, the mRNA expression levels of the cytochromes 
P450 1A1, 1A2, and 1B1 were examined by RT-PCR. Gene expression levels of CYP1A1, 
1A2, 1B1, ALDH3A1, HSD17B2, CD36, TIPARP, and AHRR are presented in Figure 38. 
 
After 24 h incubation, dioxins and dioxin-like compounds led to the extensive induction of 
CYP1A1 mRNA gene expression resulting in a 1354.66 ± 771.74-fold, 3279.75 ± 1680.61-
fold, 4409.15 ± 1690.89-fold, and 2336.97 ± 1401.35-fold increase for TCDD, 1-PnCDD,      
4-PnCDF, and PCB 126 respectively.  
CYP1A2 mRNA levels were also highly induced by treatment with dioxins and dioxin-like 
compounds leading to a 597.96 ± 398.00-fold, 464.29 ± 301.44-fold, 824.62 ± 713.43-fold, 
and 278.01 ± 168.07-fold expression after treatment with TCDD, 1-PnCDD, 4-PnCDF, and 
PCB 126. Similarly, mRNA gene expression levels were obtained for CYP1B1 after 
incubation with TCDD (628.59 ± 277.90), 1-PnCDD (419.81 ± 242.07), 4-PnCDF (807.39 ± 
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513.02), and PCB 126 (274.5 ± 198.6). PCB 153-treated hHeps led to no significant 
alterations of the CYP1A1, 1A2, and 1B1 mRNA expression. 
ALDH3A1, a selected potential novel AhR target gene, was significantly increased after 
treatment with DLCs, leading to the highest induction (20.42 ± 12.99-fold) after incubation of 
hHeps with TCDD, followed by 4-PnCDF (8.44 ± 6.58-fold), 1-PnCDD (6.37 ± 4.41-fold), 
and PCB 126 (4.49 ± 2.70-fold).  
HSD17B2 mRNA levels were only significantly induced in hHeps after treatment with TCDD 
(2.98 ± 1.20-fold) and 4-PnCDF (3.57 ± 1.78-fold). An increase of the HSD17B2 mRNA 
expression was also determined after incubation with 1-PnCDD (1.96 ± 0.57-fold) and PCB 
126 (1.81 ± 0.65-fold), although both were not statistically significant increased.  
In a similar manner TIPARP mRNA levels were affected. This resulted in a significant 
increase after treatment with TCDD (3.01 ± 0.35-fold) and 4-PnCDF (2.45 ± 1.00-fold). 
TIPARP mRNA levels were only slightly and not statistically significantly increased by        
1-PnCDD (2.13 ± 1.14-fold) and PCB 126 (1.39 ± 1.01-fold).  
Likewise as earlier shown with the CYPs, mRNA levels of ALDH3A1, TIPARP, and 
HSD17B2 were not significantly altered in hHeps after exposure to PCB 153. In hHeps CD36 
and AHRR mRNA levels were not affected by all compounds, as expected from the previously 
performed microarray experiment (IV.3.1.3 Microarray analysis).  
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Figure 38. Real-time PCR ratios of primary human hepatocytes treated with test compounds and solvent control. 
ß-actin (ACTB) served as housekeeping gene. Data represent means + SD of data from n = 5 different 
donors, normalized to solvent control. One-tailed unpaired Student’s t-test,*=p ≤ 0.05, **= p ≤ 0.01 
different from corresponding solvent control. 
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IV.3.2 Human Hepatocellular Carcinoma Cell Line HepG2 
 
IV.3.2.1 Cytotoxicity Testing 
 
In order to examine whether the chosen test compound concentrations cause cytotoxic effects, 
the viability of the human hepatocellular carcinoma cell line HepG2 was tested after 
incubation with the selected compounds for 24 h under standard conditions. Primarily, the 
Alamar Blue assay was performed aiming to identify non-cytotoxic concentration levels that 
could be applied for subsequent experimental testing. Each experiment consisted of two 
negative controls (DMSO 0.1 % and medium) and saponine (0.1 %) as positive control. No 
cytotoxic effects were determined in HepG2 cells after incubation with the 14 test compounds 
(Figure 39). The viability of the compound-treated cells was in the same range as the solvent 
control (DMSO 0.1 %). Incubation with 50 nM PCB 126 led to a significant increase in cell 
viability, but this effect is the result of the small standard deviation. Hence, the chosen test 
compound concentrations could be applied to subsequent experimental testing. 
 
 
 
 
Figure 39. Cytotoxicity testing - Alamar Blue assay results in HepG2 after exposure to seven core congeners  
(at top) and seven further compounds (at bottom).  
Data represent means ± SD of three independent experiments (n=3), results normalized to solvent  
control (DMSO 0.1 %). One-way analysis of variance (ANOVA) with Dunnett’s post-test,*= p ≤ 0.05  
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IV.3.2.2 Ethoxyresorufin-O-deethylase (EROD) Activity 
 
The catalytic activity of CYP1A1 was determined subsequent to the incubation of HepG2 
cells with seven core congeners and seven further congeners. All experiments consisted of 
one negative control (DMSO 0.1 % in culture medium) and one positive control for CYP1A1 
induction (TCDD 10 nM). Figure 40 presents the results of the performed assay by plotting 
the used test compound concentrations in a logarithmic scale against obtained EROD 
activities, whereby EC50 values were derived by sigmoidal fitting using Origin software 
(Microcal Software, Northhampton, MA, USA). The respective solvent control was regarded 
as background level and subtracted from EROD activity data. For EC20 values, the upper limit 
of the TCDD-derived EROD induction in HepG2 was set 100 % and the test compound 
concentration needed to achieve 20 % of the maximal TCDD EROD response was calculated 
as EC20. Relative effect potencies (REPs) were obtained by dividing the respective EC value 
(EC50/EC20) of the reference compound TCDD by the EC value (EC50/EC20) of the test 
compound.  
In Figure 40 (left-hand side) a concentration-dependent increase in EROD activity was 
measured for TCDD, 1-PnCDD, 4-PnCDF, and PCB 126 in HepG2 cells. No increase in 
CYP1A1 activity was determined after treatment with PCB 118, PCB 156, and PCB 153. 
Concentration-response curves of 1-PnCDD, 4-PnCDF, and PCB 126 were similar to the 
TCDD curve with only their efficiencies differing. Maximal activity for TCDD-induced,        
1-PnCDD-induced, 4-PnCDF-induced, and PCB 126-induced were 299.56 ± 51.90, 335.99 ± 
71.46, 284.10 ± 31.63, and 120.17 ± 13.33 pmol resorufin/min*mg protein, respectively. 
In Figure 40 (right-hand side) the results of the EROD assay after exposure to further 
congeners are featured. A concentration-dependent increase in EROD activity was obtained 
after exposure to DLCs, but not after HepG2 cells were exposed to PCB 77 and PCB 105. 
Maximal activity for 1,6-HxCDD-induced, 1,4,6-HpCDD-induced, TCDF-induced, 1,4-
HxCDF-induced, and 1,4,6-HpCDF-induced EROD activity were 300.23 ± 15.51, 386.72 ± 
49.34 , 241.04 ± 72.73, 255.54 ± 39.70, and 334.26 ± 38.89 pmol/min*mg protein.  
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Figure 40. EROD activity (pmol resorufin/mg protein*min) in HepG2 cells after 24 h exposure with core 
congeners (TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126, PCB 153, or PCB 156) and further 
congeners (1,6-HxCDD, 1,4,6-HpCDD, TCDF, 1,4-HxCDF, 1,4,6-HpCDF, PCB 77 or PCB 105). 
 
Table 28. Derived parameters from EROD induction in HepG2 cells. 
 
EC50 (nM) REP (EC50) EC20 (nM) REP (EC20) TEF (WHO, 2005) 
TCDD 0.269 ± 0.034 1.0 0.113 1.0 1.0 
1-PnCDD 0.176 ± 0.023 1.53 0.058 1.92 1.0 
4-PnCDF 0.107 ± 0.020 2.51 0.050 2.26 0.3 
1,6-HxCDD 4.57 ± 0.12 0.059 1.53 0.074 0.1 
1,4,6-HpCDD 2.45 ± 0.29 0.11 0.699 0.16 0.01 
TCDF 1.64 ± 0.37 0.16 0.894 0.13 0.1 
1,4-HxCDF 0.306 ± 0.041 0.88 0.137 0.82 0.1 
1,4,6-HpCDF 47.55 ± 4.82 0.0057 10.73 0.011 0.01 
PCB 77 - - - - 0.0001 
PCB 105 - - - - 0.00003 
PCB 118 - - - - 0.00003 
PCB 126 26.27 ± 3.62 0.010 25.75 0.0044 0.1 
PCB 153 - - - - - 
PCB 156 - - - - 0.00003 
 
Table 28 summarizes the results derived REPs from EROD assay in HepG2 cells. REPs 
gained from HepG2 cells confirmed to major parts the current WHO-TEFs. Nevertheless, 
several deviations were observed. In case of 4-PnCDF and 1,4-HxCDF, REP values were 8- 
and 9-fold higher than the current WHO-TEFs. REPs obtained from 1-PnCDD, 1,4-HxCDD, 
TCDF, and 1,4,6-HpCDF were within the same range as the corresponding WHO-TEFs. In 
HepG2 cells, REP values for PCB 126 were approximately 10- to 23-fold below the current 
TEF. It was not possible to derive any REPs for the other PCBs (77, 105, 118, 153, and 156) 
due to the lack of EROD induction in HepG2 cells.  
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IV.3.2.3 Protein Levels 
 
In order to confirm the present findings from EROD assay, CYP1A1 protein levels were 
determined in the human hepatocellular carcinoma cell line HepG2 by Western blot. 
Therefore, microsomes were isolated from compound-exposed HepG2 cells. 25 µg protein of 
each sample was used in electrophoresis. CYP1A1 protein levels were determined in three 
independent experiments. Voltage-dependent anion-selective channel protein 1 (VDAC1) was 
used as loading control, TCDD (10 nM) as positive control for CYP1A1 induction, and 
DMSO (0.1 % in culture medium) as solvent control. Representative Western blots are 
featured in the following Figures. 
In Figure 41 displays representative Western blots for CYP1A1 levels in HepG2 cells after 
exposure to the seven core congeners. Western Blot analysis of CYP1A1 protein levels after 
exposure to core congeners was performed by Angela Dörr as part of her diploma thesis 
(Dörr, 2010). 
As expected, a concentration-dependent increase of CYP1A1 protein was determined after 
treatment of HepG2 cells with various concentrations of TCDD. The highest protein levels 
were obtained with 10 nM TCDD. Likewise, the CYP1A1 protein levels were increased in a 
concentration-dependent manner after HepG2 cells were treated with 1-PnCDD resulting in 
the highest protein levels of CYP1A1 after incubation with 5 nM 1-PnCDD for 24 h. A 
concentration-dependent increase of CYP1A1 protein levels was determined in HepG2 cells 
after exposure to 4-PnCDF, resulting in a maximal CYP1A1 expression after incubation with 
1 nM. In case of PCB 126, only the two highest concentrations led to an increase of CYP1A1 
protein levels. CYP1A1 protein levels were not affected by exposure of HepG2 cells to PCB 
118, PCB 156, or PCB 153 (data not shown). As featured in these representative Western 
blots, some difficulties arose as the detection of CYP1A1 bands also evoked small bands for 
the respective solvent control or minor test compound concentrations. Unfortunately, several 
attempts to prevent this effect failed such as extending the blocking time, variation of 
antibody incubation time, or changing antibody diluter as well as cutting the membranes and 
subsequent separately detection of loading control and CYP1A1. However, the CYP1A1 lane 
was detected for DMSO in most cases, but this effect was considered to have no influence on 
the evaluation of the Western blot data. 
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Figure 41. Representative Western blots of CYP1A1 proteins in HepG2 cells after treatment with core congeners. 
Isolated microsomes derived from HepG2 after treatment with TCDD, 1-PnCDD, 4-PnCDF, and  
PCB 126 for 24 h. VDAC1 applied as loading control. 
Featured Western blots after exposure to 1-PnCDD, 4-PnCDF, and PCB 126 were performed by Angela 
Dörr within her diploma thesis (Dörr, 2010). 
 
Western blot analysis of CYP1A1 protein levels in HepG2 after exposure to seven further 
congeners was additionally performed. Due to their inability to induce a distinct EROD 
activity, PCB 77 and 105 were excluded from this experiment. Figure 42 displays the results 
of CYP1A1 protein level determination after treatment with further congeners for 24 h. 
CYP1A1 protein levels were increased in a concentration-dependent manner after HepG2 
cells were exposed to 1,6-HxCDD resulting in the highest CYP1A1 protein levels after 
incubation with 30 nM. This was also the case for 1,4,6-HpCDD. Exposure of HepG2 cells to 
this congener resulted in a concentration-dependent increase of CYP1A1 protein up to the 
highest applied concentration. PCDFs including TCDF, 1,4-HxCDF, and 1,4,6-HpCDF 
confirmed the findings retrieved from EROD assay, as a concentration-dependent increase of 
CYP1A1 protein levels was obtained in HepG2 cells, too. 
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Figure 42. Representative Western blots of CYP1A1 proteins in HepG2 cells after exposure to further congeners. 
Isolated microsomes derived from HepG2 after treatment with 1,6-HxCDD, 1,4,6-HpCDD, 1,4-
HxCDF, 1,4,6-HxCDF, and TCDF for 24 h.VDAC1 applied as loading control. 
 
In summary, measurement of CYP1A1 protein levels after exposure to all 14 congeners 
confirmed the obtained findings from the EROD assay. A concentration-dependent increase 
of CYP1A1 protein levels was observed for TCDD, 1-PnCDD, 4-PnCDF, 1,6-HxCDD, 1,6-
HpCDD, TCDF, 1,4-HxCDF, and 1,4,6-HpCDF. Treatment with PCB 126 for 24 h led only 
to an increase of CYP1A1 protein in the two highest applied concentrations. Incubation of 
HepG2 cells with PCB 118, 153, and 156 resulted in no increase of CYP1A1 protein levels. 
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IV.3.2.4 Gene Expression of Target Genes by RT-PCR 
 
The mRNA expression of AhR target genes was determined in this experimental approach by 
RT-PCR. First, the isolated RNA from compound-treated HepG2 cells was transcribed into 
complementary DNA (cDNA). Then, 1 µl of cDNA was used to perform each RT-PCR 
experiment. Gene-specific expression, normalized using β-actin as housekeeping gene, was 
calculated relative to the expression of the corresponding solvent control (DMSO 0.1 %). 
Each experiment consisted of two controls including DMSO (0.1 % in culture medium) and 
TCDD (10 nM) exposed HepG2 cells. 
The mRNA expression levels of the five potential AhR target genes (ALDH3A1, HSD17B2, 
TIPARP, CD36, and AHRR) and established AhR-dependent cytochromes P450 1A1, 1A2, 
and 1B1 were determined in HepG2 cells by RT-PCR after 24 h exposure to various 
concentrations of TCDD. TCDD as prototype of PCDD/Fs was used in a concentration range 
of 0.0001 nM to 10 nM. Figure 43 displays the results of the RT-PCR analysis of these eight 
target genes.  
CYP1A1 mRNA levels were induced in a concentration-dependent manner resulting in a 
575.95 ± 38.47-fold expression after exposure to 10 nM TCDD. CYP1A2 mRNA expression 
levels were not significantly altered compared to the corresponding solvent control. A 
concentration-dependent increase of the CYP1B1 mRNA levels was additionally determined, 
resulting in the highest fold-change (63.77 ± 12.37-fold) after exposure to 5 nM TCDD. 
ALDH3A1, a selected novel AhR target gene, was significantly induced after exposure to the 
two highest applied TCDD concentrations (5 and 10 nM) leading to a 3.31 ± 0.96-fold and 
4.34 ± 0.67-fold induction of ALDH3A1 mRNA levels, respectively. HSD17B2 mRNA levels 
were only significantly increased in HepG2 cells after treatment with 10 nM TCDD (2.37 ± 
0.80-fold). However, CD36, TIPARP, and AHRR mRNA gene expression levels were not 
significantly altered compared to the corresponding solvent controls subsequent to TCDD 
treatment. Based on these results, relevant alterations of HSD17B2, CD36, TIPARP, and 
AHRR mRNA levels were not expected and hence, measurements were not carried out for the 
other core congeners. 
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Figure 43. Real-time PCR ratios of HepG2 cells exposed to TCDD and DMSO 0.1%. 
β-actin (ACTB) served as housekeeping gene. Data represent means + SD of data from n = 3,  
normalized to solvent control. One-tailed unpaired Student’s t-test,*= p ≤ 0.05, **= p ≤ 0.01 different 
from corresponding solvent control. 
Exposure of HepG2 cells to 1-PnCDD, 4-PnCDF, and PCB 126 resulted in a concentration-
dependent increase of CYP1A1 mRNA expression leading to maximal a CYP1A1 expression 
of 634.39 ± 71.64-fold, 1257.28 ± 381.06-fold, and 212.15 ± 40.88-fold induction for            
1-PnCDD, 4-PnCDF, and PCB 126, respectively (Figure 44). Likewise, 1-PnCDD, 4-PnCDF, 
and PCB 126 significantly increased CYP1B1 mRNA levels resulting in a 63.59 ± 23.67-fold, 
181.27 ± 60.90-fold, and 31.44 ± 7.76-fold induction. A small, but statistically significant 
increase of CYP1A2 mRNA expression was observed after HepG2 cells were exposed to     
0.5 nM 1-PnCDD (3.41 ± 1.92). In addition, 4-PnCDF treatment resulted in a steady increase 
of CYP1A2 mRNA expression, which was proven to be statistically significant for the highest 
applied concentration (6.46 ± 2.40-fold) in HepG2 cells. After HepG2 cells were exposed to 
PCB 126, no alterations of CYP1A2 mRNA expression levels were determined by RT-PCR.  
A constant increase of ALDH3A1 mRNA levels was observed after exposure to 1-PnCDD, 
starting at 0.01 nM and reaching its maximum at 1 nM (5.09 ± 3.19-fold). This phenomenon 
was also observed with 4-PnCDF, whereby the steady increase started at 0.5 nM and stopped 
at 5 nM thus leading to the highest obtainable fold-change of 6.59 ± 1.86. ALDH3A1 mRNA 
levels were not affected by PCB 126 in HepG2 cells. In HepG2 cells CYP1A1, 1A2, 1B1, and 
ALDH3A1 mRNA levels were not significantly altered compared to the respective solvent 
controls after cells were exposed to PCB 118, 156, and 153 for 24 h. 
Summarizing the obtained results, treatment with TCDD, 1-PnCDD, 4-PnCDF, and PCB 126 
resulted in the concentration-dependent induction of CYP1A1 and CYP1B1. The maximal fold 
induction of CYP1A1 mRNA followed the relationship: 4-PnCDF > 1-PnCDD > TCDD > 
PCB 126. Similiar findings were obtained for the maximal CYP1B1 mRNA expression:       
4-PnCDF > 1-PnCDD ≈ TCDD > PCB 126. The maximal ALDH3A1 mRNA expression was 
7-fold, 5-fold, and 4-fold higher compared to the respective solvent controls for 4-PnCDF,     
1-PnCDD, and TCDD, respectively. 
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Figure 44. Real-time PCR ratios of HepG2 cells treated with 1-PnCDD, 4-PnCDF, PCB 126, PCB 118, PCB 156, 
PCB 153, and DMSO 0.1 %.  
β-actin (ACTB) served as housekeeping gene. Data represent means + SD of data from n = 3,  
normalized to solvent control. One-tailed unpaired Student’s t-test,*=p ≤ 0.05, **= p ≤ 0.01 different 
from corresponding solvent control. 
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Measurement of CYP1A1 and CYP1B1 mRNA levels led to the following concentration-
response curves (Figure 45) and derived parameters (Table 29 and 30).  
CYP1A1 curve slopes of TCDD and 1-PnCDD are similar to each other. A higher increase of 
CYP1A1 mRNA expression was obtained for 1-PnCDD when using lower compound 
concentrations compared to TCDD. The CYP1A1-derived curve slope for 4-PnCDF is in the 
low concentration range similar to the TCDD-derived curve slope, but the three highest 
applied 4-PnCDF concentrations led to an extremely high CYP1A1 mRNA expression. The 
higher efficiency of 4-PnCDF compared to TCDD at the high concentration range is 
visualized on the left-hand side of Figure 45, although the high standard deviations must be 
taken into consideration when comparing EC values. The derived concentration-response 
curve for PCB 126 is extremely flat compared to the other three potent congeners. Only the 
two highest applied PCB 126 concentrations barely surpassed the TCDD-derived EC20 level.  
No concentration-response curves were obtained for PCB 118, 153, and 156 in HepG2 cells 
because of the very low, not statistically significant expression of CYP1A1 mRNA compared 
to the respective solvent controls. 
The concentration-response curves derived from CYP1B1 mRNA expression is featured on 
the right-hand side of Figure 45. The CYP1B1 curve slope of 1-PnCDD and 4-PnCDF closely 
resembles the TCDD curve slope, but a much higher CYP1B1 mRNA response was 
determined by the use of the second highest applied 4-PnCDF concentration (5 nM). 
Sigmoidal fitting of the CYP1B1 mRNA expression after incubation with various 
concentrations of 4-PnCDF resulted in the expected efficacy, but lead to a much higher 
efficiency compared to TCDD and 1-PnCDD in HepG2 cells. This phenomenon was also 
observed for the CYP1A1 mRNA derived concentration-response curves. Likewise to 
CYP1A1, no CYP1B1 concentration-response curves were gained after incubation with PCB 
118, 153, and 156 because compound treatment of HepG2 cells did not lead to a significant 
increase of CYP1B1 mRNA levels. 
 
 
Figure 45. CYP1A1 (left) and CYP1B1 (right) mRNA concentration-response curves in HepG2 cells. 
CYP1A1/CYP1B1 gene expression (x-fold to DMSO 0.1 %) in HepG2 cells after 24 h exposure with 
core congeners (TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126, PCB 153, or PCB 156).  
β-actin (ACTB) served as housekeeping gene. Data represents means ± SD, n = 3, normalized to solvent 
control (DMSO 0.1 %). 
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Sigmoidal fitting of CYP1A1 and 1B1 mRNA data led to respective EC50 values. For EC20 
values, the upper limit of the TCDD-derived CYP1A1/CYP1B1 mRNA expression in HepG2 
cells was set 100 % and test compound concentrations needed to achieve 20 % of the maximal 
CYP1A1/CYP1B1 TCDD response were calculated as EC20. In case of TCDD, EC50 and EC20 
values derived from CYP1A1 mRNA levels were consistently confirmed by CYP1B1 mRNA 
data although EC50/EC20 values tended to be higher than their CYP1A1 counterparts. 
CYP1B1-derived EC50 and EC20 values for 1-PnCDD, 4-PnCDF, and PCB 126 were about 
twice higher than their CYP1A1-derived counterparts. This effect could be based on CYP1A1 
being the more sensitive marker for AhR activation compared to CYP1B1 which was 
confirmed by the extremely high CYP1A1 mRNA levels in HepG2 cells.  
 
Table 29.  EC50/EC20 values derived from sigmoidal fitting of CYP1A1 and 1B1 mRNA data in HepG2 cells. 
 
 
CYP1A1 mRNA CYP1B1 mRNA 
 
EC50 ± SD (nM) EC20 (nM) EC50 ± SD (nM) EC20 (nM) 
TCDD 0.583 ± 0.064 0.213 0.671 ± 0.224 0.344 
1-PnCDD 0.302 ± 0.208 0.111 0.718 ± 0.163 0.218 
4-PnCDF 0.704 ± 0.244 0.204 1.27 ± 0.52 0.398 
PCB 118 - - - - 
PCB 126 55.24 ± 14.64 88.10 126.51 ± 44.08 113.55 
PCB 153 - - - - 
PCB 156 - - - - 
 
In Table 30 REPs are summarized regarding CYP1A1 and CYP1B1 mRNA data. REPs were 
obtained by dividing the EC value (EC50/EC20) of the reference compound TCDD by the EC 
value (EC50/EC20) of the test compound. Since the TEF concept is based on TCDD being the 
reference compound, REPs for treatment with TCDD are constantly set as 1.0. REPs gained 
from EC50 and EC20 values deviated from the current TEF.  
In case of 1-PnCDD, REP values derived from CYP1A1 mRNA data were twice higher than 
the 2005-TEFs. REPs based on CYP1B1 mRNA data confirmed the current TEF. REPs for   
4-PnCDF were 2- to 3-times higher than the current TEF. A different picture was obtained for 
PCB 126. Derived REPs were far below the TEF by approximately 9- to 42-fold.  
It was not possible to derive any REPs for the PCBs 118, 153, and 156 based on the very low 
CYP1A1/CYP1B1 mRNA expression levels in HepG2 cells. 
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Table 30. Relative effect potencies derived from EC50/EC20 values of CYP1A1 and CYP1B1 mRNA expression 
levels in HepG2 cells. 
 
 
CYP1A1 mRNA CYP1B1 mRNA TEF 
(WHO, 2005) 
 
REP (EC50) REP (EC20) REP (EC50) REP (EC20) 
TCDD 1.0 1.0 1.0 1.0 1.0 
1-PnCDD 1.93 1.92 0.93 1.58 1.0 
4-PnCDF 0.83 1.04 0.53 0.87 0.3 
PCB 118 - - - - 0.00003 
PCB 126 0.011 0.0024 0.0053 0.0030 0.1 
PCB 153 - - - - - 
PCB 156 - - - - 0.00003 
 
 
IV.3.3 Microarray HepG2 vs. hHeps 
 
IV.3.3.1 Microarray Analysis  
 
This microarray study aimed to analyze similarities and differences in gene expression after 
dioxin exposure of the immortalized human hepatocellular carcinoma cell line HepG2 and 
primary human hepatocytes. Primary human hepatocytes represent the closest model to the 
human liver by expressing the complete spectrum of hepatic drug-metabolizing enzymes 
(Hewitt et al., 2007). HepG2 cells are often used in in vitro studies in which the human liver is 
the major target tissue. In order to identify novel quantifiable biomarkers for dioxin exposure, 
gene expression analysis of both human cell models could contribute important information 
concerning this topic. 
Therefore, HepG2 cells and primary human hepatocytes were exposed to TCDD (10 nM) and 
PCB 153 (1000 nM). PCB 153 belongs to the group of non dioxin-like PCBs and was used in 
this toxicogenomic study as negative control. Primary human hepatocytes were obtained from 
five different donors (Table 24) and five independent experiments (using HepG2 in five 
different passage numbers) were also performed for HepG2 cells. RNA purity and yield was 
verified by 2100 Bioanalyzer (Agilent Technologies, Waldbronn) and associated RNA 6000 
Pico LabChip kit. All samples featured high-quality RNA and could be used for microarray 
anaylsis.  
Afterwards Agilent's Two-Color Microarray-based Gene Expression Analysis was carried out 
using cyanine 3- and cyanine 5-labelled targets to measure expression in experimental and 
control samples, whereas solvent control samples and compound-treated samples were stained 
oppositionally. 100 ng per each sample was chosen as starting RNA concentration. Whole 
Human Genome Oligo Microarray 4x44K (Agilent Technologies, Waldbronn) was applied. 
Further information about the experimental procedures and conditions as well as data 
processing and statistical analysis is given in chapter six (VI Methods). 
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Microarray data from different human cell models were independently analyzed in two data 
files (hHeps and HepG2). Results in both cases were filtered by cut-off values for the signal 
intensity A ≥ 5, the log2 fc ≥ 1 or ≤ -1, and the p-value ≤ 0.05. The colour intensity was 
reduced from 7 to 5 in the present in vitro toxiconomic study. This adaptation had to be 
carried out due to the weaker colour intensity of the microarray slides from HepG2 cells. 
During the data analysis, it was noticed that CYP1B1, which also serves a marker for the 
activation of the AhR in human cell models, was missing in the list of up regulated genes. 
After evaluation of all possible reasons for this gene's absence, it was discovered that CYP1B1 
was missing as a result of the weaker colour intensity value of the respective oligonucleotide 
on the microarray slide. CYP1B1 was highly up regulated by HepG2 (log2 fc value: 3.52), but 
only with a corresponding colour intensity value of 5.66. In addition, RT-PCR analysis 
confirmed that CYP1B1 mRNA levels were strongly induced by TCDD treatment in HepG2 
(IV.3.2.6 Gene expression of target genes by RT-PCR). For this purpose, the colour intensity 
was reduced to a value of 5 in the present microarray study. 
Though in both in vitro models the same TCDD concentration (10 nM) was used for 
incubation, the number of affected genes (up and down regulated) in primary human 
hepatocytes was more than 3-times lower than in HepG2 cells. 247 unique genes were 
significantly up and 44 down regulated in HepG2, whereas TCDD exposure led to 72 up and 
only 8 down regulated genes in hHeps (Figure 46). Treatment with PCB 153 resulted in 
almost no altered gene expression compared to the respective controls in both cell models. 
Due to the large number of affected genes by TCDD treatment, only distinct characteristics 
are presented below, but the list of all up and down regulated genes in both human cell 
models is attached to the present work (Tables 96, 97, 98, 99). 
 
  
 
Figure 46. 
 
Microarray results HepG2 vs. hHeps. 
Quantity of affected genes in HepG2 cells (left) and hHeps (right) after treatment with  
TCDD (10 nM) and PCB 153 (1000 nM). 
Selected cut-off values: A ≥ 5, log2 fc ≥ 1 or ≤ -1, p-value ≤ 0.05 
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Figure 47. Up and down regulated genes in HepG2 cells and hHeps after treatment with TCDD (10 nM) for24 h. 
Microarray results illustrated as Venn diagram. 
Selected cut-off values: A ≥ 5, log2 fc ≥ 1 or ≤ -1, and p-value ≤ 0.05. 
 
 
Figure 48. Up and down regulated genes in HepG2 cells and hHeps after treatment with PCB 153 (1000 nM) for 
24 h. Microarray results illustrated as Venn diagram. 
Selected cut-off values: A ≥ 5, log2 fc ≥ 1 or ≤ -1, and p-value ≤ 0.05. 
 
When comparing both human liver cell models, there was an unexpectedly small overlap of 
genes being up or down regulated. In both cell types, only 25 genes were commonly up 
regulated by TCDD in vitro liver cell models, but none commonly down regulated. Table 31 
features the list of in common up regulated genes by TCDD in HepG2 cells and hHeps in 
alphabetical order.  
TCDD treatment of HepG2 cells for 24 h resulted in the up regulation of genes associated 
with xenobiotic metabolism. Established dioxin-inducible genes included genes associated 
with phase I (CYP1A1, CYP1A2, CYP1B1, ALDH3A1, NQO1) and phase II (UGT1A6 and 
GSTP1) of xenobiotic metabolism (Nebert et al., 2000) (Bock et al., 2005a) (Bock et al., 
2005b). Several solute carrier genes were also among the significantly up regulated genes 
such as SLC2A8, SLC2A11, SLC5A7, SLC7A5, SLC16A6, SLC19A2, SLC25A30, SLC32A2, 
and SLC43A2. Solute carriers are involved in diverse transport processes such as the 
sodium/glucose co-transport (SLC5As), the transport of amino acids (SLC7As), and glucose 
transport (SLC2As) (Babu et al., 2003) (Wright et al., 2004) (Verrey et al., 2004) (Schmidt et 
al., 2009). SLC7A5 was already identified as TCDD-responsive gene in HepG2 cells by 
Sarkar et al. (1999).  
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NKAIN1 and FMOD were also among the ten highest up regulated genes involved in HepG2 
cells (Table 31). NKAIN1 (Na+/K+ transporting ATPase interacting 1) belongs to the class of 
NKAINs which interact with the β-subunit of the Na+/K+ ATPase. The Na+/K+ ATPase is a 
plasma membrane enzyme which plays an important role in the maintenance of the 
electrochemical gradient across cellular membranes (Gorokhova et al., 2007). The FMOD 
(fibromodulin) gene encodes the fibromodulin protein. Fibromodulin is a small leucine-rich 
proteoglycan involved in extracellular matrix organization. Mormone and co-workers 
identified FMOD as an oxidative stress-sensitive proteoglycan which contributes to the 
pathogenesis of fibrosis in mice (Mormone et al., 2012). The involvement of the AhR in the 
regulation of hepatic fibrosis by modulation of the TGF-β-binding protein-1 (LTBP-1) was 
demonstrated by Corchero and co-workers (Corchero et al., 2004).  
Another highly induced gene after exposure to TCDD in HepG2 cells was WNT11 (wingless-
type MMTV integration site family, member 11). WNT6 was additionally up regulated, but to 
a lesser extent (log2 fc value: 2.66). WNT11 and WNT6 are members of the WNT protein 
family which play important roles in cell proliferation, differentiation, polarity, and migration. 
High expression levels of WNT11 in HepG2 cells have been examined by Toyama and co-
workers (Toyama et al., 2010). They discovered that the high WNT11 mRNA levels were 
based on an inactiving β-catenin mutation. The high up regulation of FMOD, NKAIN1, and 
WNT11 were consistent with the results from a recently published microarray study in which 
HepG2 cells were treated with TCDD, too (Dere et al., 2011). 
 
Treatment of hHeps resulted in the up regulation of 72 unique genes leading to the suggestion 
that hHeps are less-sensitive in terms of differently regulated genes (Table 32). TCDD 
treatment of hHeps for 24 h resulted in the up regulation of established dioxin-inducible genes 
which are associated with xenobiotic metabolism such as CYP1A1, CYP1A2, CYP1B1, 
ALDH3A1, ALDH3A2, and UGT1A6 (Nebert et al., 2000) (Bock et al., 2005a) (Bock et al., 
2005b). Several solute carrier genes were also among the significantly up regulated genes 
such as SLC7A5, SLC12A7, and SLC20A2. As described before with HepG2 cells, the 
proteins encoded by SLCs are involved in diverse transport processes such as the transport of 
amino acids (SLC7A5), potassium/chloride (SLC12A7), and sodium/phosphate (SLC20A2) 
(Buba et al., 2003) (Collins et al., 2004) (Herbert et al., 2004). 
ARHGAP44 was among the ten highest up regulated genes (Table 32). ARHGAP44 belongs 
to the GTPase superfamily which functions as molecular switches reacting to extracellular 
stimuli. Active GTP-bound Rho proteins take part in diverse cellular processes which lead to 
the regulation of gene transcription as well as structural cell aspects (actin cytoskeleton re-
arrangement) (Moon et al., 2003). The guanine nucleotide binding protein (G protein), alpha z 
polypeptide gene, in short GNAZ, was up regulated, too. Heterotrimeric G proteins are 
involved in G protein receptor signalling pathways. GNAZ only mediates signal transduction 
in pertussis toxin insensitive systems (Fong et al., 1988) (Matsuoka et al., 1990)(Casey et al., 
1990). Recently the possible involvement of GNAZ in melanoma progression was described 
causing high somatic mutation rates in this gene (Cardenas-Navia et al., 2010).  
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Table 31. Highest up regulated genes in HepG2 cells after treatment with TCDD (10 nM). 
Selected cut-off values: A ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. Annotations:   '*' Log2 fc value calculated as mean value from identical probes. 
 
Gene name Gene description Probe name Systematic name Log2 fc 
CYP1A1 Cytochrome P450 family 1, subfamily A, polypeptide 1 A_23_P163402 NM_000499 5.00 
NKAIN1 Na+/K+ transporting ATPase interacting 1 A_23_P51376 NM_024522 4.88 
LRRC25 Leucine rich repeat containing 25  A_23_P165136 NM_145256 4.88 
WNT11 Wingless-type MMTV integration site family, member 1 A_24_P253003 NM_004626 4.54 
SLC16A6 Solute carrier family 16 member 6 (monocarboxylic acid transporter 7) A_23_P152791 NM_004694 4.40 
FMOD Fibromodulin A_23_P114883 NM_002023 4.20* 
LIM2 Lens intrinsic membrane protein 2 A_23_P130435 NM_030657 4.11 
AHRR Aryl hydrocarbon receptor repressor A_23_P358709 NM_020731 3.99 
CYP1B1 Cytochrome P450 family 1, subfamily B, polypeptide 1 A_23_P209625 NM_000104 3.52 
SEC14L4 SEC14-like 4 (S. cerevisiae) transcript variant 1 A_23_P421032 NM_174977 3.47 
 
Table 32. Highest up regulated genes in hHeps after treatment with TCDD (10 nM). 
Selected cut-off values: A ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. 
 
Gene name Gene description Probe name Systematic name Log2 fc 
CYP1B1 Cytochrome P450 family 1, subfamily B, polypeptide 1 A_23_P209625 NM_000104 6.59 
CYP1B1 Cytochrome P450 family 1, subfamily B, polypeptide 1 A_33_P3290343 NM_000104 4.43 
CYP1A1 Cytochrome P450 family 1, subfamily 1, polypeptide 1 A_23_P163402 NM_000499 5.37 
LRRC25 Leucine rich repeat containing 25  A_23_P165136 NM_145256 4.58 
ALDH3A1 Aldehyde dehydrogenase 3 family A, member 1, transcript variant 2 A_23_P207213 NM_000691 4.41 
ALDH3A1 Aldehyde dehydrogenase 3 family A, member 1, transcript variant 1 A_33_P3238433 NM_001135168 4.20 
FLJ30901 cDNA FLJ30901 fis clone FEBRA2005778 A_33_P3480395 AK055463 3.60 
ARHGAP44 Rho GTPase activating protein 44 A_23_P26854 NM_014859 3.53 
C14orf135 cDNA FLJ38170 fis  clone FCBBF1000024 A_33_P3397795 AK095489 3.26 
LOC100507055 Hypothetical LOC100507055 A_32_P49867 NM_001195520 3.17 
GNAZ Guanine nucleotide binding protein (G protein) alpha z polypeptide A_23_P416581 NM_002073 3.11 
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The small number of in common up regulated genes in both human liver cell models (Table 
33) was unexpected because HepG2 cells are often used as in vitro model to investigate 
mechanisms of action of dioxins and dioxin-like compounds.  
Cytochromes P450 1A1, 1A2, 1B1 and ALDH3A1, being proven phase I xenobiotic 
metabolising enzymes, were up regulated in both human cell models. UGT1A6, a member of 
group of phase II metabolizing enzymes, was also among the group of 25 commonly up 
regulated genes. UGT1A6 is the main representative of the UGT1A family. Uridine 
diphosphate glucuronosyl transferases belong to the class of type I transmembrane proteins 
which are involved in biotransformation of exogenous and endogenous substrates. UGT1A6 
catalyzes the conjugation of the substrate with glucuronic acid to enhance the substrate's 
water solubility and to improve its biliary and uric excretion (Bock et al., 2006). HSD17B2 
was furthermore up regulated in both human liver cell models. HSD17B2 plays an important 
role in estrogen metabolism by catalyzing the inactivation of estradiol to the less potent 
estrone (Plourde et al., 2008). Hayes and co-workers discovered the AhR-dependent TCDD-
inducible up regulation of Hsd17b2 in mice (Hayes et al., 2007). Another gene being 
commonly up regulated was SLC7A5. This gene encodes the LAT1 protein which is 
responsible for the sodium-independent amino acid exchange of large neutral amino acids 
(Babuet al., 2003) (Verrey et al., 2004). SLC7A5 was already identified as TCDD-responsive 
gene in HepG2 cells by Sarkar et al. (Sarkar et al., 1999). 
Genes linked to further signal transduction processes were up regulated after TCDD 
treatment, too. LRRC25 was highly up regulated in HepG2 and hHeps by TCDD. A large 
number of leucine rich repeat containing proteins with distinguished functions in different 
cellular compartments have been identified in humans, rodents, plants, flies, and yeast so far. 
They all have specific repetitive sequences in common and are involved in protein-protein 
interactions. LRR proteins among others participate in signal transduction, DNA repair, 
recombination, transcription, or RNA processing (Kobe et al., 1995). LRRC25 was identified 
as novel AhR-regulated target gene involved in PAH-induced immunotoxicity by Iwano and 
co-workers (Iwano et al., 2010). SECTM1 encodes a transmembrane and secreted protein 
(type 1). SECTM1 is primarily expressed in epithelial cells and in peripheral blood cells 
(neutrophils and monocytes). The SECTM1 protein is involved in T cell proliferation as well 
as the secretion of various cytokines (TNFα, INFγ) due to its high affinity to the CD7 receptor 
(Huyten et al., 2011). The protein encoded by MAFF is a transcription factor without a 
transactivation domain. MAF proteins have been linked to gene regulation, differentiation, 
oncogenesis, and development in various organisms (Massrieh et al., 2006). 
The gene MBL2 was furthermore up regulated in both human liver models. The MBL2 protein 
belongs to the group of acute-phase proteins which are produced as a response to 
inflammation. MBL2 plays an important role in the innate immune system. Mannose-binding 
proteins not only function as pattern recognition molecules in the complement system by 
binding apoptotic cells but they additionally increase the engulfment of intact apoptotic cells 
and cell debris (Turner et al., 1998) (Ogden et al., 2001) (Stuart et al., 2005) (Herpers et al., 
2009). 
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Moreover, further genes involved in cellular growth, differentiation, proliferation, cell cycle 
and apoptosis were up regulated in both cell types by TCDD. The anti-apoptotic gene Bcl-2 
modifying factor (BMF) was also up regulated. Bcl-2 (B cell lymphoma 2) is the founding 
member of Bcl-2 family of proteins which regulate the programmed cell death (apoptosis) 
(Chao et al., 1998). The CDK5RAP2 gene encodes the CDK5RAP2 protein which directly 
regulates CDK5 and CDK5R1 (isoform of CDK5) activities. Both are involved in the cell 
cycle process (Kraemer et al., 2011). Furthermore, Barrera et al. (2010) demonstrated in 
mouse model that CDK5RAP2 is required for the maintenance of centriole engagement and 
cohesion (Barrerra et al., 2010). TCDD additionally induced the up regulation of the 
myoferlin gene (MYOF). Myoferlin (MYOF) is a member of the ferlin family. Ferlin proteins 
are membrane-associated proteins which are associated with diverse in biological processes 
such as endothelial cell membrane regeneration and growth, growth factor receptor stability, 
as well as endocytosis (Demonbreun et al., 2010) (Eisenberg et al., 2011). 
The protein encoded by the PDLIM2 gene, is a member of the PDZ and LIM domain 
containing protein family, which are enganged in various cellular processes such as 
cytoskeletal organization, neuronal signalling, cell linage specification, organ development, 
and oncogenesis (Loughran et al., 2005) (te Vethuis et al., 2007). Furthermore, as a nuclear 
regulator of NF-κB, PDLIM2 determines the NF-κB activity. NF-κB is a transcription factor 
taking part in innate and adaptive immunity, inflammation, cellular stress responses, cell 
adhesion, proliferation as well as apoptosis (Tanaka et al., 2007) (Mankan et al., 2009). 
GDF15 encodes the growth and differentiation factor (GDF15) protein which belongs to the 
transforming growth factor-β (TGF-β) superfamily. High levels of GDF15 were measured in 
the adult liver as a result of a liver injury (Hsiao et al., 2000). GDF15 is additionally involved 
in cardiac hypertrophy and programmed cell death (apoptosis) (Ago et al., 2006).  
Proprotein convertase subtilisin/kexin type 5 is a member of the subtilisin/kexin-like 
proprotein convertase enzymes which are responsible for functional maturation of target 
proteins (Turpeinen et al., 2011). The FBXO25 gene encodes the FBXO25 protein which is 
one of 68 human F-box proteins. It functions as one of four subunits of the ubiquitin protein 
ligase complex (SCF1-complex) and is involved in the detection of proteins which should be 
eliminated from the organism by the ubiquitin proteasome complex (Teixeira et al., 2010). 
SERTAD2 was slightly, but significantly up regulated in HepG2 cells and hHeps. SERTA 
domain containing proteins take part in various cellular processes including the regulation of 
the transcription factor E2f1 during cell cycle progression, the p53-dependent stress response, 
and cancer pathogenesis (Hsu, et. al., 2001) (Cheong et al., 2009) (Fernandez-Marcos et al., 
2010). 
DNMT3L is a member of the group of DNA methyl transferases.Transcriptional repression by 
CpG methylation is an important step which plays a key role in various processes such as 
embryonic development, genomic imprinting, as well as X-chromosome inactivation. 
DNMT3L is not able to methylate the DNA in contrast to its other family members, but it 
stimulates the enzyme activity of the DNA cytosine methyltransferase 3α as well as it acts as 
a transcriptional repressor for the histone deacetylase HDAC1 (Deplus et al., 2002) (Xu et al., 
2010). 
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The NKD2 protein is a negative regulator of the Wnt signalling pathway, in particular by 
binding to theso called Dishevelled proteins (Dsh) during the canonical Wnt signalling 
pathway (Creyghton et al., 2005) (Hu et al., 2009). NDK2 furthermore encodes a protein 
which is responsible for the transport of the transforming growth factor α to the basolateral 
plasma membrane (Li et al., 2004). The Wnt signalling pathway is involved in various cellular 
processes such as development, differentiation, as well as the maintenance of the cellular 
homeostasis (Behari et al., 2010). Interactions between the β-catenin (key regulator of the 
canonical Wnt signalling) and the AhR subsequently to TCDD treatment were demonstrated 
in liver progenitor cells (Prochazkovaet al., 2011). The slight induction of this gene implies 
that TCDD treatment leads to a possible interplay between the AhR and Wnt signalling in 
both human liver cell models.  
The suppressor of cytokine signalling 2 (SOCS2) was also up regulated in both hepatic cell 
models. Though, the HepG2 cells log2 fc value was 4-times higher than in hHeps where only 
a slight increase was observed. SOCS proteins are cytokine-inducible negative regulators of 
the cytokine receptor signalling by the JAK/STAT signalling pathway. SOCS2 plays an 
important role in growth hormone receptor signalling. Deregulation of growth hormone 
signalling was proven in Socs2-deficient mouse model in which Socs2 knockout mice 
exhibited gigantism (Alexander et al., 2003) (Rico-Bautista et al., 2006) (Vesterlund et al., 
2011). In 2004, an in vitro study performed in murine B cell lymphoma cells revealed that 
SOCS2 is not only induced by cytokines and growth hormones, but also by TCDD. 
Furthermore, the induction of SOCS2 was proven to be mediated by the activation of the AhR 
signalling pathway in the chosen in vitro model. Boverhof and co-workers demonstrated that 
SOCS2 is a negative regulator of cytokine signalling acting via a classic negative feedback 
loop (Boverhof et al., 2004). The TCDD-mediated transcriptional induction of SOCS2 in 
hHeps and HepG2 could be based on the enhanced secretion of cytokines as a cellular 
response to the TCDD-induced inflammation in both human liver cell models. 
The present toxicogenomic study in HepG2 cells and primary human hepatocytes elucidated 
the AhR-mediated effects of TCDD. TCDD treatment led to the up regulation of established 
AhR-responsive genes associated with xenobiotic metabolisms (CYP1A1, 1A2, 1B1, 
ALDH3A1, and UGT1A6). Other in both cell types commonly up regulated genes are 
associated with diverse biological processes such as cell cycle regulation (CDKRAP2), 
cellular growth and differentiation (SERTAD2, PDLIM2, GDF15), apoptosis (BMF) 
transcriptional regulation (SERTAD2, DNMTL3, MAFF), immune response (SOCS2, MBL2, 
SECTM1), and cellular transport (SLC7A5). 
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Table 33. In common up regulated genes in HepG2 cells and hHeps in alphabetical order.  
Selected cut-off values: A ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. Explanations:   '*' Log2 fc value calculated as mean value from identical probes. 
 
Gene Name Gene Description Systematic Name Probe Name 
Log2 fc 
HepG2 
Log2 fc 
hHeps 
ALDH3A1  Aldehyde dehydrogenase 3 family, member 1A, transcript variant 2 NM_000691 A_23_P207213 3.47 4.41 
ALDH3A1  Aldehyde dehydrogenase 3 family, member 1A, transcript variant 1 NM_001135168 A_33_P3238433 3.32 4.20 
BMF  Bcl-2 modifying factor (BMF) transcript variant 1  NM_001003940 A_23_P379649 2.39 2.52 
CDK5RAP2  CDK5 regulatory subunit associated protein 2 transcript variant 1  NM_018249 A_23_P83110 1.14 1.64 
CYP1A1  Cytochrome P450, family 1, subfamiliy A, polypeptide 1 NM_000499 A_23_P163402 5.00 5.37 
CYP1A2  Cytochrome P450, familiy 1, subfamiliy A, polypeptide 2  NM_000761 A_33_P3253747 1.83 2.62 
CYP1B1  Cytochrome P450, familiy 1, subfamiliy B, polypeptide 1 NM_000104 A_23_P209625 3.52 6.59 
DNMT3L  DNA (cytosine-5-)-methyltransferase 3-like transcript variant 1  NM_013369 A_23_P17673 1.46 2.08 
FBXO25  F-box protein 25 (FBXO25) transcript variant 2 NM_183421 A_23_P94159 1.36 1.84 
GDF15  Growth differentiation factor 15  NM_004864 A_23_P16523 1.39 1.38 
HSD17B2  Hydroxysteroid (17-beta) dehydrogenase 2  NM_002153 A_23_P118065 1.84* 1.24* 
LOC100507055  Hypothetical LOC100507055  NM_001195520 A_32_P49867 2.41 3.17 
LOC286161  cDNA FLJ34353 fis clone FEBRA2011665  AK091672 A_33_P3841368 1.12 1.70 
LRRC25  Leucine rich repeat containing 25  NM_145256 A_23_P165136 4.88 4.58 
MAFF  v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian), transcript variant 1 NM_012323 A_23_P103110 1.45* 1.39 
MBL2  Mannose-binding lectin (protein C) 2 soluble  NM_000242 A_23_P35529 2.21 1.64 
MYOF  Myoferlin, transcript variant 1  NM_013451 A_23_P354387 2.74 1.36 
NKD2  Naked cuticle homolog 2 (Drosophila)  NM_033120 A_23_P41804 1.14 2.24 
PCSK5  Proprotein convertase subtilisin/kexin type 5, transcript variant 2 NM_006200 A_23_P257003 1.82 2.12 
PDLIM2  PDZ and LIM domain 2 (mystique), transcript variant 3  NM_198042 A_33_P3311371 1.61 1.01 
SECTM1  Secreted and transmembrane 1 NM_003004 A_24_P48204 1.25 2.32 
SERTAD2  SERTA domain containing 2  NM_014755 A_24_P294124 1.65 1.22 
SLC7A5  Solute carrier family 7 (amino acid transporter light chain L system) member 5 NM_003486 A_24_P335620 1.50 2.14 
SOCS2  Suppressor of cytokine signalling 2 NM_003877 A_23_P128215 3.02 1.10 
UGT1A6  UDP glucuronosyltransferase 1 family, polypeptide A6  NM_001072 A_23_P60599 1.13 1.17 
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In order to find, establish, and implement novel quantifiable biomarkers for AhR activation 
due to exposure to DLCs, the gene expression of five potential AhR target genes as well as 
established markers for AhR activation (CYPs) are presented in Table 34. The table displays 
the obtained log2 fold-change values of the eight target genes from microarray analysis, 
whereby both transcript variants (transcript variants 1 and 2) of the aldehyde dehydrogenase 
(ALDH3A1) are indicated. Despite the induction of CYP1A1, CYP1A2, and CYP1B1, 
ALDH3A1 and HSD17B2 were the only genes among the group of potential novel target 
genes which were up regulated in both in vitro models. CD36 and AHRR were only up 
regulated in HepG2 cells, but not in hHeps. TIPARP, on the other hand, was only up regulated 
in hHeps, but not in HepG2 cells. Gene expression of selected target genes obtained by the 
current microarray experiment had been verified using RT-PCR analysis which is presented in 
the following chapter. 
 
Table 34. AhR target genes in hHeps and HepG2 identified by microarray. 
Table features aspects such as gene name, systematic name, and corresponding fold-change. 
Selected parameters: A ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. 
Explanations:  (1) transcript variant 1; (2) transcript variant 2; 
                        '*' Log2 fc value calculated as mean value from identical probes. 
                        '→' This gene was not up regulated in microarray experiment. 
 
Gene name Probe name Systematic name Log2 fc 
HepG2 
Log2 fc 
hHeps 
CYP1A1 A_23_P163402 NM_000499 5.00 5.37 
CYP1A2 A_33_P3253747 NM_000761 1.82 2.63 
CYP1B1 A_23_P209625 NM_000104 3.52 6.59 
ALDH3A1 (1) A_33_P3238433 NM_001135168 3.32 4.20 
ALDH3A1 (2) A_23_P207213 NM_000691 3.47 4.41 
HSD17B2 A_23_P118065 NM_002153 1.89* 1.24* 
CD36 A_23_P111583 NM_001001547 1.52 → 
TIPARP A_23_P143845 NM_015508 → 2.31 
AHRR A_23_P358709 NM_020731 3.99 → 
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IV.3.3.2 Gene Expression of Target Genes by RT-PCR 
 
After performing microarray analysis in HepG2 and hHeps, the mRNA gene expression of the 
selected eight target genes was determined by RT-PCR. The isolated RNA from compound-
treated HepG2 cells and primary human hepatocytes was first transcribed into complementary 
DNA (cDNA). 1 µl of cDNA was used to perform each RT-PCR experiment. The target gene 
expression was normalized to the selected housekeeping gene (β-actin (ACTB)) before the 
gene-specific expression was calculated relative to the expression of the corresponding 
solvent control (DMSO 0.1 %). The following two figures (Figure 49 and 50) summarize the 
results of the mRNA expression levels of the AhR-regulated cytochromes P450 1A1, 1A2, and 
1B1 as well as the selected potential biomarker genes ALDH3A1, HSD17B2, CD36, TIPARP, 
and AHRR.  
Gene expression levels of all eight target genes were not affected compared to the respective 
solvent controls after 24 h exposure to NDL-PCB 153 in both human liver cell models as 
expected, taking into account the earlier presented microarray studies. CYP1A1 mRNA 
expression was strongly induced after incubation with TCDD (10 nM) for 24 h in both cell 
models leading to a 1354.66 ± 771.74-fold and 679.34 ± 351.01-fold induction for hHeps and 
HepG2 cells, respectively. This was also the case for CYP1B1; here, CYP1B1 mRNA levels in 
hHeps were about 6-times higher than in the human hepatocellular carcinoma cell line 
resulting in a 628.59 ± 277.90 and 97.37 ± 47.32 CYP1B1 fold-induction. In contrast to these 
findings, the gene expression of CYP1A2 was highly induced in primary human hepatocytes 
(597.86 ± 389.00), but not in HepG2 cells (2.04 ± 1.32). 
ALDH3A1 was induced in both cell types (Figure 50). The ALDH3A1 mRNA levels were 
about 4-times higher (20.42 ± 12.99-fold) in hHeps than in TCDD-treated HepG2 cells (4.78 
± 1.67-fold). HSD17B2 mRNA expression was slightly, but statistically significantly induced 
after exposure to TCDD in hHeps (2.98 ± 1.20) and HepG2 cells (2.60 ± 0.53). CD36 as 
another selected potential novel target gene was slightly induced in HepG2 cells (2.23 ± 0.78-
fold), but not in primary human hepatocytes. Opposed to this, TIPARP mRNA levels were 
only enhanced in hHeps (3.01 ± 0.35-fold) compared to the solvent control, but not in HepG2 
cells. Gene expression of the aryl hydrocarbon receptor repressor (AHRR) was neither induced 
in hHeps nor in HepG2 cells. 
 
Among the potential novel target genes only ALDH3A1 was induced to a higher extend after 
exposure to TCDD (10 nM) in both human liver cell models. The maximal mRNA induction 
in hHeps was 4-times higher than in HepG2 cells. But this experiment clearly shows that 
ALDH3A1 does not by far reach the mRNA inducibility of CYP1A1 as established biomarker 
for AhR activation. CYP1A2 was strongly induced in primary human hepatocytes, but not in 
HepG2 cells. The human CYP1A2 gene is only expressed in the adult liver (Xu et. al., 2000). 
The immortalized human hepatoma cell line HepG2 was derived from a liver tumour of a 
fifteen year old Caucasian Argentine male with a hepatocellular carcinoma suggesting that the 
lack of CYP1A2 induction is an age-specific effect (Aden et al., 1979) (Knowles et al., 1980). 
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Figure 49. Real-time PCR ratios of cytochromes P450s in HepG2 (plain-coloured bars) cells and hHeps (plaid 
bars) treated with TCDD (10 nM), PCB 153 (1000 nM), or DMSO (0.1 %).  
β-actin (ACTB) served as housekeeping gene. Data represent means + SD of data from n = 5 
independent experiments or donors, normalized to solvent control. One-tailed unpaired Student’s  
t-test,*= p ≤ 0.05, **= p ≤ 0.01 different from corresponding solvent control. 
 
 
 
Figure 50. Real-time PCR ratios of selected target genes in HepG2 (plain-coloured bars) cells and  
hHeps (plaid bars) exposed to TCDD (10 nM), PCB 153 (1000 nM), and DMSO (0.1 %).  
β-actin (ACTB) served as housekeeping gene. Data represent means + SD of data from n = 5 
independent experiments or donors respectively, normalized to solvent control. One-tailed unpaired 
Student’s t-test,*= p ≤ 0.05, **= p ≤ 0.01 different from corresponding solvent control. 
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IV.3.4 Summary and Discussion in vitro Experiments 
 
In the present work, human liver cell models (primary human hepatocytes and HepG2 cells) 
were used to assess the effects mediated by dioxins and dioxin-like compounds. The liver 
represents the target tissue in which TCDD has been shown to elicit carcinogenic and tumour 
promoting effects in rodents (Knerr et. al, 2006). Hepatotoxic effects mediated by TCDD 
include hepatomegaly, hepatocellular neoplasms, inflammation, necrosis, steatosis, as well as 
alterations in the expression of genes associated with lipid metabolism and transport in the 
murine liver (Poland et al., 1982a) (Huff et al., 1991) (Boverhof et al., 2006) (Kopec et al., 
2010a) (Kopec et al., 2010b) (Angrish et al., 2011). 
Humans are predominantly exposed to PnCDD/PnCDFs and PCBs via the food chain, but 
also as a consequence to their occupations or accidents. Hepatic responses elicited by TCDD 
in humans include alteration in hepatic enzyme levels, triglyceride levels as well as liver 
enlargement and liver cirrhosis (DeVito et al., 1995) (Pelclova et al., 2006). 
Performing essential in vitro experiments by the use of primary human hepatocytes and the 
human hepatocellular carcinoma cell line (HepG2) provides important information which can 
lead to a better understanding of risks after exposure to PnCDD/Fs and DL-PCBs in humans. 
Furthermore, the challenging task was to identify, validate, and establish quantifiable novel 
biomarkers for dioxin exposure and AhR-dependent modes of action.  
A set of seven core compounds including TCDD, 1-PnCDD, 4-PnCDF, PCB 126, PCB 118, 
PCB 153, and PCB 156 and additional further congeners, i.e. TCDF, 1,4-HxCDF, 1,4,6-
HpCDF, 1,6-HxCDD, 1,4,6-HpCDD, PCB 77, and PCB 105 were selected in the present 
work. Primary human hepatocytes (hHeps) as well as the immortalized human hepatocellular 
carcinoma cell line HepG2 were used in the present work to determine concentration-
dependent effects on induction of AhR-regulated gene expression and activity after 24 h 
treatment with test compounds. The effects of core congeners were examined in hHeps and 
HepG2 cells, whereas effects of further congeners were only determined in HepG2 cells.  
 
IV.3.4.1 EROD Data HepG2 vs. hHeps  
 
The catalytic activity of CYP1A1 in primary human hepatocytes and HepG2 cells was 
examined by measuring the Ethoxyresorufin-O-deethylase (EROD) activity. EC50/EC20 values 
and respective REPs values are compiled and compared with WHO-TEFs (van den Berg et 
al., 2006) in Table 35 and 36. The EROD activities of the core congeners (TCDD, 1-PnCDD, 
4-PnCDF, PCB 118, 126, 153, and 156) were determined in both human liver cell models, 
whereas the EROD activities of the seven further congeners were only measured in HepG2 
cells.  
Based these findings, primary human hepatocytes were in summary less sensitive towards 
TCDD, 1-PnCDD, 4-PnCDF, and PCB 126 compared to HepG2 cells. Silkworth et al. 
published a similar EROD-derived EC50 value for HepG2 (0.29 nM), but a much lower EC50 
value for primary human hepatocytes (0.15 nM) (Silkworth et al., 2005). In a recently 
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published study the EROD-derived EC50 value of TCDD in hHeps was also lower than the 
obtained value in the present thesis (0.239 nM) (Budinski et al., 2010). The higher obtained 
EC50 value of TCDD in hHeps could be attributed to the human diversity in EROD response 
which is characterized by sensitivity as well as the maximal inducibility. Silkworth and co-
workers demonstrated in their study that the EC50 values from four of the five donors were 
within a seven-fold range while the fifth donor was a poor responder to TCDD (Silkworth et 
al., 2005). In the same study the EROD activity of PCB 126 in hHeps was additionally 
determined. After 48 h of treatment a 6-fold higher EC50 value in HepG2 (150 nM) and a 15-
fold lower EC50 value in hHeps (45 nM) was determined. The differences in EC50 values 
concerning hHeps could again be attributed to the donor individuality, e.g. interindividual 
response. Likewise, the difference in maximal response and sensitivity of human donors was 
also observed in case of 4-PnCDF. The EROD-derived EC50 value in hHeps was 32-fold 
higher compared to the previously published study (0.563 nM) (Budinsky et al., 2010).  
 
Table 35. EC values derived from in vitro EROD assay.  
Explanation: 'n.e.' not examined 
 
 
HepG2 Primary human hepatocytes 
 
EC50 (nM) EC20 (nM) EC50 (nM) EC20 (nM) 
TCDD 0.269 ± 0.034 0.113 1.06 ± 0.57 0.420 
1-PnCDD 0.176 ± 0.023 0.058 3.07 ± 2.44 0.158 
4-PnCDF 0.107 ± 0.020 0.050 18.00 ± 8.59 0.242 
1,6-HxCDD 4.57 ± 0.12 1.53 n.e. n.e. 
1,4,6-HpCDD 2.45 ± 0.29 0.699 n.e. n.e. 
TCDF 1.64 ± 0.37 0.894 n.e. n.e. 
1,4-HxCDF 0.306 ± 0.041 0.137 n.e. n.e. 
1,4,6-HpCDF 47.55 ± 4.82 10.73 n.e. n.e. 
PCB 77 - - n.e. n.e. 
PCB 105 - - n.e. n.e. 
PCB 118 - - - - 
PCB 126 26.27 ± 3.62 25.75 678.78 ± 90.36 216.74 
PCB 153 - - - - 
PCB 156 - - - - 
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Table 36. Relative effect potencies (REPs) derived from in vitro EROD assay. Comparison with WHO-TEFs. 
Explanation: 'n.e.' not examined 
 
 
HepG2 Primary human hepatocytes TEF  
(WHO, 2005) 
 
REP (EC50) REP (EC20) REP (EC50) REP (EC20) 
TCDD 1.0 1.0 1.0 1.0 1.0 
1-PnCDD 1.53 1.92 0.35 2.66 1.0 
4-PnCDF 2.51 2.26 0.059 1.73 0.3 
1,6-HxCDD 0.059 0.074 n.e. n.e. 0.1 
1,4,6-HpCDD 0.11 0.16 n.e. n.e. 0.01 
TCDF 0.16 0.13 n.e. n.e. 0.1 
1,4-HxCDF 0.88 0.82 n.e. n.e. 0.1 
1,4,6-HpCDF 0.0057 0.011 n.e. n.e. 0.01 
PCB 77 - - n.e. n.e. 0.0001 
PCB 105 - - n.e. n.e. 0.00003 
PCB 118 - - - - 0.00003 
PCB 126 0.010 0.0044 0.0016 0.0019 0.1 
PCB 153 - - - - - 
PCB 156 - - - - 0.00003 
 
REPs derived from HepG2 cells mostly confirmed the current WHO-TEFs (Table 36). 
Nevertheless, several deviations were observed. In case of 4-PnCDF and 1,4-HxCDF, REP 
values were 8- and 9-fold higher than the current WHO-TEFs. REPs obtained for 1-PnCDD, 
1,4-HxCDD, TCDF and 1,4,6-HpCDF were within the same range as the current WHO-TEFs. 
In HepG2 cells, REP values for PCB 126 were below the current TEF by 10- and 23-fold. It 
was not possible to derive any REPs for the PCBs (PCB 77, 105, 118, 153, and 156) due to 
the lacking EROD induction in HepG2 cells. REPs obtained from hHeps differed from the 
current WHO-TEF. No REPs could be derived for PCB 118, 153, and 156 due to the lack in 
EROD activities in hHeps. REPs derived for PCB 126 were 63-fold and 53-fold below the 
current WHO-TEF, respectively. 
An inconsistent trend was obtained for 1-PnCDD and 4-PnCDF. REPs derived from EC50 
values of 1-PnCDD and 4-PnCDF were below the current WHO-TEF, 3-fold and 5-fold in 
particular. However, REPs derived from EC20 values were higher than the current WHO-TEF, 
3-fold and 6-fold, respectively. As described before, the EC50 is the effective concentration to 
achieve 50 % maximal response and therefore is only based on the respective test compound 
itself. On the other hand, the EC20 values were calculated in relation to TCDD. 1-PnCDD and 
4-PnCDF both evoked higher EROD activities at low concentrations compared to TCDD as 
well as a higher maximal EROD response, e.g. inducibility. Based on this, the higher REPs 
derived from EC20 values can be explained.  
For EC20 values, a different calculation concept was developed than vor EC50 values. This 
calculation method was elaborated to be able to compare the less potent DL-compounds, 
which might not reach the EC50 levels, with the most potent representative of the group of 
DLCs, TCDD.  
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This EC20 calculation method was based on a consensus between all SYSTEQ project partners 
to assess the potencies of weaker test. Hence, the separate calculation of EC20 values based on 
the data from each test compound itself should be taken into consideration as possible 
calculation approach. 
As described in the previous passage, 1-PnCDD and 4-PnCDF exhibited higher EROD 
responses in terms of overall CYP1A1 inducibility as well as higher EROD activities for both 
congeners in the low concentration range compared to TCDD in hHeps. It should be further 
analyzed if this phenomenon is a donor-specific effect. Therefore, the number of experiments 
in primary human hepatocytes should be increased. The relative effect potencies derived from 
CYP1A1 EROD data of 1-PnCDD and 4-PnCDF also suggest the higher potencies of both 
congeners compared to TCDD in HepG2 cells. Nevertheless, it should be examined if these 
findings are based on a cell-type specific effect or not, e.g. by the use of a different human 
liver cell model such as the immortalized hepatocellular carcinoma cell line HepaRG. The 
current TEFs are predominantly based on in vivo animal studies. In vivo and in vitro studies 
used for TEF value calculations are among others based on different endpoints and timepoints 
providing explicable reasons for the detected differences (Haws et al., 2006) (van den Berg et 
al., 2006). 
Further analysis of DLCs including experiments in hHeps by the use of additional donors, 
other human cell types (e.g. lymphocytes) as well as other transformed and untransformed 
human and rodent in vitro cell models is necessary to derive in vitro TEFs. The 
characterization of species- and cell type-specific responses provides essential knowledge for 
assessing the human risk towards DLCs. 
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IV.3.4.2 Comparison of CYP1A1 and CYP1B1 mRNA Expression with  
              EROD Induction in HepG2 cells 
 
EC50 and EC20 values derived from EROD assay and CYP1A1/CYP1B1 mRNA are 
summarized in Table 37. When comparing EC values of CYP1A1 enzyme activity (EROD) 
with CYP1A1 mRNA, the EROD assay was the more sensitive test method. Differences in EC 
values could be attributed to different experimental approaches. When comparing CYP1A1 
with CYP1B1, CYP1A1 was the more sensitive biomarker for AhR activation due to treatment 
with dioxins and dioxin-like compounds. The maximal fold inductions of CYP1A1 mRNA 
was about 10-fold higher compared to CYP1B1 mRNA in HepG2 cells-treated with TCDD,   
1-PnCDD, 4-PnCDF, or PCB 126. 
REPs derived from EROD induction and CYP1A1 mRNA were constantly higher for             
1-PnCDD and 4-PnCDF than the current WHO-TEFs. REPs for 1-PnCDD were between 1.5 
to 2-fold and REPs for 4-PnCDF were 3 to 8.5-fold higher compared to the established TEFs 
in 2005 (van den Berg et al., 2006). On the other side, REPs derived for PCB 126 were below 
the current TEF of 0.1 by several orders of magnitude. 
As described in the previous chapter, it must be taken into account that the current TEFs are 
primarily based on REPs derived from in vivo animal studies when comparing REP values 
from the present study. Multiple endpoints, timepoints, tissues, and cell types were used for 
calculation of WHO-TEFs (2005), whereupon the deviations can be explained (Haws et al., 
2006) (van den Berg et al., 2006). Furthermore, the obtained results should be compared to 
other in vitro data (human, rat, and mouse) to derive fundamental information about species-
specific and cell type-specific effects. In summary, 1-PnCDD and 4-PnCDF seem to be more 
potent than TCDD in HepG2 cells, but further experimental approaches, for instance by the 
use of a different immortalized human hepatocarcinoma cell line (HepaRG), are required to 
confirm whether these findings are cell type-specific responses or not.  
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Table 37. EC50 and EC20 values derived by EROD assay, CYP1A1 and CYP1B1 mRNA in HepG2 cells. 
 
  
TCDD 1-PnCDD 4-PnCDF PCB 118 PCB 126 PCB 153 PCB 156 
EROD 
  
EC50 ± SD (nM) 0.269 ± 0.034 0.176 ± 0.023 0.107 ± 0.020 - 26.27 ± 3.62 - - 
EC20 (nM) 0.113 0.058 0.05 - 25.75 - - 
CYP1A1 mRNA 
  
EC50 ± SD (nM) 0.583 ± 0.064  0.302 ± 0.208 0.704 ± 0.244 - 55.24 ± 14.64 - - 
EC20 (nM) 0.213 0.111 0.204 - 88.10 - - 
CYP1B1 mRNA 
  
EC50 ± SD (nM) 0.671 ± 0.224 0.718 ± 0.163 1.27 ± 0.52 - 126.51 ± 44.08 - - 
EC20 (nM) 0.344 0.218 0.398 - 113.55 - - 
 
Table 38. Relative effect potencies (REPs) derived from EROD assay, CYP1A1 and CYP1B1 mRNA in HepG2 cells.  
Comparison to WHO-TEFs (2005). 
 
     TCDD 1-PnCDD 4-PnCDF PCB 118 PCB 126 PCB 153 PCB 156 
EROD 
  
REP (EC50)  1.0 1.53 2.51 - 0.010 - - 
REP (EC20)  1.0 1.92 2.26 - 0.0044 - - 
CYP1A1 mRNA 
  
REP (EC50)  1.0 1.93 0.83 - 0.011 - - 
REP (EC20)  1.0 1.92 1.04 - 0.0024 - - 
CYP1B1 mRNA 
  
REP (EC50)  1.0 0.93 0.53 - 0.0053 - - 
REP (EC20)  1.0 1.58 0.87 - 0.0030 - - 
TEF (WHO, 2005) 1.0 1.0 0.3 0.00003 0.1 - 0.00003 
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IV.3.5 Microarray Studies in vivo vs. in vitro and mRNA Expression of  
           Target Genes  
 
Four microarray studies were performed in the present work. Two toxicogenomic studies 
focused on the AhR-dependent and AhR-independent effects in female mouse liver by the use 
of the AhR ligand TCDD and the CAR inducer PCB 153 (mouse study I - mouse 3-day study) 
in the first place and in the second place by using a transgenic mouse model in which the 
TCDD-altered hepatic gene expression was analyzed in Ahr wild-type and Ahr knockout 
mice. The TCDD-altered gene expression was additionally determined in the human 
hepatocarcinoma cell line HepG2 and primary human hepatocytes. HepG2 cells are often used 
in in vitro studies in which the human liver is the target tissue. Comparison of the TCDD-
elicited alterations in gene expression provides essential information about similarities and 
differences in both human in vitro cell models. TCDD as the most potent congener of the 
class of dioxins and related compounds is often used in vitro models as reference for dioxin-
mediated activation of the AhR. Little is known about other potent congeners (1-PnCDD, 4-
PnCDF, and PCB 126) and their effect on gene expression, especially in hHeps. Therefore, 
the changes in gene expression patterns induced by TCDD, 1-PnCDD, 4-PnCDF, PCB 126, 
and PCB 153 were determined in primary human hepatocytes.  
In both mouse microarray studies female C57BL/6 mice received a single dose of TCDD     
(25 µg/kg bw), only the post-treatment time varied (72 h vs. 96 h). The quantity of 
significantly altered hepatic genes (A ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05) was approximately 2-
times higher in mice with an enhanced exposure time (96 h) compared to mice sacrificed 72 h 
after single dose administration. This effect can most likely be attributed to the different 
exposure times, but the age of the animals could possibly have an effect on the alterations in 
gene expression, too. C57BL/6 mice exposed to TCDD in mouse study III were older (4-6 
months) compared to the C57BL/6 mice of mouse study I (8 weeks). These factors must be 
taken into consideration when comparing the obtained results from both mouse microarray 
studies. 
However, the highest up regulated genes in both microarray studies were associated with the 
xenobiotic metabolism as was the case in all performed microarray experiments, except in 
livers of Ahr knockout mice. In TCDD-treated C57BL/6 mice of mouse study I and TCDD-
treated C57BL/6 (Ahr wild-type) mice of mouse study III, the altered hepatic gene expression 
was associated with the lipid and glucose metabolism. The profiling of differently regulated 
genes draws to the conclusion that TCDD induced the AhR-mediated increased uptake of 
fatty acids and the accumulation of triglycerides in the murine liver. These results confirmed 
the role of TCDD in the dysregulation of the hepatic lipid metabolism and suggesting the 
development of a hepatic steatosis. Nevertheless, further analysis is necessary to confirm this 
thesis and to elucidate the responsible mechanisms and pathways by measuring the mRNA 
expression of genes and corresponding enzyme activities, analyzing the serum enzyme levels 
(AST, ALT, and GGT), the microscopic examination of the liver (histopathology), as well as 
dose-response studies are required.  
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25 genes were commonly up regulated in primary human hepatocytes and HepG2 cells after 
treatment with TCDD. Microarray analysis of TCDD-altered genes revealed that hHeps were 
less sensitive in terms of differently regulated genes resulting in 72 up and 2 down in hHeps 
and 247 up and 44 down in HepG2 cells. In addition to genes associated with 
biotransformation of xenobiotics, in particular genes linked to phase I and II of xenobiotic 
metabolism, two lipolytic genes were among the group of 25. Additionally, the TCDD-
induced altered gene expression included genes associated with diverse biological processes 
such as cell cycle regulation, cellular growth and differentiation, apoptosis, regulation of 
transcription, and immune response. These findings confirmed an earlier toxicogenomic study 
in HepG2 cells in which TCDD altered genes involved in cell cycle progression, 
differentiation, and apoptosis in presence of a ligand such as TCDD (Puga et al., 2002). 
Figure 51 summarizes the commonly up regulated genes after TCDD treatment for the 
different microarray experiments using the selected parameters.  
 
 
Figure 51. 
 
In common up regulated genes by TCDD in different microarray studies.  
Featured gene names are quoted in the human gene nomenclature (HUGO Gene Nomenclature 
Committee (HGNC)). 
Annotations: 'tv' = transcription variant. 
Comparison between significantly up regulated genes in mouse 3-day study, in hHeps, and in HepG2 
cells by TCDD. Selected parameters: A ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. 
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The most extensive overlap occurred between HepG2 and hHeps (25 genes) as expected 
because both have a human origin. Interestingly, the overlap of commonly up regulated genes 
in TCDD-treated HepG2 cells and TCDD-treated female mice was bigger (11 genes) as the 
overlap between TCDD-treated hHeps and TCDD-treated female mice (6 genes). CYP1A1 
(Cyp1a1), CYP1A2 (Cyp1a2), CYP1B1 (Cyp1b1), HSD17B2 (Hsd17b2), and UGT1A6 
(Ugt1a6a) were up regulated in vivo and in vitro. 
CYP1A1 (Cyp1a1) was in almost all microarray experiments the highest up regulated gene as 
a consequence of TCDD treatment. Up to the present day, the induction of CYP1A1 is the 
best known biomarker for AhR activation due to dioxin exposure (Nebert et al., 2000) (Nebert 
et al., 2004) (Ma et al., 2007). The AhR-mediated inducibility of CYP1A1, CYP1A2, 
CYP1B1, and UGT1A6 was demonstrated in various studies (Bock et al., 2005a) (Hankinson, 
1995) (Nebert et al., 2000) (Nebert et al., 2004).  
Based on the microarray results of the mouse 3-day study (IV.1.1.1.2Microarray analysis - 
mouse study I), the microarray study performed in HepG2 cells and hHeps (IV.3.2.5 
Microarray analysis HepG2 vs. hHeps), and a microarray study performed by the SYSTEQ 
project partner from the Karoliska Institutet, Sweden, potential target genes were selected in 
order to find novel quantifiable biomarkers for AhR activation. Including the results of all 
experimental models (mouse vs. human and in vivo vs. in vitro) five target genes 
(ALDH3A1/Aldh3a1, HSD17B2/Hsd17b2, TIPARP/Tiparp, CD36/Cd36, and AHRR/Ahrr) 
were selected in a consensus between all SYSTEQ project partners.  
Aldh3a1 belongs to the 'classic' murine AhR gene battery (Nebert et al., 2000). Aldehyde 
dehydrogenases are involved in phase II of the xenobiotic metabolism of exogenous 
compounds. Aldehyde dehydrogenases catalyze the oxidation of aldehydes to the respective 
ketones and carboxylic acids (Nebert et al., 2000). ALDH3A1 predominantly detoxifies 
aromatic and medium-chain aliphatic aldehydes derived from lipid peroxidation (Vasiliou et 
al., 2000) (Muzio et al, 2012). ALDH3A1 is expressed at low concentrations, if expressed at 
all, in normal liver, but high ALDH3A1/Aldh3a1 expression levels were detected in hepatoma 
and other various cancer cells (Alnouti et al., 2008). About 50 % of patients with liver 
tumours exhibited high ALDH3A1 expression levels. A direct correlation between the activity 
and amount of ALDH3A1 and cell proliferation has been demonstrated in various studies. 
The inhibition of ALDH3A1 activity could be used to reduce tumour cell proliferation. In 
normal cells the induction of ALDH3A1 expression could possibly contribute to tissue 
regeneration (Muzio et al., 2012). The AhR-dependent TCDD-mediated induction of Aldh3a1 
has been demonstrated, although some species and cell type-specific responses were 
determined (Vasiliou et al., 1992) (Nebert et al., 2000) (Alnouti et al., 2008). ALDH3A1 is 
strongly induced by TCDD in carcinoma cell lines, in rat (in vivo and in vitro), and in in vitro 
mouse models, but not in mouse in vivo (Vasiliou et al., 1993) (Alnouti et al., 2008). The 
TCDD-mediated induction of ALDH3A1 mRNA expression has been demonstrated by several 
microarray experiments in transformed human cell lines as well as in primary human 
hepatocytes (Kim et al., 2009) (Vee et al., 2010) (Dere et al., 2011) (Black et al., 2012).  
The hydroxysteroid (17-β) dehydrogenase 2 is a member of the short-chain 
dehydrogenases/reductases family. HSD17B2 is expressed in various tissues including the 
human placenta, liver, kidney, endometrium, intestine, pancreas, colon, and prostate. It 
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catalyzes various reactions within the steroid metabolism, among others the conversion of 
17β-estradiol to estrone, the reaction of testosterone to androstendione, as well as the 
oxidation of androstendiol to dehydroepiandrosterone (Casey et al., 1994) (Sun et al., 2011). 
Polymorphisms in the HSD17B2 gene have been associated with diseases such as breast and 
prostate cancer (Plourde et al., 2008) (Sun et al., 2011). Recent studies identified novel 
functions of HSD17B2 in addition to its role in sex steroid metabolism. Hsd17b2 knockout 
mice exhibited growth retardation, several abnormalities in placenta, kidney, and brain as well 
as a 70 % increased embryonic lethality (Rantakari et al., 2008). Transgenic mice expressing 
the human HSD17B2 also featured growth retardation as well as delayed eye opening and 
disrupted spermatogenesis which resulted in the infertility of all male mice at the age of three 
months (Zhongyi et al., 2007). Implications that the phenotype-specific changes are not based 
on decreased estrogen and androgen levels, but rather are the result of the interference with 
the retinoic acid signalling, are given because the administration of a synthetic retinoid acid 
analog rescued the testis phenotype in the aforementioned study (Zhongyi et al., 2007) 
(Moeller et al., 2009). Hayes and co-workers described the AhR-dependent up regulation of 
Hsd17b2 due to TCDD treatment in mice (Hayes et al., 2007). The toxicogenomic study 
performed by Fletcher et al. also demonstrated the TCDD-induced the up regulation of the 
Hsd17b2 mRNA expression in rat liver (Fletcher et al., 2005).  
The TCDD-inducible poly(ADP-ribose) polymerase, in short TIPARP (also known as    
PARP-7), belongs to the class of poly (ADP-ribose) polymerases (PARPs). Poly ADP-
ribosylation is a posttranscriptional protein modification mechanism by which poly(ADP-
ribose) polymerases catalyze the transfer of ADP-ribose from nicotinamid adenine 
dinucleotide (NAD+) to protein acceptors. This reaction is essential for multiple cellular 
processes such as DNA repair, transcription, proliferation, and cell death (Schreiber et al., 
2006) (MacPherson et al., 2013). Tiparp is constitutively expressed in various tissues such as 
heart, kidney, testis, liver, lung and brain (Ma et al., 2001). Ma and co-workers identified 
Tiparp as AhR-regulated TCDD-inducible gene (Ma et al., 2001) (Ma, 2002). TIPARP plays 
a fundamental role in the TCDD-mediated toxicity by suppression of the hepatic 
gluconeogenesis. TCDD induces the TIPARP expression, which subsequently results in the 
suppression of hepatic glucose metabolism, as demonstrated in chicken embryo hepatocytes 
(Diani-Moore et al., 2010). TIPARP siRNA led to an increase in glucose metabolism which 
was not significantly altered by TCDD compared to the control (Diani-Moore et al., 2010). A 
recently published study revealed that TIPARP exhibits rather mono(ADP-ribosyl)transferase 
activity than poly(ADP-ribosyl)polymerase activity. As aforementioned, the expression of 
TIPARP is mediated by the AhR and inducible by TCDD. It has now been postulated that 
TIPARP possibly functions as a repressor of the AhR signalling pathway in human cell lines 
and mouse embryonic fibrolasts derived from wildtype and Tiparp-deficient mice. TIPARP 
binds to the AhR/ARNT-complex which is bound to the XREs and thereby inhibits its 
transcription as well as the transcription of other AhR target genes (Cyp1a1/CYP1A1). 
Alternatively, it has been postulated that TIPARP itself binds to the DNA, which results in the 
dissociation of the AhR from the XREs and initiates the AhR proteosomal degradation 
process (MacPherson et al., 2013). The up regulation of TIPARP by TCDD in primary human 
hepatocytes has been demonstrated in recently published toxicogenomic studies (Dere et al., 
2011) (Black et al., 2012) (Forgacs et al., 2013). 
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The aryl hydrocarbon receptor repressor (AhRR) is a member of the helix-loop-helix/Per-
ARNT-Sim (bHLH/PAS) protein family. The aryl hydrocarbon receptor repressor is 
expressed in humans and animal tissues as well as in various cell lines. In humans, the AHRR 
is constitutively expressed in various organs such as testis, liver, kidney, colon, breast, adrenal 
glands, and other tissues. The highest expression levels were by far determined in testis. In the 
mouse, highest expression levels were measured in heart and brain, followed by testis, kidney, 
ovary, liver, spleen, lung, and thymus. The up regulation of the AHRR/Ahrr expression by 
various AhR agonists has been demonstrated in vitro in various human, mouse, and rat cancer 
cell lines and in vivo (rat and mouse) (Mimura et al., 1999) (Tsuchiya et al., 2003) 
(Bernshausen et al., 2006) (Fujii-Kuriyama et al., 2010). Mimura and co-workers identified in 
vitro employing mouse reporter gene studies that the AhRR is a negative regulator of the AhR 
signalling pathway (Mimura et al., 1999). They suggested that the negative feedback 
regulation of the AhR by the AhRR is either based on the competition for its 
heterodimerization partner ARNT or competitive binding of the AhRR/ARNT-complex to the 
XREs (Mimura et al., 1999). Evans et al. revealed that the AhRR-mediated repression of AhR 
signalling is not based on sequestration for ARNT and that binding of the AhRR/ARNT-
complex to the XREs is not a prequisite, but contributes to the repression. They proposed that 
AhRR repression of AhR signalling is possibly the result of protein-protein interactions with 
promoter-bound transcription factors, e.g. by essential coactivators or by a direct interplay 
between the AhR and AhRR (Evans et al., 2008). The involvement of the AHRR as potential 
tumour suppressor gene in a variety of human cancers has been suggested (Zudaire et al., 
2008).  
CD36, also known as thrombospondin receptor, is a member of the class B type of scavenger 
receptor family. Cluster of differentiation 36 (CD36) is a transmembrane glycoprotein with a 
variety of functions and is therefore expressed by a broad range of cell types and tissues 
including adipocytes, heart muscle, vascular endothelium, erythrocytes, 
monocytes/macrophages, platelets, and various others (Febbraio et al., 1999) (Zhang et al., 
2003) (Saxena et al., 2012). CD36 binds various divergent ligands including  
thrombospondin, collagen, oxidized low density lipoproteins (LPL), long-chain fatty acids, 
native lipoproteins, oxidized phospholipids, and apoptotic cells (Silverstein et al., 1992) 
(Febbraio et al., 1999) (Zhang et al., 2003) (Bonen et al., 2004) (He et al., 2011). Results 
derived from various in vitro and in vivo studies suggest that CD36 mediates atherosclerosis, 
type 2 diabetes, obesity, inflammation and oxidative stress in various cell types (Febbraio et 
al., 1999) (Bonen et al., 2004) (He et al., 2011) (Saxena et al., 2012). Its role in fatty liver 
diseases has been characterized and elucidated in recent studies. Fatty acid transports into the 
liver is facilated by CD36 and fatty acid binding proteins (FABPs). Significantly increased 
CD36 levels were determined in patients diagnosed with the non-alcoholic fatty liver disease 
(Greco et al., 2008). A direct involvement of CD36 in the development of the AhR-regulated 
hepatic steatosis by TCDD has been demonstrated by Lee and co-workers. Transgenic mice, 
expressing a constitutively active Ahr, exhibited a significant hepatic induction of CD36 
indentified by microarray, RT-PCR, Northern and Western blot analysis compared to wild-
type animals. Additionally, in livers of Ahr wild-type mice treated with TCDD (30 µg/kg bw; 
sacrificed seven days later), the induction of CD36 was also observed which was not seen for 
Ahr knockout mice. They identified the human and mouse CD36/Cd36 gene promoters as 
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transcriptional targets for the aryl hydrocarbon receptor. To further elucidate the role of CD36 
in the TCDD-induced hepatic steatosis, Lee and co-workers created mice lacking the Cd36 
gene. TCDD (30 µg/kg bw; sacrificed seven days later)-treated wild-type mice featured 
significantly increased hepatic triglyceride and reduced plasma triglyceride levels, whereas no 
statistical alterations in hepatic and plasma triglyceride concentrations were determined in 
TCDD- and corn oil-treated Cd36 knockout mice (Lee et al., 2010). Lee and co-workers 
hence showed that Cd36 is an AhR target gene which plays a key role in AhR-mediated 
hepatic steatosis in mice.  
The performed microarray experiments elucidated that there are distinct differences between 
species (human vs. mouse) and between different cellular models (HepG2 vs. hHeps). 
Considering the fact that the numbers of differently regulated genes was the lowest in hHeps, 
primary human hepatocytes seem to be less sensitive towards TCDD. Nevertheless, to 
estimate the potential human risk a broad range of experimental testing (primary cells, human 
lymphocytes as well as target organ slices) is essential. 
For the quantitative verification of the five selected target genes the mRNA expression of 
ALDH3A1, HSD17B2, TIPARP, AHRR, and CD36 were determined by RT-PCR. Real-time 
PCR analysis is the most sensitive experimental method for mRNA quantification. A data 
summary is featured in Table 39 below. Some difficulties had to be solved when analyzing 
the microarray data from HepG2 cells. Therefore, the colour intensity value was reduced from 
7 to 5. For instance CYP1B1, an established AhR-regulated gene whose induction represents a 
marker for AhR activation due to exposure to DLCs, was assigned a high log2 fold-change, 
but had a lower colour intensity value compared to the selected cut-off value (A ≥ 7). Real-
time PCR analysis revealed that the CYP1B1 mRNA expression was in fact strongly induced. 
AHRR was additionally among the up regulated genes but its colour intensity was also 
reduced (A = 5.63). Real-time PCR analysis demonstrated that the AHRR mRNA expression 
levels were not significantly induced. These findings elucidate that it is important to verify 
after the selection of a target gene from microarray study, if the mRNA expression of the 
respective gene is in fact induced, eg. by RT-PCR. CD36 was not up regulated in the 
performed microarray experiment in HepG2 cells, but a slight up regulation (2.2-fold) was 
determined by RT-PCR, the more sensitive mRNA quantification method.  
 
Table 39. Regulation of five selected target genes in HepG2 cells and hHeps evaluated by microarray and RT-PCR 
analysis. Treatment TCDD (10 nM, 24 h).  
Selected parameters microarray: A ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. 
Annotations:     '↑' up regulation; 
                           '↓' down regulation; 
                           '→' neither up nor down regulation 
 
Gene HepG2 hHeps 
 Microarray RT-PCR Microarray RT-PCR 
ALDH3A1 ↑ ↑ ↑ ↑ 
HSD17B2 ↑ ↑ ↑ ↑ 
TIPARP → → ↑ ↑ 
AHRR ↑ → → → 
CD36 → ↑ → → 
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Among the selected target genes only ALDH3A1 was induced to a higher extend after 
exposure to TCDD in both human cell models. The induction of the ALDH3A1mRNA seems 
to be the most reliable marker for AhR activation after exposure to TCDD and related 
compounds in human liver models. A concentration-dependent increase of ALDH3A1 mRNA 
expression was determined in HepG2 cells after treatment with various concentrations of 
TCDD leading to the highest ALDH3A1 levels after application of the highest chosen 
concentration (10 nM). Higher TCDD concentrations should be subsequently analyzed and 
ALDH3A1 protein levels ought to be additionally determined, e.g. by Western blot analysis. 
Furthermore, the concentration-dependent expression and inducibility of ALDH3A1 should be 
also analyzed in primary human hepatocytes using various concentrations of TCDD and other 
DLCs. Moreover, the functions and actions in which ALDH3A1 is possibly involved in 
TCDD-mediated biological and toxic responses should be further characterized.  
HSD17B2 was also induced in both human liver models though the inducibility was very 
weak, but statistically significant in both experimental approaches. Although this gene is the 
only gene among the five selected novel AhR target genes which was induced in both human 
cell models as well as in mouse livers, it is not a suitable and reliable marker for exposure to 
DLCs due to its rather weak inducibility (2- to 3-fold). However, the biological functions and 
actions of HSD17B2 should be further elucidated since transgenic mice which ubiquitously 
expressed the human HSD17B2 gene exhibited phenotypic changes such as growth retardation 
and disrupted spermatogenesis which are typical indications also for suppressed retinoic acid 
signalling (Zhongy et al. 2007). In which way HSD17B2 potentially contributes to the TCDD-
induced AhR-mediated deregulation of the retinoic acid signalling is also subject to further 
research investigations (Abbott et al., 1989) (Fletcher et al., 2001) (Murphy et al., 2007) 
(Jacobs et al., 2011).  
TIPARP was only induced in primary human hepatocytes and in mice, but not in HepG2 cells. 
Its inducibility was weak, but statistically significant by the applied concentration/dose in 
mouse livers and hHeps. The TCDD-mediated induction of TIPARP has been linked to 
TCDD-induced suppression of gluconeogenesis (Diani-Moore et al., 2010). For human risk 
assessment, it is essential to characterize and elucidate its functions and actions in the human 
organism because it has been recently characterized as negative regulator of AhR signalling in 
various human cell lines as well as in mouse embryonic fibroblasts (MacPherson et al., 2013).  
Based on the gained knowledge from the performed microarray experiments, Ahrr and Cd36 
are predominantly involved in TCDD-mediated responses in mouse. CD36 contributes to the 
AhR-mediated TCDD-induced uptake of free fatty acids which leads to the formation of a 
hepatic steatosis in mouse. However, elevated CD36 levels have been examined in patients 
with non-alcoholic fatty liver disease which leads to the suggestion that CD36 is a key player 
in the uptake of free fatty acids also in the absence of TCDD. Additional research effort is 
required to confirm whether or not it contributes to the TCDD-mediated biological effects in 
humans. 
The performed microarray studies provided fundamental information about species- and cell 
type-specific gene expression responses. Unfortunately, no suitable in common biomarker for 
both species could be established, but novel species-specific markers for AhR activation were 
identified as well as novel TCDD-inducible genes were successfully characterized.  
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V Conclusive Summary 
 
Polychlorinated dibenzo-p-dioxins, dibenzofurans, and polychlorinated biphenyls are 
persistent environmental contaminants which occur as complex mixtures and bioaccumulate 
in the food and feed chain due to their high lipophilic properties. Dioxin-like compounds 
(DLCs) evoke a broad spectrum of biological and toxic responses in laboratory animals and in 
humans. Most, if not all, of these effects are mediated by the aryl hydrocarbon receptor. 
Although the exposure levels decreased noticeably over the last few decades in most 
European countries, sensitive population groups, such as newborns and infants or humans 
being occupationally or accidentally exposed to DLCs are subjected to much higher exposure 
levels than those the WHO established as tolerable daily intake.  
The present work ought to examine the elicited biochemical responses of a selection of 
dioxin-like compounds in mouse (in vivo) and in human liver cell models (in vitro). Emphasis 
was given to the main contributors to the total toxic equivalents in human blood and tissues 
TCDD, 1-PnCDD, 4-PnCDF, PCB 118, PCB 126, and PCB 156 which likewise contribute 
about 90 % to the total dioxin-like activity in the human food chain. Therefore, various 
experimental test systems such as the EROD assay, RT-PCR, HPLC-MS/MS, or microarray 
were established, optimized, and adjusted to the specific experimental requirements.  
The 3-day and 14-day mouse studies were performed within the framework of the SYSTEQ 
project in the Institute for Risk Assessment Sciences (IRAS) at Utrecht University, the 
Netherlands. Female C57BL/6 mice were treated with single doses of TCDD, 1-PnCDD,       
4-PnCDF, PCB 118, PCB 126, PCB 156, or non dioxin-like PCB 153 by oral gavage. Oral 
gavage was used as route of administration since ingestion of food is the major route for 
human exposure to DLCs. The hepatic mRNA expression of three selected genes (Cyp1a1, 
Cyp2b10, and Cyp3a44) was determined in both mouse studies. The respective enzyme 
inductions are associated with the activation of different xenobiotic signalling pathways 
(AhR, CAR, and PXR). The seven tested congeners can be classified into three different 
categories based on the obtained findings; the ones which are 'pure' AhR ligands (TCDD,     
1-PnCDD, 4-PnCDF, and PCB 126), or solely CAR inducers (PCB 153), and the ones which 
are AhR/CAR mixed-type inducers (PCB 118 and 156). 
Moreover, a novel experimental approach, the microarray analysis, was employed in the 
present work which permitted the analysis of thousands of genes simultaneously in female 
mouse liver samples from mice treated with single doses of TCDD or PCB 153 (mouse study 
I). In summary, the gene regulation patterns differed fundamentally. Profiling of significantly 
altered genes led to the conclusion that changes in gene expression were associated with 
different signalling pathways, in fact by AhR and CAR. The established classic AhR-
regulated target genes involved in xenobiotic metabolism were induced by TCDD in mouse 
livers. Furthermore, the alterations in expression of genes associated with lipid metabolism 
and transport implied that TCDD likely induced hepatic steatosis in female C57BL/6 mice. 
PCB 153 treatment on the contrary resulted in the up regulation of genes linked to arachidonic 
acid metabolism suggesting that the deregulation of the arachidonic acid signalling possibly 
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contributes to the biological responses of NDL-PBCs as indicated by previously performed 
studies. 
The characterization of AhR-dependent and AhR-independent responses was a major research 
objective within the present work, since overwhelming experimental evidence led to the 
conclusion that the AhR mediates the biological and toxic effects of DLCs. For investigating 
the role of the AhR in mediating biological responses, several experimental approaches were 
carried out such as the analysis of blood plasma metabolites in Ahr knockout and wild-type 
mice. In order to determine genotype specifics and similarities, a metabolite extraction 
method and HPLC-MS/MS setup was developed and successfully established. Several plasma 
metabolites could be identified in both genotypes such as various amino acids, but also 
differences detected as additional peaks in the UV chromatograms, were determined. It was 
not possible to characterize these Ahr-/--specific peaks, most likely due to the similar polarity 
of these 'hidden' metabolites. However, the gained knowledge from the performed experiment 
was used as a starting point for novel research approaches in our working group such as the 
analysis of whole blood metabolites in Ahr knockout and wild-type mice extending the 
initiated metabolomics database. 
An animal experiment was performed aiming to characterize AhR-dependent and AhR-
independent effects in female Ahr knockout and wild-type mice, which received a single dose 
of TCDD or corn oil by gavage. Microarray analysis of the mouse livers revealed that 
although the Ahr gene was knocked out in Ahr-/- mice, the quantity of affected genes were in 
the same order of magnitude as for Ahr+/+ mice, though the pattern of altered genes distinctly 
differed. Furthermore, only a vanishingly small number of altered genes could be linked to 
specific metabolic pathways in livers of female Ahr-/- mice. As opposed to this, a large 
number of genes in livers of female Ahr+/+ could be associated to different metabolic 
signalling pathways such as xenobiotic metabolism including established and novel AhR 
target genes or genes linked to lipid transport and metabolism. Further findings, such as the 
significantly increased relative liver weights of TCDD-treated Ahr+/+ mice supported the 
assumption, that TCDD induced the development of hepatic steatosis in female Ahr wild-type. 
The performed in vitro experiments aimed to analyze the effects elicited by selected DLCs 
and PCB 153 in human liver cell models. The human hepatocellular carcinoma cell line 
HepG2 and freshly isolated primary human hepatocytes were used in the present work to 
identify similarities and differences between both human cell models. The biological 
responses were measured by EROD assay, Western blot, RT-PCR, or microarray analysis. 
The measured endpoints provided important knowledge about the congeners' potencies, the so 
called relative effect potencies (REPs), which were not evaluated in human liver cell models 
for most of the congeners so far.  
In vitro REPs gained from both liver cell models widely confirmed the current TEFs (van den 
Berg et al., 2006), but some deviations occurred, e.g. in case of 1-PnCDD and 4-PnCDF, 
which are both attributed with high TEF values. These findings outline that a comprehensive 
analysis of DLCs in different human in vitro models is essential for assessing the 'complete' in 
vitro potencies. 
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A general comparison between both liver cell models revealed that primary human 
hepatocytes were less responsive than HepG2 cells. This was not only observed by the 
comparison of EC values derived from EROD assay, but also regarding microarray analysis in 
terms of differently regulated genes. The comparison of the significantly TCDD-altered genes 
in both human cell types revealed that only a considerably small number of genes (25 in total) 
was in common up regulated by both human liver cell models such as the established AhR-
regulated highly inducible cytochrome P450s 1A1, 1A2, and 1B1 as well as other AhR target 
genes. Although the overlap was rather small, the TCDD-induced genes could be associated 
with the broad spectrum of dioxin-related biological responses on e.g. cell cycle regulation, 
cellular growth and differentiation, or apoptosis. 
The gene expression pattern in primary human hepatocytes after treatment with selected 
DLCs (TCDD, 1-PnCDD, 4-PnCDF, and PCB 126) and PCB 153 was additionally 
characterized by microarray analysis. This was the first time that the alterations in gene 
expression by the four DLCs attributed with the highest TEF values were examined in a 
toxicogenomic approach in primary human hepatocytes together. The highest response in 
terms of significantly altered genes was determined for TCDD, followed by 4-PnCDF,          
1-PnCDD, and PCB 126, whereas exposure to PCB 153 did not evoke any significant changes 
in gene expression. The pattern of significantly altered genes was very homogenous among 
the four congeners. Genes associated with well-established DLC-related biological responses 
as well as novel dioxin-inducible target genes were identified. An extensive overlap occurred 
resulting in 25 in common up regulated genes by all four DLCs. These 25 represent almost the 
complete set of significantly up regulated genes by the least responsive congener (i.e. PCB 
126). 
In conclusion, the results from the in vitro experiments in primary human hepatocytes provide 
fundamental insight into the congeners' potencies and caused alterations in gene expression 
patterns. The obtained findings implicate that although the extent of enzyme inducibilities 
varied, most likely based on the interindividual variabilities (e.g. gender, age, ethnicity, or 
health status), the gene expression patterns are coincidental. The microarray analysis is an 
essential tool in the field of toxicogenomics which enables the possibility to further elucidate 
the molecular mechanisms of the toxic effects induced by DLCs in humans.  
The identification of novel quantifiable biomarkers for AhR activation by DLCs was a major 
research objective within the present work. For this purpose, the obtained results from several 
microarray experiments which dealt with the TCDD-induced alterations in gene expression 
were analyzed and compared. As a result, five genes were selected as potential biomarker 
candidates, i.e. the aldehyde dehydrogenase 3 family member A1 (ALDH3A1), the 
hydroxysteroid (17-beta) dehydrogenase 2 (HSD17B2), the TCDD-inducible poly(ADP-
ribose) polymerase (TIPARP), the aryl hydrocarbon receptor repressor (AHRR), and cluster of 
differentiation 36 (CD36). Species-specific (mouse vs. human) as well as model-specific (in 
vitro vs. in vivo and transformed cells vs. untransformed cells) differences were identified. 
ALDH3A1 turned out to be the most reliable and suitable marker for exposure to DLCs in 
both human liver cell models eliciting the highest mRNA inducibility among the five chosen 
candidates, whereas it was not up regulated in the mouse liver in vivo. TIPARP/Tiparp was 
identified as a good indicator for dioxin exposure in hHeps and in mouse livers, though the 
extent of mRNA inducibility was several times lower as for ALDH3A1. Cd36 and Ahrr were 
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both characterized as dioxin-inducible target genes in mouse livers. Although 
HSD17B2/Hsd17b2 was significantly induced by TCDD in vitro and in vivo, the up regulation 
was only weak suggesting that this gene is not suitable to use as a sensitive biomarker for 
exposure to DLCs. The molecular functions and actions in which way these species- and cell 
type-specific markers are involved in the dioxin-mediated biological and toxic responses 
should be further characterized in vivo and in vitro. The search for sensitive biomarkers for 
exposure to DLCs should be continued and extended, e.g. by analyzing tissue and blood 
samples obtained from epidemiological studies.  
The present work provides essential knowledge about the biological responses and relative 
potencies of a variety of dioxins and dioxin-like compounds in human liver cell models and in 
mouse. Established as well as novel dioxin-related responses were demonstrated and 
elucidated in the performed experimental approaches contributing fundamental information 
for human risk assessment. 
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VI Methods 
 
VI.1 in vivo Mouse Experiments 
 
The 3-day and 14-day mouse studies were performed within the framework of the European 
project SYSTEQ in the Department of Toxicology, Institute for Risk Assessment Sciences 
(IRAS) at Utrecht University, the Netherlands.  
Blood samples and different tissues were shipped to the different European project partners. 
We obtained snap frozen liver samples for further investigation. During a research stay as a 
part of this doctoral thesis at the IRAS, liver RNA was isolated and cDNA prepared from both 
mouse studies which was analyzed in the present work. 
The breeding of Ahr knockout mice and subsequent animal experiment was performed at the 
University of Kaiserslautern. 
 
VI.1.1 Mouse Study I (3-day Study) 
 
Female adult C57BL/6 mice were exposed to four dose levels of seven selected compounds 
(core congeners) TCDD, 1-PnCDD, 4-PnCDF, PCBs 118, 126, 153, and 156. Each dose 
group consisted of six female mice. On day 0, animals were orally exposed by gavage at a 
dosing volume of 10 ml/kg body weight. Test compounds were beforehand dissolved in corn 
oil. Control animals were exposed to corn oil only (dosing 0 µg/kg bw). On day 3, animals 
were killed by CO2/O2 asphyxiation. Blood and tissues were collected from animals, snap 
frozen, and stored at -80 °C. 
 
Table 40. Overview dose levels mouse 3-day study. 
 
Study Treatment Single dose (µg/kg bw) TEF (WHO, 2005) 
 
 
 
3-day 
TCDD 0 0.5 2.5 10 25 100 1.0 
1-PnCDD 0 0.5 2.5 10 25 100 1.0 
4-PnCDF 0 0.5 2.5 10 250 1000 0.3 
PCB 126 0 5 25 100 250 1000 0.1 
PCB 118 0 5000 15000 50000 150000 500000 0.00003 
PCB 153 0 5000 15000 50000 150000 500000 - 
PCB 156 0 5000 15000 50000 150000 500000 0.00003 
 
Due to initial investigative sample analysis from the project partners in the laboratories at the 
IRAS, it was decided only to perform RT-PCR analysis with the blue-marked dose-levels 
(Table 40). This decision was based on the large amount of time needed for sample 
preparation and analysis and therefore it was decided to skip the second highest dose level of 
TCDD, 1-PnCDD, 4-PnCDF, and PCB 126 because no further relevant additional information 
was expected. The lack of response determined in livers of mice exposed to PCBs in the first 
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performed experiments at Utrecht University with the PCBs lead to the decision to analyze 
only two dose levels (0 and 150000 µg/kg bw).  
 
VI.1.2 Mouse Study II (14-day Study) 
 
Female adult C57BL/6 mice were exposed to a single dose of the seven selected compounds 
TCDD, 1-PnCDD, 4-PnCDF, PCBs 118, 126, 153, and 156 by oral gavage at a dosing of      
10 ml/kg bw (Table 41). Test compounds were dissolved in corn oil. Control animals were 
exposed to corn oil only (dosing 0 µg/kg bw). On day 14, animals were euthanized by CO2/O2 
asphyxiation. Blood and tissues were collected from animals, snap frozen, and stored at           
-80 °C. 
 
Table 41. Overview dose levels mouse 14-day study. 
 
 
Study Treatment Single dose (µg/kg bw) TEF (WHO, 2005) 
14-day 
TCDD 0 25 1.0 
1-PnCDD 0 25 1.0 
4-PnCDF 0 250 0.3 
PCB 126 0 250 0.1 
PCB 118 0 150000 0.00003 
PCB 153 0 150000 - 
PCB 156 0 150000 0.00003 
 
VI.1.3 Ahr Wild-type / Knockout Mouse Study 
 
VI.1.3.1 Breeding of Ahr Knockout Mice 
 
The transgenic AhR mice (Ahr+/-) were obtained from Jackson Laboratory (Bar Habor, ME). 
Breeding of Ahr-deficient mice (Ahr-/-) was started at the Finnish Public Health Institute 
(Kuopio, Finland) and continued at the University Kaiserslautern. The strain was developed 
using a construct that removed exon 2 of the Ahr gene. The original Ahrtm1Bra mutation has 
been crossed 10 times to C57BL/6. A summary of strain details is shown in the following 
table (Table 42): Homozygous Ahr knockout mice and homozygous Ahr wild-type mice were 
achieved by mating female and male heterozygous Ahr mice (Ahr+/-). Mating of homozygous 
Ahr knockout mice was not possible due to reduced fertility of this genotype (Schmidt et al., 
1996) (Fernandez-Salguero et al., 1996) (Mimura et al., 1997). 
All mice were kept in the laboratory animal unit of the University of Kaiserslautern. The 
room was air-conditioned and artificially illuminated from 7 a.m. to 7 p.m. each day. Animals 
were subjected to regular health surveys consisting of serological and bacteriological 
screening. All mice were individually identified by earmarking.  
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The genotype of the offspring was characterized by DNA gel electrophoresis of the PCR- 
amplified DNA isolated from mouse tail or ear snips. 
 
Table 42. Summary of strain details of transgenic Ahr mice (Jackson Laboratory, Bar Habor, ME). 
 
Strain Name B6.129-Ahrtm1Bra 
Stock Number 002831 
Type JAX®GEMM®Strain - Targeted Mutation Congenic 
TJL Mating System Heterozygote x Heterozygote 
Generation N12 
ES Cell Line R1 (129) 
Donor Strain 129X1 x 129S1 via R1 (+Kitl-SlJ) ES cell line 
Donating Investigator Dr. Christopher Bradfield, McArdle Laboratory for Cancer Research 
Backcross Generation N12F10 (15-jan-2003) 
Background Strain C57BL/6 
 
VI.1.3.2 Mouse Genotyping 
 
VI.1.3.2.1 DNA Isolation 
 
First, mice (about 3-4 weeks of age) were narcotized and small pieces of the ear or tail were 
cut off by animal keepers. These snips were stored in sterile microtubes (1.5 ml) at -20 °C 
until DNA isolation. DNA from mouse tail or ear snips was isolated using E. Z. N. A. Tissue 
DNA Kit (Omega Bio-Tek) according to the manufacturer's instructions with a few 
modifications (Figure 52). 
Primarily, mouse snips were brought to room temperature, whereupon 180 µl of Buffer TL 
and 25 µl proteinase K solution (50 mg/ml ddH2O) were added to each sample. Proteinase K 
serves in combination with the Buffer TL for tissue lysis and digestion. The tissue-lysis-buffer 
solution was thoroughly mixed by vortexing for 2 min. Tissue lysis was then carried out at    
56 °C in a microtube-adapted thermomixer (Eppendorf, Hamburg) overnight. The following 
steps were performed at room temperature. The digested samples were centrifuged for 2 min 
at maximum speed to pellet insoluble tissue debris and hair. Afterwards, the supernatant was 
carefully transferred into another sterile microtube (1.5 ml) and 200 µl of Buffer BL and 200 
µl of ethanol (100 %) were added and mixed thoroughly by vortexing. Both components 
provide the basis for DNA binding to the column. Intermediately, a HiBind® DNA Mini 
column was activated by adding 100 µl of Equilibration Buffer and following centrifugation 
for 1 min at 13000 x g. The entire sample was then transferred onto the column, which was 
afterwards centrifuged for 1 min at 10000 x g. The flow-through was discarded and 500 µl of 
Buffer HB was added to bind the DNA. The column was centrifuged once again for 1 min at 
10000 x g. The bound DNA was washed with 700 µl of Wash Buffer and was subsequently 
centrifuged for 1 min at 10000 x g. The washing step was repeated using 400 µl of Wash 
Buffer before centrifugation for 3 min at 10000 x g. Care was taken to completely dry the 
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membrane of the column because any ethanol residue interferes in the DNA elution process. 
The DNA containing column was placed into a sterile 1.5 ml microtube and 100 µl of 
preheated (70 °C) Elution Buffer was added directly on the membrane of the column. After 
resting for 2 min at room temperature, the column was centrifuged for 1 min at 10000 x g. 
The elution step was repeated one more time, before measuring the DNA quality and 
concentration using NanoDrop (Peqlab, Erlangen). The isolated DNA was then stored at         
-80 °C or directly amplified in PCR. 
 
Figure 52. Illustrated protocol of the DNA isolation method (Omega Bio-Tek, 2013). 
 
VI.1.3.2.2 Amplification of Mouse DNA using PCR  
 
Polymerase chain reaction was invented 1983 by Kary Mullis (Mullis et al., 1987) and is 
nowadays a commonly used, fast method to amplify specific DNA sequences selectively and 
exponentially. This powerful tool finds many applications in diagnostics, molecular biology, 
and forensic analysis (Holland et al., 1991). PCR can be divided into three steps. First the 
double-stranded DNA template is converted into single-stranded DNA at 95 °C 
(denaturation). High temperature leads to the disruption of hydrogen bonds between 
complementary bases resulting in two single strands. Afterwards, primers (oligonucleotides 
consisting of 15-30 bases with complementary DNA sequence to the targeted DNA) anneal 
Lyse 
Adjust binding 
conditions 
Bind 
Wash 2x 
Dry 
Elute 
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complementary to DNA strands at 53 °C (annealing). As a last step, the polymerase binds to 
the primer template and is then able to add desoxynucleotides (dNTPs) at 72 °C (elongation), 
whereupon a primer-containing DNA fragment is selectively replicated. In each elongation 
step the amount of target DNA is doubled resulting in an exponential amplification of the 
DNA sequence. The amplification product is afterwards detected by DNA agarose gel 
electrophoresis. 
First, a PCR reaction mix was prepared on ice using PCR master mix (consisting of Taq 
polymerase 0.05 U/µl, 0.4 mM of each dNTP, reaction buffers, 4 mM MgCl2, and nuclease- 
free water), primers (Table 44) and isolated DNA (from mouse tail or ear snips). Then, PCR 
tubes were tightly closed, carefully mixed on a vortexer and centrifuged. The PCR reaction 
mix was placed into a MyCyler (Bio-Rad, Munich) running the optimized and established 
PCR programme (Table 45). After completing the PCR, amplified DNA was stored at -20 °C.  
 
Table 43. Components of PCR reaction mix for mouse genotyping. 
 
Components Volume (µl) Purchased from 
PCR Master Mix (2x) 12.5 Fermentas 
Primer forward Ahr wild-type 1 Eurofins MWG Operon 
Primer reversed Ahr wild-type 1 Eurofins MWG Operon 
Primer forward Ahr knockout 1 Eurofins MWG Operon 
Primer reversed Ahr knockout 1 Eurofins MWG Operon 
DNA template 8.5 - 
 
Table 44. Primer sequences for mouse genotyping. 
 
Primer 5`- 3` 
Ahr wild-type 
GACACAGAGACCGGCTGAAC 
AGCATGTACCATCCAAACAGC 
Ahr knockout 
TGAATGAACTGCAGGACGAG 
AATATCACGGGTAGCCAACG 
 
Table 45. PCR thermocycling conditions for mouse genotyping. 
 
Cycle Temperature Time Step 
1 Cycle 95 °C 4 min Denaturation 
40 Cycles 95 °C 40 s Denaturation 
 53 °C 40 s Annealing 
 72 °C 40 s Elongation 
1 Cycle 72 °C 10 min Elongation 
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VI.1.3.2.3 DNA Agarose Gel Electrophoresis 
 
Different-sized DNA fragments were separated using DNA agarose gel electrophoresis. The 
1.5 % agarose gel was prepared by melting 0.75 g of agarose dissolved in 50 ml of TAE 
buffer (1x; further information is featured in Table 46) in a microwave. After cooling down of 
the heated agarose solution (about 50 °C) 10 µl of ethidium bromide (10 mg/ml) was added. 
The ethidium bromide-containing agarose solution was carefully casted in a horizontal gel 
chamber. Bubbles were removed and a comb was inserted into the still liquid gel forming 10 
sample pockets. After the hardening of the gel (30-40 min), the gel chamber was filled 
completely with TAE buffer (1x) and the comb was carefully removed. After adding 5 µl of 
6x loading buffer (Fermentas) to the amplified DNA (25 µl), 15 µl of the DNA/loading buffer 
mix was pipetted into each sample pocket sparing one of the ten pockets in which 5 µl of 
DNA ladder was loaded. Gel electrophoresis was conducted for 75-90 min at 90 V. The 
negatively-charged DNA (due to the pH of TAE buffer) migrates through the agarose gel to 
the anode, whereby small DNA fragments move faster than larger ones. Ethidium bromide 
intercalates with the DNA and those fluorescent DNA-ethidium bromide products can be 
visualized using ultraviolet light. The separated DNA fragments were then detected by taking 
a picture with the Eagly Eye II (Stratagene). Sizes of DNA fragments were determined using 
the DNA ladder (Fermentas). The evaluation of the results was conducted by analyzing the 
DNA fragement size distribution pattern. If only one detected DNA fragment of 380 base 
pairs was detected the genotype of the respective mouse is homozygous Ahr wild-type 
(Ahr+/+). One band at 500 base pairs implies the mouse genotype is homozygous Ahr 
knockout (Ahr-/-). Two bands (380 and 500 base pairs) stand for heterozygous Ahr mice 
(Ahr+/-). 
 
Table 46. TAE (Tris-acetate-EDTA) buffers. 
 
TAE buffer (50x) Tris (2 M) 
EDTA (50 mM) 
Acetic Acid (1 M) 
ddH2O 
pH: 8.3 
Store at room temperature 
 
242.2 g 
14.6 g 
57.2 ml 
up to 1 l 
 
TAE buffer (1x) TAE buffer (50x) 
ddH2O 
Store at room temperature 
20 ml 
up to 1 l 
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VI.1.3.3 Mouse Plasma Analysis 
 
VI.1.3.3.1 Mouse Plasma Extraction 
 
Ahr wild-type and Ahr knockout mice were kept in the animal laboratory of the University 
Kaiserslautern. Mice were given standard pelleted feed and tap water ad libitum during a 
12h/12h day and night cycle. To analyze the plasma of untreated Ahr wild-type and knockout 
mice, animals were anesthetized by intraperitoneal application of 3 µl/1g bw pentobarbital 
solution (33 mg/ml ddH2O). In complete absence from pain, the abdominal cavity was opened 
and the gastro-intestinal system was thrusted aside. Mouse blood was collected from vena 
cava using a syringe which was pre-flushed with heparin. The blood was transferred into a 
sterile 1.5 microtube and immediately centrifuged at 2000 x g at room temperature for 15 min.  
Plasma extraction was carried out using the approach of Want et al. (2006) with a few 
modifications. First, cold (-20 °C) methanol (100 %) was added to the isolated plasma in a 
ratio of 2:1, whereupon the methanol-plasma mix was vortexed, and incubated on ice for 20 
min. Afterwards, the mix was centrifuged at 13000 x g for ten minutes at 4 °C. The 
supernatant was transferred into sterile 1.5 microtube leaving the precipitated proteins left 
behind. The plasma extract was subsequently dried using a vacuum centrifuge Univapo 150 
H. Until the plasma analysis by HPLC-MS/MS, the dried samples were stored at -20 °C.  
 
VI.1.3.3.2 Plasma Analysis 
 
VI.1.3.3.2.1 High Pressure Liquid Chromatography (HPLC) 
 
High pressure liquid chromatography (HPLC) is a powerful tool to separate components of a 
matrix such as blood plasma or serum using two different phases such as a stationary and a 
mobile phase. The mobile phase carries a mixture of substances when passing the stationary 
phase. Due to interactions with the stationary phase the elution of some substances is delayed, 
because of their physical and chemical properties, while other compounds just weakly interact 
with the stationary phase and are not held back resulting in an earlier compound elution and 
signal detection. Mechanisms of compound separation include the equilibrium distribution of 
the analyte between both phases as well as adsorption and desorption at the stationary phase.  
A distinction is made in HPLC methods between the different stationary phases, the normal 
phase (NP) and reversed phase (RP). In NP-HPLC a nonpolar, mobile phase passes through a 
polar, stationary phase. Typical materials of polar, stationary phases are anionic adsorbent 
agents such as silicagel or aluminium oxide, which possess hydroxyle groups on their surface. 
RP-HPLC, on the other hand, is based on the principle of a polar, mobile phase which is 
transported along a nonpolar, stationary phase. Silica, whose surface has been modified by 
alkyl dimethyl chlorsilane, is used as a stationary phase. Polar fluids like acetonitrile, 
methanol, or water are used as mobile phase (Cammann, 2001) (Meyer, 2002). 
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The setup of a HPLC system is featured in Figure 53. A solvent mixture, the mobile phase, 
was conveyed through one or more pumps after degassing in the storage vessel. The dissolved 
sample is injected into the system using a valve. Separation of analytes occurs on the 
chromatographic column, which can be thermalized by the use of a column oven. Separated 
sample components can then be detected using an appropriate detector (Cammann, 2001). 
 
 
Figure 53. Scheme of a HPLC system (modified after Cammann, 2001). 
 
One the one hand, the choice of the utilized detector is based on the special characteristics of 
the analytes of interest, and on the other hand, it is dependent onthe system’s conditions (such 
as the selection of solvents, elution conditions, and transportation rate). Various detectors are 
established for HPLC systems such as evaporative light scattering detectors (ESLD), 
refractive index detectors (RID), UV-Vis detectors, fluorescence detectors, chemo-
luminescence detectors, electrochemical detectors, or mass detectors (Cammann, 2001). 
 
VI.1.3.3.2.2 UV Spectrometry 
 
Ultraviolet/visual spectrometry is a physical method measuring light absorption by an analyte 
in the ultraviolet and visible range. UV/VIS absorption spectroscopy is based on the 
excitation of outer shell electrons by light in the ultraviolet and visible wavelength`s 
spectrum. Worldwide, absorption is the most frequently applied optical and analytical 
procedure to detect molecules in UV/VIS spectral range; however analytes must obtain at 
least one chromophoric group such as a carbonyl group or an aromatic ring. UV/VIS detectors 
possess high sensitivity, large linear range, and insensitivity against variations in temperature. 
They can be divided into different categories. A fixed wavelength detector only captures the 
sample absorption at one specific wavelength (depending on the specific applied filter, 
commonly 254 nm). A variable wavelength detector is an alternative to the first one 
mentioned. Using a variable wavelength detector has the advantage that the measured 
wavelength can be exactly applied to the sample´s absorption maximum. A diodearray 
detector (DAD) provides the opportunity to detect various wavelengths simultaneously by the 
use of many photodiodes (512 to 1024 diodes).  
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The diodearray detector offers the possibility of a high throughput screening and analysis of 
the applied matrix (Cammann, 2001) (Meyer et al., 2002). 
 
VI.1.3.3.2.3 Mass Spectrometry 
 
Mass spectrometry is a physical process that separates ions which are stable in the vacuum 
according to their respective mass to charge (m/z) ratio. Mass spectrometric analysis usually 
ensues under molecule fragmentation, or atomization and subsequent ionization of the sample 
(as gas, fluid, solid, and mixtures) which is then inserted into the vacuum of the mass 
spectrometer. Fragmentation of compounds depends on the chosen ionization method. Mass 
spectrometry is increasingly utilized in the field of qualitative and quantitative analysis of 
elements and molecules due to its speed, selectivity, and sensitivity. The identification of 
complex compound mixtures and the quantification in trace and ultra trace level is the focus 
of organic compound analysis. Commonly, organic compounds can be quantitatively detected 
until the range of 10-12 to 10-17 mol using mass spectrometry (Cammann, 2001). 
The mass spectrometer is basically structured into an inlet system which transports the sample 
into the unit's vacuum, an ionization unit, a mass separation unit, and finally a detection unit. 
The sensitivity of a mass spectrometer depends on the amount of inserted analyte and the 
obtained ion yield. In MS analysis, the inserted substances must be transferred into free 
positively or negatively charged ions in order to be separated according to their mass to 
charge ratio by the applied electronic high voltage. Ion velocity is the result of the kinetic 
energy obtained from the ionization process and subsequent acceleration in the electrical field 
(Cammann, 2001). 
 
VI.1.3.3.2.4 HPLC-ESI-MS/MS 
 
Primarily, the HPLC eluate is transferred into an interface in which compound ionization 
takes place. Different ionization techniques are available, though the choice depends on the 
examined compound properties. In the present work, electrospray ionization (ESI) was used 
under atmospheric pressure before molecular ions can enter the mass unit in which mass 
separation and detection takes places using three linear arranged quadrupoles (triple 
quadrupoles) in high vaccum. 
 
Electrospray ionization (ESI) 
 
Electrospray ionization (ESI) belongs to the group of so called 'soft' ionization techniques. 
ESI is particularly suitable for already ionized compounds and compounds which can be 
easily protonated or deprotonated without fragmentation of large and sensitive molecules.  
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Molecular ions and quasi-molecular ions for example [M+H]+, [M+Na]+, or [M-H]- are 
generated using the ESI method. Those ions are formed by adding or subtracting a hydrogen 
or a sodium atom to the compound`s molecular mass/structure (Cammann, 2001). The ESI 
process is featured in the following figure: 
 
 
Figure 54. Analyte ionization using ESI (AB Sciex, 2010). 
 
Elution solvent containing analytes are transported through a capillary biased by a high 
voltage into the ionizationunit (interface). Nitrogen acting as nebulizer gas is added 
simultaneously resulting in the formation of small charged droplets at the capillary tip. Due to 
the continuously evaporation of the solvent, the charge density increases on the droplet’s 
surface. When the droplet`s charge compared to the surface exceeds the 'Raylight limit', the 
resulting Coulomb explosion leads to the formation of smaller charged daughter droplets. 
Those charged daughter droplets are then transferred through the orifice plate into the mass 
spectrometer in which mass separation and detection takes places in high vacuum (Cammann, 
2001) (Fenn et al., 1989). 
 
Tandem mass spectrometer 
 
The most prevalent principle for mass separation is the quadrupole mass filter. The 
quadrupole filter consists of four parallel rod electrodes arranged in a concentrical manner, 
where each opposing rod pair is attached to a variable polarized direct current for given a DC 
voltage and RF frequency supply. Additionally, the system is superimposed by a high 
frequency voltage. Therefore, only ions with one m/z (mass filter) are able to reach the mass 
detector in stable helical trajectories by passing through electrodes.  
The triple quadrupole consists of three linear arranged quadrupoles (Q1-Q3) as featured in 
Figure 55. In Q1 all ions are scanned according to their mass to charge (m/z) ratio. Q2 is 
defined as quadrupole although it is a collision cell. Due to the entering gas (N2) and applied 
voltage, selected ions are fragmented. Afterwards, the mass to charge ratios of resulting 
fragment ions are determined in Q3. 
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Figure 55. Scheme of a triple quadrupole mass analyzer (AB Sciex, 2010). 
 
Different types of MS/MS experiments can be performed depending on the respective 
research objective. In the present work the method 'product ion scan' was used for 
identification of single components of the mouse plasma extract. The procedure is featured in 
the following figure: 
 
 
Figure 56. Scheme of product ion scan procedure (AB Sciex, 2008). 
 
The precursor ion of interest can selectively pass through Q1 and is transferred into Q2. 
Precursor ions with the selected mass to charge ratios are fragmented in the collision cell and 
the generated fragment ions are detected in Q3 using a predefined m/z range (Cammann, 
2001). 
 
VI.1.3.4 Mouse Study III (5 days) 
 
Four female mice of each genotype (Ahr-/- and Ahr+/+ between 6 and 8 months old) received 
either a single dose of TCDD (25 µg/kg bw) or corn oil by gavage on the first day (day 1). 
The application volume was 2.5 ml/kg bw. All mice were housed separately in Makrolon 
cages throughout the experiment. On the 5th day, the mice were anesthetized by 
intraperitoneal application of 3 µl/1 g bw pentobarbital solution (33 mg/ml ddH2O). In 
complete absence from pain, the abdominal cavity was opened and the gastro-intestinal 
system was thrusted aside. Mice livers were extracted surgically from animals, cut into slices, 
immediately snap frozen in liquid nitrogen and stored until use at -80 °C. 
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VI.2 in vitro Experiments 
 
Cells were kept during cultivation respectively subcultivation and compound exposure in an 
incubator under standard conditions (37 °C, 5 % CO2 and 97 % humidity) in a sterile 
atmosphere using disposable pipettes and autoclaved glass materials. All solutions which 
were in direct contact with cultured cells were prior tempered at 37 °C in a water bath. Both 
experimentally applied human liver cell models were exposed to test compounds for 24 h. 
 
VI.2.1 Primary Human Hepatocytes 
 
Freshly prepared primary human hepatocytes (hHeps) were purchased from LONZA 
(Verviers, Belgium). Cells were isolated from single donors and were plated on collagen-
coated 6- and 96-well plates. Detailed donor information, if possible, including age, gender, 
ethnic background, and health status (smoking, alcohol, diabetes, heart disease, hypertension, 
liver pathology) was entailed in each delivery, whereas all donors were tested negative for 
HIV 1, HBV und HCV. Viabilities of hHeps were between 82-95 %. 
 
 
Figure 57. Primary human hepatocytes in culture (light microscope picture, 10x resolution). 
 
VI.2.1.1 Handling of Primary Human Hepatocytes 
 
Freshly prepared human hepatocytes (hHeps) were delivered within 48 h after isolation from 
donor livers. Cells were plated on collagen-coated multiwell plates filled with Hepatocytes 
Maintenance Medium (HMMTM) representing the shipping medium. Primary human 
hepatocytes were cultivated using manufacturer's instruction. After arrival, the sealing cover 
was carefully peeled off from the multiwell plates and hHeps were stored for 2-3 h in an 
incubator under standard conditions. This procedure was necessary so that hHeps could 
recover from the shipping process. Afterwards, the shipping medium was replaced by 200 µl 
HCMTM BulletKit solution consisting of Hepatocyte Basal Medium (HBMTM) and Hepatocyte 
Culture Medium SingleQuots® (containing various supplements and growth factors including 
ascorbic acid, BSA-FAF, transferrin, insulin, hEGF, hydrocortisone, GA-1000) and test 
compounds (Table 47). 
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Table 47. Primary human hepatocytes culture medium according to Lonza (Verviers, Belgium). 
 
hHeps culture medium Hepatocyte Culture 
medium (HCMTM) 
BulletKit 
Hepatocyte Basal 
Medium (HBMTM) 
 
Basal Medium  
w/o phenol red 
  Hepatocyte Culture 
Medium (HCMTM) 
SingleQuots® 
Supplements and growth 
factors including  
ascorbic acid, BSA-
FAF, transferrin, insulin, 
hEGF, hydrocortisone, 
 GA-1000 
 Store at 4 °C, 4 weeks   
 
VI.2.2 Human Hepatocellular Carcinoma Cell Line HepG2 
 
HepG2 which were purchased from DSMZ, Heidelberg, is a permanent human hepatoma cell 
line which was derived from the liver tumour of a fifteen year old Caucasian Argentine male 
with hepatocellular carcinoma in 1975. HepG2 cells grow in an adherent manner with a 
doubling time of 50 - 60 hours. The epithelial-like cells accumulate mostly as monolayers and 
in small aggregates. Cells secrete various plasma proteins such as albumin, transferrin, 
plasminogen and β-lipoprotein (Aden et al., 1979) (Knowles et al., 1980). 
 
 
Figure 58. HepG2 cells in culture (light microscope picture, 10x resolution). 
 
HepG2 cells were cultivated using the culture medium described in Table 48. Test compound 
incubation was carried out using the in Table 49 described incubation medium. The 
incubation medium consists of DMEM low glucose w/o phenol red, penicillin/streptomycine, 
and dexamethasone, but instead of FCS, DCC-FCS is used as growth stimulus. Dextran 
coated charcol-FCS is free of steroid hormones. DCC-FCS containing incubation medium is 
used to prevent any kind of interaction between steroids and the aryl hydrocarbon receptor 
because the AhR features similarities to the steroid receptor (Landers et al., 1991) (Schrenk et 
al., 1995). 
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Table 48. HepG2 cell culture medium for cultivation, e.g. subcultivation. 
 
HepG2 culture medium DMEM high glucose w/o phenol red 89 %  (500 ml) 
 Fetal calve serum (FCS) 10 %  (56 ml) 
 Penicillin/streptomycin 1 %  (5.6 ml) 
 Dexamethasone 10 nM  (0.56 ml) 
 Store at 4 °C, 4 weeks  
 
Table 49. HepG2 incubation medium for EROD, Western blot, Microarray, and RT-PCR. 
 
HepG2 incubation medium DMEM high glucose w/o phenol red 89 %  (500 ml) 
 Dextran coated charcoal-fetal calve serum 
(DCC-FCS) 
10 %  (56 ml) 
 Penicillin/streptomycin 1 %  (5.6 ml) 
 Dexamethasone 10 nM  (0.56 ml) 
 Stored at 4 °C, 4 weeks  
 
VI.2.2.1 Thawing and Freezing of Cultured Cells 
 
HepG2 cells were immediately stored at -84 °C in a biofreezer after arrival. Starting the 
cultivation was realized by thawing of the hepatoma cells. Therefore, cells (stored in a 
cryotube) were taken out of the biofreezer and instantly transferred on ice. Afterwards, cells 
were defrosted instantaneously in a water bath (37 °C) by carefully swaying the cryotube in 
the water. The thawed cell suspension is then transferred into a 15 ml tube containing 12 ml 
of HepG2 culture medium. Due to the high DMSO concentration in the freezing medium, 
these steps must be performed quickly. Otherwise cells may not attach and grow in the cell 
culture flask or die. Under standard conditions the high amount of DMSO (10 %) is cytotoxic 
to the hepatoma cells, but at -84 °C DMSO has protective effects by preventing crystallization 
and partial dehydration of cell plasma (Dumont et al., 2006) (Pegg et al., 2007). Subsequently, 
the cell-medium suspension mix was centrifuged at 500 x g for 5 min at room temperature. 
The supernatant was removed and the down-centrifuged HepG2 cells were resuspended in     
1 ml culture medium by repeated pipetting. The cell solution is then transferred into a 25 cm2 
cell culture flask filled with 5 ml cell culture medium. Cells were cultivated in an incubator 
and the culture medium was changed after 24 h. After a complete monolayer was formed, 
cells were detached, counted, and splitted as described below. From this point on, cells were 
cultivated in 75 cm2 cell culture flasks. 
Performing in vitro experiments also included preparing a stock of cells with different passage 
numbers which were stored at -84 °C in the biofreezer. Therefore, HepG2 cells were frozen in 
a special freezing medium containing DMEM culture medium supplemented with 20 % FCS 
and 10 % DMSO (Table 50).  
HepG2 cells, which built a complete monolayer in the 75 cm2 flask, were detached by 
trypsination- Then cells were separated by up- and down-pipetting of the cell suspension, 
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transferred into an 15 ml tube, and centrifuged (500 x g, 5 min, room temperature). The 
supernatant was carefully removed and the residue was dissolved in 1 ml freezing medium 
and transferred into a cryo tube. 
 
Table 50. HepG2 freezing medium. 
 
HepG2 freezing medium DMEM high glucose w/o phenol red 70 %  (7 ml)  
 Fetal calve serum (FCS) 20 %  (2 ml) 
 DMSO 10 %  (1 ml) 
 Store at 4 °C, 4 weeks  
 
Cryo tubes were first kept in a special freezing box filled with 4 °C-thermalized 100 % 
isopropanol and stored at -84 °C to permit cells to gently and steadily cool down about           
1 °C/min. When cells were finally cooled down, they were stored in cryo boxes in the bio-
freezer (-85 °C) until usage. 
 
VI.2.2.2 Cultivation and Subcultivation of HepG2 Cells 
 
HepG2 cells were cultivated under standard conditions in 75 cm2 cell culture flasks with 
culture medium containing DMEM high glucose w/o phenol red, fetal calf serum, 
penicillin/streptomycin, and dexamethasone (Table 48). The culture medium was removed 
every two to three days to ensure that cells receive adequate nutrient supply. When a 
confluent cell layer was reached, cells had to be splitted. Otherwise cells would have stopped 
their growth due to contact inhibition which may result in the death of the whole culture as a 
worst case. Therefore, cells were partitioned into further cultures resulting in a continuous 
subcultivation. This process is called passaging, with each splitting step the passage number 
increases. HepG2 cells were subcultivated as long as cells showed normal growth behavior, 
and HepG2 cell-like appearance. 
When confluency was reached the culture medium was carefully removed and the cell layer 
was rinsed out by adding 3 ml trypsin/EDTA to remove dead cells. Afterwards, 1 ml 
trypsin/EDTA was added and dispensed consistently over the entire cell layer. Cells were kept 
in the incubator up to ten minutes, i.e. until they easily detach from the flask surface. The 
reaction was stopped by adding 9 ml of culture medium. By multiple up- and down-pipetting 
of the cell suspension, cells were separated and counted to perform experiments or for further 
subcultivation. 
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VI.2.2.3 Cell Counting  
 
Cell growth depends on the applied cell number at the beginning of each experiment. 
Therefore, cells were counted with the aid of the Neubauer counting chamber via 
hemocytometer by using trypan blue exclusion test. An example of the Neubauer chamber is 
presented in Figure 59 below. 
 
 
Figure 59. Neubauer counting chamber. 
 
After trypsination and separation of cells, the cell suspension was dissolved at a ratio of 1:1 
with trypan blue solution (0.4 %) and afterwards placed on the hemocytometer. Dead cells 
appear in the light microscope (10x resolution) blue, whereas viable cells are uncoloured. 
Four large squares consisting of 4x4 small squares were counted under the light microscope 
and the number of viable cells per ml was calculated as follows: 
 
Cell count cells
ml
 =  S + S + S + S
4
 × df × 10 
 
with S1-4 = cell count of a large square 
df = dilution factor = 2 
104 = hemocytometer-specific parameter of the Neubauer chamber 
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VI.2.3 Cell Seeding and Compound Treatment 
 
HepG2 cells were seeded in culture medium at the appropriate cell density depending on the 
respective multiwell plate format so that human hepatoma cells achieved approximately 70 % 
of cell confluence before compound treatment. Information about cell density and well 
volume is outlined in the following table: 
 
Table 51. Information about format, volume, and concentration of seeded cells related to cell type. 
 
 Assay, Method Format 
Volume 
(ml/well) 
Seeded cell concentration 
(cells/well) 
HepG2 Alamar Blue assay 
EROD assay 
24-well 1 8.5 x 104 
  
Preparation of microsomes 
 
Ø 94 mm 
 
7 
 
4 x 106 
  
Extraction of RNA 
 
6-well 
 
2 
 
1.5 x 106 
hHeps Alamar Blue assay 
EROD assay 
96-well 0.2 5 x 104 
  
Extraction of RNA 
 
6-well 
 
2 
 
1.8 x 106 
 
24 h (HepG2) respectively 2-3 h upon arrival (hHeps) cell culture medium was removed and 
cells were incubated with test compounds over 24 h in the assay / cell type specific culture 
medium. All test compounds were dissolved in DMSO and added to the media so that the 
final solvent concentration never exceeded 1 % (v/v). Each performed experiment included 
positive as well as negative controls which are described for each method separately. 
 
VI.2.4 Processing of Compound-treated Cultured Cells and Tissues 
 
VI.2.4.1 Preparation of Microsomes from Cells 
 
Microsomes are vesicle-like artifacts of the endoplasmatic reticulum which are obtained after 
homogenization of liver or liver cells and further differentiated centrifugation. The 
microsomal fraction contains various drug-metabolizing enzymes such as cytochromes P450 
1A1, 1A2, and 1B1 (Berg et al., 2003).  
Microsomes, as crude part of the endoplasmatic reticulum, were isolated and purified by 
homogenization of cultured HepG2 cells and subsequent differential centrifugation according 
to Sigma protocol for the endosplasmatic reticulum isolation (Sigma-Aldrich, 2005) with a 
few modifications. As described before, HepG2 cells were seeded on 95-diameter petri dishes, 
and after twenty-four hours of compound-treatment, preparation of microsomes started. 
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Cells were washed three times with 4 °C-thermalized NaCl solution (0.9 %); the subsequent 
steps were performed on ice. Primarily, 1 ml of ice-cold IEB buffer (1x), containing 0.1 % 
protease inhibitor cocktail (Sigma-Aldrich) was added to each petri dish. The protease 
inhibitor cocktail prevents the degradation of proteins in the prepared cell homogenate. Then, 
cells were manually scraped off the petri dishes and directly transferred into a sterile 1.5 ml 
microtube.  
Afterwards, the cell suspension was homogenized using ultrasound (75 %, 3 s) and 
centrifuged (12000 x g, 15 min, 4 °C). 1 ml of each obtained supernatant was transferred into 
an ultracentrifugation microtube and centrifuged at 100000 x g for 60 min at 4 °C. The 
received pellet was resuspended in 75-100 µl NaPi-buffer (50 mM, pH: 7.6) and followed by 
homogenization using an ultrasonic probe (65 %, 2 s). 10 µl of each isolated microsome 
sample was transferred into another microtube to determine the protein concentrations with 
the aid of the BSATM assay. The remaining dissolved microsomes were stored at -80 °C until 
further use. 
 
Table 52. Solutions used during microsome preparation. 
 
NaCl solution (0.9 %) NaCl 
dd H2O 
Store at room temperature 
 
9 g 
up to 1 l 
PBS  
(phosphate buffered saline) 
calcium and magnesium free 
NaCl(137 mM) 
KCl (2.7 mM) 
NaH2PO4 (6.5 mM) 
H2PO4 (1.5 mM) 
dd H2O 
pH: 7.4 
Store at room temperature 
 
8.006 g  
0.201 g 
0.923 g 
0.204 g 
up to 1 l 
Isotonic extraction buffer 5x 
(IEB 5x) 
HEPES (5 mM) 
Saccharose (1.25 M) 
EGTA (5 mM) 
KCl (125 mM) 
dd H2O 
pH: 7.8 
Sterile-filtered with an 0.45 µm filter 
Store at 4 °C 
 
1.2 g 
42.8 g 
0.19 g 
0.93 g 
up to 100 ml 
Isotonic extraction buffer 1x 
(IEB 1x) 
5x IEB 
dd H2O 
Protease inhibitor cocktail (0.1 %) 
Preparation immediately before usein a 
sterile atmosphere 
Store on ice 
2 ml 
8 ml 
10 µl 
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NaPi-buffer (50 mM) Na2HPO4*H2O 
NaH2PO4 
dd H2O 
pH: 7.6 
Store at 4 °C 
7.52 g 
1.07 g  
up to 1 l 
 
VI.2.4.2 Extraction of Total RNA from Cells 
 
Total RNA was isolated from cells with the RNeasy Mini Kit from Qiagen according to the 
manufacturer's instructions (RNeasy Mini Handbook, 2010). This technique is based on the 
binding properties of RNA to a silica-based membrane in combination with the speed of 
microspin technology (Figure 60). Using this method, all RNA molecules longer than 200 
nucleotides are purified. The procedure conveys the purification of mRNA. Most RNAs < 200 
nucleotides (e.g. 5.8S rRNA, 5S rRNA, and tRNA) do not bind to the silica-based membrane 
and thus are excluded of the extraction process. Ribonucleases (RNases) are very stable and 
active enzymes which can destroy RNA within minutes. Therefore a few precautions have to 
be considered. Before starting the isolation, all benches, pipettes, and surfaces have to be 
cleaned with RNase Away solution.  
Cells were seeded in 6-well plates, incubated with test compounds for 24 h and afterwards 
washed three times with PBS and stored at -80 °C until RNA extraction. 
All subsequent steps were performed at room temperature. Primarily, cells were lysed and 
homogenized by a highly denaturating lyses buffer containing guanidine-thiocyanate. 
Therefore, 350 µl of buffer RLT (containing 1 % (v/v) β-mercaptoethanol) was added to each 
well. After a short incubation (2 min), cells were harvested with a cell scraper and then 
directly transferred into a 1.5 ml microtube. Then, cells were vortexed for 2 min to enhance 
the disruption and homogenization process and afterwards centrifuged for 2 min at maximum 
speed. This step prevents insoluble cell components from blocking the column during RNA 
elution. The supernatant was transferred into a 1.5 ml microtube filled with 350 µl ethanol  
(70 %), and mixed well by repeated up- and down-pipetting. The entire sample (700 µl) was 
then transferred into an RNeasy spin column, and centrifuged for 15 s at 8000 x g. During this 
step total RNA was bound to the membrane. Subsequently, three washing steps were carried 
out as the purification procedure. 700 µl of Buffer RW1 was added to the column which was 
then centrifuged for 15 s at 8000 x g. After that, 500 µl of Buffer RPE was added and the spin 
column was centrifuged 15 s at 8000 x g. The previous washing step was repeated once again 
and followed by the sample centrifugation at 8000 x g for 2 min. To ensure that no ethanol is 
carried over during RNA elution, the column was transferred into a new 2 ml collection tube 
and centrifuged for 1 min at maximum speed. This step was necessary because a carryover of 
the ethanol-containing Buffer RPE would decrease the RNA amount. Finally, the dried 
column was placed in a 1.5 ml microtube and 30 µl RNase-free water (supplied in the RNeasy 
Mini Kit) was added directly to the spin column membrane and the column was centrifuged 
for 1 min at 8000 x g. The eluted RNA was kept on ice until RNA yield and purification were 
determined. RNA samples were then stored at -80 °C until further usage. 
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Figure 60. RNA extraction and purification using RNeasy technology (Qiagen, 2010). 
 
VI.2.4.3 Extraction of Total RNA from Liver Tissue  
 
Total RNA was isolated from liver tissue with Qiagen´s RNeasy Mini Kit according to the 
manufacturer`s instructions (RNeasy Mini Handbook, 2010). Tissue sample preparation from 
mouse study I and II was carried out in the laboratory units of the Institute for Risk assessment 
Sciences (IRAS), at Utrecht University, whereas RNA isolation from liver of mouse study III 
was performed at the University Kaiserslautern. Tissue disruption and homogenization 
methods differed and are therefore described separately.  
Before starting the isolation, all benches, pipettes and surfaces were cleaned with RNase 
Away solution (Thermo Fisher Scientific). Sterile, disposable RNase-free plasticware 
including special RNase-free microtubes and pipette tips were used during RNA extraction. 
Glass ware, mortar and pestle, as well as stainless steel beads, spatulas and scissors were 
thoroughly cleaned and flushed with RNase Away solution before they were autoclaved and 
dried. 
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Mini Procedure 
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Disruption and homogenization using TissueLyser  
 
Frozen liver samples (mouse study I and II) were transferred on a 95 mm petri dish which was 
placed on ice. A small piece of each liver was cut off (30 mg) using a sterile scalpel and 
directly placed into a 2 ml microcentrifuge tube containing one stainless steel bead, 600 µl of 
Buffer RTL, and 6 µl of β-mercaptoethanol. Samples were then placed in the TissueLyser 
adapter and inserted in the TissueLyser. The tissue was disrupted and homogenized for 2 min 
at 20-30 Hz. Then the adapter set was dissembled, and the rack was rotated before operating 
the TissueLyser for another 2 min at 20-30 Hz. This procedure is necessary to achieve a 
complete disruption and homogenization of the mouse liver tissue (TissueLyser Handbook, 
Qiagen, 2010). 
 
Disruption using mortar and pestle followed by homogenization by vortexing 
 
The frozen liver samples (samples for microarray analysis from mouse study I and mouse 
study III) were directly placed in a liquid nitrogen containing mortar. A small piece was cut 
off (30 mg) and grinded thoroughly by pestle. Then, the tissue powder was decanted in a 2 ml 
microcentrifuge tube containing 600 µl of Buffer RLT and 6 µl of β-mercaptoethanol. The 
sample was afterwards mixed thoroughly by vortexing each sample for at least 2 min at room 
temperature. 
 
Purification of Total RNA 
 
The disrupted and homogenized samples were centrifuged for 3 min at maximum speed at 
room temperature. The supernatant was carefully transferred into another sterile 1.5 ml 
microtube containing 600 µl of ethanol (70 %). Insoluble material would interfere in the 
following steps and could block the column. The lysate-ethanol-mixture was mixed by 
repeated up- and down-pipetting, before 700 µl of the mix was transferred into an RNeasy 
spin column. The spin column was then centrifuged for 15 s at 8000 x g to bind the RNA. 
This step was repeated with the remaining lysate-ethanol-mix (500 µl) to bind the complete 
extracted RNA from the liver tissue to the column. The flow-through was discarded after each 
centrifugation. The membrane-bound RNA was washed in three subsequent steps.  
First, 700 µl of Buffer RW1 was added to the column which was centrifuged for 15 s at 8000 
x g. After that, 500 µl of Buffer RPE was added and the spin column was centrifuged 15 s at 
8000 x g. The previous washing step was repeated once again by adding 500 µl of Buffer RPE 
to the spin column and centrifugation at 8000 x g for 2 min. To ensure that no ethanol would 
be carried over during RNA elution, the column was transferred into a new 2 ml collection 
tube and centrifuged for 1 min at maximum speed.  
The last step is crucial because a carryover of the ethanol-containing Buffer RPE would have 
decreased the RNA amount. Finally, the dried column was placed in a 1.5 ml microtube and 
30 µl of RNase-free water (supplied in the RNeasy® Mini Kit) was added directly to the spin 
column membrane and the column was centrifuged for 1 min at 8000 x g. The eluted RNA 
was kept on ice and stored at -80 °C until further usage.    
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VI.2.4.4 Quantification and Determination of RNA/DNA Quality 
 
VI.2.4.4.1 Spectrophotometer  
 
RNA concentration and quality was determined spectrophotometrically at an absorbance 
wavelength of 260 and 280 nm. Pure RNA has a 260/280 ratio between 1.9 and 2.1. A ratio of 
smaller than 1.8 indicates that the RNA is contaminated with proteins. (Berg et al., 2003) 
(RNeasy Mini Handbook, 2010). RNA samples were quantified with the NanoDrop 1000 
spectrophotometer (Peqlab), whereas 1.5 µl of the samples were applied for quantification. A 
260/280 ratio in the range of 1.8-2.3 was considered acceptable and used for further 
experimental research. 
 
VI.2.4.4.2 Bioanalyzer  
 
Purity of RNA was determined using the Agilent 2100 bioanalyzer and associated RNA 6000 
Pico LabChip kit. Figure 61 summarizes the procedure for determination of RNA purity and 
yield.  
First, RNA isolated from mouse liver was separated by gel electrophoresis on a 
microfabricated chip and afterwards examined using laser induced fluorescence detection. 
The bioanalyzer software generates the electropherogram and gel-like image as well as the 
ribosomal ratio (ratio of the 18S to 28S ribosomal subunits) as featured in Figure 62. A new 
approach of Agilent Technologies for the RNA quality assessment is the RNA Integrity 
Number (RIN). The RIN software algorithm was developed to standardize the RNA integrity 
interpretation, which before was only based on subjective visual evaluation in combination 
with the ribosomal ratio. The whole electropheric trace is embedded in the RIN software 
algorithm. Classification is based on a numbering system from 1 to 10, whereas RNA with a 
RIN of 1 is considered the most degraded sample and a RIN of 10 reflects the most intact 
RNA (Agilent Technologies, 2004). 
Bioanalyzer analysis was performed using the Agilent RNA 6000 Pico LabChip kit according 
to the RNA 6000 Pico Kit Guide. Total RNA was adapted to a concentration of 1 ng/µl with 
ddH2O. Analysis of RNA integrity was carried out using 2100 Expert Software Version 
B.02.02. 
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Figure 61. Bioanalyzer procedure according to RNA 6000 Pico Kit Guide (Agilent Technologies, 2008). 
 
 
Figure 62. Representative electropherogram and gel-like image (RNA from hHeps, RIN: 10). 
Information including RNA concentration, ribosomal ratio and RIN. 
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VI.3 Biochemical Assays 
 
VI.3.1 Alamar Blue Assay 
 
The Alamar Blue assay, also referred as resazurin reduction assay, is a sensitive, simple, and 
fast test method to determine cytotoxicity and cell proliferation in vitro based on metabolic 
cell activity. 
 
 
Figure 63. Reduction of resazurin (blue) to resorufin (pink) by usage of NADH. 
 
Oxidized, blue, non-fluorescent resazurin is reduced to the pink-fluorescent resorufin     
(Figure 63) by cell activity or mitochondrial enzymes (De Fries et al., 1995). Resorufin 
fluorescence was measured at 544 nm excitation and 590 nm emission using Fluoroscan 
Ascent microplate reader (Labsystems). 
It is proven that there is a direct correlation between the reduction of resazurin in the growth 
media and the cell proliferation of living cells. It has not been verified, if the reaction takes 
place intracellularly using mitochondrial enzyme activity, at the surface of the plasma 
membrane, or as a chemical reaction in the cell culture medium extracellularly (O´Brien et al., 
2000). 
Resazurin working solution was prepared immediately before use and protected from light   
(Table 53). The incubation medium of compound-treated HepG2 and hHeps was removed 
after 24 h and cells were washed with 1 ml/well (HepG2) or 200 µl/well (hHeps) of 
prewarmed PBS. Afterwards, 1 ml/well (HepG2) or 200 µl/well (hHeps) of resazurin working 
solution was added and cells were kept in an incubator for another 60 min (HepG2) or 90 min 
(hHeps) under standard conditions. Finally, fluorescence was measured at 544 nm excitation 
and 590 nm emission using Fluorescent Ascent plate reader. 
Saponine (0.1 %) served as positive control. Different concentrations of DMSO (0.1-1 %) 
were used as respective solvent controls as well as a blank (non-cell containing well). The 
blank value was subtracted from all fluorescence intensities. The mean of two (HepG2) or 
four (hHeps) replicates was related to the mean value of the corresponding solvent control. 
Viability of cells was calculated as the percentage of viable cells compared to control cells 
(DMSO 0.1-1 %): 
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Viability %= MVT-B
MVC-B
× 100 
with: MVT-B: measured value of compound-treated cells minus blank value 
 MVC-B: measured value of solvent control-treated cells minus blank value 
 
Table 53. Solutions used for Alamar Blue assay. 
 
PBS  
(phosphate buffered saline) 
calcium and magnesium 
free 
NaCl (137 mM) 
KCl (2.7 mM) 
NaH2PO4 (6.5 mM) 
H2PO4 (1.5 mM) 
dd H2O 
pH: 7.4 
Store at room temperature 
 
8.006 g  
0.201 g 
0.923 g 
0.204 g 
up to 1 l 
Resazurin stock solution  
(440 mM) 
Resazurin 
DMF 
Store at 4 °C for 1 week and  
exclude from light 
 
110.5 mg 
1 ml 
NaCl/Pi-buffer 
 
KH2PO4 (1.1 mM) 
NaCl (154 mM) 
Na2HPO4 (3.7 mM) 
ddH2O 
Store at 4 °C up to 4 weeks 
 
0.144 g 
9.0 g 
0.528 g 
up to 1 l 
Resazurin-NaCl/Pi solution  
(440 µM) 
Resazurin stock solution 
NaCL/Pi-buffer 
Store at 4 °C for 4 weeks and 
exclude from light 
 
 
0.1 ml 
999.9 ml 
Resazurin working solution 
HepG2 cells 
Resazurin-NaPi solution 
DMEM w/o phenol red 
Preparation immediately before 
use and exclude from light 
 
1: 10 (v/v) 
Resazurin working solution 
hHeps 
Resazurin-NaPi solution 
HMCTM medium 
Preparation immediately before 
use and exclude from light 
1: 10 (v/v) 
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VI.3.2 Ethoxyresorufin-O-deethylase (EROD) Assay 
 
The ethoxyresorufin-O-deethylase (EROD) assay is a well established and widely used test 
method to determine cytochromes P450 1A1 enzyme activity in liver tissue and cells. 
Induction of CYP1A1 is the best known biomarker for AhR activation and provides important 
information about toxicity mediated by environmental pollutants like PCDDs, PCDFs, and 
DL-PCBs. The EROD assay includes the oxidative deethylation of 7-ethoxyresorufin to the 
pink- fluorescent resorufin. This dealkylation reaction (Figure 64) is catalyzed by CYP1A1 
whereby the fluorescence intensity is direct proportional to the CYP1A1 concentration 
(Behnisch et al., 2001) (Petrulis et al., 2001) (Behnisch et al., 2002) (van Duursen et al., 
2005). Each experiment included a positive control for CYP1A1 induction (TCDD, 10 nM) as 
well as solvent controls (DMSO 0.1-1 %). 
 
 
Figure 64. Dealkylation of 7-ethoxyresorufin to the pink-fluorescent resorufin. 
 
In the present work the EROD activity was performed and measured according to van 
Duursen et al. (2005) with modifications. After a period of 24 h of compound incubation, 
cells were washed twice with 1 ml/well (HepG2) or 200 µl/well (hHeps) prewarmed PBS. 
Then, 1 ml/well (HepG2) or 200 µl/well (hHeps) of freshly prepared EROD medium was 
added to the cells and multiwell plates were directly inserted in the thermalized (37 °C) 
Fluorescent Ascent plate reader. Fluorescence was measured at an excitation wavelength of 
544 nm and emission wavelength of 590 nm every 90 s for 30 min. Afterwards, cells were 
washed with 2 ml/well or 400 µl/well (hHeps) prewarmed PBS and frozen (-80 °C) over 
night.  
A calibration curve of resorufin was used to quantify the activity. A pipetting layout is 
presented in Table 55, with DMEM high glucose w/o phenol red being used for HepG2 cells 
and HCMTM medium for primary human hepatocytes. After a period of 10 min at 37 °C in the 
Fluorescent Ascent plate reader (Labsystems, Dreieich), fluorescence was measured 
(excitation: 544 nm, emission: 590 nm).  
With the aid of the resorufin calibration curve the resorufin content per well per min was 
determined but only the linear section of the obtained line was used for calculation. Including 
the protein content of the corresponding well leads to the specific EROD activity expressed as 
pmol resorufin/mg protein* min. 
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Table 54. Solutions used in EROD assay. 
 
PBS  
(phosphate buffered saline)  
calcium and magnesium free 
NaCl(137 mM) 
KCl (2.7 mM) 
NaH2PO4 (6.5 mM) 
H2PO4 (1.5 mM) 
dd H2O 
pH: 7.4 
Store at room temperature 
 
8.006 g  
0.201 g 
0.923 g 
0.204 g 
up to 1 l 
7-ethoxyresorufin(1 mM) 7-ethoxyresorufin  
DMSO 
Store at -20 °C and  
exclude from light 
 
5 mg 
20.73 ml 
Resorufin stock solution (10 mM) Resorufin sodium salt 
DMSO 
Store at room temperature and 
exclude from light 
 
23.5 mg 
10 ml 
Resorufin working solution (10 nM) Resorufin stock solution  
DMSO 
Preparation immediately before 
use and exclude from light 
 
0.1 ml 
9.9 ml 
Magnesium chloride solution (1 M) MgCl2 
ddH20 
Store at room temperature 
 
9.521 g 
100 ml 
NaOH (0.2 M) NaOH 
ddH20 
Store at room temperature 
 
0.8 g 
100 ml 
Dicumarol (10 mM) Dicumarol  
NaOH (0.2 M) 
Store at 4 °C 
 
33.36 mg 
10 ml 
EROD medium 
HepG2 
DMEM high glucose w/o 
phenol red 
MgCl2 (1M) 
Dicumarol (10 mM) 
7-ethoxyresorufin (1 mM) 
 
25 ml 
125 µl 
25 µl 
125 µl 
EROD medium 
hHeps 
HCMTM medium  
MgCl2 (1M) 
Dicumarol (10 mM) 
7-ethoxyresorufin (1 mM) 
20 ml 
100 µl 
16 µl 
100 µl 
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Table 55. Layout of resorufin calibration curve. 
 
Vial Medium (µl) Resorufin working solution/vials Resorufin concentration (nM) 
1 9900 100 µlresorufin working solution 1000 
2 3000 3000 µl Vial 1 500 
3 3000 1000 µl Vial 1 250 
4 2400 600 µl Vial 2 100 
5 2484 216 µl Vial 1 75 
6 4000 1000 µl Vial 3 50 
7 2400 600 µl Vial 4 20 
8 2400 600 µl Vial 6 10 
9 2000 0 0 
 
 
VI.3.3 Bicinchoninic Acid (BCA) Assay 
 
The BCATM assay is a rapid and sensitive test method for quantification of the total protein 
content. The underlying reaction is based on two steps: the reduction of Cu2+ to Cu+ by 
protein in an alkaline medium (biuret reaction) and afterwards the sensitive and selective 
colourimetric detection of the cuprous cation (Cu+) by binding to bicinchoninic acid as 
pictured below: 
 
Figure 65. Scheme of the BCA reaction (Pierce). 
 
The purple-coloured reaction product is formed by the chelation of two molecules of BCA 
with one cuprous ion. This purple complex exhibits a strong absorbance at 562 nm that is 
nearly linear with increasing protein concentrations over a large concentration range (20-
20000 µg/ml) (Pierce, 2010).  
The BCA assay was used to quantify the total protein content after performing EROD assay 
respectively measuring the protein concentration in microsomes. After measuring the EROD 
activity, HepG2 cells and hHeps were frozen over night in multiwell plates at -80 °C. Cells 
were cracked by thawing three times for 15 min at room temperature and freezing (-80 °C) for 
at least 3 h in between. Depending on the used multiwell format, different volumes were 
applied as described in Table 56. 
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First of all, the cracked cells in each well were solved in a corresponding amount of double-
distilled water (Table 56). Afterwards the BCA working solution was freshly prepared by 
mixing 50 parts of Reagent A with 1 part of Reagent B and the respective volume of the 
working solution was added to each well. Then, the plates were carefully shaken to enhance 
the mixing process and kept in a humidified chamber at 37 °C for 30 min. Subsequently, 
fluorescence was measured at a wavelength of 562 nm using the MWGt plate reader (BioTek 
Instruments Inc.).  
The experimental procedure for microsomes was similar, first microsomes were defrozen on 
ice. Afterwards, microsomes were diluted with double-distilled water 1:10 whereby 50 µl of 
the diluted microsomes were transferred into a 48-well plate and mixed with the freshly 
prepared BSA working solution (Reagent A:Reagent B, 50:1). The subsequent steps were 
performed as described above.   
A BSA calibration curve was used to quantify the protein content; the pipetting layout is 
presented in Table 57. Known BSA concentrations were measured and the BSA 
concentrations were fitted against the obtained sample fluorescence at 562 nm.  
 
Table 56. Information about format-related volumes in BCA assay. 
 
Format ddH2O (µl) 
Volume 
BCA working reagent (µl) 
24-well 75 600 
48-well 50 400 
96-well 25 200 
 
Table 57. Preparation of diluted BSA standards for BSA calibration curve. 
 
Vial Volume ddH2O (µl) Volume and source of BSA BSA concentration (µg/ml) 
A 0 300 µl BSA stock solution 2000 
B 125 375 µl BSA stock solution 1500 
C 325 325 µl BSA stock solution 1000 
D 175 175 µl Vial B 750 
E 325 325 µl Vial C 500 
F 325 325 µl Vial E 250 
G 325 325 µl Vial F 125 
H 400 325 µl Vial G 25 
I 400 0 0 
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VI.3.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
The principle of the sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
is the separation of charged particles, in the present work, proteins in a homogenous electrical 
field. Adding SDS (an anionic detergent) to the samples and subsequent heating up to 95 °C 
leads to the masking of the protein self charge, thus the protein migration is directly 
proportional to the molecular weight and no longer depends on the charge distribution. 
Furthermore, the secondary and tertiary protein structure is ruptured by disconnecting the 
hydrogen bridges. The β-mercaptoethanol, as another component of the loading buffer 
(Laemmli buffer), leads to the reductive splitting of disulfide bonds in proteins. 
Proteins are separated depending on their specific molecular weight using a discontinuous 
electrophoresis. Denatured samples are loaded onto a polyacrylamide gel (consisting of a 
stacking and resolving gel) and are separated by applying a suitable voltage. Discontinuities 
in pore sizes and pH values enhance the sharpness of bands compared to a continuous 
electrophoresis. The stacking gel (pH: 6.8) with a large pore size, is placed onto the separation 
gel, the so called resolving gel (pH: 8.8) with smaller pores. In the stacking gel all proteins 
migrate at the same migration speed and build a sharp stacking line. Migration into the small 
pore-sized resolving gel leads to a sieving effect which results in a solely weight-dependent 
separation of proteins because small proteins migrate faster than larger molecules through the 
gel. A protein marker is added to each electrophoresis to monitor electrophoretic separation 
and identify protein bands (Lottspeich et al., 1998) (Cammann, 2001). 
Microsomes were diluted with double-destilled water each 15 µl sample containing 25 µg 
protein. 3 µl loading buffer (Laemmli 6x, Table 58) was added to the diluted samples. 
Samples were vortexed and centrifuged at room temperature for 5 min at maximum speed and 
subsequently denatured for 5 min at 95 °C. Afterwards, samples were cooled down on ice and 
centrifuged for 5 min at room temperature. 
First, the resolving gel solution (Table 59) was prepared and quickly casted between to glass 
plates in a gel caster. The surface of the resolving gel was coated with 2-propanol (70 %) to 
obtain a bubble-free, smooth gel surface. After 30 min, the resolving gel was polymerized and 
2-propanol was carefully removed using filtering paper. Then, the stacking gel solution was 
mixed, and quickly casted on top of the polymerized resolving gel. A comb was inserted into 
the soluble stacking gel solution to create 10 sample pockets. After another 30 min the 
resolving gel was polymerized and always two gels were placed into a vertical electrophoresis 
chamber (Mini Protean IV Apparatus, Bio-Rad) which subsequently was completely filled 
with electrophoresis buffer (1x). Afterwards, the comb was carefully removed and the 
denatured protein samples (18 µl) were loaded into the pockets. A defined protein marker 
(Precision Plus Kaleidoscope Protein Standard, Bio-Rad) was also loaded into one lane per 
gel (5 µl). At first, a constant voltage of 80 V was applied. After protein samples reached the 
resolving gel (about 15 min), the voltage was increased to 120 V. Once the dye front reached 
the end of the resolving gel, the electrophoresis was stopped (approximately after another 90 
min). 
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Table 58. Laemmli loading buffer for SDS-PAGE (6x). 
 
Laemmli (loading buffer 6x) Tris/HCl (0.5 M; pH 6.8) 
SDS 
Glycerine 
Bromophenol blue 
β-mercaptoethanol 
ddH2O 
Store at -20  C 
50 ml 
1.244 g 
40 ml 
0.16 g 
5.0 ml 
up to 100 ml 
 
 
Table 59. Solutions and combustion of resolving and stacking gel for SDS-PAGE. 
 
Tris/HCl (1.5 M) Tris 
ddH2O 
Adjust to pH: 8.8 
Store at room temperature 
 
18.2 g 
up to 100 ml 
 
Tris/HCl (0.5 M) Tris 
ddH2O 
Adjust to pH: 6.8 
Store at room temperature 
 
6.1 g 
up to 100 ml 
Resolving gel (10 %) Acrylamide (30 % solution) 
ddH2O 
Tris/HCl (1.5 M, pH: 8.8) 
SDS (10 %) 
APS (10 %) 
TEMED 
 
1.64 ml 
2.0 ml 
1.23 ml 
50 µl 
50 µl 
4 µl 
Stacking gel (4 %) Acrylamide (30 % solution) 
ddH2O 
Tris/HCl (0.5 M, pH: 6.8) 
SDS (10 %) 
APS (10 %) 
TEMED 
0.25 ml 
1.2 ml 
0.5 ml 
20 µl 
20 µl 
4 µl 
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Table 60. Electrophoresis buffer for SDS-PAGE. 
 
Electrophoresis 
buffer (10x) 
Glycine (2 M) 
Tris (250 M) 
SDS (20 % solution)  
ddH2O 
Adjust to pH 8.4 
Store at room temperature 
 
720 g 
150 g 
250 ml 
up to 5 l 
 
Electrophoresis 
buffer (1x) 
Electrophoresis buffer (10x) 
ddH2O 
Store at room temperature 
250 ml 
up to 2.5 l 
 
 
VI.3.5 Western Blot and Immunoblot 
 
Western blot was performed subsequent to protein separation using SDS-PAGE. Separated 
proteins are transferred from a gel to a membrane (polyvinylidene fluoride (PVDF)) in an 
electrical field. After proteins are bound to a membrane, they can be detected by using 
protein-specific monoclonal or polyclonal antibodies. Separated proteins are transferred from 
the polyacrylamide gel to the polyvinylidene fluoride membrane by a vertically positioned 
electrical field. Proteins stick to the PVDF membrane due to hydrophobic interactions and can 
be identified by binding of specific antibodies. The primary antibody binds directly to the 
examined protein, whereby unbound primary antibody is removed by several washing steps. 
Afterwards, the membrane is exposed to another antibody which is directed against the 
primary antibody. The secondary antibody used in the present work is linked to an enzyme 
(horseradish peroxidase) which catalyzes a chemoluminescent reaction finally visualizing the 
protein bands.The horseradish peroxidase-linked secondary antibody catalizes the oxidation 
of luminol in the presence of H2O2. The formed reaction product is in an excited state falling 
back to the ground state by emitting light (Figure 66). Phenolic compounds, such as              
p-coumaric acid, are able to enhance the light emission (Lottspeich et al., 1998) (Towbin et 
al., 1979). 
 
 
Figure 66. Chemoluminscent reaction. 
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First, separated proteins were transferred from the polyacrylamide gel to the PVDF membrane 
using a semi-dry transfer system (Hoefer). The PVDF membrane (6.5 x 8 cm) was immersed 
a few seconds in methanol (100 %), then, washed in ddH2O and afterwards equilibrated for at 
least 10 min in anode buffer I. All polyacrylamide gels were equilibrated for 10 min in 
cathode buffer before starting the following procedure. 
First, the anode of the semi-dry blot was moisturized with anode buffer I. A Whatman filter 
paper (7.5 x 9 cm) soaked with anode buffer I was placed on the anode followed by two 
Whatman filter papers soaked with anode buffer II. The equilibrated PVDF membrane was 
positioned on top of this filter paper stack. Carefully, the polyacrylamide gel was placed on 
the PVDF membrane. Three Whatman filter papers soaked with cathode buffer were put on 
top of the gel. Finally, the cathode was placed on the 'sandwich' (Figure 67). A weight of 5 kg 
was positioned on the semi-dry apparatus. Blotting was performed using constant amperage of 
0.8 mA/cm2 (45 mA per membrane) for 75 min.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. Schematic illustration of semi-dry blot apparatus. 
 
Table 61. Blotting buffers. 
 
Anode buffer I Tris (300 mM) 
Methanol 
ddH2O 
Adjust to pH: 10.4 
Store at room temperature 
 
36.3 g 
100 ml 
up to 1 l 
Anode buffer II Tris (25 mM) 
Methanol 
ddH2O 
Adjust to pH: 10.4 
Store at room temperature 
 
3 g 
100 ml 
Up to 1 l 
Cathode buffer Glycine 
Tris 
Methanol 
SDS (20 % solution) 
ddH2O 
Adjust to pH: 9.4 
Store at room temperature 
3 g 
3 g 
200 ml 
250 µl 
up to 1 l 
Cathode 
Anode 
2 Whatmanfilter paper soaked with anode buffer II 
1 Whatmanfilter paper soaked with anode buffer I 
3 Whatmanfilter paper soaked with cathode buffer 
gel 
PVDF membrane  
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After transferring the separated proteins to the PVDF membrane, the membrane was 
incubated with blocking buffer (Table 62) on a shaker for 1 h at room temperature to block 
unspecific binding sites. Then, the membrane was transferred into a 50 ml tube and washed 
three times for 5 min with TBS-T (tris buffered saline; Table 62) and subsequently incubated 
with the respective primary antibody (Table 63) for 1 h at room temperature, respectively at    
4 °C over night, on a rotating mixer. After three washing steps with TBS-T for 5 min, the 
membrane was finally incubated with the horseradish peroxidase (HPR)-labelled secondary 
antibody (Table 63) for 1 h at room temperature on a rotating mixer. Afterwards, the 
membrane was washed twice with TBS-T and once with TBS (Table 62). The membrane was 
stored in TBS until chemoluminescence detection was carried out. 
 
Table 62. Solutions used for immunoblot. 
 
TBS (20x) NaCl (2.6 M) 
Tris/HCl (0.4 M) 
ddH2O 
Adjust to pH: 7.4 
Store at room temperature 
 
304 g 
97 g 
up to 1 l 
TBS-T (1x) TBS (1x) 
Tween-20  
Store at room temperature 
 
2 l 
6 ml 
 
Blocking buffer TBS-T (1x) 
Skimmed milk powder (0.5 %) 
Prepare immediately before use 
100 ml 
5 g 
 
 
Table 63. List of primary and secondary antibodies including experimental conditions. 
 
Primary 
antibody 
Dilution 
with 
TBS-T 
Incubation 
period 
Purchased 
from 
Secondary 
antibody 
Dilution 
with 
TBS-T 
Incubation 
period 
Purchased 
from 
Rabbit anti-
CYP1A1 
1:1000 1 h Abcam Goat anti-
rabbit IgG-
HRP 
1:2000 1 h Santa Cruz 
Biotechnology 
Rabbit anti- 
VDAC1 
1:1000 Over night Cell 
Signaling 
Technology 
Goat anti-
rabbit IgG-
HRP 
1:2000 1 h Santa Cruz 
Biotechnology 
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Detection of chemoluminescence by enzyme substrate reaction was realized as described in 
the following steps. Therefore, the membrane was incubated with the chemoluminescence 
detection solution consisting of solution A (9 ml, Table 64), solution B (1 ml, Table 64), and 
100 µl of the H2O2-Tris/HCL solution (Table 64) for 1 min in a darkened box. As described in 
Figure 66, luminol is oxidized by the horseradish peroxidase in alkaline environment. The 
formed reaction product 3-aminophtalate returns from an excited state to the ground state by 
emitting light. This light was detected with the aid of the LumiImager and LumiAnalyst 3.1 
software (Roche Diagnostics). 
 
Table 64. Solutions used for chemoluminescence detection. 
 
Tris/HCl (0.1 %) Tris  
ddH2O 
Adjust to pH: 8.6 
Store at room temperature 
 
2.428 g 
up to 200 ml 
Solution A Luminol 
Tris/HCl (0.1 M) 
Store in a darkened container at 4 °C 
 
50 mg 
200 ml 
Solution B p-coumaric acid 
DMSO 
Store in a darkened container at room 
temperature 
 
22 mg 
20 ml 
H2O2-Tris/HCL- 
(0.1 %) solution 
H2O2 (30 %) 
Tris/HCL (0.1 M) 
Preparation immediately before use in a 
darkened microreaction tube 
 
50 µl 
1000 µl 
 
 
 
 
 
 
 
 
 
 
Methods 
 
188 
 
VI.3.6 Real-Time Polymerase Chain Reaction 
 
VI.3.6.1 Reverse Transcription  
 
Reverse transcription marks the first step within real-time PCR analysis. During this reaction, 
the isolated RNA (from cells or tissue) is transcribed into complementary DNA (cDNA) using 
the enzyme reverse transcriptase. The synthesized cDNA can then be applied in quantitative 
RT-PCR experiments.  
In the present work the iScriptTM cDNA Synthesis Kit (Bio-Rad) was used to transcribe RNA 
into cDNA using MMLV-derived reverse transcriptase. MMLV reverse transcriptase is 
isolated from the moloney murine leukemia virus and transcribes RNA into cDNA using a 
unique blend of oligo(dT) and random hexamer primers (Berg et al., 2003) (Bio-Rad). 
Reverse transcription was carried out using the iScriptTM cDNA Synthesis Kit according to 
the manufacturer’s instructions (Bio-Rad). A master mix consisting of 5x iScript reaction mix, 
reverse transcriptase, and nuclease-free water was prepared and added to the RNA template 
(Figure 65). Then the template-iScript solution was carefully mixed, centrifuged and placed 
into the MyCycler (Bio-Rad). The reaction protocol is featured below (Table 66). Afterwards, 
the cDNA was stored at -20 °C. 
 
Table 65. Components for reverse transcription reaction. 
 
Components Volume per reaction (µl) 
5x iScript reaction mix 4 
iScript reverse transcriptase 1 
Nuclease-free water 14 
RNA template (1 µg/µl) 1 
 
Table 66. Thermocycling conditions according to manufacturer’s instructions. 
 
Temperature Duration time (min) 
25 °C 5 
42 °C 30 
85 °C 5 
4 °C Hold 
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IV.3.6.2 Quantitative Real-Time PCR  
 
Quantitative real-time PCR (RT-PCR) is a technique which enables both amplification and 
quantification of a targeted DNA simultaneously. The reaction progress is monitored in 'real 
time' compared to a conventional PCR in which the reaction product is verified at its end, e.g. 
using an agarose gel electrophoresis.  
In the present work, the amplified targeted DNA was quantified using the fluorescence dye 
SYBR®Green. SYBR®Green is a cyanine dye which binds to the double-stranded DNA, thus 
the fluorescence of the formed SYBR Green-DNA complex can be measured at 490 nm. So 
the number of amplified DNA increases with the increasing fluorescence which is directly 
proportional to amplified DNA amount (Tichopad et al., 2003) (Bio-Rad, 2006). 
Amplification can be divided into three different stages. In the first phase, no significant 
increase of fluorescence can be detected despite product amplification (linear background 
stage). In the linear log phase (second stage), the fluorescence rises in a logarithmic manner 
until reaching the third phase (plateau stage) in which no increase of fluorescence is 
registered. Substrates are depleted and the activity of the Taq polymerase decreases due to the 
heat load throughout the PCR. The early linear log phase is used for quantification of the 
amplified product measuring the Ct-value (threshold cycle). The Ct-value represents the cycle 
at which the fluorescence rises above the background for the first time. In the present work 
this value is used for quantification of the amplified product as described below (Holland et 
al., 1991) (Pfaffl et al., 2001) (Tichopad et al., 2003) (Pfaffl et al., 2004).  
First, 1 µl of the transcribed cDNA (IV.3.6.1 Reverse transcription) was transferred into a 
PCR tube placed on ice. The RT-PCR master mix containing 12.5 µl of ABsoluteTM QPCR 
SYBR® Green Fluorescein Mix (Thermo Fisher Scientific), 2 µl of the primer mix (forward 
and reverse primer of targeted gene) and 9.5 µl of RNase-free water was added to the cDNA 
template (Table 67). All PCR tubes were covered with optic lids, spinned down, and were put 
into the iCycler (Bio-Rad) using the optimized thermocycling programme (Table 68). 
 
Table 67. Components for real-time PCR. 
 
Components Volume (µl) 
ABsoluteTM QPCR SYBR® Green Fluorescein Mix 12.5 
Primer forward 
Primer reversed 
1 
1 
RNase-free water 9.5 
cDNA template 1 
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Table 68. Thermocycling conditions for RT-PCR.  
Annotations: TA: primer specific annealing temperature 
 
  Temperature (°C) Time Process 
Cycle 1 1x 95 15 min Activation of Taq polymerase 
Cycle 2 40x 95 
TA 
72 
20 s 
30 s 
30 s 
Denaturation 
Primer specific annealing 
Product amplification 
Cycle 3 1x 95 1 min Final denaturation 
Cycle 4 1x TA 1 min Starting melting curve 
Cycle 5 80x TA + 0.5 10 s  
 
A list of the used primers is featured in Table 69 below. All primers were purchased from 
Eurofins MWG Operon and were dissolved in nuclease-free water according to 
manufacturer's instruction. The primers CYP1A1, CYP1A2, CYP1B1, ALDH3A1, CD36, and 
TIPARP were validated by our project partner in Utrecht, whereas HSD17B2 and AHRR were 
validated in our laboratory. All mouse primer were already validated and used in our 
laboratory (Roos, 2011). 
 
Table 69. Overview of primer information featuring species, gene of interest, systematic gene name, primer 
sequence, length and annealing temperature (TA). 
Annotations: a) Andersson et al., 2011; b) Chuang et al., 2009; c) Ooi et al., 2011; d) Su et al., 2007 e)   
                        designed by the use of Primer BLAST (Basic Local Alignment Search Tool) of the NCBI  
                        database; f) Roos, 2011; g) Dörr, 2010 
 
Gene Systematic name 5`- 3` Length TA 
(°C) 
Reference 
human      
CYP1A1 NM_000499 
CAGAAGATGGTCAAGGAGCA 20 
60 a) 
GACATTGGCGTTCTCATCC 19 
CYP1A2 NM_000761 
CCCAGAATGCCCTCAACA 18 
60 c) 
CCACTGACACCACCACCTGAT 21 
CYP1B1 NM_000104 
CGGCCACTATCACTGACATC 20 
60 a) 
CTCGAGTCTGCACATCAGGA 20 
ALDH3A1 NM_001135168 
GCAAGCAAGTAAGGGAGCGGA 21 
60 e) 
ACCCGAGTCCTAAGCCGAACTG 22 
HSD17B2 NM_002153 
CTGAGGAATTGCGAAGAACC 20 
60 e) 
AAGAAGCTCCCCATCAGTTG 20 
TIPARP NM_001184717 
GCGCACAAGTCTTCGTCTTCCTCC 24 
60 e) 
AAAAATCCTCCCGAGGAGCGTCCAA 25 
AHRR NM_020731 
CTTCATCTGCCGTGTGCGCT 20 
57 e) 
ATGAGTGGCTCGGGACAGCAGA 22 
CD36 NM_001127444 
AGATGCAGCCTCATTTCCAC 20 
60 b) 
CGTCGGATTCAAATACAGCA 20 
ACTB NM_001101 
CGTGCGTGACATTAAGGAGAA 21 
55.7 g) 
CAATGCCAAGGCAGGAAGG 19 
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mouse      
Cyp1a1 NM_009992 
ACTTCATTCCTGTCCTCCGTTACC 24 
52 f) 
GCCCTTCTCAAATGTCCTGTAGTG 24 
Cyp1a2 NM_009993 
CCGAGGAGAAGATTGTCAACATTG 24 
52 f) 
GCCAACCACCGTGTCCAG 18 
Cyp2b10 NM_009999 
AGTGTGGAGGAGCGGATTCAGG 22 
60 f) 
AACAGCTCCAGCAGGCGCAA 20 
Cyp3a44 NM_177380 
ACAGAGAGTCACACATACATCTGGAGG 27 
58 f) 
TGTGTACGGGTCCCATATCGGTAGAG 26 
36b4 NM_007475 
GCCACCTGGAGAACAACC 18 
58 f) 
GCCAACAGCATATCCCGAATC 21 
 
Calculation of mRNA expression 
 
Calculations were carried out using the comparative delta delta CT (∆∆CT) method according 
to Pfaffl (2001). First, the relative expression level of a target gene is compared to a reference 
gene (housekeeping gene, 36b4, or ACTB) resulting in the ∆CT value. Then, the ∆CT value of 
the control was subtracted from ∆CT value of compound-treatment leading to the x-fold 
mRNA induction of the target gene: 
 
∆CT = CT (target gene) - CT (housekeeping gene) 
∆∆CT = ∆CT (treatment) - ∆CT (control) 
x-fold induction = 2-∆∆CT 
 
The value of 2 is derived based on an optimal primer efficiency of 100 %, which means that 
with each cycle the amplified product is doubled. All primers were either already validated in 
our laboratory, in a laboratory of our project partner, published in literature or online available 
at the NCBI platform. Primer requirements included that they may only synthesize one 
specific product and have a complementary RNA sequence to the target sequence which is 
distinguished by exon bridges. Furthermore, the formed product should not be longer than 200 
base pairs. The respective primer annealing temperature was determined using a temperature 
gradient. Primers efficiency was assigned based on a serial dilution of cDNA. Only primers 
with an efficiency of approximately 100 % were applied in RT-PCR. 
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VI.3.7 Microarray 
 
Microarray technology is a powerful tool to examine large numbers of genes simultaneously. 
Microarrays were developed during the mid-nineties of the last century by down screening of 
large-sized hybridization and other interaction techniques (Müller et al., 2004) (Shena et al., 
1995). The term is composed of two words 'micro' and 'array'. Micro means something 
'extremely small'. However, only a few definitions are given for the noun array but the 
following is the most appropriate one: array - 'a large group or collection of things, usually 
arranged so that you can see them all' (Dictionary of Contemporary English, 1995). Implying 
a large number of molecules for example oligonucleotides are placed on an extremely small 
surface. Throughout the years, various improvements have been carried out resulting in a 
standardized, user friendly, and fast screening method within the field of Genomics. There are 
different types of microarrays available on the market depending on starting material (DNA or 
RNA) and requested endpoint. 
 
VI.3.7.1 Microarray Procedure  
 
In the present work, gene expression analysis was performed according to the Agilent's Two-
Color Microarray-based Gene Expression Analysis using Whole Human (or Mouse) Genome 
Oligo Microarray Kit 4 x 44K (Agilent Technologies).  
The chosen microarray experiment is based on a two-colour labelling reaction using the two 
different fluorophores cyanine 3 (Cy3) and cyanine 5 (Cy5) with an emission wavelength of 
570 nm (green part of light spectrum) and 670 nm (red part of the light spectrum) (Ernst et al., 
1989) (Tang et al., 2007). Compound-treated samples and control samples were labelled 
oppositionally. At least four independent experiments were performed within the mouse 
studies and five within the in vitro cell studies. Additionally, a dye-swap was carried out 
meaning compound-treated samples and control samples were labelled differently in each 
independent experiment. For example TCDD-treated hHeps were labelled with Cy3 in the 
first experiment and labelled with Cy5 in the second experiment. The dye change in each 
experiment was performed to reduce possible errors due to the dye colour. Figure 68 features 
the individual steps and procedures within the microarray experiment. 
First, by the use of Agilent's Low Input Quick Amp Labeling Kit, the isolated RNA (100 ng 
per sample) was transcribed into cDNA before cRNA was synthesized, dye-labelled, and 
amplified. Afterwards, the synthesized cRNA was purified using RNeasy Mini Kit (Qiagen) 
and prepared for hybridization (Gene Expression Hybridization Kit, Agilent Technology). 
Hybridization was carried out for 17 h at 65 °C in a rotating hybridization chamber. Then, 
microarray slides were washed using Agilent's Gene Expression Wash Buffer Kit and dried. 
Afterwards slides were scanned by Agilent B Microarray scanner and data was extracted 
using Agilent Feature Extraction Software (version 9.5.1). 
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Figure 68. Workflow for sample preparation and array processing (Agilent Technologies, 2010). 
 
Step 1: Preparing Spike-Ins 
 
Initially, RNA Spike-In solutions were prepared according to user's manual. The used 
oligonucleotides microarrays contain positive controls which were designed to hybridize with 
the Spike-Ins. Positive controls (in vitro synthesized polyadenylated transcripts derived from 
the Adenovirus E1A transkriptome) are used to monitor the workflow from sample 
amplification and labelling to microarray processing. This procedure provides important 
information about the system`s linearity, sensitivity, and accuracy which can later be used to 
normalize the target probes. Both Spike-In solutions (Spike A Mix labelled with Cy3; Spike B 
Mix labelled with Cy5) were prepared as described below. 
 
Table 70. Dilutions of Spike A and Spike B Mix. 
 
Starting amount of 
RNA 
Serial dilution 
Spike-In mix volume 
used in labelling reaction 
(µl) Total RNA (ng) First Second Third 
100 1:20 1:40 1:32 2 
 
 
Total RNA
cDNA synthesis
cRNA synthesis and 
amplification
cRNA purification
Preparation of 
hybridization sample
17 h Hybridization     
(65 °C)
Wash
Scan
Feature extraction
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The following description of the applied experimental procedure pertains for both Spike-In 
mixes. The first dilution was created by mixing the stock solution (Spike A / Spike B Mix) 
and transferring 2 µl in a 1.5 ml microtube containing 38 µl of provided Dilution Buffer. 
Then, the first dilution was mixed thoroughly and spinned down. Afterwards, the second 
dilution was prepared pipetting 2 µl of the first dilution into another 1.5 ml microtube 
containing 75 µl of Dilution Buffer. The second dilution was mixed by vortexing and spinned 
down. Then, the third and final dilution was carried out using 2 µl of second dilution and 62 
µl of Dilution Buffer in another 1.5 ml microtube. The third dilution was thoroughly vortexted 
and centrifuged.  
 
Step 2: Preparing labelling reaction 
 
All samples were diluted with nuclease-free water so that the starting amount of RNA for 
each sample was 100 ng in 1.5 µl. These 1.5 µl were transferred into a 1.5 ml microtube and  
2 µl of Spike A mix (cyanine 3-labelled) or respectively Spike B mix (cyanine 5-labelled) was 
added. The T7 Promotor Primer Mix was prepared (Table 71) and 1.8 µl were additionally 
transferred into the tube. Denaturation of primer and template was carried out by incubating 
the reaction mix at 65 °C in a thermomixer (Eppendorf) for 10 min. The reaction mix was 
placed on ice and incubated for 5 min. Then, samples were centrifuged at 10 000 rpm for 30 s 
at 4 °C and again placed on ice. Subsequently, 4.7 µl of the cDNA Master Mix (Table 72) was 
added to each reaction solution mix and thoroughly mixed by repeated up- and down-
pipetting. Thereafter, samples were incubated at 40 °C in a thermomixer for 2 h. During this 
step, RNA samples were transcribed into cDNA which is equipped with a T7 RNA 
polymerase promoter sequence. 
 
Table 71. T7 Promoter Primer Mix. 
 
Component Volume (µl) per reaction 
T7 Promoter Primer 0.8  
Nuclease-free water 1.0 
Total volume 1.8 
 
Table 72. cDNA Master Mix. 
 
Component Volume (µl) per reaction 
First Strand Buffer (5X) 2.0 
DDT (0.1 M) 1.0 
dNTP mix (10 mM) 0.5 
AffinityScript RNase Block Mix 1.2 
Total volume 4.7 
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Then, samples were immediately incubated at 70 °C in a thermomixer (Eppendorf) for 15 min 
to inactivate the AffinityScript enzymes. After that, samples were placed on ice for 5 min and 
briefly centrifuged (30 s, 10000 rpm, 4 °C) to spin down any contents from the walls and lid 
of the tube. The Transcription Master Mix was prepared (Table 73) and 6 µl was added to 
each sample. The sample reaction mixture was blended by up- and down-pipetting and 
incubated for another 2 h at 40 °C in a thermomixer (Eppendorf). 
 
Table 73. Transcription Master Mix. 
 
Component Volume (µl) per reaction 
Nuclease-free water 0.75 
Transcription Buffer (5X) 3.2 
DTT (0.1 M) 0.6 
NTP mix 1.0 
T7 Polymerase Blend 0.21 
Cyanine 3-CTP or cyanine 5-CTP 0.24 
Total volume 6.0 
 
Figure 69 summarizes the amplified cRNA procedure. With the aid of the T7 RNA 
polymerase cDNA is transcribed into cRNA which is subsequently amplified. Furthermore, 
the T7 RNA polymerase also incorporates cyanine 3- or cyanine 5-labelled CTP. In the 
following, cRNA samples were placed on ice for 5 min and were briefly centrifuged before 
starting purification procedure. 
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Figure 69. Generated and amplified cRNA procedure (Agilent Technologies, 2010). 
 
Step 3: Purification of labelled/amplified cRNA 
 
The purification step was carried out using the RNeasy Mini Kit (Qiagen). 84 µl of nuclease-
free water and 350 µl of Buffer RLT were added to each cRNA sample and mixed well by 
pipetting. Following this, 250 µl of ethanol (100 %) were added and mixed thoroughly by 
repeated up- and down-pipetting. The entire cRNA-ethanol sample (700 µl) was then 
transferred into an RNeasy Mini column which was then centrifuged at 4 °C for 30 s at    
13000 rpm. The generated and amplified cRNA was bound to the membrane during this step. 
Subsequently, the bound cRNA was washed using 500 µl of Buffer RPE and centrifuged at     
4 °C for 30 s at 13000 rpm.  
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This step was repeated once again, but the centrifugation time was enhanced to 1 min to 
remove any remaining traces of Buffer RPE. The column was then transferred into another 
1.5 ml tube and 30 µl of nuclease-free water were directly added onto the filter membrane. 
After a delay of 1 min, purified cRNA was eluted by centrifugation (4 °C, 30 s, 13000 rpm). 
Upon elution, the cleaned cRNA was placed on ice.  
 
Step 4: Quantification of cRNA 
 
Purified cRNA was quantified by NanoDrop 1000 using the Microarray measurements which 
records:  
- Cyanine 3 or cyanine 5 dye concentrations (pmol/µl) 
- RNA absorbance (260 nm/280 nm) 
- cRNA concentration (ng/µl) 
 
The yield of cRNA was calculated as follows: 
 
concentration of cRNA × 30 µl (elution volume)
1000
= µg of cRNA 
 
The specific activity was determined using the subsequent equation: 
 
 concentration of Cy3 or Cy5
concentration of cRNA
× 1000 = pmol Cy3 or Cy5 per µg cRNA 
 
The yield should be > 0.825 µg and the specific activity > 6 pmol Cy3 or Cy5 per µg cRNA. 
These values depend on the chosen microarray format (4-pack) and are recommended to 
proceed to the hybridization step (Agilent Technologies, 2010). 
 
Step 5: Preparation for hybridization 
 
Hybridization of the fluorescence-labelled purified cRNA was performed using Agilent`s 
Gene Expression Hybridization Kit (Agilent Technolgies, 2010). 
First, the lyophilized 10x Blocking Agent was dissolved in 500 µl nuclease-free water, 
vortexted, and incubated for 5 min at 37 °C in a thermomixer (Eppendorf). Afterwards, any 
material adhering was driven down by centrifugation for 10 s.  
In the present work, the 4 x 44K microarray format was chosen. The fragmentation mix was 
prepared according to Table 74. As described before, compound-treated samples and 
respective control samples were labelled with cyanine fluorophores complementary and were 
at this point of the experiment combined and together hybridized. The unified samples were 
incubated at 60 °C for exactly 30 min in a thermomixer (Eppendorf) to fragmentate RNA. 
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Afterwards, samples were immediately placed on ice for 1 min before 55 µl of 2x              
GEx Hybridization Buffer HI-RPM were added. The hybridization mix was carefully mixed 
by up- and down-pipetting avoiding the formation of bubbles. Then, the mix was centrifuged 
for 1 min at room temperature at 13000 rpm and samples were immediately loaded onto the 
array. 
 
Table 74. Fragmentation mix for 4-pack microarray format. 
 
Component Volume/Mass 
Cyanine 3-labelled, linearly amplified cRNA 825 µg 
Cyanine 5-labelled, linearlyamplified cRNA 825 µg 
Blocking Agent (10x) 11 µl 
Nuclease-free water Bring volume to 52.8 
Fragmentation Buffer (25x) 2.2 µl 
Total volume 55 µl 
 
A hybridization gasket slide was inserted into the chamber base with the label reading 
'Agilent' facing up. The hybridization sample was slowly dispensed onto the middle of the 
gasket well. This procedure was repeated for the other three wells noting the position of each 
sample on the gasket slide. Then, the microarray slide was slowly and gently placed on the 
gasket slide, so that the numeric barcode side was facing up. The chamber cover is placed 
onto the chamber base containing the 'sandwiched' slides. The clamp assembly was carefully 
slipped onto the chamber base and the cover resting at the centre of both and was finally 
tightened. The assembled chamber was rotated to check if the hybridization samples coat the 
entire surface of the array. Afterwards, the chambers were placed in rotisserie in a 
hybridization oven preheated at 65 °C and rotated at 10 rpm. Hybridization was carried out 
for 17 h.   
 
Step 6: Microarray slide wash 
 
After 17 h, the chamber was dissembled and the slide sandwich was carefully submerged into 
a slide-staining dish containing Wash Buffer 1. The sandwich was pried open from the 
barcode end using tweezers. The microarray slide is then placed into a slide-staining dish 
containing Wash Buffer 1 at room temperature for 1 min. Then, the slide was transferred in a 
slide-staining dish containing preheated (37 °C) Wash Buffer 2 at room temperature for 
another minute. Slowly the microarray slide was removed from the rack to avoid droplets on 
the slide. Slides were immediately put into a slide holder facing Agilent barcode up and were 
directly inserted in the scanner carousel. This procedure was repeated for each microarray 
slide.  
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Step 7: Scanning and feature extraction 
 
The microarray slides were immediately scanned after the washing procedure using the 
Agilent B Microarray scanner (Agilent Technologies). After completing the scan process, the 
user obtains the microarray image scan which was is used for data evaluation. Data was 
extracted using Agilent Feature Extraction Software (version 9.5.1). Information from probe 
features was extracted from microarray scan data.  
 
VI.3.7.2 Microarray Data Analysis and Processing 
 
Agilent Technologies Scanner System (Scanner Model G2505B) with Agilent Scan Control 
Software Version A.7.0.1 was used for microarray scanning. Preliminary processing of data 
was made using the Agilent Feature Extraction Software (9.5.1.1, Agilent Technologies). 
Data normalisation and statistical analyses were performed using Bioconductor (Gentleman 
2004) R (version 2.15.1) package limma (version 3.12.3) (Smyth et al., 2004). Raw signals 
were background corrected by subtracting local spot background. Two normalization methods 
were applied: first within arrays using the global loess method and second between the arrays 
using the Aquantile method. Differential expression was assessed using empirical Bayes 
moderated t-tests carried out in limma (Smyth et al., 2005) on the dataset. Cut-off criteria for 
further functional analysis were log2 fold change (lfc) ≥ 2, p-values ≤ 0.05 corrected by false 
discovery rate (FDR) using the Benjamini-Hochberg method (Benjamini et al., 1995) and an 
A-mean value ≥ 7 (in case of hHeps vs. HepG2 cells A ≥ 5). The clipped list was subjected to 
Gene Ontology (GO) analysis using the TopGO (version 2.8.0) package in R (Alexa et al., 
2006). Classical enrichment analysis by testing the over-representation of GO terms within 
the group of differentially expressed genes was performed using Fisher's exact test. 
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VI.4 Statistical Analysis 
 
In the present work statistical analysis of the obtained data was performed using GraphPad 
InStat 3.0 software (GraphPad Software, San Diego, CA, USA). Results are presented as 
means ± standard deviation (SD) from at least three independent experiments. One-way 
ANOVA (analysis of variance) with Dunnett`s post test was used when the difference 
between the control and various concentration of a test compound was determined 
(concentration-dependent measurements). The difference between the control and treatment 
(one test compound concentration) or between different compound treatments was determined 
using the one-tailed unpaired Student`s t-test with Welch correction. Significant effects are 
assigned in the present work with asterisks: * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
Concentration-response curves from at least three independent experiments were obtained 
using Origin 6.0 Microcal software (OriginLab, Northampton, MA, USA). Plotting the used 
concentrations in a logarithmic scale against the assay-specific parameters (EROD: EROD 
activity; RT-PCR: x-fold), EC50 values were subsequently derived by sigmoidal fitting. For 
EC20 values the upper limit of the respective TCDD-derived induction was set 100 % and the 
test compound concentrations required to achieve 20 % of the TCDD response were defined 
as EC20.  
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VII Materials 
 
VII.1 Test Compounds 
 
Test compounds used in in vivo mouse studies I and II and in vitro experiments are 
summarized in Tables 75 and 76. The purities of PCB 118, 153, and 156 were analyzed. 
Subsequently, PCB 118 and 156 were purified at the Department of Chemistry at Umeå 
University, Sweden. The final TEQ contributions of impurities after purification were 6.6 ng 
TEQ/g, 0.41 ng TEQ/g, and 36 ng TEQ/g for PCB 118, PCB 153, and PCB 156, respectively. 
These impurity values were considered to have no influence on the final outcome of the 
results (van Ede et al., 2013). The seven selected core congeners applied in mouse in vivo 
studies I and II were dissolved in corn oil and administered by oral gavage. All other 
compounds had a purity > 99 % except for 1,4,6-HpCDD (98.7 %). Compounds used in in 
vitro studies were dissolved in DMSO (dried, obtained from Sigma-Aldrich, Stockholm, 
Sweden). Prepared compound stock solutions were diluted with DMSO depending on 
compound, cell model, and assay-specific concentration range. 
 
Table 75. List of compounds applied in in vivo studies (mouse study I and II). 
Annotations: a) Wellington Laboratories Inc. (Guelph, Ontario, Canada)  
                       b) Cerilliant Corp. (Round Rock, TX, USA) 
 
Compound Chlorination position and degree Type of congener Purchased from 
TCDD 2,3,7,8-TetraCDD PCDD a) 
1-PnCDD 1,2,3,7,8-PentaCDD PCDD a) 
4-PnCDF 2,3,4,7,8-PentaCDF PCDF a) 
PCB 118 2,3',4,4',5-PentaCB Dioxin-like PCB b) 
PCB 126 3,3',4,4',5-PentaCB Dioxin-like PCB a) 
PCB 153 2,2',4,4',5,5'-HexaCB Non dioxin-like PCB b) 
PCB 156 2,3,3',4,4',5-HexaCB Dioxin-like PCB b) 
 
TCDD used in the transgenic mouse study (mouse study III) was purchased from 
AccuStandard (New Haven, CT, USA) dissolved in corn oil and administered by oral gavage. 
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Table 76. List of compounds applied in in vitro studies. 
Annotations: a) Wellington Laboratories Inc. (Guelph, Ontario, Canada)  
                       b) Cerilliant Corp. (Round Rock, TX, USA) 
                       c) Larodan Fine Chemicals (Malmö, Sweden) 
 
Compound Chlorination position and degree  Type of congener Purchased from 
TCDD 2,3,7,8-TetraCDD PCDD a) 
1-PnCDD 1,2,3,7,8-PentaCDD PCDD a) 
1,6-HxCDD 1,2,3,6,7,8-HexaCDD PCDD a) 
1,4,6-HpCDD 1,2,3,4,6,7,8-HeptaCDD PCDD a) 
TCDF 2,3,7,8-TetraPCDF PCDF a) 
4-PnCDF 2,3,4,7,8-PentaCDF PCDF a) 
1,4-HxCDF 1,2,3,4,7,8-HexaCDF PCDF a) 
1,4,6-HpCDF 1,2,3,4,6,7,8-HeptaCDF PCDF a) 
PCB 77 3,3',4,4'-TetraCB Dioxin-like PCB c) 
PCB 105 2,3,3',4,4'-PentaCB Dioxin-like PCB c) 
PCB 118 2,3',4,4',5-PentaCB Dioxin-like PCB b) 
PCB 126 3,3',4,4',5-PentaCB Dioxin-like PCB a) 
PCB 153 2,2',4,4',5,5'-HexaCB Non dioxin-like PCB b) 
PCB 156 2,3,3',4,4',5-HexaCB Dioxin-like PCB b) 
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VII.2 Chemicals, Cell Cultures, Kits, Consumables, and  
          Equipment 
 
VII.2.1 Cell Cultures 
 
The human hepatocellular carcinoma cell line HepG2 was purchased from DSMZ (Deutsche 
Sammlung von Mikroorganismen and Zellkulturen GmbH), Heidelberg, Germany. 
Primary human hepatocytes as well as culture media and supplements were purchased from 
Lonza, Verviers, Belgium. 
 
VII.2.2 Chemicals 
 
All chemicals applied in the present work are summarized in the following list: 
 
Table 77. List of chemicals/reagents in alphabetical order. 
 
Chemical Manufacturer, Purchaser  
Accutase PAA Laboratories GmbH, Coelbe, Germany 
Acetonitrile (HPLC grade) Merck, Darmstadt, Germany 
Acrylamide-Mix (rotiphorese 30) Roth, Karlsruhe, Germany 
APS Merck, Darmstadt, Germany 
Bromophenol blue Merck, Darmstadt, Germany 
Copper sulphate Merck, Darmstadt, Germany 
DCC/FCS PAA Laboratories GmbH, Coelbe, Germany 
Dexamethasone Sigma-Aldrich, Schnelldorf, Germany 
Dicumarol Sigma-Aldrich, Schnelldorf, Germany 
DMSO Fluka, Neu-Ulm, Germany 
Disodium carbonate Merck, Darmstadt, Germany 
Disodium EDTA Roth, Karlsruhe, Germany 
Disodium hydrogen phosphate Merck, Darmstadt, Germany 
DMEM low glucose w/o phenol red PAA Laboratories GmbH, Coelbe, Germany 
DMF Merck, Darmstadt, Germany 
EDTA Merck, Darmstadt, Germany 
EGTA Sigma-Aldrich, Schnelldorf, Germany 
Ethanol p.a.  Merck, Darmstadt, Germany 
Ethidium bromide solution (10 mg/ml) Sigma-Adrich, Schnelldorf, Germany 
Ethoxyresorufin  Sigma-Aldrich, Schnelldorf, Germany 
FCS Gold Standard PAA Laboratories GmbH, Coelbe, Germany 
Glucose Merck, Darmstadt, Germany 
Glycine  Sigma-Aldrich, Schnelldorf, Germany 
Heparin Serva, Heidelberg, Germany 
HEPES Roth, Karlsruhe, Germany 
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Hydrogen peroxide solution (30 %) Applichem, Darmstadt, Germany 
Isopropanol  Merck, Darmstadt, Germany 
Luminol Sigma-Aldrich, Schnelldorf, Germany 
Magnesium chloride Merck, Darmstadt, Germany 
Magnesium sulphate Merck, Darmstadt, Germany 
Mercaptoethanol Merck, Darmstadt, Germany 
Methanol (HLPC-grade) Merck, Darmstadt, Germany 
p-coumaric acid Sigma-Aldrich, Schnelldorf, Germany 
Penicilin/Streptomycin  PAA Laboratories GmbH, Coelbe, Germany 
Pentobarbital  Sigma-Aldrich, Schnelldorf, Germany 
Potassium chloride  Merck, Darmstadt, Germany 
Potassium dihydrogen phosphate  Merck, Darmstadt, Germany 
Potassium hydrogen phosphate  Merck, Darmstadt, Germany 
Potassium phosphate Merck, Darmstadt, Germany 
Primer MWG-Biotech AG, Ebersberg, Germany 
Resorufin sodium salt Sigma-Aldrich, Schnelldorf, Germany 
Saponine Sigma-Adrich, Schnelldorf, Germany 
SDS Merck, Darmstadt, Germany 
Skimmed milk powder Spinnrad GmbH, Gelsenkirchen, Germany 
Sucrose Merck, Darmstadt, Germany 
Sodium chloride Merck, Darmstadt, Germany 
Sodium hydrogen phospate  Merck, Darmstadt, Germany 
Sodium hydroxide  Merck, Darmstadt, Germany 
TEMED Serva, Heidelberg, Germany 
Tris Roth, Karlsruhe, Germany 
Trypsin/EDTA(1:250)-solution PAA Laboratories GmbH, Coelbe, Germany 
Tween 20 Sigma-Aldrich, Schnelldorf, Germany 
 
VII.2.3 Kits 
 
All used kits in the present work are summarized in the following list: 
 
Table 78. List of kits in alphabetical order. 
 
Kit Manufacturer, distributor 
E. Z. N. A.® Tissue DNA Kit (Omega Bio-Tek) VWR International GmbH, Darmstadt,Germany 
RNeasy® Mini Kit Bio-Rad Laboratories GmbH, Munich, Germany 
BCATM Protein Assay Kit (Pierce) Thermo Fisher Scientific, Karlsruhe, Germany 
iScript cDNA synthesis Kit Bio-Rad Laboratories GmbH, Munich, Germany 
ABsolute QPCR SYBR Green Fluorescein Mix Thermo Fisher Scientific, Karlsruhe, Germany 
Low Input Quick Amp Labeling Kit, Two-Color Agilent Technologies, Waldbronn, Germany 
RNA Spike-In Kit Agilent Technologies, Waldbronn, Germany 
Gene Expression Hybridization Kit Agilent Technologies, Waldbronn, Germany 
Gene Expression Wash Buffer Kit Agilent Technologies, Waldbronn, Germany 
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VII.2.4 Consumables 
 
All consumables utilized in the present work are summarized in the following list: 
 
Table 79. List of consumables in alphabetical order. 
 
Consumables Manufacturer, distributor 
Combitips (5 ml, 10 ml, 25 ml, Eppendorf Biopur) VWR International GmbH, Darmstadt,Germany 
Filter (0.2 & 0.45 µm PTFE) Roth, Karlsruhe, Germany 
Mikro reaction tubes (1.5 ml & 2 ml, PP) Greiner Bio-one GmbH, Frickenhausen, Germany 
Multiwell plates (6, 24 & 96 well, PP) Greiner Bio-one GmbH, Frickenhausen, Germany 
Pasteur pipettes (glass) Roth, Karlsruhe, Germany 
Petri dishes (94mm & 60mm) Greiner Bio-one GmbH, Frickenhausen, Germany 
Pipette tips (various sizes) Greiner Bio-one GmbH, Frickenhausen, Germany 
PCR tips (with filter; various sizes) Peqlab Biotechnology GmbH, Erlangen, Germany 
Needles single-use Sterican (26 G x 1) B׀Braun, Melsungen, Germany 
Sample tubes (15ml, 50ml, PP) Greiner Bio-one GmbH, Frickenhausen, Germany 
Syringes Omnifix®-F (1 ml) B׀Braun, Melsungen, Germany 
Cell culture flasks (250 ml, PP) Greiner Bio-one GmbH, Frickenhausen, Germany 
 
 
VII.2.5 Equipment 
 
The following table summarizes the equipment used in the present work: 
 
Table 80. List of applied equipment in alphabetical order. 
 
Equipment Manufacturer, distributor 
Autoklaves 
          Varioklav Typ 500  
          UNOLD, Electro 
 
H&P Labortechnik, Munich, Germany 
UNOLD, Hockenheim, Germany  
Bioanalyzer Agilent Technologies, Waldbronn, Germany 
Biofreezer MDF-U6086S Sanyo E&E Europe BV, AZ Etten Leur, NL 
Camera (EOS 300 Canon) Canon, Krefeld, Germany 
Centrifuges 
          Megafuge 1.0 R 
          Microfuge R 
          Rotina 35 
          Sigma 1-13 
          Sigma 1 L-12 
          Ultracentrifuge Optima TL 
 
Heraeus, Hanau, Germany 
Beckman Coulter, Krefeld, Germany 
Hettich GmbH & Co. KG, Tuttlingen, Germany 
Sigma Laboratory centrifuges GmbH, Osterode, Germany 
Sigma Laboratory centrifuges GmbH, Osterode, Germany 
Beckman Coulter, Krefeld, Germany 
Cleanbenchs 
          BSB 4A 
          Hera Safe 
 
Gelaire Flow Laboratories, Meckenheim, Germany 
Hereus, Hanau, Germany 
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Eagle Eye II Cabinet Stratagene, Amsterdam, NL 
Electrophoresis chamber  
Mini Protean III Apparatus 
Bio-Rad Laboratories GmbH, Munich, Germany 
Electrophoresis power supply  
Bio-Rad Power Pac 300 
Bio-Rad Laboratories GmbH, Munich, Germany 
Glassware (beakers, graduated pipettes & 
measuring  cylinders, screw top bottles) 
VWR International GmbH, Darmstadt, Germany 
Hand tally counter Roth, Karlsruhe, Germany 
HPLC-ESI-MS/MS  
          Massenspektrometer API 2000  
          PerkinElmer Series 2000 
          PerkinElmer Ultraviolet detector 785 A 
 
AB Sciex, Darmstadt, Germany 
PerkinElmer, Rodgau, Germany 
PerkinElmer, Rodgau, Germany 
HPLC column   
          LiChrospher® 100 RP-18  
          (125mm x 4mm, 5 µm), Merck 
 
VWR International GmbH, Darmstadt, Germany 
HPLC guard column  
          LiChrospher® 100 RP-18 (5 µm)  
          LiChroCART® 4-4, Merck  
 
VWR International GmbH, Darmstadt, Germany 
HPLC cartridge holder  
          manu-Cart® NT, Merck 
 
VWR International GmbH, Darmstadt, Germany 
Homogenizer ultrasonic needle B׀Braun, Melsungen, Germany 
Incubators  
          BBD6220 Heraeus 
          Cytosperm 
 
Heraeus, Hanau, Germany 
Heraeus, Hanau, Germany 
Light microscopes 
          Axiovert 25 
          Axioskop 
          Zeiss IM 
          Leica DM IRB 
 
Zeiss, Jena, Germany 
Zeiss, Jena, Germany 
Zeiss, Jena, Germany 
Leica, Bonn, Germany 
Lumi Imager  Roche, Mannheim, Germany 
Luminometer Lumat LB 9507 Berthold, Bad Wildbad, Germany 
Magnetic stirrer MR 3001 Heidolph Elektro, Kelheim, Germany 
Microarray scanner B G2505 Agilent Technologies, Waldbronn, Germany 
Multipette ® (Research plus, Eppendorf)  VWR International GmbH, Darmstadt, Germany 
NanoDrop®(ND-1000 Spectrophotometer) Peqlab, Erlangen, Germany 
Neubauer Counting Chamber  Roth, Karlsruhe, Germany 
pH meter  Eutech Instruments Europe B.V. AG Nijkerk, NL 
Pipettes  
          Eppendorf Research 
          Pipetman Gilson 
 
VWR International GmbH, Darmstadt, Germany 
VWR International GmbH, Darmstadt, Germany 
          Pipetus® accu-jet pro Brand GmbH & Co KG, Wertheim, Germany 
Plate readers 
          Fluoroskan Ascent FL 
          MWGt Sirius HT Injector 
 
Labsystems, Dreieich, Germany 
BioTek Instruments Inc., Winooski, VT, USA 
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Refrigerators and freezer combinations Liebherr, Karlsruhe, Germany 
Phillips, Herrsching, Germany 
Scales 
          Sartorius BP 210 S 
          Sartorius CP64-OCE 
          Sartorius CPA 2245 
OHAUS Precision Standard 
 
Sartorius AG, Goettingen, Germany 
Sartorius AG, Goettingen, Germany 
Sartorius AG, Goettingen, Germany 
OHAUS, Bradford, MA, USA 
Semi-dry blotter TE 77 Hoever Inc., San Francisco, CA, USA 
Shaker PMS-1000 Grant-bio Ltd., Cambridgeshire, UK 
Thermomixer comfort Eppendorf AG, Hamburg, Germany 
Thermal cyclers 
          MyCyclerTM 
          iCyclerTM 
 
Bio-Rad Laboratories GmbH, Munich, Germany 
Bio-Rad Laboratories GmbH, Munich, Germany 
Ultrasonic probe Sonoplus Bandelin electronics GmbH & Co. KG, Berlin, Germany 
Vortex Relax 2000 Heidolph, Frankfurt/Main, Germany 
Water baths  
          GFL 1083 
          Julabo 13 
 
GFL, Burgwedel, Germany 
Julabo, Seelbach, Germany 
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IX Appendices 
 
IX.1 Supplemental Data Microarrays  
 
Following tables display the significantly up and down regulated genes identified by 
microarray analysis as a result of compound treatment. Each table features the gene name, 
systematic name, and the official gene description. Furthermore, the specific probe name, 
corresponding colour intensity value (A-value), logarithmic fold-change (log2 fc value), and 
the p-value are additionally featured for each significantly altered gene.  
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Table 81. All significantly up regulated genes in livers of female C57BL/6 mice by TCDD (25 µg/kg bw) identified by microarray analysis - mouse 3-day study. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
10.23 9.478 0 A_51_P279693 Cyp1a1 NM_009992 ref|Mus musculus cytochrome P450 family 1 subfamily a polypeptide 1 transcript variant 1 mRNA  
7.16 5.169 0 A_51_P255456 Cyp1b1 NM_009994 ref|Mus musculus cytochrome P450 family 1 subfamily b polypeptide 1 mRNA  
13.33 3.985 0 A_52_P595871 Cyp1a2 NM_009993 ref|Mus musculus cytochrome P450 family 1 subfamily a polypeptide 2 mRNA 
7.97 3.582 0 A_55_P2032714 Fhit NM_010210 ref|Mus musculus fragile histidine triad gene mRNA  
9.92 3.379 0 A_66_P119518 Tuba8 NM_017379 ref|Mus musculus tubulin alpha 8 mRNA  
11.31 3.103 0 A_51_P299805 Slc46a3 NM_027872 ref|Mus musculus solute carrier family 46 member 3 mRNA  
7.10 2.903 0 A_55_P1985890 Tiparp NM_178892 ref|Mus musculus TCDD-inducible poly(ADP-ribose) polymerase mRNA  
9.36 2.819 0 A_55_P2032946 Gsta1 NM_008181 ref|Mus musculus glutathione S-transferase alpha 1 (Ya) mRNA  
9.22 2.722 0 A_55_P2004099 Gm9933 XM_001477458 ref|PREDICTED: Mus musculus predicted gene ENSMUSG00000054044 mRNA  
8.86 2.678 0 A_52_P515036 Htatip2 NM_016865 ref|Mus musculus HIV-1 tat interactive protein 2 homolog (human) transcript variant 1 mRNA  
10.50 2.518 0 A_55_P1983754 Pcp4l1 NM_025557 ref|Mus musculus Purkinje cell protein 4-like 1 mRNA  
9.26 2.386 0 A_55_P1972720 Pmm1 NM_013872 ref|Mus musculus phosphomannomutase 1 mRNA  
8.41 2.153 0 A_52_P183524 Tmem86b NM_023440 ref|Mus musculus transmembrane protein 86B mRNA  
7.94 2.123 0 A_51_P357561 Fbxw9 NM_026791 ref|Mus musculus F-box and WD-40 domain protein 9 mRNA  
7.17 1.978 3.00E-05 A_51_P378622 0610012H03Rik NM_028747 ref|Mus musculus RIKEN cDNA 0610012H03 gene transcript variant 1 mRNA  
11.29 1.931 0 A_55_P2178036 Serpina6 NM_007618 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A member 6 mRNA  
11.84 1.857 0 A_55_P2031668 Gstp1 NM_013541 ref|Mus musculus glutathione S-transferase pi 1 mRNA  
10.80 1.853 1.00E-05 A_55_P2102065 Gm10639 NM_001122660 ref|Mus musculus predicted gene 10639 mRNA  
8.56 1.762 0 A_55_P2059931 Prom1 NM_001163577 ref|Mus musculus prominin 1 transcript variant 2 mRNA  
7.22 1.758 0.00048 A_51_P375146 Cd36 NM_007643 ref|Mus musculus CD36 antigen transcript variant 2 mRNA  
7.17 1.702 0 A_51_P480073 Chad NM_007689 ref|Mus musculus chondroadherin mRNA  
9.85 1.696 0 A_55_P2124712 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA  
9.68 1.694 0.00083 A_55_P1989248 Gm6168 XM_885022 ref|PREDICTED: Mus musculus predicted gene EG620627 mRNA  
8.13 1.653 0 A_55_P2063312 Mgll NM_001166250 ref|Mus musculus monoglyceride lipase transcript variant 4 mRNA  
7.80 1.652 1.00E-05 A_51_P511176 Triap1 NM_026933 ref|Mus musculus TP53 regulated inhibitor of apoptosis 1 mRNA  
8.99 1.650 0 A_52_P318361 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA  
9.38 1.630 0 A_52_P627269 BC015286 NM_198171 ref|Mus musculus cDNA sequence BC015286 mRNA  
7.71 1.621 0 A_55_P1984675 Abhd6 NM_025341 ref|Mus musculus abhydrolase domain containing 6 mRNA  
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9.59 1.602 0 A_51_P411271 Nfe2l2 NM_010902 ref|Mus musculus nuclear factor erythroid derived 2 like 2 mRNA  
8.41 1.597 0 A_55_P2143765 Ugt1a6a NM_145079 ref|Mus musculus UDP glucuronosyltransferase 1 family polypeptide A6A mRNA  
8.13 1.584 0 A_55_P2178800 Ugt1a10 NM_201641 ref|Mus musculus UDP glycosyltransferase 1 family polypeptide A10 mRNA  
9.22 1.565 0 A_51_P471458 Sult5a1 NM_020564 ref|Mus musculus sulfotransferase family 5A member 1 mRNA  
12.91 1.559 0 A_55_P2008704 Gstp2 NM_181796 ref|Mus musculus glutathione S-transferase pi 2 mRNA 
9.18 1.528 0 A_55_P2066727 Serpinb6a NM_001164118 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 6a transcript variant 3 mRNA  
9.48 1.520 0 A_52_P327156 0610008F07Rik NR_027970 ref|Mus musculus RIKEN cDNA 0610008F07 gene non-coding RNA  
7.62 1.502 0 A_55_P2013038 Serpinb6c NM_148942 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 6c mRNA  
10.43 1.499 0 A_51_P181319 Dcxr NM_026428 ref|Mus musculus dicarbonyl L-xylulose reductase mRNA  
8.74 1.497 0.00084 A_51_P326685 Lrtm1 NM_176920 ref|Mus musculus leucine-rich repeats and transmembrane domains 1 mRNA  
12.41 1.481 2.00E-05 A_51_P269404 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
8.78 1.452 0 A_55_P1966438 Gstm2 NM_008183 ref|Mus musculus glutathione S-transferase mu 2 mRNA  
14.49 1.441 0 A_55_P1961014 Selenbp1 NM_009150 ref|Mus musculus selenium binding protein 1 mRNA  
9.34 1.43 0 A_51_P418526 Sfxn1 NM_027324 ref|Mus musculus sideroflexin 1 mRNA  
7.97 1.423 5.00E-05 A_55_P2060107 Pkm2 NM_011099 ref|Mus musculus pyruvate kinase muscle mRNA  
11.34 1.414 0 A_51_P441914 Hsd17b2 NM_008290 ref|Mus musculus hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
9.71 1.407 0 A_55_P2077628 ENSMUST00000106148 ENSMUST00000106148 ens|L-xylulose reductase (XR)(EC 1.1.1.10)(Dicarbonyl/L-xylulose reductase) [Source:UniProtKB/Swiss-
Prot;Acc:Q91X52]  
8.68 1.394 0 A_51_P163578 Ugt2b35 NM_172881 ref|Mus musculus UDP glucuronosyltransferase 2 family polypeptide B35 mRNA  
11.23 1.391 0 A_55_P2006236 Ugdh NM_009466 ref|Mus musculus UDP-glucose dehydrogenase mRNA  
8.87 1.391 0 A_55_P2047768 Serpinb6c NM_148942 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 6c mRNA  
8.48 1.382 3.00E-05 A_55_P2030524 Vldlr NM_013703 ref|Mus musculus very low density lipoprotein receptor transcript variant 1 mRNA  
7.60 1.374 0 A_55_P2108151 ENSMUST00000023934 ENSMUST00000023934 ens|Hemoglobin subunit beta-1 (Hemoglobin beta-1 chain)(Beta-1-globin)(Hemoglobin beta-major chain) 
[Source:UniProtKB/Swiss-Prot;Acc:P02088] 
10.70 1.371 0.00145 A_55_P2038358 Acot1 NM_012006 ref|Mus musculus acyl-CoA thioesterase 1 mRNA  
9.32 1.366 0 A_52_P154580 Cyp2c54 NM_206537 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 54 mRNA  
12.65 1.362 0 A_51_P374464 Gstp1 NM_013541 ref|Mus musculus glutathione S-transferase pi 1 mRNA  
8.64 1.328 0 A_55_P1971093 NAP096516-001 NAP096516-001 Unknown 
10.18 1.316 0 A_51_P329441 Bsg NM_009768 ref|Mus musculus basigin (Bsg) transcript variant 1 mRNA  
8.92 1.309 0.00027 A_55_P2059323 Gm13315 NR_028497 ref|Mus musculus predicted gene 13315 non-coding RNA  
11.10 1.297 0.00034 A_55_P2170454 Gsta2 NM_008182 ref|Mus musculus glutathione S-transferase alpha 2 (Yc2) mRNA  
7.90 1.290 1.00E-05 A_51_P316951 Wipf3 NM_001167860 ref|Mus musculus WAS/WASL interacting protein family member 3 transcript variant 1 mRNA  
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8.20 1.286 0 A_55_P2055742 9530008L14Rik NM_001145875 ref|Mus musculus RIKEN cDNA 9530008L14 gene transcript variant 2 mRNA  
7.63 1.282 0 A_55_P2095035 Gm1833 XM_129965 ref|PREDICTED: Mus musculus gene model 1833 (NCBI) mRNA  
7.89 1.273 1.00E-05 A_55_P2037689 A_55_P2037689 A_55_P2037689 Unknown 
9.62 1.264 0 A_51_P468329 Psmb7 NM_011187 ref|Mus musculus proteasome (prosome macropain) subunit beta type 7 mRNA  
10.75 1.259 0 A_52_P282905 Gm5158 NM_001081372 ref|Mus musculus predicted gene 5158 mRNA  
9.51 1.247 0 A_51_P458778 Hpgd NM_008278 ref|Mus musculus hydroxyprostaglandin dehydrogenase 15 (NAD) mRNA  
11.37 1.244 2.00E-05 A_55_P1959923 Cth NM_145953 ref|Mus musculus cystathionase (cystathionine gamma-lyase) mRNA  
7.53 1.244 0 A_55_P2114498 Gm8801 NR_028278 ref|Mus musculus predicted gene 8801 non-coding RNA  
9.47 1.241 0 A_55_P1995447 A_55_P1995447 A_55_P1995447 Unknown 
7.60 1.235 0.00039 A_55_P2012439 Tnfrsf19 NM_013869 ref|Mus musculus tumor necrosis factor receptor superfamily member 19 transcript variant 1 mRNA  
7.59 1.229 0 A_51_P406557 AI464131 NM_001085515 ref|Mus musculus expressed sequence AI464131 mRNA  
11.98 1.229 0 A_51_P255682 Mfge8 NM_008594 ref|Mus musculus milk fat globule-EGF factor 8 protein transcript variant 1 
 mRNA  
7.97 1.211 1.00E-05 A_55_P2029366 Abhd6 NM_025341 ref|Mus musculus abhydrolase domain containing 6 mRNA  
8.30 1.209 1.00E-05 A_55_P2035424 Hpgd NM_008278 ref|Mus musculus hydroxyprostaglandin dehydrogenase 15 (NAD) mRNA  
9.26 1.207 1.00E-05 A_55_P2118810 A_55_P2118810 A_55_P2118810 Unknown 
7.62 1.206 0 A_55_P2051796 Gm128 NM_001024841 ref|Mus musculus predicted gene 128 mRNA  
8.74 1.198 0 A_51_P459350 Dstn NM_019771 ref|Mus musculus destrin mRNA  
9.06 1.197 0 A_52_P87964 Pla2g12a NM_183423 ref|Mus musculus phospholipase A2 group XIIA transcript variant 2 mRNA  
15.43 1.187 0 A_55_P1957038 Gstp2 NM_181796 ref|Mus musculus glutathione S-transferase pi 2 mRNA  
9.45 1.183 0 A_51_P312121 Xdh NM_011723 ref|Mus musculus xanthine dehydrogenase mRNA  
9.46 1.181 0.00012 A_55_P2168781 A_55_P2168781 A_55_P2168781 Unknown 
7.98 1.178 0.00064 A_51_P391727 Slc3a1 NM_009205 ref|Mus musculus solute carrier family 3 member 1 mRNA  
7.16 1.176 0.00751 A_66_P128931 LOC100047937 XM_001479188 ref|PREDICTED: Mus musculus similar to Aldehyde dehydrogenase 1 family member L1 mRNA  
10.44 1.165 0 A_55_P2141878 Ldha NM_001136069 ref|Mus musculus lactate dehydrogenase A transcript variant 2 mRNA  
11.37 1.156 6.00E-05 A_65_P03442 Pgk1 NM_008828 ref|Mus musculus phosphoglycerate kinase 1 mRNA  
11.34 1.153 0 A_51_P502872 2200002D01Rik NM_028179 ref|Mus musculus RIKEN cDNA 2200002D01 gene mRNA  
7.12 1.150 0.00019 A_51_P297105 Ucp2 NM_011671 ref|Mus musculus uncoupling protein 2 (mitochondrial proton carrier) nuclear gene encoding mitochondrial protein 
mRNA  
8.32 1.146 0.00122 A_51_P419637 Dclk3 NM_172928 ref|Mus musculus doublecortin-like kinase 3 mRNA  
7.82 1.139 0.00078 A_55_P2078955 Aqp8 NM_007474 ref|Mus musculus aquaporin 8 transcript variant 1 mRNA  
7.55 1.138 0.00076 A_55_P2055232 Sdf4 NM_011341 ref|Mus musculus stromal cell derived factor 4 mRNA  
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7.45 1.136 0.00109 A_51_P246653 Clec7a NM_020008 ref|Mus musculus C-type lectin domain family 7 member a mRNA  
10.12 1.135 0.00047 A_55_P2013273 A_55_P2013273 A_55_P2013273 Unknown 
10.18 1.134 0.00013 A_55_P2059586 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
9.06 1.130 0 A_52_P487436 Nags NM_145829 ref|Mus musculus N-acetylglutamate synthase transcript variant 1 mRNA  
11.01 1.127 2.00E-05 A_66_P111747 NAP096647-001 NAP096647-001 tc|MUSXPGK phosphoglycerate kinase {Mus musculus} (exp=0; wgp=1; cg=0) partial (43%) [TC1657415] 
7.47 1.115 0.00289 A_51_P201904 Ndufb5 NM_025316 ref|Mus musculus NADH dehydrogenase (ubiquinone) 1 beta subcomplex 5 nuclear gene encoding mitochondrial 
protein mRNA  
10.90 1.113 0.00922 A_52_P318673 Saa1 NM_009117 ref|Mus musculus serum amyloid A 1 mRNA  
9.07 1.111 3.00E-05 A_51_P295312 Gabarap NM_019749 ref|Mus musculus gamma-aminobutyric acid receptor associated protein mRNA  
15.57 1.105 0 A_66_P125722 Cyb5 NM_025797 ref|Mus musculus cytochrome b-5 mRNA  
7.43 1.104 0 A_55_P2110512 Lmo7 NM_201529 ref|Mus musculus LIM domain only 7 mRNA  
9.44 1.103 0.00033 A_55_P2051159 Upp2 NM_029692 ref|Mus musculus uridine phosphorylase 2 mRNA  
8.36 1.094 5.00E-05 A_51_P215922 Casp6 NM_009811 ref|Mus musculus caspase 6 mRNA  
7.56 1.093 0.00067 A_51_P455647 Car2 NM_009801 ref|Mus musculus carbonic anhydrase 2 mRNA  
8.23 1.092 0 A_51_P519189 Eif3i NM_018799 ref|Mus musculus eukaryotic translation initiation factor 3 subunit I mRNA  
11.88 1.088 0.0083 A_55_P2172532 C730007P19Rik NM_009286 ref|Mus musculus RIKEN cDNA C730007P19 gene mRNA  
8.03 1.088 0 A_55_P1971962 Tmem176b NM_023056 ref|Mus musculus transmembrane protein 176B transcript variant 1 mRNA  
8.12 1.080 0.00158 A_51_P336833 Fabp4 NM_024406 ref|Mus musculus fatty acid binding protein 4 adipocyte mRNA  
7.10 1.080 0 A_52_P44030 Exoc3 NM_177333 ref|Mus musculus exocyst complex component 3 mRNA  
7.40 1.074 0.0014 A_66_P108247 Ucp3 NM_009464 ref|Mus musculus uncoupling protein 3 (mitochondrial proton carrier) nuclear gene encoding mitochondrial protein 
mRNA  
7.46 1.072 0.00026 A_51_P519385 Sacm1l NM_030692 ref|Mus musculus SAC1 (suppressor of actin mutations 1 homolog)-like (S. cerevisiae) mRNA  
8.55 1.069 1.00E-05 A_51_P386503 Abhd15 NM_026185 ref|Mus musculus abhydrolase domain containing 15 mRNA  
11.55 1.066 0 A_52_P151320 Tnfaip8l1 NM_025566 ref|Mus musculus tumor necrosis factor alpha-induced protein 8-like 1 mRNA  
9.51 1.065 0 A_51_P142896 Cd59a NM_007652 ref|Mus musculus CD59a antigen transcript variant 2 mRNA  
8.30 1.059 9.00E-05 A_51_P142515 Antxr2 NM_133738 ref|Mus musculus anthrax toxin receptor 2 mRNA  
11.11 1.057 7.00E-05 A_51_P431737 Cth NM_145953 ref|Mus musculus cystathionase (cystathionine gamma-lyase) mRNA  
7.12 1.052 7.00E-04 A_55_P2128181 A_55_P2128181 A_55_P2128181 Unknown 
8.94 1.050 0 A_55_P2110513 Lmo7 NM_201529 ref|Mus musculus LIM domain only 7 mRNA  
9.11 1.048 6.00E-05 A_55_P2038540 Hbb-b2 NM_016956 ref|Mus musculus hemoglobin beta adult minor chain mRNA  
7.45 1.045 3.00E-05 A_55_P2005859 Fn3k NM_022014 ref|Mus musculus fructosamine 3 kinase transcript variant 1 mRNA  
9.90 1.044 0.00021 A_55_P2185840 Nnmt NM_010924 ref|Mus musculus nicotinamide N-methyltransferase mRNA  
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10.20 1.043 0 A_55_P2077635 A_55_P2077635 A_55_P2077635 Unknown 
8.09 1.040 0.00762 A_51_P307168 Ddah1 NM_026993 ref|Mus musculus dimethylarginine dimethylaminohydrolase 1 mRNA  
7.40 1.039 0.00742 A_55_P2083481 Lpin1 NM_001130412 ref|Mus musculus lipin 1 transcript variant 3 mRNA  
14.14 1.039 0 A_51_P133562 Serpina6 NM_007618 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A member 6 mRNA  
8.83 1.036 0.0035 A_55_P2069969 Gm10639 NM_001122660 ref|Mus musculus predicted gene 10639 mRNA  
10.72 1.034 0 A_55_P2138097 Gm9294 NM_001081036 ref|Mus musculus predicted gene 9294 mRNA  
7.16 1.034 5.00E-04 A_55_P2157225 Nqo2 NM_020282 ref|Mus musculus NAD(P)H dehydrogenase quinone 2 transcript variant 1 mRNA  
9.91 1.028 0.00012 A_55_P2068812 AK203298 AK203298 gb|Mus musculus cDNA clone:Y1G0144G24 strand:minus reference:ENSEMBL:Mouse-Transcript-
ENST:ENSMUST00000061523 based on BLAT search 
9.20 1.027 0 A_51_P293901 Dhrs1 NM_026819 ref|Mus musculus dehydrogenase/reductase (SDR family) member 1 mRNA  
8.19 1.023 0.00108 A_51_P120461 Mina NM_025910 ref|Mus musculus myc induced nuclear antigen mRNA  
14.50 1.020 0.00029 A_55_P1966690 Cyp2e1 NM_021282 ref|Mus musculus cytochrome P450 family 2 subfamily e polypeptide 1 mRNA  
11.53 1.019 1.00E-04 A_52_P404341 Tdo2 NM_019911 ref|Mus musculus tryptophan 23-dioxygenase mRNA  
7.90 1.014 1.00E-05 A_51_P271503 Il1r1 NM_008362 ref|Mus musculus interleukin 1 receptor type I transcript variant 1 mRNA  
8.06 1.013 0 A_52_P148678 ENSMUST00000109462 ENSMUST00000109462 ens|1-phosphatidylinositol-45-bisphosphate phosphodiesterase gamma-1 (EC 3.1.4.11)(Phosphoinositide 
phospholipase C)(Phospholipase C-gamma-1)(PLC-gamma-1)(PLC-II)(PLC-148) [Source:UniProtKB/Swiss-
Prot;Acc:Q62077]  
9.56 1.003 0.00389 A_52_P579252 Gm9644 XR_005114 gb|PREDICTED: Mus musculus similar to Ribosomal protein L3 misc RNA  
7.10 1.002 0.00881 A_51_P487547 Ccdc91 NM_025911 ref|Mus musculus coiled-coil domain containing 91 mRNA  
10.58 1.002 1.00E-05 A_55_P2131027 Gm3699 XM_001477613 ref|PREDICTED: Mus musculus hypothetical protein LOC100042155 mRNA  
8.21 1.000 3.00E-05 A_55_P2048368 Fggy NM_029347 ref|Mus musculus FGGY carbohydrate kinase domain containing transcript variant 2 mRNA  
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Table 82. All significantly down regulated genes livers of female C57BL/6 mice by TCDD (25 µg/kg bw) identified by microarray analysis – mouse 3-day study. 
Selected parameters: A-value ≥ 7, log2 fc ≤ -1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
8.11 -2.846 0 A_55_P2022074 Klf10 NM_013692 ref|Mus musculus Kruppel-like factor 10 mRNA  
8.35 -2.601 5.00E-05 A_51_P249286 Rgs16 NM_011267 ref|Mus musculus regulator of G-protein signaling 16 mRNA  
9.43 -2.573 0 A_55_P1997003 Serpina4-ps1 BC031891 gb|Mus musculus serine (or cysteine) peptidase inhibitor clade A member 4 pseudogene 1 mRNA (cDNA clone 
IMAGE:5123840) 
9.98 -2.488 1.00E-05 A_55_P2004606 Serpina4-ps1 NR_002861 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A member 4 pseudogene 1 non-coding RNA  
11.37 -2.276 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.51 -2.183 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.24 -2.18 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.40 -2.176 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.34 -2.173 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.24 -2.169 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.41 -2.158 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.36 -2.157 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.42 -2.150 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
11.31 -2.141 0 A_52_P106259 Egfr NM_207655 ref|Mus musculus epidermal growth factor receptor transcript variant 1 mRNA  
8.94 -2.125 2.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA  
8.94 -2.106 3.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.74 -2.103 4.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.67 -2.090 2.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.58 -2.072 3.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.68 -2.059 3.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.77 -2.048 3.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.66 -2.038 2.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
10.36 -2.025 0 A_51_P268529 Csad NM_144942 ref|Mus musculus cysteine sulfinic acid decarboxylase mRNA  
8.67 -2.013 9.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.89 -2.003 6.00E-05 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
8.48 -1.890 0 A_55_P1954698 LOC100046261 XM_001475897 ref|PREDICTED: Mus musculus similar to myosin XV mRNA  
8.72 -1.886 0.00031 A_52_P161495 Bcl6 NM_009744 ref|Mus musculus B-cell leukemia/lymphoma 6 mRNA  
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7.59 -1.832 9.00E-05 A_55_P1992838 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA 
7.86 -1.821 0 A_55_P2073789 LOC676974 XM_001003154 ref|PREDICTED: Mus musculus similar to Glucose phosphate isomerase 1 transcript variant 2 mRNA  
9.99 -1.806 0 A_51_P463440 Elovl6 NM_130450 ref|Mus musculus ELOVL family member 6 elongation of long chain fatty acids (yeast) mRNA  
8.65 -1.752 0 A_51_P272553 Bhlhe40 NM_011498 ref|Mus musculus basic helix-loop-helix family member e40 mRNA  
7.55 -1.734 0 A_55_P1978502 H2-Q1 NM_010390 ref|Mus musculus histocompatibility 2 Q region locus 1 mRNA  
10.80 -1.694 0 A_66_P102260 Irs2 NM_001081212 ref|Mus musculus insulin receptor substrate 2 mRNA  
10.86 -1.689 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
10.87 -1.676 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
7.05 -1.675 2.00E-05 A_55_P1954393 Susd4 NM_144796 ref|Mus musculus sushi domain containing 4 mRNA  
14.31 -1.669 0.00022 A_52_P21486 Hamp2 NM_183257 ref|Mus musculus hepcidin antimicrobial peptide 2 ) mRNA  
10.97 -1.656 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
10.47 -1.654 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
11.54 -1.649 9.00E-05 A_55_P2150976 Fabp5l2 XM_886827 ref|PREDICTED: Mus musculus predicted gene EG622384mRNA  
10.50 -1.648 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
7.41 -1.645 0.00232 A_66_P122699 Cux2 ENSMUST00000111752 ens|Homeobox protein cut-like 2 (Cut-like 2)(Homeobox protein Cux-2) [Source:UniProtKB/Swiss-
Prot;Acc:P70298]  
10.61 -1.635 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
10.67 -1.629 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
10.57 -1.627 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
10.51 -1.604 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
10.92 -1.594 0 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
7.11 -1.560 0 A_66_P118430 Slc17a2 ENSMUST00000006786 ens|Sodium-dependent phosphate transport protein 3 (Sodium/phosphate cotransporter 3)(Na(+)/PI cotransporter 
3)(Solute carrier family 17 member 2) [Source:UniProtKB/Swiss-Prot;Acc:Q5SZA1]  
7.20 -1.557 0 A_51_P256384 Atp2b2 NM_009723 ref|Mus musculus ATPase Ca2+transporting plasma membrane 2 transcript variant 1 mRNA  
12.54 -1.555 0 A_66_P135391 Igfbp2 NM_008342 ref|Mus musculus insulin-like growth factor binding protein 2 mRNA  
7.66 -1.545 1.00E-04 A_55_P1992834 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA  
8.34 -1.538 9.00E-05 A_51_P501844 Cyp26b1 NM_175475 ref|Mus musculus cytochrome P450 family 26 subfamily b polypeptide 1 mRNA  
10.25 -1.531 0.00018 A_55_P2122841 NAP114472-1 NAP114472-1 Unknown 
11.07 -1.525 0.00016 A_55_P1953387 Fabp5 NM_010634 ref|Mus musculus fatty acid binding protein 5 epidermal mRNA  
12.39 -1.508 0 A_55_P2056729 Igfbp2 NM_008342 ref|Mus musculus insulin-like growth factor binding protein 2 mRNA  
10.08 -1.502 0 A_55_P2118866 Cmah NM_001111110 ref|Mus musculus cytidine monophospho-N-acetylneuraminic acid hydroxylase transcript variant 2 mRNA  
12.03 -1.481 0 A_55_P2015734 Syvn1 NM_028769 ref|Mus musculus synovial apoptosis inhibitor 1 synoviolin transcript variant 1 mRNA  
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10.43 -1.461 4.00E-05 A_55_P2032081 Dbp NM_016974 ref|Mus musculus D site albumin promoter binding protein mRNA  
7.42 -1.439 0 A_55_P2081273 Gabbr2 NM_001081141 ref|Mus musculus gamma-aminobutyric acid (GABA) B receptor 2 mRNA  
15.10 -1.432 0 A_51_P431329 Car3 NM_007606 ref|Mus musculus carbonic anhydrase 3 mRNA  
9.97 -1.429 1.00E-05 A_55_P2032079 Dbp NM_016974 ref|Mus musculus D site albumin promoter binding protein mRNA  
12.39 -1.425 0.00058 A_51_P462385 G6pc NM_008061 ref|Mus musculus glucose-6-phosphatase catalytic mRNA  
7.89 -1.423 0.00064 A_55_P2082914 Acly NM_134037 ref|Mus musculus ATP citrate lyase mRNA  
8.52 -1.405 0 A_55_P2003513 Hsph1 NM_013559 ref|Mus musculus heat shock 105kDa/110kDa protein 1 mRNA  
9.08 -1.390 0 A_66_P111562 Ccnd1 NM_007631 ref|Mus musculus cyclin D1 mRNA  
7.49 -1.387 0 A_55_P2211164 5330406M23Rik AK017236 gb|Mus musculus adult male pituitary gland cDNA RIKEN full-length enriched library clone:5330406M23 
product:unclassifiable full insert sequence 
15.00 -1.387 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA  
13.41 -1.378 0 A_55_P2422650 5031425E22Rik AK017143 gb|Mus musculus 11 days pregnant adult female ovary and uterus cDNA RIKEN full-length enriched library clone: 
5031425E22 product:unclassifiable full insert sequence 
11.83 -1.374 0 A_55_P2153517 Enho NM_027147 ref|Mus musculus energy homeostasis associated mRNA  
7.21 -1.369 0.00103 A_52_P140005 Nipal1 NM_001081205 ref|Mus musculus NIPA-like domain containing 1 mRNA  
13.29 -1.368 8.00E-05 A_66_P121110 Pck1 NM_011044 ref|Mus musculus phosphoenolpyruvate carboxykinase 1 cytosolic mRNA  
7.72 -1.367 0 A_52_P68702 Frmd4b NM_145148 ref|Mus musculus FERM domain containing 4B mRNA  
14.98 -1.363 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA  
7.35 -1.361 0.00029 A_52_P627816 Tgm1 NM_019984 ref|Mus musculus transglutaminase 1 K polypeptide transcript variant 2 mRNA  
15.15 -1.353 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA  
14.80 -1.350 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA 
14.83 -1.348 1.00E-05 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA 
14.69 -1.348 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA 
15.15 -1.345 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA 
14.98 -1.336 1.00E-05 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA 
14.72 -1.336 0 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA 
12.13 -1.335 0 A_55_P2062737 Elovl2 NM_019423 ref|Mus musculus elongation of very long chain fatty acids (FEN1/Elo2 SUR4/Elo3 yeast)-like 2 mRNA  
14.84 -1.328 1.00E-05 A_51_P408082 Apoa1 NM_009692 ref|Mus musculus apolipoprotein A-I mRNA  
11.55 -1.328 0 A_55_P2015753 Enho NM_027147 ref|Mus musculus energy homeostasis associated mRNA  
11.96 -1.313 0.00115 A_55_P2025954 Acly NM_134037 ref|Mus musculus ATP citrate lyase mRNA  
9.30 -1.309 5.00E-05 A_55_P2258261 1810008I18Rik AK050412 gb|Mus musculus adult male liver tumor cDNA RIKEN full-length enriched library clone:C730046D02 product: 
unclassifiable full insert sequence 
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10.86 -1.306 0 A_55_P2129449 Sult3a1 NM_020565 ref|Mus musculus sulfotransferase family 3A member 1 mRNA  
7.25 -1.305 0 A_66_P133450 Dnajb9 NM_013760 ref|Mus musculus DnaJ (Hsp40) homolog subfamily B member 9 mRNA  
11.12 -1.295 0 A_55_P2048518 Zfpm1 NM_009569 ref|Mus musculus zinc finger protein multitype 1 mRNA  
8.11 -1.284 0 A_55_P1960117 1190002N15Rik NM_001033145 ref|Mus musculus RIKEN cDNA 1190002N15 gene mRNA  
11.86 -1.280 0 A_55_P2025343 Mup21 NM_001009550 ref|Mus musculus major urinary protein 21 mRNA  
10.81 -1.276 0 A_55_P2165091 Acnat2 NM_145368 ref|Mus musculus acyl-coenzyme A amino acid N-acyltransferase 2 mRNA  
11.66 -1.273 2.00E-05 A_52_P662244 AI132487 NM_001012310 ref|Mus musculus expressed sequence AI132487 mRNA  
7.61 -1.239 0.0022 A_55_P2078494 Cib3 NM_001080812 ref|Mus musculus calcium and integrin binding family member 3 mRNA  
8.55 -1.237 0.00323 A_52_P100252 Fasn NM_007988 ref|Mus musculus fatty acid synthase mRNA  
9.84 -1.233 0 A_55_P2075263 Acnat2 NM_145368 ref|Mus musculus acyl-coenzyme A amino acid N-acyltransferase 2 mRNA  
11.19 -1.229 0 A_55_P1994887 Zfpm1 NM_009569 ref|Mus musculus zinc finger protein multitype 1 mRNA  
9.28 -1.214 0 A_55_P2143896 Slc17a2 NM_144836 ref|Mus musculus solute carrier family 17 (sodium phosphate) member 2 mRNA  
8.16 -1.207 9.00E-05 A_55_P2057528 Arl4d NM_025404 ref|Mus musculus ADP-ribosylation factor-like 4D mRNA  
7.07 -1.205 0.00026 A_66_P124179 Atp6v0d2 NM_175406 ref|Mus musculus ATPase H+ transporting lysosomal V0 subunit D2 mRNA  
16.38 -1.195 0 A_55_P2048607 Hp NM_017370 ref|Mus musculus haptoglobin mRNA  
8.37 -1.177 0 A_55_P2159934 Rnf186 NM_025786 ref|Mus musculus ring finger protein 186 mRNA 
9.66 -1.165 0 A_52_P70854 Tob2 NM_020507 ref|Mus musculus transducer of ERBB2 2 mRNA  
8.22 -1.154 0 A_55_P1971054 Paqr9 NM_198414 ref|Mus musculus progestin and adipoQ receptor family member IX mRNA  
7.25 -1.151 6.00E-05 A_51_P176042 Pklr NM_013631 ref|Mus musculus pyruvate kinase liver and red blood cell nuclear gene encoding mitochondrial protein transcript 
variant 1 mRNA  
9.30 -1.150 0 A_66_P121636 Ablim3 NM_198649 ref|Mus musculus actin binding LIM protein family member 3 transcript variant 1 mRNA  
9.48 -1.136 0 A_55_P2009988 Trib3 NM_175093 ref|Mus musculus tribbles homolog 3 (Drosophila) mRNA  
8.88 -1.135 0.00263 A_66_P124164 ENSMUST00000099683 ENSMUST00000099683 Unknown 
10.21 -1.125 0 A_51_P215540 Rnf4 NM_011278 ref|Mus musculus ring finger protein 4 mRNA  
9.23 -1.113 3.00E-05 A_55_P2067563 Etnk2 XM_001471861 ref|PREDICTED: Mus musculus hypothetical protein LOC100044148 mRNA  
9.34 -1.108 0 A_55_P1956863 Egfr NM_007912 ref|Mus musculus epidermal growth factor receptor transcript variant 2 mRNA  
7.44 -1.107 0 A_55_P2076984 Farp1 NM_134082 ref|Mus musculus FERM RhoGEF (Arhgef) and pleckstrin domain protein 1 (chondrocyte-derived) mRNA  
10.55 -1.103 0.00011 A_55_P2068289 Slc17a2 NM_144836 ref|Mus musculus solute carrier family 17 (sodium phosphate) member 2 mRNA  
11.59 -1.103 0.00013 A_55_P2009042 Gm4635 XM_001481023 ref|PREDICTED: Mus musculus hypothetical protein LOC100043770 mRNA  
8.77 -1.092 0.00375 A_55_P2138100 ENSMUST00000099050 ENSMUST00000099050 Unknown 
11.39 -1.089 4.00E-05 A_55_P2019058 Acaca NM_133360 ref|Mus musculus acetyl-Coenzyme A carboxylase alpha mRNA  
13.64 -1.077 0 A_55_P2076772 Hspa5 NM_022310 ref|Mus musculus heat shock protein 5 transcript variant 2 mRNA  
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7.54 -1.073 0.00471 A_55_P2165554 ENSMUST00000099046 ENSMUST00000099046 Unknown 
9.90 -1.071 0 A_51_P296036 Nrbp2 NM_144847 ref|Mus musculus nuclear receptor binding protein 2 mRNA  
11.56 -1.068 0 A_51_P295192 Nfkbia NM_010907 ref|Mus musculus nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha mRNA  
7.52 -1.066 0 A_55_P2092864 Emp2 NM_007929 ref|Mus musculus epithelial membrane protein 2 mRNA  
10.35 -1.064 0 A_66_P139387 Prlr NM_011169 ref|Mus musculus prolactin receptor mRNA  
10.97 -1.062 0 A_55_P1977314 Ulk1 NM_009469 ref|Mus musculus Unc-51 like kinase 1 (C. elegans) mRNA  
14.93 -1.060 0 A_51_P205385 Uox NM_009474 ref|Mus musculus urate oxidase mRNA  
7.12 -1.058 0.00042 A_55_P2118630 Lasp1 NM_010688 ref|Mus musculus LIM and SH3 protein 1 mRNA  
9.33 -1.055 0 A_55_P1976978 Zfp707 NM_001081065 ref|Mus musculus zinc finger protein 707 mRNA  
7.95 -1.048 0 A_66_P136632 1500003O03Rik NM_019769 ref|Mus musculus RIKEN cDNA 1500003O03 gene mRNA  
9.39 -1.045 3.00E-05 A_51_P152845 Trim24 NM_145076 ref|Mus musculus tripartite motif-containing 24 mRNA  
10.59 -1.035 0.00041 A_55_P2041723 Mid1ip1 NM_001166635 ref|Mus musculus Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish)) transcript variant 1 mRNA  
8.78 -1.035 0.00977 A_51_P148612 Cox7a1 NM_009944 ref|Mus musculus cytochrome c oxidase subunit VIIa 1 mRNA  
9.15 -1.035 0 A_66_P101519 Abcc9 NM_021041 ref|Mus musculus ATP-binding cassette sub-family C (CFTR/MRP) member 9 transcript variant 2 mRNA  
7.21 -1.031 0.0073 A_55_P1978636 ENSMUST00000099035 ENSMUST00000099035 tc|Q4YHF0_PLABE (Q4YHF0) Pb-fam-2 protein (Fragment) partial (7%) [TC1642683] 
9.03 -1.028 7.00E-05 A_55_P2014457 LOC638627 XM_914710 ref|PREDICTED: Mus musculus similar to EF-hand Ca2+ binding protein p22 mRNA  
11.32 -1.024 0 A_55_P1992555 Gys2 NM_145572 ref|Mus musculus glycogen synthase 2 mRNA  
14.26 -1.018 0.00332 A_52_P669922 Hamp NM_032541 ref|Mus musculus hepcidin antimicrobial peptide mRNA  
11.25 -1.013 2.00E-05 A_55_P2084706 Acaca BC023946 gb|Mus musculus acetyl-Coenzyme A carboxylase alpha mRNA (cDNA clone IMAGE:5151139) with apparent 
retained intron 
7.05 -1.013 0 A_55_P2124523 Gm13620 XM_988366 ref|PREDICTED: Mus musculus hypothetical LOC667106  mRNA  
8.52 -1.009 0.00085 A_55_P1960735 Gdf15 NM_011819 ref|Mus musculus growth differentiation factor 15 mRNA  
9.22 -1.006 0.00015 A_51_P418168 Manf NM_029103 ref|Mus musculus mesencephalic astrocyte-derived neurotrophic factor mRNA  
8.54 -1.002 0.00026 A_51_P280446 Sdf2l1 NM_022324 ref|Mus musculus stromal cell-derived factor 2-like 1 mRNA  
8.41 -1.001 0.00867 A_55_P2138104 ENSMUST00000099050 ENSMUST00000099050 Unknown 
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Table 83. All significantly up regulated genes in livers of female C57BL/6 mice by PCB 153 (150000 µg/kg bw) identified by microarray analysis - mouse 3-day study. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
9.36 3.556 0 A_55_P2032946 Gsta1 NM_008181 ref|Mus musculus glutathione S-transferase alpha 1 (Ya) mRNA  
12.00 3.336 0 A_55_P2116272 Cyp2c38 NM_010002 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 38 mRNA  
10.80 2.690 0 A_55_P2102065 Gm10639 NM_001122660 ref|Mus musculus predicted gene 10639 mRNA  
13.31 2.514 0 A_55_P2044653 Cyp2b10 NM_009999 ref|Mus musculus cytochrome P450 family 2 subfamily b polypeptide 10 transcript variant 2 mRNA  
9.12 2.321 0 A_51_P311958 Orm3 NM_013623 ref|Mus musculus orosomucoid 3 mRNA  
7.27 2.317 0 A_51_P331288 Akr1b7 NM_009731 ref|Mus musculus aldo-keto reductase family 1 member B7 mRNA  
14.39 2.134 0 A_55_P2293013 Ces6 NM_133960 ref|Mus musculus carboxylesterase 6 mRNA  
11.10 2.043 0 A_55_P2170454 Gsta2 NM_008182 ref|Mus musculus glutathione S-transferase alpha 2 (Yc2) mRNA  
12.98 1.965 0 A_55_P2107528 A_55_P2107528 A_55_P2107528 Unknown 
9.32 1.914 0 A_52_P154580 Cyp2c54 NM_206537 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 54 mRNA  
13.80 1.884 0 A_55_P2005213 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA  
12.76 1.846 0 A_55_P2102060 Gstm3 NM_010359 ref|Mus musculus glutathione S-transferase mu 3 mRNA  
13.12 1.774 0.00021 A_51_P246317 Mt2 NM_008630 ref|Mus musculus metallothionein 2 mRNA  
13.67 1.772 0 A_55_P1993419 Cyp2c54 NM_206537 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 54 mRNA  
8.83 1.762 1.00E-05 A_55_P2069969 Gm10639 NM_001122660 ref|Mus musculus predicted gene 10639 mRNA  
8.35 1.759 0 A_51_P421876 Irf7 NM_016850 ref|Mus musculus interferon regulatory factor 7 mRNA  
7.87 1.722 7.00E-05 A_55_P1998471 S100a9 NM_009114 ref|Mus musculus S100 calcium binding protein A9 (calgranulin B) mRNA  
7.65 1.712 0 A_66_P128537 Isg15 NM_015783 ref|Mus musculus ISG15 ubiquitin-like modifier mRNA  
7.12 1.688 0 A_51_P327751 Ifit1 NM_008331 ref|Mus musculus interferon-induced protein with tetratricopeptide repeats 1 mRNA  
14.11 1.665 0 A_55_P2020477 Cyp2c50 NM_134144 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 50 transcript variant 1 mRNA  
7.02 1.659 5.00E-05 A_51_P487690 Ifi44 NM_133871 ref|Mus musculus interferon-induced protein 44 mRNA  
8.99 1.591 0 A_52_P318361 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA  
11.58 1.588 0 A_55_P2103698 Isg15 NM_015783 ref|Mus musculus ISG15 ubiquitin-like modifier mRNA  
7.27 1.587 0 A_52_P382149 Cyp26a1 NM_007811 ref|Mus musculus cytochrome P450 family 26 subfamily a polypeptide 1 mRNA  
12.58 1.582 0 A_55_P2065231 Gstm3 NM_010359 ref|Mus musculus glutathione S-transferase mu 3 mRNA  
10.75 1.580 0 A_55_P2071906 ENSMUST00000108392 ENSMUST00000108392 ens|Cytochrome P-450b (phenobarbital-inducible) Fragment [Source:UniProtKB/TrEMBL;Acc:Q61461]  
13.03 1.549 0 A_51_P498882 Cyp2c37 NM_010001 ref|Mus musculus cytochrome P450 family 2. subfamily c polypeptide 37 mRNA  
10.64 1.546 0 A_55_P1964483 Cyp2c37 NM_010001 ref|Mus musculus cytochrome P450 family 2. subfamily c polypeptide 37 mRNA  
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9.85 1.539 0 A_55_P2124712 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA  
8.56 1.526 0 A_55_P2059931 Prom1 NM_001163577 ref|Mus musculus prominin 1 transcript variant 2 mRNA  
9.38 1.521 0 A_52_P627269 BC015286 NM_198171 ref|Mus musculus cDNA sequence BC015286 mRNA  
15.09 1.517 0 A_55_P2062190 Gstm1 NM_010358 ref|Mus musculus glutathione S-transferase mu 1 mRNA  
11.27 1.497 0.00037 A_55_P1999902 ENSMUST00000107229 ENSMUST00000107229 ens|Phosphatidylinositol-4-phosphate 5-kinase type-1 alpha (EC 2.7.1.68) (Phosphatidylinositol-4-phosphate 5-
kinase type I alpha)(PtdIns(4)P-5-kinase alpha)(PIP5KIalpha)(Phosphatidylinositol-4-phosphate 5-kinase type I 
beta)(PI4P5KIbeta)(68 kDa type I phos  
10.98 1.495 0 A_65_P02177 Gstm4 NM_026764 ref|Mus musculus glutathione S-transferase mu 4 transcript variant 1 mRNA  
14.77 1.469 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
14.59 1.466 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
8.74 1.441 6.00E-05 A_55_P2085779 Ifi27l2b NM_145449 ref|Mus musculus interferon alpha-inducible protein 27 like 2B mRNA  
14.48 1.44 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
14.77 1.437 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
7.02 1.427 0 A_66_P139683 Zbp1 NM_021394 ref|Mus musculus Z-DNA binding protein 1 transcript variant 1 mRNA  
14.57 1.424 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
14.55 1.423 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
7.74 1.419 0.00012 A_55_P2198983 4930415C11Rik AI606402 gb|mr62b05.y1 Stratagene mouse testis (#937308) Mus musculus cDNA clone IMAGE:602001 5' similar to 
gb:J03952 Mouse glutathione transferase GT8.7 mRNA complete cds (MOUSE)  
11.38 1.409 0 A_51_P304109 Cyp2c39 NM_010003 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 39 mRNA  
14.79 1.406 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
14.63 1.404 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
12.82 1.401 0 A_55_P1966432 Gstm1 NM_010358 ref|Mus musculus glutathione S-transferase mu 1 mRNA  
14.68 1.400 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
7.43 1.395 0 A_51_P387123 Oasl2 NM_011854 ref|Mus musculus 2'-5' oligoadenylate synthetase-like 2 mRNA  
8.51 1.392 0.00032 A_51_P265495 Ly6a NM_010738 ref|Mus musculus lymphocyte antigen 6 complex locus A mRNA  
14.8 1.388 0 A_51_P103706 Cyp2c29 NM_007815 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 29 mRNA  
9.07 1.387 0 A_55_P2472435 Gbp3 NM_018734 ref|Mus musculus guanylate binding protein 3 mRNA  
8.13 1.374 0 A_55_P2140042 Krt31 NM_010659 ref|Mus musculus keratin 31 mRNA  
8.02 1.339 0 A_66_P101942 Gm9706 AK019325 gb|Mus musculus adult male hippocampus cDNA RIKEN full-length enriched library clone:2900034J12 
product:interferon-stimulated protein (15 kDa) full insert sequence.  
9.83 1.283 0 A_55_P1998943 Oas1a NM_145211 ref|Mus musculus 2'-5' oligoadenylate synthetase 1A mRNA  
7.22 1.266 0.00336 A_51_P343517 Ly6d NM_010742 ref|Mus musculus lymphocyte antigen 6 complex locus D mRNA  
14.96 1.252 0 A_55_P2121225 Cyp3a11 NM_007818 ref|Mus musculus cytochrome P450 family 3 subfamily a polypeptide 11 mRNA  
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8.33 1.217 0 A_51_P154842 Oas1f NM_145153 ref|Mus musculus 2'-5' oligoadenylate synthetase 1F mRNA  
7.24 1.216 0.00303 A_55_P2052385 Mpa2l NM_194336 ref|Mus musculus macrophage activation 2 like mRNA  
7.64 1.208 0.00038 A_55_P2039044 Cyp3a59 NM_001105160 ref|Mus musculus cytochrome P450 subfamily 3A polypeptide 59 mRNA  
8.33 1.153 0 A_55_P1966833 Xaf1 NM_001037713 ref|Mus musculus XIAP associated factor 1 mRNA  
7.03 1.148 0.00025 A_51_P219505 Slc41a2 NM_177388 ref|Mus musculus solute carrier family 41 member 2 mRNA  
8.52 1.146 2.00E-04 A_55_P1960735 Gdf15 NM_011819 ref|Mus musculus growth differentiation factor 15 mRNA  
8.84 1.139 0 A_51_P359570 Ifit3 NM_010501 ref|Mus musculus interferon-induced protein with tetratricopeptide repeats 3 mRNA  
9.45 1.138 0 A_55_P2114953 Usp18 NM_011909 ref|Mus musculus ubiquitin specific peptidase 18 mRNA  
11.96 1.129 0 A_51_P377856 Gstt3 NM_133994 ref|Mus musculus glutathione S-transferase theta 3 mRNA  
10.23 1.124 0 A_52_P82765 ENSMUST00000065861 ENSMUST00000065861 ens|Testosterone 16a-hydroxylase type c Fragment [Source:UniProtKB/TrEMBL;Acc:Q61460]  
8.54 1.122 2.00E-05 A_55_P1994042 Zbp1 NM_001139519 ref|Mus musculus Z-DNA binding protein 1 transcript variant 2 mRNA  
11.20 1.118 0.00065 A_52_P90363 Ifi27l2a NM_029803 ref|Mus musculus interferon alpha-inducible protein 27 like 2A mRNA  
10.01 1.117 3.00E-05 A_55_P2070869 Lcn2 NM_008491 ref|Mus musculus lipocalin 2 mRNA  
8.94 1.112 0.00041 A_51_P304170 Rtp4 NM_023386 ref|Mus musculus receptor transporter protein 4 mRNA  
8.23 1.103 2.00E-05 A_55_P1962305 Plac8 NM_139198 ref|Mus musculus placenta-specific 8 mRNA  
13.59 1.097 7.00E-05 A_51_P334942 Aldh1a1 NM_013467 ref|Mus musculus aldehyde dehydrogenase family 1 subfamily A1 mRNA  
7.18 1.075 0.00412 A_51_P389885 Spic NM_011461 ref|Mus musculus Spi-C transcription factor (Spi-1/PU.1 related) mRNA  
10.68 1.069 0.00532 A_55_P2062246 Tgtp2 NM_001145164 ref|Mus musculus T-cell specific GTPase 2 mRNA  
7.61 1.059 0.00785 A_55_P2078494 Cib3 NM_001080812 ref|Mus musculus calcium and integrin binding family member 3 mRNA  
9.02 1.059 0 A_52_P267391 Trim12 NM_023835 ref|Mus musculus tripartite motif-containing 12 mRNA  
9.58 1.058 1.00E-05 A_55_P2086433 Oasl1 NM_145209 ref|Mus musculus 2'-5' oligoadenylate synthetase-like 1 mRNA  
11.37 1.056 0 A_55_P2158547 Cyp2c54 NM_206537 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 54 mRNA  
7.99 1.050 0 A_55_P1998942 Oas1a NM_145211 ref|Mus musculus 2'-5' oligoadenylate synthetase 1A mRNA  
11.84 1.049 1.00E-05 A_55_P2031668 Gstp1 NM_013541 ref|Mus musculus glutathione S-transferase pi 1 mRNA  
9.57 1.019 4.00E-05 A_52_P256914 Cyp2b9 NM_010000 ref|Mus musculus cytochrome P450 family 2 subfamily b polypeptide 9 mRNA  
12.91 1.006 4.00E-05 A_55_P2008704 Gstp2 NM_181796 ref|Mus musculus glutathione S-transferase pi 2 mRNA  
12.33 1.001 0.00034 A_51_P205779 Cd5l NM_009690 ref|Mus musculus CD5 antigen-like mRNA  
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Table 84. All significantly down regulated genes in livers of female C57BL/6 mice by PCB 153 (150000 µg/kg bw) identified by microarray analysis - mouse 3-day study. 
Selected parameters: A-value ≥ 7, log2 fc ≤ -1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
7.91 -2.514 0.00259 A_55_P2040893 Tnni2 NM_009405 ref|Mus musculus troponin I skeletal fast 2 mRNA  
10.70 -1.954 2.00E-05 A_55_P2038358 Acot1 NM_012006 ref|Mus musculus acyl-CoA thioesterase 1 mRNA  
7.47 -1.832 3.00E-05 A_51_P350453 Pdk4 NM_013743 ref|Mus musculus pyruvate dehydrogenase kinase isoenzyme 4 mRNA  
12.9 -1.666 5.00E-05 A_51_P238576 Cyp4a14 NM_007822 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 14 mRNA  
7.09 -1.559 0.00714 A_55_P2187043 Tpm1 NM_001164248 ref|Mus musculus tropomyosin 1 alpha transcript variant 1 mRNA  
9.34 -1.489 5.00E-05 A_55_P2162970 Gm3734 XM_001476671 ref|PREDICTED: Mus musculus hypothetical protein LOC100046708 mRNA  
8.78 -1.432 0.00057 A_51_P148612 Cox7a1 NM_009944 ref|Mus musculus cytochrome c oxidase subunit VIIa 1 mRNA  
7.74 -1.431 0.00038 A_55_P2116973 Neb NM_010889 ref|Mus musculus nebulin mRNA  
8.42 -1.368 0.00801 A_55_P1977533 Eno3 NM_001136062 ref|Mus musculus enolase 3 beta muscle transcript variant 2 mRNA  
8.92 -1.291 0.00035 A_55_P2055638 ENSMUST00000113016 ENSMUST00000113016 ens|Gelsolin Precursor (Actin-depolymerizing factor)(ADF)(Brevin) [Source:UniProtKB/Swiss-Prot;Acc:P13020]  
9.71 -1.291 0.00027 A_55_P2013948 Gsn NM_146120 ref|Mus musculus gelsolin mRNA  
8.58 -1.247 0.00221 A_55_P2024625 Ccl21a NM_011124 ref|Mus musculus chemokine (C-C motif) ligand 21A mRNA  
7.06 -1.222 0.00147 A_55_P2037141 Jsrp1 NM_028001 ref|Mus musculus junctional sarcoplasmic reticulum protein 1 mRNA  
12.64 -1.214 0.00037 A_51_P254895 Cyp4a10 NM_010011 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 10 mRNA  
12.75 -1.191 0.00054 A_55_P2011111 Cyp4a10 NM_010011 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 10 mRNA  
12.27 -1.152 8.00E-04 A_55_P2050628 Cyp4a31 NM_201640 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 31 mRNA  
8.44 -1.131 0.00346 A_55_P2038362 Acot5 NM_145444 ref|Mus musculus acyl-CoA thioesterase 5 mRNA  
7.06 -1.125 0.00077 A_55_P2183433 Rab30 NM_029494 ref|Mus musculus RAB30 member RAS oncogene family mRNA  
8.76 -1.109 0.00722 A_51_P497100 Lgals4 NM_010706 ref|Mus musculus lectin galactose binding soluble 4 mRNA  
8.66 -1.097 0.00572 A_55_P2063256 Lgals4 NM_010706 ref|Mus musculus lectin galactose binding soluble 4 mRNA  
7.95 -1.038 0.00282 A_55_P2024033 Cyp4a31 NM_201640 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 31 mRNA  
7.00 -1.019 0.00158 A_55_P2022211 Plxdc2 NM_026162 ref|Mus musculus plexin domain containing 2 mRNA  
8.34 -1.011 0.0065 A_51_P501844 Cyp26b1 NM_175475 ref|Mus musculus cytochrome P450 family 26 subfamily b polypeptide 1 mRNA  
12.41 -1.001 0.00207 A_51_P269404 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
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Table 85. All significantly up regulated genes in livers of female Ahr wild-type mice by TCDD (25 µg/kg bw) identified by microarray analysis - mouse 5 days study. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systemtatic name Gene description 
8.29 9.106 0 A_51_P279693 Cyp1a1 NM_009992 ref|Mus musculus cytochrome P450 family 1 subfamily a polypeptide 1 transcript variant 1 mRNA  
9.46 5.995 0 A_51_P255456 Cyp1b1 NM_009994 ref|Mus musculus cytochrome P450 family 1 subfamily b polypeptide 1 mRNA  
9.86 5.375 0 A_52_P595871 Cyp1a2 NM_009993 ref|Mus musculus cytochrome P450 family 1 subfamily a polypeptide 2 mRNA  
8.83 4.386 0 A_66_P119518 Tuba8 NM_017379 ref|Mus musculus tubulin alpha 8 mRNA  
11.78 3.983 0 A_55_P2032946 Gsta1 NM_008181 ref|Mus musculus glutathione S-transferase alpha 1 (Ya) mRNA  
8.14 3.895 0 A_55_P2119257 Serpine1 NM_008871 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade E member 1 mRNA  
8.43 3.728 0 A_55_P2004099 Gm9933 XM_001477458 ref|PREDICTED: Mus musculus predicted gene ENSMUSG00000054044 mRNA  
8.63 3.657 0 A_51_P459108 Insl6 NM_013754 ref|Mus musculus insulin-like 6 mRNA  
9.35 3.389 0 A_55_P1985890 Tiparp NM_178892 ref|Mus musculus TCDD-inducible poly(ADP-ribose) polymerase mRNA  
9.59 3.300 0 A_55_P2032714 Fhit NM_010210 ref|Mus musculus fragile histidine triad gene mRNA  
9.90 3.263 0 A_51_P514961 Tiparp NM_178892 ref|Mus musculus TCDD-inducible poly(ADP-ribose) polymerase mRNA  
9.16 3.179 0 A_51_P508959 Prr15 NM_030024 ref|Mus musculus proline rich 15 mRNA  
10.22 3.172 0 A_55_P2178800 Ugt1a10 NM_201641 ref|Mus musculus UDP glycosyltransferase 1 family polypeptide A10 mRNA  
9.02 3.156 0 A_55_P2059586 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
10.55 2.965 0 A_51_P269404 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
10.21 2.797 0 A_66_P108247 Ucp3 NM_009464 ref|Mus musculus uncoupling protein 3 (mitochondrial proton carrier) nuclear gene encoding mitochondrial protein 
mRNA  
12.65 2.720 0 A_55_P2031668 Gstp1 NM_013541 ref|Mus musculus glutathione S-transferase pi 1 mRNA  
10.33 2.700 0 A_55_P1983754 Pcp4l1 NM_025557 ref|Mus musculus Purkinje cell protein 4-like 1 mRNA  
8.41 2.689 0 A_51_P471458 Sult5a1 NM_020564 ref|Mus musculus sulfotransferase family 5A member 1 mRNA  
10.07 2.651 0.00129 A_55_P1994807 Saa2 NM_011314 ref|Mus musculus serum amyloid A 2 mRNA  
10.48 2.651 0 A_51_P297105 Ucp2 NM_011671 ref|Mus musculus uncoupling protein 2 (mitochondrial proton carrier) nuclear gene encoding mitochondrial protein 
mRNA  
9.23 2.648 0 A_52_P183524 Tmem86b NM_023440 ref|Mus musculus transmembrane protein 86B mRNA  
13.99 2.638 0 A_55_P2008704 Gstp2 NM_181796 ref|Mus musculus glutathione S-transferase pi 2 mRNA  
8.07 2.611 0 A_55_P1972719 Pmm1 NM_013872 ref|Mus musculus phosphomannomutase 1 mRNA  
14.51 2.599 0 A_55_P2102065 Gm10639 NM_001122660 ref|Mus musculus predicted gene 10639 mRNA 
10.22 2.593 4.00E-05 A_51_P343350 Amn NM_033603 ref|Mus musculus amnionless mRNA  
13.45 2.505 0 A_51_P374464 Gstp1 NM_013541 ref|Mus musculus glutathione S-transferase pi 1 mRNA  
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10.22 2.504 1.00E-05 A_55_P2070869 Lcn2 NM_008491 ref|Mus musculus lipocalin 2 mRNA  
11.40 2.497 0 A_51_P502872 2200002D01Rik NM_028179 ref|Mus musculus RIKEN cDNA 2200002D01 gene mRNA  
11.42 2.418 0 A_55_P1972720 Pmm1 NM_013872 ref|Mus musculus phosphomannomutase 1 mRNA  
10.35 2.417 1.00E-05 A_52_P318673 Saa1 NM_009117 ref|Mus musculus serum amyloid A 1 mRNA  
11.76 2.409 0 A_55_P2059931 Prom1 NM_001163577 ref|Mus musculus prominin 1 transcript variant 2 mRNA  
11.58 2.366 0 A_51_P299805 Slc46a3 NM_027872 ref|Mus musculus solute carrier family 46 member 3 mRNA  
8.15 2.338 3.00E-05 A_52_P608322 Maff NM_010755 ref|Mus musculus v-maf musculoaponeurotic fibrosarcoma oncogene family protein F (avian) mRNA  
11.61 2.315 0 A_55_P2060107 Pkm2 NM_011099 ref|Mus musculus pyruvate kinase muscle mRNA  
8.57 2.310 0 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
12.07 2.280 0 A_52_P627269 BC015286 NM_198171 ref|Mus musculus cDNA sequence BC015286 mRNA  
10.43 2.269 0 A_55_P1962771 Cyfip2 NM_133769 ref|Mus musculus cytoplasmic FMR1 interacting protein 2 mRNA  
15.19 2.249 2.00E-05 A_55_P1957038 Gstp2 NM_181796 ref|Mus musculus glutathione S-transferase pi 2 mRNA 
10.57 2.219 0 A_52_P515036 Htatip2 NM_016865 ref|Mus musculus HIV-1 tat interactive protein 2 homolog (human) transcript variant 1 mRNA  
9.42 2.216 0 A_55_P2080151 Hspa2 NM_008301 ref|Mus musculus heat shock protein 2 transcript variant 1 mRNA  
12.62 2.215 0 A_55_P2124712 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA 
13.44 2.156 0 A_51_P255682 Mfge8 NM_008594 ref|Mus musculus milk fat globule-EGF factor 8 protein  transcript variant 1 mRNA  
13.67 2.155 0 A_55_P2038358 Acot1 NM_012006 ref|Mus musculus acyl-CoA thioesterase 1 mRNA  
10.26 2.138 0 A_55_P2157627 NAP000319-003 NAP000319-003 Unknown 
8.55 2.129 0 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
11.6 2.127 1.00E-05 A_52_P318361 Ces2 NM_145603 ref|Mus musculus carboxylesterase 2 mRNA 
11.67 2.092 0 A_55_P2047768 Serpinb6c NM_148942 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 6c mRNA  
8.42 2.091 0 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
12.45 2.088 0 A_55_P2068812 AK203298 AK203298 gb|Mus musculus cDNA clone:Y1G0144G24 strand:minus reference:ENSEMBL:Mouse-Transcript-ENST: 
ENSMUST00000061523 based on BLAT search.  
8.22 2.077 1.00E-05 A_55_P2118520 Col1a1 NM_007742 ref|Mus musculus collagen type I alpha 1 mRNA  
9.60 2.075 0 A_55_P2069907 Acot3 NM_134246 ref|Mus musculus acyl-CoA thioesterase 3 mRNA  
8.45 2.054 2.00E-05 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
8.21 2.048 0 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
8.60 2.043 2.00E-05 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
10.17 1.986 0 A_52_P87964 Pla2g12a NM_183423 ref|Mus musculus phospholipase A2 group XIIA transcript variant 2 mRNA  
12.26 1.985 0 A_51_P455647 Car2 NM_009801 ref|Mus musculus carbonic anhydrase 2 mRNA  
8.66 1.967 1.00E-05 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
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12.24 1.964 0 A_55_P2066727 Serpinb6a NM_001164118 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 6a transcript variant 3 mRNA  
9.56 1.941 0 A_55_P1984675 Abhd6 NM_025341 ref|Mus musculus abhydrolase domain containing 6 mRNA  
9.70 1.939 0 A_55_P2157307 NAP113386-1 NAP113386-1 Unknown 
9.57 1.926 0 A_51_P357561 Fbxw9 NM_026791 ref|Mus musculus F-box and WD-40 domain protein 9 mRNA  
9.23 1.913 0 A_55_P2095035 Gm1833 XM_129965 ref|PREDICTED: Mus musculus gene model 1833 (NCBI) mRNA  
8.37 1.899 4.00E-05 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
10.30 1.897 0 A_55_P2013038 Serpinb6c NM_148942 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 6c mRNA  
9.37 1.887 0 A_51_P316951 Wipf3 NM_001167860 ref|Mus musculus WAS/WASL interacting protein family member 3 transcript variant 1 mRNA  
9.01 1.885 0 A_51_P271503 Il1r1 NM_008362 ref|Mus musculus interleukin 1 receptor type I transcript variant 1 mRNA [NM_008362] 
9.59 1.879 1.00E-05 A_55_P2038362 Acot5 NM_145444 ref|Mus musculus acyl-CoA thioesterase 5 (mRNA  
9.04 1.872 6.00E-05 A_52_P590154 Hsd17b6 NM_013786 ref|Mus musculus hydroxysteroid (17-beta) dehydrogenase 6mRNA  
8.49 1.871 1.00E-05 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
9.77 1.869 0 A_55_P2029366 Abhd6 NM_025341 ref|Mus musculus abhydrolase domain containing 6 mRNA  
10.38 1.868 1.00E-04 A_55_P2178036 Serpina6 NM_007618 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A member 6 mRNA  
7.67 1.867 0 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
10.05 1.867 0 A_55_P2141884 Tagln2 NM_178598 ref|Mus musculus transgelin 2 mRNA  
8.57 1.857 0 A_51_P363947 Cdkn1a NM_007669 ref|Mus musculus cyclin-dependent kinase inhibitor 1A (P21) transcript variant 1 mRNA  
8.32 1.817 0.00014 A_52_P525183 Acot2 NM_134188 ref|Mus musculus acyl-CoA thioesterase 2 nuclear gene encoding mitochondrial protein mRNA  
12.37 1.815 0 A_55_P2077628 ENSMUST00000106148 ENSMUST00000106148 ens|L-xylulose reductase (XR)(EC 1.1.1.10)(Dicarbonyl/L-xylulose reductase) [Source:UniProtKB/Swiss-Prot;Acc: 
Q91X52]  
7.95 1.810 7.00E-05 A_55_P1985433 Nrg1 NM_178591 ref|Mus musculus neuregulin 1 (Nrg1) mRNA  
7.53 1.806 3.00E-05 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
10.40 1.791 3.00E-05 A_51_P424338 Nqo1 NM_008706 ref|Mus musculus NAD(P)H dehydrogenase quinone 1 mRNA  
8.96 1.779 1.00E-05 A_52_P1197913 Gadd45b NM_008655 ref|Mus musculus growth arrest and DNA-damage-inducible 45 beta mRNA  
10.88 1.776 7.00E-05 A_55_P2051596 Gm4499 XM_001479558 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
8.01 1.773 0 A_51_P209736 Atoh8 NM_153778 ref|Mus musculus atonal homolog 8 (Drosophila) mRNA  
7.09 1.771 9.00E-05 A_65_P01247 Hjurp NM_198652 ref|Mus musculus Holliday junction recognition protein mRNA  
9.48 1.757 2.00E-05 A_55_P2143765 Ugt1a6a NM_145079 ref|Mus musculus UDP glucuronosyltransferase 1 family polypeptide A6A mRNA 
7.51 1.738 2.00E-05 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
7.60 1.723 0 A_51_P291501 Ccno NM_001081062 ref|Mus musculus cyclin O mRNA  
9.00 1.716 0.00059 A_52_P675395 Cxcr7 NM_007722 ref|Mus musculus chemokine (C-X-C motif) receptor 7 mRNA  
7.62 1.713 1.00E-05 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
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14.07 1.712 0 A_55_P1973352 XM_001476722 XM_001476722 ref|PREDICTED: Mus musculus hypothetical protein LOC100041156 mRNA  
11.70 1.710 9.00E-05 A_55_P1998811 Gm3430 XM_001476688 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
13.76 1.706 4.00E-04 A_51_P315904 Gadd45g NM_011817 ref|Mus musculus growth arrest and DNA-damage-inducible 45 gamma mRNA  
7.20 1.697 0 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
11.64 1.692 0 A_55_P2171116 Lgals3 NM_001145953 ref|Mus musculus lectin galactose binding soluble 3 transcript variant 1 mRNA  
12.75 1.690 4.00E-05 A_51_P265495 Ly6a NM_010738 ref|Mus musculus lymphocyte antigen 6 complex locus A mRNA  
8.91 1.682 1.00E-05 A_55_P2164075 LOC100048172 XM_001479672 ref|PREDICTED: Mus musculus hypothetical protein LOC100048172 mRNA  
11.69 1.676 0.00079 A_55_P2108151 ENSMUST00000023934 ENSMUST00000023934 ens|Hemoglobin subunit beta-1 (Hemoglobin beta-1 chain)(Beta-1-globin)(Hemoglobin beta-major chain) 
[Source:UniProtKB/Swiss-Prot;Acc:P02088]  
8.32 1.657 0 A_55_P2040860 Sunc1 NM_177576 ref|Mus musculus Sad1 and UNC84 domain containing 1 mRNA  
9.60 1.649 2.00E-05 A_51_P450278 2010003K11Rik NM_027237 ref|Mus musculus RIKEN cDNA 2010003K11 gene mRNA  
7.52 1.648 5.00E-05 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA 
8.01 1.642 2.00E-05 A_51_P163578 Ugt2b35 NM_172881 ref|Mus musculus UDP glucuronosyltransferase 2 family polypeptide B35 mRNA  
13.29 1.640 1.00E-05 A_51_P181319 Dcxr NM_026428 ref|Mus musculus dicarbonyl L-xylulose reductase mRNA  
11.04 1.636 1.00E-05 A_51_P509669 Uap1l1 NM_001033293 ref|Mus musculus UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 mRNA  
7.55 1.635 0.00017 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
13.43 1.629 1.00E-04 A_51_P329441 Bsg NM_009768 ref|Mus musculus basigin transcript variant 1 mRNA  
8.67 1.628 1.00E-05 A_51_P286488 Ier3 NM_133662 ref|Mus musculus immediate early response 3 mRNA  
7.91 1.590 0.00117 A_55_P2334424 D630024D03Rik AK158188 gb|Mus musculus adult inner ear cDNA RIKEN full-length enriched library clone:F930039G01 product: 
unclassifiable full insert sequence 
9.90 1.584 5.00E-05 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
12.06 1.570 0 A_51_P411271 Nfe2l2 NM_010902 ref|Mus musculus nuclear factor erythroid derived 2 like 2 mRNA  
10.98 1.567 0 A_51_P378622 0610012H03Rik NM_028747 ref|Mus musculus RIKEN cDNA 0610012H03 gene transcript variant 1 mRNA  
15.63 1.559 2.00E-05 A_55_P1961014 Selenbp1 NM_009150 ref|Mus musculus selenium binding protein 1 mRNA  
10.73 1.544 0 A_51_P441914 Hsd17b2 NM_008290 ref|Mus musculus hydroxysteroid (17-beta) dehydrogenase 2mRNA  
7.67 1.543 6.00E-05 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2mRNA  
7.14 1.526 4.00E-05 A_55_P1985304 Krtap5-3 NM_023860 ref|Mus musculus keratin associated protein 5-3 mRNA  
9.85 1.518 4.00E-05 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
7.53 1.518 0.00047 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
10.60 1.515 5.00E-05 A_51_P419637 Dclk3 NM_172928 ref|Mus musculus doublecortin-like kinase 3 mRNA  
12.45 1.512 0 A_55_P1952399 Cyp4a31 NM_201640 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 31 mRNA  
9.97 1.509 0 A_55_P2110512 Lmo7 NM_201529 ref|Mus musculus LIM domain only 7 mRNA  
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11.31 1.507 3.00E-05 A_55_P2024033 Cyp4a31 NM_201640 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 31 mRNA  
9.84 1.505 4.00E-05 A_51_P287198 Krt23 NM_033373 ref|Mus musculus keratin 23 mRNA 
9.78 1.504 0.00078 A_51_P515605 Col3a1 NM_009930 ref|Mus musculus collagen type III alpha 1 mRNA  
12.76 1.495 1.00E-05 A_55_P2065231 Gstm3 NM_010359 ref|Mus musculus glutathione S-transferase mu 3 mRNA  
10.27 1.491 0 A_55_P2219059 Lmnb2 NM_010722 ref|Mus musculus lamin B2 mRNA  
8.71 1.486 2.00E-05 A_55_P2140941 Tinagl1 NM_023476 ref|Mus musculus tubulointerstitial nephritis antigen-like 1 transcript variant 1 mRNA  
14.47 1.483 0.00014 A_55_P1966432 Gstm1 NM_010358 ref|Mus musculus glutathione S-transferase mu 1 mRNA  
8.64 1.482 5.00E-05 A_52_P487436 Nags NM_145829 ref|Mus musculus N-acetylglutamate synthase transcript variant 1 mRNA  
8.04 1.474 0.00038 A_52_P402786 Prom1 NM_008935 ref|Mus musculus prominin 1 transcript variant 1 mRNA  
11.33 1.467 0 A_55_P2038347 Acot3 NM_134246 ref|Mus musculus acyl-CoA thioesterase 3 mRNA  
7.30 1.463 1.00E-04 A_55_P1967196 Lamb3 NM_008484 ref|Mus musculus laminin beta 3 mRNA 
8.92 1.463 4.00E-05 A_51_P387123 Oasl2 NM_011854 ref|Mus musculus 2'-5' oligoadenylate synthetase-like 2 mRNA  
7.24 1.462 0.00035 A_55_P2051796 Gm128 NM_001024841 ref|Mus musculus predicted gene 128 mRNA  
8.98 1.459 1.00E-04 A_55_P2037121 Tmem106a NM_144830 ref|Mus musculus transmembrane protein 106A mRNA  
13.24 1.456 0 A_55_P2006236 Ugdh NM_009466 ref|Mus musculus UDP-glucose dehydrogenase mRNA  
8.63 1.455 1.00E-05 A_55_P1988368 Upp1 NM_009477 ref|Mus musculus uridine phosphorylase 1 transcript variant 1 mRNA  
8.82 1.442 0.00044 A_52_P2710 Cml5 NM_023493 ref|Mus musculus camello-like 5 mRNA  
7.90 1.441 0.00015 A_52_P552665 Fzd7 NM_008057 ref|Mus musculus frizzled homolog 7 (Drosophila) mRNA  
9.32 1.439 0.00011 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
7.71 1.437 3.00E-05 A_51_P286737 Ccl2 NM_011333 ref|Mus musculus chemokine (C-C motif) ligand 2 mRNA  
9.46 1.436 0.00017 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
16.21 1.435 1.00E-05 A_55_P1962404 Ugt1a6a NM_145079 ref|Mus musculus UDP glucuronosyltransferase 1 family polypeptide A6A mRNA  
7.68 1.412 0.00012 A_51_P390715 Tgfb1 NM_011577 ref|Mus musculus transforming growth factor beta 1 mRNA  
9.06 1.403 0.00024 A_66_P121583 Gm7120 NM_001039244 ref|Mus musculus predicted gene 7120 mRNA  
11.33 1.398 0 A_51_P215922 Casp6 NM_009811 ref|Mus musculus caspase 6 mRNA  
10.21 1.392 1.00E-04 A_52_P151320 Tnfaip8l1 NM_025566 ref|Mus musculus tumor necrosis factor alpha-induced protein 8-like 1 mRNA  
9.83 1.386 0.00029 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
10.24 1.385 2.00E-05 A_55_P2107785 Gm13105 XM_001475876 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
8.18 1.384 1.00E-05 A_52_P452166 Grpel2 NM_021296 ref|Mus musculus GrpE-like 2 mitochondrial nuclear gene encoding mitochondrial protein mRNA  
10.75 1.384 6.00E-05 A_55_P2110513 Lmo7 NM_201529 ref|Mus musculus LIM domain only 7 mRNA  
9.59 1.381 4.00E-05 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
9.90 1.381 0.00011 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA 
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7.60 1.380 4.00E-05 A_55_P1967350 Ugt2b35 NM_172881 ref|Mus musculus UDP glucuronosyltransferase 2 family polypeptide B35 mRNA  
11.29 1.380 6.00E-05 A_55_P2114318 Gm4080 XM_001478955 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
13.81 1.374 2.00E-05 A_55_P2092030 Cyp4a10 NM_010011 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 10 mRNA  
8.67 1.368 3.00E-05 A_51_P392967 Zmynd10 NM_053253 ref|Mus musculus zinc finger MYND domain containing 10 mRNA  
7.95 1.364 0.00016 A_52_P78373 Sorbs3 NM_011366 ref|Mus musculus sorbin and SH3 domain containing 3 mRNA  
8.23 1.360 3.00E-05 A_52_P322941 Gm11992 NM_001037928 ref|Mus musculus predicted gene 11992 mRNA  
7.90 1.359 0.00057 A_51_P146560 Msln NM_018857 ref|Mus musculus mesothelin mRNA  
8.21 1.358 3.00E-05 A_55_P2130627 2210404O07Rik NM_001099917 ref|Mus musculus RIKEN cDNA 2210404O07 gene mRNA  
9.41 1.351 1.00E-04 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen  type IV alpha 1 mRNA 
10.01 1.347 4.00E-05 A_51_P491350 Col4a2 NM_009932 ref|Mus musculus collagen type IV alpha 2 mRNA  
10.82 1.346 3.00E-05 A_51_P165060 Slc22a5 NM_011396 ref|Mus musculus solute carrier family 22 (organic cation transporter) member 5 mRNA  
9.66 1.341 0.00043 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
9.51 1.340 8.00E-05 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
9.21 1.330 1.00E-05 A_55_P2114953 Usp18 NM_011909 ref|Mus musculus ubiquitin specific peptidase 18 mRNA  
7.97 1.325 0.0016 A_51_P390715 Tgfb1 NM_011577 ref|Mus musculus transforming growth factor beta 1 mRNA  
9.46 1.322 0.00096 A_51_P371750 Marco NM_010766 ref|Mus musculus macrophage receptor with collagenous structure mRNA  
11.08 1.318 1.00E-05 A_55_P2063312 Mgll NM_001166250 ref|Mus musculus monoglyceride lipase transcript variant 4 mRNA  
8.33 1.317 3.00E-04 A_55_P2183914 Gm7120 NM_001039244 ref|Mus musculus predicted gene 7120 mRNA  
7.84 1.303 0.00074 A_51_P390715 Tgfb1 NM_011577 ref|Mus musculus transforming growth factor beta 1 mRNA  
9.76 1.299 3.00E-05 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
11.99 1.297 1.00E-05 A_55_P1971962 Tmem176b NM_023056 ref|Mus musculus transmembrane protein 176B transcript variant 1 mRNA  
7.42 1.295 0.00131 A_52_P354373 1190002F15Rik XM_001481164 ref|PREDICTED: Mus musculus RIKEN cDNA 1190002F15 gene mRNA  
8.72 1.292 5.00E-05 A_52_P44030 Exoc3 NM_177333 ref|Mus musculus exocyst complex component 3 mRNA  
8.35 1.29 0.00059 A_51_P322273 Ptp4a3 NM_008975 ref|Mus musculus protein tyrosine phosphatase 4a3 transcript variant 2 mRNA  
7.58 1.286 0.00018 A_51_P155755 Pld6 NM_183139 ref|Mus musculus phospholipase D family member 6 mRNA  
10.40 1.282 0.00029 A_55_P1966438 Gstm2 NM_008183 ref|Mus musculus glutathione S-transferase mu 2 mRNA  
14.04 1.281 2.00E-05 A_51_P319070 Retsat NM_026159 ref|Mus musculus retinol saturase (all trans retinol 1314 reductase) mRNA  
9.45 1.279 0.00019 A_55_P2016462 Cxcl10 NM_021274 ref|Mus musculus chemokine (C-X-C motif) ligand 10 mRNA  
9.36 1.279 6.00E-04 A_55_P2142527 Gm13770 XM_884324 ref|PREDICTED: Mus musculus similar to CGI-140 protein mRNA  
8.14 1.278 0.00011 A_51_P320304 Plod1 NM_011122 ref|Mus musculus procollagen-lysine 2-oxoglutarate 5-dioxygenase 1 mRNA  
11.54 1.275 1.00E-05 A_55_P1954718 Cyb561 NM_007805 ref|Mus musculus cytochrome b-561 mRNA  
10.94 1.275 0.00016 A_55_P2007495 Gm2034 XM_001472204 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
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7.81 1.268 0.00071 A_52_P283524 Rcan3 NM_022980 ref|Mus musculus regulator of calcineurin 3 mRNA  
9.67 1.266 0.00101 A_51_P341108 Spint1 NM_016907 ref|Mus musculus serine protease inhibitor Kunitz type 1 mRNA  
8.46 1.266 1.00E-05 A_51_P478952 N4bp2l1 NM_133898 ref|Mus musculus NEDD4 binding protein 2-like 1 mRNA  
11.63 1.265 7.00E-05 A_55_P2009861 Gm2015 XM_001472138 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
9.97 1.260 0 A_55_P1994939 Hmgb2 NM_008252 ref|Mus musculus high mobility group box 2 mRNA  
7.28 1.260 0.00032 A_55_P2106241 4930432K21Rik NM_029045 ref|Mus musculus RIKEN cDNA 4930432K21 gene transcript variant 1 mRNA  
7.96 1.260 0.00107 A_51_P347862 Actn1 NM_134156 ref|Mus musculus actinin alpha 1 mRNA  
10.10 1.256 7.00E-05 A_55_P2102060 Gstm3 NM_010359 ref|Mus musculus glutathione S-transferase mu 3 mRNA  
11.89 1.255 0.0014 A_51_P259296 Lpl NM_008509 ref|Mus musculus lipoprotein lipase mRNA  
12.20 1.251 0.00033 A_51_P346938 Lrg1 NM_029796 ref|Mus musculus leucine-rich alpha-2-glycoprotein 1 mRNA  
13.21 1.250 2.00E-05 A_55_P1987620 Cyp4a32 NM_001100181 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 32 mRNA  
8.77 1.247 0.00051 A_55_P2018417 Osbpl3 NM_001163645 ref|Mus musculus oxysterol binding protein-like 3 transcript variant 2 mRNA  
8.52 1.246 2.00E-05 A_51_P172853 Cd14 NM_009841 ref|Mus musculus CD14 antigen mRNA  
13.38 1.245 0.00016 A_55_P2071952 Wdr92 NM_178909 ref|Mus musculus WD repeat domain 92 mRNA  
12.95 1.244 8.00E-05 A_52_P515094 Tmem176a NM_025326 ref|Mus musculus transmembrane protein 176A transcript variant 1 mRNA 
9.05 1.238 2.00E-05 A_66_P134090 Grpel2 NM_021296 ref|Mus musculus GrpE-like 2 mitochondrial nuclear gene encoding mitochondrial protein mRNA  
8.15 1.237 1.00E-05 A_51_P401343 Cldn14 NM_019500 ref|Mus musculus claudin 14 transcript variant 1 mRNA  
10.24 1.236 2.00E-04 A_51_P350453 Pdk4 NM_013743 ref|Mus musculus pyruvate dehydrogenase kinase isoenzyme 4 mRNA  
11.56 1.23 0.00012 A_55_P2011436 Gm11223 XM_001474074 ref|PREDICTED: Mus musculus similar to Pr22 transcript variant 1 mRNA  
11.72 1.229 1.00E-05 A_55_P2072908 A_55_P2072908 A_55_P2072908 Unknown 
7.81 1.229 8.00E-04 A_55_P2005700 Gm10651 XM_001479811 ref|PREDICTED: Mus musculus similar to Josephin domain containing 1 mRNA  
13.41 1.228 0.00055 A_51_P447545 Igfbp1 NM_008341 ref|Mus musculus insulin-like growth factor binding protein 1 mRNA  
9.92 1.227 0.00059 A_51_P203955 Gbp2 NM_010260 ref|Mus musculus guanylate binding protein 2 mRNA  
16.38 1.222 1.00E-05 A_66_P125722 Cyb5 NM_025797 ref|Mus musculus cytochrome b-5 mRNA 
7.93 1.22 0.00166 A_51_P390715 Tgfb1 NM_011577 ref|Mus musculus transforming growth factor beta 1 mRNA  
8.32 1.219 6.00E-05 A_51_P315795 Tubb4 NM_009451 ref|Mus musculus tubulin beta 4 mRNA  
8.14 1.213 0.00012 A_52_P409731 Scamp5 NM_020270 ref|Mus musculus secretory carrier membrane protein 5 mRNA  
7.91 1.212 0.00056 A_51_P390715 Tgfb1 NM_011577 ref|Mus musculus transforming growth factor beta 1 mRNA  
12.43 1.206 4.00E-05 A_51_P189746 Pim3 NM_145478 ref|Mus musculus proviral integration site 3 mRNA  
10.04 1.202 7.00E-05 A_55_P2162815 ENSMUST00000059018 ENSMUST00000059018 ens|Putative uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:Q9D1L2]  
9.24 1.200 0.00017 A_55_P2120545 Wdtc1 NM_199306 ref|Mus musculus WD and tetratricopeptide repeats 1 mRNA  
9.84 1.199 1.00E-05 A_55_P1974645 Entpd2 NM_009849 ref|Mus musculus ectonucleoside triphosphate diphosphohydrolase 2 mRNA 
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7.22 1.196 0.00051 A_66_P114784 Pla2g7 NM_013737 ref|Mus musculus phospholipase A2 group VII (platelet-activating factor acetylhydrolase plasma) mRNA  
10.28 1.196 0.00014 A_55_P2058117 Slc35d1 NM_177732 ref|Mus musculus solute carrier family 35 (UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter) 
member D1 mRNA  
9.33 1.195 0.00102 A_55_P2007496 Gm2045 XM_001472254 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
11.11 1.194 0.00014 A_52_P681391 G0s2 NM_008059 ref|Mus musculus G0/G1 switch gene 2 mRNA  
10.42 1.192 0.00011 A_51_P312121 Xdh NM_011723 ref|Mus musculus xanthine dehydrogenase  mRNA  
7.55 1.192 0.00011 A_52_P121491 Msrb3 NM_177092 ref|Mus musculus methionine sulfoxide reductase B3 mRNA  
12.81 1.187 0.00017 A_51_P292008 Gpx3 NM_008161 ref|Mus musculus glutathione peroxidase 3 transcript variant 2 mRNA  
17.03 1.186 0.00063 A_51_P311540 Cox6a1 NM_007748 ref|Mus musculus cytochrome c oxidase subunit VI a polypeptide 1 nuclear gene encoding mitochondrial protein 
mRNA  
15.02 1.186 3.00E-05 A_55_P2170454 Gsta2 NM_008182 ref|Mus musculus glutathione S-transferase alpha 2 (Yc2) mRNA  
15.17 1.186 6.00E-05 A_55_P2050628 Cyp4a31 NM_201640 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 31 mRNA  
10.78 1.184 2.00E-05 A_55_P2043862 Stmn1 NM_019641 ref|Mus musculus stathmin 1 mRNA  
12.30 1.184 0.00011 A_65_P02177 Gstm4 NM_026764 ref|Mus musculus glutathione S-transferase mu 4 transcript variant 1 mRNA  
8.06 1.184 0.00024 A_66_P140507 Lhpp NM_029609 ref|Mus musculus phospholysine phosphohistidine inorganic pyrophosphate phosphatase mRNA  
7.88 1.182 0.00156 A_55_P1996941 Ube2c NM_026785 ref|Mus musculus ubiquitin-conjugating enzyme E2C (Ube2c) mRNA [NM_026785] 
7.52 1.178 0.00031 A_55_P2178798 LOC100048662 XM_001480833 ref|PREDICTED: Mus musculus similar to UDP glycosyltransferase 1 family polypeptide A13 mRNA  
8.13 1.177 0.00095 A_52_P447944 Epcam NM_008532 ref|Mus musculus epithelial cell adhesion molecule mRNA  
11.40 1.171 1.00E-04 A_51_P238448 Ccnd3 NM_007632 ref|Mus musculus cyclin D3 transcript variant 1 mRNA  
10.82 1.171 0.00031 A_66_P128963 Cyp2d9 NM_010006 ref|Mus musculus cytochrome P450 family 2 subfamily d polypeptide 9 mRNA  
9.08 1.170 7.00E-05 A_52_P111031 Pcdh17 NM_001013753 ref|Mus musculus protocadherin 17 mRNA  
9.84 1.169 0.00059 A_51_P124254 Col4a1 NM_009931 ref|Mus musculus collagen type IV alpha 1 mRNA  
11.83 1.169 0 A_51_P282667 Hexa NM_010421 ref|Mus musculus hexosaminidase A mRNA  
7.89 1.169 0.00033 A_55_P1967168 Lrp4 NM_172668 ref|Mus musculus low density lipoprotein receptor-related protein 4 transcript variant 1 mRNA  
12.17 1.165 2.00E-05 A_52_P358860 Gss NM_008180 ref|Mus musculus glutathione synthetase mRNA  
9.67 1.164 0.00041 A_55_P2016623 Gm5068 XM_204772 ref|PREDICTED: Mus musculus predicted gene EG277089 mRNA  
10.06 1.163 0.00019 A_55_P2006255 Txnip NM_001009935 ref|Mus musculus thioredoxin interacting protein transcript variant 1 mRNA  
15.33 1.163 0.00011 A_51_P254895 Cyp4a10 NM_010011 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 10 mRNA  
7.76 1.162 0.00059 A_51_P146753 Csf2rb2 NM_007781 ref|Mus musculus colony stimulating factor 2 receptor beta 2 low-affinity (granulocyte-macrophage) mRNA  
12.00 1.160 6.00E-05 A_55_P2036240 Gm3804 XM_001478041 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
12.83 1.159 0.00014 A_51_P191611 Cat NM_009804 ref|Mus musculus catalase  mRNA  
9.58 1.154 0.00027 A_66_P111021 Nlrp6 NM_001081389 ref|Mus musculus NLR family pyrin domain containing 6 mRNA  
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10.39 1.152 0.00053 A_55_P2024046 Slc16a5 NM_001080934 ref|Mus musculus solute carrier family 16 (monocarboxylic acid transporters) member 5 mRNA  
11.04 1.150 5.00E-05 A_52_P295533 Slc25a28 NM_145156 ref|Mus musculus solute carrier family 25 member 28 mRNA  
8.58 1.148 3.00E-04 A_55_P2164957 Slc9a3r2 NM_023055 ref|Mus musculus solute carrier family 9 (sodium/hydrogen exchanger) member 3 regulator 2 transcript variant A 
mRNA 
15.88 1.142 0.00036 A_55_P1983733 Aldh1l1 NM_027406 ref|Mus musculus aldehyde dehydrogenase 1 family member L1 mRNA  
7.98 1.139 0.00046 A_51_P418116 Tmem119 NM_146162 ref|Mus musculus transmembrane protein 119 mRNA 
9.68 1.138 1.00E-05 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
8.48 1.136 0.00028 A_66_P116888 Arid1a NM_001080819 ref|Mus musculus AT rich interactive domain 1A (SWI-like) mRNA  
8.26 1.133 0.00117 A_51_P114634 Amz1 NM_173405 ref|Mus musculus archaelysin family metallopeptidase 1 mRNA  
8.18 1.13 0.00011 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
7.76 1.128 0.00171 A_52_P452787 Pdcd6ip NM_011052 ref|Mus musculus programmed cell death 6 interacting protein transcript variant 3 mRNA  
9.76 1.127 3.00E-05 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
7.84 1.126 0.00115 A_51_P390715 Tgfb1 NM_011577 ref|Mus musculus transforming growth factor beta 1 mRNA  
10.22 1.123 4.00E-04 A_51_P351860 C1qb NM_009777 ref|Mus musculus complement component 1 q subcomponent beta polypeptide mRNA  
8.88 1.123 2.00E-05 A_52_P408757 Fcgr3 NM_010188 ref|Mus musculus Fc receptor IgG low affinity III mRNA  
7.05 1.117 0.00151 A_55_P2065249 ENSMUST00000063239 ENSMUST00000063239 ens|Putative uncharacterized protein [Source:UniProtKB/TrEMBL;Acc:Q9D605]  
7.86 1.117 0.00024 A_55_P2096599 Tsc22d4 NM_023910 ref|Mus musculus TSC22 domain family member 4 mRNA  
8.25 1.115 0.00011 A_51_P117130 Naga NM_008669 ref|Mus musculus N-acetyl galactosaminidase alpha mRNA  
7.33 1.115 8.00E-05 A_51_P116447 Xpo6 NM_028816 ref|Mus musculus exportin 6 mRNA  
8.30 1.112 0.00017 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
13.53 1.112 4.00E-05 A_51_P405606 Ndrg1 NM_008681 ref|Mus musculus N-myc downstream regulated gene 1 mRNA  
9.16 1.107 0.0018 A_52_P282905 Gm5158 NM_001081372 ref|Mus musculus predicted gene 5158 mRNA  
10.90 1.103 0.00033 A_55_P1993940 Sh3bgrl3 NM_080559 ref|Mus musculus SH3 domain binding glutamic acid-rich protein-like 3 mRNA  
13.11 1.101 2.00E-05 A_55_P2068988 Gm5678 XM_487442 ref|PREDICTED: Mus musculus predicted gene EG435489 mRNA  
8.47 1.100 0.00053 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
9.18 1.094 0.00012 A_55_P2070657 2310044H10Rik NM_197991 ref|Mus musculus RIKEN cDNA 2310044H10 gene mRNA  
10.09 1.093 5.00E-05 A_66_P119884 Wdr91 NM_001013366 ref|Mus musculus WD repeat domain 91 mRNA  
10.45 1.093 0.00018 A_55_P2065991 S100a11 NM_016740 ref|Mus musculus S100 calcium binding protein A11 (calgizzarin) mRNA  
7.79 1.092 5.00E-05 A_55_P2058783 2310016C08Rik NM_023516 ref|Mus musculus RIKEN cDNA 2310016C08 gene mRNA  
11.65 1.091 0.00041 A_55_P2068663 Stmn1 NM_019641 ref|Mus musculus stathmin 1 mRNA  
7.96 1.090 0.00165 A_55_P2010912 Jak3 NM_010589 ref|Mus musculus Janus kinase 3 mRNA  
10.91 1.089 0.00024 A_55_P2002577 Ephx1 NM_010145 ref|Mus musculus epoxide hydrolase 1 microsomal  mRNA  
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8.89 1.089 6.00E-05 A_51_P407774 Slc22a21 NM_019723 ref|Mus musculus solute carrier family 22 (organic cation transporter) member 21 mRNA  
9.74 1.085 0.00017 A_51_P244492 Nbl1 NM_008675 ref|Mus musculus neuroblastoma suppression of tumorigenicity 1 mRNA  
15.52 1.085 6.00E-05 A_55_P2011111 Cyp4a10 NM_010011 ref|Mus musculus cytochrome P450 family 4 subfamily a polypeptide 10 (Cyp4a10) mRNA  
16.62 1.082 0.00061 A_55_P1962299 Hba-a2 NM_001083955 ref|Mus musculus hemoglobin alpha adult chain 2 mRNA  
8.49 1.081 1.00E-05 A_51_P168203 Aig1 NM_025446 ref|Mus musculus androgen-induced 1 mRNA  
13.67 1.077 0 A_55_P2128821 Selk NM_019979 ref|Mus musculus selenoprotein K mRNA  
13.34 1.076 1.00E-05 A_51_P284486 Gstm2 NM_008183 ref|Mus musculus glutathione S-transferase mu 2 mRNA  
8.57 1.075 0.00011 A_55_P2077783 Tubb2a-ps2 NR_003964 ref|Mus musculus tubulin beta 2a pseudogene 2 non-coding RNA  
8.28 1.074 0.0012 A_51_P117130 Naga NM_008669 ref|Mus musculus N-acetyl galactosaminidase alpha mRNA  
8.85 1.074 0.00015 A_55_P2055875 Josd2 NM_025368 ref|Mus musculus Josephin domain containing 2 mRNA  
13.97 1.072 0.00035 A_55_P1999648 Plin2 NM_007408 ref|Mus musculus perilipin 2 mRNA  
13.53 1.072 1.00E-05 A_51_P350048 Gstt2 NM_010361 ref|Mus musculus glutathione S-transferase theta 2 mRNA  
12.04 1.072 0.00029 A_55_P2090505 Gm4382 XM_001480011 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
10.03 1.071 0.00092 A_55_P2145833 ENSMUST00000108472 ENSMUST00000108472 ens|Myotonin-protein kinase (EC 2.7.11.1)(Myotonic dystrophy protein kinase)(MDPK)(DM-
kinase)(DMK)(DMPK)(MT-PK) [Source:UniProtKB/Swiss-Prot;Acc:P54265]  
7.41 1.071 0.00012 A_51_P100573 Map3k3 NM_011947 ref|Mus musculus mitogen-activated protein kinase kinase kinase 3 mRNA  
9.64 1.068 0.00011 A_52_P188678 Pvrl2 NM_001159724 ref|Mus musculus poliovirus receptor-related 2 transcript variant 2 mRNA  
8.25 1.065 2.00E-05 A_51_P352594 St5 NM_001001326 ref|Mus musculus suppression of tumorigenicity 5  transcript variant 1 mRNA  
9.99 1.061 0.00011 A_55_P2011551 Anapc5 AK168135 gb|Mus musculus CRL-1722 L5178Y-R cDNA RIKEN full-length enriched library clone:I730060B02 product: 
anaphase-promoting complex subunit 5 full insert sequence.  
8.04 1.061 0.00043 A_55_P2174836 Vldlr NM_013703 ref|Mus musculus very low density lipoprotein receptor transcript variant 1 mRNA  
9.97 1.060 3.00E-05 A_51_P251587 Psmd9 NM_026000 ref|Mus musculus proteasome (prosome macropain) 26S subunit non-ATPase 9 mRNA  
9.60 1.059 0.00037 A_51_P460954 Ccl6 NM_009139 ref|Mus musculus chemokine (C-C motif) ligand 6 mRNA  
12.83 1.059 5.00E-05 A_55_P2105843 Gm2371 XM_001472740 ref|PREDICTED: Mus musculus similar to pol protein mRNA  
9.37 1.057 0.00014 A_51_P384754 Ldb1 NM_010697 ref|Mus musculus LIM domain binding 1 transcript variant 3 mRNA  
12.31 1.057 0.00054 A_55_P2179413 Lgals3bp NM_011150 ref|Mus musculus lectin galactoside-binding soluble 3 binding protein mRNA  
10.65 1.054 3.00E-05 A_55_P2140031 Fam129b NM_146119 ref|Mus musculus family with sequence similarity 129 member B mRNA  
9.50 1.053 0.00085 A_55_P1954643 Gm2708 XM_001474512 ref|PREDICTED: Mus musculus hypothetical protein LOC100040315 mRNA  
7.78 1.051 0.00087 A_55_P2295933 Elmo3 NM_172760 ref|Mus musculus engulfment and cell motility 3 ced-12 homolog (C. elegans) mRNA  
9.87 1.050 0.00076 A_55_P2110978 Atp6ap1 NM_018794 ref|Mus musculus ATPase H+ transporting lysosomal accessory protein 1 mRNA  
9.74 1.048 0 A_52_P148678 ENSMUST00000109462 ENSMUST00000109462 ens|1-phosphatidylinositol-45-bisphosphate phosphodiesterase gamma-1 (EC 3.1.4.11)(Phosphoinositide 
phospholipase C)(Phospholipase C-gamma-1)(PLC-gamma-1)(PLC-II)(PLC-148) [Source:UniProtKB/Swiss-
Prot;Acc:Q62077]  
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7.76 1.047 0.00133 A_55_P1974421 Itga3 NM_013565 ref|Mus musculus integrin alpha 3 mRNA  
7.07 1.045 0.00062 A_51_P362013 Rexo1 NM_025852 ref|Mus musculus REX1 RNA exonuclease 1 homolog (S. cerevisiae) transcript variant 1 mRNA  
7.52 1.045 0.00076 A_51_P118223 Gm1943 NR_002928 ref|Mus musculus predicted gene 1943 non-coding RNA  
12.97 1.044 0.00034 A_55_P2156625 A_55_P2156625 A_55_P2156625 Unknown 
9.21 1.044 0.00015 A_55_P1968193 Fhit NM_010210 ref|Mus musculus fragile histidine triad gene mRNA  
10.44 1.043 0.00051 A_51_P405476 Fcer1g NM_010185 ref|Mus musculus Fc receptor IgE high affinity I gamma polypeptide mRNA  
12.61 1.041 0.00016 A_51_P505493 Elovl5 NM_134255 ref|Mus musculus ELOVL family member 5 elongation of long chain fatty acids (yeast) mRNA  
8.15 1.039 0.00015 A_52_P46310 Dcaf7 NM_027946 ref|Mus musculus DDB1 and CUL4 associated factor 7 mRNA  
7.97 1.039 0.00103 A_51_P446825 6430573F11Rik NM_176952 ref|Mus musculus RIKEN cDNA 6430573F11 gene mRNA  
13.40 1.038 3.00E-04 A_51_P472901 Slc3a2 NM_008577 ref|Mus musculus solute carrier family 3 (activators of dibasic and neutral amino acid transport) member 2 
transcript variant 2 mRNA  
7.35 1.038 8.00E-05 A_55_P2035286 Uhrf1 NM_010931 ref|Mus musculus ubiquitin-like containing PHD and RING finger domains 1 transcript variant 1 mRNA  
7.50 1.038 0.0016 A_51_P279639 Col6a2 NM_146007 ref|Mus musculus collagen type VI alpha 2 mRNA  
10.95 1.036 3.00E-05 A_52_P215170 Acot4 NM_134247 ref|Mus musculus acyl-CoA thioesterase 4 mRNA  
10.79 1.035 0.00147 A_51_P426276 Pdk2 AF267660 gb|Mus musculus pyruvate dehydrogenase kinase 2 mRNA complete cds 
13.29 1.034 0.00012 A_55_P2063316 Mgll NM_001166251 ref|Mus musculus monoglyceride lipase transcript variant 1 mRNA  
9.37 1.034 0.00012 A_55_P2043892 Srd5a3 NM_020611 ref|Mus musculus steroid 5 alpha-reductase 3 (mRNA  
9.04 1.033 7.00E-05 A_66_P119034 Pla2g7 NM_013737 ref|Mus musculus phospholipase A2 group VII (platelet-activating factor acetylhydrolase plasma) mRNA  
9.89 1.032 0.00045 A_55_P2128181 A_55_P2128181 A_55_P2128181 Unknown 
8.57 1.030 0.00146 A_52_P680038 Cdk16 NM_011049 ref|Mus musculus cyclin-dependent kinase 16 mRNA  
11.52 1.029 9.00E-05 A_51_P450527 Tagln NM_011526 ref|Mus musculus transgelin mRNA 
10.55 1.027 0.00133 A_51_P220993 Pfn1 NM_011072 ref|Mus musculus profilin 1 mRNA  
7.46 1.027 0.00142 A_55_P2104617 Kctd5 NM_027008 ref|Mus musculus potassium channel tetramerisation domain containing 5 mRNA  
8.35 1.027 0.00174 A_55_P2183433 Rab30 NM_029494 ref|Mus musculus RAB30 member RAS oncogene family mRNA  
9.23 1.027 3.00E-05 A_52_P432570 Chdh NM_175343 ref|Mus musculus choline dehydrogenase transcript variant 2 mRNA  
9.03 1.026 3.00E-05 A_52_P602091 Csf1r NM_001037859 ref|Mus musculus colony stimulating factor 1 receptor mRNA  
8.63 1.024 0.00086 A_55_P2128646 Gmnn NM_020567 ref|Mus musculus geminin mRNA  
9.12 1.021 0.00149 A_51_P246653 Clec7a NM_020008 ref|Mus musculus C-type lectin domain family 7 member a mRNA  
13.09 1.020 0.00012 A_55_P2134004 Gstm2 NM_008183 ref|Mus musculus glutathione S-transferase mu 2 mRNA  
8.70 1.019 0.00012 A_52_P153189 Arl2bp NM_024269 ref|Mus musculus ADP-ribosylation factor-like 2 binding protein transcript variant 2 mRNA  
9.83 1.019 0.00048 A_51_P455906 Pold4 NM_027196 ref|Mus musculus polymerase (DNA-directed) delta 4 mRNA  
10.40 1.017 7.00E-05 A_52_P320193 Clec2h NM_053165 ref|Mus musculus C-type lectin domain family 2 member h mRNA  
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8.34 1.015 0.00054 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
10.56 1.015 0.00019 A_52_P481182 Stard5 NM_023377 ref|Mus musculus StAR-related lipid transfer (START) domain containing 5 mRNA  
9.45 1.014 0.00028 A_55_P2129309 ENSMUST00000105501 ENSMUST00000105501 ens|forkhead box O3  [Source:RefSeq peptide;Acc:NP_062714]  
14.35 1.010 0.00021 A_66_P108152 Cbr1 NM_007620 ref|Mus musculus carbonyl reductase 1 mRNA  
7.82 1.010 0.00017 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
10.48 1.010 0.00108 A_52_P257812 Lpl NM_008509 ref|Mus musculus lipoprotein lipase mRNA  
11.87 1.007 0.00031 A_55_P1998656 Entpd5 NM_001026214 ref|Mus musculus ectonucleoside triphosphate diphosphohydrolase 5 transcript variant 2 mRNA [ 
9.56 1.007 0.00107 A_52_P418489 Tinagl1 NM_023476 ref|Mus musculus tubulointerstitial nephritis antigen-like 1 transcript variant 1 mRNA  
9.45 1.006 1.00E-05 A_55_P2032192 Tpm1 NM_001164249 ref|Mus musculus tropomyosin 1 alpha transcript variant 2 mRNA  
8.74 1.006 0.00021 A_51_P254646 Jdp2 NM_030887 ref|Mus musculus Jun dimerization protein 2 mRNA  
7.52 1.006 0.0014 A_52_P140881 Slc26a10 NM_177615 ref|Mus musculus solute carrier family 26 member 10 mRNA  
8.14 1.005 0.00041 A_51_P439085 2310016C08Rik NM_023516 ref|Mus musculus RIKEN cDNA 2310016C08 gene mRNA  
9.79 1.000 1.00E-04 A_52_P577384 Il18bp NM_010531 ref|Mus musculus interleukin 18 binding protein mRNA  
 
 
Table 86. All significantly down regulated genes in livers of female Ahr wild-type mice by TCDD (25 µg/kg bw) identified by microarray analysis - mouse 5 days study. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description  
7.24 -4.356 0 A_55_P2129449 Sult3a1 NM_020565 ref|Mus musculus sulfotransferase family 3A member 1 mRNA  
7.70 -3.437 1.00E-05 A_52_P293682 Gm7231 XM_001477336 ref|PREDICTED: Mus musculus predicted gene EG638251 mRNA  
10.45 -3.185 0 A_55_P2006008 Serpinb1a NM_025429 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B  member 1a mRNA 
7.58 -2.970 0 A_52_P614207 LOC100047222 XM_001477680 ref|PREDICTED: Mus musculus similar to anti-glycoprotein-B of human Cytomegalovirus immunoglobulin Vl 
chain mRNA  
8.70 -2.965 0.00143 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.46 -2.960 0.00185 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.60 -2.943 0.00129 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.25 -2.930 0.00152 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.59 -2.929 0.00084 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.70 -2.922 0.001 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
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8.66 -2.915 0.00138 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.70 -2.914 0.00112 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.57 -2.906 0.00097 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
8.71 -2.906 0.00076 A_51_P485421 ENSMUST00000103426 ENSMUST00000103426 ens|Immunoglobulin heavy chain C gene segment [Source:IMGT/GENE-DB;Acc:IGHM]  
7.21 -2.890 0 A_52_P502849 ENSMUST00000103401 ENSMUST00000103401 ens|Immunoglobulin Kappa light chain V gene segment [Source:IMGT/GENE-DB;Acc:IGKV3-4]  
8.83 -2.857 0 A_66_P105270 Hao1 NM_010403 ref|Mus musculus hydroxyacid oxidase 1 liver mRNA  
7.10 -2.822 6.00E-05 A_52_P366803 Cyp3a44 NM_177380 ref|Mus musculus cytochrome P450 family 3  subfamily a polypeptide 44 mRNA  
10.88 -2.796 0.00014 A_55_P1971237 Mup3 NM_001039544 ref|Mus musculus major urinary protein 3 (Mup3) mRNA  
12.64 -2.715 0 A_51_P268529 Csad NM_144942 ref|Mus musculus cysteine sulfinic acid decarboxylase mRNA  
9.63 -2.590 0 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
8.82 -2.585 0 A_52_P100252 Fasn NM_007988 ref|Mus musculus fatty acid synthase mRNA  
8.01 -2.532 0.00058 A_55_P2038183 Insc NM_173767 ref|Mus musculus inscuteable homolog (Drosophila) mRNA  
11.07 -2.528 0.00104 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA  
8.30 -2.492 4.00E-05 A_52_P73552 A1bg NM_001081067 ref|Mus musculus alpha-1-B glycoprotein mRNA  
7.11 -2.481 0 A_66_P134171 ENSMUST00000103384 ENSMUST00000103384 ens|Immunoglobulin Kappa light chain V gene segment [Source:IMGT/GENE-DB;Acc:IGKV8-24]  
11.19 -2.479 6.00E-04 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene  mRNA  
11.03 -2.460 0 A_55_P2165091 Acnat2 NM_145368 ref|Mus musculus acyl-coenzyme A amino acid N-acyltransferase 2 mRNA  
11.18 -2.458 0.00091 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA  
11.00 -2.454 0.00153 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA 
10.59 -2.450 4.00E-05 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA 
11.11 -2.442 0.00134 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA 
10.82 -2.434 0.00026 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA 
10.95 -2.432 0.00042 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA 
9.62 -2.412 0 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
10.54 -2.392 0.0019 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA  
9.64 -2.385 0 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
9.48 -2.357 0 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
10.77 -2.353 0.00013 A_51_P108226 1100001G20Rik NM_183249 ref|Mus musculus RIKEN cDNA 1100001G20 gene mRNA  
12.20 -2.318 0 A_55_P2041723 Mid1ip1 NM_001166635 ref|Mus musculus Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish)) transcript variant 1 mRNA  
9.97 -2.310 0 A_55_P2022074 Klf10 NM_013692 ref|Mus musculus Kruppel-like factor 10 mRNA  
9.91 -2.287 1.00E-05 A_55_P2025343 Mup21 NM_001009550 ref|Mus musculus major urinary protein 21 mRNA  
10.52 -2.274 0 A_51_P440743 Celsr1 NM_009886 ref|Mus musculus cadherin EGF LAG seven-pass G-type receptor 1 (flamingo homolog Drosophila) mRNA  
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9.60 -2.260 0 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
9.14 -2.259 1.00E-05 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
10.77 -2.164 0 A_51_P189733 2810007J24Rik NM_175250 ref|Mus musculus RIKEN cDNA 2810007J24 gene mRNA  
13.71 -2.163 0 A_55_P2025954 Acly NM_134037 ref|Mus musculus ATP citrate lyase mRNA  
13.87 -2.153 0.00055 A_51_P431329 Car3 NM_007606 ref|Mus musculus carbonic anhydrase 3 mRNA  
12.01 -2.152 0 A_51_P463440 Elovl6 NM_130450 ref|Mus musculus ELOVL family member 6 elongation of long chain fatty acids (yeast) mRNA  
9.26 -2.151 0 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
10.43 -2.147 1.00E-05 A_55_P2075263 Acnat2 NM_145368 ref|Mus musculus acyl-coenzyme A amino acid N-acyltransferase 2 mRNA  
11.08 -2.058 0 A_52_P614777 Sucnr1 NM_032400 ref|Mus musculus succinate receptor 1 mRNA  
7.40 -2.026 0.00067 A_51_P513776 LOC640979 XM_918237 ref|PREDICTED: Mus musculus similar to E225 mRNA  
7.84 -1.987 0 A_55_P2258261 1810008I18Rik AK050412 gb|Mus musculus adult male liver tumor cDNA RIKEN full-length enriched library  clone:C730046D02 
product:unclassifiable 
7.20 -1.910 1.00E-05 A_51_P162955 Serpina7 NM_177920 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A (alpha-1 antiproteinase  antitrypsin) member 7 
mRNA  
14.91 -1.906 0 A_55_P1965931 Cml1 NM_023160 ref|Mus musculus camello-like 1 mRNA  
9.17 -1.882 3.00E-05 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
9.35 -1.836 0 A_52_P164136 Arrdc3 NM_001042591 ref|Mus musculus arrestin domain containing 3 mRNA   
7.35 -1.822 0.00012 A_51_P269792 Rad51l1 NM_009014 ref|Mus musculus RAD51-like 1 (S. cerevisiae) mRNA  
9.76 -1.816 0.00023 A_51_P249286 Rgs16 NM_011267 ref|Mus musculus regulator of G-protein signaling 16 mRNA  
8.10 -1.816 0 A_55_P2165324 Acsl3 NM_028817 ref|Mus musculus acyl-CoA synthetase long-chain family member 3 transcript variant 1  mRNA  
7.72 -1.802 3.00E-05 A_55_P1952156 Gm9622 XM_001487821 ref|PREDICTED: Mus musculus hypothetical LOC674389 mRNA  
10.62 -1.784 0 A_55_P2053266 St6galnac6 NM_016973 ref|Mus musculus ST6 (alpha-N-acetyl-neuraminyl-23-beta-galactosyl-1 3)-N-acetylgalactosaminide alpha-26-
sialyltransferase 6 transcript variant 1 mRNA 
8.99 -1.780 1.00E-05 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
7.42 -1.777 0.00149 A_55_P2003911 ENSMUST00000103391 ENSMUST00000103391 ens|Immunoglobulin Kappa light chain V gene segment [Source:IMGT/GENE-DB;Acc:IGKV6-17]  
8.73 -1.761 0 A_51_P161946 E130012A19Rik NM_175332 ref|Mus musculus RIKEN cDNA E130012A19 gene mRNA  
8.62 -1.757 0.00012 A_55_P2006792 Ntrk2 NM_001025074 ref|Mus musculus neurotrophic tyrosine kinase receptor type 2 transcript variant 1 mRNA  
9.04 -1.755 3.00E-05 A_55_P2096043 Acot11 NM_025590 ref|Mus musculus acyl-CoA thioesterase 11 mRNA  
7.54 -1.712 0 A_52_P89335 Tmie NM_146260 ref|Mus musculus transmembrane inner ear mRNA  
12.35 -1.700 1.00E-05 A_55_P2062737 Elovl2 NM_019423 ref|Mus musculus elongation of very long chain fatty acids (FEN1/Elo2 SUR4/Elo3 yeast)-like 2  mRNA  
10.22 -1.687 0.00032 A_55_P2115442 Clec2d NM_053109 ref|Mus musculus C-type lectin domain family 2 member d mRNA  
7.13 -1.684 0 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
8.08 -1.679 0 A_55_P2394308 Fst NM_008046 ref|Mus musculus follistatin mRNA  
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10.23 -1.650 0.00024 A_55_P2172532 C730007P19Rik NM_009286 ref|Mus musculus RIKEN cDNA C730007P19 gene mRNA  
14.93 -1.631 0 A_55_P2186961 Nat8b XM_485799 ref|PREDICTED: Mus musculus predicted gene EG434057 mRNA  
7.00 -1.623 0 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA 
11.48 -1.611 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
8.48 -1.609 3.00E-04 A_51_P483576 ENSMUST00000103743 ENSMUST00000103743 ens|Immunoglobulin Lambda light chain C gene segment [Source:IMGT/GENE-DB;Acc:IGLC3]  
7.94 -1.605 1.00E-05 A_51_P176042 Pklr NM_013631 ref|Mus musculus pyruvate kinase liver and red blood cell nuclear gene encoding mitochondrial protein transcript 
variant 1 mRNA  
11.15 -1.605 0.00081 A_51_P134142 Cyp2c70 NM_145499 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 70 mRNA  
7.24 -1.602 2.00E-05 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
12.54 -1.599 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
10.52 -1.598 0 A_55_P2015753 Enho NM_027147 ref|Mus musculus energy homeostasis associated mRNA  
10.49 -1.596 1.00E-05 A_55_P2048518 Zfpm1 NM_009569 ref|Mus musculus zinc finger protein multitype 1 mRNA  
10.18 -1.590 0.00019 A_55_P2057528 Arl4d NM_025404 ref|Mus musculus ADP-ribosylation factor-like 4D mRNA  
10.08 -1.587 0 A_55_P2143923 Slc13a2 NM_022411 ref|Mus musculus solute carrier family 13 (sodium-dependent dicarboxylate transporter) member 2 mRNA  
11.34 -1.585 1.00E-05 A_55_P2027102 Rgs3 NM_134257 ref|Mus musculus regulator of G-protein signaling 3 transcript variant 2  mRNA  
12.49 -1.583 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
12.48 -1.580 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
10.12 -1.572 6.00E-05 A_55_P2020612 Arl4d NM_025404 ref|Mus musculus ADP-ribosylation factor-like 4D mRNA  
12.45 -1.571 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
8.99 -1.568 0 A_55_P2002557 Srebf1 NM_011480 ref|Mus musculus sterol regulatory element binding transcription factor 1 mRNA  
12.39 -1.567 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
7.14 -1.560 2.00E-05 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
12.38 -1.558 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
12.49 -1.558 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
7.54 -1.555 0 A_55_P1982186 Sgsm1 NM_172718 ref|Mus musculus small G protein signaling modulator 1 transcript variant 1 mRNA  
8.24 -1.553 1.00E-05 A_51_P516085 Dntt NM_009345 ref|Mus musculus deoxynucleotidyltransferase terminal transcript variant 1 mRNA  
8.80 -1.550 3.00E-05 A_55_P2143896 Slc17a2 NM_144836 ref|Mus musculus solute carrier family 17 (sodium phosphate) member 2 mRNA  
12.43 -1.544 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
12.36 -1.544 0 A_51_P114722 Hao2 NM_019545 ref|Mus musculus hydroxyacid oxidase 2 mRNA  
9.30 -1.541 1.00E-05 A_55_P1963134 Gm6135 XM_895691 ref|PREDICTED: Mus musculus predicted gene EG620205 mRNA  
7.25 -1.531 0 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA   
7.03 -1.519 4.00E-05 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
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7.49 -1.518 0.00036 A_55_P2039044 Cyp3a59 NM_001105160 ref|Mus musculus cytochrome P450 subfamily 3A  polypeptide 59 mRNA  
10.06 -1.511 0.00013 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
9.57 -1.507 5.00E-05 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
10.93 -1.506 0 A_55_P2153517 Enho NM_027147 ref|Mus musculus energy homeostasis associated mRNA  
8.82 -1.500 5.00E-05 A_51_P217498 Slc2a4 NM_009204 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 4 mRNA  
10.67 -1.498 1.00E-05 A_55_P1994887 Zfpm1 NM_009569 ref|Mus musculus zinc finger protein multitype 1 mRNA  
13.08 -1.495 3.00E-05 A_55_P2003483 Gldc NM_138595 ref|Mus musculus glycine decarboxylase mRNA  
14.32 -1.491 3.00E-05 A_55_P1958434 Got1 NM_010324 ref|Mus musculus glutamate oxaloacetate transaminase 1 soluble mRNA  
9.63 -1.491 0 A_55_P2055423 Nat8b XM_485799 ref|PREDICTED: Mus musculus predicted gene EG434057 mRNA  
13.31 -1.488 0.00036 A_55_P2018666 Thrsp NM_009381 ref|Mus musculus thyroid hormone responsive SPOT14 homolog (Rattus) mRNA  
9.80 -1.487 0 A_51_P161830 Enpep NM_007934 ref|Mus musculus glutamyl aminopeptidase mRNA  
9.36 -1.482 0.00086 A_51_P134812 Chac1 NM_026929 ref|Mus musculus ChaC cation transport regulator-like 1 (E. coli) mRNA  
7.88 -1.477 4.00E-05 A_51_P257885 Mmd2 NM_175217 ref|Mus musculus monocyte to macrophage differentiation-associated 2 mRNA  
9.94 -1.473 7.00E-05 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
9.88 -1.469 3.00E-05 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
12.25 -1.463 1.00E-05 A_55_P2422650 5031425E22Rik AK017143 gb|Mus musculus 11 days pregnant adult female ovary and uterus cDNA RIKEN full-length enriched library 
clone:5031425E22 product:unclassifiable full insert sequence 
9.73 -1.456 4.00E-05 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
7.16 -1.455 6.00E-05 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
7.25 -1.449 0.00014 A_55_P2251974 A930038B10Rik AK044736 gb|Mus musculus adult retina cDNA RIKEN full-length enriched library clone:A930038B10 product:hypothetical 
protein full insert sequence 
9.62 -1.447 0.00021 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA 
9.94 -1.443 0.00023 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
10.56 -1.442 2.00E-05 A_51_P386648 Glod5 NM_027227 ref|Mus musculus glyoxalase domain containing 5 mRNA  
7.47 -1.440 0.00059 A_55_P1978502 H2-Q1 NM_010390 ref|Mus musculus histocompatibility 2 Q region locus 1 mRNA  
9.85 -1.438 2.00E-04 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
10.65 -1.436 8.00E-05 A_55_P2068289 Slc17a2 NM_144836 ref|Mus musculus solute carrier family 17 (sodium phosphate) member 2 mRNA  
10.06 -1.435 0.00066 A_55_P2005005 Cdk5rap1 NM_025876 ref|Mus musculus CDK5 regulatory subunit associated protein 1 mRNA  
8.96 -1.434 0 A_55_P2053459 Timd2 NM_001161355 ref|Mus musculus T-cell immunoglobulin and mucin domain containing 2 transcript variant 1 mRNA  
11.03 -1.433 0.00176 A_55_P2107182 Gm6484 NM_001080940 ref|Mus musculus predicted gene 6484 mRNA  
9.39 -1.421 2.00E-05 A_51_P400016 ENSMUST00000114964 ENSMUST00000114964 ens|Kalirin (EC 2.7.11.1)(Protein Duo)(Serine/threonine kinase with Dbl- and pleckstrin homology domain) 
[Source:UniProtKB/Swiss-Prot;Acc:A2CG49]  
9.32 -1.413 5.00E-05 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
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10.68 -1.408 0.00013 A_55_P2180086 Lrrc28 NM_175124 ref|Mus musculus leucine rich repeat containing 28 transcript variant 1 mRNA  
12.08 -1.404 0 A_51_P336622 Dexi NM_021428 ref|Mus musculus dexamethasone-induced transcript mRNA  
14.09 -1.404 0 A_52_P86693 Ifi27l1 NM_026790 ref|Mus musculus interferon alpha-inducible protein 27 like 1 transcript variant 1 
11.12 -1.379 0.00014 A_51_P382764 ENSMUST00000080361 ENSMUST00000080361 ens|aldo-keto reductase family 1 member C20  [Source:RefSeq peptide;Acc:NP_473421]  
8.39 -1.377 3.00E-05 A_51_P315042 Avpr1a NM_016847 ref|Mus musculus arginine vasopressin receptor 1A mRNA  
12.91 -1.377 1.00E-05 A_51_P452779 Pygl NM_133198 ref|Mus musculus liver glycogen phosphorylase mRNA  
7.03 -1.371 6.00E-05 A_55_P2293414 1700001C19Rik NM_029296 ref|Mus musculus RIKEN cDNA 1700001C19 gene mRNA  
11.50 -1.363 0 A_51_P353895 Sult1c2 NM_026935 ref|Mus musculus sulfotransferase family cytosolic 1C member 2 mRNA 
8.18 -1.358 0.00029 A_55_P2148071 LOC673748 XM_001481151 ref|PREDICTED: Mus musculus similar to cytochrome P450 CYP3A mRNA  
12.59 -1.349 3.00E-05 A_55_P2168267 NAP002856-002 NAP002856-002 Unknown  
9.33 -1.347 5.00E-05 A_51_P342481 Gpd2 NM_010274 ref|Mus musculus glycerol phosphate dehydrogenase 2 mitochondrial  nuclear gene encoding mitochondrial protein 
transcript variant 2 mRNA  
8.57 -1.337 0.00035 A_55_P2092730 Wdfy1 NM_001111279 ref|Mus musculus WD repeat and FYVE domain containing 1 transcript variant 1 mRNA  
13.78 -1.337 1.00E-05 A_51_P337195 Pipox NM_008952 ref|Mus musculus pipecolic acid oxidase mRNA  
9.92 -1.327 8.00E-05 A_51_P112308 1810011O10Rik NM_026931 ref|Mus musculus RIKEN cDNA 1810011O10 gene mRNA  
13.07 -1.325 1.00E-05 A_55_P2026761 NAP111402-1 NAP111402-1 Unknown  
11.12 -1.318 1.00E-05 A_51_P452768 Cyp4f14 NM_022434 ref|Mus musculus cytochrome P450 family 4  subfamily f polypeptide 14 mRNA  
9.77 -1.316 2.00E-05 A_55_P2010191 Serpina11 BC024087 gb|Mus musculus serine (or cysteine) peptidase inhibitor clade A (alpha-1 antiproteinase antitrypsin) member 11 
mRNA (cDNA clone MGC:37881 IMAGE:5101271) 
15.12 -1.304 2.00E-05 A_51_P186547 Pah NM_008777 ref|Mus musculus phenylalanine hydroxylase mRNA  
14.79 -1.304 4.00E-05 A_51_P401987 Tmem37 NM_019432 ref|Mus musculus transmembrane protein 37 mRNA  
12.31 -1.298 0 A_55_P2173702 Ebpl NM_026598 ref|Mus musculus emopamil binding protein-like mRNA  
10.31 -1.294 6.00E-05 A_55_P2042319 Cyp2d40 NM_023623 ref|Mus musculus cytochrome P450 family 2  subfamily d polypeptide 40 mRNA  
7.57 -1.293 0.0016 A_52_P402127 Mup9 NM_001126319 ref|Mus musculus major urinary protein 9 mRNA  
15.28 -1.293 0 A_51_P291749 Pecr NM_023523 ref|Mus musculus peroxisomal trans-2-enoyl-CoA reductase mRNA  
10.47 -1.291 0 A_52_P93910 Nrp2 NM_001077403 ref|Mus musculus neuropilin 2 transcript variant 1  mRNA] 
9.02 -1.287 0.00018 A_55_P2118866 Cmah NM_001111110 ref|Mus musculus cytidine monophospho-N-acetylneuraminic acid hydroxylase transcript variant 2 mRNA  
9.76 -1.286 6.00E-05 A_55_P2139087 Gm5631 NM_001013820 ref|Mus musculus predicted gene 5631 mRNA  
8.58 -1.282 0.00021 A_52_P218833 Gm5584 NM_001101534 ref|Mus musculus predicted gene 5584 mRNA  
8.46 -1.275 1.00E-05 A_52_P306357 Prok1 ENSMUST00000049852 ens|prokineticin 1 [Source:RefSeq peptide;Acc:NP_001037847]   
7.83 -1.274 9.00E-05 A_55_P1952628 Dpys NM_022722 ref|Mus musculus dihydropyrimidinase transcript variant 1 mRNA  
11.17 -1.274 6.00E-05 A_51_P296036 Nrbp2 NM_144847 ref|Mus musculus nuclear receptor binding protein 2 mRNA  
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9.62 -1.272 1.00E-05 A_51_P155196 Abtb2 NM_178890 ref|Mus musculus ankyrin repeat and BTB (POZ) domain containing 2 mRNA  
12.84 -1.269 2.00E-05 A_55_P2046411 A_55_P2046411 A_55_P2046411 Unknown  
11.72 -1.267 6.00E-05 A_51_P308048 Cmtm8 NM_027294 ref|Mus musculus CKLF-like MARVEL transmembrane domain containing 8 mRNA  
9.60 -1.259 1.00E-05 A_51_P196862 Amdhd1 NM_027908 ref|Mus musculus amidohydrolase domain containing 1 mRNA  
10.83 -1.257 0.00016 A_51_P420415 Srd5a1 NM_175283 ref|Mus musculus steroid 5 alpha-reductase 1 mRNA   
7.52 -1.244 0.00013 A_55_P2169124 ENSMUST00000120540 ENSMUST00000120540 ens|integral membrane transport protein UST1R  [Source:RefSeq peptide;Acc:NP_795976]  
9.28 -1.237 0.00086 A_51_P248122 Bbc3 NM_133234 ref|Mus musculus BCL2 binding component 3 mRNA  
13.37 -1.235 1.00E-05 A_55_P1966804 Fdps NM_134469 ref|Mus musculus farnesyl diphosphate synthetase mRNA   
8.73 -1.233 0 A_55_P2162404 LOC100047327 XM_001477908 ref|PREDICTED: Mus musculus hypothetical protein LOC100047327 mRNA  
8.06 -1.227 0.00011 A_55_P2000022 Ccdc151 NM_001163787 ref|Mus musculus coiled-coil domain containing 151 transcript variant 1  mRNA  
15.15 -1.226 1.00E-05 A_51_P253547 Ctsl NM_009984 ref|Mus musculus cathepsin L mRNA  
15.22 -1.223 3.00E-05 A_51_P394115 Aadac NM_023383 ref|Mus musculus arylacetamide deacetylase (esterase) mRNA  
7.90 -1.218 1.00E-04 A_55_P2043627 Fam89a NM_001081120 ref|Mus musculus family with sequence similarity 89 member A mRNA  
9.42 -1.217 2.00E-05 A_55_P2169417 BC021767 XM_619932 ref|PREDICTED: Mus musculus cDNA sequence BC021767 mRNA   
10.36 -1.214 2.00E-05 A_55_P2014284 Serpina11 NM_199314 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A (alpha-1 antiproteinase antitrypsin) member 11 
transcript variant 1 mRNA  
8.34 -1.212 0.00029 A_55_P2134236 Foxa2 NM_010446 ref|Mus musculus forkhead box A2 mRNA  
12.82 -1.209 0.00013 A_51_P249360 Suox NM_173733 ref|Mus musculus sulfite oxidase nuclear gene encoding mitochondrial protein mRNA  
9.83 -1.208 1.00E-05 A_55_P2097508 Mcc NM_001085373 ref|Mus musculus mutated in colorectal cancers transcript variant 1 mRNA  
13.05 -1.207 3.00E-05 A_52_P1029978 Lasp1 NM_010688 ref|Mus musculus LIM and SH3 protein 1 mRNA  
11.96 -1.205 1.00E-05 A_55_P2144285 Nnt NM_008710 ref|Mus musculus nicotinamide nucleotide transhydrogenase nuclear gene encoding mitochondrial protein transcript 
variant 1 mRNA  
11.10 -1.203 5.00E-05 A_55_P2006703 Bmp1 NM_009755 ref|Mus musculus bone morphogenetic protein 1 mRNA  
11.44 -1.196 0.0013 A_51_P418168 Manf NM_029103 ref|Mus musculus mesencephalic astrocyte-derived neurotrophic factor mRNA  
13.74 -1.195 2.00E-05 A_51_P499854 Ghr NM_010284 ref|Mus musculus growth hormone receptor transcript variant 1  mRNA  
9.80 -1.189 0.00032 A_55_P2024625 Ccl21a NM_011124 ref|Mus musculus chemokine (C-C motif) ligand 21A mRNA  
8.73 -1.187 0.00026 A_52_P641282 Pdilt NM_027943 ref|Mus musculus protein disulfide isomerase-like testis expressed mRNA  
9.96 -1.186 0.00011 A_52_P64687 Camk2n1 NM_025451 ref|Mus musculus calcium/calmodulin-dependent protein kinase II inhibitor 1 mRNA  
13.77 -1.185 0.00026 A_55_P2009952 Me1 NM_008615 ref|Mus musculus malic enzyme 1 NADP(+)-dependent cytosolic mRNA  
16.65 -1.183 2.00E-05 A_51_P337269 Aldob NM_144903 ref|Mus musculus aldolase B fructose-bisphosphate mRNA  
8.30 -1.181 9.00E-05 A_55_P2139587 NAP092820-001 NAP092820-001 Unknown  
9.62 -1.180 1.00E-05 A_51_P204845 ENSMUST00000111451 ENSMUST00000111451 ens|CUG-BP- and ETR-3-like factor 1 (CELF-1)(Bruno-like protein 2)(RNA-binding protein BRUNOL-2)(CUG 
triplet repeat RNA-binding protein 1)(CUG-BP1)(Deadenylation factor CUG-BP)(Deadenylation factor EDEN-
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BP)(50 kDa nuclear polyadenylated RNA-binding protein 
13.86 -1.178 0.00013 A_55_P2017418 Cfh NM_009888 ref|Mus musculus complement component factor h mRNA  
7.37 -1.175 0.00081 A_66_P118430 Slc17a2 ENSMUST00000006786 ens|Sodium-dependent phosphate transport protein 3 (Sodium/phosphate cotransporter 3)(Na(+)/PI cotransporter 
3)(Solute carrier family 17 member 2) [Source:UniProtKB/Swiss-Prot;Acc:Q5SZA1]  
13.64 -1.165 6.00E-05 A_55_P1970810 ENSMUST00000102901 ENSMUST00000102901 ens|1-acyl-sn-glycerol-3-phosphate acyltransferase beta (EC 2.3.1.51)(1-acylglycerol-3-phosphate O-acyltransferase 
2)(1-AGP acyltransferase 2)(1-AGPAT 2)(Lysophosphatidic acid acyltransferase beta)(LPAAT-beta) 
[Source:UniProtKB/Swiss-Prot;Acc:Q8K3K7]  
9.21 -1.163 0.00166 A_51_P111462 Arl15 NM_172595 ref|Mus musculus ADP-ribosylation factor-like 15 mRNA  
11.60 -1.161 1.00E-05 A_52_P161297 Tcea3 NM_011542 ref|Mus musculus transcription elongation factor A (SII) 3 mRNA  
12.70 -1.160 1.00E-05 A_55_P2045802 Nelf NM_001039386 ref|Mus musculus nasal embryonic LHRH factor transcript variant 1  mRNA 
9.15 -1.159 4.00E-05 A_52_P84275 Derl2 NM_033562 ref|Mus musculus Der1-like domain family member 2 mRNA  
9.91 -1.157 0.00016 A_55_P1954356 Ttc23 NM_025905 ref|Mus musculus tetratricopeptide repeat domain 23 transcript variant 1 mRNA  
8.32 -1.157 0.00162 A_55_P1954393 Susd4 NM_144796 ref|Mus musculus sushi domain containing 4 mRNA  
10.75 -1.157 2.00E-05 A_51_P329949 Fam13a NM_153574 ref|Mus musculus family with sequence similarity 13 member A mRNA  
10.84 -1.156 0.00051 A_51_P514405 Slc2a5 NM_019741 ref|Mus musculus solute carrier family 2 (facilitated glucose transporter) member 5 mRNA  
8.42 -1.154 0.00038 A_51_P354165 Apcs NM_011318 ref|Mus musculus serum amyloid P-component mRNA  
9.96 -1.148 1.00E-05 A_55_P2056496 Tk1 NM_009387 ref|Mus musculus thymidine kinase 1 mRNA  
12.11 -1.147 0.00012 A_55_P2154709 Pter NM_008961 ref|Mus musculus phosphotriesterase related mRNA  
13.04 -1.146 1.00E-05 A_55_P2059352 Col18a1 NM_001109991 ref|Mus musculus collagen type XVIII alpha 1 transcript variant 1 mRNA  
7.11 -1.145 9.00E-05 A_55_P2126192 Lgr5 NM_010195 ref|Mus musculus leucine rich repeat containing G protein coupled receptor 5 mRNA  
9.97 -1.145 1.00E-05 A_51_P354077 Svil NM_153153 ref|Mus musculus supervillin transcript variant 1 mRNA  
11.79 -1.143 2.00E-05 A_51_P479052 Tars NM_033074 ref|Mus musculus threonyl-tRNA synthetase mRNA  
9.85 -1.142 0.00028 A_51_P111462 Arl15 NM_172595 ref|Mus musculus ADP-ribosylation factor-like 15 mRNA  
7.21 -1.141 8.00E-05 A_51_P378789 Cxcl13 NM_018866 ref|Mus musculus chemokine (C-X-C motif) ligand 13 mRNA  
11.30 -1.132 3.00E-05 A_55_P2180445 Gm2742 XM_001474578 ref|PREDICTED: Mus musculus similar to Ubtf protein mRNA  
10.96 -1.130 2.00E-05 A_52_P219904 Afmid NM_027827 ref|Mus musculus arylformamidase mRNA  
8.73 -1.128 5.00E-05 A_52_P12001 Erp44 NM_029572 ref|Mus musculus endoplasmic reticulum protein 44 mRNA  
7.04 -1.125 0.00037 A_55_P2082914 Acly NM_134037 ref|Mus musculus ATP citrate lyase mRNA  
8.84 -1.123 2.00E-05 A_66_P105046 Il18 NM_008360 ref|Mus musculus interleukin 18 mRNA  
13.33 -1.117 0.00171 A_55_P2171413 Me1 NM_008615 ref|Mus musculus malic enzyme 1 NADP(+)-dependent cytosolic mRNA  
9.90 -1.117 1.00E-05 A_55_P1981992 LOC637149 XM_912753 ref|PREDICTED: Mus musculus similar to doublecortin domain containing 2 mRNA  
8.52 -1.116 0.00136 A_55_P2298319 C730029A08Rik AK083183 gb|Mus musculus adult male hippocampus cDNA RIKEN full-length enriched library clone:C630024D06 
product:unclassifiable full insert sequence 
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11.82 -1.116 1.00E-05 A_55_P2126950 Zfp467 NM_001085417 ref|Mus musculus zinc finger protein 467 transcript variant 4  mRNA  
9.74 -1.115 0.00089 A_51_P111462 Arl15 NM_172595 ref|Mus musculus ADP-ribosylation factor-like 15 mRNA  
9.14 -1.114 4.00E-05 A_55_P2024290 Fam149a NM_153535 ref|Mus musculus family with sequence similarity 149 member A mRNA  
13.29 -1.113 0 A_66_P115996 Ccbl1 NM_172404 ref|Mus musculus cysteine conjugate-beta lyase 1 mRNA  
8.48 -1.109 0.00084 A_55_P2003638 Stxbp6 NM_144552 ref|Mus musculus syntaxin binding protein 6 (amisyn) mRNA  
8.06 -1.109 5.00E-05 A_55_P2106844 Gm7475 XM_001476912 ref|PREDICTED: Mus musculus predicted gene EG665070 mRNA  
11.1 -1.102 0.00051 A_55_P2013296 Prkag2 NM_145401 ref|Mus musculus protein kinase AMP-activated gamma 2 non-catalytic subunit transcript variant 1 mRNA  
12.29 -1.096 0.00048 A_55_P1965114 Spsb3 NM_001163750 ref|Mus musculus splA/ryanodine receptor domain and SOCS box containing 3 transcript variant 1 mRNA  
13.21 -1.094 2.00E-05 A_55_P1969776 Pdhb NM_024221 ref|Mus musculus pyruvate dehydrogenase (lipoamide) beta mRNA  
10.76 -1.090 0 A_52_P539161 Rdh11 NM_021557 ref|Mus musculus retinol dehydrogenase 11 mRNA  
8.23 -1.078 0.00051 A_55_P2142222 Serpina3h NM_001034870 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade A member 3H mRNA  
8.98 -1.078 9.00E-05 A_51_P437240 Emp2 NM_007929 ref|Mus musculus epithelial membrane protein 2 mRNA  
9.28 -1.077 0.00114 A_51_P111462 Arl15 NM_172595 ref|Mus musculus ADP-ribosylation factor-like 15 mRNA  
9.62 -1.076 0.00032 A_66_P121636 Ablim3 NM_198649 ref|Mus musculus actin binding LIM protein family member 3 transcript variant 1 mRNA  
15.00 -1.074 1.00E-04 A_55_P2032966 Hmgcs1 NM_145942 ref|Mus musculus 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 mRNA   
11.93 -1.071 2.00E-05 A_51_P175424 Car14 NM_011797 ref|Mus musculus carbonic anhydrase 14 mRNA  
16.30 -1.070 2.00E-05 A_52_P72434 Khk NM_008439 ref|Mus musculus ketohexokinase mRNA  
10.37 -1.070 3.00E-05 A_55_P2002757 Blnk NM_008528 ref|Mus musculus B-cell linker mRNA  
11.78 -1.070 0.00109 A_55_P1975185 Sqle NM_009270 ref|Mus musculus squalene epoxidase mRNA  
11.23 -1.070 3.00E-05 A_51_P381618 Pla1a NM_134102 ref|Mus musculus phospholipase A1 member A mRNA  
8.19 -1.065 0.00028 A_55_P2056493 ENSMUST00000106328 ENSMUST00000106328 ens|Thymidine kinase cytosolic (EC 2.7.1.21) [Source:UniProtKB/Swiss-Prot;Acc:P04184]  
13.34 -1.062 1.00E-05 A_55_P1988789 Acss2 NM_019811 ref|Mus musculus acyl-CoA synthetase short-chain family member 2 mRNA  
14.30 -1.061 0.00052 A_51_P385598 Slc37a4 NM_008063 ref|Mus musculus solute carrier family 37 (glucose-6-phosphate transporter) member 4 mRNA 
9.59 -1.061 0.0013 A_51_P111462 Arl15 NM_172595 ref|Mus musculus ADP-ribosylation factor-like 15 mRNA  
12.80 -1.059 6.00E-05 A_51_P418056 Sc5d NM_172769 ref|Mus musculus sterol-C5-desaturase (fungal ERG3 delta-5-desaturase) homolog (S. cerevisae) mRNA  
7.00 -1.056 0.00088 A_52_P559566 ENSMUST00000103527 ENSMUST00000103527 ens|Immunoglobulin heavy chain V gene segment [Source:IMGT/GENE-DB;Acc:IGHV1-56]  
9.54 -1.048 0.00142 A_51_P111462 Arl15 NM_172595 ref|Mus musculus ADP-ribosylation factor-like 15 mRNA  
9.22 -1.046 4.00E-05 A_55_P2113723 ENSMUST00000097698 ENSMUST00000097698 ens|Peroxisomal trans-2-enoyl-CoA reductase (EC 1.3.1.38) [Source:UniProtKB/Swiss-Prot;Acc:Q99MZ7]  
14.85 -1.041 0.00016 A_51_P162162 Inmt NM_009349 ref|Mus musculus indolethylamine N-methyltransferase mRNA  
13.58 -1.038 3.00E-05 A_55_P2059412 Ghr NM_001048178 ref|Mus musculus growth hormone receptor  transcript variant 2 mRNA  
8.58 -1.037 0.00021 A_55_P2045622 Setdb2 NM_001081024 ref|Mus musculus SET domain bifurcated 2 mRNA  
11.02 -1.032 2.00E-05 A_55_P1989215 Entpd8 NM_028093 ref|Mus musculus ectonucleoside triphosphate diphosphohydrolase 8 mRNA  
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15.58 -1.029 1.00E-04 A_52_P592909 Dgat2 NM_026384 ref|Mus musculus diacylglycerol O-acyltransferase 2 mRNA  
10.22 -1.027 0 A_55_P2008926 Slc17a3 NM_134069 ref|Mus musculus solute carrier family 17 (sodium phosphate) member 3 transcript variant 1 mRNA  
12.45 -1.019 6.00E-05 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
13.68 -1.018 1.00E-05 A_51_P498831 Derl2 NM_033562 ref|Mus musculus Der1-like domain family member 2 mRNA  
10.88 -1.016 5.00E-05 A_66_P116326 ENSMUST00000108435 ENSMUST00000108435 ens|TLC domain-containing protein 2  [Source:UniProtKB/Swiss-Prot;Acc:Q8VC26]  
12.94 -1.015 0 A_55_P2021049 Ugp2 NM_139297 ref|Mus musculus UDP-glucose pyrophosphorylase 2 mRNA  
15.15 -1.012 3.00E-05 A_55_P2108171 Glud1 NM_008133 ref|Mus musculus glutamate dehydrogenase 1 nuclear gene encoding mitochondrial protein mRNA  
13.95 -1.012 0.00034 A_55_P2032079 Dbp NM_016974 ref|Mus musculus D site albumin promoter binding protein mRNA  
11.56 -1.010 0.00161 A_51_P391616 Agxt2l1 NM_027907 ref|Mus musculus alanine-glyoxylate aminotransferase 2-like 1 transcript variant 1 mRNA  
9.71 -1.010 0.00021 A_55_P2009042 Gm4635 XM_001481023 ref|PREDICTED: Mus musculus hypothetical protein LOC100043770 mRNA  
10.96 -1.009 5.00E-05 A_51_P272553 Bhlhe40 NM_011498 ref|Mus musculus basic helix-loop-helix family member e40 mRNA  
8.39 -1.005 0.00045 A_66_P124179 Atp6v0d2 NM_175406 ref|Mus musculus ATPase H+ transporting  lysosomal V0 subunit D2  mRNA  
13.61 -1.004 6.00E-05 A_55_P1987730 5730469M10Rik NM_027464 ref|Mus musculus RIKEN cDNA 5730469M10 gene mRNA  
9.71 -1.003 8.00E-05 A_66_P123155 Ddo NM_027442 ref|Mus musculus D-aspartate oxidase mRNA  
7.62 -1.002 3.00E-05 A_66_P136834 Usp7 NM_001003918 ref|Mus musculus ubiquitin specific peptidase 7 mRNA  
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Table 87. All significantly up regulated genes in livers of female Ahr knockout mice by TCDD (25 µg/kg bw) identified by microarray analysis - mouse 5 days study. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description  
10.15 3.513 0 A_52_P257625 Esm1 NM_023612 ref|Mus musculus endothelial cell-specific molecule 1 mRNA  
7.45 3.384 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA  
7.42 3.371 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.43 3.360 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.16 3.346 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.44 3.337 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.45 3.220 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.14 3.176 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.44 3.037 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA 
7.47 2.860 0 A_51_P233160 Lysmd2 NM_027309 ref|Mus musculus LysM putative peptidoglycan-binding domain containing 2 mRNA  
11.89 2.805 0 A_51_P259296 Lpl NM_008509 ref|Mus musculus lipoprotein lipase mRNA  
7.05 2.721 0 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA  
7.22 2.716 1.00E-05 A_55_P2192662 Lepr NM_001122899 ref|Mus musculus leptin receptor transcript variant 3 mRNA  
7.18 2.659 0 A_55_P2078494 Cib3 NM_001080812 ref|Mus musculus calcium and integrin binding family member 3 mRNA  
10.01 2.638 0.00112 A_55_P1981714 Rreb1 NR_033218 ref|Mus musculus ras responsive element binding protein 1 transcript variant 1 non-coding RNA  
9.79 2.517 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
9.33 2.486 1.00E-05 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
12.20 2.435 0 A_55_P2150976 Fabp5l2 XM_886827 ref|PREDICTED: Mus musculus predicted gene EG622384 mRNA  
9.80 2.430 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
8.39 2.421 0 A_55_P1959748 Asns NM_012055 ref|Mus musculus asparagine synthetase mRNA  
9.76 2.416 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
9.59 2.415 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
9.68 2.398 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
7.65 2.386 0.00156 A_51_P487690 Ifi44 NM_133871 ref|Mus musculus interferon-induced protein 44 mRNA  
9.70 2.382 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
9.66 2.313 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
9.76 2.307 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
11.70 2.307 0 A_51_P372550 Cgref1 NM_026770 ref|Mus musculus cell growth regulator with EF hand domain 1 transcript variant 1 mRNA  
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9.45 2.283 0 A_51_P137336 Cdh1 NM_009864 ref|Mus musculus cadherin 1 mRNA  
7.60 2.282 3.00E-05 A_55_P2087805 Hsd3b1 NM_008293 ref|Mus musculus hydroxy-delta-5-steroid dehydrogenase 3 beta- and steroid delta-isomerase 1 mRNA  
9.20 2.203 1.00E-05 A_51_P331288 Akr1b7 NM_009731 ref|Mus musculus aldo-keto reductase family 1 member B7 mRNA  
9.97 2.181 2.00E-05 A_55_P2043122 Arsg NM_028710 ref|Mus musculus arylsulfatase G transcript variant 1 mRNA  
11.37 2.160 9.00E-05 A_55_P2067707 Mep1a NM_008585 ref|Mus musculus meprin 1 alpha mRNA  
7.40 2.141 0 A_52_P167278 Mthfd1l NM_172308 ref|Mus musculus methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like nuclear gene encoding 
mitochondrial protein transcript variant 2 mRNA  
8.67 2.053 0 A_55_P2077048 Itih5 NM_172471 ref|Mus musculus inter-alpha (globulin) inhibitor H5mRNA  
10.68 2.011 2.00E-05 A_52_P21550 Gcnt1 NM_173442 ref|Mus musculus glucosaminyl (N-acetyl) transferase 1 core 2 transcript variant 1 mRNA  
8.48 1.978 1.00E-05 A_52_P577388 Epdr1 NM_134065 ref|Mus musculus ependymin related protein 1 (zebrafish) mRNA  
8.08 1.942 0 A_55_P2394308 Fst NM_008046 ref|Mus musculus follistatin mRNA  
12.27 1.940 1.00E-04 A_51_P336833 Fabp4 NM_024406 ref|Mus musculus fatty acid binding protein 4 adipocyte mRNA  
7.41 1.909 0.00161 A_51_P510891 Afp NM_007423 ref|Mus musculus alpha fetoprotein mRNA  
11.42 1.888 2.00E-05 A_55_P2122841 NAP114472-1 NAP114472-1 Unknown 
9.22 1.883 0.00094 A_52_P472324 Slpi NM_011414 ref|Mus musculus secretory leukocyte peptidase inhibitor mRNA  
7.79 1.872 3.00E-05 A_55_P1956488 Epb4.9 NM_013514 ref|Mus musculus erythrocyte protein band 4.9 mRNA  
10.66 1.846 2.00E-05 A_55_P2387665 9130221J18Rik AK033690 gb|Mus musculus adult male cecum cDNA RIKEN full-length enriched library clone:9130221J18 
product:unclassifiable full insert sequence 
12.09 1.836 5.00E-05 A_51_P157042 Ctgf NM_010217 ref|Mus musculus connective tissue growth factor mRNA  
8.93 1.826 4.00E-05 A_52_P566681 Gpm6a NM_153581 ref|Mus musculus glycoprotein m6a mRNA  
10.56 1.808 9.00E-05 A_51_P243755 Slc10a2 NM_011388 ref|Mus musculus solute carrier family 10 member 2 mRNA  
7.48 1.799 0 A_55_P2116689 1700024P16Rik NM_001162980 ref|Mus musculus RIKEN cDNA 1700024P16 gene mRNA  
7.88 1.794 0 A_66_P110161 Eppk1 BC026387 gb|Mus musculus epiplakin 1 mRNA (cDNA clone IMAGE:4188338) partial cds 
7.92 1.793 0.00067 A_55_P2023912 A_55_P2023912 A_55_P2023912 Unknown 
7.81 1.791 1.00E-05 A_51_P477682 Prss12 NM_008939 ref|Mus musculus protease serine 12 neurotrypsin (motopsin) mRNA  
7.22 1.785 0.00051 A_55_P1962937 Trem2 NM_031254 ref|Mus musculus triggering receptor expressed on myeloid cells 2 mRNA  
12.40 1.768 4.00E-05 A_55_P1953387 Fabp5 NM_010634 ref|Mus musculus fatty acid binding protein 5 epidermal mRNA  
8.62 1.763 0 A_55_P2112185 Nhsl1 NM_173390 ref|Mus musculus NHS-like 1 transcript variant 1 mRNA  
7.91 1.761 1.00E-05 A_55_P1967538 Hunk NM_015755 ref|Mus musculus hormonally upregulated Neu-associated kinase mRNA 
7.88 1.755 1.00E-05 A_55_P2063508 Gm4131 XM_001479179 ref|PREDICTED: Mus musculus similar to hCG28707 mRNA  
8.41 1.727 3.00E-05 A_51_P309920 Itga8 NM_001001309 ref|Mus musculus integrin alpha 8 mRNA  
13.41 1.724 3.00E-05 A_51_P447545 Igfbp1 NM_008341 ref|Mus musculus insulin-like growth factor binding protein 1 mRNA  
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10.34 1.713 0 A_55_P2057777 Fgfr1 NM_010206 ref|Mus musculus fibroblast growth factor receptor 1  transcript variant 1 mRNA  
7.27 1.712 3.00E-05 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
11.96 1.671 0 A_51_P365516 Spink3 NM_009258 ref|Mus musculus serine peptidase inhibitor Kazal type 3 mRNA  
8.03 1.659 1.00E-05 A_55_P2169356 Gm1966 XM_001000891 ref|PREDICTED: Mus musculus gene model 1966 (NCBI) transcript variant 1 mRNA  
7.01 1.659 0 A_55_P2127179 Gm379 XM_142052 ref|PREDICTED: Mus musculus gene model 379 (NCBI) mRNA  
9.78 1.642 4.00E-04 A_51_P515605 Col3a1 NM_009930 ref|Mus musculus collagen type III alpha 1 mRNA  
11.06 1.623 2.00E-05 A_51_P204247 C8a NM_146148 ref|Mus musculus complement component 8 alpha polypeptide mRNA  
8.84 1.622 0 A_51_P420547 Clic5 NM_172621 ref|Mus musculus chloride intracellular channel 5 mRNA  
7.28 1.619 0.00092 A_66_P118772 Tmem136 NM_001034863 ref|Mus musculus transmembrane protein 136 mRNA  
11.67 1.617 0 A_55_P2059010 Rbp1 NM_011254 ref|Mus musculus retinol binding protein 1 cellular mRNA  
9.03 1.602 1.00E-05 A_55_P1996973 Gvin1 NM_029000 ref|Mus musculus GTPase very large interferon inducible 1 transcript variant A mRNA  
8.22 1.596 0.00014 A_55_P2118520 Col1a1 NM_007742 ref|Mus musculus collagen type I alpha 1 mRNA  
9.28 1.587 2.00E-05 A_52_P585652 Fndc3b NM_173182 ref|Mus musculus fibronectin type III domain containing 3B mRNA  
8.73 1.585 0.00057 A_55_P1978681 Tspan8 NM_146010 ref|Mus musculus tetraspanin 8 transcript variant 1 mRNA  
8.04 1.585 4.00E-05 A_51_P295237 Lrp11 NM_172784 ref|Mus musculus low density lipoprotein receptor-related protein 11  mRNA  
11.13 1.582 0 A_51_P320852 Cd9 NM_007657 ref|Mus musculus CD9 antigen mRNA  
9.36 1.574 0.00016 A_55_P2052290 Psat1 NM_177420 ref|Mus musculus phosphoserine aminotransferase 1 mRNA  
11.23 1.554 1.00E-05 A_55_P2005984 Wfdc15b NM_138685 ref|Mus musculus WAP four-disulfide core domain 15B transcript variant 1 mRNA  
7.13 1.549 0 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
9.07 1.547 2.00E-05 A_52_P679105 Prss23 NM_029614 ref|Mus musculus protease serine 23 mRNA  
8.24 1.537 1.00E-05 A_51_P516085 Dntt NM_009345 ref|Mus musculus deoxynucleotidyltransferase terminal transcript variant 1 mRNA  
7.86 1.537 8.00E-05 A_52_P456750 Aph1b NM_177583 ref|Mus musculus anterior pharynx defective 1b homolog (C. elegans) mRNA  
8.85 1.528 3.00E-05 A_52_P312102 Sema3g ENSMUST00000090180 ens|Semaphorin-3G Precursor  [Source:UniProtKB/Swiss-Prot;Acc:Q4LFA9]  
8.77 1.527 1.00E-04 A_55_P2018417 Osbpl3 NM_001163645 ref|Mus musculus oxysterol binding protein-like 3 transcript variant 2 mRNA  
7.07 1.515 0.00024 A_55_P2157093 Bcl2l14 NM_025778 ref|Mus musculus BCL2-like 14 (apoptosis facilitator) mRNA  
9.46 1.507 0 A_51_P255456 Cyp1b1 NM_009994 ref|Mus musculus cytochrome P450 family 1 subfamily b polypeptide 1 mRNA  
8.50 1.488 0 A_52_P18765 Hsbp1l1 NM_001136181 ref|Mus musculus heat shock factor binding protein 1-like 1 mRNA  
8.35 1.476 8.00E-05 A_51_P201982 Angpt2 NM_007426 ref|Mus musculus angiopoietin 2 mRNA  
7.90 1.475 3.00E-04 A_51_P146560 Msln NM_018857 ref|Mus musculus mesothelin mRNA  
7.21 1.470 0.00116 A_52_P381484 Spon2 NM_133903 ref|Mus musculus spondin 2 extracellular matrix protein mRNA  
7.15 1.466 8.00E-05 A_55_P1984881 1700024P16Rik NM_001162980 ref|Mus musculus RIKEN cDNA 1700024P16 gene mRNA  
7.93 1.465 0.00014 A_55_P2019684 Bspry NM_138653 ref|Mus musculus B-box and SPRY domain containing mRNA  
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10.45 1.463 2.00E-04 A_55_P1980125 Sfrs3 NM_013663 ref|Mus musculus splicing factor arginine/serine-rich 3 (SRp20) mRNA 
7.23 1.459 0.00016 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
8.69 1.455 0.00072 A_55_P2168823 NAP111644-1 NAP111644-1 Unknown 
8.82 1.445 3.00E-05 A_55_P1987645 Unc13b NM_001081413 ref|Mus musculus unc-13 homolog B (C. elegans) mRNA  
7.06 1.442 0.00017 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
9.23 1.431 0.00012 A_55_P2117741 Nck2 NM_010879 ref|Mus musculus non-catalytic region of tyrosine kinase adaptor protein 2 mRNA  
9.75 1.426 3.00E-05 A_55_P2092826 Anxa1 NM_010730 ref|Mus musculus annexin A1 mRNA  
8.84 1.425 7.00E-05 A_52_P670026 Rsad2 NM_021384 ref|Mus musculus radical S-adenosyl methionine domain containing 2 mRNA  
10.40 1.420 0 A_52_P320193 Clec2h NM_053165 ref|Mus musculus C-type lectin domain family 2 member h mRNA  
10.46 1.410 0.00057 A_55_P2002903 Smoc2 NM_022315 ref|Mus musculus SPARC related modular calcium binding 2 mRNA  
7.04 1.404 0.00039 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
11.54 1.402 0 A_55_P1954718 Cyb561 NM_007805 ref|Mus musculus cytochrome b-561 mRNA  
8.61 1.398 2.00E-05 A_55_P2110351 Eppk1 NM_144848 ref|Mus musculus epiplakin 1 mRNA  
9.60 1.393 9.00E-05 A_51_P450278 2010003K11Rik NM_027237 ref|Mus musculus RIKEN cDNA 2010003K11 gene mRNA  
7.18 1.387 0.00011 A_55_P1969650 Rasgrp1 NM_011246 ref|Mus musculus RAS guanyl releasing protein 1 mRNA  
11.92 1.386 5.00E-05 A_66_P129048 2610002J02Rik NM_001033134 ref|Mus musculus RIKEN cDNA 2610002J02 gene mRNA  
8.24 1.371 0.00054 A_55_P2094060 Gzma NM_010370 ref|Mus musculus granzyme A mRNA  
7.47 1.370 0.00085 A_55_P1978502 H2-Q1 NM_010390 ref|Mus musculus histocompatibility 2 Q region locus 1 mRNA  
8.37 1.364 8.00E-05 A_55_P2047330 LOC554292 NM_001024672 ref|Mus musculus UbiE-YGHL1 fusion protein mRNA 
7.57 1.352 2.00E-04 A_55_P2073377 Mki67 NM_001081117 ref|Mus musculus antigen identified by monoclonal antibody Ki 67 mRNA  
7.68 1.352 0.00022 A_55_P1982291 Clca1 NM_009899 ref|Mus musculus chloride channel calcium activated 1 mRNA  
9.18 1.345 0.00021 A_55_P2055537 Slc16a6 NM_001029842 ref|Mus musculus solute carrier family 16 (monocarboxylic acid transporters) member 6 transcript variant 1 mRNA  
9.46 1.344 0.00085 A_51_P371750 Marco NM_010766 ref|Mus musculus macrophage receptor with collagenous structure mRNA  
8.04 1.324 4.00E-05 A_52_P228236 Tfrc NM_011638 ref|Mus musculus transferrin receptor mRNA  
8.02 1.322 0.00038 A_51_P253803 Mki67 NM_001081117 ref|Mus musculus antigen identified by monoclonal antibody Ki 67 mRNA  
7.51 1.321 2.00E-05 A_52_P281033 Socs5 NM_019654 ref|Mus musculus suppressor of cytokine signaling 5 mRNA  
9.40 1.318 0.00074 A_52_P499907 Kcnj1 NM_019659 ref|Mus musculus potassium inwardly-rectifying channel subfamily J member 1 transcript variant 2 mRNA  
8.16 1.316 1.00E-05 A_55_P1958165 Ms4a7 NM_001025610 ref|Mus musculus membrane-spanning 4-domains subfamily A member 7 transcript variant 2 mRNA  
11.03 1.314 1.00E-05 A_55_P1968433 Agpat9 NM_172715 ref|Mus musculus 1-acylglycerol-3-phosphate O-acyltransferase 9 transcript variant 1 mRNA  
10.06 1.304 0.00011 A_55_P2013586 Prss8 NM_133351 ref|Mus musculus protease serine 8 (prostasin) mRNA  
11.32 1.298 0.00022 A_55_P2115582 Slc20a1 NM_015747 ref|Mus musculus solute carrier family 20 member 1 transcript variant 1 mRNA  
10.13 1.298 0 A_55_P1998943 Oas1a NM_145211 ref|Mus musculus 2'-5' oligoadenylate synthetase 1A mRNA 
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7.86 1.298 0.00097 A_55_P2085779 Ifi27l2b NM_145449 ref|Mus musculus interferon alpha-inducible protein 27 like 2B mRNA  
10.10 1.297 0.00011 A_51_P204740 Cd34 NM_133654 ref|Mus musculus CD34 antigen transcript variant 2 mRNA  
8.89 1.295 0 A_51_P114878 Ikbkap NM_026079 ref|Mus musculus inhibitor of kappa light polypeptide enhancer in B-cells kinase complex-associated protein 
mRNA  
11.11 1.288 1.00E-05 A_52_P561936 1110002B05Rik NM_134054 ref|Mus musculus RIKEN cDNA 1110002B05 gene mRNA  
7.65 1.285 3.00E-05 A_55_P2178578 Tmprss4 NM_145403 ref|Mus musculus transmembrane protease serine 4 mRNA  
7.09 1.284 0.00012 A_55_P2119917 Ikzf4 NM_011772 ref|Mus musculus IKAROS family zinc finger 4 mRNA  
7.44 1.280 3.00E-05 A_51_P128463 Grrp1 NM_001099296 ref|Mus musculus glycine/arginine rich protein 1 mRNA  
8.83 1.279 1.00E-05 A_66_P119518 Tuba8 NM_017379 ref|Mus musculus tubulin alpha 8 mRNA  
8.71 1.278 0.00015 A_51_P114878 Ikbkap NM_026079 ref|Mus musculus inhibitor of kappa light polypeptide enhancer in B-cells kinase complex-associated protein 
mRNA  
9.28 1.278 0.00032 A_51_P502119 F11 NM_028066 ref|Mus musculus coagulation factor XI mRNA  
9.04 1.275 1.00E-05 A_51_P519555 Gnb1l NM_023120 ref|Mus musculus guanine nucleotide binding protein (G protein) beta polypeptide 1-like transcript variant 2 
mRNA  
9.31 1.269 0.00011 A_52_P142191 Aph1b NM_177583 ref|Mus musculus anterior pharynx defective 1b homolog (C. elegans) mRNA  
9.94 1.268 2.00E-05 A_52_P341449 Pgm3 NM_028352 ref|Mus musculus phosphoglucomutase 3 transcript variant 1 mRNA  
12.64 1.267 6.00E-05 A_51_P268529 Csad NM_144942 ref|Mus musculus cysteine sulfinic acid decarboxylase mRNA  
7.49 1.265 0.00012 A_51_P158210 Mcm2 NM_008564 ref|Mus musculus minichromosome maintenance deficient 2 mitotin (S. cerevisiae) mRNA 
8.56 1.260 1.00E-05 A_51_P118132 Skil NM_011386 ref|Mus musculus SKI-like transcript variant 1 mRNA  
8.30 1.257 0.00121 A_51_P191354 Acot6 ENSMUST00000056822 ens|Acyl-coenzyme A thioesterase 6 (Acyl-CoA thioesterase 6)(EC 3.1.2.-) [Source:UniProtKB/Swiss-
Prot;Acc:Q32Q92]  
10.09 1.254 2.00E-05 A_55_P1954266 Zfp672 NM_178761 ref|Mus musculus zinc finger protein 672 transcript variant 1 mRNA  
14.03 1.251 0.00024 A_55_P1973809 Hbb-b1 NM_008220 ref|Mus musculus hemoglobin beta adult major chain mRNA  
10.50 1.246 1.00E-04 A_55_P2177614 Sfrs3 NM_013663 ref|Mus musculus splicing factor arginine/serine-rich 3 mRNA  
10.27 1.243 3.00E-05 A_55_P1962305 Plac8 NM_139198 ref|Mus musculus placenta-specific 8 mRNA  
13.08 1.240 0.00016 A_55_P2003483 Gldc NM_138595 ref|Mus musculus glycine decarboxylase mRNA  
9.43 1.238 0.00016 A_55_P2033272 Treh NM_021481 ref|Mus musculus trehalase (brush-border membrane glycoprotein) mRNA  
7.74 1.236 8.00E-05 A_55_P1955309 Zfp800 NM_001081678 ref|Mus musculus zinc finger protein 800 mRNA  
7.04 1.236 6.00E-04 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
7.89 1.233 0.00032 A_55_P1997604 Pla2g4a NM_008869 ref|Mus musculus phospholipase A2 group IVA (cytosolic calcium-dependent) mRNA  
8.12 1.231 5.00E-05 A_55_P2004801 Tacc3 NM_001040435 ref|Mus musculus transforming acidic coiled-coil containing protein 3 mRNA  
10.51 1.231 0 A_51_P396752 Arl2bp NM_024191 ref|Mus musculus ADP-ribosylation factor-like 2 binding protein transcript variant 1 mRNA  
8.57 1.229 0.00138 A_55_P1983773 Birc5 NM_001012273 ref|Mus musculus baculoviral IAP repeat-containing 5 transcript variant 3 mRNA  
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11.88 1.228 1.00E-05 A_55_P2003793 Tspan3 NM_019793 ref|Mus musculus tetraspanin 3 mRNA  
8.65 1.224 1.00E-05 A_55_P2097259 ENSMUST00000065640 ENSMUST00000065640 ens|Zinc finger with UFM1-specific peptidase domain protein  [Source:UniProtKB/Swiss-Prot;Acc:Q3T9Z9]  
12.96 1.220 4.00E-05 A_55_P2038540 Hbb-b2 NM_016956 ref|Mus musculus hemoglobin beta adult minor chain mRNA  
7.48 1.218 0.00111 A_51_P397296 Marveld3 NM_028584 ref|Mus musculus MARVEL (membrane-associating) domain containing 3 transcript variant 1 mRNA  
7.12 1.216 1.00E-04 A_51_P108581 Adrbk2 NM_177078 ref|Mus musculus adrenergic receptor kinase beta 2 transcript variant 1 mRNA  
10.99 1.215 0.00069 A_51_P392687 Vim NM_011701 ref|Mus musculus vimentin mRNA  
10.03 1.215 0.00088 A_51_P421140 Tubb6 NM_026473 ref|Mus musculus tubulin beta 6 mRNA  
11.24 1.214 5.00E-05 A_51_P353252 Mal2 NM_178920 ref|Mus musculus mal T-cell differentiation protein 2 mRNA  
8.15 1.212 0.00062 A_55_P1962918 Mnda NM_001033450 ref|Mus musculus myeloid cell nuclear differentiation antigen mRNA  
7.81 1.196 5.00E-05 A_51_P165914 Zfp770 NM_175466 ref|Mus musculus zinc finger protein 770 mRNA  
11.74 1.194 3.00E-05 A_55_P1975420 Dhx40 NM_026191 ref|Mus musculus DEAH (Asp-Glu-Ala-His) box polypeptide 40 mRNA  
9.34 1.193 1.00E-05 A_51_P134262 1700052K11Rik NR_027956 ref|Mus musculus RIKEN cDNA 1700052K11 gene non-coding RNA  
9.00 1.188 9.00E-05 A_66_P107585 Taf2 NM_001081288 ref|Mus musculus TAF2 RNA polymerase II TATA box binding protein (TBP)-associated factor mRNA  
11.54 1.188 0 A_55_P1983177 Acsl4 NM_207625 ref|Mus musculus acyl-CoA synthetase long-chain family member 4 transcript variant 1 mRNA  
7.03 1.187 3.00E-05 A_55_P1955308 Sirpb1 NM_001002898 ref|Mus musculus signal-regulatory protein beta 1 transcript variant 3 mRNA  
8.76 1.185 0.00171 A_55_P2013823 Gal3st1 NM_016922 ref|Mus musculus galactose-3-O-sulfotransferase 1 (mRNA  
7.95 1.182 6.00E-05 A_55_P1961335 Ctsk NM_007802 ref|Mus musculus cathepsin K mRNA  
7.34 1.181 2.00E-05 A_51_P150087 Abhd10 NM_172511 ref|Mus musculus abhydrolase domain containing 10 mRNA  
10.40 1.177 1.00E-05 A_66_P121787 Samd9l NM_010156 ref|Mus musculus sterile alpha motif domain containing 9-like mRNA  
10.78 1.175 0.00035 A_55_P1964638 Cxadr NM_001025192 ref|Mus musculus coxsackie virus and adenovirus receptor transcript variant 1 mRNA  
8.48 1.175 3.00E-05 A_55_P2052062 Cd200 NM_010818 ref|Mus musculus CD200 antigen mRNA  
14.94 1.174 0.00087 A_51_P110301 C3 NM_009778 ref|Mus musculus complement component 3  mRNA  
8.99 1.173 0.00045 A_55_P2059382 Arl6 NM_019665 ref|Mus musculus ADP-ribosylation factor-like 6 mRNA  
8.11 1.169 0.00016 A_55_P2119985 Baiap2 NM_130862 ref|Mus musculus brain-specific angiogenesis inhibitor 1-associated protein 2 transcript variant 2 mRNA  
7.64 1.167 5.00E-04 A_52_P390944 Chst3 NM_016803 ref|Mus musculus carbohydrate (chondroitin 6/keratan) sulfotransferase 3 mRNA  
7.16 1.165 0.00039 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
9.44 1.157 1.00E-05 A_55_P2012296 Gopc NM_053187 ref|Mus musculus golgi associated PDZ and coiled-coil motif containing mRNA  
10.01 1.152 1.00E-05 A_55_P1989858 Thrap3 BC040346 gb|Mus musculus thyroid hormone receptor associated protein 3 mRNA (cDNA clone IMAGE:3498255) with 
apparent retained intron 
10.38 1.152 3.00E-05 A_55_P2071271 3110003A17Rik NM_028440 ref|Mus musculus RIKEN cDNA 3110003A17 gene mRNA  
9.78 1.151 0.00016 A_51_P251357 Ctps NM_016748 ref|Mus musculus cytidine 5'-triphosphate synthase mRNA  
8.15 1.151 3.00E-05 A_55_P2020497 Dcaf12l1 NM_178739 ref|Mus musculus DDB1 and CUL4 associated factor 12-like 1 mRNA  
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8.58 1.149 0.00011 A_55_P2078460 NAP111472-1 NAP111472-1 Unknown 
8.48 1.148 0.00049 A_55_P2126552 Zdhhc13 NM_028031 ref|Mus musculus zinc finger DHHC domain containing 13 mRNA  
8.72 1.147 0.00025 A_52_P479262 ENSMUST00000066153 ENSMUST00000066153 ens|Collagen alpha3(VI) Precursor; Fragment  [Source:UniProtKB/TrEMBL;Acc:Q9Z0I9]  
7.88 1.147 0.00029 A_51_P257885 Mmd2 NM_175217 ref|Mus musculus monocyte to macrophage differentiation-associated 2 mRNA  
7.46 1.146 4.00E-05 A_52_P481279 Gm1060 NM_001033460 ref|Mus musculus predicted gene 1060 mRNA  
7.40 1.143 0.00015 A_55_P2068977 Armcx3 NM_027870 ref|Mus musculus armadillo repeat containing X-linked 3 mRNA  
8.10 1.143 0.00033 A_55_P2061170 Tbc1d2 NM_198664 ref|Mus musculus TBC1 domain family member 2 mRNA  
7.22 1.142 0.00012 A_51_P307741 Cckar NM_009827 ref|Mus musculus cholecystokinin A receptor mRNA  
7.58 1.139 7.00E-05 A_51_P363556 Abi2 NM_198127 ref|Mus musculus abl-interactor 2 mRNA  
8.81 1.138 4.00E-05 A_55_P1978103 Hisppd1 NM_173760 ref|Mus musculus histidine acid phosphatase domain containing 1 mRNA  
8.74 1.136 2.00E-04 A_51_P114878 Ikbkap NM_026079 ref|Mus musculus inhibitor of kappa light polypeptide enhancer in B-cells kinase complex-associated protein 
mRNA  
14.96 1.135 0.00179 A_51_P110301 C3 NM_009778 ref|Mus musculus complement component 3 mRNA  
7.86 1.135 0.00059 A_51_P173709 Gprc5b NM_022420 ref|Mus musculus G protein-coupled receptor family C group 5 member B mRNA  
7.21 1.130 0.00012 A_52_P338066 Ubd NM_023137 ref|Mus musculus ubiquitin D mRNA  
7.40 1.130 0.00083 A_52_P625808 Sf3b1 NM_031179 ref|Mus musculus splicing factor 3b subunit 1 mRNA  
9.26 1.130 1.00E-05 A_51_P511949 Setd7 NM_080793 ref|Mus musculus SET domain containing (lysine methyltransferase) 7  mRNA  
8.72 1.127 3.00E-05 A_51_P193000 Bbs4 NM_175325 ref|Mus musculus Bardet-Biedl syndrome 4 (human) mRNA  
8.30 1.126 0.00044 A_55_P2011341 LOC100045268 XM_001474162 ref|PREDICTED: Mus musculus similar to precursor (AA -28 to 232) mRNA  
8.33 1.124 0.00054 A_51_P462428 Galntl2 ENSMUST00000022460 ens|Polypeptide N-acetylgalactosaminyltransferase-like protein 2 (EC 2.4.1.41)(Polypeptide GalNAc transferase-
like protein 2)(pp-GaNTase-like protein 2)(GalNAc-T-like protein 2)(Protein-UDP 
acetylgalactosaminyltransferase-like protein 2)(UDP-GalNAc:polype 
9.73 1.124 1.00E-05 A_52_P495104 LOC100045753 XM_001474871 ref|PREDICTED: Mus musculus similar to headcase homolog  mRNA  
7.03 1.122 8.00E-05 A_55_P2033041 LOC100038947 XM_001471956 ref|PREDICTED: Mus musculus similar to SIRP beta 1 cell surface protein  mRNA  
7.17 1.121 5.00E-05 A_55_P2174816 5730601F06Rik NM_001082485 ref|Mus musculus RIKEN cDNA 5730601F06 gene transcript variant 1 mRNA  
8.33 1.121 0.00033 A_52_P583458 E2f3 NM_010093 ref|Mus musculus E2F transcription factor 3 mRNA  
10.63 1.119 4.00E-05 A_51_P360492 Mcm6 NM_008567 ref|Mus musculus minichromosome maintenance deficient 6 (MIS5 homolog S. pombe) (S. cerevisiae) mRNA  
10.11 1.117 0.00096 A_55_P1998416 Ifi47 NM_008330 ref|Mus musculus interferon gamma inducible protein 47 mRNA  
8.44 1.117 0.00011 A_55_P1981205 Xrcc4 NM_028012 ref|Mus musculus X-ray repair complementing defective repair in Chinese hamster cells 4 mRNA  
8.23 1.117 0 A_51_P154842 Oas1f NM_145153 ref|Mus musculus 2'-5' oligoadenylate synthetase 1F mRNA  
10.56 1.115 0.00018 A_51_P169745 Tuba1a NM_011653 ref|Mus musculus tubulin alpha 1A mRNA  
8.52 1.112 0.00033 A_55_P2183597 Tbc1d2 NM_198664 ref|Mus musculus TBC1 domain family member 2 mRNA  
10.72 1.111 0.0015 A_52_P38627 Egf NM_010113 ref|Mus musculus epidermal growth factor mRNA  
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7.50 1.111 0.00165 A_66_P120603 Trps1 NM_032000 ref|Mus musculus trichorhinophalangeal syndrome I (human) mRNA  
7.74 1.110 8.00E-05 A_55_P2116054 Caprin1 NM_016739 ref|Mus musculus cell cycle associated protein 1 transcript variant 1 mRNA  
10.56 1.109 4.00E-05 A_52_P574697 Khdrbs1 NM_011317 ref|Mus musculus KH domain containing RNA binding signal transduction associated 1 mRNA  
10.46 1.108 2.00E-05 A_51_P386810 Gmppb NM_177910 ref|Mus musculus GDP-mannose pyrophosphorylase B mRNA  
7.16 1.106 0.00053 A_51_P452629 Tlr2 NM_011905 ref|Mus musculus toll-like receptor 2 mRNA  
12.61 1.106 6.00E-05 A_55_P1989452 Nenf NM_025424 ref|Mus musculus neuron derived neurotrophic factor mRNA  
14.74 1.104 0.00164 A_51_P110301 C3 NM_009778 ref|Mus musculus complement component 3 mRNA  
8.30 1.103 5.00E-05 A_51_P442097 Slc41a3 NM_027868 ref|Mus musculus solute carrier family 41 member 3 transcript variant 1 mRNA  
8.48 1.101 0.00156 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
11.96 1.101 1.00E-04 A_55_P2123471 Kpna2 NM_010655 ref|Mus musculus karyopherin (importin) alpha 2 mRNA  
11.09 1.101 7.00E-05 A_55_P2027278 Gas2l1 NM_030228 ref|Mus musculus growth arrest-specific 2 like 1 transcript variant alpha mRNA  
9.79 1.101 5.00E-05 A_55_P2146177 Cerk NM_145475 ref|Mus musculus ceramide kinase mRNA  
10.11 1.099 1.00E-04 A_66_P118256 Strn3 AK040913 gb|Mus musculus adult male aorta and vein cDNA RIKEN full-length enriched library clone:A530044I19 
product:nuclear autoantigen full insert sequence 
8.76 1.098 8.00E-05 A_55_P2059904 Chsy1 NM_001081163 ref|Mus musculus chondroitin sulfate synthase 1 mRNA  
9.11 1.097 4.00E-05 A_55_P1971889 F3 NM_010171 ref|Mus musculus coagulation factor III mRNA  
16.62 1.094 0.00057 A_55_P1962299 Hba-a2 NM_001083955 ref|Mus musculus hemoglobin alpha adult chain 2 mRNA  
9.86 1.090 0.00033 A_52_P638459 Ccl5 NM_013653 ref|Mus musculus chemokine (C-C motif) ligand 5 mRNA  
8.81 1.088 0.00106 A_55_P1983448 S100a4 NM_011311 ref|Mus musculus S100 calcium binding protein A4 mRNA  
11.56 1.086 0.00097 A_51_P391616 Agxt2l1 NM_027907 ref|Mus musculus alanine-glyoxylate aminotransferase 2-like 1 transcript variant 1 mRNA  
8.39 1.085 0.00025 A_66_P124179 Atp6v0d2 NM_175406 ref|Mus musculus ATPase H+ transporting lysosomal V0 subunit D2 mRNA  
11.53 1.083 2.00E-05 A_51_P434198 Anapc4 NM_024213 ref|Mus musculus anaphase promoting complex subunit 4 mRNA  
14.91 1.082 0.00122 A_51_P462385 G6pc NM_008061 ref|Mus musculus glucose-6-phosphatase catalytic mRNA  
8.74 1.080 2.00E-04 A_51_P114878 Ikbkap NM_026079 ref|Mus musculus inhibitor of kappa light polypeptide enhancer in B-cells kinase complex-associated protein 
mRNA  
10.95 1.079 2.00E-05 A_66_P112853 Eif1a NM_010120 ref|Mus musculus eukaryotic translation initiation factor 1A mRNA  
9.03 1.078 5.00E-05 A_51_P196844 Osbpl3 NM_027881 ref|Mus musculus oxysterol binding protein-like 3 transcript variant 1 mRNA  
9.33 1.078 0.00032 A_55_P2046509 Amot NM_153319 ref|Mus musculus angiomotin mRNA  
8.33 1.077 1.00E-05 A_51_P114878 Ikbkap NM_026079 ref|Mus musculus inhibitor of kappa light polypeptide enhancer in B-cells kinase complex-associated protein 
mRNA  
12.27 1.077 1.00E-05 A_55_P2000823 Rbm39 NM_133242 ref|Mus musculus RNA binding motif protein 39 mRNA  
9.61 1.075 0.00036 A_55_P2108248 Art4 NM_026639 ref|Mus musculus ADP-ribosyltransferase 4 mRNA  
12.45 1.075 4.00E-05 A_51_P122246 Creld2 NM_029720 ref|Mus musculus cysteine-rich with EGF-like domains 2 mRNA  
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10.48 1.072 7.00E-04 A_52_P257812 Lpl NM_008509 ref|Mus musculus lipoprotein lipase mRNA  
12.12 1.071 0.00021 A_55_P1984830 Fgl1 NM_145594 ref|Mus musculus fibrinogen-like protein 1 mRNA  
7.52 1.071 0.00013 A_52_P49321 Adamts9 NM_175314 ref|Mus musculus a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif 9 
mRNA  
11.95 1.070 0.00019 A_51_P146149 Napsa NM_008437 ref|Mus musculus napsin A aspartic peptidase mRNA  
9.27 1.067 0.00022 A_55_P2169415 Cgn NM_001037711 ref|Mus musculus cingulin mRNA  
9.28 1.067 1.00E-04 A_51_P388298 Mmachc NM_025962 ref|Mus musculus methylmalonic aciduria cblC type with homocystinuria mRNA  
11.18 1.067 1.00E-05 A_52_P469381 Comtd1 NM_026965 ref|Mus musculus catechol-O-methyltransferase domain containing 1 mRNA  
7.96 1.067 6.00E-05 A_65_P11306 Gm4944 XM_973961 ref|PREDICTED: Mus musculus predicted gene EG240038 mRNA  
8.39 1.056 0.00022 A_51_P444437 Ptgr1 NM_025968 ref|Mus musculus prostaglandin reductase 1 mRNA  
7.13 1.052 0.00025 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
10.89 1.052 0.00043 A_55_P2046037 Gm7083 XM_001475231 ref|PREDICTED: Mus musculus predicted gene EG632248 mRNA  
8.50 1.051 0.00056 A_55_P2119892 Erbb4 ENSMUST00000121473 ens|Receptor tyrosine-protein kinase erbB-4 Precursor (EC 2.7.10.1) [Source:UniProtKB/Swiss-Prot;Acc:Q61527]  
12.80 1.051 0.00028 A_55_P2020577 Pcolce NM_008788 ref|Mus musculus procollagen C-endopeptidase enhancer protein mRNA  
10.31 1.051 5.00E-05 A_51_P200561 4930506M07Rik NM_175172 ref|Mus musculus RIKEN cDNA 4930506M07 gene transcript variant 2 mRNA  
7.12 1.050 0.00134 A_55_P2039541 Arhgap15 NM_153820 ref|Mus musculus Rho GTPase activating protein 15 transcript variant 1 mRNA  
7.11 1.050 0.00052 A_55_P2002773 Gm2942 XM_001475175 ref|PREDICTED: Mus musculus hypothetical protein LOC100040747 mRNA  
10.25 1.048 1.00E-05 A_55_P2043554 Slc12a4 NM_009195 ref|Mus musculus solute carrier family 12 member 4 mRNA  
9.97 1.048 0.00083 A_55_P2022074 Klf10 NM_013692 ref|Mus musculus Kruppel-like factor 10 mRNA  
12.46 1.047 6.00E-05 A_55_P2183015 P2rx4 NM_011026 ref|Mus musculus purinergic receptor P2X ligand-gated ion channel 4 mRNA  
8.49 1.045 2.00E-05 A_51_P355040 Nsun3 ENSMUST00000063089 ens|Putative methyltransferase NSUN3 (EC 2.1.1.-)(NOL1/NOP2/Sun domain family member 3) 
[Source:UniProtKB/Swiss-Prot;Acc:Q8CCT7]  
15.01 1.043 0.00192 A_51_P110301 C3 NM_009778 ref|Mus musculus complement component 3 mRNA  
8.05 1.042 0.00023 A_52_P228236 Tfrc NM_011638 ref|Mus musculus transferrin receptor mRNA  
8.48 1.042 0.00131 A_55_P2003638 Stxbp6 NM_144552 ref|Mus musculus syntaxin binding protein 6 (amisyn) mRNA  
7.38 1.04 8.00E-05 A_55_P2001198 ENSMUST00000042146 ENSMUST00000042146 ens|Syntaxin-18 [Source:UniProtKB/Swiss-Prot;Acc:Q8VDS8] [ENSMUST00000042146] 
7.07 1.038 0.00104 A_55_P2335529 4921531C22Rik AK076601 gb|Mus musculus adult male testis cDNA RIKEN full-length enriched library clone:4921531C22 
product:hypothetical protein full insert sequence 
7.34 1.036 0.00087 A_55_P2096933 Cntln NM_177385 ref|Mus musculus centlein centrosomal protein  transcript variant 2 mRNA  
10.47 1.035 0.00025 A_55_P2007470 Pdgfa NM_008808 ref|Mus musculus platelet derived growth factor alpha mRNA  
7.25 1.035 5.00E-05 A_51_P452153 2010001M09Rik NM_027222 ref|Mus musculus RIKEN cDNA 2010001M09 gene mRNA  
10.75 1.034 0.00026 A_55_P2022211 Plxdc2 NM_026162 ref|Mus musculus plexin domain containing 2 mRNA  
10.39 1.031 5.00E-05 A_55_P1969645 Sdcbp NM_001098227 ref|Mus musculus syndecan binding protein transcript variant 1 mRNA  
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7.57 1.030 0.00015 A_55_P2178862 2610101N10Rik NM_001114977 ref|Mus musculus RIKEN cDNA 2610101N10 gene transcript variant 1 mRNA  
8.47 1.025 0.00088 A_51_P126437 Enc1 NM_007930 ref|Mus musculus ectodermal-neural cortex 1 mRNA  
7.08 1.024 0.00093 A_52_P436447 Slc25a35 NM_028048 ref|Mus musculus solute carrier family 25 member 35 mRNA  
10.16 1.022 1.00E-05 A_51_P349192 2210013O21Rik NR_028432 ref|Mus musculus RIKEN cDNA 2210013O21 gene non-coding RNA  
7.26 1.021 2.00E-04 A_51_P241667 Prkdc NM_011159 ref|Mus musculus protein kinase DNA activated catalytic polypeptide mRNA  
8.66 1.021 4.00E-05 A_51_P114878 Ikbkap NM_026079 ref|Mus musculus inhibitor of kappa light polypeptide enhancer in B-cells kinase complex-associated protein 
mRNA  
7.08 1.017 0.0018 A_55_P2033055 Pdp1 NM_001098230 ref|Mus musculus pyruvate dehyrogenase phosphatase catalytic subunit 1 nuclear gene encoding mitochondrial 
protein transcript variant 2 mRNA  
7.58 1.012 0.00025 A_52_P228236 Tfrc NM_011638 ref|Mus musculus transferrin receptor mRNA  
9.92 1.011 0.00026 A_55_P2029842 Hnrnpa1 NM_001039129 ref|Mus musculus heterogeneous nuclear ribonucleoprotein A1 transcript variant 2 mRNA  
11.11 1.005 0.00016 A_55_P2055557 Sdsl NM_133902 ref|Mus musculus serine dehydratase-like mRNA  
8.55 1.004 5.00E-05 A_55_P2106039 Map3k6 NM_016693 ref|Mus musculus mitogen-activated protein kinase kinase kinase 6 mRNA  
8.68 1.004 0.00158 A_55_P2173892 Isg20 NM_020583 ref|Mus musculus interferon-stimulated protein transcript variant 1 mRNA  
9.31 1.000 7.00E-04 A_51_P511482 Ift57 NM_028680 ref|Mus musculus intraflagellar transport 57 homolog (Chlamydomonas) mRNA  
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Table 88. All significantly down regulated genes in livers of female Ahr knockout by TCDD (25 µg/kg bw) identified by microarray analysis - mouse 5 days study. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
7.70 -4.345 0 A_52_P293682 Gm7231 XM_001477336 ref|PREDICTED: Mus musculus predicted gene EG638251 mRNA  
8.58 -3.964 0 A_52_P218833 Gm5584 NM_001101534 ref|Mus musculus predicted gene 5584 mRNA  
9.60 -3.712 0 A_55_P2113587 ENSMUST00000107481 ENSMUST00000107481 tc|MUP4_MOUSE (P11590) Major urinary protein 4 precursor partial (69%)  
13.16 -3.561 0.00013 A_55_P1979904 Mup9 NM_001126319 ref|Mus musculus major urinary protein 9  mRNA  
11.49 -3.482 9.00E-05 A_52_P412506 Mup5 NM_008649 ref|Mus musculus major urinary protein 5 mRNA  
9.39 -3.459 0.00023 A_55_P1952507 Gm5584 NM_001101534 ref|Mus musculus predicted gene 5584 mRNA  
10.14 -3.446 2.00E-05 A_55_P2033321 ENSMUST00000107490 ENSMUST00000107490 
gb|uo03b07.y1 Sugano mouse liver mlia Mus musculus cDNA clone IMAGE:2582293 5' similar to gb:M16358 
Mouse major urinary protein IV (MOUSE); 
7.75 -3.385 0 A_55_P2103703 LOC635091 XM_001475400 ref|PREDICTED: Mus musculus similar to Predicted gene OTTMUSG00000007485 mRNA  
9.76 -3.370 0 A_55_P2107223 Gm6957 NM_001081325 ref|Mus musculus predicted gene 6957 mRNA  
10.23 -3.229 0 A_55_P2172532 C730007P19Rik NM_009286 ref|Mus musculus RIKEN cDNA C730007P19 gene mRNA  
10.75 -3.224 0.00079 A_55_P1952517 Sult2a1 NM_001111296 ref|Mus musculus sulfotransferase family 2A dehydroepiandrosterone (DHEA)-preferring member 1 mRNA  
8.55 -3.218 0 A_55_P2046671 CU104690.1 XM_001477211 ref|PREDICTED: Mus musculus similar to Major urinary protein 1 mRNA  
7.57 -3.182 0 A_52_P402127 Mup9 NM_001126319 ref|Mus musculus major urinary protein 9 mRNA  
11.96 -3.160 0.00028 A_55_P2035029 A_55_P2035029 A_55_P2035029 Unknown 
7.24 -3.019 1.00E-05 A_55_P2129449 Sult3a1 NM_020565 ref|Mus musculus sulfotransferase family 3A member 1 mRNA  
12.02 -2.889 0.00121 A_55_P2051486 Mup20 NM_001012323 ref|Mus musculus major urinary protein 20 mRNA  
7.10 -2.826 5.00E-05 A_52_P366803 Cyp3a44 NM_177380 ref|Mus musculus cytochrome P450 family 3 subfamily a polypeptide 44 mRNA  
9.02 -2.800 1.00E-05 A_55_P2059586 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
7.13 -2.719 9.00E-05 A_55_P2116674 A_55_P2116674 A_55_P2116674 Unknown 
12.62 -2.709 1.00E-04 A_55_P2010097 Mup2 NM_001045550 ref|Mus musculus major urinary protein 2 transcript variant 2 mRNA  
7.67 -2.686 3.00E-05 A_55_P2061104 Mup6 NM_001081285 ref|Mus musculus major urinary protein 6 mRNA  
8.47 -2.629 3.00E-05 A_55_P2004132 Gm853 NM_001034872 ref|Mus musculus predicted gene 853 mRNA 
9.09 -2.592 0 A_51_P281333 St3gal6 NM_018784 ref|Mus musculus ST3 beta-galactoside alpha-23-sialyltransferase 6 mRNA  
8.39 -2.588 0 A_55_P2075127 Pax2 NM_011037 ref|Mus musculus paired box gene 2 mRNA  
8.46 -2.557 3.00E-05 A_52_P229981 Osta NM_145932 ref|Mus musculus organic solute transporter alpha mRNA  
7.55 -2.541 3.00E-05 A_52_P537827 Wdr72 NM_001033500 ref|Mus musculus WD repeat domain 72 mRNA  
10.22 -2.515 1.00E-05 A_52_P289091 Cyp2b13 NM_007813 ref|Mus musculus cytochrome P450 family 2 subfamily b polypeptide 13 mRNA  
Appendices 
 
288 
 
9.93 -2.504 0.00119 A_55_P1989248 Gm6168 XM_885022 ref|PREDICTED: Mus musculus predicted gene EG620627 mRNA  
10.45 -2.460 0 A_55_P2006008 Serpinb1a NM_025429 ref|Mus musculus serine (or cysteine) peptidase inhibitor clade B member 1a mRNA  
10.85 -2.396 0.00015 A_55_P1952512 C730007P19Rik NM_009286 ref|Mus musculus RIKEN cDNA C730007P19 gene mRNA  
10.55 -2.379 0 A_51_P269404 Fmo3 NM_008030 ref|Mus musculus flavin containing monooxygenase 3 mRNA  
8.88 -2.339 0 A_52_P315976 Tpm2 NM_009416 ref|Mus musculus tropomyosin 2 beta mRNA  
8.21 -2.324 0.00174 A_51_P333923 Tspan1 NM_133681 ref|Mus musculus tetraspanin 1 mRNA  
9.71 -2.281 5.00E-05 A_55_P2079167 Dnm1 NM_010065 ref|Mus musculus dynamin 1 mRNA  
11.15 -2.234 1.00E-05 A_55_P1960735 Gdf15 NM_011819 ref|Mus musculus growth differentiation factor 15 mRNA  
7.23 -2.194 0.00095 A_51_P326685 Lrtm1 NM_176920 ref|Mus musculus leucine-rich repeats and transmembrane domains 1 mRNA  
9.86 -2.185 0.00014 A_52_P595871 Cyp1a2 NM_009993 ref|Mus musculus cytochrome P450 family 1 subfamily a polypeptide 2 mRNA  
10.33 -2.162 0.00111 A_51_P318830 Syt10 NM_018803 ref|Mus musculus synaptotagmin X mRNA  
8.59 -2.146 8.00E-05 A_55_P1961466 Dct NM_010024 ref|Mus musculus dopachrome tautomerase mRNA  
9.86 -2.118 0.00064 A_55_P2048867 Gm2922 XM_001475122 ref|PREDICTED: Mus musculus hypothetical protein LOC100040715 mRNA  
10.33 -2.111 0 A_55_P1983754 Pcp4l1 NM_025557 ref|Mus musculus Purkinje cell protein 4-like 1 mRNA  
9.38 -2.056 1.00E-05 A_51_P224164 Slc26a4 NM_011867 ref|Mus musculus solute carrier family 26 member 4 mRNA  
7.09 -2.012 0.00081 A_55_P2345853 3830612M24 AK028406 
gb|Mus musculus 18 days pregnant adult female placenta and extra embryonic tissue cDNA RIKEN full-length 
enriched library clone:3830612M24 product:unclassifiable full insert sequence.  
7.48 -2.012 0.00131 A_55_P2065919 Macrod2 ENSMUST00000110064 ens|MACRO domain-containing protein 2  [Source:UniProtKB/Swiss-Prot;Acc:Q3UYG8]  
7.79 -2.004 0.00017 A_55_P2003053 Dct NM_010024 ref|Mus musculus dopachrome tautomerase mRNA  
8.100 -2.000 0.00079 A_55_P2065909 Macrod2 NM_001013802 ref|Mus musculus MACRO domain containing 2 transcript variant 1 mRNA  
9.05 -1.973 0 A_55_P2121408 Tpm2 NM_009416 ref|Mus musculus tropomyosin 2 beta mRNA  
8.51 -1.955 0.00032 A_55_P1973447 LOC100045903 XM_001475137 ref|PREDICTED: Mus musculus similar to Y box protein 2  mRNA  
9.30 -1.948 0 A_55_P1963134 Gm6135 XM_895691 ref|PREDICTED: Mus musculus predicted gene EG620205 mRNA  
7.80 -1.932 1.00E-05 A_55_P2007646 Cryaa NM_013501 ref|Mus musculus crystallin alpha A mRNA  
9.52 -1.900 7.00E-05 A_52_P1092823 Irx1 NM_010573 ref|Mus musculus Iroquois related homeobox 1 (Drosophila) mRNA  
11.65 -1.858 0 A_66_P122086 9030619P08Rik NM_001039720 ref|Mus musculus RIKEN cDNA 9030619P08 gene mRNA  
9.92 -1.854 0 A_55_P2157586 Gm4949 XM_001478918 ref|PREDICTED: Mus musculus similar to glutamine synthetase mRNA  
7.24 -1.836 8.00E-05 A_51_P466229 Pdgfrl NM_026840 ref|Mus musculus platelet-derived growth factor receptor-like mRNA  
9.46 -1.761 0 A_51_P164630 Fitm1 NM_026808 ref|Mus musculus fat storage-inducing transmembrane protein 1 mRNA  
9.64 -1.750 0.00134 A_51_P468073 Ggt1 NM_008116 ref|Mus musculus gamma-glutamyltransferase 1 mRNA  
9.49 -1.749 1.00E-05 A_55_P1955412 Slc1a2 NM_011393 
ref|Mus musculus solute carrier family 1 (glial high affinity glutamate transporter) member 2 transcript variant 3 
mRNA  
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7.50 -1.712 0.00094 A_52_P262219 Fos NM_010234 ref|Mus musculus FBJ osteosarcoma oncogene mRNA  
8.27 -1.703 0 A_55_P1994733 ENSMUST00000027064 ENSMUST00000027064 ens|Transmembrane protein 14A  [Source:UniProtKB/Swiss-Prot;Acc:P56983]  
7.49 -1.701 0.00037 A_52_P262219 Fos NM_010234 ref|Mus musculus FBJ osteosarcoma oncogene mRNA  
7.34 -1.689 5.00E-05 A_51_P469951 Srgap3 NM_080448 ref|Mus musculus SLIT-ROBO Rho GTPase activating protein 3 mRNA  
10.89 -1.662 1.00E-05 A_55_P2046657 Dio1 NM_007860 ref|Mus musculus deiodinase iodothyronine type I mRNA  
8.73 -1.641 0.00191 A_55_P2338200 Glb1l2 NM_153803 ref|Mus musculus galactosidase beta 1-like 2 mRNA  
8.13 -1.633 0.00058 A_66_P106238 Gm5106 XM_001473563 ref|PREDICTED: Mus musculus predicted gene EG330031 mRNA  
11.24 -1.631 0.00013 A_66_P101764 ENSMUST00000066505 ENSMUST00000066505 ens|Putative uncharacterized proteinMCG148307 ; [Source:UniProtKB/TrEMBL;Acc:Q8C950]  
11.51 -1.626 1.00E-05 A_51_P498882 Cyp2c37 NM_010001 ref|Mus musculus cytochrome P450 family 2. subfamily c polypeptide 37 mRNA  
9.60 -1.601 0 A_55_P2069907 Acot3 NM_134246 ref|Mus musculus acyl-CoA thioesterase 3 mRNA  
9.93 -1.580 0.00061 A_55_P2121618 Tox4 NM_023434 ref|Mus musculus TOX high mobility group box family member 4 mRNA  
7.94 -1.565 0.00099 A_55_P1958554 Ar NM_013476 ref|Mus musculus androgen receptor mRNA  
7.13 -1.554 0.00028 A_55_P2063937 D630033A02Rik XM_001472939 ref|PREDICTED: Mus musculus RIKEN cDNA D630033A02 gene mRNA  
9.14 -1.543 7.00E-05 A_55_P2039429 Dio1 NM_007860 ref|Mus musculus deiodinase iodothyronine type I mRNA  
9.58 -1.537 0.00027 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA  
9.36 -1.536 0.00066 A_51_P134812 Chac1 NM_026929 ref|Mus musculus ChaC cation transport regulator-like 1 (E. coli) mRNA  
11.08 -1.536 1.00E-05 A_52_P614777 Sucnr1 NM_032400 ref|Mus musculus succinate receptor 1 mRNA  
8.57 -1.528 0.00049 A_55_P2165554 ENSMUST00000099046 ENSMUST00000099046 Unknown 
9.83 -1.527 0.00117 A_51_P253481 Ces1 NM_021456 ref|Mus musculus carboxylesterase 1 mRNA  
7.20 -1.523 3.00E-04 A_52_P99807 Dpy19l3 NM_178704 ref|Mus musculus dpy-19-like 3 (C. elegans) mRNA  
10.96 -1.521 0 A_55_P2092501 Med1 NM_134027 ref|Mus musculus mediator complex subunit 1 transcript variant 2 mRNA  
9.33 -1.519 2.00E-05 A_51_P418725 Plekhf1 NM_024413 ref|Mus musculus pleckstrin homology domain containing family F (with FYVE domain) member 1 mRNA 
9.76 -1.518 9.00E-04 A_51_P249286 Rgs16 NM_011267 ref|Mus musculus regulator of G-protein signaling 16 mRNA  
9.61 -1.513 7.00E-05 A_51_P304109 Cyp2c39 NM_010003 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 39 mRNA  
8.98 -1.510 0.00099 A_55_P2093862 ENSMUST00000099037 ENSMUST00000099037 Unknown 
10.27 -1.501 0 A_55_P2219059 Lmnb2 NM_010722 ref|Mus musculus lamin B2 mRNA  
12.93 -1.495 3.00E-05 A_55_P2016842 Me1 NM_008615 ref|Mus musculus malic enzyme 1 NADP(+)-dependent cytosolic  mRNA  
9.59 -1.447 0.00029 A_51_P107362 Socs2 NM_007706 ref|Mus musculus suppressor of cytokine signaling 2 transcript variant 1 mRNA  
11.81 -1.439 1.00E-05 A_51_P451588 Plekhb1 NM_013746 
ref|Mus musculus pleckstrin homology domain containing family B (evectins) member 1 transcript variant 1 
mRNA  
7.94 -1.437 3.00E-05 A_55_P2007228 Prkaca NM_008854 ref|Mus musculus protein kinase cAMP dependent catalytic alpha mRNA  
9.28 -1.421 4.00E-05 A_55_P2071906 ENSMUST00000108392 ENSMUST00000108392 ens|Cytochrome P-450b (phenobarbital-inducible) Fragment  [Source:UniProtKB/TrEMBL;Acc:Q61461]  
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8.00 -1.413 0.00036 A_55_P1978636 ENSMUST00000099035 ENSMUST00000099035 tc|Q4YHF0_PLABE (Q4YHF0) Pb-fam-2 protein (Fragment) partial (7%)  
10.6 -1.404 1.00E-05 A_51_P185175 Fkbp4 NM_010219 ref|Mus musculus FK506 binding protein 4 mRNA  
10.21 -1.398 0.00046 A_66_P108247 Ucp3 NM_009464 
ref|Mus musculus uncoupling protein 3 (mitochondrial proton carrier) nuclear gene encoding mitochondrial protein 
mRNA  
10.56 -1.397 5.00E-05 A_55_P2051094 Rorc NM_011281 ref|Mus musculus RAR-related orphan receptor gamma mRNA  
8.96 -1.391 3.00E-04 A_55_P2031676 Gstm6 NM_008184 ref|Mus musculus glutathione S-transferase mu 6 mRNA  
8.02 -1.389 0 A_55_P1992164 E130102H24Rik XM_001472210 ref|PREDICTED: Mus musculus RIKEN cDNA E130102H24 gene mRNA  
8.67 -1.388 3.00E-05 A_51_P286488 Ier3 NM_133662 ref|Mus musculus immediate early response 3 mRNA  
11.08 -1.37 1.00E-05 A_55_P2063312 Mgll NM_001166250 ref|Mus musculus monoglyceride lipase transcript variant 4 mRNA  
10.69 -1.368 0.00016 A_55_P2088440 Arrdc2 NM_027560 ref|Mus musculus arrestin domain containing 2 mRNA  
7.05 -1.366 4.00E-05 A_55_P2136847 Slc1a2 NM_001077514 
ref|Mus musculus solute carrier family 1 (glial high affinity glutamate transporter) member 2transcript variant 1 
mRNA  
7.31 -1.361 0.00032 A_51_P100573 Map3k3 NM_011947 ref|Mus musculus mitogen-activated protein kinase kinase kinase 3 mRNA  
8.68 -1.360 9.00E-05 A_51_P245503 Ugt2b1 NM_152811 ref|Mus musculus UDP glucuronosyltransferase 2 family polypeptide B1 mRNA  
11.04 -1.359 2.00E-05 A_51_P400366 Rhbg NM_021375 ref|Mus musculus Rhesus blood group-associated B glycoprotein mRNA  
10.24 -1.355 0.00011 A_51_P144531 D630002G06Rik NM_172776 ref|Mus musculus RIKEN cDNA D630002G06 gene mRNA  
11.18 -1.352 9.00E-04 A_55_P1974788 Cfl1 NM_007687 ref|Mus musculus cofilin 1 non-muscle mRNA  
8.30 -1.340 3.00E-05 A_55_P2139587 NAP092820-001 NAP092820-001 Unknown 
8.27 -1.339 7.00E-05 A_51_P514319 Slc13a4 NM_172892 ref|Mus musculus solute carrier family 13 (sodium/sulfate symporters) member 4  mRNA  
8.42 -1.334 0.00041 A_55_P2004071 Gm2058 NM_001170345 ref|Mus musculus predicted gene 2058 mRNA  
7.05 -1.331 0.00042 A_55_P2065249 ENSMUST00000063239 ENSMUST00000063239 ens|Putative uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:Q9D605]  
8.21 -1.330 0.00185 A_55_P2039532 Pax8 NM_011040 ref|Mus musculus paired box gene 8 mRNA  
7.24 -1.328 8.00E-05 A_51_P475138 Duox1 NM_001099297 ref|Mus musculus dual oxidase 1 mRNA  
7.65 -1.325 0.00031 A_55_P1955427 Cux1 NM_009986 ref|Mus musculus cut-like homeobox 1 transcript variant 1 mRNA  
13.49 -1.323 1.00E-05 A_51_P334942 Aldh1a1 NM_013467 ref|Mus musculus aldehyde dehydrogenase family 1 subfamily A1 mRNA  
12.23 -1.322 2.00E-05 A_51_P453043 Aacs NM_030210 ref|Mus musculus acetoacetyl-CoA synthetase mRNA  
9.45 -1.319 0.00071 A_55_P2138100 ENSMUST00000099050 ENSMUST00000099050 Unknown 
12.19 -1.305 8.00E-04 A_55_P2158990 Jun NM_010591 ref|Mus musculus Jun oncogene mRNA  
9.05 -1.305 1.00E-05 A_55_P1979377 Slc16a7 NM_011391 ref|Mus musculus solute carrier family 16 (monocarboxylic acid transporters) member 7 mRNA  
7.99 -1.303 1.00E-05 A_51_P469531 Asna1 NM_019652 ref|Mus musculus arsA arsenite transporter ATP-binding homolog 1 (bacterial) mRNA  
8.62 -1.302 0.00047 A_55_P2114110 Cadm4 NM_153112 ref|Mus musculus cell adhesion molecule 4 mRNA  
12.01 -1.301 1.00E-05 A_55_P2061338 Slc16a11 NM_153081 
ref|Mus musculus solute carrier family 16 (monocarboxylic acid transporters) member 11 transcript variant 3 
mRNA  
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9.93 -1.295 3.00E-05 A_55_P1961736 Rcan2 NM_207649 ref|Mus musculus regulator of calcineurin 2 transcript variant 1 mRNA  
10.26 -1.289 0.00023 A_55_P2070976 Gm6923 XM_893647 ref|PREDICTED: Mus musculus predicted gene EG628855 mRNA  
8.93 -1.286 1.00E-05 A_66_P105422 Lonrf3 NM_028894 ref|Mus musculus LON peptidase N-terminal domain and ring finger 3 mRNA  
8.22 -1.264 0 A_55_P2123706 Plekhb1 NM_013746 
ref|Mus musculus pleckstrin homology domain containing family B (evectins) member 1 transcript variant 1 
mRNA  
7.62 -1.262 4.00E-05 A_51_P406165 Fam55b NM_030069 ref|Mus musculus family with sequence similarity 55 member B mRNA  
9.48 -1.260 5.00E-05 A_55_P2037428 Mogat1 NM_026713 ref|Mus musculus monoacylglycerol O-acyltransferase 1 mRNA  
7.63 -1.260 0.00011 A_52_P77093 1600014C10Rik NM_028166 ref|Mus musculus RIKEN cDNA 1600014C10 gene transcript variant 2 mRNA  
7.52 -1.259 0.00012 A_55_P2169124 ENSMUST00000120540 ENSMUST00000120540 ens|integral membrane transport protein UST1R  [Source:RefSeq peptide;Acc:NP_795976]  
9.36 -1.257 0.00054 A_55_P2035824 Nr1i3 NM_009803 ref|Mus musculus nuclear receptor subfamily 1 group I member 3 mRNA  
10.40 -1.246 0.00036 A_55_P1966438 Gstm2 NM_008183 ref|Mus musculus glutathione S-transferase mu 2  mRNA  
11.29 -1.245 1.00E-05 A_55_P2116290 D4Ertd22e NM_001025608 ref|Mus musculus DNA segment Chr 4 ERATO Doi 22 expressed transcript variant 1 mRNA  
9.93 -1.237 0.00045 A_55_P1957922 Arrdc2 NM_027560 ref|Mus musculus arrestin domain containing 2 mRNA  
7.16 -1.233 0.00017 A_55_P2185185 Tmem28 NM_001081283 ref|Mus musculus transmembrane protein 28 mRNA  
8.12 -1.232 0.00084 A_55_P2032770 Inpp5e NM_033134 ref|Mus musculus inositol polyphosphate-5-phosphatase E mRNA  
13.95 -1.225 5.00E-05 A_55_P2142146 Glul NM_008131 ref|Mus musculus glutamate-ammonia ligase (glutamine synthetase) mRNA  
8.06 -1.225 0.00018 A_66_P140507 Lhpp NM_029609 ref|Mus musculus phospholysine phosphohistidine inorganic pyrophosphate phosphatase mRNA  
10.56 -1.224 0.00043 A_51_P386648 Glod5 NM_027227 ref|Mus musculus glyoxalase domain containing 5 mRNA  
8.32 -1.224 6.00E-05 A_55_P2040860 Sunc1 NM_177576 ref|Mus musculus Sad1 and UNC84 domain containing 1 mRNA  
9.27 -1.223 0.00117 A_52_P423810 ENSMUST00000062980 ENSMUST00000062980 ens|Metallothionein-1 (MT-1)(Metallothionein-I)(MT-I) [Source:UniProtKB/Swiss-Prot;Acc:P02802]  
11.33 -1.222 2.00E-05 A_55_P2038347 Acot3 NM_134246 ref|Mus musculus acyl-CoA thioesterase 3 mRNA  
8.33 -1.221 0.00054 A_55_P2183914 Gm7120 NM_001039244 ref|Mus musculus predicted gene 7120 mRNA  
7.52 -1.220 0.00034 A_52_P140881 Slc26a10 NM_177615 ref|Mus musculus solute carrier family 26 member 10 mRNA  
8.26 -1.213 0.00025 A_55_P1994132 Tmem184a ENSMUST00000110832 ens|Transmembrane protein 184A  [Source:UniProtKB/Swiss-Prot;Acc:Q3UFJ6]  
7.01 -1.205 0.00053 A_55_P2131163 Sv2c AK173092 gb|Mus musculus mRNA for mKIAA1054 protein 
7.50 -1.200 1.00E-05 A_51_P113182 Lifr NM_013584 ref|Mus musculus leukemia inhibitory factor receptor transcript variant 1 mRNA  
9.75 -1.198 0.00081 A_55_P2153783 Fmo1 NM_010231 ref|Mus musculus flavin containing monooxygenase 1 mRNA  
8.85 -1.197 0 A_55_P2278775 9130016M20Rik AK050221 
gb|Mus musculus adult male liver tumor cDNA RIKEN full-length enriched library clone:C730027O05 
product:unclassifiable full insert sequence 
11.03 -1.195 0.00085 A_55_P2165091 Acnat2 NM_145368 ref|Mus musculus acyl-coenzyme A amino acid N-acyltransferase 2 mRNA  
12.38 -1.194 0.00081 A_55_P2043531 A_55_P2043531 A_55_P2043531 Unknown 
9.64 -1.194 6.00E-05 A_55_P2031671 Gstm6 NM_008184 ref|Mus musculus glutathione S-transferase mu 6 mRNA  
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10.10 -1.188 2.00E-05 A_55_P2035424 Hpgd NM_008278 ref|Mus musculus hydroxyprostaglandin dehydrogenase 15 (NAD) mRNA  
9.90 -1.186 1.00E-05 A_51_P406429 Pdk1 NM_172665 
ref|Mus musculus pyruvate dehydrogenase kinase isoenzyme 1 nuclear gene encoding mitochondrial protein 
mRNA  
10.33 -1.179 1.00E-05 A_55_P2070084 Gm13151 XM_984726 ref|PREDICTED: Mus musculus similar to crooked legs CG14938-PB mRNA  
9.93 -1.177 0.00021 A_66_P124420 NAP001637-001 NAP001637-001 Unknown 
13.33 -1.174 0.00121 A_55_P2171413 Me1 NM_008615 ref|Mus musculus malic enzyme 1 NADP(+)-dependent cytosolic mRNA  
8.36 -1.174 2.00E-05 A_55_P2177513 Chrna2 NM_144803 ref|Mus musculus cholinergic receptor nicotinic alpha polypeptide 2 (neuronal) mRNA  
8.63 -1.168 5.00E-05 A_55_P1973683 Morn4 NM_198108 ref|Mus musculus MORN repeat containing 4 mRNA  
9.17 -1.166 6.00E-05 A_51_P462814 Sars2 NM_023637 ref|Mus musculus seryl-aminoacyl-tRNA synthetase 2 mRNA  
9.59 -1.166 0.00073 A_55_P2038362 Acot5 NM_145444 ref|Mus musculus acyl-CoA thioesterase 5 mRNA  
7.05 -1.165 0.00039 A_55_P2331974 TC1653743 TC1653743 Unknown 
12.74 -1.161 0 A_55_P1963767 Npr2 NM_173788 ref|Mus musculus natriuretic peptide receptor 2 mRNA  
10.04 -1.159 1.00E-05 A_55_P1997097 Bod1 NM_001024919 ref|Mus musculus biorientation of chromosomes in cell division 1 mRNA  
10.16 -1.155 0.00024 A_55_P1988795 Acss2 NM_019811 ref|Mus musculus acyl-CoA synthetase short-chain family member 2 mRNA  
8.50 -1.154 3.00E-05 A_55_P2181348 Gm11378 XM_001476139 ref|PREDICTED: Mus musculus hypothetical protein LOC100041312 mRNA 
7.35 -1.151 0.00151 A_55_P2319020 BB557941 AK163349 
gb|Mus musculus 2 cells egg cDNA RIKEN full-length enriched library clone:B020017L01 product:unclassifiable 
full insert sequence 
9.21 -1.151 3.00E-04 A_55_P2127765 Crp NM_007768 ref|Mus musculus C-reactive protein pentraxin-related mRNA  
11.42 -1.151 0.00128 A_51_P316935 8430408G22Rik NM_145980 ref|Mus musculus RIKEN cDNA 8430408G22 gene transcript variant 1 mRNA  
7.13 -1.151 0.00019 A_51_P348672 Zdhhc17 NM_172554 ref|Mus musculus zinc finger DHHC domain containing 17 mRNA  
12.17 -1.145 4.00E-05 A_55_P1970033 Per1 NM_011065 ref|Mus musculus period homolog 1 (Drosophila) transcript variant 1 mRNA  
7.91 -1.145 3.00E-05 A_55_P2051384 Ccdc88c NM_026681 ref|Mus musculus coiled-coil domain containing 88C mRNA  
8.14 -1.143 0.00028 A_51_P340668 Bcl9l NM_030256 ref|Mus musculus B-cell CLL/lymphoma 9-like mRNA  
8.75 -1.142 0.00037 A_55_P2147136 Akr1d1 NM_145364 ref|Mus musculus aldo-keto reductase family 1 member D1 mRNA  
9.23 -1.141 0.00041 A_52_P183524 Tmem86b NM_023440 ref|Mus musculus transmembrane protein 86B mRNA  
7.91 -1.141 0.00101 A_51_P136792 Calcoco1 NM_026192 ref|Mus musculus calcium binding and coiled coil domain 1 mRNA  
14.26 -1.140 0.00057 A_55_P1966690 Cyp2e1 NM_021282 ref|Mus musculus cytochrome P450 family 2 subfamily e polypeptide 1 mRNA  
7.81 -1.131 5.00E-05 A_55_P2035804 Fzd8 NM_008058 ref|Mus musculus frizzled homolog 8 (Drosophila) mRNA  
8.63 -1.131 1.00E-05 A_52_P547662 P2ry1 NM_008772 ref|Mus musculus purinergic receptor P2Y G-protein coupled 1 mRNA  
7.07 -1.131 7.00E-05 A_52_P35377 Plagl2 NM_018807 ref|Mus musculus pleiomorphic adenoma gene-like 2 mRNA  
7.94 -1.130 0.00028 A_51_P176042 Pklr NM_013631 
ref|Mus musculus pyruvate kinase liver and red blood cell nuclear gene encoding mitochondrial protein transcript 
variant 1 mRNA  
7.57 -1.125 0.00043 A_52_P157274 Abi1 NM_001077190 ref|Mus musculus abl-interactor 1 transcript variant 1 mRNA  
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9.26 -1.123 0.00031 A_52_P82765 ENSMUST00000065861 ENSMUST00000065861 ens|Testosterone 16a-hydroxylase type c Fragment  [Source:UniProtKB/TrEMBL;Acc:Q61460]  
10.4 -1.118 9.00E-04 A_55_P2000603 Rag1ap1 NM_009057 ref|Mus musculus recombination activating gene 1 activating protein 1 mRNA  
9.08 -1.117 2.00E-05 A_52_P981697 Zfp874 NM_177712 ref|Mus musculus zinc finger protein 874 mRNA  
14.41 -1.115 1.00E-05 A_51_P267063 Ugt3a2 NM_144845 ref|Mus musculus UDP glycosyltransferases 3 family polypeptide A2 mRNA  
12.2 -1.112 0.00048 A_51_P502150 Slc9a3r1 NM_012030 ref|Mus musculus solute carrier family 9 (sodium/hydrogen exchanger) member 3 regulator 1 mRNA  
9.05 -1.110 2.00E-04 A_65_P19089 Esrrg NM_011935 ref|Mus musculus estrogen-related receptor gamma mRNA  
12.43 -1.106 2.00E-05 A_52_P240796 Rdh16 NM_009040 ref|Mus musculus retinol dehydrogenase 16 mRNA  
7.23 -1.098 9.00E-05 A_55_P2181602 Calb1 NM_009788 ref|Mus musculus calbindin 1 mRNA  
11.98 -1.094 8.00E-05 A_51_P138044 Foxo1 NM_019739 ref|Mus musculus forkhead box O1 mRNA  
9.44 -1.091 0.00048 A_55_P2130393 Pnpla1 NM_001034885 ref|Mus musculus patatin-like phospholipase domain containing 1 mRNA  
9.92 -1.091 0.00037 A_51_P214107 Tbc1d20 NM_024196 ref|Mus musculus TBC1 domain family member 20 mRNA  
11.26 -1.088 7.00E-05 A_51_P213691 Scnn1a NM_011324 ref|Mus musculus sodium channel nonvoltage-gated 1 alpha mRNA  
11.70 -1.088 0.00083 A_55_P2110290 Gm10395 XM_001472492 ref|PREDICTED: Mus musculus similar to D14Ertd449e protein transcript variant 1 mRNA  
7.93 -1.087 0.00161 A_55_P2064965 ENSMUST00000098392 ENSMUST00000098392 ens|Putative uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:Q3U3H4]  
13.69 -1.084 9.00E-05 A_51_P430082 Tst NM_009437 ref|Mus musculus thiosulfate sulfurtransferase mitochondrial nuclear gene encoding mitochondrial protein mRNA  
7.32 -1.084 0.00076 A_51_P115626 Shank3 NM_021423 ref|Mus musculus SH3/ankyrin domain gene 3 mRNA  
8.31 -1.077 0.00018 A_52_P63343 Gm129 NM_001033302 ref|Mus musculus predicted gene 129 mRNA  
11.26 -1.076 1.00E-05 A_66_P139387 Prlr NM_011169 ref|Mus musculus prolactin receptor mRNA  
12.94 -1.075 0.00058 A_55_P2030183 NAP112908-1 NAP112908-1 tc|Q5T7C3_HUMAN (Q5T7C3) High-mobility group box 1 partial (83%)  
7.33 -1.072 0.00115 A_55_P1964262 Apol7a NM_029419 ref|Mus musculus apolipoprotein L 7a  transcript variant 1 mRNA  
8.45 -1.071 2.00E-04 A_66_P113268 Mme NM_008604 ref|Mus musculus membrane metallo endopeptidase mRNA  
11.07 -1.070 0.00026 A_55_P2062262 Aspscr1 NM_026877 ref|Mus musculus alveolar soft part sarcoma chromosome region candidate 1 (human) transcript variant 1 mRNA  
13.25 -1.067 0.00053 A_55_P2030501 Ppp2r4 NM_138748 ref|Mus musculus protein phosphatase 2A regulatory subunit B (PR 53) mRNA  
8.69 -1.065 0.00043 A_52_P52263 D17Wsu92e NM_001044719 ref|Mus musculus DNA segment Chr 17 Wayne State University 92 expressed  transcript variant 2 mRNA  
7.78 -1.064 8.00E-04 A_55_P2295933 Elmo3 NM_172760 ref|Mus musculus engulfment and cell motility 3 ced-12 homolog (C. elegans) mRNA  
10.12 -1.063 0.00037 A_55_P1966528 Pmf1 NM_025928 ref|Mus musculus polyamine-modulated factor 1 mRNA  
9.63 -1.063 0.00014 A_55_P1995417 1810031K17Rik NM_026977 ref|Mus musculus RIKEN cDNA 1810031K17 gene mRNA  
11.63 -1.061 4.00E-05 A_55_P1999790 Pkdcc NM_134117 ref|Mus musculus protein kinase domain containing cytoplasmic mRNA  
7.46 -1.060 0.00014 A_55_P2149288 Cmya5 NM_023821 ref|Mus musculus cardiomyopathy associated 5 mRNA  
7.14 -1.060 9.00E-05 A_55_P2044627 Rnase10 NM_029145 ref|Mus musculus ribonuclease RNase A family 10 (non-active) transcript variant 1 mRNA  
11.01 -1.059 1.00E-05 A_55_P2088014 Cdc42ep4 NM_020006 ref|Mus musculus CDC42 effector protein (Rho GTPase binding) 4 transcript variant 1 mRNA  
10.29 -1.058 0.00037 A_51_P442053 Ptdss1 NM_008959 ref|Mus musculus phosphatidylserine synthase 1 mRNA  
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11.19 -1.058 0.00097 A_55_P2116272 Cyp2c38 NM_010002 ref|Mus musculus cytochrome P450 family 2 subfamily c polypeptide 38 mRNA  
8.98 -1.058 0.00025 A_52_P79639 Vat1 NM_012037 ref|Mus musculus vesicle amine transport protein 1 homolog (T californica) mRNA  
9.93 -1.054 0.00058 A_55_P2025368 Nkain1 NM_025998 ref|Mus musculus Na+/K+ transporting ATPase interacting 1 mRNA  
8.94 -1.049 0.00014 A_55_P2141938 1810058I24Rik NR_027875 ref|Mus musculus RIKEN cDNA 1810058I24 gene transcript variant 1 non-coding RNA  
9.67 -1.048 3.00E-05 A_55_P2367117 Pitpnb NM_019640 ref|Mus musculus phosphatidylinositol transfer protein beta mRNA  
11.64 -1.048 0.00064 A_55_P2055523 Gm3160 XM_001475214 ref|PREDICTED: Mus musculus similar to high-mobility group box 1 mRNA  
7.55 -1.046 0.00022 A_55_P2068121 Spag4l NM_029599 ref|Mus musculus sperm associated antigen 4-like mRNA  
11.16 -1.044 5.00E-05 A_51_P293901 Dhrs1 NM_026819 ref|Mus musculus dehydrogenase/reductase (SDR family) member 1 mRNA  
7.93 -1.042 6.00E-05 A_55_P2117984 Vangl2 NM_033509 ref|Mus musculus vang-like 2 (van gogh Drosophila) mRNA  
10.30 -1.037 0.00105 A_52_P486322 Fzr1 NM_019757 ref|Mus musculus fizzy/cell division cycle 20 related 1 (Drosophila) mRNA  
9.52 -1.034 0.00023 A_55_P2039289 Hspb6 NM_001012401 ref|Mus musculus heat shock protein alpha-crystallin-related B6 mRNA  
7.18 -1.034 0.00029 A_55_P1994942 Rorc NM_011281 ref|Mus musculus RAR-related orphan receptor gamma mRNA  
9.37 -1.034 0.00074 A_51_P418908 Larp1 NM_028451 ref|Mus musculus La ribonucleoprotein domain family member 1 mRNA  
10.20 -1.032 9.00E-05 A_66_P138976 Lpin2 NM_001164885 ref|Mus musculus lipin 2 transcript variant 1 mRNA  
9.84 -1.032 0.00017 A_52_P561927 Ncor1 NM_011308 ref|Mus musculus nuclear receptor co-repressor 1 mRNA  
10.79 -1.031 6.00E-05 A_55_P2120354 Cib2 NM_019686 ref|Mus musculus calcium and integrin binding family member 2 mRNA  
7.27 -1.030 0.00041 A_55_P1997211 Diras1 NM_145217 ref|Mus musculus DIRAS family GTP-binding RAS-like 1 mRNA  
7.57 -1.029 0.00014 A_66_P119074 Tbc1d22b NM_198647 ref|Mus musculus TBC1 domain family member 22B mRNA  
12.84 -1.028 0.001 A_55_P2025468 Tst NM_009437 ref|Mus musculus thiosulfate sulfurtransferase mitochondrial nuclear gene encoding mitochondrial protein mRNA  
8.03 -1.028 0.00074 A_55_P1985015 Pard3 NM_033620 ref|Mus musculus par-3 (partitioning defective 3) homolog (C. elegans) transcript variant 3 mRNA  
10.24 -1.027 4.00E-05 A_52_P112651 Lman2 NM_025828 ref|Mus musculus lectin mannose-binding 2 mRNA  
8.24 -1.026 0.00163 A_66_P136632 1500003O03Rik NM_019769 ref|Mus musculus RIKEN cDNA 1500003O03 gene mRNA  
14.42 -1.024 0.00011 A_52_P229972 Slc22a1 NM_009202 ref|Mus musculus solute carrier family 22 (organic cation transporter) member 1 mRNA  
10.17 -1.022 0.00011 A_52_P516034 Ptp4a1 NM_011200 ref|Mus musculus protein tyrosine phosphatase 4a1 mRNA  
8.55 -1.022 0.00018 A_51_P271984 Tmem45b NM_144936 ref|Mus musculus transmembrane protein 45b mRNA  
9.64 -1.021 9.00E-05 A_51_P453963 9530008L14Rik NM_175417 ref|Mus musculus RIKEN cDNA 9530008L14 gene transcript variant 1 mRNA  
8.19 -1.021 0.00154 A_52_P69558 Gm8221 XM_001475933 ref|PREDICTED: Mus musculus apolipoprotein L 3-like mRNA  
10.5 -1.020 4.00E-05 A_55_P2177721 Adra1b NM_007416 ref|Mus musculus adrenergic receptor alpha 1b mRNA  
7.40 -1.020 0.00012 A_55_P2013645 Tubg2 NM_134028 ref|Mus musculus tubulin gamma 2 mRNA  
13.3 -1.018 0.00021 A_55_P2052924 Sepw1 NM_009156 ref|Mus musculus selenoprotein W muscle 1 mRNA  
8.00 -1.018 0.00019 A_52_P576049 Inhbc NM_010565 ref|Mus musculus inhibin beta-C mRNA  
8.73 -1.017 0.00038 A_52_P404363 Cdc42bpb NM_183016 ref|Mus musculus CDC42 binding protein kinase beta mRNA  
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14.85 -1.012 0.00021 A_51_P162162 Inmt NM_009349 ref|Mus musculus indolethylamine N-methyltransferase mRNA  
7.00 -1.010 3.00E-04 A_55_P1991851 Speg NM_001085370 ref|Mus musculus SPEG complex locus transcript variant 2 mRNA 
8.83 -1.010 7.00E-04 A_51_P282837 St14 NM_011176 ref|Mus musculus suppression of tumorigenicity 14 (colon carcinoma) mRNA  
14.29 -1.010 2.00E-05 A_51_P141535 Oat NM_016978 ref|Mus musculus ornithine aminotransferase nuclear gene encoding mitochondrial protein mRNA  
11.11 -1.005 0.00011 A_51_P192089 2610028A01Rik NM_028228 ref|Mus musculus RIKEN cDNA 2610028A01 gene mRNA  
7.81 -1.004 7.00E-04 A_51_P339380 Setmar NM_178391 ref|Mus musculus SET domain and mariner transposase fusion gene  mRNA  
9.84 -1.003 4.00E-05 A_55_P2109922 Gm2921 XM_001474867 ref|PREDICTED: Mus musculus hypothetical protein LOC100040711 mRNA  
9.84 -1.001 0.00039 A_55_P2123381 Fga NM_010196 ref|Mus musculus fibrinogen alpha chain transcript variant 2 mRNA  
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Table 89. All significantly up regulated genes in hHeps after treatment with TCDD (10 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systemtatic name Gene description 
12.43 6.589 0 A_23_P209625 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
12.73 5.368 0 A_23_P163402 CYP1A1 NM_000499 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 1 mRNA  
9.01 4.578 0 A_23_P165136 LRRC25 NM_145256 ref|Homo sapiens leucine rich repeat containing 25 mRNA  
10.97 4.429 0 A_33_P3290343 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA 
8.83 4.406 0 A_23_P207213 ALDH3A1 NM_000691 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 2 mRNA  
10.10 4.197 0 A_33_P3238433 ALDH3A1 NM_001135168 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 1 mRNA  
8.03 3.604 0 A_33_P3480395 FLJ30901 AK055463 gb|Homo sapiens cDNA FLJ30901 fis clone FEBRA2005778. 
8.99 3.529 0 A_23_P26854 ARHGAP44 NM_014859 ref|Homo sapiens Rho GTPase activating protein 44 mRNA  
9.76 3.259 0 A_33_P3397795 C14orf135 AK095489 gb|Homo sapiens cDNA FLJ38170 fis clone FCBBF1000024. 
8.13 3.172 0 A_32_P49867 LOC100507055 NM_001195520 ref|Homo sapiens hypothetical LOC100507055 mRNA  
10.23 3.106 0 A_23_P416581 GNAZ NM_002073 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha z polypeptide mRNA  
9.85 2.948 0 A_24_P157370 IL17RB NM_018725 ref|Homo sapiens interleukin 17 receptor B mRNA  
12.12 2.710 0 A_33_P3222762 HULC NR_004855 ref|Homo sapiens highly up-regulated in liver cancer (non-protein coding) non-coding RNA  
15.21 2.626 0 A_33_P3253747 CYP1A2 NM_000761 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 2 mRNA  
8.52 2.343 0 A_33_P3230990 SCUBE1 NM_173050 ref|Homo sapiens signal peptide CUB domain EGF-like 1 mRNA  
11.3 2.311 0 A_23_P143845 TIPARP NM_015508 ref|Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase transcript variant 2 mRNA  
11.27 2.291 0 A_23_P57910 RTP3 NM_031440 ref|Homo sapiens receptor (chemosensory) transporter protein 3 mRNA  
8.74 2.276 0 A_33_P3734384 LOC285957 AK097526 gb|Homo sapiens cDNA FLJ40207 fis clone TESTI2020946 
9.68 2.240 0 A_23_P41804 NKD2 NM_033120 ref|Homo sapiens naked cuticle homolog 2 (Drosophila) mRNA  
8.99 2.159 0 A_23_P154806 EPB41L1 NM_012156 ref|Homo sapiens erythrocyte membrane protein band 4.1-like 1 transcript variant 1 mRNA  
7.89 2.138 0 A_24_P335620 SLC7A5 NM_003486 ref|Homo sapiens solute carrier family 7 (amino acid transporter light chain L system) member 5 mRNA  
8.85 2.137 0 A_23_P136355 HHAT NM_018194 ref|Homo sapiens hedgehog acyltransferase transcript variant 1 mRNA  
8.09 2.118 0 A_23_P257003 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5 transcript variant 2 mRNA  
7.15 2.078 0 A_23_P17673 DNMT3L NM_013369 ref|Homo sapiens DNA (cytosine-5-)-methyltransferase 3-like transcript variant 1 mRNA  
9.56 2.009 0 A_23_P75630 APOA5 NM_052968 ref|Homo sapiens apolipoprotein A-V transcript variant 1 mRNA  
8.51 1.931 0 A_23_P116942 LAG3 NM_002286 ref|Homo sapiens lymphocyte-activation gene 3 mRNA  
13.88 1.843 0 A_23_P94159 FBXO25 NM_183421 ref|Homo sapiens F-box protein 25 transcript variant 1 mRNA 
10.18 1.830 0 A_23_P24723 TMEM138 NM_016464 ref|Homo sapiens transmembrane protein 138 transcript variant 1 mRNA  
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12.98 1.808 0 A_23_P421423 TNFAIP2 NM_006291 ref|Homo sapiens tumor necrosis factor alpha-induced protein 2 mRNA  
7.31 1.758 0 A_23_P120125 COLEC11 NM_199235 ref|Homo sapiens collectin sub-family member 11 transcript variant 2 mRNA  
15.22 1.750 2.00E-05 A_23_P42868 IGFBP1 NM_000596 ref|Homo sapiens insulin-like growth factor binding protein 1 mRNA  
8.67 1.741 0.00032 A_23_P110777 LECT2 NM_002302 ref|Homo sapiens leukocyte cell-derived chemotaxin 2 mRNA  
7.80 1.717 1.00E-05 A_23_P381489 NCRNA00313 NR_026863 ref|Homo sapiens non-protein coding RNA 313 non-coding RNA  
11.35 1.713 0 A_23_P421032 SEC14L4 NM_174977 ref|Homo sapiens SEC14-like 4 (S. cerevisiae) transcript variant 1 mRNA  
7.91 1.704 0 A_33_P3841368 LOC286161 AK091672 gb|Homo sapiens cDNA FLJ34353 fis clone FEBRA2011665 
10.69 1.653 5.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
8.58 1.651 0 A_23_P259071 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
11.48 1.643 0 A_23_P83110 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
8.87 1.607 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
10.75 1.585 8.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
9.58 1.569 0 A_23_P403335 EXPH5 NM_015065 ref|Homo sapiens exophilin 5 mRNA  
10.63 1.544 5.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
9.08 1.530 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.11 1.504 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
10.45 1.482 9.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
9.01 1.482 1.00E-05 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
10.92 1.481 0 A_33_P3341676 MEF2A NM_001171894 ref|Homo sapiens myocyte enhancer factor 2A transcript variant 5 mRNA  
14.34 1.468 2.00E-05 A_23_P52986 VWCE NM_152718 ref|Homo sapiens von Willebrand factor C and EGF domains mRNA  
9.88 1.467 0 A_23_P571 SLC2A1 NM_006516 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 1 mRNA  
8.47 1.465 5.00E-05 A_23_P60627 ALOX15B NM_001141 ref|Homo sapiens arachidonate 15-lipoxygenase type B transcript variant d mRNA  
11.15 1.461 0 A_23_P17065 CCL20 NM_004591 ref|Homo sapiens chemokine (C-C motif) ligand 20 transcript variant 1 mRNA  
11.67 1.453 0 A_33_P3282394 MLLT1 NM_005934 ref|Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog Drosophila); translocated to 1 
mRNA  
9.03 1.453 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
12.68 1.444 0 A_33_P3336622 ALDH3A2 NM_001031806 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 1 mRNA  
10.02 1.437 1.00E-05 A_33_P3389060 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
10.61 1.436 5.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
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7.45 1.436 6.00E-05 A_23_P74799 SLC25A24 NM_213651 ref|Homo sapiens solute carrier family 25 (mitochondrial carrier; phosphate carrier) member 24 nuclear gene 
encoding mitochondrial protein transcript variant 2 mRNA  
9.28 1.435 1.00E-05 A_33_P3214849 KDELC2 NM_153705 ref|Homo sapiens KDEL (Lys-Asp-Glu-Leu) containing 2 mRNA  
9.07 1.427 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.04 1.427 3.00E-05 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
10.82 1.425 8.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
9.06 1.419 7.00E-05 A_33_P3682006 ENST00000425189 ENST00000425189 ens|non-protein coding RNA 118 [Source:HGNC Symbol;Acc:24155]  
10.87 1.416 3.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA 
12.28 1.406 0 A_32_P180971 LOC728323 NR_024437 ref|Homo sapiens hypothetical LOC728323  non-coding RNA  
10.73 1.403 8.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
(SERPINE1) transcript variant 1 mRNA 
10.61 1.402 3.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
(SERPINE1) transcript variant 1 mRNA 
11.28 1.400 0 A_23_P139704 DUSP6 NM_001946 ref|Homo sapiens dual specificity phosphatase 6 transcript variant 1 mRNA  
10.99 1.392 0 A_23_P126075 KCNK1 NM_002245 ref|Homo sapiens potassium channel subfamily K member 1 mRNA  
9.10 1.392 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.85 1.386 5.00E-05 A_32_P524904 C11orf86 NM_001136485 ref|Homo sapiens chromosome 11 open reading frame 86 mRNA  
9.05 1.385 1.00E-05 A_23_P431305 FAM69B NM_152421 ref|Homo sapiens family with sequence similarity 69 member B mRNA  
7.10 1.378 0 A_23_P161563 RAB38 NM_022337 ref|Homo sapiens RAB38 member RAS oncogene family mRNA  
15.86 1.375 0 A_23_P16523 GDF15 NM_004864 ref|Homo sapiens growth differentiation factor 15 mRNA  
12.46 1.371 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
10.50 1.364 3.00E-05 A_23_P354387 MYOF NM_013451 ref|Homo sapiens myoferlin transcript variant 1 mRNA  
12.28 1.363 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.58 1.363 0 A_23_P162142 TSKU NM_015516 ref|Homo sapiens tsukushi small leucine rich proteoglycan homolog (Xenopus laevis) mRNA  
10.45 1.358 6.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
(SERPINE1) transcript variant 1 mRNA 
12.37 1.355 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.41 1.351 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA 
12.37 1.351 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA 
12.58 1.347 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA 
12.61 1.341 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA 
12.38 1.340 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA 
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12.30 1.340 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA 
7.91 1.337 0 A_33_P3226650 GSTA7P NR_033760 ref|Homo sapiens glutathione S-transferase alpha 7 pseudogene non-coding RNA  
9.08 1.336 1.00E-05 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.13 1.309 0 A_23_P66881 RGS9 NM_003835 ref|Homo sapiens regulator of G-protein signaling 9 transcript variant 1 mRNA  
12.47 1.306 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.88 1.301 0 A_23_P58036 MCCC1 NM_020166 ref|Homo sapiens methylcrotonoyl-CoA carboxylase 1 (alpha) nuclear gene encoding mitochondrial protein mRNA  
8.96 1.296 4.00E-05 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.99 1.293 3.00E-05 A_23_P342131 CYBASC3 NM_153611 ref|Homo sapiens cytochrome b ascorbate dependent 3 transcript variant 2 mRNA  
13.49 1.291 0 A_33_P3357530 SLC12A7 NM_006598 ref|Homo sapiens solute carrier family 12 (potassium/chloride transporters) member 7 mRNA  
10.40 1.289 0.00026 A_33_P3218960 CACNA1H NM_021098 ref|Homo sapiens calcium channel voltage-dependent T type alpha 1H subunit transcript variant 1 mRNA 
8.84 1.289 1.00E-05 A_23_P111724 RUNDC3B NM_138290 ref|Homo sapiens RUN domain containing 3B transcript variant 1 mRNA  
15.11 1.268 1.00E-05 A_33_P3360540 AGPAT2 NM_006412 ref|Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase beta) 
transcript variant 1 mRNA  
9.51 1.268 0 A_32_P205637 PARD6B NM_032521 ref|Homo sapiens par-6 partitioning defective 6 homolog beta (C. elegans) mRNA  
10.41 1.262 0 A_23_P313389 UGCG NM_003358 ref|Homo sapiens UDP-glucose ceramide glucosyltransferase mRNA  
14.16 1.256 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.99 1.254 3.00E-05 A_33_P3245011 DAK NM_015533 ref|Homo sapiens dihydroxyacetone kinase 2 homolog (S. cerevisiae) mRNA  
13.05 1.253 0 A_33_P3336617 ALDH3A2 NM_000382 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 2 mRNA  
9.07 1.251 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
14.20 1.244 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.17 1.244 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
11.07 1.243 0 A_24_P217234 SLC3A1 NM_000341 ref|Homo sapiens solute carrier family 3 (cystine dibasic and neutral amino acid transporters activator of cystine 
dibasic and neutral amino acid transport) member 1 mRNA 
8.63 1.240 0 A_24_P256404 ENST00000356370 ENST00000356370 gb|Homo sapiens cDNA FLJ35883 fis clone TESTI2008929 
7.67 1.240 1.00E-05 A_23_P74112 IL28RA NM_170743 ref|Homo sapiens interleukin 28 receptor alpha (interferon lambda receptor) transcript variant 1 mRNA  
14.19 1.236 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.27 1.235 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.33 1.233 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.30 1.232 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.36 1.230 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
11.61 1.226 0 A_23_P94921 SLC20A2 NM_006749 ref|Homo sapiens solute carrier family 20 (phosphate transporter) member 2 mRNA  
14.29 1.222 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
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14.22 1.222 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
9.68 1.218 0 A_24_P294124 SERTAD2 NM_014755 ref|Homo sapiens SERTA domain containing 2  mRNA  
8.91 1.216 1.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
7.38 1.211 0 A_24_P46093 SLC6A6 NM_003043 ref|Homo sapiens solute carrier family 6 (neurotransmitter transporter taurine) member 6 transcript variant 1 mRNA  
7.70 1.201 2.00E-05 A_32_P175739 HK2 NM_000189 ref|Homo sapiens hexokinase 2 mRNA  
8.64 1.201 8.00E-05 A_33_P3285580 GLYCTK NM_145262 ref|Homo sapiens glycerate kinase transcript variant 1 mRNA [ 
8.92 1.201 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
11.19 1.197 0 A_33_P3334443 FAM69A NM_001006605 ref|Homo sapiens family with sequence similarity 69 member A mRNA  
7.40 1.196 0 A_33_P3419190 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
12.66 1.185 0.00025 A_23_P127948 ADM NM_001124 ref|Homo sapiens adrenomedullin mRNA  
14.94 1.168 0 A_23_P60599 UGT1A6 NM_001072 ref|Homo sapiens UDP glucuronosyltransferase 1 family polypeptide A6  transcript variant 1 mRNA  
9.11 1.163 8.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.47 1.160 0.00024 A_32_P164246 FOXQ1 NM_033260 ref|Homo sapiens forkhead box Q1 mRNA  
11.99 1.155 3.00E-05 A_23_P1682 TMEM45B NM_138788 ref|Homo sapiens transmembrane protein 45B mRNA  
7.04 1.154 1.00E-05 A_23_P102950 RSPH1 NM_080860 ref|Homo sapiens radial spoke head 1 homolog (Chlamydomonas) mRNA  
10.37 1.149 0 A_23_P210708 SIRPA NM_001040022 ref|Homo sapiens signal-regulatory protein alpha transcript variant 1 mRNA  
7.93 1.149 0 A_24_P254278 SLC23A2 NM_203327 ref|Homo sapiens solute carrier family 23 (nucleobase transporters) member 2 transcript variant 2 mRNA  
8.08 1.146 8.00E-05 A_33_P3414594 NR1I3 NM_001077474 ref|Homo sapiens nuclear receptor subfamily 1 group I member 3 transcript variant 8 mRNA  
12.28 1.139 0 A_33_P3217983 ACSL5 NM_203380 ref|Homo sapiens acyl-CoA synthetase long-chain family member 5 transcript variant 3 mRNA  
11.06 1.136 1.00E-05 A_23_P145786 MLXIPL NM_032951 ref|Homo sapiens MLX interacting protein-like transcript variant 1 mRNA  
8.97 1.124 2.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.54 1.116 0.00025 A_32_P133395 ENST00000442411 ENST00000442411 ref|PREDICTED: Homo sapiens hypothetical LOC100507500 partial miscRNA  
8.92 1.116 7.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
12.72 1.112 0 A_33_P3327986 A_33_P3327986 A_33_P3327986 Unknown 
8.99 1.102 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
13.16 1.100 0 A_23_P423197 RXRA NM_002957 ref|Homo sapiens retinoid X receptor alpha mRNA  
7.89 1.098 6.00E-05 A_23_P346673 GPRC5C ENST00000392628 ens|G protein-coupled receptor family C group 5 member C [Source:HGNC Symbol;Acc:13309]  
11.06 1.098 0.00014 A_33_P3257861 SARDH NM_001134707 ref|Homo sapiens sarcosine dehydrogenase nuclear gene encoding mitochondrial protein transcript variant 2 mRNA  
9.18 1.097 0 A_24_P154037 IRS2 NM_003749 ref|Homo sapiens insulin receptor substrate 2) mRNA  
10.25 1.097 0 A_23_P128215 SOCS2 NM_003877 ref|Homo sapiens suppressor of cytokine signaling 2 mRNA  
10.77 1.095 0 A_33_P3389728 NR5A2 NM_205860 ref|Homo sapiens nuclear receptor subfamily 5 group A member 2 transcript variant 1 mRNA  
8.94 1.092 1.00E-05 A_33_P3372699 SEC14L4 NM_174977 ref|Homo sapiens SEC14-like 4 (S. cerevisiae) transcript variant 1 mRNA  
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8.45 1.085 0 A_33_P3245006 DAK NM_015533 ref|Homo sapiens dihydroxyacetone kinase 2 homolog (S. cerevisiae) mRNA  
9.09 1.080 1.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
7.97 1.079 8.00E-05 A_23_P13772 TBX3 NM_016569 ref|Homo sapiens T-box 3 transcript variant 2 mRNA  
12.75 1.079 2.00E-05 A_33_P3302075 UGT1A8 NM_019076 ref|Homo sapiens UDP glucuronosyltransferase 1 family polypeptide A8 mRNA  
7.93 1.069 0 A_24_P583040 C17orf67 ENST00000397861 ens|chromosome 17 open reading frame 67 [Source:HGNC Symbol;Acc:27900]  
8.48 1.065 0.00022 A_23_P146855 MPPED1 NM_001044370 ref|Homo sapiens metallophosphoesterase domain containing 1 mRNA  
8.40 1.060 0.00023 A_23_P385861 CDCA2 NM_152562 ref|Homo sapiens cell division cycle associated 2 mRNA  
9.89 1.048 0.00013 A_24_P37441 PDK1 NM_002610 ref|Homo sapiens pyruvate dehydrogenase kinase isozyme 1 nuclear gene encoding mitochondrial protein mRNA  
9.20 1.047 4.00E-05 A_23_P257355 OTC NM_000531 ref|Homo sapiens ornithine carbamoyltransferase nuclear gene encoding mitochondrial protein mRNA  
9.77 1.046 6.00E-05 A_23_P319572 NR1I3 NM_001077482 ref|Homo sapiens nuclear receptor subfamily 1 group I member 3 transcript variant 1 mRNA  
7.05 1.024 3.00E-05 A_23_P383819 TBX3 NM_016569 ref|Homo sapiens T-box 3 transcript variant 2 mRNA  
11.03 1.021 0.00018 A_33_P3256858 C14orf80 NM_001134875 ref|Homo sapiens chromosome 14 open reading frame 80 transcript variant 1 mRNA  
9.14 1.016 0.00018 A_24_P928052 NRP1 NM_003873 ref|Homo sapiens neuropilin 1 transcript variant 1 mRNA  
9.15 1.012 3.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.92 1.012 0 A_33_P3311371 PDLIM2 NM_198042 ref|Homo sapiens PDZ and LIM domain 2 (mystique) transcript variant 3 mRNA  
8.97 1.010 4.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
7.32 1.009 6.00E-05 A_23_P165989 NEURL2 NM_080749 ref|Homo sapiens neuralized homolog 2 (Drosophila) mRNA  
9.18 1.000 0 A_33_P3418426 SLC3A1 NM_000341 ref|Homo sapiens solute carrier family 3 (cystine dibasic and neutral amino acid transporters activator of cystine 
dibasic and neutral amino acid transport) member 1 mRNA 
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Table 90. All significantly down regulated genes in hHeps after treatment with TCDD (10 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systemtatic name Gene description 
10.21 -1.825 0 A_23_P92161 ARL14 NM_025047 ref|Homo sapiens ADP-ribosylation factor-like 14 mRNA  
8.34 -1.734 1.00E-05 A_33_P3342752 ENST00000366873 ENST00000366873 ens|calpain 8 [Source:HGNC Symbol;Acc:1485]  
8.22 -1.488 0 A_23_P94782 CAPN8 NM_001143962 ref|Homo sapiens calpain 8 mRNA  
7.53 -1.443 0.00022 A_23_P420551 CIT NM_007174 ref|Homo sapiens citron (rho-interacting serine/threonine kinase 21) transcript variant 2 mRNA  
10.61 -1.248 0 A_33_P3398331 MMP24 NM_006690 ref|Homo sapiens matrix metallopeptidase 24 (membrane-inserted) mRNA  
9.47 -1.223 0 A_24_P405705 SLC2A2 NM_000340 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 2 mRNA  
9.28 -1.169 1.00E-05 A_23_P136978 SRPX2 NM_014467 ref|Homo sapiens sushi-repeat containing protein X-linked 2 mRNA  
10.71 -1.156 0 A_23_P333029 C8orf47 NM_173549 ref|Homo sapiens chromosome 8 open reading frame 47 transcript variant 1 mRNA  
8.53 -1.073 5.00E-05 A_23_P421401 PDGFRB NM_002609 ref|Homo sapiens platelet-derived growth factor receptor beta polypeptide mRNA  
9.48 -1.067 1.00E-04 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
8.59 -1.063 3.00E-05 A_23_P2543 CUX2 NM_015267 ref|Homo sapiens cut-like homeobox 2 mRNA  
12.82 -1.062 0 A_23_P331670 PYGB NM_002862 ref|Homo sapiens phosphorylase glycogen; brain mRNA  
9.38 -1.046 1.00E-05 A_23_P252052 FILIP1L NM_182909 ref|Homo sapiens filamin A interacting protein 1-like transcript variant 1 mRNA  
7.68 -1.039 0.00019 A_23_P122937 ELMO1 NM_014800 ref|Homo sapiens engulfment and cell motility 1 transcript variant 1 mRNA  
8.87 -1.038 1.00E-05 A_23_P55251 ITGA3 NM_002204 ref|Homo sapiens integrin alpha 3 (antigen CD49C alpha 3 subunit of VLA-3 receptor) transcript variant a mRNA  
9.80 -1.032 2.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
7.78 -1.031 0.00015 A_23_P122937 ELMO1 NM_014800 ref|Homo sapiens engulfment and cell motility 1 transcript variant 1 mRNA  
9.52 -1.023 0.00014 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.07 -1.021 0 A_33_P3247205 MOSC1 NM_022746 ref|Homo sapiens MOCO sulphurase C-terminal domain containing 1 nuclear gene encoding mitochondrial protein 
mRNA  
9.89 -1.016 7.00E-05 A_33_P3226810 TNFSF10 NM_003810 ref|Homo sapiens tumor necrosis factor (ligand) superfamily member 10 transcript variant 1 mRNA  
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Table 91. All significantly up regulated genes in hHeps after treatment with 1-PnCDD (10 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
12.43 5.462 0 A_23_P209625 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
12.73 4.610 0 A_23_P163402 CYP1A1 NM_000499 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 1 mRNA  
9.01 4.026 0 A_23_P165136 LRRC25 NM_145256 ref|Homo sapiens leucine rich repeat containing 25 mRNA  
10.97 3.892 0 A_33_P3290343 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
8.99 3.572 0 A_23_P26854 ARHGAP44 NM_014859 ref|Homo sapiens Rho GTPase activating protein 44 mRNA  
8.83 3.535 0 A_23_P207213 ALDH3A1 NM_000691 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 2 mRNA  
8.03 3.268 0 A_33_P3480395 FLJ30901 AK055463 gb|Homo sapiens cDNA FLJ30901 fis clone FEBRA2005778 
10.10 3.114 0 A_33_P3238433 ALDH3A1 NM_001135168 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 1 mRNA  
9.85 2.815 0 A_24_P157370 IL17RB NM_018725 ref|Homo sapiens interleukin 17 receptor B mRNA  
8.13 2.732 0 A_32_P49867 LOC100507055 NM_001195520 ref|Homo sapiens hypothetical LOC100507055 mRNA  
10.23 2.715 0 A_23_P416581 GNAZ NM_002073 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha z polypeptide mRNA  
11.30 2.606 0 A_23_P143845 TIPARP NM_015508 ref|Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase transcript variant 2 mRNA  
11.27 2.534 0 A_23_P57910 RTP3 NM_031440 ref|Homo sapiens receptor (chemosensory) transporter protein 3 mRNA  
12.12 2.442 0 A_33_P3222762 HULC NR_004855 ref|Homo sapiens highly up-regulated in liver cancer (non-protein coding) non-coding RNA  
8.52 2.344 0 A_33_P3230990 SCUBE1 NM_173050 ref|Homo sapiens signal peptide CUB domain EGF-like 1 mRNA  
7.89 2.195 0 A_24_P335620 SLC7A5 NM_003486 ref|Homo sapiens solute carrier family 7 (amino acid transporter light chain L system) member 5 mRNA  
9.76 2.069 0 A_33_P3397795 C14orf135 AK095489 gb|Homo sapiens cDNA FLJ38170 fis clone FCBBF1000024 
15.21 2.064 0 A_33_P3253747 CYP1A2 NM_000761 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 2 mRNA  
9.68 2.022 0 A_23_P41804 NKD2 NM_033120 ref|Homo sapiens naked cuticle homolog 2 (Drosophila) mRNA  
9.56 2.000 0 A_23_P75630 APOA5 NM_052968 ref|Homo sapiens apolipoprotein A-V transcript variant 1 mRNA  
8.09 1.851 0 A_23_P257003 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5 transcript variant 2 mRNA 
8.58 1.697 0 A_23_P259071 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
7.10 1.673 0 A_23_P161563 RAB38 NM_022337 ref|Homo sapiens RAB38 member RAS oncogene family mRNA  
9.58 1.661 0 A_23_P403335 EXPH5 NM_015065 ref|Homo sapiens exophilin 5 mRNA  
11.48 1.661 0 A_23_P83110 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
8.74 1.658 0 A_33_P3734384 LOC285957 AK097526 gb|Homo sapiens cDNA FLJ40207 fis clone TESTI2020946 
7.80 1.652 2.00E-05 A_23_P381489 NCRNA00313 NR_026863 ref|Homo sapiens non-protein coding RNA 313 non-coding RNA  
8.51 1.634 0 A_23_P116942 LAG3 NM_002286 ref|Homo sapiens lymphocyte-activation gene 3 (LAG3) mRNA  
Appendices 
 
304 
 
8.99 1.601 2.00E-04 A_23_P154806 EPB41L1 NM_012156 ref|Homo sapiens erythrocyte membrane protein band 4.1-like 1 transcript variant 1 mRNA  
8.85 1.599 3.00E-05 A_23_P136355 HHAT NM_018194 ref|Homo sapiens hedgehog acyltransferase transcript variant 1 mRNA  
7.40 1.583 0 A_33_P3419190 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
9.06 1.566 2.00E-05 A_33_P3682006 ENST00000425189 ENST00000425189 ens|non-protein coding RNA 118 [Source:HGNC Symbol;Acc:24155]  
14.34 1.418 4.00E-05 A_23_P52986 VWCE NM_152718 ref|Homo sapiens von Willebrand factor C and EGF domains mRNA  
11.15 1.407 0 A_23_P17065 CCL20 NM_004591 ref|Homo sapiens chemokine (C-C motif) ligand 20 transcript variant 1 mRNA 
10.02 1.349 2.00E-05 A_33_P3389060 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
7.04 1.347 0 A_23_P102950 RSPH1 NM_080860 ref|Homo sapiens radial spoke head 1 homolog (Chlamydomonas) mRNA  
10.18 1.343 2.00E-05 A_23_P24723 TMEM138 NM_016464 ref|Homo sapiens transmembrane protein 138 transcript variant 1 mRNA  
12.98 1.339 1.00E-04 A_23_P421423 TNFAIP2 NM_006291 ref|Homo sapiens tumor necrosis factor alpha-induced protein 2 mRNA  
13.49 1.269 0 A_33_P3357530 SLC12A7 NM_006598 ref|Homo sapiens solute carrier family 12 (potassium/chloride transporters) member 7 mRNA  
9.14 1.254 1.00E-05 A_24_P928052 NRP1 NM_003873 ref|Homo sapiens neuropilin 1 transcript variant 1 mRNA  
11.48 1.242 1.00E-05 A_23_P64879 KCNJ8 NM_004982 ref|Homo sapiens potassium inwardly-rectifying channel subfamily J member 8 mRNA  
11.01 1.241 5.00E-05 A_23_P108082 CREB3L3 NM_032607 ref|Homo sapiens cAMP responsive element binding protein 3-like 3 mRNA  
11.35 1.237 4.00E-05 A_23_P421032 SEC14L4 NM_174977 ref|Homo sapiens SEC14-like 4 (S. cerevisiae) transcript variant 1 mRNA  
9.97 1.223 0.00031 A_23_P75749 GLYAT NM_201648 ref|Homo sapiens glycine-N-acyltransferase nuclear gene encoding mitochondrial protein transcript variant 1 
mRNA  
9.13 1.209 0 A_23_P66881 RGS9 NM_003835 ref|Homo sapiens regulator of G-protein signaling 9 transcript variant 1 mRNA  
10.50 1.195 0.00016 A_23_P354387 MYOF NM_013451 ref|Homo sapiens myoferlin (transcript variant 1 mRNA  
12.68 1.191 0 A_33_P3336622 ALDH3A2 NM_001031806 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 1 mRNA  
7.38 1.178 0 A_24_P46093 SLC6A6 NM_003043 ref|Homo sapiens solute carrier family 6 (neurotransmitter transporter taurine) member 6 transcript variant 1 mRNA  
12.58 1.176 3.00E-05 A_23_P162142 TSKU NM_015516 ref|Homo sapiens tsukushi small leucine rich proteoglycan homolog (Xenopus laevis) mRNA  
9.38 1.158 0 A_23_P130376 FAM38B NM_022068 ref|Homo sapiens family with sequence similarity 38 member B mRNA  
9.05 1.153 8.00E-05 A_23_P431305 FAM69B NM_152421 ref|Homo sapiens family with sequence similarity 69 member B mRNA  
8.48 1.148 1.00E-05 A_33_P3314176 FAM46C NM_017709 ref|Homo sapiens family with sequence similarity 46 member C mRNA  
10.41 1.145 0 A_23_P313389 UGCG NM_003358 ref|Homo sapiens UDP-glucose ceramide glucosyltransferase mRNA  
12.88 1.142 0 A_23_P58036 MCCC1 NM_020166 ref|Homo sapiens methylcrotonoyl-CoA carboxylase 1 (alpha) nuclear gene encoding mitochondrial protein mRNA  
7.91 1.136 2.00E-05 A_33_P3841368 LOC286161 AK091672 gb|Homo sapiens cDNA FLJ34353 fis clone FEBRA2011665 
13.05 1.136 0 A_33_P3336617 ALDH3A2 NM_000382 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 2 mRNA  
10.99 1.129 0 A_32_P46594 LOC145837 NR_026979 ref|Homo sapiens hypothetical LOC145837 non-coding RNA  
9.28 1.123 0.00019 A_33_P3214849 KDELC2 NM_153705 ref|Homo sapiens KDEL (Lys-Asp-Glu-Leu) containing 2 mRNA  
13.88 1.121 0 A_23_P94159 FBXO25 NM_183421 ref|Homo sapiens F-box protein 25 transcript variant 1 mRNA  
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9.68 1.118 0 A_24_P294124 SERTAD2 NM_014755 ref|Homo sapiens SERTA domain containing 2 mRNA  
11.07 1.112 1.00E-05 A_24_P217234 SLC3A1 NM_000341 ref|Homo sapiens solute carrier family 3 (cystine dibasic and neutral amino acid transporters activator of cystine 
dibasic and neutral amino acid transport) member 1 mRNA  
14.16 1.110 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.30 1.109 1.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
8.64 1.102 0.00021 A_33_P3285580 GLYCTK NM_145262 ref|Homo sapiens glycerate kinase transcript variant 1 mRNA  
11.28 1.100 0 A_23_P139704 DUSP6 NM_001946 ref|Homo sapiens dual specificity phosphatase 6 transcript variant 1 mRNA  
8.48 1.099 0.00016 A_23_P146855 MPPED1 NM_001044370 ref|Homo sapiens metallophosphoesterase domain containing 1 mRNA  
10.85 1.092 0 A_24_P346431 TNS3 NM_022748 ref|Homo sapiens tensin 3 mRNA  
7.85 1.086 0.00026 A_33_P3850216 TRIM55 NM_033058 ref|Homo sapiens tripartite motif containing 55  transcript variant 2 mRNA  
10.39 1.085 0 A_23_P331895 TTYH3 NM_025250 ref|Homo sapiens tweety homolog 3 (Drosophila) mRNA  
10.92 1.073 0 A_33_P3341676 MEF2A NM_001171894 ref|Homo sapiens myocyte enhancer factor 2A transcript variant 5 mRNA  
8.99 1.068 1.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
11.71 1.067 1.00E-05 A_23_P127107 CLRN3 NM_152311 ref|Homo sapiens clarin 3 mRNA  
12.28 1.054 5.00E-05 A_32_P180971 LOC728323 NR_024437 ref|Homo sapiens hypothetical LOC728323 non-coding RNA  
13.87 1.048 1.00E-05 A_23_P386912 UGT2B4 NM_021139 ref|Homo sapiens UDP glucuronosyltransferase 2 family polypeptide B4 mRNA  
9.77 1.047 6.00E-05 A_23_P319572 NR1I3 NM_001077482 ref|Homo sapiens nuclear receptor subfamily 1 group I member 3 transcript variant 1 mRNA  
8.85 1.037 0.00012 A_24_P23625 HS3ST3B1 ENST00000360954 ens|heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 [Source:HGNC Symbol;Acc:5198]  
14.94 1.035 1.00E-05 A_23_P60599 UGT1A6 NM_001072 ref|Homo sapiens UDP glucuronosyltransferase 1 family polypeptide A6 transcript variant 1 mRNA  
14.20 1.032 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
9.18 1.018 0 A_33_P3418426 SLC3A1 NM_000341 ref|Homo sapiens solute carrier family 3 (cystine dibasic and neutral amino acid transporters activator of cystine 
dibasic and neutral amino acid transport) member 1 mRNA  
14.36 1.015 1.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.33 1.004 2.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
11.67 1.000 0 A_33_P3282394 MLLT1 NM_005934 ref|Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog Drosophila); translocated to 1 
mRNA 
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Table 92. All significantly down regulated genes in hHeps after treatment with 1-PnCDD (10 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≤ -1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
8.43 -1.510 0.00013 A_24_P331704 KRT80 NM_182507 ref|Homo sapiens keratin 80 transcript variant 1 mRNA  
9.55 -1.396 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
8.34 -1.387 0.00012 A_33_P3342752 ENST00000366873 ENST00000366873 ens|calpain 8 [Source:HGNC Symbol;Acc:1485]  
9.80 -1.354 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.66 -1.342 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.49 -1.291 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.38 -1.276 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
10.21 -1.271 2.00E-05 A_23_P92161 ARL14 NM_025047 ref|Homo sapiens ADP-ribosylation factor-like 14 mRNA  
9.48 -1.265 1.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
10.61 -1.246 0 A_33_P3398331 MMP24 NM_006690 ref|Homo sapiens matrix metallopeptidase 24 (membrane-inserted) mRNA  
9.52 -1.235 1.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.48 -1.234 8.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.58 -1.153 3.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.51 -1.126 0.00012 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.47 -1.097 0 A_24_P405705 SLC2A2 NM_000340 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 2 mRNA  
8.53 -1.065 5.00E-05 A_23_P421401 PDGFRB NM_002609 ref|Homo sapiens platelet-derived growth factor receptor beta polypeptide mRNA  
10.71 -1.028 0 A_23_P333029 C8orf47 NM_173549 ref|Homo sapiens chromosome 8 open reading frame 47 transcript variant 1 mRNA  
9.38 -1.026 1.00E-05 A_23_P252052 FILIP1L NM_182909 ref|Homo sapiens filamin A interacting protein 1-like transcript variant 1 mRNA  
7.24 -1.024 5.00E-05 A_33_P3354374 LOC100507410 NR_040018 ref|Homo sapiens hypothetical LOC100507410 transcript variant 1 non-coding RNA  
8.22 -1.018 6.00E-05 A_23_P94782 CAPN8 NM_001143962 ref|Homo sapiens calpain 8 mRNA  
8.63 -1.010 0 A_23_P202837 CCND1 NM_053056 ref|Homo sapiens cyclin D1 mRNA  
8.47 -1.003 6.00E-05 A_23_P202837 CCND1 NM_053056 ref|Homo sapiens cyclin D1 mRNA  
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Table 93. All significantly up regulated genes in hHeps after treatment with 4-PnCDF (30 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
12.43 5.963 0 A_23_P209625 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
12.73 4.933 0 A_23_P163402 CYP1A1 NM_000499 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 1 mRNA  
9.01 4.315 0 A_23_P165136 LRRC25 NM_145256 ref|Homo sapiens leucine rich repeat containing 25 mRNA  
10.97 4.107 0 A_33_P3290343 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
8.99 3.929 0 A_23_P26854 ARHGAP44 NM_014859 ref|Homo sapiens Rho GTPase activating protein 44 mRNA  
8.83 3.787 0 A_23_P207213 ALDH3A1 NM_000691 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 2 mRNA  
8.03 3.696 0 A_33_P3480395 FLJ30901 AK055463 gb|Homo sapiens cDNA FLJ30901 fis clone FEBRA2005778 
8.13 3.523 0 A_32_P49867 LOC100507055 NM_001195520 ref|Homo sapiens hypothetical LOC100507055 mRNA  
10.1 3.406 0 A_33_P3238433 ALDH3A1 NM_001135168 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 1 mRNA  
9.85 2.714 0 A_24_P157370 IL17RB NM_018725 ref|Homo sapiens interleukin 17 receptor B mRNA  
9.76 2.644 0 A_33_P3397795 C14orf135 AK095489 gb|Homo sapiens cDNA FLJ38170 fis clone FCBBF1000024 
10.23 2.614 0 A_23_P416581 GNAZ NM_002073 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha z polypeptide mRNA  
11.27 2.471 0 A_23_P57910 RTP3 NM_031440 ref|Homo sapiens receptor (chemosensory) transporter protein 3 mRNA  
12.12 2.445 0 A_33_P3222762 HULC NR_004855 ref|Homo sapiens highly up-regulated in liver cancer (non-protein coding) non-coding RNA  
8.52 2.292 0 A_33_P3230990 SCUBE1 NM_173050 ref|Homo sapiens signal peptide CUB domain EGF-like 1 mRNA  
7.89 2.284 0 A_24_P335620 SLC7A5 NM_003486 ref|Homo sapiens solute carrier family 7 (amino acid transporter light chain L system) member 5 mRNA  
15.21 2.231 0 A_33_P3253747 CYP1A2 NM_000761 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 2 mRNA  
11.30 2.193 0 A_23_P143845 TIPARP NM_015508 ref|Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase transcript variant 2 mRNA  
7.09 2.169 9.00E-05 A_33_P3459365 LOC339894 NR_034007 ref|Homo sapiens hypothetical LOC339894 non-coding RNA  
9.56 2.083 0 A_23_P75630 APOA5 NM_052968 ref|Homo sapiens apolipoprotein A-V transcript variant 1 mRNA  
8.74 2.016 0 A_33_P3734384 LOC285957 AK097526 gb|Homo sapiens cDNA FLJ40207 fis clone TESTI2020946 
8.09 1.973 0 A_23_P257003 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5 transcript variant 2 mRNA  
8.51 1.939 0 A_23_P116942 LAG3 NM_002286 ref|Homo sapiens lymphocyte-activation gene 3 mRNA  
11.48 1.875 0 A_23_P83110 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
7.88 1.874 2.00E-05 A_33_P3232504 C9orf169 NM_199001 ref|Homo sapiens chromosome 9 open reading frame 169 mRNA  
8.99 1.857 3.00E-05 A_23_P154806 EPB41L1 NM_012156 ref|Homo sapiens erythrocyte membrane protein band 4.1-like 1 transcript variant 1 mRNA  
7.15 1.851 2.00E-05 A_23_P17673 DNMT3L NM_013369 ref|Homo sapiens DNA (cytosine-5-)-methyltransferase 3-like transcript variant 1 mRNA  
12.98 1.843 0 A_23_P421423 TNFAIP2 NM_006291 ref|Homo sapiens tumor necrosis factor alpha-induced protein 2 mRNA  
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9.68 1.839 0 A_23_P41804 NKD2 NM_033120 ref|Homo sapiens naked cuticle homolog 2 (Drosophila) mRNA  
7.64 1.834 3.00E-05 A_33_P3318668 C9orf169 NM_199001 ref|Homo sapiens chromosome 9 open reading frame 169 mRNA  
8.85 1.810 1.00E-05 A_23_P136355 HHAT NM_018194 ref|Homo sapiens hedgehog acyltransferase  transcript variant 1 mRNA  
9.06 1.726 1.00E-05 A_33_P3682006 ENST00000425189 ENST00000425189 ens|non-protein coding RNA 118 [Source:HGNC Symbol;Acc:24155]  
10.18 1.723 0 A_23_P24723 TMEM138 NM_016464 ref|Homo sapiens transmembrane protein 138 transcript variant 1 mRNA  
8.58 1.688 0 A_23_P259071 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
10.02 1.684 0 A_33_P3389060 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
7.40 1.632 0 A_33_P3419190 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
7.80 1.621 2.00E-05 A_23_P381489 NCRNA00313 NR_026863 ref|Homo sapiens non-protein coding RNA 313 non-coding RNA  
10.50 1.606 0 A_23_P354387 MYOF NM_013451 ref|Homo sapiens myoferlin transcript variant 1 mRNA  
11.15 1.564 0 A_23_P17065 CCL20 NM_004591 ref|Homo sapiens chemokine (C-C motif) ligand 20 transcript variant 1 mRNA  
8.01 1.557 0.00027 A_23_P79803 VSTM2L NM_080607 ref|Homo sapiens V-set and transmembrane domain containing 2 like mRNA  
7.85 1.541 0 A_33_P3850216 TRIM55 NM_033058 ref|Homo sapiens tripartite motif containing 55 transcript variant 2 mRNA  
9.14 1.540 0 A_24_P928052 NRP1 NM_003873 ref|Homo sapiens neuropilin 1 transcript variant 1 mRNA  
9.58 1.535 0 A_23_P403335 EXPH5 NM_015065 ref|Homo sapiens exophilin 5 mRNA  
7.10 1.523 0 A_23_P161563 RAB38 NM_022337 ref|Homo sapiens RAB38 member RAS oncogene family mRNA  
11.28 1.467 0 A_23_P139704 DUSP6 NM_001946 ref|Homo sapiens dual specificity phosphatase 6 transcript variant 1 mRNA  
8.47 1.418 7.00E-05 A_23_P60627 ALOX15B NM_001141 ref|Homo sapiens arachidonate 15-lipoxygenase type B transcript variant d mRNA  
13.49 1.416 0 A_33_P3357530 SLC12A7 NM_006598 ref|Homo sapiens solute carrier family 12 (potassium/chloride transporters) member 7 mRNA  
9.28 1.414 1.00E-05 A_33_P3214849 KDELC2 NM_153705 ref|Homo sapiens KDEL (Lys-Asp-Glu-Leu) containing 2 mRNA  
8.92 1.385 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.07 1.360 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
12.11 1.349 0.00029 A_23_P315364 CXCL2 NM_002089 ref|Homo sapiens chemokine (C-X-C motif) ligand 2 mRNA  
9.18 1.313 0 A_33_P3418426 SLC3A1 NM_000341 ref|Homo sapiens solute carrier family 3 (cystine dibasic and neutral amino acid transporters activator of cystine 
dibasic and neutral amino acid transport) member 1 mRNA  
8.97 1.311 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
10.41 1.309 0 A_23_P313389 UGCG NM_003358 ref|Homo sapiens UDP-glucose ceramide glucosyltransferase mRNA  
11.01 1.305 3.00E-05 A_23_P108082 CREB3L3 NM_032607 ref|Homo sapiens cAMP responsive element binding protein 3-like 3 mRNA  
8.97 1.297 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.11 1.289 2.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
8.91 1.288 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
8.85 1.276 1.00E-05 A_24_P23625 HS3ST3B1 ENST00000360954 ens|heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 [Source:HGNC Symbol;Acc:5198]  
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9.97 1.274 2.00E-04 A_23_P75749 GLYAT NM_201648 ref|Homo sapiens glycine-N-acyltransferase nuclear gene encoding mitochondrial protein transcript variant 1 
mRNA  
8.92 1.273 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
7.91 1.267 1.00E-05 A_33_P3841368 LOC286161 AK091672 gb|Homo sapiens cDNA FLJ34353 fis clone FEBRA2011665 
11.48 1.266 0 A_23_P64879 KCNJ8 NM_004982 ref|Homo sapiens potassium inwardly-rectifying channel subfamily J member 8 mRNA  
9.15 1.263 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.38 1.251 0 A_23_P130376 FAM38B NM_022068 ref|Homo sapiens family with sequence similarity 38 member B mRNA  
8.64 1.249 5.00E-05 A_33_P3285580 GLYCTK NM_145262 ref|Homo sapiens glycerate kinase transcript variant 1 mRNA  
14.27 1.229 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
9.68 1.221 0 A_24_P294124 SERTAD2 NM_014755 ref|Homo sapiens SERTA domain containing 2 mRNA  
14.16 1.216 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.33 1.208 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
9.05 1.207 5.00E-05 A_23_P431305 FAM69B NM_152421 ref|Homo sapiens family with sequence similarity 69 member B mRNA  
12.58 1.204 2.00E-05 A_23_P162142 TSKU NM_015516 ref|Homo sapiens tsukushi small leucine rich proteoglycan homolog (Xenopus laevis) mRNA  
14.22 1.203 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.36 1.202 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA 
14.30 1.202 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA 
14.17 1.199 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA 
9.99 1.193 9.00E-05 A_23_P342131 CYBASC3 NM_153611 ref|Homo sapiens cytochrome b ascorbate dependent 3 transcript variant 2 mRNA  
9.13 1.192 0 A_23_P66881 RGS9 NM_003835 ref|Homo sapiens regulator of G-protein signaling 9 transcript variant 1 mRNA  
10.92 1.180 0 A_33_P3341676 MEF2A NM_001171894 ref|Homo sapiens myocyte enhancer factor 2A transcript variant 5 mRNA  
8.99 1.180 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
9.01 1.169 0.00024 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
7.62 1.166 1.00E-05 A_24_P13381 TRPV4 NM_147204 ref|Homo sapiens transient receptor potential cation channel subfamily V member 4 transcript variant 2 mRNA  
11.07 1.163 1.00E-05 A_24_P217234 SLC3A1 NM_000341 ref|Homo sapiens solute carrier family 3 (cystine dibasic and neutral amino acid transporters activator of cystine 
dibasic and neutral amino acid transport) member 1 mRNA  
7.05 1.159 1.00E-05 A_23_P383819 TBX3 NM_016569 ref|Homo sapiens T-box 3 transcript variant 2 mRNA  
12.51 1.153 0 A_23_P99661 ARHGEF40 NM_018071 ref|Homo sapiens Rho guanine nucleotide exchange factor (GEF) 40 mRNA  
7.91 1.147 1.00E-05 A_33_P3226650 GSTA7P NR_033760 ref|Homo sapiens glutathione S-transferase alpha 7 pseudogene non-coding RNA  
10.39 1.146 0 A_23_P331895 TTYH3 NM_025250 ref|Homo sapiens tweety homolog 3 (Drosophila) mRNA  
9.10 1.144 4.00E-05 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA 
7.32 1.144 1.00E-05 A_23_P165989 NEURL2 NM_080749 ref|Homo sapiens neuralized homolog 2 (Drosophila) mRNA  
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11.35 1.142 1.00E-04 A_23_P421032 SEC14L4 NM_174977 ref|Homo sapiens SEC14-like 4 (S. cerevisiae) transcript variant 1 mRNA  
7.26 1.133 2.00E-05 A_23_P432573 MRGPRF NM_145015 ref|Homo sapiens MAS-related GPR member F transcript variant 2 mRNA  
7.01 1.125 2.00E-05 A_23_P212089 NFKBIZ NM_031419 ref|Homo sapiens nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor zeta transcript variant 
1 mRNA  
7.30 1.122 0.00024 A_32_P84242 FAM169A NM_015566 ref|Homo sapiens family with sequence similarity 169 member A mRNA  
9.09 1.115 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
14.19 1.114 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.05 1.108 0 A_33_P3336617 ALDH3A2 NM_000382 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 2 mRNA  
14.29 1.106 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.20 1.105 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
7.17 1.101 1.00E-05 A_33_P3404316 MIR100HG NR_024430 ref|Homo sapiens mir-100-let-7a-2 cluster host gene (non-protein coding) non-coding RNA  
8.87 1.095 0.00032 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
8.02 1.093 1.00E-05 A_33_P3620881 LOC728218 BC065757 gb|Homo sapiens cDNA clone IMAGE:4556546 partial cds 
9.51 1.073 0 A_32_P205637 PARD6B NM_032521 ref|Homo sapiens par-6 partitioning defective 6 homolog beta (C. elegans) mRNA  
9.78 1.065 2.00E-05 A_23_P89431 CCL2 NM_002982 ref|Homo sapiens chemokine (C-C motif) ligand 2 mRNA  
13.88 1.064 1.00E-05 A_23_P94159 FBXO25 NM_183421 ref|Homo sapiens F-box protein 25 transcript variant 1 mRNA  
12.28 1.063 1.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
10.85 1.059 0 A_24_P346431 TNS3 NM_022748 ref|Homo sapiens tensin 3 mRNA  
7.93 1.056 1.00E-05 A_24_P254278 SLC23A2 NM_203327 ref|Homo sapiens solute carrier family 23 (nucleobase transporters) member 2 transcript variant 2 mRNA  
11.06 1.055 4.00E-05 A_23_P145786 MLXIPL NM_032951 ref|Homo sapiens MLX interacting protein-like transcript variant 1 mRNA  
7.38 1.054 2.00E-05 A_24_P46093 SLC6A6 NM_003043 ref|Homo sapiens solute carrier family 6 (neurotransmitter transporter taurine) member 6 transcript variant 1 mRNA  
8.63 1.051 1.00E-05 A_24_P256404 ENST00000356370 ENST00000356370 gb|Homo sapiens cDNA FLJ35883 fis clone TESTI2008929 
12.61 1.041 1.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
7.67 1.031 1.00E-04 A_23_P74112 IL28RA NM_170743 ref|Homo sapiens interleukin 28 receptor alpha (interferon lambda receptor) transcript variant 1 mRNA  
9.03 1.030 0.00021 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
12.46 1.029 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
10.60 1.029 6.00E-05 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
12.30 1.028 1.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
9.08 1.026 0.00021 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
13.16 1.025 0 A_23_P423197 RXRA NM_002957 ref|Homo sapiens retinoid X receptor alpha mRNA  
9.07 1.023 0.00012 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
12.37 1.021 9.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
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12.47 1.021 0 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
7.96 1.020 7.00E-05 A_23_P169039 SNAI2 NM_003068 ref|Homo sapiens snail homolog 2 (Drosophila) mRNA  
11.61 1.016 3.00E-05 A_23_P94921 SLC20A2 NM_006749 ref|Homo sapiens solute carrier family 20 (phosphate transporter) member 2 mRNA  
9.11 1.015 0.00015 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.58 1.013 5.00E-05 A_23_P89431 CCL2 NM_002982 ref|Homo sapiens chemokine (C-C motif) ligand 2 mRNA  
15.86 1.013 0 A_23_P16523 GDF15 NM_004864 ref|Homo sapiens growth differentiation factor 15 mRNA  
12.44 1.013 1.00E-05 A_33_P3383233 NDRG2 NM_201535 ref|Homo sapiens NDRG family member 2 transcript variant 1 mRNA  
9.77 1.009 9.00E-05 A_23_P319572 NR1I3 NM_001077482 ref|Homo sapiens nuclear receptor subfamily 1 group I member 3 transcript variant 1 mRNA  
10.72 1.009 5.00E-05 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
11.67 1.009 0 A_33_P3282394 MLLT1 NM_005934 ref|Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog Drosophila); translocated to 1 
mRNA  
10.34 1.008 2.00E-05 A_23_P8240 FAM50B NM_012135 ref|Homo sapiens family with sequence similarity 50 member B mRNA 
12.38 1.005 1.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
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Table 94. All significantly down regulated genes in hHeps after treatment with 4-PnCDF (30 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≤ -1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
8.34 -1.536 3.00E-05 A_33_P3342752 ENST00000366873 ENST00000366873 ens|calpain 8 [Source:HGNC Symbol;Acc:1485]  
8.43 -1.426 0.00025 A_24_P331704 KRT80 NM_182507 ref|Homo sapiens keratin 80 transcript variant 1 mRNA  
8.53 -1.421 0 A_23_P421401 PDGFRB NM_002609 ref|Homo sapiens platelet-derived growth factor receptor beta polypeptide mRNA  
9.49 -1.317 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.51 -1.297 2.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.66 -1.283 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.80 -1.277 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
10.71 -1.266 0 A_23_P333029 C8orf47 NM_173549 ref|Homo sapiens chromosome 8 open reading frame 47 transcript variant 1 mRNA  
10.21 -1.238 3.00E-05 A_23_P92161 ARL14 NM_025047 ref|Homo sapiens ADP-ribosylation factor-like 14 mRNA  
9.55 -1.224 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.38 -1.223 0 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.52 -1.180 3.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
10.61 -1.146 1.00E-05 A_33_P3398331 MMP24 NM_006690 ref|Homo sapiens matrix metallopeptidase 24 (membrane-inserted) mRNA  
9.58 -1.107 5.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.48 -1.097 0.00028 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
9.48 -1.090 8.00E-05 A_23_P104798 IL18 NM_001562 ref|Homo sapiens interleukin 18 (interferon-gamma-inducing factor) mRNA  
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Table 95. All significantly up regulated genes in hHeps after treatment with PCB 126 (100 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 7, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
12.43 5.452 0 A_23_P209625 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
12.73 4.713 0 A_23_P163402 CYP1A1 NM_000499 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 1 mRNA  
10.97 4.015 0 A_33_P3290343 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
8.83 3.327 0 A_23_P207213 ALDH3A1 NM_000691 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 2 mRNA  
9.01 3.185 0 A_23_P165136 LRRC25 NM_145256 ref|Homo sapiens leucine rich repeat containing 25 mRNA  
8.99 3.090 0 A_23_P26854 ARHGAP44 NM_014859 ref|Homo sapiens Rho GTPase activating protein 44 mRNA  
10.1 2.807 0 A_33_P3238433 ALDH3A1 NM_001135168 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 1 mRNA  
15.21 2.190 0 A_33_P3253747 CYP1A2 NM_000761 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 2 mRNA  
8.13 2.106 1.00E-05 A_32_P49867 LOC100507055 NM_001195520 ref|Homo sapiens hypothetical LOC100507055 mRNA  
10.23 1.907 0 A_23_P416581 GNAZ NM_002073 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha z polypeptide mRNA  
11.27 1.901 0 A_23_P57910 RTP3 NM_031440 ref|Homo sapiens receptor (chemosensory) transporter protein 3 mRNA  
8.74 1.871 0 A_33_P3734384 LOC285957 AK097526 gb|Homo sapiens cDNA FLJ40207 fis clone TESTI2020946 
9.76 1.844 0 A_33_P3397795 C14orf135 AK095489 gb|Homo sapiens cDNA FLJ38170 fis clone FCBBF1000024 
8.58 1.766 0 A_23_P259071 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA 
7.89 1.645 0 A_24_P335620 SLC7A5 NM_003486 ref|Homo sapiens solute carrier family 7 (amino acid transporter light chain L system) member 5 mRNA  
7.40 1.639 0 A_33_P3419190 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
12.12 1.496 8.00E-05 A_33_P3222762 HULC NR_004855 ref|Homo sapiens highly up-regulated in liver cancer (non-protein coding) non-coding RNA  
11.30 1.454 0 A_23_P143845 TIPARP NM_015508 ref|Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase transcript variant 2 mRNA  
9.68 1.414 5.00E-05 A_23_P41804 NKD2 NM_033120 ref|Homo sapiens naked cuticle homolog 2 (Drosophila) mRNA  
12.98 1.360 9.00E-05 A_23_P421423 TNFAIP2 NM_006291 ref|Homo sapiens tumor necrosis factor alpha-induced protein 2 mRNA  
9.85 1.326 1.00E-05 A_24_P157370 IL17RB NM_018725 ref|Homo sapiens interleukin 17 receptor B mRNA  
9.56 1.313 0.00013 A_23_P75630 APOA5 NM_052968 ref|Homo sapiens apolipoprotein A-V transcript variant 1 mRNA  
11.48 1.281 0 A_23_P83110 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2  transcript variant 1 mRNA  
8.51 1.230 3.00E-05 A_23_P116942 LAG3 NM_002286 ref|Homo sapiens lymphocyte-activation gene 3 mRNA  
10.02 1.163 0.00011 A_33_P3389060 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
9.58 1.134 1.00E-05 A_23_P403335 EXPH5 NM_015065 ref|Homo sapiens exophilin 5 mRNA  
8.09 1.099 4.00E-05 A_23_P257003 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5 transcript variant 2 mRNA  
10.41 1.067 0 A_23_P313389 UGCG NM_003358 ref|Homo sapiens UDP-glucose ceramide glucosyltransferase mRNA  
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8.98 1.030 0.00023 A_23_P52082 INTS7 NM_015434 ref|Homo sapiens integrator complex subunit 7 transcript variant 1 mRNA  
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Table 96. All significantly up regulated genes in HepG2 cells after treatment with TCDD (10 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
10.68 5.003 0 A_23_P163402 CYP1A1 NM_000499 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 1 mRNA  
7.41 4.880 0 A_23_P51376 NKAIN1 NM_024522 ref|Homo sapiens Na+/K+ transporting ATPase interacting 1 mRNA  
7.56 4.879 0 A_23_P165136 LRRC25 NM_145256 ref|Homo sapiens leucine rich repeat containing 25 mRNA  
7.16 4.544 0 A_24_P253003 WNT11 NM_004626 ref|Homo sapiens wingless-type MMTV integration site family member 11 mRNA  
6.25 4.505 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
7.78 4.402 0 A_23_P152791 SLC16A6 NM_004694 ref|Homo sapiens solute carrier family 16 member 6 (monocarboxylic acid transporter 7) transcript variant 2 mRNA  
6.46 4.393 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
6.47 4.295 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
6.16 4.269 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
6.32 4.258 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
6.62 4.194 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
6.52 4.107 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
8.44 4.107 0 A_23_P130435 LIM2 NM_030657 ref|Homo sapiens lens intrinsic membrane protein 2 19kDa transcript variant 1 mRNA  
6.15 4.100 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin mRNA  
5.63 3.989 1.00E-05 A_23_P358709 AHRR NM_020731 ref|Homo sapiens aryl-hydrocarbon receptor repressor transcript variant 1 mRNA  
6.35 3.981 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin) mRNA  
6.61 3.851 0 A_23_P114883 FMOD NM_002023 ref|Homo sapiens fibromodulin  mRNA  
5.66 3.518 0 A_23_P209625 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
6.60 3.499 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
6.04 3.471 0 A_23_P421032 SEC14L4 NM_174977 ref|Homo sapiens SEC14-like 4 (S. cerevisiae) transcript variant 1 mRNA  
7.85 3.469 0 A_23_P207213 ALDH3A1 NM_000691 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 2 mRNA  
5.26 3.378 0 A_23_P165783 MLPH NM_024101 ref|Homo sapiens melanophilin transcript variant 1 mRNA  
7.45 3.323 0 A_33_P3222977 TEKT5 NM_144674 ref|Homo sapiens tektin 5 mRNA  
8.66 3.319 0 A_33_P3238433 ALDH3A1 NM_001135168 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1  transcript variant 1 mRNA  
6.61 3.261 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
6.26 3.254 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
7.96 3.125 0 A_24_P115932 GPR44 NM_004778 ref|Homo sapiens G protein-coupled receptor 44 mRNA  
6.49 3.077 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
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6.66 3.061 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
6.36 3.056 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
6.71 3.033 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
7.73 3.025 0 A_23_P37410 CYP19A1 NM_031226 ref|Homo sapiens cytochrome P450 family 19 subfamily A polypeptide 1 transcript variant 2 mRNA  
6.69 3.024 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
7.07 3.015 0 A_23_P128215 SOCS2 NM_003877 ref|Homo sapiens suppressor of cytokine signaling 2 mRNA  
5.54 2.999 0 A_33_P3365142 GAD1 NM_013445 ref|Homo sapiens glutamate decarboxylase 1 (brain 67kDa) transcript variant GAD25 mRNA  
5.91 2.996 1.00E-05 A_33_P3346618 LOC441179 XR_112948 ref|PREDICTED: Homo sapiens hypothetical LOC441179 miscRNA  
6.40 2.961 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
11.42 2.915 0 A_33_P3360540 AGPAT2 NM_006412 ref|Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase beta) 
transcript variant 1 mRNA  
6.48 2.896 0 A_23_P202658 GSTP1 NM_000852 ref|Homo sapiens glutathione S-transferase pi 1 mRNA  
7.22 2.893 1.00E-05 A_23_P64721 HCAR3 NM_006018 ref|Homo sapiens hydroxycarboxylic acid receptor 3 mRNA  
10.43 2.766 0 A_23_P408376 HSPA12A NM_025015 ref|Homo sapiens heat shock 70kDa protein 12A mRNA  
6.87 2.738 0 A_23_P354387 MYOF NM_013451 ref|Homo sapiens myoferlin transcript variant 1 mRNA  
7.46 2.686 0 A_24_P63019 IL1R2 NM_004633 ref|Homo sapiens interleukin 1 receptor type II  transcript variant 1 mRNA  
7.48 2.662 1.00E-05 A_23_P119916 WNT6 NM_006522 ref|Homo sapiens wingless-type MMTV integration site family member 6 mRNA  
11.51 2.613 0 A_23_P138717 RGS10 NM_001005339 ref|Homo sapiens regulator of G-protein signaling 10 transcript variant 1 mRNA  
8.28 2.595 0 A_24_P126210 MRAP NM_178817 ref|Homo sapiens melanocortin 2 receptor accessory protein  transcript variant 1 mRNA  
6.28 2.566 2.00E-05 A_33_P3348224 SEC14L6 NM_001193336 ref|Homo sapiens SEC14-like 6 (S. cerevisiae) mRNA  
7.66 2.540 0 A_23_P404667 BIK NM_001197 ref|Homo sapiens BCL2-interacting killer (apoptosis-inducing) mRNA  
6.84 2.524 2.00E-05 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
6.35 2.498 0 A_33_P3351371 CYP19A1 NM_031226 ref|Homo sapiens cytochrome P450 family 19 subfamily A polypeptide 1 transcript variant 2 mRNA  
8.35 2.462 0 A_33_P3356406 SOS1 NM_005633 ref|Homo sapiens son of sevenless homolog 1 (Drosophila) mRNA  
7.01 2.431 0 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
6.77 2.430 0 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
16.43 2.420 0 A_23_P42868 IGFBP1 NM_000596 ref|Homo sapiens insulin-like growth factor binding protein 1 mRNA  
6.97 2.420 0 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
5.98 2.408 0 A_32_P49867 LOC100507055 NM_001195520 ref|Homo sapiens hypothetical LOC100507055 mRNA  
8.38 2.389 0 A_23_P379649 BMF NM_001003940 ref|Homo sapiens Bcl2 modifying factor transcript variant 1 mRNA  
9.02 2.379 0 A_23_P128974 BATF NM_006399 ref|Homo sapiens basic leucine zipper transcription factor ATF-like mRNA  
5.49 2.367 7.00E-05 A_23_P166087 RASSF2 NM_014737 ref|Homo sapiens Ras association (RalGDS/AF-6) domain family member 2 transcript variant 1 mRNA  
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6.06 2.332 0 A_33_P3741022 FLJ26484 NR_033876 ref|Homo sapiens hypothetical LOC400619 non-coding RNA  
6.95 2.328 0 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
7.02 2.309 5.00E-05 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1  transcript variant 1 mRNA  
5.76 2.291 5.00E-05 A_33_P3243023 ADRA1D NM_000678 ref|Homo sapiens adrenergic alpha-1D- receptor mRNA  
7.03 2.277 0 A_23_P421423 TNFAIP2 NM_006291 ref|Homo sapiens tumor necrosis factor alpha-induced protein 2 mRNA  
7.15 2.266 0 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
6.92 2.265 2.00E-05 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
6.83 2.243 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
7.01 2.239 0 A_23_P142878 ATOH8 NM_032827 ref|Homo sapiens atonal homolog 8 (Drosophila) mRNA  
5.43 2.229 0.00049 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
8.29 2.212 0 A_23_P35529 MBL2 NM_000242 ref|Homo sapiens mannose-binding lectin (protein C) 2 soluble mRNA  
5.08 2.203 0 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
7.00 2.179 1.00E-05 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
5.42 2.174 0 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
6.94 2.173 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1  transcript variant 1 mRNA  
6.35 2.151 5.00E-05 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
6.81 2.122 0.00026 A_23_P112482 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
5.33 2.118 0 A_33_P3371999 TPPP NM_007030 ref|Homo sapiens tubulin polymerization promoting protein mRNA  
9.36 2.096 0 A_23_P31407 AGR2 NM_006408 ref|Homo sapiens anterior gradient homolog 2 (Xenopus laevis) mRNA  
9.49 2.066 0 A_23_P331928 CD109 NM_133493 ref|Homo sapiens CD109 molecule transcript variant 1 mRNA  
6.92 2.057 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
9.34 2.054 0 A_23_P92042 ITPR1 NM_002222 ref|Homo sapiens inositol 145-trisphosphate receptor type 1 transcript variant 2 mRNA  
5.22 2.046 5.00E-04 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
6.93 2.037 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
8.27 2.016 0 A_23_P205370 ASB2 NM_016150 ref|Homo sapiens ankyrin repeat and SOCS box containing 2 transcript variant 2 mRNA  
6.86 2.013 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
8.12 1.987 0 A_32_P108254 FAM20A NM_017565 ref|Homo sapiens family with sequence similarity 20 member A transcript variant 1 mRNA  
14.28 1.979 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
14.33 1.970 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
14.41 1.969 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
8.03 1.966 0 A_24_P88763 LOXL3 NM_032603 ref|Homo sapiens lysyl oxidase-like 3 mRNA  
7.03 1.960 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
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14.33 1.959 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
14.15 1.952 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
9.15 1.951 0 A_33_P3268472 CTSC NM_001114173 ref|Homo sapiens cathepsin C transcript variant 3 mRNA  
14.15 1.949 0 A_23_P87049 SORL1 NM_003105 ref|Homo sapiens sortilin-related receptor L(DLR class) A repeats containing mRNA  
14.21 1.948 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
14.35 1.946 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
5.21 1.934 3.00E-05 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
14.36 1.929 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
6.95 1.923 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
14.30 1.918 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
14.36 1.903 0 A_23_P106682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
6.41 1.894 2.00E-05 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
10.65 1.891 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2  mRNA  
10.42 1.883 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.94 1.878 0 A_33_P3210561 A_33_P3210561 A_33_P3210561 Unknown 
10.51 1.873 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
5.38 1.873 0.00119 A_24_P105933 VIPR1 NM_004624 ref|Homo sapiens vasoactive intestinal peptide receptor 1 mRNA  
7.13 1.872 0.00011 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
7.15 1.868 0.00081 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
6.15 1.866 0.00013 A_24_P237036 TNFSF14 NM_003807 ref|Homo sapiens tumor necrosis factor (ligand) superfamily member 14 transcript variant 1 mRNA  
9.19 1.858 0 A_24_P658584 SASH1 NM_015278 ref|Homo sapiens SAM and SH3 domain containing 1 mRNA  
16.42 1.851 0 A_23_P106844 MT2A NM_005953 ref|Homo sapiens metallothionein 2A mRNA  
10.64 1.842 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
10.43 1.837 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
10.42 1.835 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2  mRNA  
5.31 1.830 3.00E-05 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
5.54 1.829 2.00E-04 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
7.32 1.827 0 A_33_P3253747 CYP1A2 NM_000761 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 2 mRNA  
10.08 1.821 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
10.62 1.821 0 A_23_P257003 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5  transcript variant 2 mRNA  
10.59 1.817 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
10.36 1.816 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
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8.33 1.816 0 A_23_P343808 SOS1 NM_005633 ref|Homo sapiens son of sevenless homolog 1 (Drosophila) mRNA  
9.92 1.815 0 A_33_P3215768 GALNT6 NM_007210 ref|Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 
(GalNAc-T6) mRNA [ 
12.47 1.805 0 A_23_P304682 EMP2 NM_001424 ref|Homo sapiens epithelial membrane protein 2 mRNA  
11.26 1.799 0 A_33_P3336720 HAMP NM_021175 ref|Homo sapiens hepcidin antimicrobial peptide mRNA  
7.30 1.785 1.00E-04 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
10.32 1.775 0 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
6.62 1.769 0 A_23_P12363 ROR1 NM_005012 ref|Homo sapiens receptor tyrosine kinase-like orphan receptor 1 transcript variant 1 mRNA  
5.57 1.761 7.00E-05 A_33_P3209591 AQP3 NM_004925 ref|Homo sapiens aquaporin 3 (Gill blood group) mRNA  
10.16 1.759 0 A_23_P166823 TNNC1 NM_003280 ref|Homo sapiens troponin C type 1 (slow) mRNA  
5.31 1.735 4.00E-05 A_23_P105012 HRASLS2 NM_017878 ref|Homo sapiens HRAS-like suppressor 2 mRNA  
8.72 1.727 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
8.92 1.726 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
8.90 1.719 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
9.26 1.719 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
9.38 1.716 0 A_23_P50946 RAMP1 NM_005855 ref|Homo sapiens receptor (G protein-coupled) activity modifying protein 1 mRNA  
7.09 1.716 0.00063 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
5.75 1.709 0.00025 A_23_P27306 COLEC12 NM_130386 ref|Homo sapiens collectin sub-family member 12 mRNA  
7.17 1.703 0 A_24_P363100 RGMB NM_001012761 ref|Homo sapiens RGM domain family member B mRNA  
9.07 1.701 0 A_24_P340128 P2RY8 NM_178129 ref|Homo sapiens purinergic receptor P2Y G-protein coupled 8) mRNA  
7.15 1.696 8.00E-05 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
9.43 1.696 0 A_23_P74112 IL28RA NM_170743 ref|Homo sapiens interleukin 28 receptor alpha (interferon lambda receptor) transcript variant 1 mRNA  
9.30 1.688 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
9.18 1.683 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
9.26 1.677 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
8.91 1.675 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
8.66 1.667 0 A_23_P431305 FAM69B NM_152421 ref|Homo sapiens family with sequence similarity 69 member B mRNA  
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9.19 1.657 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
10.69 1.652 0 A_24_P294124 SERTAD2 NM_014755 ref|Homo sapiens SERTA domain containing 2 mRNA  
8.42 1.646 0 A_23_P23947 MAP3K8 NM_005204 ref|Homo sapiens mitogen-activated protein kinase kinase kinase 8 mRNA  
8.35 1.634 0 A_24_P224488 MAPT NM_016835 ref|Homo sapiens microtubule-associated protein tau transcript variant 1 mRNA  
13.15 1.624 1.00E-05 A_23_P128919 LGALS3 NM_002306 ref|Homo sapiens lectin galactoside-binding soluble 3 transcript variant 1 mRNA  
5.89 1.624 0 A_23_P147025 RAB33A NM_004794 ref|Homo sapiens RAB33A member RAS oncogene family mRNA  
6.80 1.621 1.00E-05 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
9.31 1.615 0 A_23_P104563 CPT1A NM_001031847 ref|Homo sapiens carnitine palmitoyltransferase 1A (liver) nuclear gene encoding mitochondrial protein transcript 
variant 2 mRNA  
10.89 1.615 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1  mRNA  
10.78 1.609 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
10.43 1.607 0 A_23_P206661 NQO1 NM_000903 ref|Homo sapiens NAD(P)H dehydrogenase quinone 1 transcript variant 1 mRNA  
10.74 1.605 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
5.60 1.604 6.00E-05 A_33_P3382999 PSAPL1 NM_001085382 ref|Homo sapiens prosaposin-like 1 (gene/pseudogene) mRNA  
7.51 1.589 0 A_33_P3358731 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5 transcript variant 2 mRNA  
15.00 1.588 0 A_23_P37983 MT1B NM_005947 ref|Homo sapiens metallothionein 1B mRNA  
13.76 1.585 0 A_23_P252783 SLC2A8 NM_014580 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 8 mRNA  
10.45 1.582 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
8.85 1.578 0 A_33_P3368358 NEDD9 NM_182966 ref|Homo sapiens neural precursor cell expressed developmentally down-regulated 9 transcript variant 2 mRNA  
10.77 1.577 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
10.77 1.577 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
10.69 1.576 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
8.13 1.573 0 A_23_P254079 STBD1 NM_003943 ref|Homo sapiens starch binding domain 1 mRNA  
9.25 1.572 0 A_24_P239606 GADD45B NM_015675 ref|Homo sapiens growth arrest and DNA-damage-inducible beta mRNA  
10.82 1.570 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
5.24 1.568 0 A_33_P3355921 LOC100130894 NR_034083 ref|Homo sapiens hypothetical LOC100130894 non-coding RNA  
6.01 1.567 1.00E-04 A_23_P80570 AADAC NM_001086 ref|Homo sapiens arylacetamide deacetylase (esterase) mRNA  
10.89 1.565 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
6.44 1.563 1.00E-04 A_33_P3282683 LOC100130027 XR_110587 ref|PREDICTED: Homo sapiens hypothetical LOC100130027 partial miscRNA  
10.75 1.562 0 A_23_P120863 GAL3ST1 NM_004861 ref|Homo sapiens galactose-3-O-sulfotransferase 1 mRNA  
7.15 1.559 9.00E-05 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
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6.73 1.554 1.00E-05 A_33_P3209279 SASH1 NM_015278 ref|Homo sapiens SAM and SH3 domain containing 1 mRNA  
6.28 1.553 4.00E-05 A_23_P381172 MRAP NM_206898 ref|Homo sapiens melanocortin 2 receptor accessory protein transcript variant 2 mRNA  
15.20 1.548 0 A_23_P427703 MT1L NR_001447 ref|Homo sapiens metallothionein 1L (gene/pseudogene) non-coding RNA  
8.19 1.546 1.00E-05 A_23_P8801 CYP3A5 NM_000777 ref|Homo sapiens cytochrome P450 family 3 subfamily A polypeptide 5 transcript variant 1 mRNA  
6.63 1.546 4.00E-05 A_23_P77756 GALR2 NM_003857 ref|Homo sapiens galanin receptor 2  mRNA  
5.60 1.544 2.00E-04 A_23_P131036 ENST00000443196 ENST00000443196 gb|Homo sapiens cDNA clone IMAGE:4300770 
12.80 1.539 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
10.50 1.537 0 A_23_P344555 NEDD9 NM_006403 ref|Homo sapiens neural precursor cell expressed developmentally down-regulated 9 transcript variant 1 mRNA  
10.15 1.536 0 A_24_P254278 SLC23A2 NM_203327 ref|Homo sapiens solute carrier family 23 (nucleobase transporters) member 2 transcript variant 2 mRNA  
12.41 1.531 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
12.89 1.530 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
5.86 1.526 0.00036 A_32_P4018 ROR1 ENST00000371079 ens|receptor tyrosine kinase-like orphan receptor 1 [Source:HGNC Symbol;Acc:10256]  
10.95 1.524 0 A_33_P3282688 LOC100130027 XR_110587 ref|PREDICTED: Homo sapiens hypothetical LOC100130027 partial miscRNA  
9.02 1.523 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
14.68 1.522 0 A_24_P109214 APOC1 NM_001645 ref|Homo sapiens apolipoprotein C-I mRNA  
12.74 1.519 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
6.01 1.518 1.00E-05 A_24_P222872 UGT1A6 NM_001072 ref|Homo sapiens UDP glucuronosyltransferase 1 family polypeptide A6 transcript variant 1 mRNA  
8.59 1.515 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
12.40 1.515 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
12.72 1.515 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
12.75 1.513 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
12.85 1.511 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
12.76 1.503 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
12.55 1.502 0 A_24_P335620 SLC7A5 NM_003486 ref|Homo sapiens solute carrier family 7 (amino acid transporter light chain L system) member 5 mRNA  
11.17 1.502 0 A_33_P3254460 DLK2 NM_206539 ref|Homo sapiens delta-like 2 homolog (Drosophila) transcript variant 2 mRNA  
5.54 1.498 0.00021 A_23_P343398 CCR7 NM_001838 ref|Homo sapiens chemokine (C-C motif) receptor 7 mRNA  
7.32 1.498 7.00E-05 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
9.13 1.494 0 A_23_P358917 CYP3A7 NM_000765 ref|Homo sapiens cytochrome P450 family 3 subfamily A polypeptide 7 mRNA  
12.92 1.486 0 A_23_P120883 HMOX1 NM_002133 ref|Homo sapiens heme oxygenase (decycling) 1 mRNA  
9.39 1.475 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
8.50 1.469 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
8.48 1.468 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
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15.05 1.466 0 A_33_P3399788 SERPINA3 NM_001085 ref|Homo sapiens serpin peptidase inhibitor clade A (alpha-1 antiproteinase antitrypsin) member 3 mRNA  
8.96 1.466 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
8.98 1.464 0 A_33_P3404588 FGD4 NM_139241 ref|Homo sapiens FYVE RhoGEF and PH domain containing 4 mRNA  
8.49 1.460 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
8.96 1.460 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
12.23 1.459 0 A_23_P44964 FAM171A1 NM_001010924 ref|Homo sapiens family with sequence similarity 171 member A1 mRNA  
6.07 1.459 0 A_23_P17673 DNMT3L NM_013369 ref|Homo sapiens DNA (cytosine-5-)-methyltransferase 3-like transcript variant 1 mRNA  
8.50 1.458 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
13.33 1.455 0 A_33_P3244347 PC NM_001040716 ref|Homo sapiens pyruvate carboxylase nuclear gene encoding mitochondrial protein transcript variant 3 mRNA  
7.93 1.452 0 A_32_P57810 RNF157 NM_052916 ref|Homo sapiens ring finger protein 157 mRNA  
10.52 1.451 2.00E-05 A_32_P160972 C6orf115 NM_021243 ref|Homo sapiens chromosome 6 open reading frame 115 mRNA  
9.47 1.449 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
6.99 1.447 0 A_33_P3229953 EEF1A2 NM_001958 ref|Homo sapiens eukaryotic translation elongation factor 1 alpha 2 mRNA  
8.03 1.442 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
8.10 1.440 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
9.20 1.440 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.44 1.439 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.45 1.438 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
9.28 1.434 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
8.11 1.430 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
5.56 1.425 2.00E-04 A_23_P64611 P2RY6 NM_176798 ref|Homo sapiens pyrimidinergic receptor P2Y G-protein coupled 6 transcript variant 2 mRNA  
9.95 1.423 0 A_24_P296508 SLC43A2 NM_152346 ref|Homo sapiens solute carrier family 43 member 2 mRNA  
12.47 1.418 0 A_23_P63798 KLF6 NM_001300 ref|Homo sapiens Kruppel-like factor 6 transcript variant A mRNA  
8.58 1.417 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
11.00 1.416 0 A_23_P130376 FAM38B NM_022068 ref|Homo sapiens family with sequence similarity 38 member B mRNA  
9.54 1.415 1.00E-05 A_23_P383819 TBX3 NM_016569 ref|Homo sapiens T-box 3 transcript variant 2 mRNA  
5.94 1.412 0.00021 A_23_P39799 LOXL3 NM_032603 ref|Homo sapiens lysyl oxidase-like 3 mRNA  
10.45 1.399 0 A_24_P158946 FGD4 NM_139241 ref|Homo sapiens FYVE RhoGEF and PH domain containing 4 mRNA  
6.78 1.398 0 A_33_P3233906 RAMP1 NM_005855 ref|Homo sapiens receptor (G protein-coupled) activity modifying protein 1 mRNA  
8.49 1.397 0 A_23_P111583 CD36 NM_001001547 ref|Homo sapiens CD36 molecule (thrombospondin receptor) transcript variant 2 mRNA  
8.92 1.397 0 A_23_P69810 AGPAT9 NM_032717 ref|Homo sapiens 1-acylglycerol-3-phosphate O-acyltransferase 9 mRNA  
9.37 1.394 0 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
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16.06 1.388 0 A_23_P16523 GDF15 NM_004864 ref|Homo sapiens growth differentiation factor 15 mRNA  
7.80 1.387 0 A_23_P7562 ACSL6 NM_001009185 ref|Homo sapiens acyl-CoA synthetase long-chain family member 6 transcript variant 2 mRNA  
7.21 1.386 4.00E-05 A_33_P3402868 GRIN2D NM_000836 ref|Homo sapiens glutamate receptor ionotropic N-methyl D-aspartate 2D mRNA  
7.37 1.378 1.00E-05 A_33_P3254708 ARHGAP40 NM_001164431 ref|Homo sapiens Rho GTPase activating protein 40 mRNA  
10.74 1.374 0 A_23_P108082 CREB3L3 NM_032607 ref|Homo sapiens cAMP responsive element binding protein 3-like 3 mRNA  
10.14 1.372 1.00E-05 A_23_P6771 LMCD1 NM_014583 ref|Homo sapiens LIM and cysteine-rich domains 1 mRNA  
12.25 1.371 0 A_23_P67381 SULT2A1 NM_003167 ref|Homo sapiens sulfotransferase family cytosolic 2A dehydroepiandrosterone (DHEA)-preferring member 1 
mRNA  
5.01 1.368 0.00086 A_33_P3345534 KRT14 NM_000526 ref|Homo sapiens keratin 14 mRNA  
9.09 1.360 0 A_33_P3298430 FAM171A1 NM_001010924 ref|Homo sapiens family with sequence similarity 171 member A1 mRNA  
8.38 1.359 0.00012 A_33_P3289251 LOC644727 AK095971 gb|Homo sapiens cDNA FLJ38652 fis clone HHDPC2008843 
12.83 1.355 2.00E-05 A_23_P94159 FBXO25 NM_183421 ref|Homo sapiens F-box protein 25 transcript variant 1 mRNA  
12.79 1.351 0 A_23_P162918 SERPINA3 NM_001085 ref|Homo sapiens serpin peptidase inhibitor clade A (alpha-1 antiproteinase antitrypsin) member 3 mRNA  
14.32 1.341 0 A_23_P2920 SERPINA3 NM_001085 ref|Homo sapiens serpin peptidase inhibitor clade A (alpha-1 antiproteinase antitrypsin) member 3 mRNA  
5.75 1.338 2.00E-05 A_33_P3341474 ZBTB38 NM_001080412 ref|Homo sapiens zinc finger and BTB domain containing 38 mRNA  
8.67 1.331 0 A_23_P166280 ICOSLG ENST00000407780 ens|inducible T-cell co-stimulator ligand [Source:HGNC Symbol;Acc:17087]  
10.24 1.330 0 A_24_P340066 ELF4 NM_001421 ref|Homo sapiens E74-like factor 4 (ets domain transcription factor) transcript variant 1 mRNA  
6.87 1.329 1.00E-05 A_23_P129367 CCDC135 NM_032269 ref|Homo sapiens coiled-coil domain containing 135 mRNA  
11.79 1.325 2.00E-05 A_23_P81898 UBD NM_006398 ref|Homo sapiens ubiquitin D mRNA  
14.29 1.319 0 A_33_P3350056 MT1X NM_005952 ref|Homo sapiens metallothionein 1X mRNA  
11.03 1.312 0 A_23_P46429 CYR61 NM_001554 ref|Homo sapiens cysteine-rich angiogenic inducer 61 mRNA  
10.53 1.312 0 A_23_P13772 TBX3 NM_016569 ref|Homo sapiens T-box 3 transcript variant 2 mRNA  
10.22 1.308 0 A_23_P324754 KIAA1199 NM_018689 ref|Homo sapiens KIAA1199 mRNA  
10.54 1.307 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
9.34 1.306 0 A_24_P88850 MRAS NM_012219 ref|Homo sapiens muscle RAS oncogene homolog  transcript variant 1 mRNA  
5.41 1.300 0.00051 A_33_P3211727 FAM176B NM_018166 ref|Homo sapiens family with sequence similarity 176 member B mRNA  
10.98 1.298 5.00E-05 A_33_P3294002 A4GALT NM_017436 ref|Homo sapiens alpha 14-galactosyltransferase mRNA  
7.66 1.296 4.00E-05 A_23_P65386 OTUB2 NM_023112 ref|Homo sapiens OTU domain ubiquitin aldehyde binding 2 mRNA  
8.42 1.291 0 A_33_P3351150 FAM38B NM_022068 ref|Homo sapiens family with sequence similarity 38 member B mRNA  
12.75 1.288 0 A_23_P143143 ID2 NM_002166 ref|Homo sapiens inhibitor of DNA binding 2 dominant negative helix-loop-helix protein  mRNA  
9.16 1.285 7.00E-05 A_23_P19657 LRP11 NM_032832 ref|Homo sapiens low density lipoprotein receptor-related protein 11 mRNA  
10.14 1.283 0 A_33_P3418158 SLC2A8 NM_014580 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 8 mRNA  
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10.63 1.283 2.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
7.08 1.282 0 A_33_P3318117 CYP3A7 NM_000765 ref|Homo sapiens cytochrome P450 family 3 subfamily A polypeptide 7 mRNA  
11.57 1.282 0 A_32_P180971 LOC728323 NR_024437 ref|Homo sapiens hypothetical LOC728323  non-coding RNA  
6.78 1.281 4.00E-05 A_23_P397376 MAF NM_001031804 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) transcript variant 2 mRNA  
7.37 1.277 0 A_23_P342727 STARD13 NM_178006 ref|Homo sapiens StAR-related lipid transfer (START) domain containing 13 transcript variant alpha mRNA  
11.07 1.276 0 A_33_P3767927 NR3C1 NM_001018077 ref|Homo sapiens nuclear receptor subfamily 3 group C member 1 (glucocorticoid receptor) transcript variant 5 
mRNA  
14.86 1.272 0 A_33_P3315314 MT1H NM_005951 ref|Homo sapiens metallothionein 1H mRNA  
6.84 1.271 0.00023 A_23_P121665 SORCS2 NM_020777 ref|Homo sapiens sortilin-related VPS10 domain containing receptor 2 mRNA  
9.36 1.271 1.00E-05 A_24_P100551 SH3RF1 NM_020870 ref|Homo sapiens SH3 domain containing ring finger 1 mRNA  
11.87 1.268 0 A_33_P3233841 IL6ST NM_002184 ref|Homo sapiens interleukin 6 signal transducer (gp130 oncostatin M receptor) transcript variant 1 mRNA  
10.66 1.266 0 A_32_P152437 AKAP12 NM_005100 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 1 mRNA  
8.54 1.265 0 A_24_P107859 SPRED1 NM_152594 ref|Homo sapiens sprouty-related EVH1 domain containing 1 mRNA  
11.64 1.262 0 A_32_P69368 ID2 NM_002166 ref|Homo sapiens inhibitor of DNA binding 2 dominant negative helix-loop-helix protein mRNA  
5.45 1.260 0.00091 A_23_P70814 C6orf123 NR_026773 ref|Homo sapiens chromosome 6 open reading frame 123 non-coding RNA  
10.62 1.258 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
9.96 1.256 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
11.35 1.255 8.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
11.01 1.255 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
11.35 1.254 4.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
9.13 1.252 2.00E-05 A_24_P48204 SECTM1 NM_003004 ref|Homo sapiens secreted and transmembrane 1 mRNA  
6.14 1.249 0.00029 A_23_P206806 ITGAL NM_002209 ref|Homo sapiens integrin alpha L (antigen CD11A (p180) lymphocyte function-associated antigen 1; alpha 
polypeptide) transcript variant 1 mRNA  
11.46 1.249 5.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
10.61 1.248 0 A_33_P3262020 C8G NM_000606 ref|Homo sapiens complement component 8 gamma polypeptide (C8G) mRNA  
9.04 1.248 7.00E-05 A_23_P502470 IL6ST NM_002184 ref|Homo sapiens interleukin 6 signal transducer (gp130 oncostatin M receptor) transcript variant 1 mRNA  
9.10 1.248 5.00E-05 A_23_P77415 OSGIN1 NM_013370 ref|Homo sapiens oxidative stress induced growth inhibitor 1 transcript variant 1 mRNA  
8.24 1.248 0 A_32_P167471 CLMN NM_024734 ref|Homo sapiens calmin (calponin-like transmembrane) mRNA  
11.45 1.247 7.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
9.95 1.242 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
11.49 1.240 3.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
15.48 1.238 0 A_23_P54840 MT1A NM_005946 ref|Homo sapiens metallothionein 1A mRNA  
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7.52 1.237 0 A_33_P3233843 IL6ST NM_001190981 ref|Homo sapiens interleukin 6 signal transducer (gp130 oncostatin M receptor) transcript variant 3 mRNA  
11.08 1.235 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
11.08 1.234 2.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase  mRNA  
6.96 1.233 0 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
13.33 1.230 0 A_33_P3236881 C1orf15-NBL1 NM_001204088 ref|Homo sapiens C1ORF15-NBL1 readthrough transcript variant 1 mRNA  
11.12 1.230 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
7.67 1.229 0 A_33_P3420078 LRP11 ENST00000367368 ens|low density lipoprotein receptor-related protein 11 [Source:HGNC Symbol;Acc:16936]  
17.03 1.228 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
7.17 1.228 0.00011 A_24_P928052 NRP1 NM_003873 ref|Homo sapiens neuropilin 1 transcript variant 1 mRNA  
8.23 1.223 0 A_33_P3216297 NR3C1 NM_001018077 ref|Homo sapiens nuclear receptor subfamily 3 group C member 1 (glucocorticoid receptor) transcript variant 5 
mRNA  
10.05 1.222 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
9.81 1.221 0 A_33_P3378556 F11 NM_000128 ref|Homo sapiens coagulation factor XI mRNA  
17.05 1.220 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA 
9.00 1.220 1.00E-05 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
11.34 1.219 6.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
11.42 1.218 7.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
13.89 1.216 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
10.10 1.216 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
10.68 1.214 0 A_23_P162142 TSKU NM_015516 ref|Homo sapiens tsukushi small leucine rich proteoglycan homolog (Xenopus laevis) mRNA  
10.06 1.214 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) (transcript variant 1 mRNA  
8.46 1.211 0 A_23_P310483 C8orf58 NM_001013842 ref|Homo sapiens chromosome 8 open reading frame 58 transcript variant 1 mRNA  
9.19 1.211 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
9.16 1.211 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA 
9.13 1.210 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
10.70 1.209 0 A_33_P3380417 SLC25A30 NM_001010875 ref|Homo sapiens solute carrier family 25 member 30 nuclear gene encoding mitochondrial protein mRNA  
10.91 1.209 2.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
17.09 1.208 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
10.14 1.208 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
8.29 1.207 9.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
7.60 1.206 0.00016 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
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14.71 1.206 0 A_23_P206724 MT1E NM_175617 ref|Homo sapiens metallothionein 1E mRNA  
8.91 1.206 0 A_23_P308305 TTC39C NR_024232 ref|Homo sapiens tetratricopeptide repeat domain 39C transcript variant 3 non-coding RNA  
8.39 1.205 5.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
11.05 1.204 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
11.05 1.202 6.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
11.45 1.200 7.00E-05 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
8.85 1.199 0 A_33_P3233834 IL6ST NM_001190981 ref|Homo sapiens interleukin 6 signal transducer (gp130 oncostatin M receptor) transcript variant 3 mRNA  
17.02 1.195 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
6.72 1.195 0.00018 A_23_P49145 ZG16 NM_152338 ref|Homo sapiens zymogen granule protein 16 homolog (rat) mRNA  
16.73 1.193 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
10.76 1.192 1.00E-05 A_23_P67042 MOCOS NM_017947 ref|Homo sapiens molybdenum cofactor sulfurase mRNA  
16.64 1.191 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
10.14 1.191 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
16.66 1.190 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
13.97 1.189 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
6.80 1.188 0 A_33_P3227990 MBP NM_001025101 ref|Homo sapiens myelin basic protein transcript variant 7 mRNA  
12.64 1.186 0 A_23_P41314 F11 NM_000128 ref|Homo sapiens coagulation factor XI mRNA  
11.81 1.184 0 A_33_P3399373 TPRA1 NM_001142646 ref|Homo sapiens transmembrane protein adipocyte asscociated 1 transcript variant 3 mRNA  
13.92 1.181 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
10.95 1.179 0.00012 A_23_P116414 PLA2G16 NM_007069 ref|Homo sapiens phospholipase A2 group XVI transcript variant 1 mRNA  
9.41 1.178 0 A_23_P390068 C19orf21 NM_173481 ref|Homo sapiens chromosome 19 open reading frame 21 mRNA  
11.12 1.176 1.00E-05 A_23_P61960 ATP6V0E2 NM_145230 ref|Homo sapiens ATPase H+ transporting V0 subunit e2 transcript variant 1 mRNA  
16.58 1.173 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
9.30 1.173 0 A_24_P402080 MBP NM_001025100 ref|Homo sapiens myelin basic protein transcript variant 8 mRNA  
13.92 1.171 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
8.06 1.169 0 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
6.59 1.168 0.00044 A_24_P13381 TRPV4 NM_147204 ref|Homo sapiens transient receptor potential cation channel subfamily V member 4 transcript variant 2 mRNA  
16.94 1.167 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA 
10.65 1.167 0 A_23_P72668 SDPR NM_004657 ref|Homo sapiens serum deprivation response mRNA  
9.25 1.167 4.00E-05 A_33_P3353791 ITGA1 NM_181501 ref|Homo sapiens integrin alpha 1 mRNA  
10.05 1.165 0 A_33_P3231156 ENST00000379816 ENST00000379816 ens|metallothionein 1C pseudogene [Source:HGNC Symbol;Acc:7395]  
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8.44 1.165 1.00E-04 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
10.69 1.161 1.00E-05 A_33_P3311371 PDLIM2 NM_198042 ref|Homo sapiens PDZ and LIM domain 2 (mystique) transcript variant 3 mRNA  
10.07 1.158 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
8.20 1.157 0 A_33_P3841368 LOC286161 AK091672 gb|Homo sapiens cDNA FLJ34353 fis clone FEBRA2011665 
7.37 1.157 2.00E-05 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
17.01 1.156 0 A_23_P107653 ETFB NM_001014763 ref|Homo sapiens electron-transfer-flavoprotein beta polypeptide transcript variant 2 mRNA  
10.02 1.156 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
9.29 1.155 0 A_23_P25706 CLMN NM_024734 ref|Homo sapiens calmin (calponin-like transmembrane) mRNA  
10.29 1.154 0 A_24_P192914 AMICA1 NM_153206 ref|Homo sapiens adhesion molecule interacts with CXADR antigen 1 transcript variant 2 mRNA  
10.10 1.152 0 A_23_P121527 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
9.16 1.152 0 A_23_P66948 FAM59A NM_022751 ref|Homo sapiens family with sequence similarity 59 member A transcript variant 2 mRNA  
9.81 1.147 0 A_33_P3313929 CCR6 NM_031409 ref|Homo sapiens chemokine (C-C motif) receptor 6 transcript variant 2 mRNA  
5.61 1.146 0.00011 A_33_P3269924 ENST00000535831 ENST00000535831 ens|huntingtin interacting protein 1 related [Source:HGNC Symbol;Acc:18415]  
6.03 1.145 0.00079 A_33_P3283480 CTSC NM_148170 ref|Homo sapiens cathepsin C transcript variant 2 mRNA  
13.41 1.144 0 A_33_P3294608 MVP NM_017458 ref|Homo sapiens major vault protein transcript variant 1 mRNA  
11.79 1.144 0 A_23_P83110 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
10.02 1.141 0 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
8.50 1.138 9.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
14.12 1.138 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
8.52 1.138 0 A_24_P17719 KLHL5 NM_015990 ref|Homo sapiens kelch-like 5 (Drosophila) transcript variant 1 mRNA  
9.23 1.138 1.00E-05 A_23_P41804 NKD2 NM_033120 ref|Homo sapiens naked cuticle homolog 2 (Drosophila) mRNA  
14.32 1.137 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
13.77 1.134 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
8.64 1.134 2.00E-05 A_33_P3240532 RGL1 NM_015149 ref|Homo sapiens ral guanine nucleotide dissociation stimulator-like 1 mRNA  
7.63 1.133 0 A_23_P60599 UGT1A6 NM_001072 ref|Homo sapiens UDP glucuronosyltransferase 1 family polypeptide A6 transcript variant 1 mRNA  
7.42 1.133 0 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
9.78 1.132 0 A_33_P3402783 A_33_P3402783 A_33_P3402783 Unknown 
14.32 1.131 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
8.06 1.129 1.00E-05 A_33_P3333317 OPTN NM_001008211 ref|Homo sapiens optineurin transcript variant 1 mRNA  
14.30 1.128 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
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14.13 1.125 0 A_23_P101208 CYB5A NM_001914 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 2 mRNA  
7.85 1.124 0.00019 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
6.67 1.124 1.00E-05 A_33_P3221989 CACNB4 NM_001005747 ref|Homo sapiens calcium channel voltage-dependent beta 4 subunit transcript variant 1 mRNA  
10.37 1.124 0 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
9.19 1.124 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
6.68 1.118 3.00E-05 A_23_P27734 NPAS1 NM_002517 ref|Homo sapiens neuronal PAS domain protein 1 mRNA  
8.37 1.117 6.00E-05 A_33_P3412438 A_33_P3412438 A_33_P3412438 Unknown 
7.87 1.116 0.00025 A_23_P390518 TNFRSF11A NM_003839 ref|Homo sapiens tumor necrosis factor receptor superfamily member 11a NFKB activator mRNA  
9.15 1.112 4.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
7.94 1.112 1.00E-05 A_23_P80503 ROBO1 NM_133631 ref|Homo sapiens roundabout axon guidance receptor homolog 1 (Drosophila) transcript variant 2 mRNA  
9.76 1.109 0 A_33_P3287338 IL6ST NM_001190981 ref|Homo sapiens interleukin 6 signal transducer (gp130 oncostatin M receptor) transcript variant 3 mRNA  
8.07 1.108 2.00E-05 A_23_P348636 FOXJ1 NM_001454 ref|Homo sapiens forkhead box J1 mRNA  
8.28 1.108 1.00E-05 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
9.18 1.107 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
9.37 1.107 1.00E-05 A_23_P165989 NEURL2 NM_080749 ref|Homo sapiens neuralized homolog 2 (Drosophila) mRNA  
9.29 1.104 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
7.94 1.104 1.00E-05 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
8.26 1.103 0 A_32_P62211 BX538057 BX538057 gb|Homo sapiens mRNA; cDNA DKFZp686J1595 (from clone DKFZp686J1595)  
10.43 1.101 1.00E-05 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
9.13 1.101 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
9.15 1.100 1.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
8.98 1.100 1.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
7.72 1.099 7.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
8.92 1.098 0 A_23_P100654 ZBTB4 NM_020899 ref|Homo sapiens zinc finger and BTB domain containing 4 transcript variant 1 mRNA  
9.73 1.096 0 A_23_P385017 G6PC NM_000151 ref|Homo sapiens glucose-6-phosphatase catalytic subunit mRNA  
7.37 1.095 0.00075 A_24_P382187 IGFBP4 NM_001552 ref|Homo sapiens insulin-like growth factor binding protein 4 mRNA  
9.05 1.095 3.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
10.05 1.094 0 A_23_P82523 ABCB1 NM_000927 ref|Homo sapiens ATP-binding cassette sub-family B (MDR/TAP) member 1 mRNA  
7.07 1.093 0 A_33_P3390656 ACSL6 NM_001009185 ref|Homo sapiens acyl-CoA synthetase long-chain family member 6 transcript variant 2 mRNA  
10.46 1.092 1.00E-05 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
8.00 1.092 1.00E-05 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
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10.35 1.088 4.00E-04 A_23_P85015 MAOB NM_000898 ref|Homo sapiens monoamine oxidase B nuclear gene encoding mitochondrial protein mRNA  
7.33 1.084 1.00E-05 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
7.74 1.081 6.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
7.69 1.081 1.00E-05 A_24_P36890 RAP1GAP NM_002885 ref|Homo sapiens RAP1 GTPase activating protein transcript variant 3 mRNA 
8.42 1.080 0 A_33_P3246505 MAP3K8 ENST00000375322 ens|mitogen-activated protein kinase kinase kinase 8 [Source:HGNC Symbol;Acc:6860]  
10.23 1.078 1.00E-05 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
7.78 1.078 0 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
14.20 1.078 0 A_23_P146798 SEPHS2 NM_012248 ref|Homo sapiens selenophosphate synthetase 2 mRNA  
8.49 1.077 3.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
8.52 1.076 3.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
6.37 1.076 0.00045 A_33_P3225522 OAS2 NM_001032731 ref|Homo sapiens 2'-5'-oligoadenylate synthetase 2 69/71kDa transcript variant 3 mRNA  
7.77 1.074 5.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
8.86 1.074 0 A_23_P416142 DLG1 NM_004087 ref|Homo sapiens discs large homolog 1 (Drosophila) transcript variant 2 mRNA  
12.25 1.073 1.00E-04 A_23_P500300 TRIM15 NM_033229 ref|Homo sapiens tripartite motif containing 15 mRNA  
10.54 1.070 0 A_32_P45168 IL6ST NM_002184 ref|Homo sapiens interleukin 6 signal transducer (gp130 oncostatin M receptor) transcript variant 1 mRNA  
9.66 1.069 8.00E-05 A_33_P3298024 ABCC3 NM_001144070 ref|Homo sapiens ATP-binding cassette sub-family C (CFTR/MRP) member 3 transcript variant 2 mRNA  
8.89 1.068 5.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
8.42 1.067 0 A_33_P3236102 IER5L NM_203434 ref|Homo sapiens immediate early response 5-like mRNA  
8.35 1.066 0 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
13.84 1.065 0 A_23_P23996 MAT1A NM_000429 ref|Homo sapiens methionine adenosyltransferase I alpha mRNA  
10.43 1.065 0 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
7.07 1.065 0.00018 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
10.42 1.065 0 A_33_P3389060 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
10.31 1.065 0 A_32_P162150 TAB3 NM_152787 ref|Homo sapiens TGF-beta activated kinase 1/MAP3K7 binding protein  mRNA  
7.92 1.062 3.00E-05 A_24_P264943 COMP NM_000095 ref|Homo sapiens cartilage oligomeric matrix protein mRNA  
8.24 1.06 0.00018 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
8.08 1.058 7.00E-05 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
transcript variant 1 mRNA  
10.48 1.058 0 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
10.40 1.058 1.00E-05 A_23_P415401 KLF9 NM_001206 ref|Homo sapiens Kruppel-like factor 9 mRNA  
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7.81 1.058 3.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
5.31 1.058 0.00116 A_23_P215111 ATP6V0A4 NM_020632 ref|Homo sapiens ATPase H+ transporting lysosomal V0 subunit a4 transcript variant 1 mRNA  
9.99 1.056 0 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
10.3 1.056 2.00E-05 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
13.95 1.056 0 A_33_P3311076 CYB5A NM_001190807 ref|Homo sapiens cytochrome b5 type A (microsomal) transcript variant 3 mRNA  
12.50 1.056 0 A_33_P3289296 TMEM37 NM_183240 ref|Homo sapiens transmembrane protein 37 mRNA  
7.19 1.055 0 A_23_P394545 KIAA1033 NM_015275 ref|Homo sapiens KIAA1033 mRNA  
7.88 1.052 1.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
7.80 1.051 2.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
14.11 1.051 0 A_23_P166459 LGALS1 NM_002305 ref|Homo sapiens lectin galactoside-binding soluble 1 mRNA  
9.09 1.050 1.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
10.25 1.047 1.00E-05 A_23_P1102 ACTA1 NM_001100 ref|Homo sapiens actin alpha 1 skeletal muscle mRNA  
8.12 1.045 5.00E-05 A_23_P216679 CDC14B NM_033331 ref|Homo sapiens CDC14 cell division cycle 14 homolog B (S. cerevisiae) transcript variant 2 mRNA  
9.03 1.044 1.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
9.47 1.043 0 A_23_P1043 C1orf106 NM_018265 ref|Homo sapiens chromosome 1 open reading frame 106 transcript variant 1 mRNA  
7.43 1.042 1.00E-05 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
9.63 1.034 0 A_23_P1043 C1orf106 NM_018265 ref|Homo sapiens chromosome 1 open reading frame 106 transcript variant 1 mRNA  
9.70 1.033 2.00E-05 A_23_P406330 SMAP2 NM_022733 ref|Homo sapiens small ArfGAP2 transcript variant 1 mRNA  
13.36 1.030 0 A_23_P30666 TNFRSF21 NM_014452 ref|Homo sapiens tumor necrosis factor receptor superfamily member 21 mRNA  
7.52 1.025 0 A_33_P3226832 F3 NM_001993 ref|Homo sapiens coagulation factor III (thromboplastin tissue factor) transcript variant 1 mRNA  
7.05 1.023 2.00E-05 A_23_P24104 PLAU NM_002658 ref|Homo sapiens plasminogen activator urokinase transcript variant 1 mRNA  
12.14 1.023 0 A_23_P160466 SLC19A2 NM_006996 ref|Homo sapiens solute carrier family 19 (thiamine transporter) member 2 mRNA  
7.04 1.021 3.00E-05 A_33_P3258265 SEMA6C NM_030913 ref|Homo sapiens sema domain transmembrane domain (TM) and cytoplasmic domain (semaphorin) 6C transcript 
variant 2 mRNA  
8.95 1.020 0 A_33_P3268649 SLC2A11 NM_030807 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 11 transcript variant 1 mRNA  
8.93 1.019 2.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
10.52 1.018 0.00015 A_33_P3280801 LMO7 NM_005358 ref|Homo sapiens LIM domain 7 transcript variant 1 mRNA  
9.13 1.017 2.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
8.16 1.017 3.00E-05 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
9.75 1.014 0 A_33_P3283828 CCDC154 NM_001143980 ref|Homo sapiens coiled-coil domain containing 154 mRNA  
9.26 1.012 0 A_23_P1043 C1orf106 NM_018265 ref|Homo sapiens chromosome 1 open reading frame 106 transcript variant 1 mRNA  
8.53 1.011 0.00053 A_24_P158089 SERPINE1 NM_000602 ref|Homo sapiens serpin peptidase inhibitor clade E (nexin plasminogen activator inhibitor type 1) member 1 
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transcript variant 1 mRNA  
5.15 1.009 0.00054 A_33_P3238290 FAM65C NM_080829 ref|Homo sapiens family with sequence similarity 65 member C mRNA  
8.91 1.008 6.00E-05 A_23_P122976 GNAI1 NM_002069 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha inhibiting activity polypeptide 1 mRNA  
8.43 1.008 0 A_23_P111311 AKAP12 NM_144497 ref|Homo sapiens A kinase (PRKA) anchor protein 12 transcript variant 2 mRNA  
7.77 1.005 1.00E-05 A_23_P119886 GCKR NM_001486 ref|Homo sapiens glucokinase (hexokinase 4) regulator mRNA  
9.23 1.005 0 A_23_P1043 C1orf106 NM_018265 ref|Homo sapiens chromosome 1 open reading frame 106 transcript variant 1 mRNA  
7.94 1.004 0 A_33_P3568387 ASB4 NM_016116 ref|Homo sapiens ankyrin repeat and SOCS box containing 4 transcript variant 1 mRNA  
7.61 1.002 0.00106 A_23_P37942 CLDN6 NM_021195 ref|Homo sapiens claudin 6 mRNA  
 
 
Table 97. All significantly down regulated genes in HepG2 cells after treatment with TCDD (10 nM) identified by microarray analysis. 
Selected parameters: A-value ≥ 5, log2 fc ≤ -1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
12.36 -2.305 0 A_32_P142440 PCSK9 NM_174936 ref|Homo sapiens proprotein convertase subtilisin/kexin type 9 mRNA  
7.62 -1.819 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
11.36 -1.797 0 A_23_P24129 DKK1 NM_012242 ref|Homo sapiens dickkopf homolog 1 (Xenopus laevis) mRNA  
10.98 -1.785 0 A_32_P196193 PAQR9 NM_198504 ref|Homo sapiens progestin and adipoQ receptor family member IX mRNA  
7.68 -1.737 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
9.05 -1.715 0 A_24_P228550 TUBB1 NM_030773 ref|Homo sapiens tubulin beta 1 mRNA  
7.77 -1.677 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
7.69 -1.662 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
8.70 -1.637 0 A_23_P63432 RHBDL2 NM_017821 ref|Homo sapiens rhomboid veinlet-like 2 (Drosophila) mRNA  
7.75 -1.615 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
7.40 -1.585 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
9.65 -1.572 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
10.12 -1.557 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
10.02 -1.543 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
9.91 -1.542 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
10.00 -1.534 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
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6.72 -1.532 0 A_23_P94275 DKK4 NM_014420 ref|Homo sapiens dickkopf homolog 4 (Xenopus laevis) mRNA  
7.97 -1.523 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
10.06 -1.518 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
10.07 -1.488 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
7.87 -1.487 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
9.05 -1.477 0 A_32_P46571 RHBDL2 NM_017821 ref|Homo sapiens rhomboid veinlet-like 2 (Drosophila) mRNA  
7.61 -1.466 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
13.33 -1.453 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
7.77 -1.450 0 A_23_P120243 HOXD1 NM_024501 ref|Homo sapiens homeobox D1 mRNA  
13.39 -1.447 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
13.29 -1.446 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
9.90 -1.440 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
13.42 -1.439 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
13.37 -1.437 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
13.26 -1.433 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
13.40 -1.433 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
9.47 -1.433 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
13.12 -1.427 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
12.98 -1.413 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
13.17 -1.410 0 A_23_P120902 LGALS2 NM_006498 ref|Homo sapiens lectin galactoside-binding soluble 2 mRNA  
9.57 -1.404 0 A_23_P109636 LRIG1 NM_015541 ref|Homo sapiens leucine-rich repeats and immunoglobulin-like domains 1 mRNA  
7.36 -1.384 3.00E-04 A_23_P57709 PCOLCE2 NM_013363 ref|Homo sapiens procollagen C-endopeptidase enhancer 2 mRNA  
9.16 -1.350 0 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase  transcript variant 1 mRNA  
9.61 -1.338 0 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
8.30 -1.337 0 A_23_P421401 PDGFRB NM_002609 ref|Homo sapiens platelet-derived growth factor receptor beta polypeptide mRNA  
9.49 -1.316 0 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
6.52 -1.314 1.00E-05 A_24_P237270 ADORA2A NM_000675 ref|Homo sapiens adenosine A2a receptor mRNA  
11.81 -1.295 0 A_24_P224727 CEBPA NM_004364 ref|Homo sapiens CCAAT/enhancer binding protein (C/EBP) alpha mRNA  
9.49 -1.292 1.00E-05 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
9.51 -1.287 0 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
7.12 -1.286 0 A_23_P8452 LFNG NM_001040167 ref|Homo sapiens LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase transcript variant 1 mRNA  
9.64 -1.283 2.00E-05 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
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9.53 -1.270 0 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
7.45 -1.239 5.00E-05 A_24_P387875 KCNJ10 NM_002241 ref|Homo sapiens potassium inwardly-rectifying channel subfamily J member 10 mRNA  
9.63 -1.228 0 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
9.48 -1.224 1.00E-05 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
8.20 -1.219 0 A_23_P154962 RIMBP3 NM_015672 ref|Homo sapiens RIMS binding protein 3 mRNA  
8.24 -1.188 1.00E-05 A_33_P3263533 SCN1A NM_001202435 ref|Homo sapiens sodium channel voltage-gated type I alpha subunit transcript variant 4 mRNA 
6.94 -1.181 1.00E-05 A_23_P93141 GSTA5 NM_153699 ref|Homo sapiens glutathione S-transferase alpha 5 mRNA  
8.11 -1.174 0 A_33_P3329974 CGN NM_020770 ref|Homo sapiens cingulin mRNA  
7.84 -1.170 0 A_23_P206359 CDH1 NM_004360 ref|Homo sapiens cadherin 1 type 1 E-cadherin (epithelial) mRNA  
8.46 -1.168 1.00E-05 A_24_P131522 ANTXR1 NM_032208 ref|Homo sapiens anthrax toxin receptor 1 transcript variant 1 mRNA  
11.11 -1.167 0 A_23_P76901 PLEKHG3 NM_015549 ref|Homo sapiens pleckstrin homology domain containing family G (with RhoGef domain) member 3 mRNA  
8.46 -1.167 0 A_23_P391443 PPM1H NM_020700 ref|Homo sapiens protein phosphatase Mg2+/Mn2+ dependent 1H mRNA  
7.85 -1.166 0 A_23_P153964 INHBB NM_002193 ref|Homo sapiens inhibin beta B mRNA  
8.19 -1.157 2.00E-05 A_23_P206359 CDH1 NM_004360 ref|Homo sapiens cadherin 1 type 1 E-cadherin (epithelial) mRNA  
11.40 -1.156 0 A_23_P383986 CHST15 NM_015892 ref|Homo sapiens carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 transcript variant 1 
mRNA  
8.83 -1.152 2.00E-05 A_23_P19030 ARSI NM_001012301 ref|Homo sapiens arylsulfatase family member I mRNA  
8.19 -1.152 1.00E-05 A_23_P160336 LEFTY1 NM_020997 ref|Homo sapiens left-right determination factor 1 mRNA  
9.60 -1.149 0 A_23_P200710 PIK3C2B NM_002646 ref|Homo sapiens phosphoinositide-3-kinase class 2 beta polypeptide mRNA  
9.09 -1.140 1.00E-05 A_23_P122216 LOX NM_002317 ref|Homo sapiens lysyl oxidase transcript variant 1 mRNA  
12.37 -1.139 4.00E-04 A_23_P19663 CTGF NM_001901 ref|Homo sapiens connective tissue growth factor mRNA  
7.78 -1.134 4.00E-05 A_23_P25396 NR1H4 NM_005123 ref|Homo sapiens nuclear receptor subfamily 1 group H member 4 transcript variant 3 mRNA  
7.25 -1.123 0.00089 A_23_P218331 CYB561 NM_001017916 ref|Homo sapiens cytochrome b-561 transcript variant 2 mRNA  
6.64 -1.123 0.00026 A_23_P15101 TMC5 NM_024780 ref|Homo sapiens transmembrane channel-like 5 transcript variant 3 mRNA  
7.72 -1.118 1.00E-05 A_23_P206359 CDH1 NM_004360 ref|Homo sapiens cadherin 1 type 1 E-cadherin (epithelial) mRNA  
8.11 -1.117 3.00E-05 A_23_P206359 CDH1 NM_004360 ref|Homo sapiens cadherin 1 type 1 E-cadherin (epithelial) mRNA  
7.36 -1.115 2.00E-05 A_33_P3305288 PAQR9 NM_198504 ref|Homo sapiens progestin and adipoQ receptor family member IX mRNA  
11.23 -1.108 0 A_33_P3304212 PLEKHG3 NM_015549 ref|Homo sapiens pleckstrin homology domain containing family G (with RhoGef domain) member 3 mRNA  
8.18 -1.099 1.00E-05 A_23_P206359 CDH1 NM_004360 ref|Homo sapiens cadherin 1 type 1 E-cadherin (epithelial) mRNA  
14.56 -1.086 5.00E-05 A_23_P330070 TFPI NM_001032281 ref|Homo sapiens tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) transcript variant 2 
mRNA  
10.09 -1.076 0 A_23_P48997 PSTPIP1 NM_003978 ref|Homo sapiens proline-serine-threonine phosphatase interacting protein 1 mRNA  
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8.70 -1.075 9.00E-05 A_24_P261567 GDPD5 NM_030792 ref|Homo sapiens glycerophosphodiester phosphodiesterase domain containing 5 mRNA  
8.22 -1.075 0 A_24_P383609 NANOS1 NM_199461 ref|Homo sapiens nanos homolog 1 (Drosophila) mRNA  
7.06 -1.073 1.00E-05 A_23_P28224 SCN1A NM_006920 ref|Homo sapiens sodium channel voltage-gated type I alpha subunit transcript variant 2 mRNA 
6.13 -1.063 1.00E-05 A_33_P3394689 SLC6A2 NM_001172501 ref|Homo sapiens solute carrier family 6 (neurotransmitter transporter noradrenalin) member 2 transcript variant 2 
mRNA  
8.19 -1.055 1.00E-05 A_23_P206359 CDH1 NM_004360 ref|Homo sapiens cadherin 1 type 1 E-cadherin (epithelial) mRNA  
8.04 -1.051 0 A_23_P372923 FGFR1 NM_001174066 ref|Homo sapiens fibroblast growth factor receptor 1 transcript variant 13 mRNA  
6.28 -1.045 0.00011 A_33_P3610138 LOC400568 BC043554 gb|Homo sapiens cDNA clone IMAGE:5176687 
9.74 -1.044 0 A_23_P30098 ADH4 NM_000670 ref|Homo sapiens alcohol dehydrogenase 4 (class II) pi polypeptide mRNA  
12.18 -1.024 2.00E-05 A_23_P145644 DDC NM_000790 ref|Homo sapiens dopa decarboxylase (aromatic L-amino acid decarboxylase) transcript variant 2 mRNA  
7.70 -1.011 1.00E-05 A_24_P62505 GLT25D2 NM_015101 ref|Homo sapiens glycosyltransferase 25 domain containing 2 mRNA  
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Table 98. All significantly up regulated genes in hHeps after treatment with TCDD (10 nM) identified by microarray analysis - separate data processing. 
Selected parameters: A-value ≥ 5, log2 fc ≥ 1, p-value ≤ 0.05. 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
10.65 6.589 0 A_23_P209625 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
10.63 5.368 0 A_23_P163402 CYP1A1 NM_000499 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 1 mRNA  
8.43 4.578 0 A_23_P165136 LRRC25 NM_145256 ref|Homo sapiens leucine rich repeat containing 25 mRNA  
9.16 4.429 0 A_33_P3290343 CYP1B1 NM_000104 ref|Homo sapiens cytochrome P450 family 1 subfamily B polypeptide 1 mRNA  
7.77 4.406 0 A_23_P207213 ALDH3A1 NM_000691 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 2 mRNA  
9.37 4.197 0 A_33_P3238433 ALDH3A1 NM_001135168 ref|Homo sapiens aldehyde dehydrogenase 3 family member A1 transcript variant 1 mRNA  
7.97 3.604 1.00E-05 A_33_P3480395 FLJ30901 AK055463 gb|Homo sapiens cDNA FLJ30901 fis clone FEBRA2005778 
8.38 3.529 0 A_23_P26854 ARHGAP44 NM_014859 ref|Homo sapiens Rho GTPase activating protein 44 mRNA  
9.71 3.259 0 A_33_P3397795 C14orf135 AK095489 gb|Homo sapiens cDNA FLJ38170 fis clone FCBBF1000024 
7.57 3.172 0 A_32_P49867 LOC100507055 NM_001195520 ref|Homo sapiens hypothetical LOC100507055 mRNA  
9.64 3.106 0 A_23_P416581 GNAZ NM_002073 ref|Homo sapiens guanine nucleotide binding protein (G protein) alpha z polypeptide mRNA  
9.09 2.948 0 A_24_P157370 IL17RB NM_018725 ref|Homo sapiens interleukin 17 receptor B mRNA  
11.94 2.710 0 A_33_P3222762 HULC NR_004855 ref|Homo sapiens highly up-regulated in liver cancer (non-protein coding) non-coding RNA  
13.05 2.626 0 A_33_P3253747 CYP1A2 NM_000761 ref|Homo sapiens cytochrome P450 family 1 subfamily A polypeptide 2 mRNA  
6.31 2.518 1.00E-05 A_23_P379649 BMF NM_001003940 ref|Homo sapiens Bcl2 modifying factor  transcript variant 1 mRNA  
8.35 2.343 2.00E-05 A_33_P3230990 SCUBE1 NM_173050 ref|Homo sapiens signal peptide CUB domain EGF-like 1 mRNA  
6.38 2.324 5.00E-05 A_24_P48204 SECTM1 NM_003004 ref|Homo sapiens secreted and transmembrane 1 mRNA  
10.44 2.311 0 A_23_P143845 TIPARP NM_015508 ref|Homo sapiens TCDD-inducible poly(ADP-ribose) polymerase transcript variant 2 mRNA  
10.93 2.291 0 A_23_P57910 RTP3 NM_031440 ref|Homo sapiens receptor (chemosensory) transporter protein 3  mRNA  
7.24 2.276 0 A_33_P3734384 LOC285957 AK097526 gb|Homo sapiens cDNA FLJ40207 fis clone TESTI2020946 
8.88 2.240 1.00E-05 A_23_P41804 NKD2 NM_033120 ref|Homo sapiens naked cuticle homolog 2 (Drosophila) mRNA  
8.66 2.159 4.00E-05 A_23_P154806 EPB41L1 NM_012156 ref|Homo sapiens erythrocyte membrane protein band 4.1-like 1 transcript variant 1 mRNA  
7.13 2.138 1.00E-05 A_24_P335620 SLC7A5 NM_003486 ref|Homo sapiens solute carrier family 7 (amino acid transporter light chain L system) member 5 mRNA  
8.56 2.137 1.00E-05 A_23_P136355 HHAT NM_018194 ref|Homo sapiens hedgehog acyltransferase transcript variant 1 mRNA  
8.35 2.118 0 A_23_P257003 PCSK5 NM_006200 ref|Homo sapiens proprotein convertase subtilisin/kexin type 5 transcript variant 2 mRNA  
6.79 2.078 3.00E-05 A_23_P17673 DNMT3L NM_013369 ref|Homo sapiens DNA (cytosine-5-)-methyltransferase 3-like transcript variant 1 mRNA  
9.94 2.009 1.00E-05 A_23_P75630 APOA5 NM_052968 ref|Homo sapiens apolipoprotein A-V transcript variant 1 mRNA  
7.99 1.931 1.00E-05 A_23_P116942 LAG3 NM_002286 ref|Homo sapiens lymphocyte-activation gene 3 mRNA  
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6.00 1.883 1.00E-05 A_23_P416395 STC2 NM_003714 ref|Homo sapiens stanniocalcin 2 mRNA  
5.75 1.861 2.00E-05 A_23_P79518 IL1B NM_000576 ref|Homo sapiens interleukin 1 beta mRNA  
13.46 1.843 0 A_23_P94159 FBXO25 NM_183421 ref|Homo sapiens F-box protein 25 transcript variant 1 mRNA  
6.72 1.838 3.00E-05 A_23_P60990 C2orf54 NM_024861 ref|Homo sapiens chromosome 2 open reading frame 54 transcript variant 2 mRNA  
9.53 1.830 3.00E-05 A_23_P24723 TMEM138 NM_016464 ref|Homo sapiens transmembrane protein 138 transcript variant 1 mRNA  
7.47 1.717 0 A_23_P381489 NCRNA00313 NR_026863 ref|Homo sapiens non-protein coding RNA 313 non-coding RNA  
7.67 1.704 0 A_33_P3841368 LOC286161 AK091672 gb|Homo sapiens cDNA FLJ34353 fis clone FEBRA2011665 
8.01 1.651 4.00E-05 A_23_P259071 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
11.35 1.643 0 A_23_P83110 CDK5RAP2 NM_018249 ref|Homo sapiens CDK5 regulatory subunit associated protein 2 transcript variant 1 mRNA  
6.30 1.635 2.00E-05 A_23_P35529 MBL2 NM_000242 ref|Homo sapiens mannose-binding lectin (protein C) 2 soluble mRNA  
6.09 1.584 5.00E-05 A_33_P3415240 LOC730091 NR_038387 ref|Homo sapiens hypothetical LOC730091 non-coding RNA  
9.47 1.569 0 A_23_P403335 EXPH5 NM_015065 ref|Homo sapiens exophilin 5 mRNA  
10.36 1.481 1.00E-05 A_33_P3341676 MEF2A NM_001171894 ref|Homo sapiens myocyte enhancer factor 2A  transcript variant 5 mRNA  
11.11 1.453 0 A_33_P3282394 MLLT1 NM_005934 ref|Homo sapiens myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog Drosophila); translocated to 1 
mRNA  
12.04 1.444 0 A_33_P3336622 ALDH3A2 NM_001031806 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 1 mRNA  
8.76 1.435 0 A_33_P3214849 KDELC2 NM_153705 ref|Homo sapiens KDEL (Lys-Asp-Glu-Leu) containing 2 mRNA  
10.42 1.400 0 A_23_P139704 DUSP6 NM_001946 ref|Homo sapiens dual specificity phosphatase 6  transcript variant 1 mRNA  
8.16 1.392 7.00E-05 A_23_P103110 MAFF NM_012323 ref|Homo sapiens v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian) transcript variant 1 mRNA  
6.94 1.378 1.00E-05 A_23_P161563 RAB38 NM_022337 ref|Homo sapiens RAB38 member RAS oncogene family mRNA  
15.21 1.375 0 A_23_P16523 GDF15 NM_004864 ref|Homo sapiens growth differentiation factor 15 mRNA  
11.96 1.371 3.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
9.67 1.364 1.00E-05 A_23_P354387 MYOF NM_013451 ref|Homo sapiens myoferlin transcript variant 1 mRNA  
11.92 1.363 4.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
11.84 1.351 5.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.02 1.351 4.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.13 1.347 4.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.20 1.341 2.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.04 1.340 3.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
11.95 1.340 4.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
8.21 1.337 1.00E-05 A_33_P3226650 GSTA7P NR_033760 ref|Homo sapiens glutathione S-transferase alpha 7 pseudogene non-coding RNA  
8.65 1.309 4.00E-05 A_23_P66881 RGS9 NM_003835 ref|Homo sapiens regulator of G-protein signaling 9 transcript variant 1 mRNA  
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12.11 1.306 5.00E-05 A_23_P112531 FAM102A NM_001035254 ref|Homo sapiens family with sequence similarity 102 member A transcript variant 1 mRNA  
12.63 1.301 2.00E-05 A_23_P58036 MCCC1 NM_020166 ref|Homo sapiens methylcrotonoyl-CoA carboxylase 1 (alpha) nuclear gene encoding mitochondrial protein mRNA  
13.03 1.291 4.00E-05 A_33_P3357530 SLC12A7 NM_006598 ref|Homo sapiens solute carrier family 12 (potassium/chloride transporters) member 7 mRNA  
6.92 1.277 2.00E-05 A_23_P102950 RSPH1 NM_080860 ref|Homo sapiens radial spoke head 1 homolog (Chlamydomonas) mRNA  
8.98 1.268 3.00E-05 A_32_P205637 PARD6B NM_032521 ref|Homo sapiens par-6 partitioning defective 6 homolog beta (C. elegans) mRNA  
6.95 1.268 5.00E-05 A_23_P102950 RSPH1 NM_080860 ref|Homo sapiens radial spoke head 1 homolog (Chlamydomonas) mRNA  
9.33 1.262 0 A_23_P313389 UGCG NM_003358 ref|Homo sapiens UDP-glucose ceramide glucosyltransferase mRNA  
13.35 1.256 1.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
12.80 1.253 0 A_33_P3336617 ALDH3A2 NM_000382 ref|Homo sapiens aldehyde dehydrogenase 3 family member A2 transcript variant 2 mRNA  
8.40 1.251 0 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
13.45 1.244 3.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.79 1.244 2.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.80 1.236 1.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.86 1.235 1.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.90 1.233 2.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.57 1.232 4.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
14.11 1.230 2.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
11.29 1.226 5.00E-05 A_23_P94921 SLC20A2 NM_006749 ref|Homo sapiens solute carrier family 20 (phosphate transporter) member 2 mRNA  
14.04 1.222 2.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
13.38 1.222 2.00E-05 A_23_P118065 HSD17B2 NM_002153 ref|Homo sapiens hydroxysteroid (17-beta) dehydrogenase 2 mRNA  
9.08 1.218 1.00E-05 A_24_P294124 SERTAD2 NM_014755 ref|Homo sapiens SERTA domain containing 2 mRNA  
8.19 1.216 1.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
8.18 1.201 2.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
10.32 1.197 5.00E-05 A_33_P3334443 FAM69A NM_001006605 ref|Homo sapiens family with sequence similarity 69 member A mRNA  
7.06 1.196 3.00E-05 A_33_P3419190 AREG NM_001657 ref|Homo sapiens amphiregulin mRNA  
14.15 1.168 1.00E-05 A_23_P60599 UGT1A6 NM_001072 ref|Homo sapiens UDP glucuronosyltransferase 1 family polypeptide A6 transcript variant 1 mRNA  
7.36 1.154 1.00E-05 A_23_P102950 RSPH1 NM_080860 ref|Homo sapiens radial spoke head 1 homolog (Chlamydomonas) mRNA  
9.98 1.149 5.00E-05 A_23_P210708 SIRPA NM_001040022 ref|Homo sapiens signal-regulatory protein alpha transcript variant 1 mRNA  
11.86 1.139 4.00E-05 A_33_P3217983 ACSL5 NM_203380 ref|Homo sapiens acyl-CoA synthetase long-chain family member 5 transcript variant 3 mRNA  
8.20 1.124 2.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
8.20 1.116 1.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
8.39 1.102 3.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
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12.95 1.100 0 A_23_P423197 RXRA NM_002957 ref|Homo sapiens retinoid X receptor alpha mRNA  
8.46 1.097 7.00E-05 A_24_P154037 IRS2 NM_003749 ref|Homo sapiens insulin receptor substrate 2 mRNA  
9.61 1.097 2.00E-05 A_23_P128215 SOCS2 NM_003877 ref|Homo sapiens suppressor of cytokine signaling 2 mRNA  
10.20 1.095 5.00E-05 A_33_P3389728 NR5A2 NM_205860 ref|Homo sapiens nuclear receptor subfamily 5 group A member 2 transcript variant 1 mRNA  
7.23 1.069 3.00E-05 A_24_P583040 C17orf67 ENST00000397861 ens|chromosome 17 open reading frame 67 [Source:HGNC Symbol;Acc:27900]  
10.25 1.015 8.00E-05 A_24_P141707 INHBE NM_031479 ref|Homo sapiens inhibin beta E mRNA  
9.52 1.012 1.00E-05 A_33_P3311371 PDLIM2 NM_198042 ref|Homo sapiens PDZ and LIM domain 2 (mystique) transcript variant 3 mRNA  
8.23 1.010 5.00E-05 A_23_P123402 TRIM55 NM_184086 ref|Homo sapiens tripartite motif containing 55 transcript variant 3 mRNA  
 
 
Table 99. All significantly down regulated genes in hHeps after treatment with TCDD (10 nM) identified by microarray analysis - separate data processing. 
Selected parameters: A-value ≥ 5, log2 fc ≤ -1, p-value ≤ 0.05. 
 
A Log2 fc p-value Probe name Gene name Systematic name Gene description 
8.52 -1.488 4.00E-05 A_23_P94782 CAPN8 NM_001143962 ref|Homo sapiens calpain 8 mRNA  
6.92 -1.304 9.00E-05 A_33_P3278362 ANKRD2 NM_020349 ref|Homo sapiens ankyrin repeat domain 2 (stretch responsive muscle) transcript variant 1 mRNA  
6.23 -1.261 1.00E-05 A_23_P215720 CFTR NM_000492 ref|Homo sapiens cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C  
member 7) mRNA  
9.82 -1.223 1.00E-05 A_24_P405705 SLC2A2 NM_000340 ref|Homo sapiens solute carrier family 2 (facilitated glucose transporter) member 2 mRNA  
10.71 -1.156 7.00E-05 A_23_P333029 C8orf47 NM_173549 ref|Homo sapiens chromosome 8 open reading frame 47  transcript variant 1 mRNA  
12.64 -1.062 3.00E-05 A_23_P331670 PYGB NM_002862 ref|Homo sapiens phosphorylase glycogen; brain mRNA  
9.17 -1.038 3.00E-05 A_23_P55251 ITGA3 NM_002204 ref|Homo sapiens integrin alpha 3 (antigen CD49C alpha 3 subunit of VLA-3 receptor) transcript variant a mRNA 
8.11 -1.034 1.00E-05 A_23_P122937 ELMO1 NM_014800 ref|Homo sapiens engulfment and cell motility 1  transcript variant 1 mRNA  
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